
Official Journal of Korean College of Rheumatology

pISSN 2093-940X eISSN 2233-4718



Journal of Rheumatic Diseases

Vol. 29, Suppl. 1, May, 2022

KCR 2022 42nd KCR Annual Scientific Meeting and The 16th International Symposium

Date May 19(Thu) - 21(Sat), 2022

Vanue | Seoul Dragon City, Seoul, Korea









KCR 2022

42nd Korean College of Rheumatology Annual Scientific Meeting & 16th International Symposium

May 19(Thu) - 21(Sat), 2022

Day 2 May 20 (Fri)

Sponsored Symposium 1

The Role of Baricitinib in the Treatment of RA

Lecture Title: Baricitinib in the real-world data

DATE	12:00-13:00, May 20 (Fri)
CHAIR	Yong-Beom Park Yonsei Univ., Korea
SPEAKER	Yun-Hong Cheon Gyeongsang Nat'l Univ., Korea



Sponsored Symposium 2

Ixekizumab : Recent updates on the treatment of **Spondyloarthritis**

Lecture Title: IL-17 inhibition in spondyloarthritis: The efficacy of Ixekizumab and clinical relevance

DATE 08:00-09:00, May 21 (Sat)

Seong-Ho Kim CHAIR Inje Univ., Korea

SPEAKER

Yeon-Ah Lee

Kyung Hee Univ., Korea



1일 1회 복용하는 젤잔즈 XR 11mg이 RA 치료에 승인되었습니다.³



IS NOW APPROVED IN RA³

(as of 2020.12.07)

MTX 포함 2가지 csDMARDs-IR RA 환자에게 젤잔즈 5mg과 약동학적으로 동등한, 하루 한 번 복용하는 젤잔즈 XR 11mg을 고려해주세요!³









#HUMIRA #RINVOQ #MIRACLE #BTS #ADD UP THE HOPE #ADalimumab #UPadacitinib

The set of the set of

- 첫 주에 80mg 부여하고 못 투여 후 2주 후에 40mg 부여 40kg 이상 : 특별 고프카운 연아이호 필요가 있는 국강에는 프랑안의 유도오법 동안 이상시례에 대한 위험성이 증가한다는 것을 알리고 아래 용량을 투여할 수 있다. 첫 주에 160mg 부여하고 첫 투여 후 2주 후에 80mg 부여							
조선한 1980년 나무나지 있는 회자의 경험 운영하여 신문한 초대를 입을 수 있고, 40 나이면 가고 가지가 위한 주의 《소비가 이날 손가지 위한 주의 노래가 위한 두의 가지가 다 만들을 나타지기 않는 지역 1984년 우리가 44 사람은 사람의 지금이는 것이 사람들 가 관람이 다 관람이 가 관람이 가 이 것이 다 가지가 위한 주의 가 가지가 다 가 가 가 주 주의 가 가지가 다 한 전체를 선수감 전 것이 되는 역시 위한 위해 용안된 회용을 가던으로 만나, 이 약은 별로드로워서라고 방물하여 두 가진다. 에트트루워이드에 날아갔어 않기 수 에트트 가 하기 수 하는 것이 수 별로드 제가도도 함께 마 수 에트는 것이 사람들 것이 하는 것이 하는 것이 하는 것이 하는 것이 같이 하는 것이 하는 것 데 하는 것이							
체중 (kg)	80						
10kg 이상 30kg 미만	20mg 격주 투여						
30kg 이상	40mg 격주 투여						
임 관련 관절암: 만 6세 이상의 골부착부위염 관련 관절염 환자	주 이내에 도달한다. 이 기간 내에 빈응을 보이지 않은 환자의 경우 투여 지속여부를 신중히 재고한다. (2 1에 대한 이 약의 권장 투여 용량은 체중을 기반으로 한다.) 골부착부위					
체중 (kg)	88						
15kg 이상 30kg 미만	20mg 격주 투여						
30kg 이상	40mg 격주 투여						
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~							
체중 (kg)	82						
15kg 이상 30kg 미만	20mg을 처음 2회는 매주 피하주사하고, 이후에는 격주 투여						
30kg 이상 40mg을 처음 2회는 매주 피하주사하고, 이후에는 격주 뿌여							
면서의 약근 그는 11 비행을 접근, 해외가 해외가 해공가 비용가가 비용가가 비용가가 하는 스가 있는 가는 가는 가지 하는 가 아니는 것이 가지 않는 것이 가지 않는 것이 있는 것이 있는 것이 가지 않는 것이 있는 것이 있는 것이 가지 않는 것이 있는 것이 있 이 것이 것이 있는 것이 있다. 것이 있는 것이 있는 것이 있는 것이 있는 것이 있는 것이 있다. 것이 있는 것이 있는 것이 있 같이 있다. 것이 있는 것이 있는 것이 있는 것이 있다. 것이 있는 것이 있는 것이 있다. 것이 있는 것이 있 같이 않이 있다. 것이 있는 것이 있는 것이 있다. 것이 있는 것이 있는 것이 있다. 것이 있는 것이 있는 것이 있는 것이 있다. 것이 있는 것이 것이 있다. 것이 것이 있다. 것이 있다. 것이 있다. 것이 것이 있다. 것이 있다. 것이 있다. 것이 것이 있다. 것이 있다. 것이 것이 것이 있다. 것이 것이 있다. 것이 있다. 것이 것이 것이 있다. 것이 것이 있다. 것이 있다. 것이 것이 있다. 것이 것이 것이 있다. 것이 있다. 것이 있다. 것이 것이 있다. 것이 있다. 것이 있다. 것이 것이 있다. 것이 있다. 것이 것이 것이 있다. 것이 것이 있다. 것이 있다. 것이 있다. 것이 있다. 것이 것이 있다. 것이 있다. 것이 것이 있다. 것이 있다.							
리버ㅋ현서반전(오파다니티니바스히뷴) 제품으여전답							

·효과	] (15	밀리	그램)	1, #0	비스	관절문	] 하니	이상의	1 항류	마티스	.제제()	DMAR	Ds)에	적절	히반원	하지	않거	- 나바	각성이	없는	성인의	김 충동	중에서	38	3의 휨	동성	류미E	신
팀의 치	료 0	(약은	단독루	여또	는메의	트레	세이트	나다	튼 비성	(留학) 전	1 항류	마티스	제제()	DMAR	RDs)2	병용	투여 3	같수:	있다.	기약	은 생물	학적	항류미	티스	제제()	OMAR	Ds) 9	έĿ
								는다. 2																				
								4 DM4																				
								세이성																				
								용량 1)																				
								각의 권																				
치료 중	문을	고려	#야 한	다. 초	기에 녹	#분적	인 반응	을보	긴 일박	* 환자	의 경두	2 16주	이상의	비지속	적인	치료 3	2에 가	선될	수있	구, 4)	아토프	티피부	염,성	<u>u</u> : 0	약의	권장	888	15

[화절 관절 다른성 료서 미명]

중대한 감염이 발생한 경우에는 감염이 조절될 때까지 이 약 치료를 증지해야 한다(경고 향 참조).
--------------------------------------------------------

실험실 수치	조치
절대 중성구 수(ANC)	ANC가 <1000 cells/mm ¹ 인 경우에는 치료를 증지해야 하며 ANC가 이 수치 이상으로 회복되면 치료를 제개할 수 있다.
절대 힘프구 수(ALC)	ALC가 <500 cells/mm ¹ 인 경우에는 치료를 증지해야 하며 ALC가 이 수치 아상으로 회복되면 치료를 재개할 수 있다.
해모글로빈(Hb)	Hb가 <8 g/dL 인 경무에는 치료를 증지해야 하며 Hb가 이 수치 이상으로 회복되면 치료를 재개할 수 있다.
간 트랜스아미나제	약인성 간 손상이 의심되는 경우에는 치료를 일시적으로 중지해야 한다.







아달로체®는 국내 최초 아달리무맙 바이오시밀러입니다.

DC-A11-172-202109 1. 의약품 안전나라 의약품통합정보시스템(http://nedrug.mfds.go.kr/index)





### **BELIEF IN RELIEF***

Remission Remission



Here with you

Safety

Retention

# diographic progression

R R

# 스[®]는 AS로 고통받고 있는 환자들에게 RELIEF, 그 이상의 가치를 제공합니다¹⁻⁶

# FAST & LONG LASTING RELIEF^{3,6}

* The proportions of patients achieving ASDAS-CRP inactive disease were 25.8% and 16.8% at week 52 and 25.0% and 18.4% at week 156 with secukinumab 300 and 150 mg, respectively. ⁺ Cosentyx[®] Patient Numbers From Launch Until October 2020. This numbers included patients with PsO, PsA, and AS.

Study design': 4-year results from the MEASURE 1 study; Patients opting to enroll had completed 2 years' treatment in the MEASURE 1 core study with s.c secukinumab 150 or 75mg every 4weeks , following IV loading to Week 4, or

Study design¹: 4-year results from the MEASURE 1 study. Patients opting to enroll had completed 2 years' treatment in the MEASURE 1 core study with s.c secukinumab 150 or 75mg every 4weeks, following IV loading to Week 4, or placebo treatment to week 16/24. Up-titation from secukinumab 75-150mg q4week was permitted following a protocol amendment. Efficacy is reported for patients originally randomized to secukinumab. Radiographic changes were assessed using the mSASSS and changes in MRI measures of inflammation using the Berlin scoring method. Safety and tolerability were evaluated. Among 274 extension study participants, 89.7% (78/87) and 93.0% (93/100) originally randomized to secukinumab 150 and 75 mg, respectively, completed 200 weeks. Study design²: 3-year long-term end of study results, Randomized, double blinded, parallel group, placebo-controlled phase 3 study. A total of 226 patients were randomized to IV secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by s.c. secukinumab 300 mg (IV-300 mg) or 150 mg (IV-150 mg) every 4 weeks, or a matched placebo. Patients in the placebo group were re-randomized to s.c. secukinumab at a dose of 300 or 150 mg at week 16. Analysis at week 156 included patients initially randomized to secukinumab and those who switched from placebo to secukinumab at week 16 (any secukinumab 200 or 150 mg). Outcome measures at week 156 included ASAS 2P, ASAS 5P6, and ASDAS-CRP inactive disease. Study design², After the 2-year MEASURE 1 trial, 274 patients receiving s.c. secukinumab 150 or 75 mg (following IV loading or initial placebo treatment to 16/24 weeks) every 4 weeks were invited to enter the 3-year extension study.

Dose escalation from 75 to 150 mg (approved dose) was allowed at or after week 156 based on the judgement of the treating physician. Assessments at week 260 (5 years) included ASAS 20/40 and other efficacy outcomes. Data are presented as observed. Safety assessment included all patients who received ≥1 dose of study treatment.

Study design*: Randomized, double blinded, parallel group, placebo-controlled phase 3 study. A total of 226 patients were randomized to IV secukinumab 10 mg/kg (baseline, weeks 2 and 4) followed by s.c secukinumab 300 mg (IV-300 mg) or 150 mg (IV-150 mg) every 4 weeks, or a matched placebo. Patients in the placebo group were re-randomized to s.c. secukinumab at a dose of 300 or 150 mg at week 16. The primary endpoint was ASAS20 response rate at week 16 in the IV-300 mg or IV-150 mg versus placebo. Other endpoints assessed through week 52 included improvements in ASAS40, ASAS 5/6, BASDAI, and ASAS PR, as well as the change from baseline in hsCRP levels.

AS, ankylosing spondylitis; ASDAS-CRP, Ankylosing Spondylitis Disease Activity Score-C-Reactive Protein; PsO, psoriasis; PsA, psoriatic arthritis; s.c., subcutaneous; IV, intravenous; mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score; MRI, magnetic resonance imaging; ASAS20, Assessment of SpondyloArthritis international Society criteria for 20% improvement; ASAS40, Assessment of SpondyloArthritis international Society criteria for 20% improvement; ASAS40, Assessment of SpondyloArthritis international Society partial remission; ASAS, Assessment in SpondyloArthritis international Society protein

References 1. Braun J, et al. Rheumatology (Oxford). 2018. doi: 10.1093/rheumatology/key375 2. Pavelka K, et al. ACR Open Rheumatol. 2020 Feb;2:119-127. 3. Baraliakos X, et al. RMD Open. 2019 Sep 3;5:e001005. 4. Data on file. COSENTYX® access. Novartis Pharmaceuticals Corp; October 2020. 5. Marzo-Ortega H, et al. Arthritis Rheumatol. 2020; 72 (suppl 10). 6. Pavelka K, et al. Arthritis Res Ther. 2017 Dec 22;19(1):285.

# U NOVARTIS 한국 노바티스주식회사 서울시 영등포구 국제금융로10 Three IFC 49층

**Product Information** 

처방하시기 전 QR 코드 또는 식품의약품안전처 의약품통합정보시스템(https://nedrug.mfds.go.kr)을 통해 상세 제품정보를 참조하시기 바랍니다.

**코센틱스센소레디펜** (세쿠키누맙,유전자재조합)

٦S



ちんのなかっ それよく りですっなな ストレットを ひろろろろのしん Help her move forward with the relentless protection of **Prolia**®1-2

로 녹색 보호대를 밀어서는 안된다. [보관 및 (2-8°C) 보관. [수입판매원] 암젠코리아유한회사 (서울특별시 중구 을) 주시기 바랍니디



AMGEN 암첸코리아유현화사 서울특별시 중구 울지로5길 19, 20종 Tel. 02 3434 4899 For further medical information, please contact: ] 수신자 부담 : 00798 611 3554 [e-mail : medinfo.JAPAC@am



중근당주식회사 서울특별시 서대문구 충정로 8 (충정로 3가) TEL 02-2194-0300 FAX 02-2194-0369 소비지상담실 : 080-6776-080(수신지부담) 제품상세정보 : www.ckdpharm.com 침

KR-03518-PRO-2019-Oc

# 30 Active life with Orencia

3가지 benefit (효과, 안전성, persistence)을 5세 이상 RA환자들이 누릴 수 있도록 Orencia®로 시작하세요!^{t‡*}

#65세 이상 RA 환자의 경우 동반질환 및 감염 위험이 높이질 수 있으므로 치료에 주의를 요합니다. † 오렌시아는 연령에 관계없이 remission rate, EULAR 반응율, DAS28-ESR 감소율이 모두 비슷하게 나타났습니다.! * 오렌시아는 65세 이상 RA 환자에서 효과 부족으로 안한 치료 중단 및 안전성 문제로 안한 치료 중단이 낮았으며 이로 안한 높은 persistence를 확인하였습니다.? RA, rheumatoid arthritis: DAS28, 28-joint disease activity score; ESR, erythrocyte sedimentation rate

#### 오렌시아®주 250mg(아바타셉트)

[효용·효과] 1 성인 뮤마티스 관찰암: 중동종 주중의 활동성 류마티스 관찰암을 가진 성인 환자 2 소아 특별성 관찰암: 중동종 주중의 활동성 류마티스 관찰암을 가진 6세 아상의 소아 환자 [용법·용량] 1 상인 뮤마티스 관찰암: 오렌시아는 표 때에 재사한 체종 범위별 투여하여 한날다. 오렌시아는 전동 것 관 이 추가 주 입으로 투여해야 합니다. 것 특이 추여 이 적 교실시하는 것 주집 이후 2주 및 4주 후, 그리고 그 이후에는 매4주이다 투여해야 합니다. 오렌시아는 인독지료 제료 부사용하거나 만드 타지료 제로 사용하거나 만드 TNT 관광제를 제외한 DMARD와 범용으로 투여할 수 있습니다. 소아 특별성 관찰馆 환자에는 그 환자의 체종을 기준으로 계산 용 관리 온 사용하거나 모든 TNT 관광제를 제외한 DMARD와 범용으로 투여할 수 있습니다. 소아 특별성 관찰馆 환자에는 그 환자의 체종을 기준으로 계산 용 당 분사용합니다. 2 소아 특별성 관찰압 75% 미만의 체종인 6 내지 TM의 소아 특별성 관찰馆 환자에는 그 인사아이의 민준정용으로 매운에서 환자의 체종 당을 사용합니다. 2 소와 특별장 선물감 가정의 미단의 새동간 이 데이 [세계 소와 특별장 연물감 문서세계 코프사이가의 관련장당은 내 부사시 전자계 세종 을 가초로 1000/08을 투여합니다. TXSk 이상인 체정한 소와 환자시에서는 상인의 관장 용량을 따라 오랜시/이란를 투여해이하며, 최고 1000/08을 츠러하지 않습니다. 오랜시/이는 30분간의 장맥 주인으로 투여해야 합니다. 첫 투여 이후에, 오랜시/이는 첫 투여후 구주 및 수주 후에 투여하고 그 이후 때 4구미다 두 여합니다. 오랜시/이는 단독요법 또는 메토르렉세이트(mTX)와 방용하여 사용할 수 있습니다. [**시용상의 주의사항]** 다음 환자에는 투여하지 말 것: 이후 은 주상분(이바타센트)이나 또는 이후의 구성 성분에 과란반응을 나타내는 것으로 알려진 환자에게 투여해서는 안 됩니다. "최신 제품정보는 (주)한국묘MS 제약 홈페이지(bms.com/kr) 또는 식약처 홈페이지 의약품정보란에서 확인하실 수 있습니다. **[제조회사]** BMS Company **[판매회사]** 한국BMS지약

#### 표1. 정맥 투여 시 오렌시아* 주 250mg(아바F-넵트)의 용량

환자 체중	용량	바이알 개수*
< 60kg	500mg	2
60 내지 100kg	750mg	3
> 100kg	1g	4

◦각 바이알에는 아버타셉트 250mg이 들어있다.

오렌시아® 서브큐 프리필드시린지 125mg(아바타셉트)

조 전사이 ~ 시드규 쓰더 클드시던시 123111g(아미다 검느) [1호: 6 회과] 성인 류미티스 관점함: 중등증에서 중증의 활동성 류미티스 관점염을 가진 성인 환자. [8법 · 8량] 성인 류미티스 관점함: 아비타냅트는 단독치조제로 사용하거나 또는 TNF 저해제를 제인한 DMARD와 방동으로 투여할 수 있습니다. 1 피하 투여 요합: 이 약은 일주일에 한 번 피하 투여용으 로만 사용해야 합니다. 이 약은 오랜시아 * 중 7 조0mg(아비타냅트) 정택 부하 용량 투여 없이 시작할 수 있습니다. 9 나가 필요하다. 관단하는 경우, 정택 부하 용량 투여금 지료를 사장하는 환자는 표 1의 체증에 따른 분류에 따한 한 번의 장맥 주인으로 시작하여야 합니다. 정택 투여 후 하루 이내에 이 약의 첫 피하 투여를 실시해야 합니다. 2랜시아 * 정택 투여를 받고 있던 환자가 피하 투여로 반경하는 경우에는 다음에 계획된 장택 투여 후 하루 이내에 이 약의 첫 회하 투여를 실시해야 합니다. 2랜시아 * 정택 투여를 받고 있던 환자가 피하 투여로 반경하는 경우에는 다음에 계획된 장택 투여 용량 대신에 첫 피하 투여 용량을 적용합니다. 2 전체사이 * 정택 투여를 받고 있던 환자가 피하 투여로 반경하는 정약에 투여는 표 1에 제사한 체중 범위별 투여량 등 참고하여 3억분간 장맥 대 주인으로 투여해야 합니다. [N용상] 주 200mg(이 반타냅트)를 이용한 정택 투여는 표 1에 제사한 체중 범위별 투여량 응 참고해 3억분간 장맥 대 주인으로 투여해야 합니다. [N용상] 주 201%] 다운 환자에는 투여하지 말 것: 이 약은 주상분(아이타냅트)이나 또는 이 의의 구성성분에 과민반응을 나타내는 것으로 알려진 환자에게 투여해서는 안 됩니다. *최신 제품정보는 (주)한국요에스에서 100ms.com/kr) 또는 식약처 홈페이지 의약품정보란에서 확인하실 수 있습니다. [제조회사] BMS Company [판매회사] 한국BMS계약

References 1. Lahaye C, et al. Rheumatology (Oxford) 2016;55:874-84. 2. Ebina K, et al. PLoS One. 2019 May 8;14(5):e0216624. 3. Harigai M, et al. Mod Rheumatol 2016;26:491-498. 4. Zhang J, et al. Ann Rheum Dis. 2016;75(10):1813-8.



#### ( Bristol Myers Squibb[™] 서울시 강남구 테헤란로 504 해성1빌딩 12층, 02-3404-1300, bms.com/kr





국내에서 수행된 MTX에 반응하지 않는 75명의 RA환지를 대상으로 한 4상 임상시험에서

# TAC 병용은 LEF 병용에 비해 **비열등한 DAS28 개선 효과**를 보였으며, **양호한 내약성**을 LIEF냈습니다.¹

24주 시점에서 **DAS28 score**를 보았을 때 TAC+MTX군은 LEF+MTX군에 비해 **비열등 하였습니다.**¹

mean difference of DAS28: -0.1812, 95% CI: -0.8073, 0.4450

TAC+MTX 군의 경우 37명 중 18명, LEF+MTX 군의 경우 38명 중 27명에서 **이상사례가 보고**되었습니다.²



프로그랍 캡슐 제품설명서 프로그랍 주사 제품설명서 trexate (MTX) to investigate the efficacy and safety of tacrolimus(TAC) then increased to 2 capsules/day until the end of the study).

[Study information] A 24-week multi-center, double-blind, randomized, non-inferiority study in 75 rheumatoid arthritis(RA) patients with inadequate response to methotrexate (MTX) to investigate the efficacy and safety of tacrolimus(TAC) versus leffunomide(LEF) when combined with MTX in RA patients. Initial add-on dose: 1 capsule/day (TAC 1.5 mg/day) or LEF (10 mg/day) for 4 weeks(lf tolerable, doses were then increased to 2 capsules/day until the end of the study). [References] 1. Shin, K, et al. Efficacy and safety of add-on tacrolimus versus leffunomide in rheumatoid arthritis patients with inadequate response to methotrexate. *Int J Rheum Dis.* 2019 Jun;22(6):1115-1122. 2. Shin, K, et al. Efficacy and safety of add-on tacrolimus versus leffunomide in rheumatoid arthritis patients with inadequate response to methotrexate. *Int J Rheum Dis.* 2019 Jun;22(6):1115-1122. Supplementary Table 2. RineLA 2019 bix0ld TAC SM MTX, 기타항류마티스제(DMARD) 또는 항 TNF알파제제를 방용했을 때의 유효성 및 안전성은 확립되어 있지 않습니다. 또한 면역억제작용을 가진 약물(면역억제제: 부신피질호르몬 등, 항류마티스제(DMARD): MTX 등) 과의 방용 시, 둘다 면역억제작용을 가지므로 과도한 면역 억제가 일어날 수 있으므로 방용에 주의 해야 합니다.(Ref: 사용상의 주의사항 5. 일반적 주의 및 6-2) 방용주의 항 참고) * 보다 자사한 안전성 정보는 제품/업서를 참고해 주십시오.

한국아스텔라스제약(주) (06164) 서울특별시 강남구 테헤란로 521 파르나스타워 7층, Tel. 02-3448-0504



C ACTEMRA® tocilizumab



#### 악템라®는 DMARD 병용요법 뿐만 아니라 단독요법에서도 유효성이 입증된 생물학적 제제입니다.

- 악템라 단독요법과 adalimumab 단독요법의 head-to-head 임상에서 우위적 유효성을 입증하였습니다.1
- 방사선학적 평가를 통해 단독요법, DMARDs 병용요법에서 관절손상 억제효과를 확인하였습니다.23
- 5년 장기투여시에도 관해율(ACR70, DAS28<2.6)이 유의하게 유지되었습니다.4
- IV제제와 SC제제의 비열등성 시험에서 두 제제의 동등한 유효성 및 내약성을 입증하였습니다.5
- 이상 반응 발현율은 타 생물학적 제계의 류마티스 관절염 환자 대상 임상시험과 유사한 수준이었습니다.6

Reference. 1. Gabay C et al, Lancet. 2013 May 4;381 (9877):1541-50. 2. Yamanaka H et al, Mod Rheumatol. 2011;21(2):122-33. 3. Dougados M et al, Ann Rheum Dis. 2013 Jan;72(1):43-50. 4. Nishimoto N et al, Ann Rheum Dis. 2009 Oct;68(10):1580-4. 5. Ogata A et al, Arthritis Care Res (Hoboken). 2014 Mar;66(3):344-54. 6. Schiff MH et al, Arthritis Res Ther. 2011;13(5):R141.

Ann Rheum Dis. 2009 Oct;68(10): 1580-4. 5. Ogata A et al, Arthritis Care Res (Hoboken). 2014 Mar;66(3):344-54. 6. Schiff MH et al, Arthritis Res Ther. 2011;13(5):R141.

# Simple dosing

# **Proven persistence**²⁻⁶



#### 주사 한 번을 한 달에 한 번만


#### 신뢰할 수 있는 치료 유지율²⁻⁶

References 1, 심퍼니®프리필드시린지주 허가사항(최근변경일: 2021-03-02), 2, Mahlich J, et al. Patient Prefer Adherence, 2016;10:1509-1519, 3, Bhoi P, et al. BMJ Open, 2017;7(9):e015872, 4, Takacs P, et al. Patient Prefer Adherence. 2019;13:157-163, 5, Kim HA, et al. Front Med (Lausanne). 2021;8:689609. 6, Lee JS, et al. Korean J Intern Med. 2018;33(3):622-628.

#### 심퍼니[®]프리필드시린지주(골리무맙)

janssen 🕽








#### The First High-Concentration Adalimumab Biosimilar

With proven outcomes, reduced pain, and improved convenience, Yuflyma® offers patient-centric treatment for your patients.^{1,2}

1. 유플라이마펜주 40mg/0.4mL 식약처 하기사항(개정년월일 2021. 10. 15) 2. Kay J. et al. (Nov, 2020). A Randomized, Double-Blind, Phase 3 Study to Compare the Efficacy and Safety of a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar (CT-P17) with Reference Adalimumab in Patients with Moderate-to-Severe Active Rheumatoid Arthritis. [Poster presentation]. ACR Convergence 2020.







# Journal of Rheumatic Diseases

Vol. 29, Suppl. 1, May, 2022

자문위원	고은미 (성균관의대 명예교수) 김동집 (가톨릭의대) 김호연 (김호연내과) 박성환 (가톨릭의대) 송영욱 (송영욱내과) 유 빈 (울산의대) 이충기 (영남의대) 최일용 (한양의대)	김기용 (울산의대) 김신규 (한양의대) 문명상 (제주한라병원) 박 원 (인하의대) 유대현 (한양의대) 이수곤 (차의대) 정덕환 (경희의대) 최정윤 (대구가톨릭의대)	김동수 (연세의대) 김중곤 (서울의료원) 박병문 (광명성애병원) 송관규 (고려의대) 유명철 (경희의대) 이윤우 (위더스내과) 최영길 (강남차병원)
회 장	이상헌 (건국의대)		
이 사 장	김태환 (한양의대)		
기획이사	송정수 (중앙의대)	이신석 (전남의대)	
총무이사	이창근 (울산의대)		
재무이사	김완욱 (가톨릭의대)		
간행이사	이영호 (고려의대)		
학술이사	성윤경 (한양의대)		
국제이사	심승철 (충남의대)		
보험이사	윤보영 (인제의대)	홍승재 (경희의대)	
홍보이사	이명수 (원광의대)		
교육수련이사	윤종현 (가톨릭의대)		
연구이사	신기철 (서울의대)		
정보이사	김근태 (고신의대)		
의료정책이사	백한주 (가천의대)		
법제윤리이사	박용범 (연세의대)		
무임소이사	공현식 (서울의대) 이상일 (경상의대)	김현아 (한림의대) 이은봉 (서울의대)	엄완식 (한양류마엄완식내과) 차훈석 (성균관의대)
이사	강태영 (강태영내과) 김성수 (울산의대) 김진석 (제주의대) 서창희 (아주의대) 임승재 (성균관의대)	김건우 (대구파티마병원) 김성호 (인제의대) 김해림 (건국의대) 안종균 (연세의대) 주지현(가톨릭의대)	김성규 (대구가톨릭의대) 김종민 (울산의대) 남언정 (경북의대) 이규훈 (한양의대)
감사	이성원 (동아의대)	서영일 (한림의대)	

#### 대한류마티스학회 임원명단

JOURNAL OF RHEUMATIC DISEASES

# 대한류마티스학회 위원회명단

응무원회         이상근 (물산의대)         허진욱 (물자의대)         길재훈 (고려의대)           위원         일소영 (한양의대)         허진욱 (물자의대)         길재훈 (고려의대)           이사         김왕옥 (가톨릭의대)         소량 (경영의대)         천봉종 (경상의대)           위원         김해린 (건국의대)         서양일 (한림의대)         천봉종 (경상의대)           관점 (고려의대)         한승우 (경북의대)         천봉종 (경상의대)           이사         이영호 (고려의대)         한승우 (경북의대)         변환종 (경상의대)           건사         조수경 (한양의대)         일태종 (전남의대)         박인찬 (연세의대)           인사         이영호 (고려의대)         인종종 (성균관의대)         한 (연세의대)           이사         이영호 (고려의대)         인종종 (성균관의대)         호령 (성균관의대)           이사         이영호 (고려의대)         인종종 (성균관의대)         한 (연세의대)           이수 (동경 (한양의대))         인종종 (성균관의대)         한 (연세의대)           이사         신종경 (한양의대)         전송기 (가톨릭의대)         관향 (한양의대)           기사         인종경 (성균관의대)         관승기 (가톨릭의대)         김기종 (강향의대)           기사         인종경 (성균관의대)         관승기 (가톨릭의대)         김기종 (강향의대)           기원         인종경 (성문의대)         관승기 (안양의대)         전승경 (양양의대)           기관         관중점 (성용의대)         전상품 (전양의대)         전승경 (양양의대)           이건여 (가톨릭의대)         건산통 (순성형의대)         전상품 (안양의대)		t	다이이치	
위원         방소영 (한양의대)         허진욱 (울지의대)         김재혼 (고려의대)           오지선 (서울아산병원)         송 한 (경회의대)         ************************************			· 구위권외	
위원         오지신 (서용아신병원)         승 란 (경희의대)           기부위원회         기부위원회           이사         김왕목 (가톨릭의대)         신영일 (한희의대)         천융홍 (경상의대)           위원         김해팀 (건국의대)         서영일 (한희의대)         천융홍 (경상의대)           기사         이영호 (고려의대)         한승우 (경북의대)         1           2년         지역기(고려의대)         한승우 (경북의대)         1           2년         조수경 (한양의대)         1         1           2년         조수경 (한양의대)         1         1           위원         백진군 (서울의대)         인종군 (연서의대)         1           이승근 (부산의대)         인종군 (연서의대)         2         1           이승근 (부산의대)         인동종 (성군관의대)         2         1           이승경 (성군관의대)         인종경 (성군관의대)         2         1           이사         신흥경 (성군관의대)         김정유 (만양의대)         2         1           관원         인종경 (성군관의대)         관심감 (서울의대)         2         1         1           위원         김정유 (대극관리대)         학승기 (가톨릭의대)         2         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1         1	٥١٨٢		취지요 (유지이네)	기계층 /ㄱㄱ이이\\
재무위원회           이사         김완욱 (가톨릭의대)           위원         김해님 (건국의대)         서영일 (한팀의대)         찬윤흥 (경상의대)           위원         최성재 (고려의대)         한승우 (경복의대)         전행위원회           이사         이영호 (고려의대)         한승우 (경북의대)         도           건사         조수경 (한양의대)         김태종 (전남의대)         박민찬 (연세의대)           위원         박진교 (서울의대)         인종준 (연사의대)         안중경 (성균관의대)           이승근 (부산의대)         입두호 (출산의대)         전형위원회           이승금 (부산의대)         인두호 (출산의대)         전성종 (선양의대)           전체         선훈경 (성균관의대)         입기도 (가톨릭의대)           이상         성문경 (한양이대)         감기도 (가톨릭의대)           관원         관련적 (서울의대)         확승기 (가톨릭의대)         김기도 (가톨릭의대)           관원 (선용의대)         확승기 (가톨릭의대)         김치한 (양의대)         조수경 (한양의대)           관원         관련적 (서울의대)         전찬종 (순찬양의대)         조수경 (한양의대)           인야 (경희의대)         전찬종 (순산양의대)         조수경 (한양의대)         조수경 (한양의대)           인위원         의 기원 (기톨릭의대)         진산종 (성급의대)         의 지원 (성당의대)           인사         식승철 (성금의대)         이 지준 (성균관의대)         유인 (성급의대)           이사         소청경 (한양의대)         중 취 (경희의대)         김 신수 (출산의대)           한 연 (인제의대)         양 성	위원			김새운 (고려의내)
이사         김한욱 (가톨릭의대)         서영일 (한팀의대)         천윤홍 (경상의대)           위원         최성재 (고려의대)         한승우 (경복의대)            이사         이영호 (고려의대)         한승우 (경복의대)            건사         조수경 (한양의대)             건사         조수경 (한양의대)             관심 (대구가톨릭의대)         김태종 (전남의대)         박민찬 (언세의대)            위원         신승규 (대구가톨릭의대)         인태종 (전남의대)         안중경 (성균관의대)           이사         성문경 (한양의대)         일루호 (출산의대)         주영빈 (한양의대)           건사         안중경 (성균관의대)         의로호 (순산의대)         주영빈 (한양의대)           건사         안중경 (성균관의대)		· · ·		
위원김해림 (건국의대)서영일 (한림의대)천요홍 (경상의대)최성재 (고려의대)한승우 (경북의대)이사이영호 (고려의대)한승우 (경북의대)건사조수경 (한양의대)대간사조수경 (한양의대)인종중 (연세의대)반원찬 (연세의대)위원법진군 (서울의대)인종중 (연세의대)안중경 (성균관의대)이스이승근 (부산의대)인동중 (연세의대)전중경 (성균관의대)이사성문경 (한양의대)일부호 (출산의대)주명빈 (한양의대)간사안중경 (성균관의대)감기조 (기톨릭의대)관원김성규 (대구가톨릭의대)김승길 (일산의대)김진현 (승남의대)김성규 (대구가톨릭의대)김용길 (일산의대)김진현 (승남의대)김성규 (대구가톨릭의대)김용길 (일산의대)김진현 (승남의대)김성규 (대구가톨릭의대)김용길 (일산의대)조수경 (한양의대)관원김성규 (대구가톨릭의대)김정현 (소생활이대)조신형 (현남의대)이연아 (경희의대)전산홍(순천황의대)조수경 (한양의대)전사이연아 (기톨릭의대)김성홍 (한양의대)조수경 (한양의대)기사실승철 (충남의대)이제준 (성고관의대)정상운 (차의대)위원이유연 (기톨릭의대)관성렬 (인하의대)유인설 (충남의대)이원운보형 (인정의대)조성렬 (인하의대)유인설 (충남의대)이사운보형 (인제의대)종종재 (경희의대)김성우 (출산의대)관원김한영 (관리에대)유향령 (한립의대)김성우 (응산의대)이사운보형 (인지의대)종종재 (경희의대)김성우 (응산의대)이사운보형 (인감의대)유향령 (한립의대)김성우 (응산의대)이유원인종기 (건국의대)위한령 (간행에대)김성종 (한입의대)이사운보형 (인금의대)관방형 (간행명대과)김성주 (안의대)이사유산형 (한입의대)김성종 (주순 양원)이주하 (가물리의대)이사양형 (유대엔정내과)최성재 (고려의대)취한법 (안에대)신청 (한명의 (1)최상품 (안의대)취한법 (안에 (1) <t< th=""><th></th><th></th><th>H무위원회</th><th></th></t<>			H무위원회	
위원최성재 (고려의대)한승우 (경북의대)이사이영호 (고려의대)간체조수경 (한양의대)감사조수경 (한양의대)감사조수경 (한양의대)위원법진규 (서국가들록의대)감태종 (진납의대)반진찬 (연세의대)위원백진균 (서울의대)안종균 (연세의대)안종경 (성균관의대)이승근 (부산의대)입투호 (울산의대)주명빈 (한양의대)***********************************	이사	김완욱 (가톨릭의대)		
최정재 (고려의대)         한응우 (경목의대)           간행위원회         건값위원회           이사         이영호 (고려의대)         건           간사         조수경 (한양의대)         법태종 (전남의대)         박민찬 (연세의대)           위원         김성규 (대구가톨릭의대)         김태종 (전남의대)         박민찬 (연세의대)           이승는 (부산의대)         인종금 (연세의대)         안중경 (성균관의대)           이승는 (부산의대)         입투호 (물산의대)         주영빈 (한양의대)           전사         성운경 (천문관)         지역 (전문관)         지 (기톨릭)           이사         성운경 (천문관)         관승기 (가톨릭)         김기조 (가톨릭)           위원         김정규 (대구가톨릭)         김용길 (물산의대)         김기조 (기톨릭)           김정규 (대구가톨릭)         김용길 (물산의대)         김기조 (기톨릭)           기업 (서울의대)         학승기 (가톨릭)         김기조 (기톨릭)           이었 (경희의대)         전환종 (순천양의대)         조수경 (한양의대)           기업 (이 (기톨릭)         전환종 (순천양의대)         조수경 (한양의대)           이시         심승철 (충남의대)         전환종 (산천황이대)         조수경 (한양의대)           이사         심승철 (충남의대)         전성별 (인하의대)         유인실 (충남의대)           이지 연 (기톨릭의대)         관심 (성물 (인희 대))         유인실 (충남의 대)         전 (전 등 (논의 대))           이위원         이유명 (인제의대)         홍승재 (경희의대)         김 전 수 (음산 대)           이위원         양 (인희 대)         양 (전 등	위원		서영일 (한림의대)	천윤홍 (경상의대)
이사         이영호 (고려의대)           간사         조수경 (한양의대)           김성규 (대구가톨릭의대)         김태종 (전남의대)         박민찬 (연세의대)           위원         박진교 (서울의대)         안종균 (연세의대)         안중경 (성균관의대)           이사         성운경 (한양의대)         입두호 (울산의대)         주영빈 (한양의대)           간사         안중경 (성균관의대)         감종권(1/)톨릭의대)         김기조 (가톨릭의대)           위원         공현식 (서울의대)         객승기 (가톨릭의대)         김기조 (가톨릭의대)           김성규 (대구가톨릭의대)         김용길 (출산의대)         김진현 (충남의대)           김현아 (아주의대)         백건교 (서울의대)         종정식 (연세의대)           이어         실승결 (충남의대)         전차홍(순천향의대)         조수경 (한양의대)           이어         실승철 (충남의대)         전상활 (안하의대)         종수정 (양화의대)           가장         이지연 (가톨릭의대)         이재준 (성균관의대)         유인실 (충남의대)           위원         이유일 (한양의대)         이재준 (성균관의대)         유인실 (흥남의대)           이사         음일성 (안집의대)         위 문성 (안집의대)         유인실 (한양의대)           이사         응일성 (안집의대)         이재준 (성균관의대)         유인실 (향남의대)           이유원         인증경 (한경의대)         기 전 산 (양식의대)         유인실 (한임·의대)           이사         응물 (안집의대)         양 (한 대의대)         이 전 양 (한 양의대)           인용 (신승철 (한입의대)         양 (한 양의대)         양 (한 양의대) </th <th></th> <th>최성재 (고려의대)</th> <th>한승우 (경북의대)</th> <th></th>		최성재 (고려의대)	한승우 (경북의대)	
간사         조수경 (한양의대)           김성규 (대구가톨릭의대)         길태종 (전남의대)         박민찬 (연세의대)           박진교 (서울의대)         안종균 (연세의대)         안중경 (성균관의대)           이사         성운경 (한양의대)         입두호 (울산의대)         주영빈 (한양의대)           간사         안중경 (성균관의대)         감승기 (가톨릭의대)         국영빈 (한양의대)           감사         안중경 (성균관의대)         객승기 (가톨릭의대)         김기조 (가톨릭의대)           관험식 (서울의대)         객승기 (가톨릭의대)         김지양 (종남의대)         김진현 (종남의대)           감천규 (대구가톨릭의대)         김용길 (울산의대)         김진현 (종남의대)         김진현 (종남의대)           김현아 (아주의대)         박진균 (서울의대)         종직성식 (연세의대)         이이 (종회의대)         조수경 (한양의대)           관험         대대가톨릭의대         김성철 (인하의대)         조수경 (한양의대)         조수경 (한양의대)           이사         심승철 (종남의대)         전찬활 (인하의대)         종신실 (홍남의대)         이 (종 (성용의대))         이 (종 (성용의 (전))         유 (성용)         이 (종 (한명의대))         이 (종 (한명의대))         이 (종 (한명의 (한명의대))         이 (종 (한명의 (한명의 (한명)))         이 (종 (한명의 (한명))         이 (종 (인제 (대)))         이 (종 (한명) (한명)         이 (종 (인제 (대)))         이 (종 (한명) (한명)         이 (종 (한명) (한 (현 (한 (한 (한 (한 (한 (한 () (1 () () () () () () () () () () () () ()		2	한해위원회	
김성규 (대구가톨릭의대)         김태종 (전남의대)         박민찬 (연세의대)           박진교 (서울의대)         안종균 (연세의대)         안중경 (성균관의대)           이승근 (부산의대)         입두호 (홍산의대)         주영빈 (한양의대)           이사         성운경 (한양의대)         ····································	이사	이영호 (고려의대)		
위원         박진교 (서울의대)         안종균 (연세의대)         안중경 (성교관의대)           이슈         성운경 (한양의대)         김두호 (울산의대)         주영빈 (한양의대)           간사         안중경 (성교관의대)         ************************************	간사	조수경 (한양의대)		
이승근 (부산의대)         임두호 (울산의대)         주영빈 (한양의대)           이사         성윤경 (한양의대)         ····································		김성규 (대구가톨릭의대)	김태종 (전남의대)	박민찬 (연세의대)
학술위원회           이사         성윤경 (한양의대)           간사         안중경 (성균관의대)           공현식 (서울의대)         각승기 (가톨릭의대)         김기조 (가톨릭의대)           김성규 (대구가톨릭의대)         김용길 (울산의대)         김진현 (충남의대)           김성규 (대구가톨릭의대)         김용길 (울산의대)         김진현 (충남의대)           김성규 (대구가톨릭의대)         김용길 (울산의대)         중징식 (연세의대)           이아 (경희의대)         박진균 (서울의대)         조수경 (한양의대)           전체         신승철 (충남의대)         조수경 (한양의대)           전사         이지연 (가톨릭의대)         권성렬 (인하의대)         유인설 (충남의대)           이시         신승철 (충남의대)         권성렬 (인하의대)         유인설 (충남의대)           위원         이유연 (가톨릭의대)         권성렬 (인하의대)         유인설 (충남의대)           관승기 (가톨릭의대)         권성렬 (인하의대)         유인설 (충남의대)           위원         이유연 (가톨릭의대)         관성렬 (인하의대)         유인설 (충남의대)           위원         이유명 (신뢰의대)         유인설 (충남의대)         유인설 (충남의대)           이유럽 (인체의대)         우승점 (연희의대)         유증진 (한립의대)         신성수 (울산의대)           인하         원보명 (안권의대)         유증진 (한립의대)         신성수 (울산의대)           인상 (한립의대)         우태명 (강태명 (강태명 대과)         김성수 (울산의대)           인용기         한태 (안감에대)         서 영일 (한립의대)           신청 (안문의 (대)         의 주하 (가톨릭의대) <th>위원</th> <td>박진균 (서울의대)</td> <td>안종균 (연세의대)</td> <td>안중경 (성균관의대)</td>	위원	박진균 (서울의대)	안종균 (연세의대)	안중경 (성균관의대)
이사         성윤경 (한양의대)           간사         안중경 (성균관의대)           공현식 (서울의대)         곽승기 (가톨릭의대)         김기조 (가톨릭의대)           김성규 (대구가톨릭의대)         김용길 (울산의대)         김지현 (총남의대)           김현아 (아주의대)         박진균 (서울의대)         총정식 (연세의대)           이어아 (경희의대)         전찬흥(순천향의대)         조수경 (한양의대)           이어아 (경희의대)         전찬흥(순천향의대)         조수경 (한양의대)           이지연 (가톨릭의대)         전성렬 (인하의대)         유인설 (총남의대)           건사         이지연 (가톨릭의대)         권성렬 (인하의대)         유인설 (총남의대)           위원         이지연 (가톨릭의대)         전성렬 (인하의대)         유인설 (총남의대)           이신         심승철 (총남의 대)         이지연 (가톨릭의대)         지성령 (신의 이대)           위원         이지연 (가톨릭의대)         진성렬 (인하의대)         유인설 (총남의대)           이신         의 응 (기 / 톨릭의대)         이제준 (성교관의대)         중상료 (차의대)           위원         이유현 (신뢰의대)         위원         이유현 (종립 (한양의대)           인형 (서울의 이대)         홍승재 (경희의대)         김성수 (출산의대)           전상 (한림의대)         홍승재 (경희의대)         김성수 (출산의대)           인상 (한림의대)         양태영 (한림의대)         김성수 (출산의대)           인상 (한림의대)         양태영 (한림의대)         김성수 (출산의대)           인상 (한림의대)         양태 (가영 (강태영 (관리)         김성수 (출산의대)           인		이승근 (부산의대)	임두호 (울산의대)	주영빈 (한양의대)
간사         안중경 (성균관의대)           공현식 (서울의대)         곽승기 (가톨릭의대)         김기조 (가톨릭의대)           김성규 (대구가톨릭의대)         김용길 (울산의대)         김진현 (충남의대)           김현아 (아주의대)         박진균 (서울의대)         송정식 (연세의대)           이어야 (경희의대)         전찬홍(순천향의대)         조수경 (한양의대) <b>오이아</b> (경희의대)         전찬홍(순천향의대)         조수경 (한양의대) <b>가지위원회</b>		ė	<b>ነ술위원회</b>	
공현식 (서울의대)         곽승기 (가톨릭의대)         김기조 (가톨릭의대)           김성규 (대구가톨릭의대)         김용길 (울산의대)         김진현 (충남의대)           김현아 (아주의대)         박진균 (서울의대)         송정식 (연세의대)           이연아 (경희의대)         전찬홍(순천향의대)         조수경 (한양의대)           이사         심승철 (충남의대)         조수경 (한양의대)           각자         이지연 (가톨릭의대)         권성렬 (인하의대)         유인실 (충남의대)           인사         이지연 (가톨릭의대)         권성렬 (인하의대)         유인실 (충남의대)           위원         이지연 (가톨릭의대)         권성렬 (인하의대)         유인실 (충남의대)           이은영 (서울의대)         이제준 (성균관의대)         중상윤 (차의대)           위원         이은영 (서울의대)         이제준 (성균관의대)         중상윤 (차의대)           회찬범 (한양의대)         토성명 (외의대)         동         (정상윤 (차의대)           기관 (건국의대)         홍승재 (경희의대)         도         (11)           가방 (한양의대)         우종진 (한림의대)         (11)         (11)           이사         운보영 (인제의대)         홍승재 (경희의대)         (11)         (11)           이사         운보영 (인제의대)         홍승재 (경희의대)         (11)         (11)           이사         운보영 (인제의대)         홍승재 (경희의대)         (11)         (11)           이사         운보영 (인제의대)         양 (한림의대)         (11)         (11)           이사 </th <th>이사</th> <th>성윤경 (한양의대)</th> <th></th> <th></th>	이사	성윤경 (한양의대)		
위원김성규 (대구가톨릭의대)김용길 (울산의대)김진현 (충남의대)김현아 (아주의대)박진균 (서울의대)송정식 (연세의대)이연아 (경희의대)전찬홍(순천향의대)조수경 (한양의대) <b>국제위원회</b> 이사심승철 (충남의대)·································	간사	안중경 (성균관의대)		
위원         김현아 (아주의대)         박진균 (서울의대)         송정식 (연세의대)           이연아 (경희의대)         전찬홍(순천향의대)         조수경 (한양의대) <b>국제위원회</b> 이사         심승철 (충남의대)         도           간사         이지연 (가톨릭의대)         권성렬 (인하의대)         유인설 (충남의대)           위원         이유영 (서울의대)         이재준 (성균관의대)         유인설 (충남의대)           위원         이유영 (서울의대)         이재준 (성균관의대)         중상준 (차의대)           위원         이유영 (서울의대)         이재준 (성균관의대)         정상운 (차의대)           이사         운보영 (인제의대)         홍승재 (경희의대)         도           이사         운보영 (인제의대)         홍승재 (경희의대)         도           이사         운보영 (인제의대)         우종진 (한림의대)         김성수 (울산의대)           인사         김현숙 (순천향의대)         우종진 (한림의대)         김성수 (울산의대)           인용         전승인 (한림의대)         양태영 (강태영내과)         김성수 (울산의대)           위원         진형숙 (현림의대)         아주현 (인제의대)         성명 (한립의대)           신형영옥 (류마앤정내과)         최성재 (고려의대)         이주현 (인제의대)           취정관         지영 (상애병원)         최찬범 (한양의대)		공현식 (서울의대)	곽승기 (가톨릭의대)	김기조 (가톨릭의대)
김현아 (아주의대)         박진균 (서울의대)         송정식 (연세의대)           이연아 (경희의대)         전찬홍(순천향의대)         조수경 (한양의대)           국제위원회             이사         심승철 (충남의대)         조수경 (한양의대)           간사         이지연 (가톨릭의대)         국성철릴 (인하의대)         유인설 (충남의대)           위원         이은영 (서울의대)         이재준 (성균관의대)         유인설 (충남의대)           회찬범 (한양의대)         지상춘 (차의대)         회상윤 (차의대)           보험위원회             이우 (소년 양의대)         이자준 (성균관의대)         정상윤 (차의대)           기관         모등의 (신뢰의대)         위원           이우 (소년 양의대)         우종진 (한림의대)         도           인사         김현숙 (순천향의대)         유종진 (한림의대)         1 성수 (울산의대)           인사         김현숙 (순천향의대)         우종진 (한림의대)         1 성수 (울산의대)           인흥 (조 (한림의대)         강태영 (강태영 대과)         김성수 (울산의대)           인홍기 (건국의대)         박민찬 (연세의대)         서영일 (한림의대)           손일웅 (조 (종 (종 (원)))         이주하 (가톨릭의대)         의 인아 (충북의대)           정영옥 (류마앤정내과)         최성재 (고려의대)         최인아 (충북의대)           최정관 (포항성모병원)         최지영 (상애병원)         최찬범 (한양의대)	0101	김성규 (대구가톨릭의대)	김용길 (울산의대)	김진현 (충남의대)
국제위원회           이사         심승철 (충남의대)           간사         이지연 (가톨릭의대)           관승기 (가톨릭의대)         권성렬 (인하의대)         유인설 (충남의대)           위원         이은영 (서울의대)         이재준 (성균관의대)         정상윤 (차의대)           회찬범 (한양의대)         지준 (성균관의대)         정상윤 (차의대)           회찬범 (한양의대)         도         보험위원회           이사         운보영 (인제의대)         홍승재 (경희의대)           건사         김현숙 (순천향의대)         유종진 (한림의대)           건사         김현숙 (순천향의대)         우종진 (한림의대)           건상훈 (한림의대)         강태영 (강태영내과)         김성수 (울산의대)           민홍기 (건국의대)         박민찬 (연세의대)         서영일 (한림의대)           신영옥 (조은손병원)         이주하 (가톨릭의대)         이주현 (인제의대)           정영옥 (류마앤정내과)         최성재 (고려의대)         최인아 (충북의대)           최정란 (포항성모병원)         최지영 (상애병원)         최찬범 (한양의대)	취권	김현아 (아주의대)	박진균 (서울의대)	송정식 (연세의대)
이사         심승철 (총남의대)           간사         이지연 (가톨릭의대)           곽승기 (가톨릭의대)         권성렬 (인하의대)         유인실 (총남의대)           위원         이은영 (서울의대)         이재준 (성균관의대)         정상윤 (차의대)           최찬범 (한양의대)         도보험위원회         도           이사         윤보영 (인제의대)         홍승재 (경희의대)         도           가         김현숙 (순천향의대)         유종진 (한림의대)         김성수 (울산의대)           가성훈 (한림의대)         강태영 (강태영내과)         김성수 (울산의대)           인흥기 (건국의대)         박민찬 (연세의대)         서영일 (한림의대)           은일응 (조은손병원)         이주하 (가톨릭의대)         의주현 (인제의대)           정영옥 (류마앤정내과)         최성재 (고려의대)         최산범 (한양의대)           최정란 (포항성모병원)         최지영 (성애병원)         최찬범 (한양의대)		이연아 (경희의대)	전찬홍(순천향의대)	조수경 (한양의대)
간사         이지연 (가톨릭의대)           곽승기 (가톨릭의대)         권성렬 (인하의대)         유인실 (충남의대)           이은영 (서울의대)         이재준 (성균관의대)         정상윤 (차의대)           최찬범 (한양의대)         최찬범 (한양의대)         정상윤 (차의대)           보험위원회             이사         윤보영 (인제의대)         홍승재 (경희의대)            간사         김현숙 (순천향의대)         유종진 (한림의대)            감성훈 (한림의대)         강태영 (강태영 내과)         김성수 (울산의대)           민홍기 (건국의대)         박민찬 (연세의대)         서영일 (한림의대)           신영옥 (류마앤정내과)         최성재 (고려의대)         최인아 (충북의대)           최정란 (포항성모병원)         최지영 (성애병원)         최찬범 (한양의대)		=	·제위원회	
곽승기 (가톨릭의대)         권성렬 (인하의대)         유인설 (충남의대)           이은영 (서울의대)         이재준 (성균관의대)         정상윤 (차의대)           최찬범 (한양의대)         보험위원회            이사         윤보영 (인제의대)         홍승재 (경희의대)            간사         김현숙 (순천향의대)         유종진 (한림의대)            강성훈 (한림의대)         우종진 (한림의대)             위원         신영옥 (한립의대)         양태영 (강태영내과)         김성수 (울산의대)           우원         감성후 (한립의대)         이주하 (가톨릭의대)         이주하 (?타용이대)           신영옥 (주은손병원)         이주하 (가톨릭의대)         의주현 (인제의대)           최정란 (포항성모병원)         최지영 (성애병원)         최찬범 (한양의대)	이사	심승철 (충남의대)		
위원         이은영 (서울의대)         이재준 (성균관의대)         정상윤 (차의대)           최찬범 (한양의대) <td< th=""><th>간사</th><th>이지연 (가톨릭의대)</th><th></th><th></th></td<>	간사	이지연 (가톨릭의대)		
최찬범 (한양의대)         보험위원회         이사       윤보영 (인제의대)       홍승재 (경희의대)         간사       김현숙 (순천향의대)       유종진 (한림의대)         간사       김현숙 (순천향의대)       우종진 (한림의대)         인홍 (한림의대)       강태영 (강태영내과)       김성수 (울산의대)         민홍기 (건국의대)       박민찬 (연세의대)       서영일 (한림의대)         위원       전영옥 (류마앤정내과)       최성재 (고려의대)       최인아 (충북의대)         최정란 (포항성모병원)       최지영 (성애병원)       최찬범 (한양의대)		곽승기 (가톨릭의대)	권성렬 (인하의대)	유인설 (충남의대)
보험위원회           이사         윤보영 (인제의대)         홍승재 (경희의대)           간사         김현숙 (순천향의대)         유종진 (한림의대)           강성훈 (한림의대)         강태영 (강태영내과)         김성수 (울산의대)           민홍기 (건국의대)         박민찬 (연세의대)         서영일 (한림의대)           위원         전영옥 (류마앤정내과)         최성재 (고려의대)         최인아 (충북의대)           최정란 (포항성모병원)         최지영 (성애병원)         최찬범 (한양의대)	위원	이은영 (서울의대)	이재준 (성균관의대)	정상윤 (차의대)
이사         윤보영 (인제의대)         홍승재 (경희의대)           간사         김현숙 (순천향의대)         유종진 (한림의대)           시상훈 (한림의대)         강태영 (강태영내과)         김성수 (울산의대)           민홍기 (건국의대)         박민찬 (연세의대)         서영일 (한림의대)           손일웅 (조은손병원)         이주하 (가톨릭의대)         이주현 (인제의대)           정영옥 (류마앤정내과)         최성재 (고려의대)         최인아 (충북의대)           최정란 (포항성모병원)         최지영 (성애병원)         최찬범 (한양의대)		최찬범 (한양의대)		
간사       김현숙 (순천향의대)       유종진 (한림의대)         강성훈 (한림의대)       강태영 (강태영내과)       김성수 (울산의대)         민홍기 (건국의대)       박민찬 (연세의대)       서영일 (한림의대)         손일웅 (조은손병원)       이주하 (가톨릭의대)       이주현 (인제의대)         정영옥 (류마앤정내과)       최성재 (고려의대)       최인아 (충북의대)         최정란 (포항성모병원)       최지영 (성애병원)       최찬범 (한양의대)		토	험위원회	
간사       김현숙 (순천향의대)       유종진 (한림의대)         강성훈 (한림의대)       강태영 (강태영내과)       김성수 (울산의대)         민홍기 (건국의대)       박민찬 (연세의대)       서영일 (한림의대)         손일웅 (조은손병원)       이주하 (가톨릭의대)       이주현 (인제의대)         정영옥 (류마앤정내과)       최성재 (고려의대)       최인아 (충북의대)         최정란 (포항성모병원)       최지영 (성애병원)       최찬범 (한양의대)	이사	윤보영 (인제의대)	홍승재 (경희의대)	
민홍기 (건국의대)         박민찬 (연세의대)         서영일 (한림의대)           손일웅 (조은손병원)         이주하 (가톨릭의대)         이주현 (인제의대)           정영옥 (류마앤정내과)         최성재 (고려의대)         최인아 (충북의대)           최정란 (포항성모병원)         최지영 (성애병원)         최찬범 (한양의대)	간사	김현숙 (순천향의대)	유종진 (한림의대)	
민홍기 (건국의대)         박민찬 (연세의대)         서영일 (한림의대)           손일웅 (조은손병원)         이주하 (가톨릭의대)         이주현 (인제의대)           정영옥 (류마앤정내과)         최성재 (고려의대)         최인아 (충북의대)           최정란 (포항성모병원)         최지영 (성애병원)         최찬범 (한양의대)		강성훈 (한림의대)		김성수 (울산의대)
위원       손일웅 (조은손병원)       이주하 (가톨릭의대)       이주현 (인제의대)         정영옥 (류마앤정내과)       최성재 (고려의대)       최인아 (충북의대)         최정란 (포항성모병원)       최지영 (성애병원)       최찬범 (한양의대)		민홍기 (건국의대)		서영일 (한림의대)
정영옥 (류마앤정내과)       죄성재 (고려의대)       죄인아 (중북의대)         최정란 (포항성모병원)       최지영 (성애병원)       최찬범 (한양의대)				
최정란 (포항성모병원) 최지영 (성애병원) 최찬범 (한양의대)	위원	정영옥 (류마앤정내과)	최성재 (고려의대)	최인아 (충북의대)
하유정 (서울의대)				
			· · · ·	

# 대한류마티스학회 위원회명단

	**************************************	보위원회	
이사	이명수 (원광의대)		
간사	허진욱 (을지의대)		
	강은하 (서울의대)	구본산 (인제의대)	김상현 (계명의대)
	김윤성 (조선의대)	김현숙 (순천향의대)	김현옥 (경상의대)
위원	박경수 (가톨릭의대)	박동진 (전남의대)	배영덕 (류마내과)
	이승근 (부산의대)	임미진 (인하의대)	정재현 (고려의대)
	채지영 (분당제생병원)		
	교육	수련위원회	
이사	윤종현 (가톨릭의대)		
간사	이주하 (가톨릭의대)	이창훈 (원광의대)	
	김근태 (고신의대)	김상현 (계명의대)	김재훈 (고려의대)
위원	성윤경 (한양의대)	송 란 (경희의대)	엄완식 (한양류마엄완식내과)
취권	이상원 (연세의대)	이윤종 (서울의대)	천윤홍 (경상의대)
	최상태 (중앙의대)		
	ප	구위원회	
이사	신기철 (서울의대)		
간사	한승우 (경북의대)		
	고정희 (가톨릭의대)	구본산 (인제의대)	김진현 (충남의대)
	김태종 (전남의대)	김해림 (건국의대)	김현아 (아주의대)
위원	문수진 (가톨릭의대)	박동진 (전남의대)	오지선 (서울아산병원)
112	이상엽 (동아의대)	이상진 (경북의대)	이재준 (성균관의대)
	이화정 (대구가톨릭의대)	주지현 (가톨릭의대)	최인아 (충북의대)
	하유정 (서울의대)	홍석찬 (울산의대)	
	정	보위원회	
이사	김근태 (고신의대)		
간사	채지영 (분당제생병원)		
	고혁재 (가톨릭의대)	김성수 (울산의대)	문기원 (강원의대)
위원	박성훈 (대구가톨릭의대)	손창남 (계명의대)	이상엽 (동아의대)
비견	이상원 (연세의대)	장성혜 (순천향의대)	정상윤 (차의대)
	정주양 (아주의대)	정종혁 (원광의대)	최윤정 (전북의대)

## 대한류마티스학회 위원회명단

	의료정책위원회					
이사	백한주 (가천의대)					
간사	이은봉 (서울의대)	최병용(서울의료원)				
	강은하 (서울의대)	김건우 (대구파티마병원)	김형진 (성균관의대)			
	문기원 (강원의대)	박은정 (국립의료원)	서미령 (가천의대)			
위원	엄완식 (한양류마엄완식내과)	윤종현 (가톨릭의대)	이광훈 (동국의대)			
	이명수 (원광의대)	이성원 (동아의대)	이승원 (한양류마티스내과)			
	이지수 (이화의대)	홍승재 (경희의대)				
	법제	윤리위원회				
이사	박용범 (연세의대)					
간사	최상태 (중앙의대)					
	박희진 (가톨릭관동의대)	방소영 (한양의대)	이광훈 (동국의대)			
위원	이창훈 (원광의대)	정재현 (고려의대)	정주양 (아주의대)			
	표정윤 (연세의대)					

#### List of Korean College of Rheumatology Executive Directors

	Eun-Mi Koh (Sungkyunkwan Univ. Professor Emeritus)	Key-yong Kim (Univ. of Ulsan)
	Dong Soo Kim (Yonsei Univ.)	Dong-Jip Kim (The Catholic Univ. of Korea)
	Think-You Kim (Hanyang Univ.)	Joong-Gon Kim (Seoul Medical Center)
	Ho-Youn Kim (Ho Youn Kim's Clinic)	Myung-Sang Moon (Halla General Hosp.)
	Byeong Mun Park (Gwangmyeong Seongae Hosp.)	Sung-Hwan Park (The Catholic Univ. of Korea)
Advisory Board	Won Park (Inha Univ.)	Gwan Gyu Song (Korea Univ.)
Auvisory Board	Yeong-Wook Song (Song Rheumatology Clinic)	Dae Hyun Yoo (Hanyang Univ.)
	Myung-Chul Yoo (Kyung Hee Univ.)	Bin Yoo (Univ. of Ulsan)
	Soo-Kon Lee (CHA Univ.)	Yun-Woo Lee (Withus Medical Clinic)
	Choong-Ki Lee (Yeungnam Univ.)	Duke Whan Chung (Kyung Hee Univ.)
	Young Kil Choi (Kangnam CHA Hosp.)	II-Yong Choi (Hanyang Univ.)
	Jung-Yoon Choe (Daegu Catholic Univ.)	
President	Sang-Heon Lee (Konkuk Univ.)	
Chairman of the Board	Tae-Hwan Kim (Hanyang Univ.)	
Director of Planning	Jung Soo Song (Chung-Ang Univ.)	Shin-Seok Lee (Chonnam Nat'l Univ.)
Executive Secretary	Chang Keun Lee (Univ. of Ulsan)	
Director of Finance	Wan-Uk Kim (The Catholic Univ. of Korea)	
Director of Editorial Board	Young Ho Lee (Korea Univ.)	
Director of Academic Affairs	Yoon-Kyoung Sung (Hanyang Univ.)	
Director of International Cooperation	Seung-Cheol Shim (Chungnam Nat'l Univ.)	
Director of Insurance	Bo Young Yoon (Inje Univ.)	Seung-Jae Hong (Kyung Hee Univ.)
Director of Public Relation	Myeung Su Lee (Wonkwang Univ.)	
Director of Education & Training	Chong-Hyeon Yoon (The Catholic Univ. of Korea)	
Director of Research	Kichul Shin (Seoul Nat'l Univ.)	
Director of Medical Information	Geun-Tae Kim (Kosin Univ.)	
Director of Health Policy Affairs	Han Joo Baek (Gachon Univ.)	
Director of Legislation & Ethics	Young-Beom Park (Yonsei Univ.)	

	Hyun Sik Gong (Seoul Nat'l Univ.)	Hyun Ah Kim (Hallym Univ.)
Director at Large	Wan Sik Uhm (Uhm's Hanyang Rheumatism Clinic)	Sang-II Lee (Gyeongsang Nat'l Univ.)
	Eun Bong Lee (Seoul Nat'l Univ.)	Hoon-Suk Cha (Sungkyunkwan Univ.)
	Tae Young Kang (Kang Tae Young Internal Medicine Clinic)	Gun Woo Kim (Daegu Fatima Hosp.)
	Seong-Kyu Kim (Daegu Catholic Univ.)	Sung Soo Kim (Univ. of Ulsan)
	Seong-Ho Kim (Inje Univ.)	Jong-Min Kim (Univ. of Ulsan)
Board Members	Jinseok Kim (Jeju Nat'l Univ.)	Hae-Rim Kim (Konkuk Univ.)
	Eon Jeong Nam (Kyungpook Nat'l Univ.)	Chang-Hee Suh (Ajou Univ.)
	Jong Gyun Ahn(Yonsei Univ.)	Kyu Hoon Lee (Hanyang Univ.)
	Seung-Jae Lim (Sungkyunkwan Univ.)	Ji Hyeon Ju (The Catholic Univ. of Korea)
Auditor	Sung Won Lee (Dong-A Univ.)	Young-II Seo (Hallym Univ.)

#### List of Korean College of Rheumatology Committee Members

	Executive Secretary Committee	2 <b>e</b>
Director	Chang Keun Lee (Univ. of Ulsan)	
	So-Young Bang (Hanyang Univ.)	Jin-Wuk Hur (Eulji Univ.)
Member	Jae Hoon Kim (Korea Univ.)	Ji Seon Oh (Asan Medical Center)
	Ran Song (Kyung Hee Univ.)	
	Finance Committee	
Director	Wan-Uk Kim (The Catholic Univ. of Korea)	
_	Hae-Rim Kim (Konkuk Univ.)	Young-Il Seo (Hallym Univ.)
Member	Yun-Hong Cheon (Gyeongsang Nat'l Univ)	Sung Jae Choi (Korea Univ.)
	Seungwoo Han (Kyungpook Nat'l Univ.)	
	Publication Committee	
Director	Young-Ho Lee (Korea Univ.)	
Executive Secretary	Soo-Kyung Cho (Hanyang Univ.)	
_	Seong-Kyu Kim (Daegu Catholic Univ.)	Tae-Jong Kim (Chonnam Nat'l Univ.)
_	Min-Chan Park (Yonsei Univ.)	Jin Kyun Park (Seoul Nat'l Univ.)
Member	Jong Gyun Ahn (Yonsei Univ.)	Joong Kyong Ahn (Sungkyunkwan Univ.)
	Seung-Geun Lee (Pusan Nat'l Univ.)	Doo-Ho Lim (Univ. of Ulsan)
	Young Bin Joo (Hanyang Univ.)	
	Academic Affairs Committee	9
Director	Yoon-Kyoung Sung (Hanyang Univ.)	
Executive Secretary	Joong Kyong Ahn (Sungkyunkwan Univ.)	
	Hyun Sik Gong (Seoul Nat'l Univ.)	Seung-Ki Kwok (The Catholic Univ.of Korea
	Ki-Jo Kim (The Catholic Univ. of Korea)	Seong-Kyu Kim (Daegu Catholic Univ.)
-	Yong-Gil Kim (Univ. of Ulsan)	Jinhyun Kim (Chungnam Nat'l Univ.)
Member	Hyoun-Ah Kim (Ajou Univ.)	Jin Kyun Park (Seoul Nat'l Univ.)
	Jungsik Song (Yonsei Univ.)	Yeon-Ah Lee (Kyung Hee Univ.)
	Chan Hong Jeon (Soonchunhyang Univ.)	Soo-Kyung Cho (Hanyang Univ.)
	Internatioanl Cooperation Comm	ittee
Director	Seung-Cheol Shim (Chungnam Nat'l Univ.)	
Executive Secretary	Ji Yeon Lee (The Catholic Univ. of Korea)	
	Seung-Ki Kwok (The Catholic Univ. of Korea)	Seong-Ryul Kwon (Inha Univ.)
-	Inseol Yoo (Chungnam Nat'l Univ.)	Eun Young Lee (Seoul Nat'l Univ.)
Member	Jaejoon Lee (Sungkyunkwan Univ.)	Sang Youn Jung (CHA Univ.)
	Chan-Bum Choi (Hanyang Univ.)	

National Health Insurance Committee			
Director	Bo Young Yoon (Inje Univ.)	Seung-Jae Hong (Kyung Hee Univ.)	
Executive Secretary	Hyun-Sook Kim (Soonchunhyang Univ.)	Jong Jin Yoo (Hallym Univ.)	
	Seonghun Kang (Hallym Univ.)	Tae Young Kang (Kang Tae Young Internal Medicine Clinic	
_	Sung Soo Kim (Univ. of Ulsan)	Hong Ki Min (Konkuk Univ.)	
	Min-Chan Park (Yonsei Univ.)	Young-Il Seo (Hallym Univ.)	
Member	ll Woong Sohn (Joeunson Clinic)	Jennifer Jooha Lee (The Catholic Univ. of Korea	
	Joo-Hyun Lee (Inje Univ.)	Young-Ok Jung (Jung's Rheumatism Clinic)	
	Sung Jae Choi (Korea Univ.)	In Ah Choi (Chungbuk Nat'l Univ.)	
	Jung Ran Choi (Pohang St. Mary's Hosp.)	Ji-Young Choi (Sungae Hosp.)	
	Chan-Bum Choi (Hanyang Univ.)	You Jung Ha (Seoul Nat'l Univ.)	
	Publicity Committee		
Director	Myeung Su Lee (Wonkwang Univ.)		
Executive Secretary	Jin-Wuk Hur (Eulji Univ.)		
	Eun Ha Kang (Seoul Nat'l Univ.)	Bon San Koo (Inje Univ.)	
_	Sang-Hyon Kim (Keimyung Univ.)	Yun Sung Kim (Chosun Univ.)	
	Hyun-Sook Kim (Soonchunhyang Univ.)	Hyun-Ok Kim (Gyeongsang Nat'l Univ.)	
Member	Kyung-Su Park (The Catholic Univ. of Korea)	Dong-Jin Park (Chonnam Nat'l Univ.)	
_	Young Deok Bae (Rheuma Medical Clinic)	Seung-Geun Lee (Pusan Nat'l Univ.)	
	Mie Jin Lim (Inha Univ.)	Jae Hyun Jung (Korea Univ.)	
	Ji-Young Chai (Bundang Jasang General Hosp.)		
	Education and Training Committ	ee	
Director	Chong-Hyeon Yoon (The Catholic Univ. of Korea)		
Executive Secretary	Jennifer Jooha Lee (The Catholic Univ. of Korea)	Chang Hoon Lee (Wonkwang Univ.)	
	Geun-Tae Kim (Kosin Univ.)	Sang-Hyon Kim (Keimyung Univ.)	
	Jae Hoon Kim (Korea Univ.)	Yoon-Kyoung Sung (Hanyang Univ.)	
Member	Song Ran (Kyung Hee Univ.)	Wan Sik Uhm (Uhm's Hanyang Rheumatism Clinic	
_	Sang-Won Lee (Yonsei Univ.)	Yun Jong Lee (Seoul Nat'l Univ.)	
	Yun-Hong Cheon (Gyeongsang Nat'l Univ.)	Sang Tae Choi (Chung-Ang Univ.)	

#### List of Korean College of Rheumatology Committee Members

	Research Committee	
Director	Kichul Shin (Seoul Nat'l Univ.)	
Executive Secretary	Seungwoo Han (Kyungpook Nat'l Univ.)	
	Jung-Hee Koh (The Catholic Univ. of Korea)	Bon San Koo (Inje Univ.)
	Jinhyun Kim (Chungnam Nat'l Univ.)	Tae-Jong Kim (Chonnam Nat'l Univ.)
	Hae-Rim Kim (Konkuk Univ.)	Hyoun-Ah Kim (Ajou Univ.)
	Su-Jin Moon (The Catholic Univ. of Korea)	Dong-Jin Park (Chonnam Nat'l Univ.)
Member	Ji Seon Oh (Asan Medical Center)	Sang Yeob Lee (Dong-A Univ.)
_	Sang Jin Lee (Kyungpook Nat'l Univ.)	Jaejoon Lee (Sungkyunkwan Univ.)
_	Hwajeong Lee (Daegu Catholic Univ.)	Ji Hyeon Ju (The Catholic Univ. of Korea)
_	In Ah Choi (Chungbuk Nat'l Univ.)	You-Jung Ha (Seoul Nat'l Univ.)
	Seokchan Hong (Univ. of Ulsan)	
	Intelligence Committee	
Director	Geun-Tae Kim (Kosin Univ.)	
Executive Secretary	Ji-Young Chai (Bundang Jasang General Hosp.)	
	Hyeok-Jae Ko (The Catholic Univ. of Korea)	Sung Soo Kim (Univ. of Ulsan)
_	Kiwon Moon (Kangwon Nat'l Univ.)	Sung-Hoon Park (Daegu Catholic Univ.)
Member -	Changnam Son (Keimyung Univ.)	Sang Yeob Lee (Dong-A Univ.)
Member	Sang-Won Lee (Yonsei Univ.)	Sung Hae Chang (Soonchunhyang Univ.)
	Sang-Youn Jung (CHA Univ.)	Ju-Yang Jung (Ajou Univ.)
	Chong Hyuk Chung (Wonkwang Univ.)	Yunjung Choi (Chonbuk Nat'l Univ.)
	Health Policy Committee	
Director	Han Joo Baek (Gachon Univ.)	
Executive Secretary	Eun Bong Lee (Seoul Nat'l Univ.)	Byoongyong Choi (Seoul Medical Center)
	Eun Ha Kang (Seoul Nat'l Univ.)	Gun Woo Kim (Daegu Fatima Hosp.)
_	Hyungjin Kim (Sungkyunkwan Univ.)	Kiwon Moon (Kangwon Naťl Univ.)
	Eun-Jung Park (Nat'l Medical Center)	Mi Ryoung Seo (Gachon Univ.)
Member	Wan Sik Uhm (Uhm's Hanyang Rheumatism Clinic)	Chong-Hyeon Yoon (The Catholic Univ. of Kore
	Kwanghoon Lee (Dongguk Univ.)	MyeungSu Lee (Wonkwang Univ.)
	Sung Won Lee (Dong-A Univ.)	Seung-Won Lee (Hanyang Clinic)
	Jisoo Lee (Ewha Womans Univ.)	Seung-Jae Hong (Kyung Hee Univ.)

	Legislation and Ethics Comr	nittee
Director	Yong-Beom Park (Yonsei Univ.)	
Executive Secretary Sang Tae Choi (Chung-Ang Univ.)		
	Heejin Park (Catholic Kwandong Univ.)	So-Young Bang (Hanyang Univ.)
Manshar	Kwanghoon Lee (Dongguk Univ.)	Chang Hoon Lee (Wonkwang Univ.)
Member	Jae Hyun Jung (Korea Univ.)	Ju-Yang Jung (Ajou Univ.)
_	Jung Yoon Pyo (Yonsei Univ.)	

#### Program at a Glance

#### Day 1: May 19(Thu), 2022

Time	Room A (Grand Ballroom Hanra A & B, 3F)	Room B (Grand Ballroom Baekdu A & B, 5F)	<b>Room C</b> (Grand Ballroom Hanra C, 3F)	<b>Room D</b> (Shilla Room, 3F)	
09:00 - 10:00	Registration		Musculoskeletal		
10:00 - 12:00	Year in Review (Clinical)	Year in Review (Basic)		US Workshop I Advanced Course	
	Luncheon Symposium I	Luncheon Symposium II	Luncheon Symposium III		
12:00 - 13:00	<b>E</b> Pfizer Korea	<b>C</b> • ACTEMRA° tocilizumab	abbvie		
13:00 - 13:10		Opening Remark &	Welcome Address		
13:10 - 14:00	Presidential Plenary Session				
		-			
14:00 - 16:00	International Free Paper Session (Clinical)	Basic Research Workshop for Rheumatologist Animal Models of Key Arthropathies		Musculoskeletal US Workshop II Basic Course	
16:00 - 16:30	Coffee Break				
16:30 - 18:30	International Free Paper Session (Basic)	Clinical Research Workshop for Rheumatologist Planning and Conducting Clini- cal Research	Editorial Committee Workshop		

#### Day 2: May 20(Fri), 2022

Time	Room A (Grand Ballroom Hanra A & B, 3F)	<b>Room B</b> (Grand Ballroom Baekdu A & B, 5F)	<b>Room C</b> (Grand Ballroom Hanra C, 3F)	
	Breakfast Symposium I	Breakfast Symposium II	Breakfast Symposium III	
08:00 - 09:00	abbvie	CELLTRION PHARM CELLTRION	<b>C</b> Pfizer	
09:00 - 10:00	Keynote Lecture			
10:00 - 10:30		Coffee Break		
10:30 - 12:00	International Symposium Recent Advances in Pathogenesis of Systemic Lupus Erythematosus	Free Paper Session Epidemiology & Health Services Research	<b>Free Paper Session</b> Sjögren's Syndrome, Systemic Sclerosis, and Inflammatory Myositis	
	Luncheon Symposium IV	Luncheon Symposium V	Luncheon Symposium VI	
12:00 - 13:00	Lilly	ر ^{ال} ا Bristol Myers Squibb	<b>YUHAN</b> SAMSUNG BIOEPIS	
13:00 - 14:30	International Symposium 2022 Clinical Research Update of Sjögren's Syndrome	KCR-KAI Joint Symposium	Free Paper Session Osteoarthritis and Orthopedics	
14:30 - 15:30	Poster Viewing a	and Coffee Break		
15:30 - 17:00	International Symposium Vasculitis Session	Free Paper Session Rheumatoid Arthritis Clinical Research	<b>Medical Humanities</b> Work Ethics and Labor Relation in the COVID-19 Era	
17:00 - 17:30	Academic Awards			
17:30 - 18:00	General Assembly			
	1			

#### Program at a Glance

#### Day 3: May 21(Sat), 2022

Time	<b>Room A</b> (Grand Ballroom Hanra A & B, 3F)	<b>Room B</b> (Grand Ballroom Baekdu A & B, 5F)	<b>Room C</b> (Grand Ballroom Hanra C, 3F)
08:00 - 09:00	Breakfast Symposium IV	Breakfast Symposium V <i>Lilly</i>	Breakfast Symposium VI Janssen Jehmen-Gehmen
09:00 - 10:00	Keynote Lecture		
10:00 - 10:30		Coffee Break	
10:30 - 12:00	International Symposium Treatment of Osteoarthritis: To be Used and Abused?	Free Paper Session Spondyloarthritis	Free Paper Session Systemic Lupus Erythematosus
	Luncheon Symposium VII	Luncheon Symposium VIII	Luncheon Symposium IX
12:00 - 13:00	<b>U</b> NOVARTIS	<b>AMGEN</b> °	astellas
13:00 - 14:30	International Symposium Synovial Macrophage and Fibroblast in RA KCR-KSBMR Joint Symposium Vasculitis and Metabolic Bone Dis		Free Paper Session Vasculitis and Metabolic Bone Disease
14:30 - 15:30	Poster Viewing and Coffee Break		
15:30 - 17:00	International Symposium New Horizon of Systemic Sclerosis	Free Paper Session Rheumatoid Arthritis Basic Research	Coding and Insurance Guideline in Rheumatic Disease
17:00 - 17:30	Presentation Awards Session		
17:30 - 18:00		Closing Remark	

10:00 - 12:00	[Symposium] Year in Review (Clinical)	Room A Korean
Chairs	Won Park (Inha Univ., Korea) Sung Soo Kim (Univ. of Ulsan, Korea)	
10:00 - 10:30	Clinical update of systemic lupus erythematosus Seung-Ki Kwok (The Catholic Univ. of Korea, Korea)	
10:30 - 11:00	<b>Idiopathic inflammatory myositis</b> Jinhyun Kim ( <i>Chungnam Nat'l Univ., Korea</i> )	
11:00 - 11:30	<b>Update of IgG4 related disease</b> Yong Gil Kim ( <i>Univ. of Ulsan, Korea</i> )	
11:30 - 12:00	<b>Behçet's disease</b> Sang-Won Lee ( <i>Yonsei Univ., Korea</i> )	
10:00 - 12:00	[Symposium] Year in Review (Basic)	Room B Korean
Chairs	Sung-Hwan Park (The Catholic Univ. of Korea, Korea) Sang-Hyon Kim (Keimyung Univ., Korea)	
10:00 - 10:30	Emerging concepts of endotypes/phenotypes in osteoarthritis	

	Gunil Im (Dongguk Univ., Korea)	
10:30 - 11:00	Gout: Basic science of gout Seokchan Hong (Univ. of Ulsan, Korea)	
11:00 - 11:30	<b>SpA: Insight into the pathogenesis of SpA</b> Tae-Jong Kim ( <i>Chonnam Nat'l Univ., Korea</i> )	
11:30 - 12:00	Update in the pathogenesis of Sjögren's syndrome Jennifer Jooha Lee (The Catholic Univ. of Korea, Korea)	

09:00 - 12:00	[Workshop] Musculoskeletal US Workshop I -Advanced Course	<b>Room D</b> Korean
Chair	Chong-Hyeon Yoon (The Catholic Univ. of Korea, Korea)	

#### Session 1 : Practical Applications of Musculoskeletal Ultrasound in Rheumatology Clinic

09:00 - 09:30	How to use ultrasonic equipment settings Hyun Ok Kim (Gyeongsang Nat'l Univ., Korea)
09:30 - 10:00	Ultrasonographic perspectives in giant cell arteritis, polymyalgia rheumatica and Sjögren's syndrome Hyun-Sook Kim (Soonchunhyang Univ., Korea)
10:00 - 10:30	Assessment of rheumatoid arthritis disease activity with ultrasound Ran Song (Kyung Hee Univ., Korea)

Chair

Hye-Soon Lee (Hanyang Univ., Korea)

#### Session 2 : Ultrasound-guided Injection

10:30 - 11:00	<b>Ultrasound-guided intra-articular injection</b> Hyoun-Ah Kim ( <i>Ajou Univ., Korea</i> )
11:00 - 11:30	Ultrasound-guided extra-articular injection Chang Hoon Lee (Wonkwang Univ., Korea)
11:30 - 12:00	The tips and considerations for ultrasound-guided injection Jae Hoon Kim (Korea Univ., Korea)

12:00 - 13:00	[Luncheon Symposium I – Pfizer] Recent Update of Advanced RA Treatment Korean
Chair	Sung-Hwan Park (The Catholic Univ. of Korea, Korea)
12:00 - 12:40	<b>The role of tofacitinib as a JAK pioneer</b> Hyoun-Ah Kim ( <i>Ajou Univ., Korea</i> )

12:00 - 13:00		<b>Room B</b> Korean
Chair	Chang Keun Lee (Univ. of Ulsan, Korea)	
12:00 - 12:40	<b>Evolution of tocilizumab: From rheumatoid arthritis to CAR T cell therapy and COVID-19</b> Seung-Ki Kwok ( <i>The Catholic Univ. of Korea, Korea</i> )	

12:00 - 13:00	[Luncheon Symposium III – AbbVie] Strategies to Solve the Problem of Ankylosing Spondylitis with AbbVie's Assets	<b>Room C</b> Korean
Chair	Sung Won Lee (Dong-A Univ., Korea)	
12:00 - 12:40	The present and future of ankylosing spondylitis treatments Tae-Jong Kim (Chonnam Nat'l Univ., Korea)	

13:10 - 14:00	[Special Lecture] Presidential Plenary Session	Room A, B, C Korean
Chairs	Tae-Hwan Kim (Hanyang Univ., Korea) Sang-Heon Lee (Konkuk Univ., Korea)	
13:10 - 13:35	Changing role of rheumatologist in Korea Sang-Heon Lee (Konkuk Univ., Korea)	
13:35 - 14:00	Past, present and future of rheumatology in Korea Yeong-Wook Song (Song Rheumatology Clinic., Korea)	

14:00 - 16:00	[Free Paper Session] International Free Paper Session (Clinical)	Room A English
Chairs	Dae Hyun Yoo (Hanyang Univ., Korea) Chan Hong Jeon (Soonchunhyang Univ., Korea)	
IO-01	Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with JAK inhibitors : A nationwide population-based study Yeo-Jin Song (Hanyang Univ., Korea)	
10-02	Increased thromboembolic risk of JAK inhibitors after switching from biologic DMARDs in patients with rheumatoid arthritis Yeonghee Eun (Sungkyunkwan Univ., Korea)	
IO-03	Gut microbiome in patients with established rheumatoid arthritis: Factors associated with the composition, and its value of predicting treatment response Jung Hee Koh (The Catholic Univ. of Korea, Korea)	
10-04	Time-averaged DAS28 and HAQ predict cardiovascular disease in patients with rheumat Data from KORONA registry Hong Ki Min (Konkuk Univ., Korea)	toid arthritis:
IO-05	Increased cardiovascular risk in patients with systemic lupus erythematosus: population Cohort Study in Korea Jungyong Han (Hanyang Univ., Korea)	-based
IO-06	Long-term exposure to PM10 and systemic-lupus-erythematosus-related mortality in the Kore Ji-Hyoun Kang (Chonnam Nat'l Univ., Korea)	an population
IO-07	Neutralizing antibody formation after COVID-19 vaccination in elderly patients with rheuma Eunsong Kang (Asan Medical Center, Korea)	atoid arthritis
IO-08	Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus Ho So (The Chinese Univ. of Hong Kong, Hong Kong)	
IO-09	Clinical characteristics and prognosis of patients with anti-melanoma differentiation-rela gene 5 (MDA5) related diseases Chen Yu (Peking Union Medical College Hosp., China)	ited
IO-10	Three-dimensional analysis of the trapezium subchondral bone and its association with trapeziometacarpal joint osteoarthritis Ji Sup Hwang (Seoul Nat'l Univ., Korea)	

14:00 - 16:00	[Workshop] Basic Research Workshop for Rheumatologist: Animal Models of Key Arthropathies	<b>Room B</b> Korean
Chairs	Young Mo Kang (Kyungpook Nat'l Univ., Korea) Jun-Ki Min (The Catholic Univ. of Korea, Korea)	
14:00 - 14:30	<b>Animal models of osteoarthritis (OA)</b> Je-Hwang Ryu (Chonnam Nat'l Univ., Korea)	
14:30 - 15:00	Experimental procedures of mouse OA research Gyuseok Lee (Chonnam Nat'l Univ., Korea)	
15:00 - 15:30	Animal models of rheumatoid arthritis Seung-Ah Yoo (The Catholic Univ. of Korea, Korea)	
15:30 - 16:00	Experimental procedures of mouse arthritis models Saseong Lee (The Catholic Univ. of Korea, Korea)	

13:30 - 16:30	[Workshop] Musculoskeletal US Workshop II -Basic Course	Room D Korean
Chair	Hae-Rim Kim (Konkuk Univ., Korea)	

#### Session 1: Introduction to Musculoskeletal Ultrasound in Rheumatology

13:30 - 14:00	<b>Musculoskeletal ultrasound in rheumatology – Upper extremities</b> Jae Hyun Jung ( <i>Korea Univ., Korea</i> )
14:00 - 14:30	<b>Musculoskeletal ultrasound in rheumatology – Lower extremities</b> Ju-Yang Jung ( <i>Ajou Univ., Korea</i> )
14:30 - 15:30	Workshop – Upper extremities Tutors Wrist & elbow : Yun Sung Kim (Chosun Univ. Hosp., Korea), Jin Su Park (NHIS Ilsan Hosp., Korea) Shoulder : Young Bin Joo (Hanyang Univ., Korea), Yune-Jung Park (The Catholic Univ. of Korea, Korea)
15:30 - 16:30	Workshop – Lower extremities Tutors Knee : Min Kyung Chung (Ewha Womans Univ., Korea), Jinhee Lee (The Catholic Univ. of Korea, Korea) Ankle & Foot : In Ah Choi (Chungbuk Nat'l Univ., Korea), Young Sun Suh (Gyeongsang Nat'l Univ., Korea)

16:30 - 18:30	[Free Paper Session] International Free Paper Session (Basic)
Chairs	Yeong-Wook Song (Song Rheumatology Clinic., Korea) Jason Jungsik Song (Yonsei Univ., Korea)
IO-11	Identification of a key regulator of MYH9 for synoviocyte migration and invasion through secretome profiling Saseong Lee (The Catholic Univ. of Korea, Korea)
10-12	Multi-omics identifies S100 proteins as biomarkers of RA progression which can be regulated by epigenetic drugs Marzena Ciechomska (Nat'l Institute of Geriatrics, Poland)
IO-13	<b>Dysfunction of parkin increases osteoclast activity linking to bone erosion of inflammatory arthri</b> Ji-Eun Kim (Univ. of Ulsan, Korea)
IO-14	Cell-specific activation of PADI4 promoter in human fibroblast-like synoviocytes from patients with rheumatoid arthritis Khrystyna Malysheva (S. Gzhytskyi Nat'l Univ. of Veterinary Medicine and Biotechnologies, Ukraine)
IO-15	Effect of disease-modifying anti-rheumatic drugs on lung microenvironment of SKG mice Sung Hae Chang (Soonchunhyang Univ., Korea)
IO-16	Peptoniphilus gorbachii ameliorates collagen-Induced arthritis in mice by improving intestinal homeostasis and immune regulation Young Sun Suh (Gyeongsang Nat'l Univ., Korea)
IO-17	The immune mechanism of Janus kinase inhibitors on Shingles in rheumatoid arthritis patients Hong Ki Min (Konkuk Univ., Korea)
IO-18	Identification of the HLA-B*51:01 immunopeptidome in Behçet's disease Ye-Ji Lee (Seoul Nat'l Univ., Korea)
IO-19	Inhibition of NADPH oxidases prevent the development of osteoarthritis Jin Han (Kyungpook Nat'l Univ., Korea)

16:30 - 18:30	[Workshop] Clinical Research Workshop for Rheumatologists: Planning and Conducting Clinical Research	<b>Room B</b> Korean
Chairs	Gwan Gyu Song (Korea Univ., Korea) Kichul Shin (Seoul Nat'l Univ., Korea)	
16:30 - 17:00	Setting up a prospective cohort Sang-Cheol Bae (Hanyang Univ., Korea)	
17:00 - 17:30	Conducting a retrospective clinical study using Korea National Health Insurance data Hyun Jung Kim (Korea Univ., Korea)	
17:30 - 18:00	How to start IITs from scratch Howard Lee (Seoul Nat'l Univ., Korea)	
18:00 - 18:30	e-CRF tools for Investigator Initiated Trial Soo-Hwan Kim (Dt&CRO, Korea)	

16:30 - 18:30		<b>oom C</b> Korean
Chairs	Young Ho Lee (Korea Univ., Korea) Seong-Kyu Kim (Daegu Catholic Univ., Korea)	
16:30 - 17:00	Suggestions to be indexed in SCIE and get high impact factor Hyun Jun Park (Pusan Nat'l Univ., Korea)	
17:00 - 17:30	Successful submission strategy on SCI journal Hwichool Kim (Editage, Korea)	
17:30 - 18:00	<b>Biostatistics for clinical researchers</b> Hyonggin An <i>(Korea Univ., Korea)</i>	
18:00 - 18:30	New PubMed: Searching tips & more! Sung Ae Park (Korea Univ. Medical Library, Korea)	

### Day 2. May 20(Fri)



The Session with the icon provides English-Korean translation 통역 아이콘이 표시된 세션은 한-영 동시통역을 제공합니다.

08:00 - 09:00	[Breakfast Symposium I – AbbVie] Strategies to Solve the Problem of Rheumatoid Arthritis with AbbVie's Assets	<b>Room A</b> Korean
Chair	Seung-Jae Hong (Kyung Hee Univ., Korea)	
08:00 - 08:40	Management of rheumatoid arthritis considering safety Ki-Jo Kim (The Catholic Univ. of Korea, Korea)	

08:00 - 09:00	[Breakfast Symposium II – Celltrion] Real-world Switching Case of CT-P17	<b>Room B</b> English
Chair	Shin-Seok Lee (Chonnam Nat'l Univ., Korea)	
08:00 - 08:40	<b>Clinical data and real-world switching case of CT-P17</b> Hubert Marotte (Centre Hospitalier Universitaire(CHU) de Saint-Étienne, France)	

08:00 - 09:00	[Breakfast Symposium III – Pfizer] Real-World Perspectives of Ankylosing Spondylitis Management	Room C Korean
Chair	Eun Young Lee (Seoul Nat'l Univ., Korea)	
08:00 - 08:40	Insights from real-world: Practical approach to anti TNF therapy for AS treatment Jun Won Park (Seoul Nat'l Univ., Korea)	

09:00 - 10:00	[Keynote Lecture] Keynote Lecture	<b>Room A, B, C</b> English
Chair	Tae-Hwan Kim (Hanyang Univ., Korea)	
09:00 - 10:00	<b>Current threats to the specialty of rheumatology in the US and internationally: A call to action</b> Kenneth Saag ( <i>The Univ. of Alabama at Birmingham, USA</i> )	

#### JOURNAL OF RHEUMATIC DISEASES

#### Day 2. May 20(Fri)

10:30 - 12:00	[International Symposium] Recent Advances in Pathogenesis of Systemic Lupus Erythematosus	
Chairs	Sang-Cheol Bae (Hanyang Univ., Korea) Seung-Cheol Shim (Chungnam Nat'l Univ., Korea)	
10:30 - 11:00	New concepts on the pathogenesis of lupus nephritis George Tsokos (Harvard Medical School, Beth Israel Deaconess Medical Center, USA)	
11:00 - 11:30	New insights into the role of antinuclear antibodies in systemic lupus erythematosus Peter E. Lipsky (AMPEL BioSolutions, USA)	
11:30 - 12:00	<b>ETV5 promotes Tfh cell differentiation and the pathogenesis of systemic lupus erythematosus</b> Yoontae Lee ( <i>POSTECH, Korea</i> )	

10:30 - 12:00	[Free Paper Session] Epidemiology & Health Services Research Korean
Chairs	Choong-Ki Lee (Yeungnam Univ., Korea) Jinseok Kim (Jeju Nat'l Univ., Korea)
0-01	Safety and clinical influences of COVID-19 vaccination in patients with autoimmune rheumatic diseases Youngjae Park (The Catholic Univ. of Korea, Korea)
0-02	Autoantibody profiles in patients with COVID-19 infection Hyemin Jeong (Soonchunhyang Univ., Korea)
0-03	Association between cardiovascular outcome and rheumatoid arthritis : nationwide population- based cohort study Seonyoung Kang (Sungkyunkwan Univ., Korea)
0-04	Increased risk of malignancy in patients with Takayasu's arteritis: A population-based cohort study in Korea Seulkee Lee (Sungkyunkwan Univ., Korea)
O-05	Increased risk of herpes zoster in patients with rheumatoid arthritis using tofacitinib compared with tumor necrosis factor inhibitor Yeo-Jin Song (Hanyang Univ., Korea)
0-06	Clinical course and risk factors for development and progression of interstitial lung disease in primary Sjögren's syndrome: a single centered, retrospective, observational study Kyung-Ann Lee (Soonchunhyang Univ., Korea)
0-07	Comparison of prescription drug use patterns during pregnancy and postpartum in Korean women with rheumatic conditions: A national population-based study Jin Su Park (Nat'l Health Insurance Service IIsan Hosp., Korea)
O-08	Multidimensional correlates to chronic pain among patients with musculoskeletal pain in different rheumatic diseases: Based on the Biopsychosocial approach Hyoun-Ah Kim (Ajou Univ., Korea)

10:30 - 12:00	[Free Paper Session] Sjögren's Syndrome, Systemic Sclerosis, and Inflammatory Myositis	
Chairs	Seong Wook Kang (Chungnam Nat'l Univ., Korea) Myeung Su Lee (Wonkwang Univ., Korea)	
O-09	IL-17 and CCR9+α4β7– Th17 cells promote salivary gland inflammation, dysfunction, and cell death in Sjögren's syndrome Jin-Sil Park (The Catholic Univ. of Korea, Korea)	
0-10	Correlations between salivary scintigraphic and histopathologic data of salivary glands in patients with Sjögren's syndrome Ji-Won Kim (Ajou Univ., Korea)	
0-11	Impact of age on the diagnostic performance of unstimulated salivary flow rates and salivary gland ultrasound for primary Sjögren's syndrome Kyung-Ann Lee (Soonchunhyang Univ., Korea)	
0-12	<b>Reduced Rxr-α signaling increases dry eye disease inducing γδ T17 cells in the conjunctiva</b> Jehan Alam ( <i>Baylor College of Medicine, USA</i> )	
0-13	Angiographic characteristics of vasculopathy in patients with idiopathic inflammatory myopathies and systemic sclerosis Jina Yeo (Gachon Univ., Korea)	
0-14	The association of anti-cyclic citrullinated peptide antibody with interstitial lung disease in systemic sclerosis: a retrospective analysis Jangwoo Ha (Yonsei Univ, Korea)	
0-15	<b>Ultrasound may detect subclinical interstitial lung disease in systemic sclerosis</b> MARWIN Gutierrez (Instituto Nacional de Rehabilitacion, Italy)	
0-16	Expressions of CCR2 and CCL2, and association between their expression and NET stimulation in adult-onset Still's disease Ju-Yang Jung (Ajou Univ., Korea)	
0-17	Increased expression of receptor for advanced glycation end-products in sarcopenic patient skeletal musuli Sup Hwang (Seoul Nat'l Univ., Korea)	

12:00 - 13:00	[Luncheon Symposium IV - Lilly] The Role of Baricitinib in the Treatment of RA	<b>Room A</b> Korean
Chair	Yong-Beom Park (Yonsei Univ., Korea)	
12:00 - 12:40	<b>Baricitinib in the real-world data</b> Yun-Hong Cheon ( <i>Gyeongsang Nat'l Univ., Korea</i> )	

#### JOURNAL OF RHEUMATIC DISEASES

#### Day 2. May 20(Fri)

12:00 - 13:00	[Luncheon Symposium V – BMS] Real World Evidences in Long-term RA Treatment with Biologics Korean
Chair	Wan-Uk Kim (The Catholic Univ. of Korea, Korea)
12:00 - 12:20	Real world evidences and considerations for long-term persistence of biologics in RA Sang-Hyon Kim (Keimyung Univ., Korea)
12:20 - 12:40	Real world evidences of RA treatment with biologics in Korea Jennifer Jooha Lee (The Catholic Univ. of Korea, Korea)
12:00 - 13:00	[Luncheon Symposium VI – Yuhan] The New Adalimumab Option in Rheumatic Diseases Treatment English
Chair	Seung-Cheol Shim (Chungnam Nat'l Univ., Korea)
12:00 - 12:40	ADALLOCE [®] (SB5) adalimumab in rheumatic diseases: Data from clinical trials and the real world Carlo Selmi (Humanitas Univ., Italy)
13:00 - 14:30	[International Symposium] 2022 Clinical Research Update of Sjögren's Syndrome English
Chairs	Shin-Seok Lee (Chonnam Nat'l Univ., Korea) Yun Jong Lee (Seoul Nat'l Univ., Korea)
13:00 - 13:30	<b>Big data Sjögren project consortium</b> Manuel Ramos-Casals (Univ. of Barcelona, Spain)
13:30 - 14:00	<b>ESSPRI, a single term with multiple meanings: A consideration based on Korean studies</b> Yun Jong Lee (Seoul Nat'l Univ., Korea)
14:00 - 14:30	Current and future treatment of primary Sjögren's syndrome Xavier Mariette (Hôpitaux Universitaires Paris-Sud Bicêtre, France)
13:00 - 14:30	[Symposium] KCR-KAI Joint Symposium Korean
Chairs	Tae-Hwan Kim (Hanyang Univ., Korea) Wan-Uk Kim (The Catholic Univ. of Korea, Korea)
13:00 - 13:30	Role of bystander T cells in autoimmune diseases Je-Min Choi (Hanyang Univ., Korea)
13:30 - 14:00	Exploration of the key driving molecules in systemic sclerosis-associated interstitial lung disease by the advanced bioinformatic analysis Ki-Jo Kim (The Catholic Univ. of Korea, Korea)
14:00 - 14:30	<b>ZIP8 exacerbates collagen-induced arthritis by increasing pathogenic T cell responses</b> Sung-Gyoo Park (Seoul Nat'l Univ., Korea)

13:00 - 14:30	[Free Paper Session] Osteoarthritis and Orthopedics	<b>Room C</b> English & Korean
Chairs	Sung Won Lee (Dong-A Univ., Korea) Hyun Sik Gong (Seoul Nat'l Univ., Korea)	
0-18	Sodium chloride affects cartilage associated marker expression during in vitro chond from induced pluripotent stem cell Kijun Lee (The Catholic Univ. of Korea, Korea)	rogenesis
0-19	Immunomodulation by mesenchymal stromal cell exosomes in osteoarthritis Kristeen Ye Teo (Nat'l Univ. of Singapore, Singapore)	
0-20	Mitochondrial transplantation ameliorates the development and progression of osteo A Ram Lee (The Catholic Univ. of Korea, Korea)	arthritis
0-21	Soluble CCR2 gene therapy controls joint inflammation, cartilage damage, and the pro of osteoarthritis by targeting MCP-1 in a monosodium iodoacetate (MIA)-induced OA Hyun Sik Na (The Catholic Univ. of Korea, Korea)	•
0-22	The potential role of SIRT1 in osteoarthritis pain treatment by blocking the nerve grow Sang Yeob Lee (Dong-A Univ., Korea)	vth factors
0-23	Coenzyme Q10 encapsulated in micelles ameliorates osteoarthritis by inhibiting inflamment of Korea, Korea)	matory cell deat
0-24	Associations between body composition measurements of obesity and the radiograp progression of hand osteoarthritis: Data from the Dong-gu Study Sung-Eun Choi (Chonnam Nat'l Univ., Korea)	hic
0-25	Association of serum uric acid level with bone mineral density in peri-menopausal and postmenopausal Korean women: A single-center study of 3566 cases Seongmin Kang (Univ. of Ulsan, Korea)	
0-26	The relationship between the osteoporosis and cortial index of the mandibular bone in rhe Gürkan Iden (Dr. Yaşar Eryılmaz Doğubeyazıt Devlet Hastanesi, Turkey)	eumatoid arthriti

15:30 - 17:00	[International Symposium] Vasculitis Session	A.21	<b>Room A</b> English
Chairs	Bin Yoo (Univ. of Ulsan, Korea) Chan-Bum Choi (Hanyang Univ., Korea)		
15:30 - 16:00	Somatic mutations in rheumatologic diseases: VEXAS syndrome and beyo Peter C. Grayson ( <i>Nat'l Institutes of Health, USA</i> )	nd	
16:00 - 16:30	Recent basic studies in ANCA-associated vasculitis Akihiro Ishizu (Hokkaido Univ., Japan)		
16:30 - 17:00	<b>Systemic vasculitis in Korea</b> Chan-Bum Choi ( <i>Hanyang Univ., Korea</i> )		

# Day 2. May 20(Fri)

15:30 - 17:00	[Free Paper Session]	
Chairs	Rheumatoid Arthritis Clinical Research       English & Ko         Jung-Yoon Choe (Daegu Catholic Univ., Korea)       Jung Soo Song (Chung-Ang Univ., Korea)	orean
0-27	Comparative effectiveness of janus kinase inhibitors and biologic disease-modifying antirheur drugs in Korean patients with rheumatoid arthritis; an interim analysis of the real-world study Soo-Kyung Cho (Hanyang Univ., Korea)	matic
0-28	Comparative Effectiveness and Safety profiles of baricitinib and tofacitinib in Rheumatoid arthritic A Real-World, Single Center Study Bong-Woo Lee (The Catholic Univ. of Korea, Korea)	is:
0-29	Comparative efficacy and safety of IL-6/JAK/STAT pathway inhibitors in rheumatoid arthritis: systematic review and network meta-analysis Rudra Goswami (AIIMS, India)	
O-30	Impact of early age at menopause on disease outcomes in postmenopausal women with rheum arthritis: Results from a large observational cohort of Korean patients with rheumatoid arthritis Eun Hye Park (Chung-Ang Univ., Korea)	atoid
0-31	The implication of persistent pain in patients with rheumatoid arthritis albeit in DAS28-remission data from the KOBIO registry Hyoun-Ah Kim (Ajou Univ., Korea)	ו:
0-32	Increased risk of dementia in patients with rheumatoid arthritis: a nationwide population-based cohort s Younghee Eun (Sungkyunkwan Univ., Korea)	study
0-33	Retention rate and safety of biologics or targeted synthetic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis associated with interstitial lung disease: Results from the KOBIO regulatory of the KOBIO regulatory of the transformation of tran	gistry
0-34	Tumor Necrosis Factor (TNF) inhibitors does not accelerate the progression of RA-ILD: results from the KORAIL cohort Sang Wan Chung (Kyung Hee Univ., Korea)	

15:00 - 17:00	[Symposium] Medical Humanities: Work Ethics and Labor Relation in the COVID-19 Era	<b>Room C</b> Korean
Chairs	Yong-Beom Park (Yonsei Univ., Korea) Geun-Tae Kim (Kosin Univ., Korea)	
15:00 - 16:00	The ethics of hospital human resource development during the pandemic: Ethical prin Ilhak Lee (Yonsei Univ., Korea)	nciples
16:00 - 17:00	Labor issues in the COVID-19 situation: Cases and alternatives Dong Wook Yun (Law Firm Seo-Hee, Korea)	

# Day 3. May 21(Sat)



The Session with the icon provides English-Korean translation 통역 아이콘이 표시된 세션은 한-영 동시통역을 제공합니다.

08:00 - 09:00	[Breakfast Symposium IV – Yuhan] Valuable Options for Treatment Rheumatic Disease	<b>Room A</b> Korean
Chair	Jinseok Kim (Jeju Nat'l Univ., Korea)	
08:00 - 08:40	Biosimilar: Past, present and future Seung-Jae Hong (Kyung Hee Univ., Korea)	

08:00 - 09:00	[Breakfast Symposium V – Lilly] Ixekizumab: Recent Updates on the Treatment of Spondyloarthritis	<b>Room B</b> Korean
Chair	Seong-Ho Kim (Inje Univ., Korea)	
08:00 - 08:40	IL-17 inhibition in spondyloarthritis: The efficacy of Ixekizumab and clinical relevance Yeon-Ah Lee (Kyung Hee Univ., Korea)	

08:00 - 09:00	[Breakfast Symposium VI – Janssen] Redefine Persistence in AS Management	<b>Room C</b> Korean
Chair	Chang-Hee Suh (Ajou Univ., Korea)	
08:00 - 08:40	Long-lasting Golimumab in AS: Learnings from real-world evidence Bon San Koo (Inje Univ., Korea)	

09:00 - 10:00	[Keynote Lecture] Keynote Lecture	Room A, B, C English
Chair	Sang-Heon Lee (Konkuk Univ., Korea)	
09:00 - 10:00	The future of rheumatology Antony Rosen (The Johns Hopkins Univ. School of Medicine)	

# Day 3. May 21(Sat)

10:30 - 12:00	[International Symposium] Treatment of Osteoarthritis: To be Used and Abused?	AZł	<b>Room A</b> English
Chairs	Han Joo Baek (Gachon Univ., Korea) Hyun Ah Kim (Hallym Univ., Korea)		
10:30 - 11:00	Hype and truth - treatment paradigm of osteoarthritis David Hunter (Univ. of Sydney, Australia)		
11:00 - 11:30	Addicted to prescription, medical abuse of osteoarthritis Yuqing Zhang (Massachusetts General Hosp., USA)		
11:30 - 12:00	Use or abuse? APM for degenerative meniscus in osteoarthritis Hyun Ah Kim (Hallym Univ., Korea)		

10:30 - 12:00	[Free Paper Session] Spondyloarthritis	<b>Room B</b> Korean
Chairs	Hoon-Suk Cha (Sungkyunkwan Univ., Korea) Eun Young Lee (Seoul Nat'l Univ., Korea)	
0-35	Physical trauma exacerbates arthritis and enthesitis in curdlan-administered SKG mice Seung Hoon Lee (Hanyang Univ., Korea)	e model
O-36	PPM1A promotes matrix mineralization of osteoblasts differentiation via FOXO1A-RU in ankylosing spondylitis Subin Weon (Hanyang Univ., Korea)	INX2 pathway
0-37	A pilot study on deep learning-based grading of the corner of vertebral body for the as of radiographic progression in patients with ankylosing spondylitis Bon San Koo (Inje Univ., Korea)	ssessment
O-38	Analysis of radiographic progression in patients with ankylosing spondylitis: Using gro trajectory modeling and decision trees Juyeon Kang (Inje Univ., Korea)	oup-based
O-39	The spinal radiographic change correlates with past alkaline phosphatase levels in par with ankylosing spondylitis Bon San Koo (Inje Univ., Korea)	tients
0-40	<b>CCL20 inhibition for treating inflammation in ankylosing spondylitis</b> Hui-Ju Kim (Chonnam Univ., Korea)	
0-41	Metagonimus yokogawai-derived protein attenuates inflammation in ankylosing spon Moon-Ju Kim (Chonnam Univ., Korea)	dylitis
0-42	Long-term treatment with ixekizumab in patients with axial spondyloarthritis: Two-yea from COAST-Y Young In Eom (Lilly Korea Ltd, Korea)	ar results

10:30 - 12:00	[Free Paper Session] Room C English & Korea
Chairs	<b>Jisoo Lee</b> (Ewha Womans Univ., Korea) <b>Chang-Hee Suh</b> (Ajou Univ., Korea)
0-43	B cell-specific deletion of Crif1 drives lupus-like autoimmunity by activation of IL-17, IL-6, and pathogenic Tfh cells Jin-Sil Park (The Catholic Univ. of Korea, Korea)
0-44	Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study Xianyong Yin (Univ. of Michigan, USA)
0-45	The association between CD40 rs4810485 polymorphism and susceptibility of systemic lupus erythematosus: Systematic review and meta analysis Rizki Febriawan (Utama Hosp Belitung, Indonesia)
0-46	The role of sphingolipids in patients with systemic lupus erythematosus Ji-Won Kim (Ajou Univ., Korea)
0-47	Combined model of renal histopathology and clinical parameters better predict one year renal outcomes in lupus nephritis: Analysis of 334 kidney biopsies Aishwarya Gopal (Jawaharlal Institute of Postgraduate Medical Education and Research, India)
0-48	Coexisting tubulointerstitial inflammation and damage is a risk factor for chronic kidney disease in patients with lupus nephritis: Results from the KORNET registry Dong-Jin Park (Chonnam Nat'l Univ., Korea)
0-49	Subtherapeutic hydroxychloroquine concentration is associated with increased disease activity ar greater organ damage during 5-year follow-up in patients with systemic lupus erythematosus Ji-Hyoun Kang (Chonnam Nat'l Univ., Korea)
O-50	Effect of smoking on thrombotic events in antiphospholipid syndrome: A large prospective cohort stud Hui Jang (Chinese Academy of Medical Sciences & Peking Union Medical College, China)
0-51	Efficacy of rivoraxaban in patients with antiphospholipid syndrome Zumrad Ubaydullaeva (Republican Specialized Scientific Practical Medical Center of Therapy and Medical Rehabilitation, Uzbekista

12:00 - 13:00	[Luncheon Symposium VII – Novartis] Understanding IL-17 Inhibition in SpA	<b>Room A</b> English
Chair	Hoon-Suk Cha (Sungkyunkwan Univ., Korea)	
12:00 - 12:40	The role of IL-17A in Ankylosing spondylitis and axial PsA Matthew Brown ( <i>King's College London, UK</i> )	

# Day 3. May 21(Sat)

12:00 - 13:00	[Luncheon Symposium VIII – Amgen] Move Forward with the Long-term Protection of Prolia	<b>Room B</b> Korean
Chair	Dae Hyun Yoo (Hanyang Univ., Korea)	
12:00 - 12:40	<b>Denosumab key clinical questions</b> Sung-Soo Kim (Univ. of Ulsan, Korea)	

12:00 - 13:00	[Luncheon Symposium IX – Astellas] <b>Tacrolimus</b>	<b>Room C</b> Korean
Chair	Jung-Yoon Choe (Daegu Catholic Univ., Korea)	
12:00 - 12:40	Tacrolimus in rhematoid arthritis Chan-Bum Choi (Hanyang Univ., Korea)	

13:00 - 14:30	[International Symposium] Synovial Macrophage and Fibroblast in RA English
Chairs	Yong-Wook Park (Chonnam Nat'l Univ., Korea) Seungwoo Han (Kyungpook Nat'l Univ., Korea)
13:00 - 13:30	Synovial macrophages as gatekeepers of inflammation Gerhard Krönke (Univ. of Erlangen, Germany)
13:30 - 14:00	Cellular deconstruction of inflamed synovium defines diverse inflammatory phenotypes in rheumatoid arthritis Soumya Raychaudhuri (Brigham & Women's Hosp., Harvard Medical School, USA)
14:00 - 14:30	Roles of stromal cells and potential significance for future therapy in RA Sang-il Lee (Gyeongsang Nat'l Univ., Korea)

13:00 - 14:30	[Symposium] KCR-KSBMR Joint Symposium	<b>Room B</b> Korean
Chairs	Sang-Heon Lee (Konkuk Univ., Korea) Yong-Chan Ha (Seoul Bumin Hosp., Korea)	
13:00 - 13:30	Anabolic therapy for osteoporosis Ha Young Kim (Univ. of Ulsan, Korea)	
13:30 - 14:00	<b>Ideal sequential therapy in osteoporosis management</b> Kyoung Min Kim ( <i>Yonsei Univ., Korea</i> )	
14:00 - 14:30	Prevention and treatment of fracture in RA Jun-Ki Min (The Catholic Univ. of Korea, Korea)	

13:00 - 14:30	[Free Paper Session] Vasculitis and Metabolic Bone Disease	<b>Room C</b> Iglish & Korean
Chairs	Soo Kon Lee (CHA Univ., Korea) Chang Keun Lee (Univ. of Ulsan, Korea)	
0-52	Update on comparative cardiovascular safety of febuxostat versus allopurinol among patie with gout Se Rim Choi (Seoul Nat'l Univ., Korea)	ents
O-53	The utility of dual-energy computed tomography in predicting gout flares in gout patients after discontinuing colchicine prophylaxis Min Jung Kim (Seoul Nat'l Univ., Korea)	5
0-54	Effects of long-term febuxostat or allopurinol on the progression of chronic kidney diseas Byeongzu Ghang (Jeju Nat'l Univ., Korea)	se
O-55	A cross-sectional internet survey of gout management and outcomes during established COVID-19 pandemic in 2020-2021 Jasvinder Singh (Univ. of Alabama at Birmingham, USA)	l
0-56	The effect of Behçet's disease on carotid intima media thickness and its relationship with dis Merve Polat (Karadeniz Technical Univ., Turkey)	sease activity
0-57	Reclassification of patients with previously diagnosed GPA according to both the 2012 C definitions and the 2007 EMA algorithm using the 2022 ACR/EULAR criteria Jung Yoon Pyo (Yonsei Univ., Korea)	HCC
O-58	Patterns of coronary involvement of antineutrophil cytoplasmic antibody (ANCA) -associ vasculitis in Korean patients Jinseok Kim (Yonsei Univ., Korea)	ated
O-59	Comparison of ultrasound-guided trigger-point needling and blinded needling for myofascial pain syndrome Recep Sade (Ataturk Univ., Turkey)	

15:30 - 17:00	[International Symposium] New Horizon of Systemic Sclerosis	<b>Room A</b> English
Chairs	Jae-Bum Jun (Hanyang Univ., Korea) Eun Bong Lee (Seoul Nat'l Univ., Korea)	
15:30 - 16:00	Update in the pathogenesis of systemic sclerosis Christopher Denton ( <i>Royal Free Hosp., UK</i> )	
16:00 - 16:30	<b>Update in interstitial lung disease in SSc</b> Oliver Distler ( <i>Univ. Hosp. Zurich, Switzerland</i> )	
16:30 - 17:00	Update in pulmonary arterial hypertension in SSc Eun Bong Lee (Seoul Nat'l Univ., Korea)	

# Day 3. May 21(Sat)

15:30 - 17:00	[Free Paper Session] Rheumatoid Arthritis Basic Research English & Korear	
Chairs	Ho-Youn Kim (Ho-Youn Kim's Clinic for Arthritis-Rheumatism, Korea) Sang-il Lee (Gyeongsang Nat'l Univ., Korea)	
0-60	Orosomucoid acid-2, an acute phase reactant, promotes rheumatoid inflammation Kimyo Kim (The Catholic Univ. of Korea, Korea)	
O-61	LKB1 regulates the migration of fibroblast-like synoviocytes via oxidative stress-induced inflammatory cytokines in patients with rheumatoid arthritis Ha-Reum Lee (Chungnam Nat'l Univ., Korea)	
0-62	Postranslational modification in mammals protects citrullinated MCP1/CCL2 chemokine from partial degradation Nataliia Korchynska ( <i>Rzeszow Univ., Poland</i> )	
0-63	Assessment of disease activity in patients with rheumatoid arthritis utilizing plasma tumor M2-pyruvate kinase test Sung Soo Ahn (Yonsei Univ., Korea)	
0-64	Association analysis of a MUC5B promoter variant rs35705950 with rheumatoid arthritis-interstitial lung disease in Korea Young Bin Joo (Hanyang Univ., Korea)	
0-65	Therapeutic effect of folic acid in collagen-induced arthritis mouse model Kijun Lee (The Catholic Univ. of Korea, Korea)	

15:30 - 17:00	[Symposium] Coding and Insurance Guideline in Rheumatic Disease	Room C Korean
Chairs	Young II Seo (Hallym Univ., Korea) Seung-Jae Hong (Kyung Hee Univ., Korea)	
15:30 - 16:00	Rheumatic diseases and KCD 8th revision Sukil Kim (The Catholic Univ. of Korea, Korea)	
16:00 - 16:30	<b>Principles and future prospects of insurance benefits in rheumatoid diseases</b> Gihyeon Seo (Health Insurance Review and Assessment Service, Korea)	
16:30 - 17:00	Insurance guideline and tips for treatment of rheumatic disease Seung-Jae Hong (Kyung Hee Univ., Korea)	

No.	Title	Presenter	
	RA-pathogenesis and animal model & Cytokines and mediators		
P-001	Anti-arthritic activities of the Eleutherococcus senticosus, Achyranthes japonica, and Atractylodes japonica mixed extract fermented with nuruk in a type II collagen-in- duced arthritis mouse model	Chong Hyuk Chung (School of Medicine, Wonkwang Univ., Korea)	
P-002	A green-lipped mussel prevents rheumatoid arthritis via regulation of inflammatory response and osteoclastogenesis	Hong Ki Min (Department of Internal Medicine, Konkuk Univ. Medical Center, Korea)	
P-003	HLA-DRB1 non-SE fine specificity associations with anti-RA33 autoantibody positivity in rheumatoid arthritis patients stratified by different serological phenotypes	Nurul Aain Ahmad fauzi (Institute for Medical Research, Nat'l Institutes of Health Complex, Ministry of Health Malaysia, Malaysia)	
P-004	Precision nanomedicine in rheumatoid arthritis: customized multifunctional polymeric nanocarriers for alleviation of inflammation severity in rheumatoid arthritic rats	ANAS Ahmad (Cumming School of Medicine, Univ. of Calgary, Canada)	
P-005	APE1 inhibits the inflammation of fibroblast-like synoviocytes via oxidative stress regulation in patients with rheumatoid arthritis	Ha-Reum Lee (Chungnam Nat'l Univ. School of Medicine, Korea)	
P-006	A novel cytokine consisting of p40 and EBI3 subunits suppresses experimental autoimmune arthritis via reciprocal regulation of Th17 and Treg cells	Seon-Yeong Lee (The Catholic Univ. of Korea, Korea)	

No.	Title	Presenter
RA-clinical aspects		
P-007	Seasonal analysis of relative search volume of rheumatoid arthritis in Korea	Eunsung Kim (Bumin Hosp., Korea)
P-008	Cardiac hydatid cyst in a patient with rheumatoid arthritis	Giorgi Apkhazava (Tbilisi City Medical, Georgia)
P-009	Course of COVID-19 in patients with rheumatoid arthritis (own data)	Eugenia Aronova (V.A. Nasonova Research Institute of Rheuma- tology, Russian Federation)
P-010	Study of the features of post-covid syndrome in patients with rheumatoid arthritis	Eugenia Aronova (V.A. Nasonova Research Institute of Rheuma- tology, Russian Federation)
P-011	Ultrasound as a potential tool to detect interstitial lung disease in daily clinical setting of patients with rheumatoid arthritis	MARWIN Gutierrez (Instituto Nacional de Rehabilitacion, Mexico)
P-012	Rheumatoid factor (RF) and anti-cyclic citrullinated protein autoantibodies (ACPA) seroconversion and seroreversion in rheumatoid arthritis patients between 2005 and 2021	Chun Lai Too (Immunogenetic Unit. Allergy and Immunology Research Center. Institute for Medical Research. MOH, Malaysia)
P-013	Autoantibodies sustainability in rheumatoid arthritis (RA) patients and their clinical characteristics: Malaysian real-world data between 2005 and 2021	Chun Lai Too (Immunogenetic Unit. Allergy and Immunology Research Center. Institute for Medical Research. MOH, Malaysia)
P-014	Use of disease-modifying anti-rheumatic drugs after cancer diagnosis in rheumatoid arthritis patients	Kyung-Su Park (Catholic Univ. St. Vincent's Hosp., Korea)
P-015	The relationship between Anti-CCP, C-reactive protein in serum and rheumatoid factor in synovial fluid in patients with rheumatoid arthritis in the Kyrgyz Republic	Nazgul Omurzakova (Nat'l Center of Cardiology and Internal Medi- cine, Kyrgyzstan)
P-016	Impact of comorbidity on disease activity and functional status in patients with rheumatoid arthritis receiving biologic DMARDs, a longitudinal analysis of the KOBIO-RA	Ju Yeon Kim (Seoul Nat'l Univ. Hosp., Korea)

No.	Title	Presenter	
	RA-treatment		
P-017	Is a cumulative dose of methotrexate important for rapid remission in rheumatoid arthritis?	Galina Gridneva (V.A.Nasonova Rheumatology Research Insti- tute, Russian Federation)	
P-018	Clinical predictors of inadequate response to conventional synthetic and biologic DMARDs in Chinese patients with rheumatoid arthritis	Hui Zhong (Peking Union Medical College Hosp., China)	
P-019	"Stereotypical" adverse reactions to non-biologic Disease Modifying Anti-Rheumatic Drugs in patients with rheumatoid arthritis requiring biological therapy	Elena Matianova (VA.Nasonova Rheumatology Research Insti- tute, Russian Federation)	
P-020	The efficacy and safety of biologic DMARDs on progression of RA-ILD	Sang Wan Chung (Kyung Hee Univ. Medical Center, Korea)	
P-021	Management of rheumatoid arthritis in China: a study of the implementation of 2021 ACR guideline	Shangyi Jin (Peking Union Medical College Hosp., China)	
P-022	Study of methotrexate metabolism in patients taking statins	Galina Gridneva (VA.Nasonova Rheumatology Research Insti- tute, Russian Federation)	
P-023	Digital aging and mental health deteriorations: how can we mitigate the risk among the elderly with rheumatoid arthritis disease in Indonesia?	Rosinta Hotmaida Pebrianti Purba (Bappenas, Indonesia)	
P-024	Comparison of drug persistence between tumor necrosis factor-a inhibitors and tocilizumab in patients as first-line treatment with rheumatoid arthritis using the Korean Health Insurance Review and Assessment Service database	Byung Wook Song (Pusan Nat'l Univ. Hosp., Korea)	
P-025	Impact of Korean red ginseng on fatigue in patients with rheumatic disease: A randomized, double-blind study	Soo-Kyung Cho (Hanyang Univ. Hosp. for Rheumatic Diseases, Korea)	
P-026	The Preoperative Patient's Expectations and It's Clinical Outcomes After Rheumatoid Forefoot Deformity Surgery	Dong Hong Kim (Hanyang Univ. Hosp., Korea)	

No.	Title	Presenter		
	SLE-clinical aspects, APS			
P-027	Effect of systemic lupus erythematosus on carotid intima media thickness and its relationship with disease activity	Gökhan Polat (Atatürk Univ., Turkey)		
P-028	Wernicke encephalopathy secondary to systemic lupus erythematosis enteropathy	Arzu Shahveranova (Adana Çukurova Üniversity, Turkey)		
P-029	Prognostic factors for the development of systemic lupus erythematosus in patients with immune thrombocytopenia	Soo Min Ahn (Asan Medical Center, Korea)		
P-030	A case of portal and hepatic vein occlusion in systemic lupus erythematosis	Mehmet Selim Kan (Atatürk Univ., Turkey)		
P-031	Disease flare of systemic lupus erythematosus in patients with end-stage renal disease on dialysis	Young-Eun Kim (Asan Medical Center, Univ. of Ulsan College of Medicine, Korea)		
P-032	Clinical relevance according to staining patterns and titers of antinuclear antibody	Mi Ryoung Seo (Gil Medical Center, Gachon Univ. College of Medicine, Korea)		
P-033	Long-term renal outcomes of patients with non-proliferative lupus nephritis	Eunsong Kang (Asan Medical Center, Korea)		

No.	Title	Presenter
	SLE-clinical aspects, APS	
P-034	Computer aided detection of the white matter lesions associated with systemic lupus erythematosus in cranial magnetic resonance imaging	Ahmet Yalcin (Ataturk Univ., Faculty of Medicine, Turkey)
P-035	Internuclear ophthalmoplegia in lupus cerebritis: double jeopardy	Paul Shiu (St Joseph's Medical Center - Graduate Medical Education, USA)
P-036	Working memory and processing speed in systemic lupus erythematosus: Correlation with disease activity	Rudrani Chatterjee (Clinical Psychologist, India)
P-037	Etiology of raised serum creatinine in patients with systemic lupus erythematosus at presentation and association of number of crescents in renal biopsy with rapidly progressive renal failure	RAJAT Kharbanda (Senior Resident, India)
P-038	CRP elevation in SLE pericarditis: Not all patients with SLE pericarditis have an elevated CRP value	Hyunsue Do (Severance Hosp., Yonsei Univ. College of Medicine, Korea)
P-039	Prevalence of latent tuberculosis infection and its associations with clinical and serological parameters in systemic lupus erythematosus	Gayathri Ms (Jawaharlal Institute of Postgraduate Medical Education and Research, India)
P-040	Comparison of physical functions of systemic lupus erythematosis and healthy persons and their relationship with disease activity	Yasin Baki Baydas (Bezmialem Univ., Turkey)

No.	Title	Presenter	
	SLE-pathogenesis and animal model		
P-041	Vitronectin, a novel urinary proteomic biomarker, promotes cell pyroptosis in juvenile systemic lupus erythematosus	Zhe Cai (Guangzhou Women and Children's Medical Center, China)	
P-042	Effect of tumor necrosis factor- $\alpha$ gene polymorphisms in risk of systemic lupus ery-thematosus patients susceptibility: Update meta-analysis	Steven Irving (Faculty of Medicine, Univ. of Sebelas Maret, Indonesia)	

No.	Title	Presenter
SLE-treatment		
P-043	A retrospective single center study of the clinical response of tacrolimus treatment in patients with lupus nephritis	Ji-Won Kim (Ajou Univ. School of Medicine, Korea)
P-044	Acute pancreatitis after corticosteroid pulse therapy in rheumatic disease: Acute pan- creatitis is common adverse reaction after corticosteroid pulse therapy	Jinseok Kim (Yonsei Univ. College of Medicine, Korea)
P-045	Myelodysplastic syndrome occurrence in post-therapeutic systemic lupus erythema- tosus patients	Ninda Devita (Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Indonesia)

No.	Title	Presenter	
	Spondyloarthropathies and psoriatic arthritis		
P-046	Vitronectin-derived bioactive peptide prevents spondyloarthritis by modulating Th17/ Treg imbalance in mice with curdlan-induced spondyloarthritis	Hong Ki Min (Konkuk Univ. Medical Center, Korea)	
P-047	The relationship between the osteoporosis and cortial index of the mandibular bone in psoriatic arthritis	Viliam Gasanova (Bahçeşehir İstinye Univ., Turkey)	
P-048	Evaluation of the relationship between ankylosing spondylitis and its inflammation indicator calprotectin and its relationship with disease activity	Mehmet Alperen Tezcan (Ataturk Univ., Turkey)	
P-049	Investigation of the relationship of ankylosing spondylit and varicocele	Muhammed Emre Isıktas (Atatürk Univ., Turkey)	
P-050	The effect of ankylosing spondylitis on carotis intima media thickness and its rela- tionship with disease activity	Elshad İsmailov (Atatürk Univ., Turkey)	
P-051	Predictive role of neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio and platelet-to-lymphocyte ratio in the assessment of clinical response and drug persistence of tumor necrosis factor-alpha inhibitors in patients with ankylosing spondylitis	Dong Hyuk Moon (Pusan Nat'l Univ. School of Medicine, Pusan Nat'l Univ. Hosp., Korea)	
P-052	A deep-learning-based approach for automated assessment of modified Stoke anky- losing spondylitis spine score (mSASSS) on spine radiographs: a preliminary study	Sun Yeop Lee (Deepnoid, Inc., Korea)	
P-053	Intra-articular corticosteroids for sacroiliitis in treatment of spondyloarthritis	Pallavi Vij (All India Institute of Medical Sciences, India)	
P-054	Drug retention of biologic agents in Korean patients with psoriatic arthritis	Ju Yeon Kim (Seoul Nat'l Univ. Hosp., Korea)	
P-055	Safety profile of ixekizumab for the treatment of psoriatic arthritis and axial spondyloarthritis up to 3 years: An updated integrated safety analysis	Young In Eom (Lilly Korea Ltd, Korea)	
P-056	A comparison of physical functions and its relationship with disease activity of persons with ankylosing spondilitis	Aysenur Kara (Atatürk Univ., Turkey)	

No.	Title	Presenter	
	Behçet's disease & Vasculitis		
P-057	Diagnostic value of 3D T1-weighted sampling perfection with application optimized contrast evolution (SPACE) magnetic resonance imaging in patients with giant cell arteritis	Recep Sade (Ataturk Univ., Turkey)	
P-058	Determination of the frequency of entositis and its relationship with disease activity in Behçet's disease by ultrasonography	Serhat Kaya (Tunceli Devlet Hastanesi, Turkey)	
P-059	NeuroBehçet with spinal leptomeningeal involvement	Oğuzhan mete (Atatürk Univ., Turkey)	
P-060	Investigation of the frequency of varicocele in Behçet's disease	Cafer Koçak (Atatürk Univ., Turkey)	
P-061	The relationship of venous involvement with disease activity in Behçet's syndrome	Muhammed Halid Yener (Atatürk Univ., Turkey)	
P-062	Serum albumin, prealbumin, and ischemia-modified albumin levels in patients with ANCA-associated vasculitis: A prospective cohort study	Sung Soo Ahn (Yongin Severance Hosp., Yonsei Univ. College of Medicine, Korea)	

No.	Title	Presenter	
	Behçet's disease & Vasculitis		
P-063	Comparison of physical functions of people with Behçet's disease and healthy and their relationship with disease activity	Yusuf Geylani (Bitlis State Hosp., Turkey)	
P-064	COVID-19 vaccination related small vessel vasculitis with multi-organ involvement	Yunkyung Kim (Department of Internal Medicine, Kosin Univ. College of Medicine, Korea)	
P-065	BVAS version 3 and BVAS/GPA	Jangwoo Ha (Yonsei Univ. College of Medicine, Korea)	
P-066	Application of the 2022 new criteria for microscopic polyangiitis to patients with previously diagnosed microscopic polyangiitis	Jung Yoon Pyo (Yonsei Univ. College of Medicine, Korea)	
P-067	Effect of the number of metabolic syndrome components on all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis	PIL GYU Park (Severance Hosp., Korea)	
P-068	Aortic involvement as a rare complication of granulomatosis with polyangiitis: A case report	Su Jin Choi (Ulsan Univ. Hosp., Univ. of Ulsan College of Medicine, Korea)	
P-069	ANCA sero-positivity and AAV occurrence after SARS-CoV-2 infection	Eunju Lee (Yonsei Univ. College of Medicine, Korea)	
P-070	New-onset IgA vasculitis in adult patients following SARS-CoV-2 vaccines	Yunjung Choi (Jeonbuk Nat'l Univ. Hosp., Korea)	
P-071	A case of microscopic polyangiitis with periaortitis treated with cyclophosphamide	Seoung Wan Nam (Wonju Severance Christian Hosp., Korea)	
P-072	Churg-strauss syndrome presenting as acute abdomen- A case report	Subbarayudu Boda (GITAM Institute of Medical Sciences and Research (GIMSR), India)	

No.	Title	Presenter	
	Crystal induced arthropathies		
P-073	Identification of tofuses and diagnosis of gout disease with dual-energy CT	Iraklı Tortladze (TSSU First Univ. Clinic, Georgia)	
P-074	Spondylodiscitis and paravertebral abscess associated with calcium pyrophosphate dihydrate deposition disease	Burak Sarilar (Pamukkale Univ., Turkey)	
P-075	Urate-lowering efficacy and renal safety of febuxostat in patients with advanced chronic kidney disease not yet on dialysis: A meta-analysis of observational studies	Changnam Son (Keimyung Univ. School of Medicine, Korea)	
P-076	A rare coexistence of quadriceps tendon calcification and patellar tendon calcification	Muhammed Eyyüp Çelik (Atatürk Univ., Turkey)	
P-077	Diagnosis and treatment of gout patients at emergency room	Mi Ryoung Seo (Gil Medical Center, Gachon Univ. College of Medicine, Korea)	
P-078	Genetic analysis for inflammasome genes polymorphisms in the gout susceptibility	Denise Clavijo-cornejo (Instituto Nacional de Rehabilitación, Mexico)	
P-079	Depletion, activation, and stimulation of bone destruction of innate and innate-like immune cells in gout	Ki-Jeong Park (Chonnam Nat'l Univ. Hosp., Korea)	

No.	Title	Presenter	
	Crystal induced arthropathies		
P-080	Gout disease modification: Proposal for a definition	Jasvinder Singh (Univ. of Alabarna at Birmingham, USA)	
P-081	Predictors of increased vascular stiffness in gout patients	Wooseong Jeong (Division of Rheumatology, Jeju Nat'l Univ. School of Medicine, Korea)	
P-082	Clinical features of Korean patients with calcium pyrophosphate crystal deposition disease: A retrospective multicenter study	Eun Hye Park (Chung-Ang Univ. College of Medicine, Korea)	
P-083	Effect of lifestyle change on incident gout: a nationwide population-based cohort of young men	Yeonghee Eun (Kangbuk Samsung Hosp., Sungkyunkwan Univ. School of Medicine, Korea)	
P-084	Gout is associated with the risk of osteoporosis: a population-based study	Jihyoun Kim (Department of internal medicine, Chungbuk Nat'l Univ. Hosp., Korea)	

No.	Title	Presenter	
	Pediatric rheumatology		
P-085	Vascular imaging findings with high-pitch low-dose dual-source CT in atypical Kawasaki disease	Recep Sade (Ataturk Univ., Turkey)	
P-086	Bilateral calcification of ear cartilage	Gökhan Polat (Atatürk Univ., Turkey)	
P-087	The treatment effect of tofacitinib on Blau syndrome: A case series of Chinese pediatric patients	Zhe Cai (Guangzhou Women and Children's Medicai Center, China)	
P-088	The evaluation of MRI findings of sacroiliitis in patients with juvenile idiopathic arthritis for detection of active and structural damage lesions according to updated preliminary OMERACT pediatric JAMRIS scoring system	Berhan Pirimoglu (Ataturk Univ. School of Medicine, Turkey)	
P-089	The clinical characteristics of 15 IgG4 related disease in pediatric patients	Zheng Liu (Peking Union Medical College Hosp., China)	
P-090	Predictors of long-term functional outcomes of enthesitis related arthritis (ERA) category of juvenile idiopathic arthritis (JIA) in adulthood: A single centre experience from a tertiary care hospital	Naveen R (Sanjay Gandhi Postgraduate Institute of Medical Sciences, India)	
P-091	Secondary hemophagocytic lymphohistiocytosis: Overwhelming clinical manifestations may cause more chemotherapy than necessary	Soo-Young Lee (College of Medicine, The Catholic Univ. of Korea, Korea)	
P-092	Interstitial lung disease in pediatric systemic lupus erythematosus: A case report	Soo-Young Lee (College of Medicine, The Catholic Univ. of Korea, Korea)	
P-093	A20 Haploinsufficiency identified in a girl presented with systemic juvenile idiopathic arthritis: A case report	Jung-Woo Rhim (College of Medicine, The Catholic Univ. of Korea, Korea)	
P-094	Withdrawn	-	
P-095	Flare-up of juvenile idiopathic arthritis (JIA) the day after receiving a booster shot of BNT162b2 mRNA vaccine	Hyong Suk Park (Myongji Hosp., Korea)	
P-096	Challenges and management for pediatric rheumatology patient's in the COVID-19 era: Perspectives from several countries	Putri Ayu (Andalas Univ., Indonesia)	

No.	Title	Presenter
Fibromyalgia and soft tissue disorders		
P-097	The use of shear-wave elastography for myofascial pain syndrome's severity	Recep Sade (Ataturk Univ., Turkey)
P-098	Amigos de fibro (Fibro Friends): Validation of an educational program for health promotion in fibromyalgia	Mateus Antunes (Univ. of São Paulo (USP), Brazil)
P-099	Amigos de fibro (Fibro Friends): Validation of an educational e-book to promote the health of patients with fibromyalgia in Brazil	Mateus Antunes (Univ. of São Paulo (USP), Brazil)

No.	Title	Presenter	
	Idiopathic inflammatory myositis and muscle biology		
P-100	Withdrawn	-	
P-101	Erdheim-Chester disease mimicking coronary artery disease in a systemic lupus erythematosus patient	Grigol Nemsadze (TSSU First Univ. Clinic, Georgia)	
P-102	New onset clinically amyopathic dermatomyositis following SARS-CoV-2 vaccine: A case report	Eric Ranniel Guevarra (Univ. of Santo Tomas Hosp., Philippines)	
P-103	Rare case of dermatomyositis following SARS-CoV-2 vaccination	Mark Andrian Yano (Philippine General Hosp., Philippines)	
P-104	Clinical characteristics and outcomes of adult patients with anti-MDA5 dermatomyositis- A single centre experience from South India	Shivraj Padiyar (Christian medical College, India)	
P-105	Changes in quantitative interstitial lung disease scores on high-resolution CT in idiopathic inflammatory myositis	Jina Yeo (Gil Medical Center, Gachon Univ. College of Medicine, Korea)	
P-106	Time-dependent changes in rapidly progressive-interstitial lung disease and mortality risk in anti-MDA5 antibody positive dermatomyositis patients: A cohort study of 272 cases in China	Hanxiao You (The First Affiliated Hosp. of Nanjing Medical Univ., China)	
P-107	Coexisting of anti-Ro52 autoantibodies on anti-MDA5 autoantibodies-positive dermatomyositis is highly associated with rapidly progressive interstitial lung disease and mortality risk	Hanxiao You (The First Affiliated Hosp. of Nanjing Medical Univ., China)	
P-108	Galectin-9 and CXCL-10 as biomarkers in assessing disease activity in Dermatomyositis and Polymyositis - A single centre cohort study	SAI KUMAR Dunga (Jawaharlal institute of postgraduate medical education and research, India)	
P-109	Role of semiquantitative thigh magnetic resonance imaging (tMRI) in determining skeletal muscle outcomes at baseline and on follow up in idiopathic inflammatory myopathies (IIMs)	Mamatha Gorijavolu (Jawaharlal institute of postgraduate medical education and research, India)	

No.	Title	Presenter	
	Sjögren's syndrome		
P-110	Hyperglobulinemia in primary Sjögren's syndrome predicts the poor outcome: From multicenter registration study	Hui Zhong (Peking Union Medical College Hosp., China)	
P-111	Primary Sjögren's syndrome is associated with increased risks of not just lymphoma: a systematic review and meta-analysis	Hui Zhong (Peking Union Medical College Hosp., China)	
P-112	Salivary ultrasonography and histopathologic evaluation of secondary Sjögren's syndrome in rheumatoid arthritis patients	Minae Oh (Seoul St. Mary's Hosp., The Catholic Univ. of Korea, Korea)	
P-113	STAT4 gene polymorphisms in risk of Sjögren's syndrome patients susceptibility: Update systematic review and meta-analysis	Rendra Ristian wibowo (Sebelas Maret Univ., Indonesia)	
P-114	Interstitial lung disease in Sjögren's syndrome: Prevalence, patterns, treatment, and prognosis	Jung Hee Koh (College of Medicine, The Catholic Univ. of Korea, Korea)	
P-115	Distinct metabolic biomarkers to distinguish immunoglobulin G4-related disease from Sjögren's syndrome and pancreatic cancer and predict disease prognosis	Yu Peng (Peking Union Medical College Hosp., China)	
P-116	Predictors of the future development of systemic lupus erythematosus (SLE) in Korean primary Sjögren's syndrome (pSS) patients with anti-DNA antibody (+) by the Farr method.	Bong-Woo Lee (Yeouido St. Mary's Hosp., College of Medicine The Catholic Univ. of Korea, Korea)	

No. Title Presenter		Presenter	
Systemic sclerosis and Raynaud's phenomenon			
P-117	Analysis of clinical features of myocardial involvement in systemic sclerosis	Huilin He (Peking Union Medical College Hosp., China)	

No.	Title	Presenter
Miscellaneous rheumatic and inflammatory diseases		
P-118	Brain magnetic resonance imaging finding in autoimmune rheumatic disease	Recep Sade (Ataturk Univ., Turkey)
P-119	Spontaneous knee hemarthrosis associated with enoxaparin treatment in a post COVID-19 patient	Mark Andrian Yano (Philippine General Hosp., Philippines)
P-120	Clinical profile and outcome of adult Filipino patients with septic arthritis in a tertiary hospital in the Philippines	Mark Andrian Yano (Chong Hua Hosp., Philippines)
P-121	Tuberculosis fasciitis of the neck in Behçet's patient	Yunus Fersan (Atatürk Univ., Turkey)
P-122	Chronic inflammatory demyelinating polyneuropathy (CIDP) in polyangiitis granulomatosis with cyclophosphamide	Kadem tüysüz (Atatürk Univ., Turkey)
P-123	A rare combination of autoimmune pancreatitis and focal cranial eosinophilic granuloma	Tamar Melkadze (TSSU First Univ. Clinic, Georgia)
P-124	Diagnostic value of the inflammatory scores in polymyalgia rheumatica	Ji-Won Kim (Ajou Univ. School of Medicine, Korea)
P-125	A short long way from juvenile idiopathic arthritis to pachydermoperiostosis (Touraine–Solente–Gole syndrome)	Bogdan Ion Gavrila (Univ. of Medicine and Pharmacy, Carol Davila, Romania)

No.	Title	Presenter	
Miscellaneous rheumatic and inflammatory diseases			
P-126	Allopurinol and febuxostat hypersensitivity in a patient with young onset gout	Mark Andrian Yano (Philippine General Hosp., Philippines)	
P-127	Curative-intent resection is a strong indicator of steroid-free remission in IgG4-related disease	Jung Gon Kim (Division of Rheumatology, Seoul St. Mary's Hosp., College of Medicine, Korea)	
P-128	Application of HScore and MS score in diagnosis of macrophage activation syndrome associated with adult onset Still's disease	Zhao Peng (Chinese Academy of Medical Sciences & Peking Union Medical College, China)	
P-129	The role of interleukin-18 as a diagnostic biomarker to differentiate active adult-onset Still's diseas from COVID-19	Roland Helmizar (Indonesian Univ., Indonesia)	
P-130	Cancer-associated vasculitis: A single-centre pilot study	Hyunsue Do (Severance Hosp., Yonsei Univ. College of Medicine, Korea)	
P-131	Withdrawn	-	
P-132	Cerebellar infarction as the initial presentation of IgG4-Related Disease	Gaurav Nepal (Tribhuvan Univ. Institute of Medicine, Nepal)	

No.	Title	Presenter	
Epidemiology & Public health			
P-133	Relationship between Lung Involvement and Gout in COVID-19 disease	Fatih işik (Atatürk Univ., Turkey)	
P-134	Post-COVID mesial temporal sclerosis	Megi Kurtanidze (Tbilisi City Medical, Georgia)	
P-135	Incidence of rheumatic diseases during the COVID-19 pandemic in Korea: A nationwide claims study	Soo Min Ahn (Asan Medical Center, Korea)	
P-136	Changes in the lungs that develop with COVID-19 in patients with rheumatoid arthritis	Eugenia Aronova (V.A. Nasonova Research Institute of Rheumatology, Russian Federation)	
P-137	Incidence, prevalence, and clinical characteristics in ANCA-associated vasculitis: A National Health Insurance Service Database (2002-2018)	Jinsu Park (Nat'l Health Insurance Service Ilsal Hosp., Korea)	
P-138	Association between sarcopenia and rheumatoid arthritis in the Korean population: a nationwide cross-sectional study	Jae Hyun Jung (Korea Univ. College of Medicine, Korea)	
P-139	Psychometric properties of the PHQ-8 in individuals with osteoarthritis	Patrick Brzoska (Witten/Herdecke Univ, Faculty of Health, School of Medicine, Germany)	
P-140	The Barriers Of Patients With Osteoporosis In Various Countries During The COVID-19 Pandemic	NURALIAH Nuraliah (West Sulawesi Research and Empowerment Center, Indonesia)	
P-141	Use of telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak: A randomized controlled trial	Ho So (The Chinese Univ. of Hong Kong, Hong Kong)	

No.	Title	Presenter		
	Epidemiology & Public health			
P-142	Immunopathological process in the Chronic arthritis and Rheumatic Heart Diseases caused by streptococcus of Group A	Nazgul Omurzakova (Nat'l Center of Cardiology and Internal Medicine, Kyrgyzstan)		
P-143	Comparison of renal outcomes and mortality in early and delayed onset lupus nephritis	Soo-Kyung Cho (Hanyang Univ. Hosp. for Rheumatic Diseases, Korea)		
P-144	Level of knowledge on systemic lupus erythematosus among nursing students in selected universities in the Philippines	Cherry Ann Garcia Durante (Emilio Aguinaldo College - Manila, Philippines)		
P-145	Comparative safety of tofacitinib and TNF inhibitor in Korean patients with rheumatoid arthritis: A prospective, single-center cohort study	Yeo-Jin Song (Hanyang Univ. Hosp. for Rheumatic Diseases, Korea)		
P-146	A tale of three paths: singaporean patient journeys from initial symptoms of gout to presentation for health care	Aloysius Chow (Lee Kong Chian School of Medicine, Nanyang Technological Univ., Singapore)		

No.	Title	Presenter		
	Osteoporosis and metabolic bone diseases			
P-147	Two novel mutations in TCIRG1 induced infantile malignant osteopetrosis: A case report	Ping Wu (Guangzhou Women and Children's Medical Center, China)		
P-148	Relationship between Vitamin D, Body mass index with Bone mineral density of Mongolian miners	Garamjav Khishigdavaa (Medipas Hosp., Mongolia)		
P-149	Application of Machine Learning to identify osteoporosis based on the extreme learning machine (ELM) model algorithm	Rifaldy Fajar (Univ. of ĽAquila, Italy)		
P-150	FRAX model is useful for prediction of major fractures in RA patients with glucocorticoid-induced osteoporosis	Yoon-Kyoung Sung (Hanyang Univ. Hosp. for Rheumatic Diseases, Korea)		
P-151	Genetic variation of susceptibility gene of osteoporosis, measuring method of osteoporosis risk	Ahmad Ahmad (Universitas Al Asyariah Mandar, Indonesia)		
P-152	Patient preference and efficacy of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis in patients with autoimmune diseases	Ji-Won Kim (Ajou Univ. School of Medicine, Korea)		

No.	Title	Presenter	
Osteoarthritis and biology of bone and joint			
P-153	The potential targets of San-Miao-San in the treatment of osteoarthritis	Zhe Cai (Guangzhou Women and Children's Medical Center, China)	
P-154	Serum, synovial visfatin level during flare-up and remission of primary knee OA	Haytham Abd elaal (MOH, Egypt)	
P-155	Influence of metabolic syndrome in patients with knee osteoarthritis	Jamol Uzokov (Republican Specialized Scientific Practical Medical Center of Therapy and Medical Rehabilitation, Uzbekistan)	

No.	Title	Presenter	
Osteoarthritis and biology of bone and joint			
P-156	Efficacy of joint treatment with metformin and NSAIDS in patients with knee osteoarthritis and metabolic syndrome	Bakzod Karimov (Republican specialized scientific practical medical center of therapy and medical rehabilitation, Uzbekistan)	
P-157	Detection of the sesamoid bone of the metacarpal joint in patients with osteoarthritis using the deep learning model	Bon San Koo (Inje Univ. Seoul Paik Hosp., Inje Univ. College of Medicine, Korea)	
P-158	Blood D-dimer level after COVID-19 in patients with knee osteoarthritis	Zumrad Ubaydullaeva (Republican Specialized Scientific Practical Medical Center of Therapy and Medical Rehabilitation, Uzbekistan)	
P-159	Lactobacillus (LA-1) and butyrate inhibit osteoarthritis by controlling autophagy and inflammatory cell death of chondrocytes	JooYeon Jhun (The Catholic Univ. of Korea, Korea)	

No.	Title	Presenter
Orthopedics & Rehabilation		
P-160	Effects of conventional rehabilitative and aerobic training in patients with idiopathic inflammatory myopathy	Mingwei Tang (Peking Union Medical College Hosp., Chinese Academy of Medical Science, China)

## CONTENTS

E Day 1	May 19(Thu), 2022	
[Symposium] Year in Review	r (Clinical)	(KOR)
1. Clinical update of systemic	c lupus erythematosus	Seung-Ki Kwok ····· 093
2. Idiopathic inflammatory m	nyositis	Jinhyun Kim ····· 094
3. Update of IgG4 related dis	ease	Yong Gil Kim ····· 095
4. Behçet's disease		Sang-Won Lee ····· 096

mposium] Year in Review (Basic) (K	
1. Emerging concepts of endotypes/phenotypes in osteoarthritis	Gunil Im 098
2. Gout: Basic Science of gout	Seokchan Hong 099
3. SpA: Insight into the pathogenesis of SpA	Tae-Jong Hong 100
4. Update in the pathogenesis of Sjögren's syndrome	Jennifer Jooha Lee 101

[Workshop] Musculoskeletal US Workshop I - Advanced Course		(KOR)
Session1: Practical Applications of Musculoskeletal Ultrasound in Rheumatology Clinic		
1. How to use ultrasonic equipment setting	Hyun Ok Kim	
2. Ultrasonographic perspectives in giant cell arteritis, polymyalgia rheumatica and Sjögren's syndrom	Hyun-Sook Kim	
3. Assessment of rheumatoid arthritis disease activity with ultrasound	Ran Song	
Session2: Ultrasound-guided Injection		
1. Ultrasound-guided intra-articular injection	Hyoun-Ah Kim	
2. Ultrasound-guided extra-articular injection	Chang Hoon Lee	
3. The tips and considerations for ultrasound-guided injection	Jae Hoon Kim	

[Lunchoen Symposium I – Pfizer] Recent Update of Advanced RA Treatment	(KOR)
1. The role of tofacitinib as a JAK pioneer	Hyoun-Ah Kim 103

[Lunchoen Symposium II - JW Phamaceutical] IL-6R Inhibition: Transforming People's	Lives, for a Future on Their Ter	m (KOR
1. Evolution of tocilizumab: From rheumatoid arthritis to CAR T cell therapy and COVID-1	9 Seung-Ki Kwok	10
[Lunchoen SymposiumI III – AbbVie] Strategies to Solve the Problem of Ankylosing Sp	ondylitis with AbbVie's Assets	(KOR
1. The present and future of ankylosing spondylitis treatments	Tae-Jong Kim	10
[Special Lecture] Presidential Plenary Session		(KOR
1. Changing role of rheumatologist in Korea	Sang-Heon Lee	10
2. Past, present and future of rheumatology in Korea	Yeong-Wook Song	11
[Free Paper Session] International Free Paper Session (Clinical)		(ENG&KOR
IO-01 Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with JAK inhibitors nationwide population-based study <u>Yeo-Jin Song</u> , Soo-Kyung Cho, Seu Hyoungyoung Kim, Sun-Yo	ng-Hun You, Jeong-yeon Kim, ung Jung, Yoon-Kyoung Sung	112
IO-02 Increased thromboembolic risk of JAK inhibitors after switching from biologic DMARDs in patients with rheumatoid arthritis <u>Yeonghee Eun</u> , , Gi Hyeon Seo, S		
	Cha, Eun-Mi Koh, Jaejoon Lee	113
IO-03 Gut microbiome in patients with established rheumatoid arthritis: Factors associated wi and its value of predicting treatment response	th the composition,	
Jung Hee Koh,	Dong-Hyun Kim, Wan-Uk Kim	114
IO-04 Time-averaged DAS28 and HAQ predict cardiovascular disease in patients with rheuma Data from KORONA registry	toid arthritis:	
<u>Hong Ki Min</u> , Seung-Ki Kwok, I Kwi Y	Hae-Rim Kim, Sang-Heon Lee, Young Kang, Sung-Hwan Park	11
IO-05 Increased cardiovascular risk in patients with systemic lupus erythematosus: Population	n-based Cohort Study in Korea	
<u>Jungyong Han</u> , Hyoungyoung Kim, Yena Jeon, C Eun Jin Jang, Soo-K	Gaeun Kang, Sun-Young Jung, yung Cho, Yoon-Kyoung Sung	116
IO-06 Long-term exposure to PM10 and systemic-lupus-erythematosus-related mortality in the	e Korean population	
	ng Kyun Choi, Sung-Eun Choi, Dong-Jin Park, Shin-Seok Lee	117

## CONTENTS

10-07

	Eunsong Kang, Yong Gil Kim, Ji Seon Oh, Seokchan Hong, Soomin Ahn, Chang Keun Lee, Bin Yoo
IO-08 Immunogenicity and safety of in:	activated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus
	Ho So, Tena Li, Vivien Chan, Lai Shan Tam, Paul Chan 119
IO-09 Clinical characteristics and prog	nosis of patients with anti-melanoma differentiation-related gene 5 (MDA5) related diseases
	<u>Chen Yu</u> , Luwei Yang, Li Zhang, Shuang Zhou, Chaojun Hu, Jiuliang Zhao, Dong Xu, Mengtao Li, Chanyuan Wu, Qian Wang, Lindi Jiang, Zuojun Xu, Xiaofeng Zeng

Three-dimensional analysis of the trapezium subchondral bone and its association with trapeziometacarpal joint osteoarthritis

Ji Sup Hwang, Hyun Sik Gong ------ 121

[Workshop] Basic Research Workshop for Rheumatologist: Animal Models of Key Arthropathies	(KOR)
1. Animal models of osteoarthritis (OA)	Je-Hwang Ryu 123
2. Experimental procedures of mouse OA research	Gyuseok Lee 124
3. Animal models of rheumatoid arthritis	Seung-Ah Yoo 125
4. Experimental procedures of mouse arthritis models	Saseong Lee 126

[Workshop] Musculoskeletal US Workshop II - Basic Course		(KOR)
Session 1: Introduction to musculoskeletal ultrasound in rheumatology		
1. Musculoskeletal ultrasound in rheumatology – Upper extremities	Jae Hyun Jung	
2. Musculoskeletal ultrasound in rheumatology – Lower extremities	Ju-Yang Jung	
3. Workshop – Upper extremities		
	Tutors	
	Wrist & elbow: Yun Sung Kim ,Jin Su Park	
	Shoulder: Young Bin Joo, Yune-Jung Park	
4. Workshop – Lower extremities		
	Tutors	
	Knee: Min Kyung Chung, Jinhee Lee	
	Ankle & Foot: In Ah Choi, Yong Sun Suh	

[Free Paper Session] International Free Paper Session (Basic)	(E	ENG)
IO-11 Identification of a key regulator of MYH9 for synoviocyte migration and invasion through secretome profiling		
Saseong Lee, Eunbyeol Choi, Sehyun Chae, Seung-Ah Yoo, Daehee Hwang, Wan-Uk Kim		128
IO-12 Multi-omics identifies S100 proteins as biomarkers of RA progression which can be regulated by epigenetic drugs		
Marzena Ciechomska, Leszek Roszkowski, Dominik Cysewski, Włodzimierz Maslinski		129
IO-13 Dysfunction of parkin increases osteoclast activity linking to bone erosion of inflammatory arthritis		
<u>Ji-Eun Kim</u> , Eun-Young Kim, Bongkun Choi, Dong Hyun Sohn, Yeon-Ho Chung, Ji-Eun Park, Sion Park, Soyoon Oh, Ha Rim Shin, Yongsub Kim, Dohee Yoon, Yu Mi Hwang, So Hye Nam, William H. Robinson, Yong-Gil Kim, Eun-Ju Chang		130
IO-14 Cell-specific activation of PADI4 promoter in human fibroblast-like synoviocytes from patients with rheumatold arthriti	S	
Khrystyna Malysheva, Justyna Czarnik-kwaśniak, Oleksandr Korchynskyi		131
IO-15 Effect of disease-modifying anti-rheumatic drugs on lung microenvironment of SKG mice		
Sung Hae Chang, Jeong Seok Lee, Jeongjun Choe, Seon Uk Kim, Jeong Yeon Kim, Eun Young Lee		132
IO-16 Peptoniphilus gorbachii ameliorates collagen-Induced arthritis in mice by improving intestinal homeostasis and immune regulation		
<u>Young Sun Suh</u> , Sung Hak Chun, Seong-Tshool Hong, Hanna Lee, Mingyo Kim, Yun-Hong Cheon, Hyun-Ok Kim, Suhee Kim, Sang-II Lee		133
IO-17 The immune mechanism of Janus kinase inhibitors on Shingles in rheumatoid arthritis patients		
Hong Ki Min, Ji-Yeon Lee, Se Hee Kim, Hae-Rim Kim, Sang-Heon Lee		134
IO-18 Identification of the HLA-B*51:01 immunopeptidome in Behçet's disease		
Ye Ji Lee, Kyung-Cho Cho, So Hyun Kim, Byung Kyu Cho, Eugene C. Yi, Eun Bong Lee		135
IO-19 Inhibition of NADPH oxidases prevent the development of osteoarthritis		
Jin Han, Seungwoo Han		136

## CONTENTS

[Workshop] Clinical Researcch Workshop for Rheumatologist: Planning and Conducting Clinic	al Research (K	(OR)
1. Setting up a prospective cohort	Sang-Cheol Bae	138
2. Conducting a retrospective clinical study using Korea National Health Insurance data	Hyun Jung Kim	139
3. How to start IITs from scratch	Howard Lee	140
4. e-CRF tools for Investigator Initiated Trial	Soo-Hwan Kim	141

[Workshop] Editorial Committee Workshop	(KOR)
1. Suggestions to be indexed in SCIE and get high impact factor	Hyun Jun Park 143
2. Successful submission strategy on SCI journal	Hwichool Kim 144
3. Biostatistics for clinical researchers	Hyonggin An 145
4. New PubMed: Searching tips & more!	Sung Ae Park 146

[Breakfast Symposium I - AbbVie] Strategies to Solve the Problem of Rheumatoid Arthritis with	AbbVie's Assets	(KOR
1. Management of rheumatoid arthritis considering safety	Ki-Jo Kim	15
[Breakfast Symposium II – Celltrion] Real-world Switching Case of CT-P17		(ENG
1. Clinical data and real-world switching case of CT-P17	Hubert Marotte	15
[Breakfast Symposium III – Pfizer] Real-World Perspectives of Ankylosing Spondylitis Manager	nent	(KOR
1. Insights from real-world: Practical approach to anti TNF therapy for AS treatment	Jun Won Park	154
[Keynote Lecture]		(ENG
1. Current threats to the specialty of rheumatology in the US and internationally: A call to action	Kenneth Saag	150
[International Symposium] Recent Advances in Pathogenesis of Systemic Lupus Erythematosus	S	(ENG
1. New concepts on the pathogenesis of lupus nephritis	George Tsokos	158
2. New insights into the role of antinuclear antibodies in systemic lupus erythematosus	Peter E. Lipsky	159
3. ETV5 promotes Tfh cell differentiation and the pathogenesis of systemic lupus erythematosus	Yoontae Lee	160
[Free Paper Session] Epidemiology & Health Services Research		(KOR)
O-01 Safety and clinical influences of COVID-19 vaccination in patients with autoimmune rheumatic di	seases	
<u>Youngjae Park</u> , Hanna Park, Minae Oh, Jung Gon k Howook Jeon, Jennifer Jooha Lee, Su-Jin N		162
O-02 Autoantibody profiles in patients with COVID-19 infection		
Hyemin Jeo	<u>ng</u> , Chan Hong Jeon	163

Seonyoung Kang, Kyung-Do Han, Yeonghee Eun, Seulkee Lee, Hoon-Suk Cha, Eun-Mi Koh, Jaejoon Lee, Hyungjin Kim

## **CONTENTS**

#### 0-04

0-04 Increased risk of malignancy in patients with Takayasu's arteritis: A population-based cohort study in Korea
Seulkee Lee, Seonyoung Kang, Yeonghee Eun, Hyungjin Kim, Jaejoon Lee,
Eun-Mi Koh, Hoon-Suk Cha
0-05
Increased risk of herpes zoster in patients with rheumatoid arthritis using tofacitinib compared with tumor necrosis factor inhibitor
Yeo-Jin Song, Soo-Kyung Cho, Hyoungyoung Kim, Hye Won Kim, Eunwoo Nam, Ja-Young Jeon, Hyun-Jeong Yoo, Chan-Bum Choi, Tae-Hwan Kim, Jae-Bum Jun, Sang-Cheol Bae, Dae Hyun Yoo, Yoon-Kyoung Sung
0-06
Clinical course and risk factors for development and progression of interstitial lung disease in primary Sjögren's syndrome: A single centered, retrospective, observational study
Kyung-Ann Lee, Bo-Da Nam, Jung Hwa Hwang, Hyun-sook Kim 10
0-07
Comparison of prescription drug use patterns during pregnancy and postpartum in Korean women with rheumatic conditions: A national population-based study
Jisoo Lee, Chan Hee Lee, Min Kyung Chung, Jin Su Park, Hyunsun Lim
0-08 Multidimensional correlates to chronic pain among patients with musculoskeletal pain in different rheumatic diseases: Based on the Biopsychosocial approach
Hee Jun Kim, <u>Hyoun-Ah Kim</u> , Ju-Yang Jung, Ji-Won Kim
[Free Paper Session] Sjögren's Syndrome, Systemic Sclerosis, and Inflammatory Myositis
0-09 IL-17 and CCR9+α4β7– Th17 cells promote salivary gland inflammation, dysfunction, and cell death in Sjögren's syndrome
<u>Jin-Sil Park</u> , Sun-Hee Hwang, Jin Seok Woo, SeungCheon Yang, JeongWon Choi, Mi-La Cho, Sung-Hwan Park
0-10
Correlations between salivary scintigraphic and histopathologic data of salivary glands in patients with Sjögren's syndrome
li-Won Kim Young-Sil An Jin Rob. Jae ho Han

Ji-Won Kim, Young-Sil An, Jin Roh, Jae ho Han, Ju-Yang Jung, Chang-Hee Suh, Hyoun-Ah Kim

#### 0-11

Impact of age on the diagnostic performance of unstimulated salivary flow rates and salivary gland ultrasound for primary Sjögren's syndrome

#### 0-12

Reduced Rxr- $\alpha$  signaling increases dry eye disease inducing  $\gamma\delta$  T17 cells in the conjunctiva

Jehan Alam ----- 174

#### 0-13

Angiographic characteristics of vasculopathy in patients with idiopathic inflammatory myopathies and systemic sclerosis

Jina Yeo, Eun-Ah Park, Eun Bong Lee, Jin Kyun Park ..... 175

Free Paper Session] Sjögren's Syndrome, Systemic Sclerosis, and Inflammatory Myositis	(ENG & KOR
D-14	
The association of anti-cyclic citrullinated peptide antibody with interstitial lung disease in systemic sclerosis: A retrospective analysis	
<u>Jangwoo Ha</u> , Yoo Jin Hong, Hyun Jin Cha, Jeonghun Daniel Moon, Jung Yoon Py Sang-Won Lee, Yong-Beom Park, Chul Hwan Park, Jason Jungsik Sor	· ····· //ł
0-15	
Ultrasound may detect subclinical interstitial lung disease in systemic sclerosis	
<u>MARWIN Gutierrez</u> , Luis E. Gomez-quiroz, Chiara Bertolaz Esteban Cruz-arenas, Denise Clavijo-cornejo, Fausto Sala	1/.
D-16	
Expressions of CCR2 and CCL2, and association between their expression and NET stimulation in adult-onset Still's	disease
Ju-Yang Jung, Mi-Hyun Ahn, Ji-Won Kim, Chang-Hee Suh, Hyoun-Ah Ki	m 178
D-17	
ncreased expression of receptor for advanced glycation end-products in sarcopenic patient skeletal muscle	
<u>Ji Sup Hwang</u> , Hyun Sik Gor	ng 179

[Luncheon Symposium IV - Lilly] The Role of Baricitinib in the Treatment of RA	(KOR)
1. Baricitinib in the real-world data	Yun-Hong Cheon 181

[Luncheon Symposium V - BMS] Real World Evidences in Long-term RA Treatment with Biologic	s	(KOR)
1. Real world evidences and considerations for long-term persistence of biologics in RA	Sang-Hyon Kim	183
2. Real world evidences of RA treatment with biologics in Korea	Jennifer Jooha Lee	184

[Luncheon Symposium VI - Yuhan] The New Adalimumab Option in Rheumatic Diseases Treatment	(ENG)
1. ADALLOCE®(SB5) adalimumab in rheumatic diseases: Data from clinical trials and the real world	Carlo Selmi 186

[International Symposium] 2022 Clinical research Update of Sjögren's Syndrome	(ENG)
1. Big data Sjögren project consortium	Manuel Ramos-Casals 188
2. ESSPRI, a single term with multiple meanings: A consideration based on Korean studies	Yun Jong Lee 189
3. Current and future treatment of primary Sjögren's syndrome	Xavier Mariette 190

## CONTENTS

[Symposium] KCR-KAI Joint Symposium		(KOR)
1. Role of bystander T cells in autoimmune diseases	Je-Min Choi	192
2. Exploration of the key driving molecules in systemic sclerosis-associated interstitial lung disease by the advanced bioinformatic analysis	Ki-Jo Kim	193
3. ZIP8 exacerbates collagen-induced arthritis by increasing pathogenic T cell responses	Sung-Gyoo Park	194
[Free Paper Session] Osteoarthritis and Orthopedics		(ENG & KOR)
0-18 Sodium chloride affects cartilage associated marker expression during in vitro chondrogenesis fr	rom induced pluripotent	stem cell
Kijun Lee, Son Bye	onggwan, Ji Hyeon Ju	196
0-19 Immunomodulation by mesenchymal stromal cell exosomes in osteoarthritis		
<u>Kristeen Ye Wen Teo</u> , Shipin Zhang, Sai Kiar	ng Lim, Wei Seong Toh	197
O-20 Mitochondrial transplantation ameliorates the development and progression of osteoarthritis		
<u>A Ram Lee</u> , Seon-Yeong Lee, Jin Seok Woo, Chae Rim Seok Jung Kim, Sung-	Lee, Keun-Hyung Cho, Hwan Park, Mi-La Cho	198
O-21 Soluble CCR2 gene therapy controls joint inflammation, cartilage damage, and the progression in a monosodium iodoacetate (MIA)-induced OA rat model	of osteoarthritis by targ	eting MCP-1
<u>Hyun Sik Na</u> , Seon-Yeong Lee, Keun -Hyung Cho, A Ra Seok Jung Kim, Sung-	am Lee, Chae Rim Lee, Hwan Park, Mi-La Cho	199
0-22 The potential role of SIRT1 in osteoarthritis pain treatment by blocking the nerve growth factors	3	
<u>Sang Yeob Lee</u> , So You Won Tae C	n Park, Sung Won Lee, Chung, Jun Young Park	200
0-23 Coenzyme Q10 encapsulated in micelles ameliorates osteoarthritis by inhibiting inflammatory o	cell death	
	ok Woo, Jeong Su Lee, Cho, Sung-Hwan Park	201
O-24 Associations between body composition measurements of obesity and the radiographic progre Data from the Dong-gu study	ession of hand osteoart	hritis:
<u>Sung-Eun Choi</u> , Dong-Jii Min-F	n Park, Ji-Hyoun Kang, Io Shin, Shin-Seok Lee	202
O-25 Association of serum uric acid level with bone mineral density in peri-menopausal and postmer A single-center study of 3566 cases	nopausal Korean wome	n:
Seongmin Kang, Seung Won Choi, Su	ı Jin Choi, Doo-Ho Lim	203

#### 0-26

The relationship between the osteoporosis and cortial index of the mandibular bone in rheumatoid arthritis

	Gürkan Iden		204
--	-------------	--	-----

(ENG & KOR)

[International Symposium] Vasculitis Session	(ENG)
1. Somatic mutations in rheumatologic diseases: VEXAS syndrome and beyond	Peter C. Grayson 206
2. Recent basic studies in ANCA-associated vasculitis	Akihiro Ishizu 207
3. Systemic vasculitis in Korea	Chan-Bum Choi 208

[FIEE Faper Session] Kneumatolu Arthintis Chinical Research		[Free Paper Session] Rheumatoid Arthritis Clinical Research
-------------------------------------------------------------	--	-------------------------------------------------------------

#### 0-27

Comparative effectiveness of janus kinase inhibitors and biologic disease-modifying antirheumatic drugs in Korean patients with rheumatoid arthritis; An interim analysis of the real-world study

in Korean patients with meumatoid artimus, An interim analysis of the real-world study
<u>Soo-Kyung Cho</u> , Hyoungyoung Kim, Yeo-Jin Song, Hye Won Kim, Eunwoo Nam, Shin-Seok Lee, Jae Hoon Kim, Seung-Ki Kwok, Yeon Ah Lee, Sung Hae Chang, Hyun-Sook Kim, Bo Young Yoon, Min-Chan Park, Yong-Gil Kim, Hae-Rim Kim, Hye soon Lee, Jisoo Lee, Hyoun-Ah Kim, Sung-Hoon Park, Jeongim Choi, Wan-sik Uhm, Yoon-Kyoung Sung
0-28 Comparative effectiveness and safety profiles of baricitinib and tofacitinib in Rheumatoid arthritis:
A real-world, single center study
Bong-Woo Lee, Youngjae Park, Seung-Ki Kwok, Ji Hyeon Ju, Wan-Uk Kim, Sung-Hwan Park, Jennifer Lee
0-29 Comparative efficacy and safety of IL-6/JAK/STAT pathway inhibitors in rheumatoid arthritis: Systematic review and network meta-analysis
Rudra Goswami, Pallavi Vij, Arindam Banerjee 212
0-30 Impact of early age at menopause on disease outcomes in postmenopausal women with rheumatoid arthritis: Results from a large observational cohort of Korean patients with rheumatoid arthritis
Eun Hye Park, Sang Tae Choi, Jung Soo Song, Eun Ha Kang, Yun Jong Lee, You-Jung Ha
0-31 The implication of persistent pain in patients with rheumatoid arthritis albeit in DAS28-remission: Data from the KOBIO registry
Hyoun-Ah Kim, So Young Park, Kichul Shin 214
0-32 Increased risk of dementia in patients with rheumatoid arthritis: A nationwide population-based cohort study
Yeonghee Eun, Kyungdo Han, Seonyoung Kang, Seulkee Lee, Hoon-Suk Cha, Eun-Mi Koh, Jaejoon Lee, Hyungjin Kim

0-33

Retention rate and safety of biologics or targeted synthetic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis associated with interstitial lung disease: Results from the KOBIO registry

Sun-Kyung Lee, Kichul Shin, Hyoun-ah Kim ..... 216

## CONTENTS

0-34

Tumor Necrosis Factor (TNF) inhibitors does not accelerate the progression of RA-ILD: Results from the KORAIL cohort

<u>Yeon-Ah Lee</u>, Sang Wan Chung, Sujin Jeong, Ji Sung Lee, Jeong Seok Lee, Chan Ho Park, Min Uk Kim, You-Jung Ha, Eun Ha Kang, Sung Hae Chang, Yongbeom Park, Ji Won Kim, Jung-Yoon Choe, Eun Young Lee

[Symposium] Medical Humanities: Work Ethics and Labor Relation in the COVID-19 Era	(KOR)
1. The ethics of hospital human resource development during the pandemic: Ethical principles	Ilhak Lee 219
2. Labor issues in the COVID-19 situation: Cases and alternatives	Dong Wook Yun 220

Bay 3 May 21(Sat) 2022		
[Breakfast Symposium I – Yuhan] Valuable Options for Treatment Rheumatic Disease		(KOR)
1. Biosimilar: Past, present and future	Seung-Jae Hong	224
[Breakfast Symposium – Lilly] Ixekizumab: Recent Updates on the Treatment of Spondyloarthri	itis	(KOR)
1. IL-17 inhibition in spondyloarthritis: The efficacy of Ixekizumab and clinical relevance	Yeon-Ah Lee	226
[Breakfast Symposium – Janssen] Redefine Persistence in AS Management		(KOR)
1. Long-Lasting golimumab in AS: Learning from real-world evidence	Bon San Koo	228
[Keynote Lecture]		(ENG)
1. The Future of rheumatology	Antony Rosen	230
[International Symposium] Treatment of Osteoarthritis: To be Used and Abused?	David Hunter	(ENG)
2. Addicted to prescription, medical abuse of osteoarthritis		233
3. Use or abuse? APM for degenerative meniscus in osteoarthritis	Hyun Ah Kim	234
[Free Paper Session] Spondyloarthritis		(KOR)
0-35 Physical trauma exacerbates arthritis and enthesitis in curdlan-administered SKG mice model		
Seung Hoon Lee, Chanhyeok Jeon, Sungs	in Jo, Tae-Hwan Kim	236
0-36 PPM1A promotes matrix mineralization of osteoblasts differentiation via FOXO1A-RUNX2 pathw	vay in ankylosing spon	dylitis
<u>Subin Weon</u> , Sungsin Jo, Ye-Soo Park, Yong-Gi	l Kim, Tae-Hwan Kim	237
O-37 A pilot study on deep learning-based grading of the corner of vertebral body for the assessment of in patients with ankylosing spondylitis	of radiographic progre	ssion
Bon San Koo, Jae Joon Lee, Jae-Woo Ju Kyung Bin Joo, Tae-Hwai		238

## CONTENTS

#### 0-38

Analysis of radiographic progression in patients with ankylosing spondylitis: Using group-based trajectory modeling and decision trees

Se	<u>Juyeon Kang</u> , Tae-Han Lee, Bon San Koo, o Young Park, Seunghun Lee, Tae-Hwan Kim	239
	o roung ran, occurring ran Lee, rae riwarrain	
0-39 The spinal radiographic change correlates with past alkaline phosphatas	e levels in patients with ankylosing spondylitis	3
S	<u>Bon San Koo</u> , Seo Young Park, Ji Hui Shin, Seunghun Lee, Kyung Bin Joo, Tae-Hwan Kim	240
0-40 CCL20 inhibition for treating inflammation in ankylosing spondylitis		
<u>Hui-Ju Kim</u> , Hae-in Lee, So-Hee Jin, Ah-Ra Cho Kyeong Hwan Byeon, Seor	oi, Soon Mi Choi, Moon-ju Kim, Yu Jeong Lee, ng Hoon Kim, Eun Jeong Won, Tae-Jong Kim	241
0-41 Metagonimus yokogawai-derived protein attenuates inflammation in ank	ylosing spondylitis	
<u>Moon-Ju Kim</u> , Yu Jeong Lee, Kyeong Hwan Byeon, Seong H Ah-Ra Choi, Soon Mi Choi, Sungsin Jo, Ta	oon Kim, Hae-in Lee, Hui-Ju Kim, So-Hee Jin, ae-Hwan Kim, Eun Jeong Won, Tae-Jong Kim	242
0-42 Long-term treatment with ixekizumab in patients with axial spondyloarthi	ritis: Two-year results from COAST-Y	
Jürgen Braun, Uta Kiltz, Atul Deodhar, Tetsuya Tomita, Maxime David Adams,	e Dougados, Rebecca Bolce, David Sandoval, , Chen-Yen Lin, Jessica Walsh, <u>Young In Eom</u>	243
[Free Paper Session] Systemic Lupus Erythematosus		(ENG & KOR)
0-43		
B cell-specific deletion of Crif1 drives lupus-like autoimmunity by activate	on of IL-17, IL-6, and pathogenic Tfh cells	
<u>Jin-Sil Park</u> , SeungCheon Yang, Sun-F	on of IL-17, IL-6, and pathogenic Tfh cells lee Hwang, JeongWon Choi, Seung-Ki Kwok, g, Jeehee Youn, Mi-La Cho, Sung-Hwan Park	245
<u>Jin-Sil Park</u> , SeungCheon Yang, Sun-F	lee Hwang, JeongWon Choi, Seung-Ki Kwok, g, Jeehee Youn, Mi-La Cho, Sung-Hwan Park	
<u>Jin-Sil Park</u> , SeungCheon Yang, Sun-H Young-Yun Kon 0-44 Biological insights into systemic lupus erythematosus through an immur	lee Hwang, JeongWon Choi, Seung-Ki Kwok, g, Jeehee Youn, Mi-La Cho, Sung-Hwan Park	
<u>Jin-Sil Park</u> , SeungCheon Yang, Sun-H Young-Yun Kon 0-44 Biological insights into systemic lupus erythematosus through an immur	Hee Hwang, JeongWon Choi, Seung-Ki Kwok, g, Jeehee Youn, Mi-La Cho, Sung-Hwan Park ne cell-specific transcriptome-wide association rong Yin, Kwangwoo Kim, Hiroyuki Suetsugu, Chikashi Terao, Yong Cui, Sang-Cheol Bae	n study
0-44 Biological insights into systemic lupus erythematosus through an immur Xiany 0-45 The association between CD40 rs4810485 polymorphism and susceptib	Hee Hwang, JeongWon Choi, Seung-Ki Kwok, g, Jeehee Youn, Mi-La Cho, Sung-Hwan Park ne cell-specific transcriptome-wide association rong Yin, Kwangwoo Kim, Hiroyuki Suetsugu, Chikashi Terao, Yong Cui, Sang-Cheol Bae	n study 246
0-44 Biological insights into systemic lupus erythematosus through an immur Xiany 0-45 The association between CD40 rs4810485 polymorphism and susceptib	Hee Hwang, JeongWon Choi, Seung-Ki Kwok, g, Jeehee Youn, Mi-La Cho, Sung-Hwan Park ne cell-specific transcriptome-wide association <u>rong Yin</u> , Kwangwoo Kim, Hiroyuki Suetsugu, Chikashi Terao, Yong Cui, Sang-Cheol Bae ility of systemic lupus erythematosus:	n study 246
Jin-Sil Park, SeungCheon Yang, Sun-HYoung-Yun Kon         0-44         Biological insights into systemic lupus erythematosus through an immur         Xiany         0-45         The association between CD40 rs4810485 polymorphism and susceptib         Systematic review and meta analysis         0-46         The role of sphingolipids in patients with systemic lupus erythematosus	Hee Hwang, JeongWon Choi, Seung-Ki Kwok, g, Jeehee Youn, Mi-La Cho, Sung-Hwan Park ne cell-specific transcriptome-wide association <u>rong Yin</u> , Kwangwoo Kim, Hiroyuki Suetsugu, Chikashi Terao, Yong Cui, Sang-Cheol Bae ility of systemic lupus erythematosus:	n study 246 247
Jin-Sil Park, SeungCheon Yang, Sun-HYoung-Yun Kon         0-44         Biological insights into systemic lupus erythematosus through an immur         Xiany         0-45         The association between CD40 rs4810485 polymorphism and susceptib         Systematic review and meta analysis         0-46         The role of sphingolipids in patients with systemic lupus erythematosus	Hee Hwang, JeongWon Choi, Seung-Ki Kwok, g, Jeehee Youn, Mi-La Cho, Sung-Hwan Park ne cell-specific transcriptome-wide association <u>rong Yin</u> , Kwangwoo Kim, Hiroyuki Suetsugu, Chikashi Terao, Yong Cui, Sang-Cheol Bae ility of systemic lupus erythematosus: <u>Rizki Febriawan</u> , Nurul Fajri Widyasari u-Yang Jung, Hyoun-Ah Kim, Chang-Hee Suh	n study 246 247 248
Jin-Sil Park, SeungCheon Yang, Sun-Hyoung-Yun Kon         0-44         Biological insights into systemic lupus erythematosus through an immur         Xiany         0-45         The association between CD40 rs4810485 polymorphism and susceptib         Systematic review and meta analysis         0-46         The role of sphingolipids in patients with systemic lupus erythematosus         Ji-Won Kim, Jule         0-47         Combined model of renal histopathology and clinical parameters better panalysis of 334 Kidney Biopsies	Hee Hwang, JeongWon Choi, Seung-Ki Kwok, g, Jeehee Youn, Mi-La Cho, Sung-Hwan Park ne cell-specific transcriptome-wide association <u>rong Yin</u> , Kwangwoo Kim, Hiroyuki Suetsugu, Chikashi Terao, Yong Cui, Sang-Cheol Bae ility of systemic lupus erythematosus: <u>Rizki Febriawan</u> , Nurul Fajri Widyasari u-Yang Jung, Hyoun-Ah Kim, Chang-Hee Suh	n study 246 247 248

O-48 Coexisting tubulointerstitial inflammation and damage is a risk factor for chronic kidney disease in Results from the KORNET registry	n patients with lupus	nephritis:
Dong-Jin Park, Sung-Eun Choi, Ji-Hyoun K	ang, Shin-Seok Lee	250
O-49 Subtherapeutic hydroxychloroquine concentration is associated with increased disease activity an 5-year follow-up in patients with systemic lupus erythematosus	d greater organ dam	age during
<u>Ji-Hyoun Kang</u> , Sung-Eun Choi, Dong-Jin F	Park, Shin-Seok Lee	25
O-50 Effect of smoking on thrombotic events in antiphospholipid syndrome: A large prospective cohort	study	
<u>Hui Jang</u> , Jiuliang Zhao, M	lentao Li, Yan Zhao	252
0-51 Efficacy of rivoraxaban in patients with antiphospholipid syndrome		
Zumrad Ubaydullaeva, Anis Alyavi, Jamol Uzoko	ov, Bekzod Karimov	253
[Luncheon Symposium VII - Novartis] Understanding IL-17 Inhibition in SpA 1. The role of IL-17A in Ankylosing spondylitis and axial PsA	Matthew Brown	(ENG
[Luncheon Symposium VIII - Amgen] Move Forward with the Long-term Protection of Prolia		(KOR
1. Denosumab key clinical questions	Sung-Soo Kim	25
[Luncheon Symposium IX – Astellas] Tacrolimus		(KOR
1. Tacrolimus in rhematoid arthritis	Chan-Bum Choi	25
[International Symposium] Synovial Macrophage and Fibroblast in RA		(ENG
1. Synovial macrophages as gatekeepers of inflammation	Gerhard Krönke	26

Soumya Raychaudhuri ----- 262 rheumatoid arthritis

Sang-il Lee ----- 263 3. Roles of stromal cells and potential significance for future therapy in RA

2. Cellular deconstruction of inflamed synovium defines diverse inflammatory phenotypes in

## CONTENTS

		()
[Symposium] KCR-KSBMR Joint Symposium		(KOR)
1. Anabolic therapy for osteoporosis	Ha Young Kim	265
2. Ideal sequential therapy in osteoporosis management	Kyoung Min Kim	266
3. Prevention and treatment of fracture in RA	Jun-Ki Min	267
[Free Paper Session] Vasculitis and Metabolic Bone Disease		(ENG & KOR)
0-52 Update on comparative cardiovascular safety of febuxostat versus allopurinol among p	atients with gout	
Anna Shin, <u>Se Rim Choi</u> , Minji Han, You-Jung Ha, Yun Jong Le	e, Eun Bong Lee, Eun Ha Kang	269
O-53 The utility of dual-energy computed tomography in predicting gout flares in gout patients <u>Min Jung Kim</u> , Mi Hyeon I		ophylaxis
Jiin Jung, Ju Yeon Kim, Sang Hee K		2/0
O-54 Effects of long-term febuxostat or allopurinol on the progression of chronic kidney disea	ase	
<u> </u>	<u>Byeongzu Ghang</u> , Jinseok Kim	271
0-55 A cross-sectional internet survey of gout management and outcomes during establishe	d COVID-19 pandemic in 2020-2	2021
Jasvinde	<u>er Singh</u> , N Lawrence Edwards	272
O-56 The effect of Behçet's disease on carotis intima media thickness and its relationship wi	th disease activity	
Merve Polat, 0	Gökhan Polat, Elshad İsmailov	273
O-57 Reclassification of patients with previously diagnosed GPA according to both the 2012 and the 2007 EMA algorithm using the 2022 ACR/EULAR criteria	CHCC definitions	
<u>Jung Yoon Pyo</u> , Sung Soo Ahn, Jason Jungsik Song, Yo	ng-Beom Park, Sang-Won Lee	274
0-58 Patterns of coronary involvement of antineutrophil cytoplasmic antibody (ANCA) -assoc	ciated vasculitis in Korean patie	nts
	<u>Jinseok Kim</u> , Sang-won Lee	275

0-59

Comparison of Ultrasound-Guided Trigger-Point Needling and blinded needling for Myofascial Pain Syndrome

Recep Sade, Meltem Alkan melikoglu ..... 276

[International Symposium] New Horizon of Systemic Sclerosis	(ENG)
1. Update in the pathogenesis of systemic sclerosis	Christopher Denton 278
2. Update in interstitial lung disease in SSc	Olivier Distler 279
3. Update in pulmonary arterial hypertension in SSc	Eun Bong Lee 280

[Free Paper Session] Rheumatoid Arthritis Basic Research	(ENG & KOR)
O-60 Orosomucoid Acid-2, an acute phase reactant, promotes rheumatoid inflammation	
Kimyo Kim, Bong-Ki Hong, Seung-Ah Yoo, Wan Uk Kim	282
0-61 LKB1 regulates the migration of fibroblast-like synoviocytes via oxidative stress-induced inflammatory cytokines in patients with rheumatoid arthritis	
<u>Ha-Reum Lee</u> , Jinhyun Kim, Su-Jin Yoo, Ji Ah Park, Seong Wook Kang	283
0-62 Postranslational modification in mammals protects citrullinated MCP1/CCL2 chemokine from partial degradation	
<u>Nataliia Korchynska</u> , Ken Yoshida, Paul Peter Tak, Ger J.M. Pruijn, Takeo Isozaki, Jeffrey H. Ruth, Phillip L. Campbell, M.Asif Amin, Alisa E. Koch, Olexandr Korchynskyi	284
0-63 Assessment of disease activity in patients with rheumatoid arthritis utilizing plasma tumor M2-pyruvate kinase test	
Sung Soo Ahn, Younhee Park	285
0-64 Association analysis of a MUC5B promoter variant rs35705950 with rheumatoid arthritis-interstitial lung disease in Ko	rea
<u>Young Bin Joo</u> , So-Young Bang, Soo-Kyung Cho, Chan-Bum Choi, Yoon-Kyoung Sung, Tae-Hwan Kim, Jae-Bum Jun, Dae Hyun Yoo, Sang-Cheol Bae, Hye-Soon Lee	286
0-65 Therapeutic effect of folic acid in collagen-induced arthritis mouse model	
<u>Kijun Lee</u> , Young Woo Ryu, Ji Hyeon Ju	287
[Symposium] Coding and Insurance Guideline in Rheumatic Disease	(KOR)
1. Rheumatic diseases and KCD 8th revision Sukil Kim	289

2. Principles and future prospects of insurance benefits in rheumatoid diseases

3. Insurance guideline and tips for treatment of rheumatic disease

Gihyeon Seo ----- 290

Seung-Jae Hong ----- 291

## **E-POSTER PRESENTATION**

RA-pathogenesis and animal model & Cytokines and mediators
------------------------------------------------------------

P-001

Anti-arthritic activities of the Eleutherococcus senticosus, Achyranthes japonica, and Atractylodes japonica mixed extract fermented with nuruk in a type II collagen-induced arthritis mouse model

extract remember with holds in a type in conagen induced artimus moder	
Chong Hyuk Chung, Ju-Young Kim, Yoon-Hee Cheon,	295
So-Young Eun, Chang-hoon Lee, Myeung-Su Lee	
P-002 A green-lipped mussel prevents rheumatoid arthritis via regulation of inflammatory response and osteoclastogenesis	
Seungcheon Yang, Hong Ki Min, Jin-Sil Park, Hyun Sik Na,	
Jooyeon Jhun, Mi-La Cho, Sung-Hwan Park	296
P-003 HLA-DRB1 non-SE fine specificity associations with anti-RA33 autoantibody positivity in rheumatoid arthritis patients stratified by different serological phenotypes	
<u>Nurul Aain Ahmad fauzi</u> , Shereen Ch'ng suyin, Hazlyna Baharuddin, Mollyza Mohd zain, Ing Soo Lau, Habibah Yusoof, Azlin Ahmad, Azmillah Rosman, Siti Aisyah Abdul ahmad, Wahinuddin Sulaiman, Heselynn Hussein, Nor Shuhaila Shahril, Suk Chyn Gun, Eashwary Mageswaran, Mohd Shahrir Mohamed said, Ainon Mohd mokhtar, Muhaini Othman, Shahnaz Murad, Leonid Padyukov, Lars Alfredsson, Lars Klareskog, Johan Rönnelid, Chun Lai Too	297
P-004 Precision nanomedicine in rheumatoid arthritis: customized multifunctional polymeric nanocarriers for alleviation of inflammation severity in rheumatoid arthritic rats	
Anas Ahmad	298
P-005 APE1 inhibits the inflammation of fibroblast-like synoviocytes via oxidative stress regulation in patients with rheumatoid arthritis	
Ha-Reum Lee, Jinhyun Kim, Su-Jin Yoo, Ji Ah Park, Hee Kyoung Joo, Yu Ran Lee,	299
Sungmin Kim, Byeong Hwa Jeon, Seong Wook Kang	299
P-006 A novel cytokine consisting of p40 and EBI3 subunits suppresses experimental autoimmune arthritis via reciprocal regulation of Th17 and Treg cells	
<u>Seon-Yeong Lee,</u> Young-Mee Moon, Su-Jin Moon, A Ram Lee, Chae Rim Lee, Seung-Ki Kwok, Sung-Hwan Park, Mi-La Cho	300
RA-clinical aspects	
P-007 Seasonal analysis of relative search volume of rheumatoid arthritis in Korea	
Eunsung Kim	302
P-008 Cardiac hydatid cyst in a patient with rheumatoid arthritis	
<u>Giorgi Apkhazava</u> , Grigol Nemsadze, Megi Kurtanidze	303

RA-clinical aspects	
P-009 Course of COVID-19 in patients with rheumatoid arthritis (own data)	
<u>Eugenia Aronova</u> , Galina Gridneva, Boris Belov	304
P-010 Study of the features of post-covid syndrome in patients with rheumatoid arthritis	
Eugenia Aronova, Galina Gridneva, Boris Belov	305
P-011 Ultrasound as a potential tool to detect interstitial lung disease in daily clinical setting of patients with rheumatoid arthritis	
<u>MARWIN Gutierrez</u> , Santiago Ruta, Denise Clavijo-cornejo, Gabriela Fuentes-moreno, Samuel Reyes-long, Chiara Bertolazzi	306
P-012 Rheumatoid factor (RF) and anti-cyclic citrullinated protein autoantibodies (ACPA) seroconversion and seroreversion in rheumatoid arthritis patients between 2005 and 2021	
<u>Chun Lai Too</u> , Nurul Aain Ahmad-fauzi, Haziqah Itqan Alias, Nur Aida Sabrina Mohd-rashid, Siti Aisyah Abdul-ahmad, Mollyza Mohd-zain, Ing Soo Lau, Hazlyna Baharuddin, Diana Lee Min Ang, Lisa Mohamed-nor, Rashidah Bahari, Amnahliza Abdul-rahman, Ping Seung Ong, Noraini Mat-husin, Wahinnudin Sulaiman, Suk Chyn Gun, Nadiah Mohd-nor, Heselynn Hussein, Eashwary Mageswaran, Mohd Shahrir Mohamed-said, Ainon Mohd-mokhtar, Azmillah Rosman, Muhaini Othman, Mohd Zainuldin Taib, Shahnaz Murad, Leonid Padyukov, Lars Alfredsson, Lars Klareskog, Johan Ronnelid, Nor Shuhaila Shahril	307
P-013 Autoantibodies sustainability in rheumatoid arthritis (RA) patients and their clinical characteristics: Malaysian real-world data between 2005 and 2021	
<u>Chun Lai Too</u> , Nurul Aain Ahmad-fauzi, Haziqah Itqan Alias, Nur Aida Sabrina Mohd-rashid, Siti Aisyah Abdul-ahmad, Mollyza Mohd-zain, Ing Soo Lau, Hazlyna Baharuddin, Diana Lee Min Ang, Lisa Mohamed-nor, Rashidah Bahari, Amnahliza Abdul-rahman, Ping Seung Ong, Noraini Mat-husin, Wahinuddin Sulaiman, Suk Chyn Gun, Nadiah Mohd-noor, Heselynn Hussein, Eashwary Mageswaran, Mohd-shahrir Mohamed-said, Ainon Mohd-mokhtar, Azimillah Rosman, Muhaini Othman, Mohd Zainuddin Taib, Shahnaz Murad, Leonid Padyukov, Lars Alfredsson, Lars Klareskog, Johan Ronnelid, Nor Shuhaila Shahril	308
P-014 Use of disease-modifying anti-rheumatic drugs after cancer diagnosis in rheumatoid arthritis patients	
<u>Kyung-Su Park</u> , Young-Bin Joo, Seung Min Jeong, Yune-Jung Park, Ki-Jo Kim	309
P-015 The relationship between Anti-CCP, C-reactive protein in serum and rheumatoid factor in synovial fluid in patients with rheumatoid arthritis in the Kyrgyz Republic	
Nazgul Omurzakova, Akpay Sarybaev	310
P-016 Impact of comorbidity on disease activity and functional status in patients with rheumatoid arthritis receiving biologic DMARDs, a longitudinal analysis of the KOBIO-RA	
Ju Yeon Kim, Kichul Shin, Eun Bong Lee, Jun Won Park	311

RA-treatment	
2-017	
s a cumulative dose of methotrexate important for rapid remission in rheumatoid arthritis?	
<u>Galina Gridneva</u> , Eugenia Aronova, Natalia Baymeeva, Svetlana Glukhova, Yury Muraviev	31:
2-018 Clinical predictors of inadequate response to conventional synthetic and biologic DMARDs in Chinese patients vith rheumatoid arthritis	
Hui Zhong, Yanhong Wang, Jiuliang Zhao, Nan Jiang, Qian Wang, Xinping Tian, Dong Xu, Mengtao Li, Xiaofeng Zeng	314
2-019 Stereotypical" adverse reactions to non-biologic Disease Modifying Anti-Rheumatic Drugs in patients vith rheumatoid arthritis requiring biological therapy	
Elena Matianova, Galina Gridneva, Eugenia Aronova	315
P-020 The efficacy and safety of biologic DMARDs on progression of RA-ILD	
<u>Sang Wan Chung</u> , Sujin Jeong, Ji Sung Lee, Jeong Seok Lee, Chan Ho Park, Min Uk Kim, You-Jung Ha, Eun Ha Kang, Sung Hae Chang, Yongbeom Park, Jung-Yoon Choe, Eun Young Lee, Yeon Ah Lee	316
2-021 Management of rheumatoid arthritis in China: a study of the implementation of 2021 ACR guideline	
Shangyi Jin, Nan Jiang, Qian Wang, Mengtao Li, Xinping Tian	317
P-022 Study of methotrexate metabolism in patients taking statins	
Galina Gridneva, Eugenia Aronova, Elena Samarkina, Natalia Baymeeva	318
P-023 Digital aging and mental health deteriorations: How can we mitigate the risk among the elderly with rheumatoid arthritis disease in indonesia?	
Rosinta Hotmaida Pebrianti Purba	319
P-024 Comparison of drug persistence between tumor necrosis factor-α inhibitors and tocilizumab in patients as first-line reatment with rheumatoid arthritis using the Korean health insurance review and assessment service database.	
Byung Wook Song, Dong-Hyuk Moon, Aran Kim, Seung-Geun Lee	320
2-025 mpact of Korean red ginseng on fatigue in patients with rheumatic disease: A randomized, double-blind study	
Soo-Kyung Cho, Hyoungyoung Kim, Yeo-Jin Song, Hye Won Kim, Eunwoo Nam, Yoon-Kyoung Sung	32
P-026 The Preoperative Patient's Expectations and It's Clinical Outcomes After Rheumatoid Forefoot Deformity Surgery	
	322

SLE-clinical aspects, APS	
2-027 Effect of systemic lupus erythematosus on carotid intima media thickness and its relationship with disease activity	
Gökhan Polat, Elshad Ismailov, Merve Polat	324
P-028 Vernicke encephalopathy secondary to systemic lupus erthematosis enteropathy	
Arzu Shahveranova	
P-029 Prognostic factors for the development of systemic lupus erythematosus n patients with immune thrombocytopenia	
Soo Min Ahn, Eun-Ji Choi, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo, Seokchan Hong	326
P-030 A case of portal and hepatic vein occlusion in systemic lupus erythematosis	
Mehmet Selim Kan, Muhammed Eyyüp Çelik, Elshad İsmailov	327
2-031 Disease flare of systemic lupus erythematosus in patients with end-stage renal disease on dialysis	
<u>Young-Eun Kim</u> , Su Jin Choi, Doo-Ho Lim, Soo Min Ahn, Ji Seon Oh, Yong-Gil Kim, Chang-Keun Lee, Bin Yoo, Seokchan Hong	328
P-032 Clinical relevance according to staining patterns and titers of antinuclear antibody	
Mi Ryoung Seo, Jina Yeo, Hyo-Jin Choi, Han Baek	329
2-033 .ong-term renal outcomes of patients with non-proliferative lupus nephritis	
<u>Eunsong Kang</u> , Seokchan Hong, Yong Gil Kim, Ji Seon Oh, Soomin Ahn, Chang Keun Lee, Bin Yoo	330
P-034 Computer aided detection of the white matter lesions associated with systemic lupus erythematosus n cranial magnetic resonance imaging	
Ahmet Yalcin, Fatih Alper	331
2-035 nternuclear ophthalmoplegia in lupus cerebritis: Double jeopardy	
Paul Shiu, Navneet Kaur, Anil Harrison, Howard Feinberg	332
2-036 Vorking memory and processing speed in systemic lupus erythematosus: Correlation with disease activity	

P-037 Etiology of raised serum creatinine in patients with systemic lupus erythematosus at presentation and association of number of crescents in renal biopsy with rapidly progressive renal failure	
RAJAT Kharbanda, Able Lawrence	33
P-038 CRP elevation in SLE pericarditis: Not all patients with SLE pericarditis have an elevated CRP value	
<u>Hyunsue Do</u> , Yong-Beom Park	33
P-039 Prevalence of latent tuberculosis infection and its associations with clinical and serological parameters in systemic upus erythematosus	
<u>Gayathri Ms</u> , Prakash Babu Narasimhan, Chengappa Kavadichanda, Aishwarya Gopal, Devender Bairwa, Molly Mary Thabah, Sonali Sarkar, Vir Singh Negi	3:
P-040 Comparision of physical functions of systemic lupus erythematosis and healthy persons and their relationship with disease activity	
Yasin Baki Baydas	3:
SLE-pathogenesis and animal model	
P-041 Vitronectin, a novel urinary proteomic biomarker, promotes cell pyroptosis in juvenile systemic lupus erythematosus	
	3:
Vitronectin, a novel urinary proteomic biomarker, promotes cell pyroptosis in juvenile systemic lupus erythematosus	
Vitronectin, a novel urinary proteomic biomarker, promotes cell pyroptosis in juvenile systemic lupus erythematosus <u>Zhe Cai</u> , Song Zhang, Huasong Zeng P-042 Effect of tumor necrosis factor-α gene polymorphisms in risk of systemic lupus erythematosus patients susceptibility	:
Vitronectin, a novel urinary proteomic biomarker, promotes cell pyroptosis in juvenile systemic lupus erythematosus <u>Zhe Cai</u> , Song Zhang, Huasong Zeng P-042 Effect of tumor necrosis factor-α gene polymorphisms in risk of systemic lupus erythematosus patients susceptibility Update meta-analysis <u>Steven Irving</u> , Bastomy Eka Rezkita,	:
Vitronectin, a novel urinary proteomic biomarker, promotes cell pyroptosis in juvenile systemic lupus erythematosus <u>Zhe Cai</u> , Song Zhang, Huasong Zeng P-042 Effect of tumor necrosis factor-α gene polymorphisms in risk of systemic lupus erythematosus patients susceptibility Update meta-analysis <u>Steven Irving</u> , Bastomy Eka Rezkita,	:
Vitronectin, a novel urinary proteomic biomarker, promotes cell pyroptosis in juvenile systemic lupus erythematosus <u>Zhe Cai</u> , Song Zhang, Huasong Zeng P-042 Effect of tumor necrosis factor-α gene polymorphisms in risk of systemic lupus erythematosus patients susceptibility Update meta-analysis <u>Steven Irving</u> , Bastomy Eka Rezkita, Rabbinu Rangga Pribadi, Marcellus Simadibrata	:
Vitronectin, a novel urinary proteomic biomarker, promotes cell pyroptosis in juvenile systemic lupus erythematosus Zhe Cai, Song Zhang, Huasong Zeng P-042 Effect of tumor necrosis factor-α gene polymorphisms in risk of systemic lupus erythematosus patients susceptibility Update meta-analysis <u>Steven Irving</u> , Bastomy Eka Rezkita, Rabbinu Rangga Pribadi, Marcellus Simadibrata	:
Vitronectin, a novel urinary proteomic biomarker, promotes cell pyroptosis in juvenile systemic lupus erythematosus Zhe Cai, Song Zhang, Huasong Zeng P-042 Effect of tumor necrosis factor-α gene polymorphisms in risk of systemic lupus erythematosus patients susceptibility Update meta-analysis <u>Steven Irving</u> , Bastomy Eka Rezkita, Rabbinu Rangga Pribadi, Marcellus Simadibrata SLE-treatment P-043 A retrospective single center study of the clinical response of tacrolimus treatment in patients with lupus nephritis	:
Vitronectin, a novel urinary proteomic biomarker, promotes cell pyroptosis in juvenile systemic lupus erythematosus Zhe Cai, Song Zhang, Huasong Zeng P-042 Effect of tumor necrosis factor-α gene polymorphisms in risk of systemic lupus erythematosus patients susceptibility Update meta-analysis Steven Irving, Bastomy Eka Rezkita, Rabbinu Rangga Pribadi, Marcellus Simadibrata SLE-treatment P-043 A retrospective single center study of the clinical response of tacrolimus treatment in patients with lupus nephritis Ji-Won Kim, Ju Jung, Hyoun-Ah Kim, Chang-Hee Suh P-044 Acute pancreatitis after corticosteroid pulse therapy in rheumatic disease: Acute pancreatitis is common adverse reaction after corticosteroid pulse therapy	: 3,
Vitronectin, a novel urinary proteomic biomarker, promotes cell pyroptosis in juvenile systemic lupus erythematosus Zhe Cai, Song Zhang, Huasong Zeng P-042 Effect of tumor necrosis factor-a gene polymorphisms in risk of systemic lupus erythematosus patients susceptibility Update meta-analysis <u>Steven Irving</u> , Bastomy Eka Rezkita, Rabbinu Rangga Pribadi, Marcellus Simadibrata SLE-treatment P-043 A retrospective single center study of the clinical response of tacrolimus treatment in patients with lupus nephritis <u>Ji-Won Kim</u> , Ju Jung, Hyoun-Ah Kim, Chang-Hee Suh P-044 Acute pancreatitis after corticosteroid pulse therapy in rheumatic disease: Acute pancreatitis is common adverse reaction after corticosteroid pulse therapy <u>Jinseok Kim</u> , Yong-Beom Park	: 3,
Vitronectin, a novel urinary proteomic biomarker, promotes cell pyroptosis in juvenile systemic lupus erythematosus Zhe Cai, Song Zhang, Huasong Zeng P-042 Effect of tumor necrosis factor-α gene polymorphisms in risk of systemic lupus erythematosus patients susceptibility Update meta-analysis Steven Irving, Bastomy Eka Rezkita, Rabbinu Rangga Pribadi, Marcellus Simadibrata SLE-treatment P-043 A retrospective single center study of the clinical response of tacrolimus treatment in patients with lupus nephritis Ji-Won Kim, Ju Jung, Hyoun-Ah Kim, Chang-Hee Suh P-044 Acute pancreatitis after corticosteroid pulse therapy in rheumatic disease: Acute pancreatitis is common adverse reaction after corticosteroid pulse therapy	: 3,

Spondyloarthropathies and psoriatic arthritis	
P-046 Vitronectin-derived bioactive peptide prevents spondyloarthritis by modulating Th17/Treg imbalance in mice with curdlan-induced spondyloarthritis	
<u>Hong Ki Min</u> , JeongWon Choi, Seon-Yeong Lee, A Ram Lee, Byung-Moo Min, Mi-La Cho, Sung-Hwan Park	 346
P-047 The relationship between the osteoporosis and cortial index of the mandibular bone in psoriatic arthritis	
<u>Viliam Gasanova</u> , Gürkan İden	 347
P-048 Evaluation of the relationship between ankylosing spondylitis and its inflammation indicator calprotectin and its relationship with disease activity	
<u>Mehmet Alperen Tezca</u> n, Ekin Başak Doğancı	 348
P-049 Investigation of the relationship of ankylosing spondylit and varicocele	
Muhammed Emre Isıktas, Cafer Koçak, Halid Yener	 349
P-050 The effect of ankylosing spondylitis on carotis intima media thickness and its relationship with disease activity	
Elshad İsmailov, Merve Polat, Gökhan Polat	 350
P-051 Predictive role of neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio and platelet-to-lymphocyte ratio in the assessment of clinical response and drug persistence of tumor necrosis factor-alpha inhibitors in patients with ankylosing spondylitis	
Dong Hyuk Moon, Seung-Geun Lee, Aran Kim, Byung Wook Song	 351
P-052 A deep-learning-based approach for automated assessment of modified stoke ankylosing spondylitis spine score (mSASSS) on spine radiographs: A preliminary study	
<u>Sun Yeop Lee,</u> Dong Hyun Kim, Hee-Dong Chae, Hongjun Yoon, Hyo Jin Kim, Jiwoon Seo, Jee Won Chai, Sung Hwan Hong, Ja-Young Choi, Burnyoung Kim, Ara Seo, Songhwan Lim	352
P-053 Intra-articular corticosteroids for sacroiliitis in treatment of spondyloarthritis	
<u>Pallavi Vij</u> , Rudra P Goswami, Danveer Bhadu, Uma Kumar	 353
P-054 Drug retention of biologic agents in Korean patients with psoriatic arthritis	 
<u>Ju Yeon Kim</u> , Min Jung Kim, Sun Im Yun, So Young Park, Jiyu Sun, Jung Hee Koh, Hyoun-Ah Kim, Jinhyun Kim, Kichul Shin	354
P-055 Safety profile of Ixekizumab for the treatment of psoriatic arthritis and axial spondyloarthritis up to 3 Years: An updat- ed integrated safety analysis	
Sergio Schwartzman, Atul Deodhar, Bernard Combe, Ana Accioly, Andris Kronbergs, Boris Janos, Danting Zhu, David Sandoval, Proton Rahman, Denis Poddubnyy, <u>Young In eom</u>	355

### Spondyloarthropathies and psoriatic arthritis

P-056

A comparison of physical functions and its relationship with disease activity of persons with ankylosing spondilitis

<u>Aysenur Kara</u>		356
Behçet's disease & Vasculitis		
P-057 Diagnostic value of 3D T1-weighted sampling perfection with application optimized contrast evolution (SPACE) magnetic resonance imaging in patients with giant cell arteritis		
Recep Sade, Meltem Alkan melikoglu		358
P-058 Determination of the frequency of entositis and its relationship with disease activity in Behçet's disease by ultrasonography		
Serhat Kaya		359
P-059 NeuroBehçet with spinal leptomeningeal involvement		
<u>Oğuzhan Mete</u> , Gökhan Polat		360
P-060 Investigation of the frequency of varicocele in Behçet's disease		
<u>Cafer Koçak</u> , Halid Yener, Emre Işıktaş		361
P-061 The relationship of venous involvement with disease activity in Behçet's syndrome		
Muhammed Halid Yener, Emre Isıktas, Cafer Koçak		362
P-062 Serum albumin, prealbumin, and ischemia-modified albumin levels in patients with ANCA-associated vasculitis: A prospective cohort study		
Sung Soo Ahn, Taejun Yoon, Jason Jungsik Song, Yong-Beom Park, Sang-Won Lee		363
P-063 Comparison of physical functions of people with Behçet's disease and healthy and their relationship with disease activ	ity	
Yusuf Geylani		364
P-064 COVID-19 vaccination related small vessel vasculitis with multi-organ involvement		
<u>Yunkyung Kim</u> , Geun-Tae Kim		365
P-065 BVAS version 3 and BVAS/GPA		
Jangwoo Ha, Sung Soo Ahn, Yong-Beom Park, Sang-Won Lee		366

Behçet's disease & Vasculitis	
P-066 Application of the 2022 new criteria for microscopic polyangiitis to patients with previously diagnosed microscopic polyangiitis	
Jung Yoon Pyo, Sung Soo Ahn, Jason Jungsik Song, Yong-Beom Park, Sang-Won Lee	367
P-067 Effect of the number of metabolic syndrome components on all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis	
PIL GYU Park ······	368
P-068 Aortic involvement as a rare complication of granulomatosis with polyangiitis: A case report	
Su Jin Choi, Doo-Ho Lim, Seung Won Choi	369
P-069 ANCA sero-positivity and AAV occurrence after SARS-CoV-2 infection	
Eunju Lee, Wooyong Jeong, Jung Yoon Pyo, Jason Jungsik Song, Yong-Beom Park, Su Jin Jeong, Sang-Won Lee	370
P-070 New-onset IgA vasculitis in adult patients following SARS-CoV-2 vaccines	
Yunjung Choi, Wan-Hee Yoo	371
P-071 A case of microscopic polyangiitis with periaortitis treated with cyclophosphamide	
Seoung Wan Nam	372
P-072 Churg-strauss syndrome presenting as acute abdomen-A case report	
Subbarayudu Boda	373
Crystal induced arthropathies	
P-073 Identification of tofuses and diagnosis of gout disease with dual-energy CT	
Iraklı Tortladze, Giorgi Apkhazava, Grigol Nemsadze	375
P-074 Spondylodiscitis and paravertebral abscess associated with calcium pyrophosphate dihydrate deposition disease	
Burak Sarılar	376
P-075 Urate-lowering efficacy and renal safety of febuxostat in patients with advanced chronic kidney disease not yet on dialysis: A meta-analysis of observational studies	
Changnam Son, Hye-Jin Jeong, Woo Yeong Park, Sang-Hyon Kim	377

Crystal induced arthropathies         P-076         A rare coexistence of quadriceps tendon calcification and patellar tendon calcification         Muhammed Eyyüp Çelik, Mehmet Selim Kan, Elshad İsmailov         P-077         Diagnosis and treatment of gout patients at emergency room         Mil Ryoung Seo, Jina Yeo, Hyo-Jin Choi, Han Joo Baek         P-078         Genetic analysis for inflammasome genes polymorphisms in the gout susceptibility         Denise Clavijo-cornejo, Alberto Lopez-reyes, Esteban Cruz-arenas, Leonor Jacobo-albavera, Gabriela Fuentes-moreno, Adriana Francisco-balderas, Mayra Dominguez-perez, Janitzia Vazquez-mellado, Luis H Silveira, Carlos Pineda, Gabriela Martínez-nava, Marwin Gutierrez         P-079         Depletion, activation, and stimulation of bone destruction of innate and innate-like immune cells in gout         Ki-Jeong Park, Young-Nan Cho, Hye-Mii Jin, Hye-Min Jeong, Sung-Eun Choi, Ji-Hyoun Kang, Dong-Jin Park, Tae-Jong Kim, Shin-Seok Lee, Yong-Wook Park         P-080         Gout disease modification: Proposal for a definition         Jasvinder Singh       382         P-081         Predictors of increased vascular stiffness in gout patients       383         P-082       Wooseong Jeong, Jinseok Kim, Joon Hyouk Choi       383
A rare coexistence of quadriceps tendon calcification and patellar tendon calcification       378         Muhammed Eyyüp Çelik, Mehmet Selim Kan, Elshad İsmailov       378         P-077       Diagnosis and treatment of gout patients at emergency room       379         P-078       Mi Ryoung Seo, Jina Yeo, Hyo-Jin Choi, Han Joo Baek       379         P-078       Genetic analysis for inflammasome genes polymorphisms in the gout susceptibility       380         Denise Clavijo-cornejo, Alberto Lopez-reyes, Esteban Cruz-arenas, Leonor Jacobo-albavera, Gabriela Fuentes-moreno, Adrinan Francisco-balderas, Mayra Dominguez-perez, Janitzia Vazquez-mellado, Luis H Silveira, Carlos Pineda, Gabriela Martínez-nava, Marvin Gutierrez       380         P-079       Depletion, activation, and stimulation of bone destruction of innate and innate-like immune cells in gout       381         P-080       Gout disease modification: Proposal for a definition       382         P-081       P-081       Predictors of increased vascular stiffness in gout patients       383         P-082       Clinical features of Korean patients with calcium pyrophosphate crystal deposition disease:       383
Muhammed Eyyüp Çelik, Mehmet Selim Kan, Elshad İsmailov       378         P-077       Diagnosis and treatment of gout patients at emergency room       379         P-078       Mi Ryoung Seo, Jina Yeo, Hyo-Jin Choi, Han Joo Baek       379         P-078       Genetic analysis for inflammasome genes polymorphisms in the gout susceptibility       380         Denise Clavijo-cornejo, Alberto Lopez-reyes, Esteban Cruz-arenas, Leonor Jacobo-albavera, Gabriela Fuentes-moreno, Adriana Francisco-balderas, Mayra Dominguez-perez, Janitzia Vazquez-mellado, Luis H Silveira, Carlos Pineda, Gabriela Martínez-nava, Marvin Gutierrez       380         P-079       Depletion, activation, and stimulation of bone destruction of innate and innate-like immune cells in gout       381         P-080       Gout disease modification: Proposal for a definition       382         P-081       Predictors of increased vascular stiffness in gout patients       383         P-082       Clinical features of Korean patients with calcium pyrophosphate crystal deposition disease:       383
P-077       Diagnosis and treatment of gout patients at emergency room       Mi Ryoung Seo, Jina Yeo, Hyo-Jin Choi, Han Joo Baek       379         P-078       Genetic analysis for inflammasome genes polymorphisms in the gout susceptibility       379         P-078       Genetic analysis for inflammasome genes polymorphisms in the gout susceptibility       380
Diagnosis and treatment of gout patients at emergency room       Mi Ryoung Seo, Jina Yeo, Hyo-Jin Choi, Han Joo Baek       379         P-078       Genetic analysis for inflammasome genes polymorphisms in the gout susceptibility       380         Denise Clavijo-cornejo, Alberto Lopez-reyes, Esteban Cruz-arenas, Leonor Jacobo-albavera, Gabriela Fuentes-moreno, Adriana Francisco-balderas, Mayra Dominguez-perez, Janitzia Vazquez-mellado, Luis H Silveira, Carlos Pineda, Gabriela Martínez-nava, Marwin Gutierrez       380         P-079       Depletion, activation, and stimulation of bone destruction of innate and innate-like immune cells in gout       381         P-080       Gout disease modification: Proposal for a definition       382         P-081       Predictors of increased vascular stiffness in gout patients       383         P-082       Wooseong Jeong, Jinseok Kim, Joon Hyouk Choi       383
Mi Ryoung Seo, Jina Yeo, Hyo-Jin Choi, Han Joo Baek       379         P-078       Genetic analysis for inflammasome genes polymorphisms in the gout susceptibility       380         Denise Clavijo-cornejo, Alberto Lopez-reyes, Esteban Cruz-arenas, Leonor Jacobo-albavera, Gabriela Fuentes-moreno, Adriana Francisco-balderas, Mayra Dominguez-perez, Janitzia Vazquez-mellado, Luis H Silveira, Carlos Pineda, Gabriela Martínez-nava, Marwin Gutierrez       380         P-079       Depletion, activation, and stimulation of bone destruction of innate and innate-like immune cells in gout       381         P-080       Gout disease modification: Proposal for a definition       382         P-081       Predictors of increased vascular stiffness in gout patients       383         P-082       Clinical features of Korean patients with calcium pyrophosphate crystal deposition disease:       383
P-078       Genetic analysis for inflammasome genes polymorphisms in the gout susceptibility         Denise Clavijo-cornejo, Alberto Lopez-reyes, Esteban Cruz-arenas, Leonor Jacobo-albavera, Gabriela Fuentes-moreno, Adriana Francisco-balderas, Mayra Dominguez-perez, Janitzia Vazquez-mellado, Luis H Silveira, Carlos Pineda, Gabriela Martínez-nava, Marwin Gutierrez       380         P-079       Depletion, activation, and stimulation of bone destruction of innate and innate-like immune cells in gout       381         P-079       Depletion, activation, and stimulation of bone destruction of innate and innate-like immune cells in gout       381         P-080       Gout disease modification: Proposal for a definition       382         P-081       Predictors of increased vascular stiffness in gout patients       383         P-082       Clinical features of Korean patients with calcium pyrophosphate crystal deposition disease:       383
Genetic analysis for inflammasome genes polymorphisms in the gout susceptibility       Denise Clavijo-cornejo, Alberto Lopez-reyes, Esteban Cruz-arenas, Leonor Jacobo-albavera, Gabriela Fuentes-moreno, Adriana Francisco-balderas, Mayra Dominguez-perez, Janitzia Vazquez-mellado, Luis H Silveira, Carlos Pineda, Gabriela Martínez-nava, Marwin Gutierrez       380         P-079       Depletion, activation, and stimulation of bone destruction of innate and innate-like immune cells in gout
Denise Clavijo-cornejo, Alberto Lopez-reyes, Esteban Cruz-arenas, Leonor Jacobo-albavera, Gabriela Fuentes-moreno, Adriana Francisco-balderas, Mayra Dominguez-perez, Janitzia Vazquez-mellado, Luis H Silveira, Carlos Pineda, Gabriela Martínez-nava, Marwin Gutierrez       380         P-079       Depletion, activation, and stimulation of bone destruction of innate and innate-like immune cells in gout       381         Ki-Jeong Park, Young-Nan Cho, Hye-Mi Jin, Hye-Min Jeong, Sung-Eun Choi, Ji-Hyoun Kang, Dong-Jin Park, Tae-Jong Kim, Shin-Seok Lee, Yong-Wook Park       381         P-080       Gout disease modification: Proposal for a definition       382         P-081       Predictors of increased vascular stiffness in gout patients       383         P-082       Clinical features of Korean patients with calcium pyrophosphate crystal deposition disease:       383
Gabriela Fuentes-moreno, Adriana Francisco-balderas, Mayra Dominguez-perez, Janitzia Vazquez-mellado, Luis H Silveira, Carlos Pineda, Gabriela Martínez-nava, Marwin Gutierrez       380         P-079       Depletion, activation, and stimulation of bone destruction of innate and innate-like immune cells in gout       381         Ki-Jeong Park, Young-Nan Cho, Hye-Mi Jin, Hye-Min Jeong, Sung-Eun Choi, Ji-Hyoun Kang, Dong-Jin Park, Tae-Jong Kim, Shin-Seok Lee, Yong-Wook Park       381         P-080       Gout disease modification: Proposal for a definition       382         P-081       Predictors of increased vascular stiffness in gout patients       383         P-082       Clinical features of Korean patients with calcium pyrophosphate crystal deposition disease:       383
Depletion, activation, and stimulation of bone destruction of innate and innate-like immune cells in gout       Image: Stimulation of bone destruction of innate and innate-like immune cells in gout         Ki-Jeong Park, Young-Nan Cho, Hye-Mi Jin, Hye-Min Jeong, Sung-Eun Choi, Ji-Hyoun Kang, Dong-Jin Park, Tae-Jong Kim, Shin-Seok Lee, Yong-Wook Park       381         P-080       Gout disease modification: Proposal for a definition       Jasvinder Singh       382         P-081       Predictors of increased vascular stiffness in gout patients       Wooseong Jeong, Jinseok Kim, Joon Hyouk Choi       383         P-082       Clinical features of Korean patients with calcium pyrophosphate crystal deposition disease:       Stime       Stime
P-080 Gout disease modification: Proposal for a definition          Jasvinder Singh
Gout disease modification: Proposal for a definition       Jasvinder Singh       382         P-081       Predictors of increased vascular stiffness in gout patients       383         P-082       Clinical features of Korean patients with calcium pyrophosphate crystal deposition disease:       383
P-081 Predictors of increased vascular stiffness in gout patients <u>Wooseong Jeong</u> , Jinseok Kim, Joon Hyouk Choi 383 P-082 Clinical features of Korean patients with calcium pyrophosphate crystal deposition disease:
Predictors of increased vascular stiffness in gout patients <u>Wooseong Jeong</u> , Jinseok Kim, Joon Hyouk Choi 383 P-082 Clinical features of Korean patients with calcium pyrophosphate crystal deposition disease:
P-082 Clinical features of Korean patients with calcium pyrophosphate crystal deposition disease:
Clinical features of Korean patients with calcium pyrophosphate crystal deposition disease:
A retrospective multicenter study
Eun Hye Park, Ji Hyoun Kim, Sang Wan Chung, You-Jung Ha, Eun Ha Kang, Yun Jong Lee, Jong Jin Yoo
P-083 Effect of lifestyle change on incident gout: a nationwide population-based cohort of young men
Yeonghee Eun, Kyungdo Han, Seung Woo Lee, Seonyoung Kang, Seulkee Lee, Hoon-Suk Cha, Eun-Mi Koh, Jaejoon Lee, Hyungjin Kim
P-084 Gout is associated with the risk of osteoporosis: a population-based study
Jihyoun Kim, So Rae Kim, Gilwon Kang, In Ah Choi 386

P-085

Vascular imaging findings with high-pitch low-dose dual-source CT in atypical Kawasaki disease

Mecit Kantarci, Elif Güven, Naci Ceviz, Hayri Oğul, Recep Sade 388

### Pediatric rheumatology

### P-086 Bilateral calcification of ear cartilage

Bilateral calcinication of ear cartilage		
<u>Gökhan Polat</u> , Recep Sade		389
P-087 The treatment effect of tofacitinib on Blau syndrome: A case series of Chinese pediatric patients		
Zhe Cai, Song Zhang, Huasong Zeng		390
P-088 The evaluation of MRI findings of sacroiliitis in patients with juvenile idiopathic arthritis for detection of active and structural damage lesions according to updated preliminary OMERACT pediatric JAMRIS scoring system		
Berhan Pirimoglu, Alperen Tezcan, Cagatay Engin, Gokhan Polat, Ahmet Yalcin, Recep Sade		391
P-089 The clinical characteristics of 15 IgG4 related disease in pediatric patients		
Zheng Liu, Wen Zhang		392
P-090 Predictors of long-term functional outcomes of enthesitis related arthritis (ERA) category of juvenile idiopathic arthritis (JIA) in adulthood: A single centre experience from a tertiary care hospital		
Naveen R, Shivika Guleria, Anu Balakrishnan, Sanjukta Majumder, Amita Aggarwal		393
P-091 Secondary hemophagocytic lymphohistiocytosis: Overwhelming clinical manifestations may cause more chemotherapy than necessary		
Hye Yeon Choi, Jung Woo Rhim, Dae Chul Jeong, <u>Soo-Young Lee</u>		394
P-092 Interstitial lung disease in pediatric systemic lupus erythematosus: A case report		
Soo Young Lee, HYE YEON Choi, JUNG-WOO Rhim, HYE JIN Lee, HYUN MI Kang, DAE-CHUL Jeong		395
P-093 A20 haploinsufficiency identified in a girl presented with systemic juvenile idiopathic arthritis: A case report		
JUNG-WOO Rhim, HYE YEON Choi, IN HYUK Yoo, Soo Young Lee, DAE-CHUL Jeong		396
P-094 Withdrawn		
P-095 Flare-up of juvenile idiopathic arthritis (JIA) the day after receiving a booster shot of BNT162b2 mRNA vaccine		
Kwang Nam Kim, <u>Hyong Suk Park</u>		397
P-096 Challenges and management for pediatric rheumatology patient's in the COVID-19 era: Perspectives from several cour	ntries	

Putri Ayu ----- 398

ibromyalgia and soft tissue disorders	
-097	
-097 The use of shear-wave elastography for myofascial pain syndrome's severity	
Recep Sade, Meltem Alkan melikoglu	400
2-098	
Amigos de fibro (Fibro Friends): Validation of an educational program for health promotion in fibromyalgia	
Mateus Antunes, Ana Carolina Schmitt, Amélia Marques	401
2-099 Amigos de fibro (Fibro Friends): Validation of an educational e-book to promote the health of patients vith fibromyalgia in Brazil	
Mateus Antunes, Ana Carolina Schmitt, Amélia Marques	402
diopathic inflammatory myositis and muscle biology	
P-100 Vithdrawn	
2-101	
rdheim-chester disease mimicking coronary artery disease in a systemic lupus erythematosus patient	
<u>Grigol Nemsadze</u> , Megi Kurtanidze, Tamar Melkadze	404
P-102 New onset clinically amyopathic dermatomyositis following SARS-CoV-2 vaccine: A case report	
Eric Ranniel Guevarra, Sandra Teresa Navarra	405
p-103	
Rare case of dermatomyositis following SARS-CoV-2 vaccination	
Mark Andrian Yano, Geraldine Zamora	406
P-104 Clinical characteristics and outcomes of adult patients with anti-MDA5 dermatomyositis- A single centre experience from South India	
Abhilasha Manwatkar, John Mathew	407
2-105 Changes in quantitative interstitial lung disease scores on high-resolution CT in idiopathic inflammatory myositis	
ling Van Soon He Voon, Ju Voon Kim, Joong Sook Loo Eur Voung Loo, Jin Ma Koo	
Lila Pourzand, Jonathan G Goldin, Grace-Hyun J Kim, You-Jung Ha	408
P-106 Time-dependent changes in rapidly progressive-interstitial lung disease and mortality risk in anti-MDA5 antibody Dositive dermatomyositis patients: A cohort study of 272 cases in China	
Hanxiao You, Lingxiao Xu, Lei Wang, Chengyin Lv, Fenghong Yuan, Ju Li, Min Wu, Shiliang Zhou, Zhanyun Da, Jie Qian, Hua Wei, Wei Yan, Lei Zhou, Yan Wang, Songlou Yin, Dongmei Zhou, Jian Wu, Yan Lu, Dinglei Su, Zhichun Liu, Lin Liu, Longxin Ma, Xiaoyan Xu, Yinshan Zang, Huijie Liu, Tianli Ren, Fang Wang, Miaojia Zhang, Wenfeng Tan	40

#### Idiopathic inflammatory myositis and muscle biology

#### P-107

Coexisting of anti-Ro52 autoantibodies on anti-MDA5 autoantibodies-positive dermatomyositis is highly associated with rapidly progressive interstitial lung disease and mortality risk

Hanxiao You, Chengyin Lv, Lingxiao Xu, Lei Wang, Fenghong Yuan, Ju Li, Min Wu, Shiliang Zhou, Zhanyun Da, Jie Qian, Hua Wei, Wei Yan, Lei Zhou, Yan Wang, Songlou Yin, Dongmei Zhou, Jian Wu, Yan Lu, Dinglei Su, Zhichun Liu, Lin Liu, Longxin Ma, Xiaoyan Xu, Yinshan Zang, Huijie Liu, Tianli Ren, Fang Wang, Miaojia Zhang, Wenfeng Tan

### P-108

Galectin-9 and CXCL-10 as biomarkers in assessing disease activity in dermatomyositis and polymyositis-a single centre cohort study

SAI KUMAR Dunga, Chengappa Kavadichanda, Devender Bairwa, Molly Mary Thabah, Vir Singh Negi

### P-109

Role of semiquantitative thigh magnetic resonance imaging (tMRI) in determining skeletal muscle outcomes at baseline and on follow up in idiopathic inflammatory myopathies (IIMs)

Mamatha Gorijavolu, Devender Bairwa, Chengappa Kavadichanda, Aishwarya Gopal, Sai Kumar Dunga, Molly Mary Thabah, Vir Negi

#### Sjögren's syndrome

### P-110

Hyperglobulinemia in primary Sjögren's syndrome predicts the poor outcome: From multicenter registration study

Hui Zhong, Yanhong Wang, Pingting Yang, Xinwang Duan, Yongfu Wang, Jian Xu, Lijun Wu, Qin Li	, 414
Xiaodan Kong, Liyun Zhang, Xiaomei Li, Dong Xu, Mengtao Li, Yan Zhao, Xiaofeng Zeng	J 414

### P-111

Primary Sjögren's syndrome is associated with increased risks of not just lymphoma:

a systematic review and meta-analysis

Hui Zhong, Siyao Liu, Yanhong Wang, Dong Xu, Mengtao Li, Yan Zhao, Xiaofeng Zeng

### P-112

Salivary ultrasonography and histopathologic evaluation of secondary Sjögren's syndrome in rheumatoid arthritis patients

Minae Oh, Youngjae Park, Youn Soo Lee, Wan-Uk Kim 416
-------------------------------------------------------

### P-113

STAT4 gene polymorphisms in risk of Sjögren's syndrome patients susceptibility: Update systematic review and meta-analysis

Rendra Ristian wibowo, Bastomy Eka rezkita, Ambar Mudigdo, Dyah Ratna ------ 417

### P-114

Interstitial lung disease in Sjögren's syndrome: Prevalence, patterns, treatment, and prognosis

Jung Hee Koh, Su-Jin Moon, Yong Hyun Kim, Jun-Ki Min ------ 418

### P-115

Distinct metabolic biomarkers to distinguish immunoglobulin G4-related disease from Sjögren's syndrome and pancreatic cancer and predict disease prognosis

Yu Peng, Wen Zhang ----- 419

### Sjögren's syndrome

P-116

Predictors of the future development of systemic lupus erythematosus (SLE) in Korean primary Sjögren's syndrome (pSS) patients with anti-DNA antibody (+) by the Farr method.

Bong-Woo Lee, Youngjae Park, Jennifer Lee, Sung-Hwan Park, Seung-Ki Kwok ------ 420

Systemic sclerosis and Raynaud's phenomenon
P-117 Analysis of clinical features of myocardial involvement in systemic sclerosis
Huilin He 4
Miscellaneous rheumatic and inflammatory diseases
P-118 Brain magnetic resonance imaging finding in autoimmune rheumatic disease
Recep Sade, Meltem Alkan melikoglu
P-119 Spontaneous knee hemarthrosis associated with enoxaparin treatment in a post COVID-19 patient
Mark Andrian Yano, Geraldine Zamora, Karen Anne Claridad, Ralph Elvi Villalobos 4
P-120 Clinical profile and outcome of adult Filipino patients with septic arthritis in a tertiary hospital in the Philippines
Mark Andrian Yano, Alfonso Juan Miranda
P-121 Tuberculosis fasciitis of the neck in Behçet's patient
Yunus Fersan, Mehmet Aksit, Gökhan Polat 4
P-122 Chronic inflammatory demyelinating polyneuropathy (CIDP) in polyangiitis granulomatosis with cyclophosphamide
Kadem Tüysüz, Mehmet Aksit, Gökhan Polat
P-123 A rare combination of autoimmune pancreatitis and focal cranial eosinophilic granuloma
Tamar Melkadze, Iraklı Tortladze, Giorgi Apkhazava
P-124 Diagnostic value of the inflammatory scores in polymyalgia rheumatica
Ji-Won Kim, Hyoun-Ah Kim, Ju-Yang Jung, Chang-Hee Suh
P-125 A short long way from Juvenile idiopathic arthritis to pachydermoperiostosis (Touraine–Solente–Gole Syndrome)
BOGDAN ION Gavrila, Ioan Ancuta, Mihai Bojinca, Claudia Silvia Ciofu

Miscellaneous rheumatic and inflammatory diseases		
P-126 Allopurinol and febuxostat hypersensitivity in a patient with young onset gout		
	Mark Andrian Yano	43
P-127 Curative-intent resection is a strong indicator of steroid-free remission in IgG4	-related disease	
Jung Gon Kim, Wan-U	Sunhee Jang, Jennifer Lee, Ji Hyeon Ju, Ik Kim, Sung-Hwan Park, Seung-Ki Kwok	43
P-128 Application of HScore and MS score in diagnosis of macrophage activation syndr	ome associated with adult onset Still's disease	
Zhao Peng,	, Shuang Zhou, Qian Wang, Xinping Tian, Mengtao Li, Yan Zhao, Xiaofeng Zeng	43
P-129 The role of interleukin-18 as a diagnostic biomarker to differentiate active adu	lt-onset still's disease from COVID-19	
	Roland Helmizar	43
P-130 Cancer-associated vasculitis: A single-centre pilot study		
	Hyunsue Do, Sangwon Lee	43
P-131 Withdrawn		
P-132 Cerebellar infarction as the initial presentation of IgG4-related disease		
	Gaurav Nepal, Vikash Jaiswal	43
Epidemiology & Public health		
P-133 Relationship between lung involvement and gout in Covid-19 disease		
Fa	<u>itih Işık</u> , Zeynep Tüzün, Fatma Beyza Isık	43
P-134 Post-COVID mesial temporal sclerosis		
<u>Megi Kurt</u>	anidze, Tamar Melkadze, Iraklı Tortladze	44
P-135 Incidence of rheumatic diseases during the COVID-19 pandemic in Korea: A n	ationwide claims study	
<u>Soo Min Ahn</u> , Seongho	b Eun, Seokchan Hong, Chang-Keun Lee, Bin Yoo, Ji Seon Oh, Yong-Gil Kim	44
P-136 Changes in the lungs that develop with COVID-19 in patients with rheumatoid	arthritis	
	ia Aronova, Galina Gridneva, Boris Belov	

Epidemiology & Public health
P-137 Incidence, prevalence, and clinical characteristics in ANCA-associated vasculitis: A national health insurance service database (2002-2018)
Sung Ahn, Hyunsun Lim, Chan Hee Lee, Young-Beom Park, Sang-Won Lee, <u>Jinsu Park</u> 443
P-138 Association between sarcopenia and rheumatoid arthritis in the Korean population: a nationwide cross-sectional study
Jae Hyun Jung, Yu Jin Lee, Eui Seop Song, Gwan Gyu Song
P-139 Psychometric properties of the PHQ-8 in individuals with osteoarthritis
Patrick Brzoska ········· 445
P-140 The barriers of patients with osteoporosis in various countries during the COVID-19 pandemic
NURALIAH Nuraliah ·········· 446
P-141 Use of telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak: a randomized controlled trial
Ho So, Everlyn Chow, Isaac Cheng, Xerox Chow, Tena Li, Cheuk Chun Szeto, Lai Shan Tam
P-142 Immunopathological process in the chronic arthritis and rheumatic heart diseases caused by streptococcus of group A
Nazgul Omurzakova, Akpay Sarybaev 448
P-143 Comparison of renal outcomes and mortality in early and delayed onset lupus nephritis
Soo-Kyung Cho, Hyoungyoung Kim, Jungyong Han, Yena Jeon, Sun-Young Jung, Eun Jin Jang, Yoon-Kyoung Sung449
P-144 Level of knowledge on systemic lupus erythematosus among nursing students in selected universities in the Philippines
Cherry Ann Garcia Durante, Jeeno Jay Frani 450
P-145 Comparative safety of tofacitinib and TNF inhibitor in Korean patients with rheumatoid arthritis: A prospective, single-center cohort study
<u>Yeo-Jin Song</u> , Soo-Kyung Cho, Hyoungyoung Kim, Hye Won Kim, Eunwoo Nam, Ja-Young Jeon, Hyun-Jeong Yoo, Chan-Bum Choi, Tae-Hwan Kim,451 Jae-Bum Jun, Sang-Cheol Bae, Dae Hyun Yoo, Yoon-Kyoung Sung
P-146 A tale of three paths: Singaporean patient journeys from initial symptoms of gout to presentation for health care
Aloysius Chow, Laurie J. Goldsmith, Delfinn Tan, Madelynn Chan, Richard Lee, Christian Mallen, Bernadette Bartlam, Helen Elizabeth Smith

Osteoporosis and metabolic bone diseases	
P-147 Two novel mutations in TCIRG1 induced infantile malignant osteopetrosis: A case report	
Ping Wu	454
P-148 Relationship between Vitamin D, Body mass index with Bone mineral density of Mongolian miners	
<u>Garamjav Khishigdavaa</u> , Tuvshinjargal Dashdavaa, Agiimaa Ulziibadrakh, Buyankhishig Lhagvatogoo, Uuriintuya Altankhuyg, Ariuntungalag Khishigbadrakh	455
P-149 Application of Machine Learning to identify osteoporosis based on the extreme learning machine (ELM) model algorith	n
<u>Rifaldy Fajar</u> , Asfirani Umar, Sahnaz Vivinda Putri	456
P-150 FRAX model is useful for prediction of major fractures in RA patients with glucocorticoid-induced osteoporosis	
<u>Yoon-Kyoung Sung</u> , Hyoungyoung Kim, Yeo-Jin Song, Tae-Han Lee, Hye Won Kim, Eunwoo Nam, Soo-Kyung Cho	457
P-151 Genetic variation of susceptibility gene of osteoporosis, measuring method of osteoporosis risk	
Ahmad Ahmad	458
P-152 Patient preference and efficacy of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis in patients with autoimmune diseases	
Ji-Won Kim, Ju-Yang Jung, Hyoun-Ah Kim, Chang-Hee Suh	459
Osteoarthritis and biology of bone and joint	
P-153 The potential targets of San-Miao-San in the treatment of osteoarthritis	
Zhe Cai, Ping Wu, Yu Feng	461
P-154 Serum, synovial visfatin level during flare-up and remission of primary knee OA	
Haytham Abd elaal	462
P-155 Influence of metabolic syndrome in patients with knee osteoarthritis	
Jamol Uzokov, Anis Alyavi, Bakhromkhon Alyavi	463
P-156 Efficacy of joint treatment with metformin and NSAIDS in patients with knee osteoarthritis and metabolic syndrome	

### Osteoarthritis and biology of bone and joint

P-157

Detection of the sesamoid bone of the metacarpal joint in patients with osteoarthritis using the deep learning model

<u>Bon San K</u>	<u>oo</u> , Wonjung Kim, Gaeu	in Lee, Seunghun Lee, J	lune-Goo Lee, Jae-Bum Jun	465
------------------	-------------------------------	-------------------------	---------------------------	-----

P-158

Blood d-dimer level after COVID-19 in patients with knee osteoarthritis

#### P-159

Lactobacillus (LA-1) and butyrate inhibit osteoarthritis by controlling autophagy and inflammatory cell death of chondrocytes


Keun-Hyung Cho, <u>JooYeon Jhun</u>, Hyun Sik Na, Jin Seok Woo, A Ram Lee, Seon-Yeong Lee, JeongWon Choi, Sung-Hwan Park, Mi-La Cho

### **Orthopedics & Rehabilitation**

P-160

Effects of conventional rehabilitative and aerobic training in patients with idiopathic inflammatory myopathy

Guangyu Zhang, <u>Mingwei Tang</u>, Xiao Zhang, Shuang Zhou, Chanyuan Wu, Jiuliang Zhao, Dong Xu, Qian Wang, Mengtao Li, Lixia Chen, Xiaofeng Zeng



## Journal of Rheumatic Diseases

Vol. 29, Suppl. 1, May, 2022

## KCR 2022

42nd Korean College of Rheumatology Annual Scientific Meeting and the 16th International Symposium

May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



## May 19(Thu)

## Symposium

Year in Review (Clinical)

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



## **Clinical update of systemic lupus erythematosus**

### Seung-Ki Kwok

The Catholic Univ. of Korea, Korea

Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by the production of diverse autoantibodies and immune complex deposit in target tissues. It affects multiple organs and has significant morbidity and mortality. Identification and development of new treatment strategy for SLE is currently an area of intense investigation. This talk will include the general update of SLE in clinical aspect. It will also provide recent clinical updates in SLE including novel treatments such as Anifrolumab which binds to the type I interferon receptor, blocking the activity of type I interferons (interferon- $\alpha$  and interferon- $\beta$ ) as well as Volcosporin, a new calcineurin inhibitor.



Journal of Rheumatic Diseases Vol. 29, Suppl. 1, May, 2022

## Idiopathic inflammatory myositis

### Jinhyun Kim

Chungnam Nat'l Univ., Korea

Idiopathic inflammatory myopathies (IIM) are a heterogeneous group of autoimmune muscle diseases with systemic involvement. Based on the different clinical features and pathologic findings, they are classified into five subtypes: dermatomyositis, polymyositis, immune-mediated necrotizing myositis, inclusion-body myositis and antisynthetase syndrome. Several other organs may be affected, particularly lungs, heart, skin, gastrointestinal tract and joints, often determining the morbidity and mortality associated with these autoimmune disorders. Due to clinical heterogeneity, patients with IIM present with varying degrees of muscle disease, cutaneous manifestations, and internal organ involvement. The diagnosis and classification of IIM is based primarily on the classification system composed of clinical features, laboratory value and muscle biopsy. The course is generally chronic and variable. Recently, many studies have also demonstrated that the physician can define the clinical syndromes, establish treatment strategy and predict outcomes based on the patients myositis-specific autoantibodies and myositis-associated antibodies profiles.

To control IIMs and prevent disease complication, high-dose corticosteroids in combination with immunosuppressant has been the mainstay of treatment. With the rarity of these conditions, diagnosis and management of patients can be a clinical challenge for the physician. The scientific research makes continuous advances in the understanding of these diseases, in particular with regards to the serological findings, diagnostic strategies and therapeutic approaches. The aim of this review is to highlight the most relevant literature contributions focused on the clinical aspects of IIMs.



## Update of IgG4 related disease

Yong Gil Kim

Univ. of Ulsan, Korea

Immunoglobulin G4-related disease (IgG4-RD) is a systemic fibro-inflammatory condition of unknown etiology. This disorder is characterized by lymphoplasmacytic tissue infiltration with IgG4-positive plasma cells and elevation of serum IgG4 levels. Diffuse swelling or mass formation can occur in most organs, and the pancreas, biliary tree, lacrimal gland, salivary glands, and retroperitoneum/aorta are frequently involved. The mainstay treatment for the achievement of remission is a glucocorticoid, and most patients respond well to the initial treatment. However, patients often experience relapses during glucocorticoid tapering or maintenance therapy. In patients with a high risk of relapse, more stringent treatment and follow-up strategies may be considered to prevent frequent relapse, organ damage, and additional glucocorticoid use. Therefore, I have reviewed interesting results published after 2021 including the clinical parameters associated with prognosis and diagnostic algorithms.



## **Behçet's disease**

Sang-Won Lee

Yonsei Univ., Korea

Behcet syndrome (BS), which has been widely used instead of Behcet disease by the European Alliance of Associations for Rheumatology (EULAR) since 2018, is a variable vessel vasculitis affecting from capillaries to the aorta. According to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides, BS is characterised by recurrent oral and/or genital Aphthous ulcers accompanied by cutaneous, ocular, articular, gastrointestinal, and/ or central nervous system inflammatory lesions. In addition, BS may exhibit small vessel vasculitis, thromboangiitis, thrombosis, arteritis and arterial aneurysms. BS occurs in Mediterranean basins, Middle East and Far East Asia more often than in Europe and North America. The prevalence of BS in Turkey, Iran, Saudi Arabia and Japan was 370, 80, 20 and 11.9, respectively, whereas that in overall Europe and the United States was 7.1 and 5.2. The genetic factors of BS include HLA-B*51, ERAP1 variations, IL10, IL23-IL12RBs, STAT4, NF-kB, and IFNGR1, which may enhance the susceptibility of individuals. The environmental aetiology is comprised of three categories such as infectious factors, microbiome and additional trigger factors. Also, the immunological aetiology consists of two important mechanisms: neutrophil mediated mechanism of damage including neutrophil extracellular traps (NETs), and other immunological mechanisms including Th1/Th17 expansion, JAK/STAT and NF-kB pathways, Treg downregulation, and NK and gamma delta T cells dysregulation. Since BS exhibits various organ-specific manifestations and the laboratory, radiologic and histologic evidence for the diagnosis still remains insufficient, the classification criteria for BS have been modified and supplemented very slowly to date. The criteria for diagnosis of Behcet's disease proposed by the international study group in 1990 are currently used and the revised criteria proposed by the International Criteria for Behçet's Disease (ICBD) in 2014 are also used. In particular, the 2014 ICBD criteria are composed of the scoring system in which different weights are assigned to organ-based lesions and put an item of ocular lesions on top of the algorithm. The latest version of the treatment guidelines is the 2018 update of the EULAR recommendation for the management of Behcet's syndrome. A review paper published in 2021 classified the 2018 recommendations by organ and listed the drugs to be applied, which made it easy to understand. Finally, during the COVID-19 pandemic, BS was reported to not affect the symptoms or outcomes due to COVID-19.

## Symposium

Year in Review (Basic)

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



### **Emerging concepts of endotypes/phenotypes in osteoarthritis**

### Gunil Im

Dongguk Univ., Korea

Osteoarthritis (OA) has been investigated as one of important target diseases for regenerative medicine. The concept of early OA has recently emerged under the assumption that if OA is detected and intervened early, progression of OA might be arrested or delayed before irreversible destruction of the joint occurs. This concept also matters in regenerative medicine for OA because new regenerative technologies can work better when joint damage is minimal.

Diagnostic criteria for early OA have been suggested in this background to find a group of patients who have a higher possibility of developing full-blown OA. However, as currently suggested criteria of early OA are mostly expert opinions lacking higher level of evidence, clinical validations are necessary to prove their value in patient care. While new treatment methods that can suppress or prevent symptoms at an early stage of OA before progressive and irreversible changes occur are being developed, detailed definition and classification of early OA agreed upon by major stakeholders in OA field and validated by prospective studies are necessary to prove the efficacy of these methods.

As clinical outcome of regenerative treatment is related to patient characteristics and the status of the whole joint, it is of critical significance to predict which patient will progress and who will be responsive to regenerative treatment. While diagnostic criteria for early OA should be highly sensitive and applicable without employing biomarkers or magnetic resonance imaging, a subclassification and comprehensive endotyping /phenotyping using these techniques might be needed to detect the population who would be responsive to regenerative medicine.



## **Gout: Basic science of gout**

Seokchan Hong

Univ. of Ulsan, Korea

Gouty arthritis is a type of inflammatory arthritis characterized by the deposition of monosodium urate (MSU) crystals in the joints and/or various tissues. This disorder presents as painful acute inflammatory arthritis, usually affecting the big toe and foot. A key pathogenic factor in gout is hyperuricemia, which promotes the precipitation of MSU crystals. MSU crystals elicit acute and chronic inflammatory responses, mainly through activation of NLRP3 inflammasome complex, leading to the secretion of pro-inflammatory cytokines, IL-1 $\beta$  and IL-18. Although, the underlying mechanism of MSU crystals driven inflammation for the development of gouty arthritis has been studied, further studies are still needed. Thus, studies investigating the role of MSU crystals in the various immune system are ongoing.



## SpA: Insight into the pathogenesis of SpA

### Tae-Jong Kim

Chonnam Nat'l Univ., Korea

Spondyloarthritis (SpA) comprises a group of inflammatory diseases of the joints and spine, with various clinical manifestations. The group includes ankylosing spondylitis, reactive arthritis, psoriatic arthritis, arthritis associated with inflammatory bowel disease, and undifferentiated spondyloarthritis. The exact etiology and pathogenesis of spondyloarthritis are still unknown, but several hypotheses explaining the pathogenesis exist. These hypotheses suggest that spondyloarthritis is caused by arthritogenic peptides, an unfolded protein response, HLA-B*27 homodimer formation, malfunctioning endoplasmic reticulum aminopeptidases, and, last but not least, gut inflammation and dysbiosis. The gut–joint axis of inflammation in SpA is further reinforced by similarities in immunopathogenesis at both anatomical sites and by the clinical success of therapies blocking TNF and IL-23 in IBD and in some forms of SpA.

This review addresses these two critical pathways of inflammation, discussing their nature and these factors that may activate or enhance the pathways in patients with SpA. In addition, genetic and other markers important to the inflammatory pathways implicated in SpA are explored.



### Update in the pathogenesis of Sjögren's syndrome

Jennifer Jooha Lee

The Catholic Univ. of Korea, Korea

Primary Sjogren's syndrome (pSS) is a chronic systemic autoimmune disease of the exocrine glands characterized by primarily immune-mediated pathological features. Various immune cells are infiltrated in the glands resulting in glandular dysfunction. The presence of autoantibodies - anti SSA/Ro and SSB/La is characteristic which suggests that T cell-mediated initial inflammation subsequently invokes B cell activation and production of autoantibodies.

The initial event of this immune dysregulation involves activation of plasmacytoid dendritic cell (pDC) resulting in type I interferons. Interferon signature genes (ISGs) are highly expressed in some of the patients and the ISG score is usually correlated with systemic disease activity of pSS. B cell activating factor (BAFF) secreted from DCs contributes to B cell activation and production of autoantibodies. The epithelial cells in the gland have been considered as the target of the dysregulated immune cells. However, at the same time, they are not innocent targets but they are actively involved with inflammation in the gland acting as antigen presenting cells and producing inflammatory cytokines.

Genetic predisposition is one of the explanations for the susceptibility of the disease. There was a large scale GWAS study that delineate susceptible genes including non-HLA genes such as STAT4, IRF5, CXCR5 and IL12. Further a recent study found 10 novel genes that had mutations in European pSS patients. In addition to genetic risk, epigenetic modification such as methylation profile or non-coding RNA expression affect the gene expressions in pSS. Further, integrative analyses combining genetic, epigenetic, transcriptive information suggest the potential biomarker and key pathways of the pSS. Those analyses are performed not only with peripheral blood data but also salivary glands data.

Another approach to explain the pathogenesis of the disease is to suggest the role of microbiome. The role of gut microbiome was reported in many autoimmune diseases in regulating immune cells especially Th17/Treg cells. In line with this, strategies using gut microbiome or metabolites to alleviate the manifestations of pSS have been reported. Oral microbiome also affects the local environment of the target organ and is thought to contribute to salivary gland inflammation.

In this update, recent studies of the pathogenesis regarding aspects mentioned above will be addressed.

## Luncheon Symposium I Pfizer

Recent Update of Advanced RA Treatment

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



## The role of tofacitinib as a JAK pioneer

Hyoun-Ah Kim

Ajou Univ., Korea

Rheumatoid arthritis (RA) is a chronic inflammatory arthritis characterized by destruction of synovial joints and systemic inflammation. In recent years, there have been many improvements in treatment of RA with the emergence of biologics or targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs). Novel small molecule JAK inhibitors that are orally administered have challenged the treatment of RA by providing evidence of superiority to first- and second-line standards-of-care through innovative head-to-head clinical trials. RA treatment recommendations have evolved over the years and currently focus on a treating to a target (T2T) approach. The guidelines recommend initiations of treatment with DMARDs as soon as the disease is confirmed, and the treatment should be adjusted at least every 3 months to reach a targeted, sustained remission or low disease activity. This lecture addresses the major clinical studies and long-term outcomes of tofacitinib. Tofacitinib demonstrated significant reduction in the signs and symptoms of RA vs. placebo, as measured by ACR20, as early as week 2. Tofacitinib with and without MTX improved signs and symptoms of RA in adults with moderate to severe RA. Drug persistence over 8.5 years was similar for tofacitinib with and without MTX. Tofacitinib demonstrated a consistent safety profile (as monotherapy or combination therapy) in open-label long-term extension data reported up to 9.5 years. Tofacitinib provided improvement in RA signs and symptoms over 24 months in patients from the Asia-Pacific region. Frequency of AEs and SAEs in the Asia-Pacific patient population over 92 months was generally consistent with that reported in global studies.

Tofacitinib may be an effective treatment option to consider for long- term treatment in RA.

## Luncheon Symposium II JW Pharmaceutical

IL-6R Inhibition: Transforming People's Lives, for a Future on Their Term

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



# Evolution of tocilizumab: From rheumatoid arthritis to CAR T cell therapy and COVID-19

Seung-Ki Kwok

The Catholic Univ. of Korea, Korea

Interleukin 6 (IL-6) is an interleukin that acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine. IL-6 has pleotrophic activities in diverse biologic processes and has been deeply implicated in the pathogenesis of various immune-mediated inflammatory diseases. Tocilizumab, a humanized anti-IL-6 receptor antibody, has shown remarkable efficacy in rheumatoid arthritis (RA), juvenile idiopathic arthritis, and adult-onset Still's disease. Emerging evidence has demonstrated the benefit of tocilizumab for several types of acute inflammatory diseases, including cytokine storms induced by chimeric antigen receptor (CAR) T cell therapy and coronavirus disease 19 (COVID-19). This talk will include a brief introduction of the development of tocilizumab. In addition, it will summarize not only the pivotal clinical trials which play major roles in the approval by regulatory agencies but also real word data of tocilizumab in the treatment of RA. Finally, this lecture will also include the clinical study results of tocilizumab in diverse acute inflammatory diseases, especially cytokine storms induced by CAR T cell therapy and COVID-19.

## Luncheon Symposium III AbbVie

Strategies to Solve the Problem of Ankylosing Spondylitis with AbbVie's Assets

> KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



### The present and future of ankylosing spondylitis treatments

Tae-Jong Kim

Chonnam Nat'l Univ., Korea

Axial spondyloarthritis is a chronic, progressive rheumatic disease characterised by inflammatory back pain, limited spinal mobility, enthesitis, and peripheral articular and extra-articular manifestations. With limited treatment options in the past, the need for early diagnosis and treatment was less crucial, but with the availability of new effective treatment options (biologic agents blocking tumor necrosis factor alpha (TNF-a), interleukin (IL)-17, JAKi) and with the evidence that early treatment may retard the radiological progression, it becomes imperative that we make efforts to identify these patients and institute treatments as early as possible after the onset of symptoms.

In 2002, Humira, the originator adalimumab, became the third TNFi to be approved in the USA after infliximab and etanercept. Adalimumab significantly reduced the signs and symptoms of active AS and established a sustained clinical response in patients who had an inadequate response or intolerance to NSAID therapy in ATLAS study. The ABILITY study was developed to further evaluate the efficacy and safety of adalimumab in the treatment of patients with nr-axSpA. This represented the first randomised controlled clinical trial to use the ASAS axial SpA criteria in classifying patients with nr-axSpA.

The unmet medical need for treatment remains high, especially in patients who have an inadequate response to biological disease-modifying antirheumatic drugs. JAK inhibitors have emerged as a new therapeutic class for immune-mediated inflammatory diseases and have received marketing approval by regulatory agencies for rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. SELECT-AXIS 1 is a multi-centre, randomised, double blind, parallel-group, placebo-controlled, phase 2/3, two-period study of upadacitinib. oral upadacitinib 15 mg once daily significantly improved disease activity, function, and MRI-detected axial inflammation in patients with active ankylosing spondylitis after 14 weeks of treatment.

# **Special Lecture**

**Presidential Plenary Session** 

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



# Changing role of rheumatologist in Korea

# Sang-Heon Lee

Konkuk Univ., Korea

A rheumatologist is an internal medicine doctor who specializes in diagnosing and treating inflammatory conditions that affect the joints, tendons, ligaments, bones, and muscles. Rheumatologists diagnose and treat musculoskeletal conditions, but they do not perform surgery.

Since rheumatology was introduced in mid 1980s in Korea, rheumatology has been established as an important subspecialty in internal medicine. When I started rheumatology fellowship in 1992, there were few hospitals that can train and run the rheumatology training program. At that time, role of rheumatology in tertiary hospital was mainly focused on consulting physician, when the diagnosis and management of systemic autoimmune disease was neglected for long time. Pioneers of Korean rheumatology did hard work to develop the diagnosis and treatment of systemic rheumatic diseases, which was barren land in Korean medical society. Since 1990s, the number of rheumatology fellow was rapidly increasing supported by medical needs for rheumatic diseases, especially in university hospital. Now, all university hospitals have rheumatology subspecialty as a division of internal medicine, most of which have 2 to 4 staffs in one center. I am highly confident that Korean rheumatology is the top specialty in terms of growing up fast for basic research and clinical practice for past decades. With the rapid growing immunological sciences, rheumatology is now equipped with excellent medicine to treat refractory rheumatic diseases, which lead to remarkable treatment outcome. Currently, rheumatology subspecialty board members reach around 460, which is still not enough to satisfy medical needs. However, we are faced with grim prediction for the rheumatology workforce, suggested by rapid drop in applicant of rheumatology fellowship. To maintain and develop the rheumatology in the future, we have to pay attention to the role of rheumatologist. I suggest that the future rheumatology should be developed in parallel in basic research and clinical practice. The tertiary hospital or center should concentrate on basic research and refractory systemic autoimmune disease. Private clinic should expand the spectrum of musculoskeletal problems. Since aging society continues to accelerate, the medical needs for musculoskeletal disease, including degenerative joint diseases, soft tissue pain are expected to increase year by year. We have superior advantages over other musculoskeletal specialists such as orthopaedic surgeon, anesthesiologist in term of treating combined medical comorbidities. The main reason for unpopularity to apply rheumatology among internal medicine residency, is the grim position and uncertainty in rheumatology prospect. Since the number of rheumatology staffs in tertiary hospital remain plateau, we should make steady and persistent effort to expand the clinical spectrum covering most of musculoskeletal problems in private clinic base. To achieve this goal, we do more pay attention to promote the role of rheumatologist to the public, and concentrate on the development of better clinical practice program in KCR.



# Past, present and future of rheumatology in Korea

# Yeong-Wook Song

Song Rheumatology Clinic., Korea

Rheumatology was first recognized as a distinct clinical specialty in Korea 41 years ago. Young physicians who were trained in rheumatology in the USA and afterwards returned to Korea contributed substantially to advances in rheumatology clinical practice, educational programs and research activities. They also established the Korean Rheumatism Association, later renamed the Korean College of Rheumatology. Rheumatologists had a major role not only in raising the level of clinical and scientific activities, but also in promoting academic exchanges around the Asia–Pacific region, the USA and Europe. Today, continued efforts are required to raise the standard of clinical and basic research, to optimize clinical practice in the translational era in medicine, to exploit personalized and targeted therapies for the rheumatic diseases. Approach to rheumatic disease need to be multi-disciplinary and patient centered. Clinical examination of the patients should not be neglected.

# **Free Paper Session**

International Free Paper Session (Clinical)

> KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



## 10-01

# Risk of venous thromboembolism in Korean patients with rheumatoid arthritis treated with JAK inhibitors : A nationwide population-based study

<u>Yeo-Jin Song</u>^{1,2}, Soo-Kyung Cho^{1,2}, Seung-Hun You³, Jeong-yeon Kim³, Hyoungyoung Kim^{1,2}, Sun-Young Jung³, Yoon-Kyoung Sung^{1,2}

¹ Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea ² Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea ³ College of Pharmacy, Chung-Ang University, Seoul, Republic of Korea

## Background

There has been a safety concern about an increased risk of thromboembolic events in patients with rheumatoid arthritis (RA) treated with Janus kinase inhibitors (JAKis). In this study, we aimed to determine the risk of venous thromboembolism (VTE) in Korean patients with RA treated with JAKis compared with tumor necrosis factor (TNF) inhibitors.

## **Methods**

Using the National Health Insurance Service database between 2015 and 2019, patients with prevalent RA who started JAKi or TNF inhibitor were selected as study population. All participants were naïve to targeted therapy, and those who ever experienced any VTE event; or used anticoagulant agents within 30 days were excluded. Demographic and clinical characteristics were all balanced by stabilized inverse probability of treatment weighting (IPTW) using propensity score. Then, cox proportional hazard model with considering death as competing risk was used to evaluate the risk of VTE in JAKi users compared with TNF inhibitor users.

## **Results**

A total of 4,178 patients were included: 871 JAKi users and 3,307 TNF inhibitor users followed up for 1,029.2 person-years (PYs) and 5,940.3 PYs, respectively. The crude incidence rate of VTE were 0.29 per 100 PYs (95% confidence interval [CI] 0.09–0.90) in JAKi users and 0.35 per 100 PYs (CI 0.23–0.54) in TNF inhibitor users. After stabilized IPTW, weighted hazard ratio (HR) by cox proportional hazard model was 0.55 (CI 0.09–3.21). When additionally adjusting imbalanced variables even after stabilized IPTW, HR was 0.54 (CI 0.09–3.15).

# Conclusions

There was no increased risk of VTE in RA patients treated with JAKis compared with TNF inhibitors in Korea.

## **Keywords**

thromboembolism, rheumatoid arthritis, Janus kinase inhibitor



# Increased thromboembolic risk of JAK inhibitors after switching from biologic DMARDs in patients with rheumatoid arthritis

<u>Yeonghee Eun</u>¹, Gi Hyeon Seo², Seonyoung Kang³, Seulkee Lee³, Hyungjin Kim^{3,4}, Hoon-Suk Cha³, Eun-Mi Koh³, Jaejoon Lee³

¹ Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Republic of Korea ² N/A, Health Insurance Review and Assessment Service, Republic of Korea

³ Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Republic of Korea

⁴ Department of Medical Humanities, Samsung Medical Center, Sungkyunkwan University School of Medicine, Republic of Korea

# Background

Safety concerns regarding JAK inhibitors have grown since the ORAL surveillance trial reported that their use was associated with an increase in major adverse cardiovascular events compared to TNF inhibitors. However, real-world data on the association between JAKi and thromboembolic events are sparse. We compared the incidence of thromboembolic events (TEs) before and after switching to Janus kinase inhibitors (JAKi) from biologic disease-modifying anti-rheumatic drugs (bDMARDs) in patients with rheumatoid arthritis (RA).

## **Methods**

Among patients with a diagnostic code for RA taking bDMARDs, patients who switched to JAKi or another bD-MARD between March 2015 and December 2020 were included in this self-controlled case series study. The outcome was the occurrence of TEs. The incidence rate ratios (IRRs) for TEs in the period after switching to JAKi or another bDMARD compared with the period before switching were calculated based on an assumed Poisson distribution.

## Results

There were 1,150 and 2,254 patients who switched to JAKi and another bDMARD, respectively. The mean follow-up duration was  $4.5 \pm 1.8$  years. In the JAKi group, the IRR for TE after drug switching was 1.56 (95% confidence interval [CI] 1.22–1.98, P < 0.001) compared with the period before the drug switch; in the bDMARD group, the IRR was 1.16 (95% CI 0.98–1.38, P = 0.079).

# Conclusions

Switching from bDMARDs to JAKi was associated with an increase in TE incidence in RA patients in a real-world



10-03

# Gut microbiome in patients with established rheumatoid arthritis: Factors associated with the composition, and its value of predicting treatment response

# Jung Hee Koh^{1,2}, Dong-Hyun Kim³, Wan-Uk Kim^{1,2}

¹ Division of Rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Republic of Korea
² Center for Integrative Rheumatoid Transcriptomics and Dynamics, College of Medicine, The Catholic University of Korea, Republic of Korea
³ Biomedical Sciences, Seoul National University College of Medicine, Republic of Korea

# Background

The gut microbiota has been proposed to be an important environmental factor in the development of rheumatoid arthritis (RA). However, changes in the gut microbiome of RA patients who were already treated with disease-modifying anti-rheumatic drugs (DMARDs) have not been studied well. The aim of the present study was to characterize the gut microbiota profile of patients with established RA and to investigate its association with certain characteristics of RA. Especially, we focused on whether the abundance and composition of gut microbiota were influenced by biological DMARDs (bDMARDs). In addition, pretreatment gut microbial community can differentiate clinical response to the additional conventional synthetic DMARDs (csD-MARDs) treatment in patients already treated with csD-MARDs and responded inadequately.

## **Methods**

A total of 99 patients with RA and 30 healthy participants were recruited. The microbiome composition was assessed using 16S rRNA amplificon sequencing. For RA patients with moderate-to-high disease activity, treatment change after stool collection and treatment response in 6 months follow-up were further observed.

# **Results**

The diversity of gut microbiota was not different between established RA and healthy participants, regardless of disease activity. Young (<45 years), hypertensive, and anti-citrullinated protein antibody (ACPA) negative patients showed less diversity of gut microbiota. Patients treated with tumor necrosis factor  $\alpha$  inhibitors had an overabundance of genera Bifidobacterium, Anaerostipes, Blautia, Subdoligranulum, and Lachnospiraceae ND3007 group, among other bDMARDs users. Gut microbiota including genera Subdoligranulum and Fusicantenibacter were associated with future clinical response of additional csD-MARDs therapy in patients who had been treated with csD-MARDs.

## Conclusions

Patients with established RA appear to have a distinct gut microbiota composition, which is influenced by age, comorbidity, ACPA, and DMARDs. In addition, our results support the value of the gut microbiome as a possible prognostic tool in RA therapeutics.

## **Keywords**

Rheumatoid arthritis, Microbiota, treatment



IO-04

# Time-averaged DAS28 and HAQ predict cardiovascular disease in patients with rheumatoid arthritis: Data from KORONA registry

Hong Ki Min¹, Seung-Ki Kwok², Hae-Rim Kim³, Sang-Heon Lee³, Kwi Young Kang², Sung-Hwan Park²

¹ Rheumatology, Konkuk University Medical Center, Republic of Korea
 ² Rheumatology, College of Medicine, The Catholic University of Korea, Republic of Korea
 ³ Rheumatology, Konkuk University School of Medicine, Republic of Korea

# Background

To evaluate the predictive role of time-averaged disease activity score (DAS)28 and Health Assessment Questionnaire (HAQ) on cardiovascular disease (CVD) events in patients with rheumatoid arthritis (RA).

# **Methods**

Patients with RA were recruited from 23 tertiary hospitals. Baseline and annual follow-up data of demographic, laboratory, questionnaire, RA-associated parameters, and occurrence of CVD were collected. Patients were divided into three groups according to time-averaged DAS28: 1) low (<3.2), 2) moderate (3.2 – 5.1), and 3) high (>5.1). Kaplan–Meier curves was performed to compare the cumulative probability of CVD. Hazard ratios of each factor on the occurrence of CVD were obtained using univariate and multivariate Cox regression analyses.

## **Results**

A total of 4034 RA patients with 1764 for low, 2002 for moderate, and 268 for high time-averaged DAS28 groups were included. Baseline age, disease duration, ESR, CRP, DAS28, and HAQ scores were higher in the high time-averaged DAS28 group. The incidence rate of CVD was 2.78, 3.53, and 8.13 events per 1000 person-years for the low, moderate, and high time-averaged DAS28 groups, respectively. The incidence rate ratio of CVD in the high time-averaged DAS28 group was 2.194 (95% confidence interval 1.142 – 5.111). The cumulative hazard for CVD in the high time-averaged DAS28 group was significantly high (logrank p = 0.04). In multivariate Cox regression analysis, age, high time-averaged DAS28, and time-averaged HAQ >0.5, were positively associated with CVD events in RA patients.

# Conclusions

In patients with RA, time-averaged DAS28 and HAQ could predict the occurrence of CVD.

# **Figure & Table**




Figure. Cumulative incidence rates of CVD in RA patients

#### **Keywords**

cardiovascular disease, DAS28, Rheumatoid arthritis



10-05

# Increased cardiovascular risk in patients with systemic lupus erythematosus: Population-based Cohort Study in Korea

<u>Jungyong Han</u>^{1,2}, Hyoungyoung Kim^{1,2}, Yena Jeon³, Gaeun Kang³, Sun-Young Jung⁴, Eun Jin Jang⁵, Soo-Kyung Cho^{1,2}, Yoon-Kyoung Sung^{1,2}

¹ Rheumatology, Hanyang University Seoul Hospital, Republic of Korea
 ² Rheumatology, Hanyang University Institute for Rheumatology Research, Republic of Korea
 ³ Statistics, Kyungpook National University, Republic of Korea
 ⁴ Pharmacy, Chung-Ang University, Republic of Korea
 ⁵ Information Statistics, Andong National University, Republic of Korea

## Background

Patients with systemic lupus erythematosus (SLE) have a higher frequency of traditional cardiovascular risk factors and cardiovascular disease (CVD) is known to be one of major causes of mortality. This study aimed to investigate the risk of CVD in SLE patients compared to general population in Korea.

# **Methods**

We identified incident SLE patients and age- and sexmatched control group (1:4 ratio) from National Health Insurance Service (NHIS) database in Korea between 2008 and 2018. The incidence rates of CVD (ischemic heart disease, stroke, and cardiac arrest) and major adverse cardiac event (MACE, myocardial infarction, stroke, and sudden cardiac death) were calculated and increased risk of CVD and MACE in SLE patients compared to general population were estimated using cox proportional hazard models.

# **Results**

We analyzed 8,568 SLE patients, and age- and sexmatched 34,272 controls. The incident rate ratios (IRRs) for CVD and MACE of SLE patients compared to general population were 3.77 (95% confidence interval [CI] 3.33-4.26), and 3.14 (95% CI 2.58-3.81), respectively. After adjusting for the confounders, the CVD risk of SLE patients was remained higher than general population (hazard ratio [HR] 1.49, 95% CI 2.58-3.42), while the HR of MACE was decreased to 1.15 (95% CI 0.87-1.51).

# Conclusions

In Korea, SLE patients have significant increased cardiovascular risk compared to general population.

# Figure & Table

	SLE patients (n=8,568)		General population (n=34,272)			
	No. of cases	Incidence per 1,000 PYs	No. of cases	Incidence per 1,000 PYs	IRR (95% CI)	HRsd (95% CI) *
CVD events	477	11.16	536	2.96	3.77 (3.33, 4.26)	1.49 (1.25, 1.76)
Ischemic heart disease	295	6.84	375	2.07	3.31 (2.84, 3.86)	1.43 (1.16, 1.77)
Cardiovascular mortality	75	1.70	13	0.07	23.92 (13.28, 43.11)	5.02 (2.48, 10.15)
Stroke	140	3.21	191	1.05	3.06 (2.46, 3.80)	1.09 (0.79, 1.49)
MACE	178	4.08	237	1.30	3.14 (2.58, 3.81)	1.15 (0.87. 1.51)
Myocardial infarction	40	0.91	51	0.28	3.25 (2.15, 4.92)	1.37 (0.81, 2.33)
Cardiac sudden death	0	NC	0	NC	NC	NC
Stroke	140	3.21	191	1.05	3.06 (2.46, 3.80)	1.09 (0.79, 1.49)

HR adjusted for age, sex, insurance, comorbidities (hypertension, diabetes mellitus, and hyperlipidemia). Charlson comorbidity index, and medication history (e.g. antiplatelet agents, cholesterol lowering agents, ACE inhibitor, ARB, beta-blocker, calcium-channel blocker, diuretics, NSAIDs, and steroid)

Table. The incidence rate ratio and adjusted hazard ratio of CVD risk in SLE patients compared to general population

## **Keywords**

Systemic lupus erythematosus, Cardiovascular risk, Hazard ratio



# Long-term exposure to PM10 and systemic-lupus-erythematosus-related mortality in the Korean population

# Ji-Hyoun Kang¹, Chang Kyun Choi², Sung-Eun Choi¹, Dong-Jin Park¹, Shin-Seok Lee¹

¹ Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Republic of Korea ² Department of Preventive Medicine, Chonnam National University Medical School, Republic of Korea

# Background

The effect of air pollutants on the risk or progression of systemic lupus erythematosus (SLE) has been evaluated in several studies. However, their results were inconsistent and large-scale investigations are lacking. We evaluated the effect of particulate matter (PM) 10 on the risk or prognosis of SLE in a cohort drawn from a very large number of SLE cases registered in a nationwide database.

# **Methods**

A case-cohort study consisting of 23,511 SLE cases and 204,521 cohorts was conducted using NHIS customized data. The district-specific annual average PM10 concentration for the year 2004 was estimated using a land-use regression model. A mixed Cox proportional hazard regression with random intercepts for districts was performed to evaluate the association between PM10 and the SLE risk for the general population and between PM10 and mortality for SLE patients.

# Results

There was no significant association between PM10 exposure and SLE risk. However, the plot of the association between PM10 exposure and mortality in male SLE patients followed an inverted U-shape. Compared to the first quintile, the hazard ratios of mortality for the second, third, fourth, and fifth quintiles were 1.541 (95% confidence interval [CI]: 1.049–2.185), 1.278 (95% CI: 0.893–1.829), 1.395 (95% CI: 0.972–2.002), and 1.266 (95% CI: 0.881–1.818). Those associations were not significant in females.

# Conclusions

A past PM10 exposure was associated with high mortality in male SLE patients. Further studies of the risk associated with a higher than average PM exposure level are needed.

## **Keywords**

PM10, mortality, systemic lupus erythematosus



**IO-07** 

KCR 2022

May 19(Thu) - 21(Sat), 2022

# Neutralizing antibody formation after COVID-19 vaccination in elderly patients with rheumatoid arthritis

<u>Eunsong Kang</u>¹, Yong Gil Kim¹, Ji Seon Oh², Seokchan Hong¹, Soomin Ahn¹, Chang Keun Lee¹, Bin Yoo¹

¹ Rheumatology, Asan medical center, Republic of Korea ² Department of Information Medicine, Asan medical center, Republic of Korea

#### Background

The guidelines of COVID-19 vaccination in patients with rheumatoid arthritis (RA) have been continuously updated concerning whether disease modifying anti-rheumatic drugs (DMARDs) need to be discontinued before vaccination. Furthermore, there is great discussion on the effectiveness of COVID-19 booster vaccine. We investigated the differences in antibody production between patients who received two doses of ChAdOx1-S nCoV-19 and those who received the third dose of mRNA vaccine. Also, antibody production under different medication scenarios and clinical parameters was analysed.

#### Methods

From October 14, 2021 to January 21, 2022 at a tertiary referral center, two patient groups diagnosed with RA were studied prospectively; one group that completed two doses of ChAdOx1-S nCoV-19 vaccine, second group that completed mRNA 3rd vaccine.

SARS-CoV-2 antibody titres were determined by semiquantitative anti-SARS-CoV-2 S enzyme immunoassay. Differences in antibody titres were analysed in patients who received corticosteroid and different DMARDs. The results were expressed as box and whisker plots and statistical analysis with a multivaiate logistic regression model was performed.

#### Results

In a total of 261 patients, 153 patients had completed two doses of ChAdOx1-S nCoV-19, 108 patients had completed mRNA 3rd vaccine. The positive rates of anti-SARS-CoV-2 neutralizing antibody (titre > 0.8U/mL) were 97% (149/153) and 99% (107/108) respectively. However, regarding acquisition of high antibody titre (> 250U/mL), the positive rates were found to be only 31% (47/153) for group 1 but 94% (102/108) for group 2. Multivariate analysis revealed that corticosteroid use (OR 0.35;95% CI:0.16-0.75), older age

(OR 0.91;95% CI:0.86-0.98), and male (OR 0.23;95% CI:0.07-0.74) were associated with low rate of high antibody titres after two doses of ChAdOx1-S nCoV-19.

#### Conclusions

We can support the suggestion that a third dose of mRNA vaccine might be required in RA patients who have already received two doses of ChAdOx1-S nCoV-19, especially older male patients treated with corticosteroid.

#### Figure & Table




Figure. Anti-SARS-CoV RBD antibody titre in RA patients who received two doses of ChAdOx1-S nCoV-19 (A) and in patients who received an additional mRNA vaccine after two doses of ChAdOx1-S nCoV-19 (B)

#### **Keywords**

Rheumatoid Arthritis, COVID-19 vaccination, antibody formation



**IO-08** 

# Immunogenicity and safety of inactivated and mRNA COVID-19 vaccines in patients with systemic lupus erythematosus

Ho So¹, Tena Li¹, Vivien Chan¹, Lai Shan Tam¹, Paul Chan²

¹ Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong ² Microbiology, The Chinese University of Hong Kong, Hong Kong

# Background

Vaccination against SAR-CoV-2 is believed to be the key to end the pandemic. Currently, there are two COVID-19 vaccines available in Hong Kong - they are the inactivated virus vaccine CoronaVac® (Sinovac) and the mRNA-based vaccine Comirnaty® (BioNTech/Fosun). However, the efficacy and safety of COVID-19 vaccines in patients with SLE is uncertain due to a complex interplay of underlying autoimmunity and immunosuppressive therapies used.

# **Methods**

This was a prospective, case-control study. Patients with SLE planning to receive COVID-19 vaccines were recruited and matched 1:1 with healthy controls. The immunogenicity of the COVID-19 vaccines was assessed by a surrogate neutralization assay at 28 days after the second dose. The main outcomes included the antibody response and adverse effects comparing SLE patients and controls. Predictors of responses in SLE patients were analyzed. The change of SLE disease activity was evaluated.

# **Results**

Sixty-five SLE patients received 2 doses of COVID-19 vaccines (Comirnaty: 38; CoronaVac: 27) were recruited. Many of them were on systemic glucocorticoids (75.8%) and immunosuppressants (54.5%). At day 28 after the second dose of vaccines, 92.3% (Comirnaty: 100%; CoronaVac: 81.5%, p=0.01) had positive neutralizing antibody. However, compared to the age, gender, vaccine type matched controls, the level was significantly lower (p<0.001) in patients with SLE (figure). The self-reported side-effects of the vaccines in lupus patients were common but mild, and were more frequent in the Comirnaty group. There was no significant change in lupus disease activity up to 28 days after vaccination. The independent predictors of neutralizing antibody level included the dosage of systemic glucocorticoids, use of mycophenolate and type of vaccines (table).

# Conclusions

COVID-19 vaccines produced satisfactory but impaired serological response in SLE patients compared to controls which was dependent on the immunosuppressive medications use and type of vaccines received. There was no new safety signal. Booster dose is encouraged.

# Figure & Table




Figure. Distribution of neutralizing antibody levels after COV-ID-19 vaccines comparing (A) SLE patients and matched controls, (B) SLE patients and matched controls in two vaccine subgroups, and (C) two vaccine types in SLE patients. Data for each group are presented as box plots: central values within boxes correspond to median; the range between the lower (Q1) and upper (Q3) bounds of the boxes is the IQR. Whiskers represent scores outside IQR and ends in maximum (higher "calculated value" = Q3 + 1.5 x IQR) and minimum (lower "calculated value" = Q1 - 1.5 x IQR). Spots are outliers above the maximum or under the minimum values. Data regarding were analyzed using Mann-Whitney-U test. Dotted line denotes the cut-off level for positivity (30%).

# Keywords

SLE, COVID, vaccine



KCR 2022

# Clinical characteristics and prognosis of patients with anti-melanoma differentiation-related gene 5 (MDA5) related diseases

<u>Chen Yu</u>¹, Luwei Yang², Li Zhang¹, Shuang Zhou¹, Chaojun Hu¹, Jiuliang Zhao¹, Dong Xu¹, Mengtao Li¹, Chanyuan Wu¹, Qian Wang¹, Lindi Jiang², Zuojun Xu³, Xiaofeng Zeng¹

¹ Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences & Peking Union Med, China ² Department of Rheumatology, Zhongshan Hospital, Fudan University (Xiamen Branch), China ³ Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital (PUMCH),

Chinese Academy of Medical Sciences & Peking Union Med, China

#### Background

Idiopathic inflammatory myopathy (IIM) is a group of heterogeneous systemic autoimmune diseases, of which patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody are of specific clinical characteristics. Our study is aimed to propose the concept of patients with anti-MDA5 related diseases (Anti-MDA5-RD), and to describe the clinical characteristics and prognosis of these patients.

#### **Methods**

Patients with anti-MDA5 admitted to Peking Union Medical College Hospital from November 2015 to December 2018 were retrospectively studied. Patients were divided into either remission or progression group according to their prognosis. Demographic data and clinical outcomes were compared between the two groups. A multivariate Logistic regression model was applied to explore independent risk factors for poor prognosis. Furthermore, the clinical manifestations and prognosis of patients with both anti-MDA5 and anti-Ro-52 were compared with patients with only anti-MDA5.

#### Results

A total of 126 patients were included. Rash is the most common initial symptom (65.1%) and clinical amyopathic dermatomyositis (CADM) is the most common clinical subtype (74.8%). Logistics analysis showed anti-Ro-52 (OR 9.17, 95%CI 1.97-42.62, P = 0.005), serum ferritin > 1000ng/ml (OR 2.91, 95%CI 1.03-8.21, P = 0.044), age > 50 (OR 7.78, 95%CI 1.75-34.66, P = 0.007) and hypoxemia at diagnosis (PaO2 < 60 mmHg) (OR 30.68, 95%CI 6.48-145.33, P < 0.001) were independent risk factors for poor prognosis. Patients with anti-MDA5 combined with anti-Ro-52 had a higher risk of rapidly progressive interstitial lung disease (RP-ILD) (42.0% vs 24.6%, P = 0.04) and a worse response to intensive immunosuppressive therapy.

## Conclusions

Anti-MDA5 related disease is a high-risk clinical subtype. Patients with anti-Ro-52 are prone to RP-ILD and have a poor response to traditional immunosuppressive therapy. Early combination therapy with biologics may improve the prognosis of these patients.

#### Figure & Table




Figure. Kaplan-Meier survival estimates based on patients combined with anti-Ro-52 antibody

#### **Keywords**

inflammatory myopathy, anti-melanoma differentiation associated gene 5, interstitial lung disease



10-10

# Three-dimensional analysis of the trapezium subchondral bone and its association with trapeziometacarpal joint osteoarthritis

# Ji Sup Hwang¹, Hyun Sik Gong¹

¹ Department of Orthopedic Surgery, Seoul National University Bundang Hospital, Republic of Korea

# Background

Studies suggest that subchondral bone properties are associated with the pathogenesis of osteoarthritis (OA), but this relationship has not been confirmed in the trapeziometacarpal joint (TMCJ). The purposes of this study are (1) to evaluate the thickness and density of three-dimensional (3D) trapezium subchondral bone models derived from conventional computed tomography (CT) images, and (2) to evaluate the relationship between subchondral bone properties and early stage TMCJ OA.

# **Methods**

We reviewed patients with a distal radius fracture who underwent conventional CT scans and such osteoporosis evaluations as bone mineral density (BMD) and bone turnover markers (BTMs). From 3D trapezium subchondral bone models, we measured SBT and SBD according to the OA stage and performed multivariate analyses to evaluate their associations with age, gender, body mass index, BMD, and BTMs.

## **Results**

Out of the 156 patients (78 men and 78 age-matched women; mean age,  $67\pm10$  years), there were 30 (19%) with grade 0 TMCJ OA, 71 (45%) with grade 1, 13 (8%) with grade 2, and 42 (27%) with grade 3. The average SBT and SBD were 1.84  $\pm$  0.41 mm and 568.4  $\pm$  69.0 Hounsfield units (HU), respectively. In the multivariate analysis, SBT was significantly lower in patients with grade 1 OA than those with grade 0 or grade 3 OA, but SBD generally increased according to the OA severity. Low SBT was associated with female sex and low hip BMD, and low SBD was associated with female sex, low hip BMD, and high osteocalcin.

# Conclusions

Patients with early-stage radiographic TMCJ OA have a lower SBT at the trapezium, which may support the potential role of subchondral bone in OA pathogenesis. This study also shows that subchondral bone properties are associated with BMD and osteocalcin levels. Further studies are necessary to determine whether patients with early OA can benefit with osteoporosis therapies.

# **Figure & Table**




Figure. The subchondral bone thickness and density were measured from the three-dimensional trapezium models.

## **Keywords**

Trapeziometacarpal joint, Osteoarthritis, Subchondral bone

# Workshop

Basic Research Workshop for Rheumatologist: Animal Models of Key Arthropathies

> KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



Journal of Rheumatic Diseases Vol. 29, Suppl. 1, May, 2022

# Animal models of osteoarthritis (OA)

# Je-Hwang Ryu

Chonnam Nat'l Univ., Korea

Osteoarthritis (OA), which is the most common chronic degenerative joint disorder worldwide, is characterized primarily by cartilage degradation and narrowing of the joint spaces. Both genetic and acquired factors, such as obesity, mechanical influences and age, are involved in the complex pathogenesis of OA, whereby cartilage homeostasis is disrupted by biophysical factors (for example, mechanical stress) and biochemical factors (for example, proinflammatory cytokines). The chondrocyte is a unique resident cell that synthesizes cartilage-specific extracellular matrix (ECM) components as well as various catabolic and anabolic factors. The pathogenesis of OA activates various biochemical pathways in chondrocytes, leading to proinflammatory cytokine production, inflammation, degradation of the ECM by matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS), and cessation of ECM synthesis via the dedifferentiation and apoptosis of chondrocytes. The culture of chondrocytes is one of the most powerful tools for exploring the intracellular and molecular features of chondrocyte differentiation and activation. However, chondrocytes tend to dedifferentiate into fibroblasts when they are subcultured, which is a major problem. Here we introduce the method of primary culture and phenotyping of murine chondrocytes. In addition to in vitro cell culture, various in vivo studies are currently ongoing to understand OA pathophysiology and develop successful treatment regimens based on this knowledge. Animal models have played a key role in achieving this goal. Experimental animal models currently used to study OA can be classified based on the etiology under investigation.



# **Experimental procedures of mouse OA research**

# Gyuseok Lee

Chonnam Nat'l Univ., Korea

Disease animal models that accurately reflect disease progression and symptoms are essential for further elucidation of disease pathogenesis and the development of treatments. Currently, various animal models are used to study osteoarthritis (OA), which is one of the most common degenerative diseases in the world.

Based on disease etiology, OA can be classified into primary (idiopathic) and secondary OA. Primary OA is a disease that occurs naturally due to degenerative changes (dedifferentiation) in chondrocytes. Secondary OA is an inducible disease associated with some causes and risk factors, including trauma, congenital causes, obesity, or bone deformities. According to this classification of OA, animal models have been categorized into spontaneous and induced OA models. However, the causes of OA are not completely understood and recent studies have proposed novel OA-inducing pathways related to adipokines or metabolic disorders such as hypercholesterolemia. The diverse etiology of OA has raised the need for a new classification of OA based on clinical phenotype. Five OA phenotypes have been proposed to replace the conventional primary and secondary classifications with disease features. These include post-traumatic, metabolic, aging, genetic, and pain phenotypes.

In this lecture, OA animal models which reflect these five OA phenotypes will be introduced and detailed experimental processes will be explained. Surgically induced OA models such as destabilized media meniscus (DMM) surgery or anterior cruciate ligament transection (ACLT) on mice reflect post-traumatic phenotype. Metabolic OA models including high-fat diets or high cholesterol diets showed metabolic phenotypes of OA. Spontaneous OA models such as STR/ort mouse strain or aged mice and senescent cell transplantation model have aging phenotypes of OA. Intra-articular (IA) injection models of adenovirus expressing the gene of interest have been used to study the genetic phenotype of OA. Monoiodoacetate (MIA) IA injection models with pain assay such as the von Frey test or hot plate test have been used to study pain phenotypes of OA.

Furthermore, the analytic method for assessment of disease progression of OA animal models including histological analysis of cartilage damage, osteophyte maturation, and subchondral bone thickening will be explained and the microCT-based knee joint imaging method using a contrasting agent will be introduced in this lecture.



# Animal models of rheumatoid arthritis

# Seung-Ah Yoo

The Catholic Univ. of Korea, Korea

Rheumatoid arthritis (RA) is a common autoimmune disorder that afflicts ~1% of the population. Despite the advent of anticytokine therapies that ameliorate the inflammatory manifestations of disease, there is no cure, and the pathogenesis of RA is not fully understood. In RA joints, various inflammatory cells, including innate immune cells, adaptive immune cells, endothelial cells, and fibroblast-like synoviocytes (FLSs), are activated. To understand the pathogenic processes of RA in humans, animal models are helpful and essential tools. These are also important for testing the novel and existing drugs for their potency, efficacy and safety. The rodent models are used widely because of low cost, homogeneity of the genetic background, ease of handling. In this presentation, we focus on animal models of arthritis induced in various species along with the genetic models.



# **Experimental procedures of mouse arthritis models**

# Saseong Lee

The Catholic Univ. of Korea, Korea

Collagen induced arthritis (CIA) is an essential experimental tool for pre-clinical research on rheumatoid arthritis. Using lyophilized bovine collagen and Freund's adjuvant, DBA-1 mice are immunized to acquire an autoimmune response on collagen to get inflamed in articular joints. The procedure in this model requires multiple steps that need to be performed properly, from initial collagen emulsification with adjuvants before immunization to clinical assessment and histological analysis of the affected joint, making this experimental arthritis model complicated and difficult to replicate the same results. In this lecture, we will look at specific materials and methods for accurately performing CIA model without omitting crucial details including dissolving collagen adequately, injecting the collagen-adjuvant emulsion in the right position, and animal facility issues, etc., which will be of practical help to the performers in deriving successful results.

# **Free Paper Session**

International Free Paper Session (Basic)

> KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



# Identification of a key regulator of MYH9 for synoviocyte migration and invasion through secretome profiling

# Saseong Lee¹, Eunbyeol Choi¹, Sehyun Chae², Seung-Ah Yoo^{1,3}, Daehee Hwang⁴, Wan-Uk Kim^{1,5}

¹ Center for Integrative Rheumatoid Transcriptomics and Dinamics, The Catholic University of Korea, Republic of Korea
² Department of Developmental Disorders & Rare Diseases Research Group, Korea Brain Research Institute, Republic of Korea
³ Department of Medical Life Sciences, The Catholic University of Korea, Republic of Korea
⁴ Department of Biological Sciences, Seoul National University, Republic of Korea
⁵ Department of Internal Medicine, The Catholic University of Korea, Republic of Korea

# Background

Invasive pannus, mainly composed of fibroblast-like synoviocytes (FLSs), is a hallmark of rheumatoid arthritis (RA) pathology. In the present study, we sought to present a pannus-derived secretome profile in rheumatoid synovium in an unbiased manner and reveal a pathogenic mechanism of a newly identified secretome protein.

# **Methods**

The secreted proteins from RA-FLSs were identified through a proteomics approach using liquid chromatography-mass spectrometry (LC-MS). To further narrow into a group of proteins that are increased in RA synovial fluid (SF) when compared to osteoarthritis (OA) SF, the SFs were proceeded with parallel reaction monitoring (PRM), a quantitative proteomics method. In vitro migration and invasion assays were performed under MYH9 deficient or blebbistatin-treated conditions in RA-FLSs.

# Results

The 843 secretory proteins from RA-FLSs treated with TNF $\alpha$  and IL-1 $\beta$  were profiled by using LC-MS/MS analysis. Gene ontology analysis revealed that 493 proteins were involved in pannus-driven RA pathologies. Among these, 151 proteins were selected to be further quantitatively analyzed in 117 RA and 45 OA SFs using PRM method. Total 16 differentially expressed proteins (DEPs) were selected according to whether it was significantly higher in RA compared to OA SF, and whether it was correlated with synovial hyperplasia, articular vascularity, or inflammatory levels of RA patients. Among the DEPs, MYH9 has met all the criteria for the DEPs and is a novel factor in terms of RA pathogenesis. MYH9 levels were increased in RA-FLSs under disease-aggravating conditions. RA-FLSs depleted with MYH9 gene expression or molecular function significantly defected in cell migration and invasion.

## Conclusions

The present study clearly suggested a pannus-derived secretome profile of RA synovium through a stepwise approach starting from RA-FLS-secreted proteins to synovial fluids that were under a series of disease severity in inflammatory arthritis and proposed a pathogenic role of a newly discovered molecular player, MYH9, in RA-FLS-driven articular tissue destruction.

## **Keywords**

Secretome, Pannus, Fibroblast-like Synoviocytes



#### IO-12

# Multi-omics identifies S100 proteins as biomarkers of RA progression which can be regulated by epigenetic drugs

Marzena Ciechomska¹, Leszek Roszkowski¹, Dominik Cysewski¹, Wlodzimierz Maslinski¹

¹ Department of Pathophysiology and Immunology, National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland

# Background

Monocytes are key players in the initiation and maintenance of inflammation through production of proinflammatory cytokines and S100 proteins in rheumatoid arthritis (RA). A number of studies demonstrated that epigenetic drugs affecting DNA methylation are able to modulate the production of proinflammatory mediators. Therefore, the aim of this study was to test specific DNA methylation inhibitor (RG108) or activator (budesonide) in regulation of proinflammatory cytokines and S100 proteins in RA monocytes.

# **Methods**

High-throughput analyses were performed including RNA sequencing (RNA-seq) of healthy control (HC) and RA monocytes and proteomic analysis of HC sera and sera from early RA and advanced RA sera. Cell viability was determined in THP-1 monocytic cell line following RG108 and budesonide treatment. Pro- and anti-inflammatory genes such as the S100 family, TNF, IL-8, MyD88, IL-10RA, TGIF1 were validated by qRT-PCR following DNA methylation-targeted drug treatment.

## Results

Based on the RNA-seq analysis, RA monocytes had significantly increased level of S100 family, TNF, IL-8, MyD88 and decreased level of anti-inflammatory IL-10RA and TGIF1. Proteomic analysis also revealed increased level of S100 proteins in sera from advanced RA compared to HC and early RA, suggesting that S100 family might be promising marker of RA progression. In addition, THP-1 monocytic cell line treated with RG108 (DNA methylation activator) had increased level of S100 family (S100A8, -A9, -A11, -A12), IL-8, TNF. In contrast, stimulation of THP-1 cells with budesonide (DNA methylation inhibitor) reduced expression of S100 family, IL-8, TNF genes.

# Conclusions

Using multi-omics analysis we have demonstrated that S100 proteins are increased in RA monocytes (transcriptomics) similarly to enhanced S100 production in sera (proteomics) of patients with advanced RA. Interestingly, S100 proteins can be regulated by epigenetic drugs, suggesting their potential use in targeting of RA inflammation.

# **Keywords**

multi-omics, rheumatoid arthritis, biomarkers



# Dysfunction of parkin increases osteoclast activity linking to bone erosion of inflammatory arthritis

<u>Ji-Eun Kim</u>^{1,3}, Eun-Young Kim^{1,3}, Bongkun Choi^{1,3}, Dong Hyun Sohn⁴, Yeon-Ho Chung¹, Ji-Eun Park^{1,3}, Sion Park^{1,3}, Soyoon Oh^{1,3}, Ha Rim Shin^{1,3}, Yongsub Kim^{1,3}, Dohee Yoon^{1,3}, Yu Mi Hwang^{1,3}, So Hye Nam⁵, William H. Robinson⁶, Yong-Gil Kim⁵, Eun-Ju Chang^{1,2,3}

¹ Department of Biomedical Sciences, University of Ulsan College of Medicine, Republic of Korea
 ² Department of Biochemistry and Molecular Biology, University of Ulsan College of Medicine, Republic of Korea
 ³ Stem Cell Immunomodulation Research Center, University of Ulsan College of Medicine, Republic of Korea
 ⁴ Department of Microbiology and Immunology, Pusan National University School of Medicine, Republic of Korea
 ⁵ Department of Rheumatology, Asan Medical Center, Republic of Korea
 ⁶ Division of Immunology and Rheumatology, Stanford University School of Medicine, USA

# Background

Dysfunction of parkin related to the progression of parkinsonism contributes to a progressive systemic skeletal disease characterized by low bone mineral density. However, the role of parkin in bone remodeling has not been elucidated in detail.

# **Methods**

To check the linkage between parkin and inflammatory arthritis, synovial tissues of rheumatoid arthritis (RA) and osteoarthritis (OA) patients were analyzed by using immunofluorescence. The femurs from wild-type (WT) and Parkin-deficient mice were examined by micro-computed tomography. Osteoclast (OC) differentiation was evaluated by tartrate-resistant acid phosphatase staining and bone resorbing activity was determined using dentin. To induce arthritis mouse model, the serum of arthritic K/BxN mice were injected to recipient WT or Parkin-deficient mice and K/BxN serum transfer-induced arthritis mouse model was employed to evaluate inflammatory arthritis.

# Results

Parkin expression was significantly downregulated in monocytes of the inflamed synovial tissues of RA patients. Given that monocytes are considered as osteoclast (OC) precursor cells, we thus clarified whether the decrease in parkin in monocytes is linked to the osteoclastic bone resorbing activity. Parkin-deficient mice exhibited an osteoporotic phenotype with a lower bone volume accompanied by increased OC-mediated bone resorbing capacity compared to WT mice. Intriguingly, parkin co-localized with microtubules and parkin depleted-OC precursor cells displayed augmented acetylation of  $\alpha$ -tubulin. The Parkin-deficiency mice increased the susceptibility to inflammatory arthritis reflected by higher arthritis score and a marked bone loss after K/BxN serum transfer.

## **Conclusions**

These results reveal parkin as a potential determinant of the maintenance of bone turnover balance by altering microtubule dynamics in OC and assign a homeostatic role to parkin that would limit inflammatory arthritis.

## **Keywords**

Parkin, Inflammatory Arthritis, Osteoclast



IO-14

# Cell-specific activation of PADI4 promoter in human fibroblast-like synoviocytes from patients with rheumatoid arthritis

# Khrystyna Malysheva^{1,2,3}, Justyna Czarnik-kwaśniak^{2,3}, Oleksandr Korchynskyi^{1,2,3}

¹ Department of Biotechnology and Radiology, S. Gzhytskyi National University of Veterinary Medicine and Biotechnologies, Ukraine ² Department of Immunology, Institute of Medical Sciences, College for Medical Sciences, University of Rzeszow, Poland ³ Centre for Innovative Research in Medical and Natural Sciences, Medical College of Rzeszów University, Poland ⁴ Academic Medical Center, University of Amsterdam, Netherlands

⁵ Department of Molecular Immunology, Palladin Institute of Biochemistry of the National Academy of Sciences of Ukraine, Ukraine

# Background

Citrullination is a normal physiological process which represents conversion of peptidylarginine to peptidylcitrulline catalyzed by peptidylarginine deiminases (PADs). PAD2 and PAD4 are found in hematopoietic cells invading synovial tissue in RA. In Asian population the PADI4 gene that encodes a PAD4 has been associated with susceptibility to RA. To date nothing is known about the regulation of PAD2/4 expression by inflammation. Thus, the study goal was to understand the regulation features of PADI4 gene expression in RA.

## **Methods**

hPADI4 promoter was cloned from HEK293 cells genomic DNA. To perform in vitro analysis of hPADI4 promoter a panel of serial deletion and point mutant constructs was used. Adenoviral constructs were generated to perform assays on undamaged FLS. Luciferase reporter assays were performed to monitor PADI4 promoter activation in NIH-3T3 mouse fibroblasts and hFLS from RA patients upon treatment with proinflammatory cytokines. To study transcription factors that activate PADI4 expression a ChIP assay was performed.

## Results

PADI4 mRNA is transiently upregulated in FLS from RA patients upon IL-1 $\beta$  treatment. In silico analysis of PADI4 gene demonstrated that hPADI4 promoter contains NF- $\kappa$ B or c-Rel binding sites that could mediate transcriptional control of PADI4 expression. Thus, hPADI4 gene can be regulated by NF- $\kappa$ B pathway. A serial 5'-deletions gradually increase the activation of the hPADI4 promoter in NIH-3T3 mouse fibroblasts that is in a strong conflict with analysis of PADI4 mRNA expression upon proinflammatory stimulation of primary FLS derived from RA patients. Moreover ChIP assay demonstrated that RA-associated gene C-Rel bound to hPADI4 promoter in human FLS upon their stimulation with proinflammatory cytokines.

# Conclusions

Proinflammatory cytokines stimulated activation of PADI4 expression in FLS might be cell-type specific and possibly contributes to RA pathology. Therefore, a detailed investigation of regulation of PADI4 expression in FLS can provide an important insight into understanding of RA pathophysiology.

# **Figure & Table**




Figure. C-Rel is bound to hPADI4 promoter upon NF- $\kappa$ B activation

## **Keywords**

Rheumatoid Arthritis, Fibroblast-like Synoviocytes, Citrullination



# Effect of disease-modifying anti-rheumatic drugs on lung microenvironment of SKG mice

# Sung Hae Chang^{1,2}, Jeong Seok Lee^{3,4}, Jeongjun Choe⁵, Seon Uk Kim^{6,7}, Jeong Yeon Kim^{4,6}, Eun Young Lee^{6,7}

¹ Department of Internal Medicine, Division of Rheumatology, Soonchunhyang University College of Medicine, Republic of Korea
² Department of Internal Medicine, Division of Rheumatology, Soonchunhyang University College of Medicine, Cheonan Hospital, Republic of Korea
³ Graduate school of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, KAIST, Republic of Korea
⁴ Department of Multiomics, GENOME INSIGHT Technologies, Republic of Korea

⁵Department of Health Science and Technology, SAIHST, Sungkyunkwan University, Republic of Korea ⁶Laboratory of Autoimmunity, Seoul National University Cancer Research Institute, Republic of Korea

⁷ Department of Internal Medicine, Division of Rheumatology, Seoul National University College of Medicine, Republic of Korea

# Background

Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is one of the pivotal extrapulmonary conditions. However, the pathophysiology of RA-ILD, including the effect of disease-modifying anti-rheumatoid drugs (DMARDs) is largely unknown. To study the effect of methotrexate and TNFa inhibitor on lung microenvironment of SKG mice using single-nucleus RNA sequencing.

## **Methods**

Male SKG mice of eight to ten weeks received a single intraperitoneal zymosan A (ZyA) injection to induce arthritis and pneumonitis. We gave them twice-weekly intraperitoneal injections of PBS, methotrexate (7.5 mg/kg; MilliporeSigma), or TNFa inhibitor (100  $\mu$ g/kg; R&D Systems, Inc., Minneapolis, MN, USA). Nuclei were prepared from frozen lung tissue under ribonuclease-free conditions by a method adapted from an existing protocol.

## **Results**

Macroscopically, pneumonitis was most evident in SKG mice with ZyA and methotrexate treatment. A total of 59,860 nuclei were obtained from sixteen mice, four mice from each of the four groups. We classified each cell type using previous reports on the single-nucleus cells of mouse lungs. The most frequently observed cell was the type 2 alveolar (AT2) cell among all four groups. Alveolar epithelial cells were further subclustered into six clusters. Cluster 2 highly expressed type 1 alveolar (AT1) cell marker genes. Interestingly, a distinct cluster 3 was observed after methotrexate treatment. This distinctive alveolar epithelial cell cluster (cluster 3) showed IL-1, TNF, IFNa, and IFNy perturbation-response signatures using Library of Integrated Network-Based Cellular Signatures (LINCS) 1000 ligand perturbation analysis. In addition, enrichment analysis revealed that cluster 3, as well as cluster 2 (i.e., AT1 cells) significantly enriched genes of BMI1 knockout mice that fail to self-renew their lung cells after damage.

## Conclusions

The current study shows that methotrexate exacerbates lung inflammation via attenuation of the regenerative potential of AT2 cells.

## **Keywords**

rheumatoid arthritis-associated interstitial lung disease, single nucleus RNA sequencing, SKG mouse



# Peptoniphilus gorbachii ameliorates collagen-induced arthritis in mice by improving intestinal homeostasis and immune regulation

Young Sun Suh¹, Sung Hak Chun², Seong-Tshool Hong³, Hanna Lee², Mingyo Kim², Yun-Hong Cheon², Hyun-Ok Kim¹, Suhee Kim², Sang-II Lee²

¹ Internal Medicine, College of Medicine, Gyeongsang National University and Changwon Hospital, Changwon, Republic of Korea ² Internal Medicine, College of Medicine, Gyeongsang National University and Hospital, Jinju, Republic of Korea ³ Biomedical Sciences and Institute for Medical Science, Chonbuk National University Medical School, Jeonju, Republic of Korea

# Background

Although numerous studies demonstrated altered microbiome in rheumatoid arthritis (RA), there is still a lack of information about the RA-specific microbial species. Recent studies reported that specific microbial species and derived molecules in the blood reflect systemic pathological events. Thus, the aim of this study was to identify RA-related microbial species in the serum of RA patients and explore the therapeutic effect and mechanism of candidate microbial species.

# **Methods**

Serum antibody microarray for 384 microbial species was performed from RA patients (n=81) and healthy control (n=50). We verified the therapeutic effect and mechanism of the candidate microbial species by evaluating arthritis severity, immune response, intestinal barrier integrity, and fecal microbiota using collagen-induced arthritis (CIA) mice.

# **Results**

Total 36 microbial species were altered in the serum of RA patients with increased 15 and decreased 21 microbial species compared to controls. Of reduced microbial species, Peptoniphilus gorbachii (PG) was inversely correlated with RA disease activity and produced acetate and butyrate in culture. The administration of PG suppressed arthritis in CIA mice by reducing inflammatory monocytes in mesenteric and inguinal lymph nodes. Moreover, PG supplementation restored intestinal barrier integrity with a decreased level of serum zonulin and increased expression of intestinal tight junction (Zo-1 and Ocln). Fecal microbiota abundant in PG-treated mice was correlated with improved intestinal barrier integrity and decreased inflammatory reaction.

# Conclusions

This study provided serum microbial species associated with RA and suggested the therapeutic effect of PG through restoring the intestinal barrier function and suppressing the immune response against RA.

## **Keywords**

Rheumatoid arthritis, Peptoniphilus gorbachii, Serum microbial species



10-17

# The immune mechanism of Janus kinase inhibitors on Shingles in rheumatoid arthritis patients

Hong Ki Min¹, Ji-Yeon Lee², Se Hee Kim¹, Hae-Rim Kim², Sang-Heon Lee²

¹ Rheumatology, Konkuk University Medical Center, Republic of Korea ² Rheumatology, Research Institute of Medical Science, Konkuk University School of Medicine, Republic of Korea

# Background

Incidence of shingles is increased in rheumatoid arthritis (RA) patients than healthy control (HC), and this is especially increased in RA patients with janus kinase inhibitor (JAKi) use. We aimed to investigate immune response of JAKi in aspect of CD4+/CD8+ T cells, cytokines production, and regulation of transcriptional factors in RA patients, then compared these with HC.

# **Methods**

Peripheral blood mononuclear cells (PBMCs) were obtained from RA patients and HCs. Varicella zoster virus lysates (5 µg/ml) was pre-stimulated with PBMCs for 24hrs, then three JAKi (ruxolitinib 10/20 µM [JAK1/2 inhibitor], AG490 20/40 µM [JAK2 inhibitor], WHI-P154 125/250 µM [JAK3 inhibitor]) + methotrexate (10 nM) were administrated in vitro. Population of CD4+IFN-γ+, CD4+CD69+IFN-γ+, CD8+IFN-γ+, CD8+CD69+IFN-γ+, CD4+CD25highFoxp3+ cells were measured by flow cytometry. Cytokines levels of culture media were evaluated by ELISA. Last, the transcriptional factors were measured by RT-qPCR.

# **Results**

Experiments were conducted in a total 14 RA patients and 7 HCs. The decrease CD4+IFN- $\gamma$ +, CD4+CD69+IFN- $\gamma$ +, CD8+IFN- $\gamma$ +, CD8+CD69+IFN- $\gamma$  cells and increase of CD4+CD25highFoxp3+ cells by three JAKi were observed in both RA patients and HCs, and the amount of changes were similar between RA group and HC group. In ELISA, the expression levels of IFN- $\gamma$  and granzyme B were decreased by JAKi dose-dependently. The mRNA levels of STAT1 and Tbet decreased, however, STAT5 and Foxp3 increased by JAKi. Addition of methotrexate did not significantly altered population of T cells, levels of IFN- $\gamma$  and granzyme B, and expression levels of transcriptional factors.

# Conclusions

The present study showed immune regulatory effects of JAKi toward decreasing Th1/cytotoxic T cell response, and increasing Treg response. However, these were not only presented in RA patients driven cells, but also in HCs driven cells. These imply that virulent factor or memory T cell function may be more important on explanation of increased Shingle risk in RA patients than HCs.

## **Keywords**

rheumatoid arthritis, Shingles, janus kinase inhibitor



# Identification of the HLA-B*51:01 immunopeptidome in Behçet's disease

<u>Ye-Ji Lee¹</u>, Kyung-Cho Cho², So Hyun Kim², Byung Kyu Cho², Eugene C. Yi², Eun Bong Lee^{1,2}

¹ Internal Medicine, Seoul National University College of Medicine, Republic of Korea ² Molecular Medicine and Biopharmaceutical Sciences, Seoul National University, Republic of Korea

# Background

Immunopeptidomes are peptides, bound to human leukocyte antigens (HLA), that play a key role in immune responses. HLA-B*51:01 is an HLA allele associated with Behçet's disease (BD)¹. However, the characteristics and the role of HLA-B*51:01 immunopeptidome are not revealed in Behçet's disease.

# **Methods**

HLA-bound peptide profiles were established through analysis of plasma samples from HLA-B*51:01–positive BD patients and HCs. HLA-class I molecules were immunoprecipitated, and liquid chromatography-tandem mass spectrometry (LC-MS/MS) was performed. Then, HLA-B*51:01– binding peptides were assessed in terms of binding affinity using NetMHCpan. Finally, the immunological characteristics of selected peptides were analyzed in BD patients and HCs, using ELISpot, flow cytometry, and dextramer staining.

## **Results**

2,306 peptides were present only in BD patients, while 3,145 peptides were detected only in HCs. Immunopeptidome of BD patients preferentially showed hydrophobic amino acids at amino acid position 2 (Figure 1). Ten peptides were selected which were confirmed to be preferentially expressed in BD patients compared with HCs. When bound to HLA-B*51:01 in monocyte-derived dendritic cells (Mo-DCs) or peripheral blood mononuclear cells, these peptides activated T cells and induced surface expression of CD69 and CD107 $\alpha$ , as well as the secretion of inflammatory cytokines such as interferon (IFN)- $\gamma$  and tumor necrosis factor (TNF)- $\alpha$ .

# Conclusions

HLA-B*51:01 immunopeptidome can play a critical role in the development of BD by activating T cells and inducing the secretion of inflammatory cytokines.

# Figure & Table




Figure. Venn diagram of the identified 8–13-mer peptides and graphs showing the motif clusters.

# **Keywords**

Immunopeptidome, Behçet's disease, Proinflammatory cytokines



10-19

# Inhibition of NADPH oxidases prevent the development of osteoarthritis

# Jin Han¹, Seungwoo Han²

¹Laboratory for Arthritis and Cartilage Biology, Kyungpook National University, Republic of Korea ²Departments of Internal Medicine, School of Medicine, Kyungpook National University, Republic of Korea

## Background

Increased oxidative stress in osteoarthritic (OA) cartilage mediates catabolic signal transduction leading to extracellular matrix degradation and chondrocyte apoptosis. This study aimed to explore the contribution of NADPH oxidase (NOX), a major source of cellular reactive oxygen species (ROS), to the catabolic process of chondrocytes and to OA.

## **Methods**

Primary chondrocytes were obtained from E15.5 C57BL/6 mouse long bones. Interleukin (IL)-1 $\beta$  (10 ng/mL) was applied to recapitulate the catabolic stress mimicking OA conditions, and the function of NOX isoforms was inhibited with a pan-NOX inhibitor (APX-115). Surgical OA was induced in 12-week-old male C57BL/6 mice by destabilization of the medial meniscus (DMM), and 60 mg/kg APX-115 was intraperitoneally injected twice a week. NOX-induced changes in chondrocyte metabolism were analyzed using the Seahorse XF Extracellular Flux Analyzer.

#### **Results**

The inhibition of NOX isoforms with APX-115 significantly decreased IL-1 $\beta$ -induced ROS production in chondrocytes and most potently suppressed the expression of oxidative stress marker genes and catabolic proteases compared with the inhibition of other ROS sources. Catabolic stimuli by IL-1 $\beta$ -treatment and in post-traumatic OA conditions upregulated the expression of NOX2 and NOX4 in chondrocytes. In the post-traumatic OA model, the pharmacologic inhibition of NOX protected mice against OA by modulating oxidative stress and the expression of MMP-13 and Adamts5 in chondrocytes. Mechanistically, NOX inhibition suppresses p38, JNK, and NF-kB signaling and restores oxidative phosphorylation in IL-1 $\beta$ -treated chondrocytes.

## Conclusions

NOX inhibition prevented the development of OA by attenuating catabolic signaling and restoring mitochondrial metabolism, and can thus be a promising class of drug for OA.

#### **Keywords**

Osteoarthritis, NADPH oxidase, Oxidative stress

# Workshop

Clinical Research Workshop for Rheumatologists: Planning and Conducting Clinical Research

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



# Setting up a prospective cohort

Sang-Cheol Bae

Hanyang Univ., Korea

This talk will briefly summarize the concept of clinical research and the study design for clinical research. And then the practical issues of setting up a prospective cohort study will be discussed with the examples of cohorts of rheumatoid arthritis and systemic lupus erythematosus which I and my colleagues have established: 1) Getting started: Objectives, Planning choosing study subjects and data collection, Sample size and Power calculation, IRB issue, 2) Data collection period with quality control, 3) Data cleaning period, 4) Data analysis period, 5) Dissemination period. For setting up a prospective cohort well, a better coordination among patients, clinicians, clinical researchers is required.



# Conducting a retrospective clinical study using Korea National Health Insurance data

Hyun Jung Kim Korea Univ., Korea

Medical researches are increasingly conducted using large data sets based on routinely collected administration data and patient's health care institution utilization data. While these data are collected primarily for health insurance reimbursement and healthcare administration, the nature and scale of the data make them potentially exciting resources for research.

In Korea, such large databases that are managed by the National Health Insurance Service (NHIS). The NHIS database of South Korea is a repository of claims data collected in the process of reimbursing healthcare providers. Under the universal coverage system, having fee-for-services covering all citizens in South Korea, the NHIS database contains comprehensive information pertaining to healthcare services such as treatments, pharmaceuticals, procedures, and diagnoses for almost 50 million beneficiaries. The NHIS database includes data on all children, regardless of presence of disability.

The National Health Screening Program NHSP is a screening program which offers all beneficiaries biannual health checkups that include lifestyle habits and metabolic profile, which are recorded in the database. The NHSP questionnaire contains questions on drinking status, other lifestyle characteristics of each study participant, including body mass index (BMI), blood pressure, fasting blood glucose and cholesterol levels.

National Health Screening Program for Infants and Children (NHSIC) database records screening data of the growth and development of all children. The Korean government launched the NHSIC program in November 2007 as a population surveillance system, While the NHSIC screening is not mandatory but optional, children can participate in the NHSIC program up to maximal 7 times, from the age of 4–71 months. Physicians conduct anthropometric measurements as well as history taking, physical examination, screening for visual acuity, and health education. The NHSIC database and the NHIS database are linked using a personal identifier number.

The advantages of these database include large sample size, population coverage and heterogeneity, which allow researchers to reflect the "real world" practice Moreover, data are usually available for quite long periods, allowing trend analysis. Other advantages are the absence of additional costs for gathering data, long observation periods, and the possibility of linking different databases that contain information on the patient.

The disadvantages include the variable quality of collected data, which will be discussed in the following section, and the absence of specific information of interest for clinical research.

In using coded in these data, validation of coding accuracy is key. This is important for both the methodologic evaluation of articles. Other disadvantages are the difficulties in drawing causal conclusions due to the presence of bias or confounding and the misclassification bias.



# How to start IITs from scratch

Howard Lee

Seoul Nat'l Univ., Korea

An IIT, also known as an investigator-initiated study (IIS) or research (IIR), is a clinical trial, where the investigator has to play a dual-role, i.e., as an investigator and sponsor. This is why an investigator in any IIT is frequently referred to as a sponsor-investigator. He/she has to conceive the research idea, to develop the protocol, to conduct the trial, to oversight the research team and to provide it with required resources, and to be responsible for the regulatory mandates. Therefore, the obligations and work amounts of a sponsor-investigator in any IIT are huge, preventing many want-to-be sponsor-investigators from starting an IIT on their own. However, the importance of IITs cannot be underestimated because they are truly narrowing the difference between sponsor-initiated trials and day-to-day, real-world clinical practices. In addition, IITs may demonstrate how efficiently participating investigators, institutions, and organizations collaborate, commit, and manage to attain a set of overarching research objectives.

The presenter has introduced the concept and utilities of the microdosing and microtracing study in new drug development since 2014. As of today, the presenter has completed a total of five microdosing/microtracing studies with 2 more studies under plan, four of which were IITs. In this presentation, the presenter will share his experiences in starting an IIT from scratch as to what obstacles he had to overcome and how.



# e-CRF tools for Investigator Initiated Trial

# Soo-Hwan Kim Dt&CRO, Korea

Clinical trial management that includes specified software systems and processes can help to produce timely and efficient project outcomes. Specially, clinical data management is one of the most critical functions in overall clinical trial management.

Clinical trial data management activities include that CRF design, annotation, tracking / DB design, build, and testing / Data collecting and entry including lab data / Query generation / Medical Coding / DB locking / Data extraction and transmission / Data archiving. Every data management procedure should be limited based on the assigned roles and responsibilities of the users. All study members have different levels of access to the software (or system), as designated in the protocol or delegation. Data management steps also ensure there is an audit trail and the users can only access their respective required functions without the ability to make other changes.

Some of data management processes in IIT will necessarily be from paper forms filled out by the patient or investigators on their behalf. Instead of paper, some activities may use devices or software to fill out this direct-entry data electronically. If investigators use electronic systems, they can easily confirm data and track data changing history. However, it is not easy to use an electronic system because most of investigators do not have enough time to set-up system or their own staffs for data management.

In this session, we will be familiar with what data management is and find an easy way to management clinical data.

# Workshop

# Editorial Committee Workshop

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



# Suggestions to be indexed in SCIE and get high impact factor

Hyun Jun Park

Pusan Nat'l Univ., Korea

In order to evaluate the excellence of a medical journal, the most important measure is how high-quality research papers are published. All medical journals want their published papers to be widely exposed to readers and also to be cited as material for new research. This increases the value of journals and improves their reputation. In order for papers to be widely exposed and cited, the journal must be listed in a reputable database. Currently, the world-recognized database is Science Citation Index Expanded (SCIE), a Web of Science core collection managed by Clarivate, and Scopus, operated by ELSEVIER. Among them, SCIE is the more well-known and highly trusted. Being indexed in the SCIE means that the journal has been recognized for its academic value worldwide. Among the many conditions for inclusion in the SCIE, the most important is the impact factor of the journal. In this lecture, I am going to cover the factors necessary to be indexed in the SCIE and how to increase the impact factor.



# Successful submission strategy on SCI journal

Hwichool Kim Editage, Korea

We would like to learn about successful submission strategies on sci(e) journal. Specifically, we focus on author order, title expression, keywords selection, importance of abstract, method of reviewing, importance of flowchart in research method, result expression, logical process for results and the most common mistakes when writing medical research papers etc.



## **Biostatistics for clinical researchers**

Hyonggin An

Korea Univ., Korea

In this talk, I would like to review statistical considerations in clinical articles. These include study design, sample size, statistical analysis, presentation of results, and common statistical errors in clinical articles.



## New PubMed: Searching tips & more!

Sung Ae Park

Korea Univ. Medical Library, Korea

This lecture is about the concept of PubMed and offers searching principles, rules, and some helpful tips for using PubMed. Understanding the information about PubMed will help you find out the research papers efficiently.

PubMed is the most famous free searching engine in the field of bioscience and biomedical science, which is made and managed by the National Library of Medicine(NLM) of the National Institutes of Health(NIH). Medline database including Old Medline(1946-1966) contains citations and abstracts of 5,281 journals in 40 different languages. Also, you can use the full text of journals archived in PubMed Central(PMC) and the books kept in NLM for free.

The biggest feature of PubMed is to index research papers using a medical thesaurus named MeSH. PubMed's Automatic Term Mapping (ATM) is also related to this. The lecture will help you understand the search principles of PubMed and learn how search results can vary by different ways of searching on the same topic, including keyword(natural language) search, field tag search, MeSH search, and a combination of MeSH and keyword search. Consequently, you will be able to plan your search strategy by using proper keywords and making searching formula based on the information in the lecture.

Finally, the lecture will offer some useful abilities of PubMed: Filters that can limit search results, Clinical Queries that can look up clinical papers efficiently, and My NCBI, which allows you to receive customized services using your account.

Hope this lecture helps you choose your search methods and find out the valuable papers you want.

# KCR 2022

42nd Korean College of Rheumatology Annual Scientific Meeting and the 16th International Symposium



# PROGRAM

## May 20(Fri)

# Breakfast Symposium I AbbVie

Strategies to Solve the Problem of Rheumatoid Arthritis with AbbVie's Assets



### Management of rheumatoid arthritis considering safety

### Ki-Jo Kim

The Catholic Univ. of Korea, Korea

Safety of medication is one of the most important issues in the management of rheumatoid arthritis. 2019 EULAR guideline recommended that treatment decisions are based on not only disease activity but also safety issues and other patient factors, such as comorbidities. And safety issue of tofacitinib was mentioned in ACR guideline updated in 2021.

Recent JAK inhibitor safety issues were started by press release of Pfizer in Jan 2021 about ORAL Surveillance which is the post marketing long-term safety study comparing major adverse cardiovascular events (MACE) and malignancies excluding nonmelanoma skin cancer (NMSC) between tofacitinib and TNF inhibitors; adalimumab and etanercept. The results of ORAL surveillance were published in NEJM Jan 2022. In this article, it was reported that MACE and cancers occurred more often with tofacitinib than with a TNF inhibitor in patients with rheumatoid arthritis who were 50 years of age or older and had at least one additional cardiovascular risk factor. However, the higher hazard ratio of MACE and malignancies excluding NMSC in North Americans and patients aged 65 years or older suggests that there may be limitations in the study design of this study.

TNF inhibitors were used as a control in ORAL Surveillance to demonstrate tofacitinib's non-inferiority in the risk of MACE and malignancies. This might be due to the proven safety profile of TNF inhibitors in MACE and malignancies. Patients with rheumatic and musculoskeletal diseases (RMD) including rheumatoid arthritis (RA) have higher risk of atherosclerosis and malignances versus general population. In contrast to other non-TNF inhibitors, it was already well reported that the use of TNF inhibitor was associated with a decreased risk of MACE in patients with RMDs including RA. And the long-term safety of adalimumab in malignancies was reported to be similar to that of the normal population.

Considering recently published data and selectivity for Janus kinases (JAK), it seems that all JAK inhibitors may not be more dangerous than TNF inhibitors in MACE and malignancies. Upadacitinib is a selective and reversible JAK inhibitor engineered by AbbVie, which showed 40~190 times higher JAK1 selectivity other than JAK2, JAK3 or TYK2. The safety profile of upadacitinib has been established across six clinical trials for RA indication with over 7,000 patient-years of exposure. The risk of MACE, venous thromboembolism (VTE), and malignances excluding NMSC of upadacitinib were similar to that of adalimumab in the integrated safety analysis up to 4.5 years exposure. In SELECT-COMPARE, the safety profile of upadacitinib 15mg was generally comparable to adalimumab for adverse events of special interest, including MACE, VTE, malignancies, and deaths through 3 years. Also, upadacitinib continued to demonstrate consistently better clinical responses compared with adalimumab including remission rates, physical function, and pain severity through 3 years. In conclusion, upadacitinib 15mg can be the one of the reasonable options for inadequate responder to methotrexate based on its favorable benefit-risk profile for RA patients.

# Breakfast Symposium II Celltrion

## Real-world Switching Case of CT-P17



## Clinical data and real-world switching case of CT-P17

### Hubert Marotte

Centre Hospitalier Universitaire (CHU) de Saint-Étienne, INSERM, 1059, Saint-Étienne, France

Adalimumab is an anti-TNF monoclonal antibody that effectively improves rheumatoid arthritis (RA). Biosimilars are highly similar to their reference products in terms of quality characteristics, biological activity, safety, and efficacy. Since 2016, several adalimumab biosimilars have been licensed by the EMA and the US FDA. European League Against Rheumatism (EULAR) recommendations for the treatment of RA position biosimilar DMARDs (bsDMARDs) equivalently to their reference products in treatment algorithms, and suggest that lower-priced biosimilars are preferred for their potential to reduce healthcare expenditures. CT-P17 is administered at 100 mg/mL, reflecting the high-concentration, low volume formulation of reference adalimumab, and is also citrate and latex free, which could reduce discomfort during injection. In addition, CT-P17 can be stored at ambient temperature (<25°C) up to 30 days which is more convenient for patients in case of vacation for example. In this talk, I am going to briefly introduce the pivotal study (phase III) of CT-P17 and review the features of CT-P17. In addition, I am also going to share several real-world switching cases from reference adalimumab to CT-P17.

# Breakfast Symposium III Pfizer

Real-World Perspectives of Ankylosing Spondylitis Management



# Insights from real-world: Practical approach to anti TNF therapy for AS treatment

Jun Won Park Seoul Nat'l Univ., Korea

# **Keynote Lecture**



## Current threats to the specialty of rheumatology in the US and internationally: A call to action

Kenneth Saag The Univ. of Alabama at Birmingham, USA

The Covid pandemic has highlighted many challenges to the field of rheumatology but it has also created some unique opportunities for our collective growth. Covid has created a sense of new-found vulnerability that has shaped the way many rheumatologists see their day to day activities and many have re-evaluated their work-life balance. It has had profound impact on our daily clinical operations, created new telehealth opportunities and promoted "hybrid" work for some in the clinical research community and those doing departmental and organizational administration. Some doctors have begun to feel more "burned out" and there is a heightened recognition in many geographical areas about the need for more health care providers addressing rheumatic and musculoskeletal disorders. In particular, we are seeing shortages in trainees pursuing careers in clinical and fundamental science, which threatens the future of our specialty. Enhanced training opportunities and funding for early stage investigators offer hope to maintain this critical element of our workforce. Our specialty organizations are under special strain as the typical sources of their support are also challenged by pandemic-related issues. Creative new sources of revenue will assure their continued ability to support our profession. The ACR, through its new strategic plan, fully embraces the opportunity to build international collaborations around research, teaching and patient care. Underlying all these concerns is a recognition of greater medical mistrust, fueled by the pandemic and social media. We must do everything we can to exercise our cautious authority as experts in our disease and trusted counselors to our patients with whom we have long-standing relationships.

# **International Symposium**

Recent Advances in Pathogenesis of Systemic Lupus Erythematosus



### New concepts on the pathogenesis of lupus nephritis

George Tsokos

Harvard Medical School, Beth Israel Deaconess Medical Center, USA

Lupus nephritis (LN) is common in people with systemic lupus erythematosus (SLE) and is invariably linked to high morbidity and mortality. We still lack reliable disease biomarkers and the golden diagnostic tool, kidney biopsy, is not easily repeatable and not without risks. Treatment still relies on the use of immunosuppressive and cytotoxic drugs while the newly approved Benslysta and Voclosporin may offer minimal advantage. While trying to understand why T cells from patients with SLE do not produce interleukin (IL)-2 while the produce excessive amounts of IL-17 we discovered that a serine/threonine kinase, calcium/calmodulin kinase 4 (CaMK4) shuts off the IL-2 locus while it opens the IL-17 locus. Subsequently we found that podocytes, mesangial cells and tubular epithelial cells in people and mice with lupus display increased amounts of CaMK4 and that this accounts for the malfunction of these cells. We found that IgG from patients with LN is abnormally glycosylated and after entering podocytes to suppress proteins responsible for the function and structure of podocytes. CaMK4 overexpression in mesangial cells was found to cause increased proliferation. In parallel we discovered that in mice and people with SLE that besides mesangial cells, podocytes and tubular epithelial cells express increased levels of IL-23 receptor. IL-23, which is increased in lupus, causes podocyte malfunction, whereas in tubular epithelial cells suppresses the levels of arginase 1 which leads to abundance of arginine in the surrounding microenvironment and lymphocyte proliferation in the tubulointerstitial space. Genetic deficiency of CaMK4 in podocytes or in tubular epithelial cells suppresses LN and more importantly, cell-targeted delivery of a CamK4 inhibitor to podocytes or tubular epithelial cells suppresses LN thus offering great therapeutic opportunities. In parallel we have developed two novel approaches of liquid kidney biopsy to replace needle kidney biopsy. In the first, we find that CaMK4 expression is increased only in podocytes from people with LN whereas in the second, only IgG from people with active LN can upregulate CaMK4 in cultured podocytes. In summary, our work offers new insights in the interface between the autoimmune response and kidney resident cells through which kidney damage is eventually executed and two novel liquid kidney approaches.



## New insights into the role of antinuclear antibodies in systemic lupus erythematosus

Peter E. Lipsky

AMPEL BioSolutions, USA

Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease characterized by antinuclear antibodies (ANAs) that form immune complexes and mediate disease pathogenesis by tissue deposition or cytokine induction. Some ANAs bind DNA or associated nucleosome proteins, whereas others bind protein components of complexes of RNA and RNA binding proteins (RBPs).

Levels of anti-DNA antibodies can fluctuate widely, unlike those of anti-RBP antibodies, which tend to be stable. Because anti-DNA antibody levels can reflect disease activity, repeat testing is common; by contrast, a single anti-RBP antibody determination is classically thought to suffice for clinical purposes.

Of the mechanisms for the generation of tissue lesions in SLE, the formation and deposition of immune complexes in the kidney has received the most investigative interest. DNA and anti-DNA antibodies can form immune complexes that localize to the kidney, where complement is activated. Immune complexes and their components (such as immunoglobulins and complement) have been demonstrated in the kidney of lupus nephritis by light, electron and immunofluorescence microscopy. Increased anti-DNA antibody levels and decreased amounts of complement component proteins C3 and C4 during active disease also support a pathogenic role for immune complexes. As immune complex formation and deposition can take place over time and precede clinical events, concentrations of immunoreactants might not be raised at the time of patient presentation. Indeed, autoantibody levels might be reduced because of tissue deposition.

In the pathogenesis of nephritis, cytokines released by cells, such as monocytes and macrophages, can promote inflammation. In addition to inducing complement activation in the kidney, immune complexes can induce the production of pro-inflammatory cytokines, most notably type I interferon. Anti-DNA antibodies can bind to DNA and effectively be internalized into innate immune cells, most prominently plasmacytoid dendritic cells. Once inside the cell, DNA can interact with the endosomal Toll-like receptor (TLR), TLR9, as well as with other nucleic acid sensors in the cytoplasm. These sensors can either access DNA following its uptake as part of an immune complex, or they can respond to DNA that is aberrantly present in the cell as a result of infection by intracellular organisms, mitochondrial release of DNA from stressed or damaged mitochondria, or the formation of micronuclei in response to genotoxic agents or chromosomal instability. Thus, nucleic acid sensors represent a type of internal host defence system, for which DNA in immune complexes is just one potential trigger.

Of these sensors, the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) system mediates the production of type I interferon and other cytokines. Once bound by DNA, cGAS catalyzes the formation of cyclic GMP-AMP that binds to STING. The outcome of these interactions is the stimulation of type I interferon production and its downstream effects. This stimulation only occurs with certain anti-DNA antibodies; however, the properties of the antibodies that enable the formation of immune complexes that can stimulate type I interferon production are not known. Furthermore, it is not clear whether the DNA-anti-DNA immune complexes that are deposited in the kidney can induce cytokine production by plasmacytoid dendritic cells.

Although initial studies on cytokine induction by immune complexes implicated anti-DNA antibodies as an important factor, subsequent research has shown that immune complexes with anti-RBP antibodies can stimulate type I interferon production and appear to be the main promoters of this pathway. The differing results of these studies probably reflects the demographics of the patient populations studied, as there is increased expression of anti-RBP antibodies in patients with African ancestry. In this mechanism, immune complexes containing RNA are ingested by phagocytes, after which the cargo interacts with internal RNA sensors in the endosome (such as TLR3 and TLR7) or in the cytoplasm. In addition, cytoplasmic sensors of RNA, including the retinoic acid-inducible gene 1 (RIG-I) and melanoma differentiation-associated protein 5 (MDA5) pathways, can lead to the production of type I interferon when stimulated by RNA that has entered cells in the form of immune complexes with anti-RBP antibodies. Studies suggest that anti-RBP antibodies of all known specificities can form immune complexes that have immunostimulatory activity; however, it is possible that, depending on the immunochemical properties of autoantibodies such as fine specificity or avidity, only certain anti-RBP antibodies can induce these responses.

Notably, although signalling via TLR7 and TLR9 superficially seems similar, the induction of proinflammatory cytokines and pathological outcomes can be quite different. In mouse models of SLE, TLR7 engagement seems to exacerbate disease, whereas TLR9 engagement seems to suppress disease; nevertheless, both TLR7 and TLR9 can bias the production of autoantibodies that recognize RNA and DNA, respectively. The differences in clinical and serological outcomes following TLR7 and TLR9 engagement likely reflect the various effects of TLR stimulation during cellular development and activation.



## ETV5 promotes Tfh cell differentiation and the pathogenesis of systemic lupus erythematosus

Yoontae Lee POSTECH, Korea

Follicular helper T (Tfh) cells induce germinal center response to produce high affinity antibodies against a specific pathogen. Excessive formation of Tfh cells is closely associated with the onset of antibody-mediated systemic autoimmune diseases, such as systemic lupus erythematosus (SLE). Our previous study has shown that ETV5 promotes murine Tfh cell differentiation. However, its role in human Tfh cell differentiation and the pathogenesis of SLE has not been investigated. In this study, we show that ETV5 is a transcription factor that promotes the pathogenesis of lupus autoimmune disease via enhancing Tfh cell differentiation. ETV5 deficiency in T cells substantially suppresses autoimmunity in lupus mouse models. Tfh cells have higher levels of ETV5 than non-Tfh cells in humans as well as mice. ETV5 overexpression also promotes human Tfh cell differentiation. Furthermore, ETV5 levels are significantly higher in CD4 T cells from SLE patients than in those from healthy control, suggesting that ETV5 may be an SLE-promoting factor. We are currently investigating the molecular mechanism of how ETV5 promotes Tfh cell differentiation.

# **Free Paper Session**

Epidemiology & Health Services Research



# Safety and clinical influences of COVID-19 vaccination in patients with autoimmune rheumatic diseases

<u>Youngjae Park</u>¹, Hanna Park¹, Minae Oh¹, Jung Gon Kim¹, Se Gwang Jang², Howook Jeon³, Jennifer Jooha Lee¹, Su-Jin Moon³, Seung-Ki Kwok¹

¹ Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's hospital, The Catholic University of Korea, Republic of Korea
 ² The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Republic of Korea
 ³ Division of Rheumatology, Department of Internal Medicine, Uijeongbu St Mary's Hospital, The Catholic University of Korea, Republic of Korea

#### Background

Since the beginning of COVID-19 pandemic, various types of vaccines against SAR-CoV-2 have been introduced. Although these vaccines demonstrated efficacy in clinical trials involving healthy populations, information on their safety and clinical impacts on disease activities in patients with autoimmune rheumatic diseases (ARDs) is still limited. In this multi-centered observational study, we aimed to evaluate safety profiles and clinical influences of COVID-19 vaccines in patients with various ARDs.

#### **Methods**

Between July 2021 and December 2021, 494 ARD patients who completed COVID-19 vaccinations were enrolled from two university-affiliated hospitals for the present study. Data on adverse events related to COVID-19 vaccinations and indices representing disease activities for each ARD were collected. In addition, immunogenicity in ARD patients was measured using a commercialized kit for SARS-CoV-2 neutralizing antibody.

#### **Results**

Until February 2022, 278 ARD patients completed evaluations. Targeted patients included 129 rheumatoid arthritis (RA), 55 ankylosing spondylitis (AS), 47 systemic lupus erythematosus (SLE), 38 Sjogren's syndrome, and 9 systemic sclerosis patients. Median ages and disease durations were 52 years and 71 months, respectively. There was no case of severe adverse events requiring medical interventions. Incidence rate of adverse events at the first and the second dose of vaccines were similar. Most frequent local events were pain (18%) and tenderness (4%) at the site of injection while fatigue (11%) and headache (9%) were most frequent among systemic reactions. Seven cases (5%) of disease flares were observed in RA patients after vaccinations while 4 cases (7%) in AS and 1 case (2%) in SLE patients, respectively. About 97% of ARD patients acquired immunogenicity after complete COVID-19 vaccinations. Remaining 3% of patients who failed to acquire immunogenicity included 4 RA, 2 AS, and 2 SLE patients.

#### Conclusions

The COVID-19 vaccination is safe and effective, and rarely results in disease flares in patients with ARDs.



### Autoantibody profiles in patients with COVID-19 infection

#### Hyemin Jeong¹, Chan Hong Jeon¹

¹ Internal Medicine, Soonchunhyang University Hospital, Bucheon, Republic of Korea

#### Background

Triggering of autoimmunity by severe COVID-19 infection has been proposed. However, there is insufficient data on the profiles of autoantibodies. The aim of this study was to evaluate positivity of autoimmune serologic markers in patients with COVID-19 infection and to analyze the association between autoantibody positivity and the prognosis of COVID-19 infection.

#### **Methods**

We retrospectively collected 80 consecutive patients who referred to Soonchunhyang university hospital for COVID-19 infection. All patients were tested for presence of antinuclear antibody (ANA), rheumatoid factor (RF), anti-citrullinated peptide antibody (ACPA), and anticytoplasmic neutrophil antibody (ANCA). Laboratory data, comorbidities, and outcomes were collected.

#### **Results**

Mean age was 67.4 ± 14.0 years and 35 (43.8%) patients were women. Thirty-one (38.8%) patients tested positive for ANA, 16 (20%) patients were positive for RF, and 2 (2.5%) patients were positive for ACPA. ANCA was negative in all patients. Connective tissue disease was not present nearly all patients except one patient with rheumatoid arthritis. Hypertension was (52.5%) was most common comorbidity, followed by diabetes (38.8%). Forty-four (55.5%) patients were required care in the intensive care unit (ICU) and 34 (42.5%) patients underwent intubation. Fifteen (18.8%) patients were expired due to severe respiratory failure. Patients who were positive for RF showed significantly higher rates of intubation and death than others (32.4 vs 11.6%, p = 0.026 and 40.0 vs. 16.1%. p = 0.041, respectively). In univariable analysis, RF positivity was associated with mechanical ventilation (OR 3.63. 95% CI 1.12-11.79, p = 0.032), but not in multivariable analysis. In multivariable analysis, D-dimer (OR 1.25, 95% CI 1.01-1.53, p = 0.036) and C-reactive protein (OR 1.13, 95% CI 1.02-1.25, p = 0.015) were associated with mechanical ventilation.

#### Conclusions

Patients who positive for RF showed poor prognosis in COVID-19 infection. Further study will be required to investigate the association of RF and severe pneumonia in COVID-19 infection.



### Association between cardiovascular outcome and rheumatoid arthritis: Nationwide population-based cohort study

Seonyoung Kang¹, Kyung-Do Han³, Yeonghee Eun², Seulkee Lee¹, Hoon-Suk Cha¹, Eun-Mi Koh¹, Jaejoon Lee¹, Hyungjin Kim⁴

¹ Department of Internal Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea ² Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea ³ Department of Statistics and Actuarial Science, Soongsil University, Seoul, Republic of Korea

⁴Department of Medical Humanities, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea

#### Background

Large scale studies which examined the association between characteristic of RA patients and cardiovascular disease (CVD) risk, and studies which adjusted for various confounding factors are lacking. This study aimed to investigate the association between CVD risk and RA in largescale, nationwide cohort of Korean population.

#### **Methods**

We enrolled 136,469 patients with RA who participated in national health examinations within 2 years of RA diagnosis between 2010 and 2017 and non-RA controls matched by age and sex (n= 682,345). The cohort was followed until the end of 2019 . The outcome was occurrence of myocardial infarction (MI) or stroke. The Cox proportional hazard model and Kaplan Meier curve were used for the analysis.

#### Results

The incidence rate of CVD was higher in RA group than control (MI: 3.20 vs 2.08; stroke: 2.84 vs 2.33 per 1,000 person-years). The risk of CVD was higher in RA patients. (MI: adjusted HR 1.54, 95% CI 1.46-1.61; Stroke: adjusted HR 1.22, 95% CI 1.16-1.28). The association between RA and CVD was prominent in female (MI: adjusted HR 1.41 in male, 1.60 in female, p for interaction = 0.0293; Stroke: adjusted HR 1.13 in male, 1.27 in female, p for interaction = 0.03) and younger-age subgroups (MI: adjusted HR 2.9 in <40 years, 1.52 in 40-64 years, 1.51 in ≥65 years, p for interaction<0.0001; Stroke: adjusted HR 2.35 in <40 years, 1.21 in 40-64 years, 1.21 in  $\geq$ 65 years, p for interaction = 0.0100) after adjusting for confounding variables. The association between RA and risk of MI was significant in those without DM. (adjusted HR 1.30 in DM, 1.61 in non-DM, p for interaction = 0.0005)

#### Conclusions

RA patients had increased risk of CVD events compared to age- and sex-matched control group, and this association was stronger in female and younger-age subgroups.



### Increased risk of malignancy in patients with Takayasu's arteritis: A population-based cohort study in Korea

<u>Seulkee Lee</u>¹, Seonyoung Kang¹, Yeonghee Eun², Hyungjin Kim¹, Jaejoon Lee¹, Eun-Mi Koh¹, Hoon-Suk Cha¹

¹ Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Republic of Korea ² Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Republic of Korea

#### Background

This study aimed to evaluate the relative risk of malignancy in patients with Takayasu's arteritis compared to that in the general population.

#### **Methods**

This retrospective nationwide cohort study used data from the Korean Health Insurance Review and Assessment Service database. All newly diagnosed patients with Takayasu's arteritis were identified between January 2009 and December 2019. They were observed until the diagnosis of malignancy, death, or end of the observational period, December 2020. The standardized incidence ratios (SIRs) of the overall and site-specific malignancies were estimated and compared with the incidence of cancer in the general population retrieved from the National Cancer Registry.

#### Results

We identified 1,449 newly diagnosed patients with Takayasu's arteritis during the observational period (9,196 person-years). A total of 74, 66, and 8 patients had overall, solid, and hematologic malignancies, respectively. The risks of overall (SIR, 1.62; 95% confidence interval [CI], 1.27-2.03), solid (SIR, 2.04; 95% CI, 1.56-2.61), and hematologic (SIR, 4.05; 95% CI, 3.72-7.98) malignancies were increased compared to those in the general population. In solid malignancies, breast (SIR, 2.07; 95% CI, 1.16-3.42), ovarian (SIR, 4.45; 95% CI, 1.21-11.39), and major salivary gland (SIR, 19.04; 95% CI, 2.31-68.76) cancers had an increased risk. In hematologic malignancies, the risk of myelodysplasia increased (SIR, 18.02; 95% CI, 3.72-52.66). Immunosuppressive agent use was not associated with malignancy. There was no specific period when cancer more frequently occurred.

#### **Conclusions**

An increased risk of malignancy was observed in patients with Takayasu's arteritis compared to that in the general population in this large-scale nationwide population study of Korean health insurance data.

#### **Keywords**

Takayasu, Malignancy, Population study



### Increased risk of herpes zoster in patients with rheumatoid arthritis using tofacitinib compared with tumor necrosis factor inhibitor

Yeo-Jin Song^{1,2}, Soo-Kyung Cho^{1,2}, Hyoungyoung Kim^{1,2}, Hye Won Kim², Eunwoo Nam², Ja-Young Jeon³, Hyun-Jeong Yoo³, Chan-Bum Choi^{1,2}, Tae-Hwan Kim^{1,2}, Jae-Bum Jun^{1,2}, Sang-Cheol Bae^{1,2}, Dae Hyun Yoo^{1,2}, Yoon-Kyoung Sung^{1,2}

¹ Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
² Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea
³ Pfizer Pharmaceuticals Korea Ltd., Seoul, Republic of Korea

#### Background

There have been studies suggesting an increased risk of herpes zoster (HZ) in patients with rheumatoid arthritis (RA) treated with tofacitinib, especially in East Asia. This study aimed to determine the increased risk of HZ in Korean patients using tofacitinib compared with tumor necrosis factor (TNF) inhibitor.

#### **Methods**

From two prospective cohorts of RA patients who started tofacitinib or TNF inhibitor in Hanyang University Hospital for Rheumatic Diseases, patients who started tofacitinib between March 2017 and May 2021; and those who started TNF inhibitor between July 2011 and May 2021 were included. Baseline features of tofacitinib users and TNF inhibitor users were balanced through inverse probability of treatment weighting (IPTW) using propensity score. Then, incidence rate (IR) of HZ in each group and incidence rate ratio (IRR) were calculated. The IRR of severe HZ was further analyzed.

#### **Results**

A total of 912 patients were included: 200 tofacitinib users and 712 TNF inhibitor users with observation period of 329.4 person-years (PYs) and 1950.7 PYs, respectively. Tofacitinib users were older, and had longer disease duration of RA than TNF inhibitor users. In addition, disease activity including patient-reported outcomes was higher in tofacitinib users. The crude IR of HZ was 6.37 cases per 100 PYs in tofacitinib users and 1.85 cases per 100 PYs in TNF inhibitor users. In IPTW analysis with a balanced sample, IRR was 8.80 (95% confidence interval [CI] 3.24–32.93). When the outcome was severe HZ, however, the IRR was 0.99 (CI 0.12–8.20).

#### Conclusions

Tofacitinib use increased the risk of HZ compared with TNF inhibitor in Korean patients with RA, but not the severity of HZ.

#### **Keywords**

herpes zoster, rheumatoid arthritis, tofacitinib



### Clinical course and risk factors for development and progression of interstitial lung disease in primary Sjögren's syndrome: a single centered, retrospective, observational study

Kyung-Ann Lee¹, Bo-Da Nam², Jung Hwa Hwang², Hyun-Sook Kim¹

¹ Internal medicine, Soonchunhyang University Seoul Hospital, Republic of Korea ² Radiology, Soonchunhyang University Seoul Hospital, Republic of Korea

#### Background

Interstitial lung disease (ILD) is the most common lung manifestation in patients with primary Sjögren syndrome (pSS) and is associated with poor outcomes. This study aimed to investigate the long term clinical course and prognostic factors in patients with pSS-ILD.

#### **Methods**

This single-centered, retrospective study included 120 pSS patients who underwent at least two high-resolution computed tomography (HRCT) and had relatively complete clinical data. Clinical symptoms, laboratory data, high-resolution computed tomography (HRCT), and pulmonary function test (PFT) results were collected. HRCT were scored blindly by two expert thoracic radiologists: extent of ground glass opacities (GGO), fine/coarse reticulations, presence of honeycombing (HC), and coarseness score of fibrosis.

#### Results

In patients without pSS-ILD at baseline (n=81), any development of ILD was not found during median follow up 2.7 (1.1-4.1) years. Among those with pSS-ILD (n=39) at baseline, 19 (48.7%) had progressive ILD, 4 (10.3%) patients died, and 3 (7.7%) experienced acute exacerbation during median 3.2 (1.4-4.9) years of follow-up. In progressive ILD group, extent of coarse reticulations (p=0.003), coarseness score of fibrosis (p=0.037) and HC involved sections increased significantly, while extent of GGO and fine reticulations did not. Age (Odds ratio [OR]: 1.158, p=0.003), smoking (HR=16.420, p=0.038), lactic dehydrogenase (LDH) (OR=1.015, p=0.007), and anti-Ro52 (OR=1.626, p=0.007) were significantly associated with presence of ILD. UIP pattern was an independent risk factor for ILD progression (OR 8.769, p=0.024). Baseline PFT, extent of ILD, auto-antibody profiles, glandular and extra-glandular manifestations except ILD were not associated with ILD progression.

#### Conclusions

No development of ILD was observed in pSS patients without ILD at baseline. ILD progressed occurred in 48.7% of the patients with pSS-ILD. pSS patients with older age, smoking, LDH, and high titers of anti-Ro52 were at higher risk of presence of ILD. UIP pattern on HRCT indicated ILD progression.

#### **Keywords**

Sjogren syndrome, Interstitial lung disease



# Comparison of prescription drug use patterns during pregnancy and postpartum in Korean women with rheumatic conditions: A national population-based study

Jin Su Park², Jisoo Lee¹, Chan Hee Lee², Min Kyung Chung¹, Hyunsun Lim²

¹ Rheumatology/Internal Medicine, Ewha Womans University College of Medicine, Republic of Korea ² Rheumatology/Internal Medicine, National Health Insurance Service IIsan Hospital, Republic of Korea

#### Background

The aim of this study was to compare the patterns of medication use before, during, and after pregnancy in women with systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), or ankylosing spondylitis (AS) to gain knowledge regarding disease activity and management during pregnancy and postpartum of women with rheumatic diseases.

#### **Methods**

We identified pregnancies ending in delivery in women aged 20 - 44 years with SLE (n=1,753), seropositive RA (n=1,652), or AS (n=879) in Korean National Health Insurance Service-National Health Information Database (NHIS-NHID), 2009–2016. We assessed proportions of pregnancies exposed to prescribed antirheumatic drugs including nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids (CSs), and disease-modifying anti-rheumatic drugs (DMARDs) in 8 window periods; 3 months before pregnancy (pre-pregnancy), each trimester of pregnancy (T1, T2, T3) and 3, 6, 9, 12 months postpartum (PP1, PP2, PP3, PP4).

#### **Results**

More pregnancies among women with SLE were exposed to antirheumatic drugs (62.4%) than in women with RA (42.9%) or women with AS (14.6%). CSs and hydroxychloroquine (HCQ) were most frequently used agents during pregnancy. Overall, use of antirheumatic drugs during pregnancy and postpartum in rheumatic diseases showed V shaped pattern, i.e. decreased use as pregnancy progressed from T1 to T3 and increased use in postpartum. In SLE, use of CSs did not decrease during pregnancy and postpartum, but rather increased in T2 and PP1 compared with pre-pregnancy. Use of HCQ decreased during SLE pregnancies with 65.9% in pre-pregnancy, 58.6% in T1, 53.9% in T2, and 48.4% in T3.

#### Conclusions

This population-based study offer real-world data regarding the disease activity and management of the disease during pregnancy and postpartum in women with rheumatic conditions. The decreased use of medications including HCQ during pregnancy suggest a need for strategies to improve medication adherence.

#### **Keywords**

rheumatic diseases, medication, pregnancy



### Multidimensional correlates to chronic pain among patients with musculoskeletal pain in different rheumatic diseases: Based on the Biopsychosocial approach

Hee Jun Kim¹, <u>Hyoun-Ah Kim²</u>, Ju-Yang Jung², Ji-Won Kim²

¹ College of Nursing, Ajou Medical Center, Ajou University, Republic of Korea ² Department of Rheumatology, Ajou University School of Medicine, Republic of Korea

#### Background

Chronic pain is a complex and subjective experience influenced by multiple factors, including biological, psychological, and social factors. Chronic pain is a condition known to be difficult to treat and comprehensive and accurate assessment on chronic pain and long-term plans based on evidence of factors influencing pain outcomes are necessary to better serve the patients.

#### Methods

An exploratory, cross-sectional design was used to explore multi-dimensional factors associated with clinical pain intensity. In total, 220 patients with musculoskeletal chronic pain from various rheumatic diseases were participated. Experimental pain sensitivity was measured using quantitative sensory testing (QST) for pressure pain threshold, mechanical cutaneous pain threshold, and temporal summation of mechanical cutaneous pain . Pain catastrophizing , depressive symptoms, and pain intensity was measured using Brief Pain Inventory. Descriptive analyses and a multivariate linear regression was conducted.

#### **Results**

Fifty five percent of the participants were having rheumatoid arthritis, 23.6% were diagnosed with ankylosing spondylitis, and 14.1% were diagnosed with osteoarthritis. First multivariate regression model included biological measures, including age, gender, pain-related disease type, pain duration, and comorbidity. The model was significant, F (10, 208) =2.63, p = .005, accounting for 11.2% of the variance in the pain intensity. Adding the QST measures explained an additional 0.6% of variation in pain intensity (F (14, 204) =1.97, p = .022). Introducing social factors, including levels of education and perceived economic status, religion, marital status, and types of residency, explained an additional 9.6 % of the variance in the dependent variable (F (23, 194) =2.30, p = .001). Depressive symptoms and pain catastrophizing explained the additional 22.2% of the variation in pain intensity (F (25, 190) =7.66, p < .001).

#### Conclusions

Psychological factors, including depressive symptoms and pain catastrophizing influenced pain experience the most significantly, and these factors should be included in pain assessment and pain management.

# **Free Paper Session**

Sjögren's Syndrome, Systemic Sclerosis, and Inflammatory Myositis



# IL-17 and CCR9+α4β7– Th17 cells promote salivary gland inflammation, dysfunction, and cell death in Sjögren's syndrome

<u>Jin-Sil Park</u>¹, Sun-Hee Hwang¹, Jin Seok Woo¹, SeungCheon Yang¹, JeongWon Choi¹, Mi-La Cho^{1,2}, Sung-Hwan Park^{1,3}

¹ Rheumatism Research Center, The Catholic University of Korea, Republic of Korea
² Department of Medical Lifescience, The Catholic University of Korea, Republic of Korea
³ Division of Rheumatology, The Catholic University of Korea, Republic of Korea

#### Background

Previous studies have evaluated the roles of T and B cells in the pathogenesis of Sjögren's syndrome (SS); however, their relationships with age-dependent and metabolic abnormalities remain unclear.

#### **Methods**

We examined the impacts of changes associated with aging or metabolic abnormalities on populations of T and B cells and SS disease severity.

#### **Results**

We detected increased populations of IL-17-producing T and B cells, which regulate inflammation, in the salivary glands of NOD/ShiLtJ mice. Inflammation-induced human submandibular gland cell death, determined based on p-MLKL and RIPK3 expression levels, was significantly increased by IL-17 treatment. Among IL-17-expressing cells in the salivary gland, peripheral blood, and spleen, the  $\alpha4\beta7$  (gut-homing integrin)-negative population was significantly increased in aged NOD/ShiLtJ mice. The  $\alpha4\beta7$ -positive population markedly increased in the intestines of aged NOD/ShiLtJ mice following retinoic acid (RA) treatment.

#### Conclusions

A significant increase in  $\alpha 4\beta$ 7-negative IL-17-expressing cells in salivary glands may be involved in the onset and progression of SS. These results suggest the potential therapeutic utility of RA in SS treatment.



# Correlations between salivary scintigraphic and histopathologic data of salivary glands in patients with Sjögren's syndrome

Ji-Won Kim¹, Young-Sil An², Jin Roh³, Jae ho Han³, Ju-Yang Jung¹, Chang-Hee Suh¹, Hyoun-Ah Kim¹

¹Department of Rheumatology, Ajou University School of Medicine, Republic of Korea ²Department of Nuclear Medicine and Molecular Imaging, Ajou University School of Medicine, Republic of Korea ³Department of Pathology, Ajou University School of Medicine, Republic of Korea

#### Background

Our aim was to evaluate the association of salivary scintigraphic and clinical parameters with histological characteristics of salivary glands in patients with Sjogren's syndrome (SS).

#### **Methods**

In 41 patients with suspected SS, salivary scintigraphy and salivary gland biopsy were performed. Salivary scintigraphy was interpreted as semi-quantitative methods obtained by calculating peak uptake and washout of each gland using region of interests. All specimens were examined by pathologists for focus scores and positivity for leukocyte common antigen (LCA) explaining the degree of inflammatory infiltration. The correlations between histological data of salivary gland and salivary scintigraphic and clinical parameters were analyzed.

#### Results

The mean age of SS patients was 46.4 years, 82.9% of them were female, and the mean symptom duration was 2.5 years. The focus score was negatively correlated to the mean peak uptake (r=-0.396, p=0.019) and mean washout (r=-0.391, p=0.02). In addition, the focus score and number of LCA positive cell per mm2 were correlated with the clinical parameters including ESR (r=0.582, p<0.001 and r=0.591, p<0.001, respectively), globulin (r=0.521, p=0.001 and r=0.608, p<0.001, respectively), unstimulated (UWS) (r=-0.512, p=0.006 and r=-0.471, p=0.013, respectively) and stimulated whole saliva flow (SWS) (r=-0.491, p=0.009 and r=-0.519, p=0.006) and only number of LCA positive cell per mm2 was negatively correlated to leukocyte (r=-0.37, p =0.019), and hemoglobin (r=-0.367, p=0.02).

#### **Conclusions**

Salivary gland biopsy in patients with SS showed a significant correlation with the mean peak uptake and washout of both parotid and submandibular gland in salivary scintigraphy, and clinical features such as cytopenia, high ESR, lower UWS and SWS. Although the diagnostic role of salivary gland biopsy is widely accepted according to the classification criteria of SS, salivary scintigraphy may be an alternative method if non-invasive test is required.



### Impact of age on the diagnostic performance of unstimulated salivary flow rates and salivary gland ultrasound for primary Sjögren's syndrome

Kyung-Ann Lee¹, Se-Hee Kim², Hae-Rim Kim², Hyun-Sook Kim¹

¹ Internal medicine, Soonchunhyang University Seoul Hospital, Republic of Korea ² Internal medicine, Konkuk University Medical Center, Republic of Korea

#### Background

Age-related changes and different patterns of salivary gland abnormalities according to age may affect the diagnostic performance of unstimulated salivary flow rate (USFR) and salivary gland ultrasound (SGUS) for primary Sjögren's syndrome (pSS). To evaluate the threshold and diagnostic performance of USFR and whether incorporating SGUS or replacing USFR with SGUS affects the performance of the ACR/EULAR criteria for pSS according to age.

#### **Methods**

This retrospective study included patients with suspected pSS who completed evaluations for pSS. Patients were classified based on age at pSS evaluation: elderly ( $\geq$ 65 years), middle-aged (40–64), and young (<40). The USFR's optimal thresholds were evaluated using the ROC curve. The diagnostic performances of the USFR and modified ACR/EULAR criteria were compared.

#### Results

In total, 239 pSS patients and 92 controls were included. The cut-off of USFR ≤0.1 mL/min was irrelevant to age, demonstrating the best sensitivity (44.3–53.0%) and specificity (74.1–90.9%). SGUS had a significantly better AUC than USFR in the young (p<0.01) and middle-aged groups (p<0.01). The middle-aged group demonstrated better diagnostic performance of the ACR/EULAR criteria incorporating SGUS (AUC 0.957) (p<0.01) and criteria replacing USFR with SGUS (AUC 0.957) (p<0.001) compared to the original criteria (AUC 0.916). In the young and elderly groups, adding SGUS to the ACR/EULAR criteria or replacing USFR with SGUS to the ACR/EULAR criteria the ACR/EULAR criteria SGUS and set the ACR/EULAR criteria or replacing USFR with SGUS did not significantly increase the AUC.

#### **Conclusions**

We confirmed the thresholds of USFR  $\leq 0.1$  mL/min for all age groups. Using SGUS would improve diagnostic accuracy by supplementing the USFR, especially in middle-aged patients.

#### **Figure & Table**




Figure. ROC curves of USFR for diagnosis of pSS according to age groups

#### **Keywords**

Sjogren syndrome, Saliva, Diagnosis



# Reduced Rxr- $\alpha$ signaling increases dry eye disease inducing $\gamma\delta$ T17 cells in the conjunctiva

#### <u>Jehan Alam</u>¹

¹Ophthalmology, Baylor College of Medicine, USA

#### Background

To investigate the mechanism for developing dry eye disease in the Pinkie mouse strain with a loss of function RXRa mutation.

#### **Methods**

Measures of dry eye disease were assessed in the cornea and conjunctiva. Expression profiling was performed by single-cell RNA sequencing (scRNA-seq) to compare gene expression in conjunctival immune cells. Conjunctival immune cells were immunophenotyped by flow cytometry and confocal microscopy. The activity of RXRa ligand 9-cis retinoic acid (RA) was evaluated in cultured monocytes and  $\gamma\delta$  T cells.

#### **Results**

Compared to wild type (WT) C57BL/6, Pinkie has increased signs of dry eye disease, including corneal barrier disruption, corneal/conjunctival cornification and goblet cell loss, and corneal vascularization, opacification, and ulceration with aging. ScRNA-seq of conjunctival immune cells identified yo T cells as the predominant IL-17 expressing population in both strains and there is a 4-fold increased percentage of vo T cells in Pinkie. Compared to WT, significantly increased expression of IL-17a and IL-17f in conventional T cells and IL-17f in  $\gamma\delta$  T cells was found in Pinkie. Flow cytometry and immunostaining revealed an increased number of IL-17+ γδ T cells in Pinkie. Tear concentration of the IL-17 inducer IL-23 is significantly higher in Pinkie. 9-cis RA treatment suppresses stimulated IL17 production by  $\gamma\delta$ T and stimulatory activity of monocyte supernatant on  $\gamma\delta$ T cell IL-17 production. Compared to WT bone marrow chimeras, Pinkie chimeras have increased IL17+ γδ T cells in the conjunctiva after desiccating stress and anti-IL-17 treatment suppresses dry eye induced corneal MMP-9 production/activity and conjunctival goblet cell loss.

#### Conclusions

These findings indicate that RXRa suppresses generation of dry eye disease inducing  $\gamma\delta$  T17 cells in the conjunctiva and identifies RXRa as a potential therapeutic target in dry eye.

#### Figure & Table




Figure. Summary of RXRa mediated suppression of IL-17 production by  $\gamma\delta$  T cells and IL-17 mediated dry eye disease.

#### **Keywords**

gamma delta T cells, Sjögren's syndrome, Retinoic acid

# Angiographic characteristics of vasculopathy in patients with idiopathic inflammatory myopathies and systemic sclerosis

### Jina Yeo^{1,2}, Eun-Ah Park³, Eun Bong Lee², Jin Kyun Park²

¹ Rheumatology, Gil Medical Center, Gachon University College of Medicine, Republic of Korea
² Rheumatology, Seoul National University Hospital and College of Medicine, Republic of Korea
³ Radiology, Seoul National University Hospital and College of Medicine, Republic of Korea

#### Background

To describe the peripheral angiographic features of non-thrombotic proliferative vasculopathy in idiopathic inflammatory myositis (IIM) and systemic sclerosis (SSc) in comparison to polyarteritis nodosa (PAN).

#### **Methods**

Angiograms of 47 extremities (24 upper and 23 lower) of 11 patients with IIM (n=5) and SSc (n=6), and 12 patients with PAN who presented with critical limb ischemia were retrospectively analyzed with regards to the presence of stenosis, occlusion, aneurysms and delayed distal flow, and degree of neovascularization.

#### **Results**

Diffuse narrowing was more frequent (66.1 vs. 38.0%, p=0.001), whereas multifocal stenosis (6.5% vs. 26.8%, p=0.002), abrupt occlusion (11.3% vs. 29.6%, p=0.010) and aneurysm formation (1.6% vs. 11.3%, p=0.037) were less frequent in IIM/SSc than PAN. In distal arteries, tapered occlusion (95.5% vs. 72.0%, p=ns) and delayed flow (77.3% vs. 48.0%, p=0.039) were more common in IIM/SSc than PAN. After 1 year, auto- or surgical amputation tended to be more frequent in IIM/SSc than PAN (36.4% vs. 16.7%, p=ns).

#### Conclusions

In conclusion diffuse narrowing, tapered occlusion and delayed distal flow on conventional angiograms tend to be more frequent in IIM/SSc than PAN. Moreover, IIM/SSc-vasculopathy might be associated with a worse outcome than PAN. Further studies are needed to verify these findings in a larger prospective cohort.

#### Figure & Table




Figure. Angiographic parameters in the extremities of patients with IIM/SSc-vasculopathy and PAN.

#### **Keywords**

Vasculopathy, Idiopathic inflammatory myositis, Systemic sclerosis



### The association of anti-cyclic citrullinated peptide antibody with interstitial lung disease in systemic sclerosis: a retrospective analysis

### Jangwoo Ha¹, Yoo Jin Hong², Hyun Jin Cha^{1,3}, Jeonghun Daniel Moon⁴, Jung Yoon Pyo¹, Sang-Won Lee¹, Yong-Beom Park¹, Chul Hwan Park⁵, Jason Jungsik Song^{1,6}

¹ Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Republic of Korea ² Department of Radiology and Research Institute of Radiological Science, Severance Hospital, Yonsei University College of Medicine, Republic of Korea ³ Synapse Center, Yonsei University College of Medicine, Republic of Korea

⁴ Division of Rheumatology, University of Washington Medicine, Valley Medical Center, USA

⁵Department of Radiology and Research Institute of Radiological Science, Gangnam Severance Hospital, Yonsei University College of Medicine, Republic of Korea ⁶Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Republic of Korea

#### Background

An anti-cyclic citrullinated peptide (CCP) antibody test is a diagnostic test for rheumatoid arthritis (RA), which is associated with clinical features of interstitial lung disease (ILD). In this study, we aimed to investigate the clinical and radiographic features of ILD in patients with systemic sclerosis (SSc) who tested positive for anti-CCP antibody.

#### **Methods**

We performed a retrospective analysis at a tertiary medical center in Seoul, South Korea, between 2005 and 2019. Patients with SSc, systemic lupus erythematosus (SLE), and polymyositis/dermatomyositis (PM/DM) were evaluated for anti-CCP antibody and ILD. Additionally, medical records of SSc patients with ILD were retrospectively reviewed for clinical, laboratory, high resolution computed tomography (HRCT), and pulmonary function test data.

#### **Results**

Patients with SSc had the highest anti-CCP antibody positivity rate compared to those with SLE and PM/DM (9.2% [SLE, n=936] vs. 11.5% [PM/DM, n=156] vs. 16.2% [SSc, n=260], p=0.006). The incidence of ILD was higher in SSc patients with anti-CCP antibody than in those without (64.3% vs. 41.3%, p=0.006). The usual interstitial pneumonia incidence was higher in the anti-CCP antibody-positive group than in the anti-CCP antibody-negative group (55.6% vs. 31.1%, p=0.021). The DLCO was lower in the anti-CCP antibody-negative group (57.5% vs. 67.0%, p=0.023).

#### Conclusions

Anti-CCP antibody positivity may be associated with a higher incidence and a more severe course of ILD in SSc

### Figure & Table

	ILD with anti-CCP antibody (-)	ILD with anti-CCP antibody (+)	P-value
SLE	59/850 (6.9%)	14/86 (16.3%)	0.002
PM/DM	59/138 (42.8%)	7/18 (38.9%)	0.755
SSc	90/218 (41.3%)	27/42 (64.3%)	0.006

Bold text indicates statistical significance. Values are expressed as n (%).

SLE, systemic lupus erythematous; PM, polymyositis; DM, dermatomyositis; SSc, systemic sclerosis; ILD, interstitial lung disease

Table. Relationship between anti-CCP antibody and interstitial lung disease in connective tissue diseases

#### **Keywords**

Anti-cyclic citrullinated peptide antibody, Systemic sclerosis, interstitial lung disease



### Ultrasound may detect subclinical interstitial lung disease in systemic sclerosis

<u>MARWIN Gutierrez</u>^{1,2}, Luis E. Gomez-quiroz³, Chiara Bertolazzi¹, Esteban Cruz-arenas⁴, Denise Clavijo-cornejo¹, Fausto Salaffi⁵

¹ Division of Musculoskeletal and Reumatic Diseases, Instituto Nacional de Rehabilitacion, Mexico
 ² Rheumatology, Excellence Center of Rheumatoogy, Mexico
 ³ Departamento de Ciencias de la Salud, Universidad Autónoma Metropolitana, Mexico
 ⁴ Epidemiology Unit, Instituto Nacional de Rehabilitacion, Mexico
 ⁵ Clinica Reumatologica, Università Politecnica delle Marche, Italy

#### Background

Interstitial lung disease (ILD) is common in systemic sclerosis (SSc) patients and despite recent advances in the treatment represents still the major cause of death. It may be established within the first 4 years of SSc and frequently is subclinical.

We investigated the validity of US in detecting subclinical ILD in SSc and to determine its potential in the follow-up of these patients

#### **Methods**

133 patients without respiratory symptoms and 133 healthy controls were included. Borg scale dyspnea index, Rodnan skin score (RSS), and pulmonary auscultation were performed. X-ray and respiratory function tests (RFT) were performed the same day. An expert rheumatologist blinded to the clinical assessment performed the US. To determine the concurrent validity high-resolution CT (HRCT) scans were performed. HRCT findings were scored according to Warrick score whereas US findings were classified according to the previously proposed scale. Inter-observer reliability was performed. A follow-up including US, RFT, and Borg scale was done every 3 months for 12 months

#### Results

A total of 54 of 133 SSc patients (40.6%) showed US signs of ILD in contrast to healthy controls (4.8%) (p=0.0001). The clinical and laboratory variables associated with ILD were anti-centromere antibodies (p=0.005) and RSS (p=0.004). A positive correlation was demonstrated between the US and HRCT findings (p=0.001). The sensitivity and specificity of US in detecting ILD was 91.2% and 88.6% respectively. Good inter-observer reliability was also observed (k = 0.72). In the follow-up, a total of 30 patients (22.6%) that demonstrated US signs of ILD at baseline showed the US worsening. Nine patients (30%) developed symptoms of ILD

#### Conclusions

US is valid to detect subclinical ILD-SSc. Our results showed a high prevalence of this complication. Despite encouraging data. it seems still controversial its role in monitoring the ILD progression in SSc

#### **Keywords**

Systemic Sclerosis, Ultrasound, interstitial lung diseases



### Expressions of CCR2 and CCL2, and association between their expression and NET stimulation in adult-onset Still's disease

Ju-Yang Jung¹, Mi-Hyun Ahn¹, Ji-Won Kim¹, Chang-Hee Suh¹, Hyoun-Ah Kim¹

¹ Department of Rheumatology, Ajou University School of Medicine, Republic of Korea

#### Background

Adult-onset Still's disease (AOSD) is a systemic inflammatory disease, which is characterized by the activation of monocyte-derived cells and release of neutrophil extracellular traps (NET). C-C motif ligand 2 (CCL2), known as monocyte chemoattractant protein -1, is a chemoattractant attracting monocytes, and interaction with its ligand, C-C motif chemokine receptor (CCR) 2, mediates monocyte recruitment and activation.

#### **Methods**

CCL2 and CCR2 levels in serum were measured by enzyme-linked immunosorbent assay (ELISA) and their expressions in tissue were detected by immunohistochemistry staining. After stimulation of NET formation using neutrophils from patients with AOSD, THP-1 cell lysates were analyzed by western blot and ELISA.

#### Results

Concentration of CCL2 in serum was higher in AOSD patients (476.4  $\pm$  689.1 pg/mL) compared to rheumatoid arthritis (RA) patients (169.2  $\pm$  118.7 pg/mL, p = 0.007) and healthy controls (HC) (135.1  $\pm$  71.7 pg/mL, p = 0.003). Expressions of CCL2 in skin of AOSD were increased compared with those in HC (p = 0.03), and expressions of CCR2 in lymph node of AOSD were increased compared with those in tuberculosis (p = 0.02) and reactive hyperplasia (p = 0.04). THP-1 cells stimulated with NET induced increased secretion of CCR2 and inflammatory cytokines including IL-1 $\beta$ , IL-6, and IL-18.

#### Conclusions

CCL2 was expressed highly in serum and skin, and CCR2 was expressed highly in the lymph node in patients with AOSD. In addition, CCR2 expression was associated with NET formation in AOSD.

#### **Keywords**

Adult-onset Still's disease, CCL2, neutrophil extracellular traps



### Increased expression of receptor for advanced glycation end-products in sarcopenic patient skeletal muscle

#### Ji Sup Hwang¹, Hyun Sik Gong¹

¹ Department of Orthopedic Surgery, Seoul National University Bundang Hospital, Republic of Korea

#### Background

Animal studies suggest that advanced glycation end-products (AGEs) and their interaction with receptor for AGEs (RAGE) are involved in sarcopenia, but their relationship in human skeletal muscles has yet to be elucidated. We aimed to determine whether RAGE expression in human skeletal muscle is associated with serum AGE levels and sarcopenia-related changes.

#### **Methods**

We reviewed 33 consecutive women (mean age, 65 years) with distal radius fracture who had consented to donate a sample of forearm muscle for research purposes, which was taken during surgical fracture repair. The muscle RAGE expression was measured with immunohistochemistry staining and serum AGE levels using ELISA method. We compared RAGE expression and AGE levels in patients with and without sarcopenia. We also correlated RAGE expression with such clinical parameters as demographic factors, as well as sarcopenia-related changes, including grip strength, appendicular skeletal muscle mass, and muscle cross-sectional area (CSA) ratios.

#### **Results**

Twelve patients (36%) were diagnosed with sarcopenia. They had a significantly higher RAGE expression (p = 0.044) and AGE level (p < 0.001) than those without sarcopenia. The RAGE expression correlated significantly with a high AGE level (r = 0.510, p = 0.011) and correlated inversely with a muscle CSA ratio (r = -0.696, p < 0.001).

#### Conclusions

This study shows that RAGE expression increases in sarcopenic patient skeletal muscles. This expression also correlates positively with serum AGE levels and inversely with muscle CSA ratios. Further studies are necessary to determine whether targeting RAGEs can be a therapeutic option for sarcopenia.

#### **Figure & Table**




Figure. Disparity in RAGE expression in skeletal muscle tissues obtained from two different patients

#### **Keywords**

Sarcopenia, Advanced glycation end-product, Skeletal muscle

# Luncheon Symposium IV Lilly

The Role of Baricitinib in the Treatment of RA



# Baricitinib in the real-world data

Yun-Hong Cheon

Gyeongsang Nat'l Univ., Korea

Current guidelines for the management of rheumatoid arthritis (RA) recommend early treatment and a treat-to-target goal of remission or low disease activity. Long-term treatments that are safe and efficacious are needed to reduce disease symptoms, to prevent irreversible joint damage, and to reduce the burden of disease from comorbidities.

Janus Kinases (JAK) mediate the intracellular signaling of pivotal cytokines implicated in the pathogenesis of rheumatoid arthritis (RA). Targeting the JAK pathway represents a novel approach to inhibiting the effects of multiple cytokines. Baricitinib, an oral, selective and reversible Janus kinase (JAK) 1 and 2 inhibitor approved for the treatment of adult patients with moderately to severely active RA, was the first JAK inhibitor to demonstrate superiority to MTX and adalimumab.

Baricitinib has now been evaluated in four phase III clinical trials, the data to date suggest that this drug with its once daily dosing, rapid onset of action and efficacy as monotherapy represents an important addition to the RA therapeutic armamentarium. In RA BEAM Baricitinib provided significantly greater improvement in most PROs compared with placebo and adalimumab, including physical function MJS, pain, fatigue and quality of life. Improvement was maintained to the end of the study.

Emerging real-world data helps to provide further insights in the use of Baricitinib in routine clinical practice, including treatment patterns (bio-naïve vs bio-experienced, monotherapy, discontinuations, drug retention). High remission and low disease activity rates were observed from 6 months to 12 months, regardless of the activity index used. Baricitinib demonstrated a significantly higher overall drug maintenance than TNFi, and similar drug maintenance to OMA, both in a bDMARD-naïve population and in the overall population. Baricitinib retention rates are consistent across different Real World Data sources, with retention rates at 6 months ranging between 75% and 82%.

Baricitinib is well tolerated with treatment experience out to 9.3 years; incidence rates for safety topics of interest in DMARD therapy, including serious infections, major adverse cardiovascular event (MACE), venous thromboembolism (VTE), and malignancy are in-line with incidences observed in the overall RA population and have not increased over time.

Baricitinib demonstrated consistent efficacy and acceptable safety outcomes over the long-term and it is supported by global real-world data. Since its launch, Baricitinib has been prescribed to ~3,000 rheumatoid arthritis patients in Korea.

# Luncheon Symposium V BMS

Real World Evidences in Long-term RA Treatment with Biologics

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



# Real world evidences and considerations for long-term persistence of biologics in RA

Sang-Hyon Kim Keimyung Univ., Korea

As treatment of rheumatoid arthritis evolves with various treatment options of biologics, treatment choice based on patient conditions is getting more important.

Especially as long-term management of biologics treatment becomes more important recently, it is crucial to consider factors that are related to drug persistence.

Drug persistence, drug maintenance or drug retention are defined as 'the duration of time from initiation to discontinuation therapy'. It is thought to reflect both the effectiveness and the tolerance of a given drug, representing an outcome close to clinical decision-making, although numerous other factors may influence drug persistence and make it hard to interpret. Although treatment persistence is thought to reflect mainly a drug's tolerance and its effectiveness, other reasons may lead to discontinuation of a treatment, such as pregnancies or remission. Ideally, the broad reasons for discontinuation should be analysed separately, when analysing drug persistence.

In this lecture we will explore real world data to understand considerations for long-term persistence of biologics in RA. This includes studies on drug retention by serostatus, by disease duration, by co-morbidities and by age from many different regions around the world including US, EU and Japan.



## Real world evidences of RA treatment with biologics in Korea

Jennifer Jooha Lee

The Catholic Univ. of Korea, Korea

Rheumatoid arthritis (RA) is a chronic, autoimmune inflammatory disease characterized by progressive synovitis resulting in, if untreated, bone erosion and joint destruction.

The disease-modifying antirheumatic drugs (DMARDs) is known to change the natural course of the disease. At the time of the diagnosis, DMARDs should be initiated as early as possible. First, conventional synthetic DMARDs (cSDMARDs) including methotrexate are prescribed. According to aim of treat-to-target, patients with inadequate response to csDMARDs are then treated with biological DMARDs (bDMARDs) or targeted synthetic DMARDs (tsDMARDs). Since the introduction of first bDMARDs targeting Tumor necrosis factor (TNF), several different classes of bDMARDs have been developed. More recently, small molecule inhibitors –tsDMARDs- are developed and added as therapeutic options.

Data from clinical trials suggest that the efficacies of these targeted therapies (bDMARDs and tsDMARDs) are comparable between the drugs in general, and the recommendations for RA treatment recommend with no priority of one drug upon another one. Therefore, the choice of a certain drug is rather dependent on other conditions such as ages, infection risks, or comorbidities as recently suggested in the 2021 ACR recommendations for RA treatment. Furthermore, recent studies suggest auto antibody status may affect the effectiveness of the certain DMARDs.

In general, real world evidences (RWEs) have many limitations to interpret the results of analyses because we can't control possible biases. However, on the other hands, they reflect the real data of the daily practices and provide physicians with practical data which can be applied in the clinics.

Here we show the RWEs of RA treatment with biologics in Korea focusing on the good performance of abatacept compared to other biologics used in Korean RA patients. The first population-level study to compare the persistence of TNF inhibitors and non-TNF inhibitors in South Korean RA patients showed that non-TNF inhibitors presented relatively higher treatment persistence than those on TNF inhibitors in both bDMARD initiators and switchers. Further, abatacept was effective and had better tolerability in patients without adequate response to methotrexate or TNF inhibitors, and also significantly higher persistence in patients with inadequate response to previous bDMARDs. Abatacept showed highest persistence rate in bio-naïve patients as well.

# Luncheon Symposium VI Yuhan Corporation

The New Adalimumab Option in Rheumatic Diseases Treatment

> KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



# ADALLOCE[®](SB5) adalimumab in rheumatic diseases: Data from clinical trials and the real world

Carlo Selmi Humanitas Univ., Italy

This lecture is intended to review the available data from clinical trials and real-world evidence regarding the use of SB5 biosimilar adalimumab in rheumatic diseases and its comparison with the originator. Critical issues and advantages in terms of safety and efficacy will be discussed.

# International Symposium

2022 Clinical Research Update of Sjögren's Syndrome

> KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



Journal of Rheumatic Diseases Vol. 29, Suppl. 1, May, 2022

# Big data Sjögren project consortium

Manuel Ramos-Casals

Univ. of Barcelona, Spain

The Big Data Sjögren Project Consortium is an international, multicentre registry that was designed in 2014 to take a "high-definition" picture of the main features of primary Sjögren syndrome (SjS) using worldwide data-sharing cooperative merging of pre-existing clinical SjS databases from leading centres in clinical research in SjS from the five continents. The centres share a harmonized data infrastructure and conduct cooperative online efforts in order to refine alreadycollected data in each centre. The codebook containing instructions on the variables and data codification was firstly discussed and approved by the Steering Committee members, and was further shared with the consortium partners. Data bases from each centre were harmonized into a single data base by applying specific pre-processing techniques such as the detection and treatment of outliers, influential observations, errors and missing data. By January 2022, the participant centres had included more than 15000 valid patients from 70 research centers of 24 countries. The Big Data Sjögren Project has provided the first evidence for a strong influence of geolocation and ethnicity on the phenotype of primary SjS at diagnosis. It also confirmed a strong influence of immunological markers on the phenotype of primary SjS at diagnosis in the largest multi-ethnic international cohort ever analysed, with a greater influence for cryoglobulinaemicrelated markers in comparison with Ro/La autoantibodies and ANA. The Sjögren Big Data Project has achieved to multiply by 7 the largest number of patients ever included in an international registry, and by 15 the largest number of patients included in Nationwide multicentric cohorts. The individual contribution of every participating centre, even those that included a modest number of cases, continues to increase progressively year by year, which reflects that participation in the project serves as an enhancer of the clinical experience and acknowledgement that each centre acquires at a regional/national level. And the almost 5 years of close collaboration has created a solid nucleus of clinical research, led by internists and rheumatologists but with active participation of many other medical specialties, with more than 100 people currently involved. And with the active participation in each centre of young researchers, who will be the future experts in Sjögren. could also be successfully addressed through the use of Big Data Sharing.



# ESSPRI, a single term with multiple meanings: A consideration based on Korean studies

Yun Jong Lee Seoul Nat'l Univ., Korea

Although Sjögren's syndrome (SS) has originally been described as a disease affecting the lacrimal and salivary glands, many studies continue to add valuable and additional insights as a systematic disease. But our understanding on this Janus-faced disease remains incomplete yet. Consequently, there is a large perception gap between physicians as well as between physicians and patients.

The assessment of SS disease activity has been a challenge because SS is a clinically heterogeneous and has a lower incidence of flares. EULAR task force on SS developed two validated measurements, EULAR SS Patient Reported Index (ESSPRI) and EULAR SS disease activity index (ESSDAI), in 2011 and 2015 respectively. ESSPRI is a patient's reported, subjective symptom index and consists of three questions on the cardinal symptoms such as dryness, fatigue, and joint or muscle pain. The patient acceptable symptom state (PASS) has been defined as ESSPRI score <5. Additionally, its minimal clinical improvement has been defined as a decrease of 1 point or more or decrease by 15% from baseline score. On the other hand, ESSDAI is an established outcome measure for objective systemic disease activity. ESSDAI classifies disease activity in 3 to 4 levels according and consists of 12 organ-specific domains. Because ESSPRI and ESSDAI reflect two different facets, benign sicca symptoms and severe systemic manifestations, their correlation level is quite smaller.

This lecture will discuss the clinical implications of ESSPRI beyond its definition, based on observational studies in Korean SS patients. First, ESSPRI is clearly related with health-related quality of life (HR-QOL) in Korean SS. A high ESSPRI level can be translated into poor HR-QOL state of SS patients. Second, high ESSPRI levels are linked with poor sleep quality in Korean SS. It may indicate that improved sleep can improve patients' HR-QOL or ESSPRI. Third, in total SS patients, longitudinal ESSPRI and clinical ESSDAI levels are not significantly changed. But, although the response rates varied according to different criteria, 17% to 51% showed a treatment response to currently available standards of care in Korean SS patients. Low ESSPRI is a predictor for a better treatment response or subsequent PASS state. Especially, low ESSPRI and high ESSDAI may lead to favorable outcome even with conventional care. Fourth, ESSPRI or ESSDAI alone may not be an adequate endpoint in clinical trials because Korean studies suggest no small effect of background medications. Additionally, several randomized controlled clinical trials with ESSDAI as primary endpoint had failed and showed large response rates in placebo group. Therefore, we make the effort to develop new composite measurements in SS. Fifth, SS is a relatively stable disease because ESSPRI, clinical ESSDAI, or symptom-based phenotypes remain constant over 3 to 5 years in Korean SS. It means that there is a high level of unmet therapeutic need in SS. Also, it can be said that early diagnosis of SS is important, especially when SS patients have residual exocrine function. Furthermore, the stable course of SS, unlike SLE and RA, informs us that we must be careful about overtreatment with immunosuppressive drugs.

Conclusively, ESSPRI is easy to calculate and is something more than the simple sum of symptom triads. It should be considered that ESSPRI is incorporated in routine clinical practice.



# Current and future treatment of primary Sjögren's syndrome

### Xavier Mariette

Hôpitaux Universitaires Paris-Sud Bicêtre, France

Primary Sjögren syndrome (pSS) is a systemic autoimmune disease that is characterized by a triad of symptoms that affect all patients (dryness, pain and fatigue). In addition, systemic involvement can affect between one-third and one-half of patients. The management of patients with pSS has been negatively affected by a lack of effective treatments; however, knowledge of the epidemiology of pSS has increased, and advances in developing classification criteria, systemic disease activity scoring and patient-reported outcomes have been made during the past decade. Progress has also been made in understanding the mechanisms that underlie the pathogenesis of pSS, which has enabled a more targeted therapeutic approach to be taken. At present, therapeutic decisions rely on the evaluation of symptoms and systemic manifestations and are mostly formed on the basis of experience, rather than evidence, and on similarities with other autoimmune diseases, although the 2019 management recommendations from EULAR are now being used to inform clinical management of pSS. This Review summarizes the available evidence for systemic treatments for pSS and includes discussions of advances in outcome assessment, the current evidence for DMARD use and an overview of promising future therapeutics.

# Symposium

KCR-KAI Joint Symposium

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



# Role of bystander T cells in autoimmune diseases

### Je-Min Choi

Hanyang Univ., Korea

Autoimmune disease is known to be caused by unregulated self-antigen specific T cells, causing tissue damage. Although antigen specificity is an important mechanism of the adaptive immune system, antigen non-related T cells have been found in the inflamed tissues in various conditions. Bystander T cell activation refers to the activation of T cells without specific antigen recognition. During an immune response to a pathogen, bystander activation of self-reactive T cells via inflammatory mediators such as cytokines can trigger autoimmune diseases. Other antigen-specific T cells can also be bystander-activated to induce innate immune response resulting in autoimmune disease pathogenesis along with self-antigen-specific T cells. In this presentation, we discuss the role of innate-like T cell response in autoimmune diseases. In our studies, memory phenotype CD4 T cells (CD62L^{high}/CD44^{low}) can be activated by inflammatory cytokines without TcR stimulation, and their effector functions contributed MOG antigen specific T cell response in experimental autoimmune encephalomyelitis model. CCR6^{high} memory phenotype cells are bystander-activated by IL-1β and IL-23 and infiltrate the spinal cord with producing IL-17A, interferon (IFN)- $\gamma$ , and GM-CSF. These bystander-activated T cells contributed to the susceptibility of the recipients to encephalomyelitis in an IL-1 receptor, Bhlhe40, and GM-CSF dependent manner. Therefore, we propose the innate-like pathogenic function of antigen non-related memory CD4 T cells are important contributor for development, progression, or relapse of autoimmune diseases. A better understanding of bystander-activated T cells versus antigen-stimulated T cells would provide a novel insight to control autoimmune disease pathogenesis.



## Exploration of the key driving molecules in systemic sclerosis-associated interstitial lung disease by the advanced bioinformatic analysis

### Ki-Jo Kim

The Catholic Univ. of Korea, Korea

Interstitial lung disease (ILD) is a significant comorbidity and the leading cause of mortality in patients with systemic sclerosis (SSc). Transcriptomic data of SSc-associated ILD (SSc-ILD) were analyzed to evaluate the salient molecular and cellular signatures in comparison with those in related pulmonary diseases, and to identify the key driver genes and target molecules in the disease module. A transcriptomic dataset of lung tissues from patients with SSc-ILD (n=52), idiopathic pulmonary fibrosis (IPF) (n=549), non-specific interstitial pneumonia (n=49), and pulmonary arterial hypertension (n=81), and normal healthy controls (n=331) was subjected to filtration of differentially expressed genes, functional enrichment analysis, network-based key driver analysis, and kernel-based diffusion scoring. The association of enriched pathways with clinical parameters was evaluated in patients with SSc-ILD. SSc-ILD shared key pathogenic pathways with other fibrosing pulmonary diseases but was distinguishable in some pathological processes. SSc-ILD showed general similarity with IPF in molecular and cellular signatures but stronger signals for myofibroblasts, which in SSc-ILD were in a senescent and apoptosis-resistant state. The p53 signaling pathway was the most enriched signature in lung tissues and lung fibroblasts of SSc-ILD and significantly correlated with carbon monoxide diffusing capacity of lung, cellular senescence, and apoptosis. EEF2, EFF2K, PHKG2, VCAM1, PRKACB, ITGA4, CDK1, CDK2, FN1, and HDAC1 were key regulators with high diffusion scores in the disease module. Integrative transcriptomic analysis of lung tissues revealed key signatures of fibrosis in SSc-ILD. A network-based Bayesian approach provides deep insights into key regulatory genes and molecular targets applicable to treating SSc-ILD.



# ZIP8 exacerbates collagen-induced arthritis by increasing pathogenic T cell responses

Sung-Gyoo Park Seoul Nat'l Univ., Korea

Rheumatoid arthritis (RA) is a type of autoimmune disease, which is characterized by chronic inflammation and T cell activation. Thus, the disease condition is affected by T cell activation induced by autoantigen-specific T cell receptor (TCR). During the T cell activation, antigen recognition by TCR induces intracellular signaling cascade, which processes are essential for T cell proliferation and function. The TCR-induced signaling cascades activates transcription factors including NF- $\kappa$ B, NF-AT, AP-1, etc. These transcription factor activations turn on many T cell function-related genes for expression of cytokines, adhesion molecules, receptors, etc. The TCR-induced signaling is mainly mediated by molecule-molecules interactions and kinase cascades. In addition, some of the molecule-molecule interactions and the kinase cascades are regulated by intracellular ion concentrations such as zinc. Thus, during the T cell activation, intracellular ion flux control affects the TCR-mediated T cell activation. In here, we identified that zinc transporter ZIP8 regulates zinc flux during the collagen-induced arthritis. Even though some reports have suggested that the zinc supplement is beneficial for immune regulation, our data suggest the specific zinc flux possible exacerbates inflammatory disease such as RA. Thus, specific targeting of zinc transporter such as inhibition of ZIP8 may beneficial outcome for RA treatment.

# **Free Paper Session**

# Osteoarthritis and Orthopedics

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



### Sodium chloride affects cartilage associated marker expression during in vitro chondrogenesis from induced pluripotent stem cell

#### Kijun Lee¹, Son Byeonggwan¹, Ji Hyeon Ju^{1,2}

¹ CiSTEM Laboratory, Catholic iPSC Research Center, College of Medicine, The Catholic university, Republic of Korea ² Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, The Catholic University, Republic of Korea

#### Background

Induced pluripotent stem cells (iPSC) have the ability to differentiate into various lineages and are one of the sources of stem cells that have been studied in recent years. Upregulation of osmotic pressure has been found to have a positive effect in the differentiation process of chondrocytes and is known to affect inflammation and hypertrophy, but the results of studies on cartilage differentiation in 3D cell culture have not been accurately performed. Sodium chloride (NaCl) has been reported in several studies in terms of inflammation and cartilage formation in osteoarthritis and various cartilage-related diseases. We aimed to investigate whether sodium chloride could help cartilage formation in the 3D cartilage differentiation process of iPSCs.

#### **Methods**

In order to create high osmotic pressure environments, a chondrogenic differentiation medium with a high osmolarity of up to 420 mOsm was prepared using NaCl as well as mannitol, one of the sugar alcohols. Embryoid body-outgrowth cells (EBOGCs) derived from iPSCs were differentiated in a chondrogenic differentiation medium supplemented with different concentrations of NaCl or mannitol for 4 weeks, and pro-inflammatory mediators, cartilage-related markers, and hypertrophy-related markers were evaluated.

#### **Results**

Here we demonstrate that NaCl affects cartilage-associated marker expression during in vitro chondrogenesis from iPSC. Depending on which osmotic agent is used under the same osmotic pressure, various effects on inflammatory markers including hypertrophy, bone, and cartilage-related markers can be obtained. Appropriate concentration and use of NaCl during chondrogenesis may play an important role in cartilage regeneration or the inflammatory milieu of joints.

#### **Conclusions**

Our findings suggest that it is important to properly use Hyperosmotic conditions for high cartilage formation, which is potentially applicable for cell therapy in patients with cartilage lesions.

#### **Keywords**

iPSC-derived chondrocyte, anti-inflammation, NaCl



### Immunomodulation by mesenchymal stromal cell exosomes in osteoarthritis

<u>Kristeen Ye Wen Teo</u>¹, Shipin Zhang¹, Sai Kiang Lim^{2,3}, Wei Seong Toh^{1,4,5} ¹ Faculty of Dentistry, National University of Singapore, Singapore

² Institute of Molecular and Cell Biology, Agency for Science, Technology and Research (A*STAR), Singapore
 ³ Department of Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
 ⁴ Department of Orthopaedic Surgery, Yong Loo Lin School of Medicine, National University of Singapore, Singapore
 ⁵ Tissue Engineering Program, Life Sciences Institute, National University of Singapore, Singapore

#### Background

Mesenchymal stromal cell (MSC) exosomes were reported to be efficacious in alleviating joint pain and degeneration in temporomandibular joint osteoarthritis (TMJ-OA). However, the immunomodulatory effects of MSC exosomes in TMJ-OA remain to be elucidated.

#### **Methods**

Forty-seven rats were randomly assigned to OA+Exo, OA+PBS, sham, and naïve groups. Two weeks after OA induction by monoiodoacetate injection, OA+Exo rats received 3 weekly intra-articular injections of exosomes (1.3×10¹^{II} particles), whereas OA+PBS rats received equivalent phosphate-buffered saline (PBS) injections. Sham rats received needle pricks while naïve rats were age-matched unoperated control. Weekly nociceptive response was analysed by head withdrawal threshold (HWT) measurement. At 1 week, TMJ condylar cartilage and synovium tissues were harvested for transcriptomic analysis. At 1 and 8 weeks, TMJs were harvested for micro-computed tomography and histology, and blood samples for immunophenotyping and multiplex cytokine assay.

#### Results

At 1 week, OA+Exo rats showed preferential infiltration of anti-inflammatory CD2068 M2 over pro-inflammatory CD861 M1 macrophages in the synovium, and increased M2 over M1-related genes in both cartilage and synovium, that culminated in an improved synovium inflammation score of 0.7±0.5 over 1.8±1.0 in OA+PBS rats (P=0.032). Relative to OA+PBS rats, OA+Exo rats also showed early suppression of systemic inflammation, with significantly reduced circulating SSCHiCD43HiRP1Hi neutrophils and CD43LoHis48Hi classical monocytes, and suppressed levels of pro-inflammatory cytokines including IL6, IL12, IL17A, IFNy and TNFa. By 8 weeks, OA+Exo rats showed pain recovery with increased HWT, enhanced cartilage and subchondral bone restoration with improved Mankin score (1.9±0.9 vs 5.9±2.6, P=0.043) and augmented bone structural parameters that were significantly better than OA+PBS rats, and were comparable to that of sham and naïve rats (P>0.05).

#### **Conclusions**

MSC exosomes alleviate local inflammation by enhancing M2 over M1 macrophage infiltration, and suppress systemic inflammation with reduction of circulating neutrophils, classical monocytes and associated pro-inflammatory cytokines, to collectively promote joint repair and pain recovery.

#### **Keywords**

osteoarthritis, exosomes, immunomodulation



### Mitochondrial transplantation ameliorates the development and progression of osteoarthritis

<u>A Ram Lee^{1,2}</u>, Seon-Yeong Lee¹, Jin Seok Woo¹, Chae Rim Lee^{1,2}, Keun-Hyung Cho^{1,2}, Seok Jung Kim⁴, Sung-Hwan Park⁵, Mi-La Cho^{1,2,3}

¹ The Rheumatism Research Center, The Catholic University of Korea, Republic of Korea

² Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Republic of Korea

³Department of Medical Lifescience, College of Medicine, The Catholic University of Korea, Republic of Korea

⁴ Department of Orthopedic Surgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Republic of Korea

⁵ Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Republic of Korea

#### Background

Osteoarthritis (OA) is a common degenerative joint disease characterized by breakdown of joint cartilage. Mitochondrial dysfunction of the chondrocyte is a risk factor for OA progression. We examined the therapeutic potential of mitochondrial transplantation for OA.

#### **Methods**

Mitochondria were injected into the knee joint of monosodium iodoacetateinduced OA rats. Chondrocytes from OA rats or patients with OA were cultured to examine mitochondrial function in cellular pathophysiology.

#### Results

Pain, cartilage destruction, and bone loss were improved in mitochondrial transplanted-OA rats. The transcript levels of IL-1 $\beta$ , TNF- $\alpha$ , matrix metallopeptidase 13, and MCP-1 in cartilage were markedly decreased by mitochondrial transplantation. Mitochondrial function, as indicated by membrane potential and oxygen consumption rate, in chondrocytes from OA rats was improved by mitochondrial transplantation. Likewise, the mitochondrial function of chondrocytes from OA patients was improved by coculture with mitochondria. Furthermore, inflammatory cell death was significantly decreased by coculture with mitochondria.

#### Conclusions

Mitochondrial transplantation ameliorated OA progression, which is caused by mitochondrial dysfunction. These results suggest the therapeutic potential of mitochondrial transplantation for OA.



## Soluble CCR2 gene therapy controls joint inflammation, cartilage damage, and the progression of osteoarthritis by targeting MCP-1 in a monosodium iodoacetate (MIA)-induced OA rat model

<u>Hyun Sik Na</u>^{1,2}, Seon-Yeong Lee¹, Keun -Hyung Cho^{1,2}, A Ram Lee^{1,2}, Chae Rim Lee^{1,2}, Seok Jung Kim⁵, Sung-Hwan Park⁴, Mi-La Cho^{1,2,3}

¹ The Rheumatism Research Center, The Catholic University of Korea, Republic of Korea

² Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Republic of Korea

³ Department of Medical Lifescience, College of Medicine, The Catholic University of Korea, Republic of Korea

⁴ Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Republic of Korea

⁵Department of Orthopedic Surgery, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Republic of Korea

#### Background

Osteoarthritis (OA) is the most common type of degenerative arthritis and affects the entire joint, causing pain, joint inflammation, and cartilage damage. Various risk factors are implicated in causing OA, and in recent years, a lot of research and interest have been directed toward chronic low-grade inflammation in OA. Monocyte chemoattractant protein-1 (MCP-1; also called CCL2) acts through C-C chemokine receptor type 2 (CCR2) in monocytes and is a chemotactic factor of monocytes that plays an important role in the initiation of inflammation. The targeting of CCL2–CCR2 is being studied as part of various topics including the treatment of OA.

#### **Methods**

In this study, we evaluated the potential therapeutic effects the sCCR2 E3 gene may exert on OA. The effects of sCCR2 E3 were investigated in animal experiments consisting of intra-articular injection of sCCR2 E3 in a monosodium iodoacetate (MIA)-induced OA rat model. The effects after intra-articular injection of sCCR2 E3 (fusion protein encoding 20 amino acids of the E3 domain of the CCL2 receptor) in a monosodium iodoacetate-induced OA rat model were compared to those in rats treated with empty vector (mock treatment) and full-length sCCR2.

#### **Results**

Pain improved with expression of the sCCR2 gene. Improved bone resorption upon sCCR2 E3 gene activation was confirmed via bone analyses using micro-computed tomography. Histologic analyses showed that the sCCR2 E3 gene exerted protective effects against cartilage damage and anti-inflammatory effects on joints and the intestine.

#### Conclusions

These results show that sCCR2 E3 therapy is effective in reducing pain severity, inhibiting cartilage destruction, and suppressing intestinal damage and inflammation. Thus, sCCR2 E3 may be a potential therapy for OA.



### The potential role of SIRT1 in osteoarthritis pain treatment by blocking the nerve growth factors

Sang Yeob Lee¹, So Youn Park¹, Sung Won Lee¹, Won Tae Chung¹, Jun Young Park¹

¹ Division of Rheumatology, Internal medicine, Dong-A university hospital, Republic of Korea

#### Background

Background: Current treatment of osteoarthritis (OA) is variable, including compounds targeting nerve growth factor (NGF). In this study, we showed the blocking of NGF, BD-KRB2 and TAC1, by SIRT1 in OA synoviocytes in vivo and vitro and we showed the potential role of SIRT1 in OA pain treatment.

#### **Methods**

GEO DataSets were analyzed for OA pain gene. OA synoviocytes were isolated from synovium of OA knee patients. NGF, BDKRB2 and TAC1 expression was analyzed using immunohistochemistry, immunofluorescence, and immunoblot. IL-1 $\beta$ , IL-2, IL-15 expression was measured by ELISA assay. Experiments were also conducted in SIRT1-tg mice model.

#### **Results**

NGF, BDKRB2 and TAC1 was expressed in human OA synoviocytes and IL-1 $\beta$ , IL-2 and IL-15 had a synergic effect on the expression of NGF, BDKRB2 and TAC1 in human OA synoviocytes. But, SIRT1 had inhibitory role in expression of NGF, BDKRB2 and TAC1. Furthermore, SIRT1 inhibitory mechanism was associated with the expression of IL-1 $\beta$ , IL-2 and IL-15 in OA human synoviocytes. We also reproduced the SIRT1 inhibitory mechanisms on SIRT1-tg mice model.

#### Conclusions

SIRT1 had suppressed in pain signaling transmitters and had potential role in OA pain management.

#### Figure & Table




Figure. TAC1, BDKRB2 and nerve growth factor were expressed in synoviocyte from osteoarthritis patients, after administration of IL-2 and IL-1 $\beta$ .

#### **Keywords**

osteoarthritis



### Coenzyme Q10 encapsulated in micelles ameliorates osteoarthritis by inhibiting inflammatory cell death

#### Hyun Sik Na^{1,2,3}, Jin Seok Woo^{1,3}, Jeong Su Lee^{1,2,3}, In Gyu Um^{1,2,3}, Mi-La Cho^{1,2,3}, Sung-Hwan Park⁴

¹ The Rheumatism Research Center, Rheumatism Research Center, Catholic Research Institute of Medical Science, College of Medicine, The, Republic of Korea ² The Catholic University of Korea, Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Republic of Korea ³ Lab of Translational ImmunoMedicine, Lab of Translational ImmunoMedicine, Catholic Research Institute of Medical Science, College of Med, Republic of Korea ⁴ Devision of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Med, Seoul St. Mary's Hospital, Republic of Korea

#### Background

Osteoarthritis (OA) is the most common degenerative joint disease and is characterized by breakdown of joint cartilage. Coenzyme Q10 (CoQ10) exerts diverse biological effects on bone and cartilage; observational studies have suggested that CoQ10 may slow OA progression and inflammation. However, any effect of CoQ10 on OA remains unclear. Here, we investigated the therapeutic utility of CoQ10-micelles.

#### **Methods**

Six-week-old male Wistar rats were injected with monosodium iodoacetate (MIA) to induce OA. CoQ10-micelles were administered orally to MIA-induced OA rats; celecoxib served as the positive control. Pain, tissue destruction, and inflammation were measured. The expression levels of catabolic and inflammatory cell death markers were assayed in CoQ10-micelle-treated chondrocytes.

#### Results

Oral supplementation with CoQ10-micelles attenuated OA symptoms remarkably, including pain, tissue destruction, and inflammation. The expression levels of the inflammatory cytokines IL-1 $\beta$ , IL-6, and MMP-13, and of the inflammatory cell death markers RIP1, RIP3, and pMLKL in synovial tissues were significantly reduced by CoQ10-micelle supplementation, suggesting that CoQ10-micelles might attenuate the synovitis of OA. CoQ10-micelle addition to cultured OA chondrocytes reduced the expression levels of catabolic and inflammatory cell death markers.

#### Conclusions

CoQ10-micelles might usefully treat OA.

#### **Keywords**

Osteoarthritis, Inflammatory cell death, Coenzyme Q10 (CoQ10)



## Associations between body composition measurements of obesity and the radiographic progression of hand osteoarthritis: Data from the Dong-gu Study

#### Sung-Eun Choi¹, Dong-Jin Park¹, Ji-Hyoun Kang¹, Min-Ho Shin², Shin-Seok Lee¹

¹ Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Republic of Korea ² Department of Preventive Medicine, Chonnam National University Medical School, Republic of Korea

## Background

Previous studies have found that obesity is a risk factor for hand osteoarthritis (OA), but most have been cross-sectional studies and thus causality is uncertain. Longitudinal studies are instead needed to explore the association between obesity-related characteristics, including fat deposition/distribution and hand OA. The present study examined the association between changes in body composition measurements and the radiographic progression of hand OA in a longitudinal cohort.

#### **Methods**

In the Dong-gu Study population, 1,277 patients had hand radiographs at baseline and at the 4-year follow-up. X-rays of the hand joints were scored using a semi-quantitative grading method. Body composition was simultaneously measured in a bioelectrical impedance analysis using an InBody 520 analyzer. The relationship between changes in body composition measurements and the radiographic progression of hand OA was assessed in a multiple linear regression analysis.

#### **Results**

Total hand joint scores increased from  $16.3 \pm 5.74$  at baseline to  $18.8 \pm 8.11$  at year 4 (P < 0.001). Changes of body mass index, hip circumference (HC), waist-to-hip circumference (WHC), and fat mass were significantly associated with changes in the total hand joint scores (P = 0.012, P < 0.001, P = 0.017, P = 0.008, respectively). HC and WHC were significantly associated with radiographic progression of the hand joints, after adjusting for age, sex, physical activity, education status, smoking, alcohol consumption, hypertension, diabetes mellitus, dyslipidemia, chronic pulmonary disease, chronic liver disease, cardiovascular disease, cerebrovascular disease, and malignancy (P < 0.001, P = 0.001, respectively).

#### Conclusions

Changes in fat distribution were significantly associated with the radiographic progression of hand OA over 4 years, suggesting a role for the systemic effect of adipose tissue.

#### **Keywords**

hand osteoarthritis, obesity, radiographic progression



# Association of serum uric acid level with bone mineral density in peri-menopausal and postmenopausal Korean women: A single-center study of 3566 cases

#### Seongmin Kang¹ Seung Won Choi¹, Su Jin Choi¹, Doo-Ho Lim¹

¹ Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Republic of Korea

#### Background

Uric acid (UA) may be related to bone health through its role as either an anti-oxidant or pro-oxidant properties, or through its effect on vitamin D-parathyroid hormone axis. Although the association of serum UA level with bone mineral density (BMD) has been investigated in previous studies, the results are conflicting. This study investigated the influence of serum UA on BMD among peri-menopausal and postmenopausal Korean women.

#### **Methods**

We evaluated 3566 women without renal disease (estimated glomerular filtration rate>60mL/min/1.73m2), aged 50-80 years, who voluntarily underwent laboratory tests and BMD measurement by dual-energy X-ray absorptiometry as a part of general health examination from May 2014 to September 2019. The participants were stratified into quartiles according to their serum UA levels. Between-group comparisons were performed using Pearson's chi-square test for categorical variables, and the one-way analysis of variance for numerical variables, as appropriate. Univariable and multivariable analyses were performed using a linear regression model to analyze the association between Serum UA and BMD.

#### **Results**

The mean age of individuals was  $56.9 \pm 5.8$  years. The BMD at all sites was significantly higher in the group of women with high serum UA and increased continuously across quartiles of serum UA (Table). In simple linear regression analysis, significant R-square (R2) values were obtained at all skeletal sites (lumbar spine, femur neck and total hip) (p<0.001). Furthermore, serum UA level showed independent positive associations with BMD at all site [lumbar spine BMD (unstandardized coefficients (B)=0.010, p<0.001), femoral neck BMD (B=0.004, p=0.016) and total hip BMD (B=0.007, p<0.001)], after adjustment for confounding factors including age, body mass index, smoking, drinking, diabetes and alkaline phosphatase.

#### Conclusions

Our results suggest that raised serum UA levels are associated with higher BMD in peri-menopausal and postmenopausal Korean women, suggesting its protective role in bone metabolism.

#### Figure & Table

variables	Total	Uric acid						
		quartile 1	quartile 2	quartile 3	quartile 4 > 5.10 mg/dl	p-value		
	n = 3566	< 3.80 mg/dl	3.91 ~ 4.30 mg/dl	4.31 ~ 5.10 mg/dl				
		(n = 867)	(n = 929)	(n = 945)	(n = 825)			
BMD (g/cm ² )								
L1 spine	0.823 ± 0.129	0.814 ± 0.129	0.818 ± 0.131	0.827 ± 0.128	0.833 ± 0.126	< 0.00		
L2 spine	0.879 ± 0.141	0.867 ± 0.140	0.873 ± 0.143	0.884 ± 0.140	0.894 ± 0.140	< 0.00		
L3 spine	0.932 ± 0.151	0.914 ± 0.147	0.924 ± 0.153	0.941 ± 0.151	0.950 ± 0.149	< 0.00		
L4 spine	0.959 ± 0.161	0.941 ± 0.157	0.947 ± 0.160	0.965 ± 0.159	0.985 ± 0.164	< 0.00		
L spine, total	0.903 ± 0.140	0.888 ± 0.138	0.895 ± 0.141	0.909 ± 0.139	0.921 ± 0.139	< 0.00		
Hip neck	0.689 ± 0.104	0.682 ± 0.106	0.685 ± 0.103	0.692 ± 0.103	0.700 ± 0.101	0.00		
Hip trochanter	0.611 ± 0.092	0.600 ± 0.093	0.607 ± 0.089	0.615 ± 0.092	0.624 ± 0.092	< 0.00		
Hip inter-trochanter	1.016 ± 0.139	0.999 ± 0.140	1.009 ± 0.138	1.020 ± 0.141	1.036 ± 0.136	< 0.00		
Hip, total	0.836 ± 0.113	0.822 ± 0.114	0.832 ± 0.111	0.840 ± 0.114	0.852 ± 0.110	< 0.00		

Table. Bone mineral density according to the quartiles of serum uric acid levels.

#### **Keywords**

Uric acid, Bone mineral density, Osteoporosis



# The relationship between the osteoporosis and cortial index of the mandibular bone in rheumatoid arthritis

#### <u>Gürkan Iden</u>¹

¹ orthopedics and traumatology, R. Yaşar Eryılmaz Doğubeyazıt Devlet Hastanesi, Turkey

#### Background

Osteoporosis is a common finding in rheumatic diseases. The aim of this study is to determine the detectability of systemic osteoporosis in rheumatoid arthritis using mandibular radiography and indices.

#### **Methods**

In our study, 93 patients with rheumatoid arthritis whose radiographs were taken were evaluated. Data consists of DXA, mandibular radiography and rheumatologic status, body mass index (BMI) and demographic values. The morphology of the mandibular inferior cortex (MCI) was determined by two observers and classified according to the Klemetti scale (1) (G1-G2-G3). Student's t test, ANOVA and Kappa statistics were applied. In addition, sensitivity, specificity and positive and negative predictive values of MCI were determined in the detection of systemic bone loss.

#### **Results**

93 rheumatoid arthritis patients were included in the study. There was no significant difference between the groups in terms of age and gender. Considering the lumbar spine values, 26% of the patients were found to have osteoporosis (G3), 43% to have osteopenia (G2) and 31% to be healthy (G1). Considering the femoral head values, 17% of the patients were found to have osteoporosis (G3), 28% to have osteopenia (G2) and 55% to be healthy (G1). A strong agreement (kappa=0.677) was found between the 2 observers in the evaluation of MCI on mandibular radiography. The mean sensitivity, specificity, and positive and negative predictive values were 68.9, 83.8, 63.9, and 82.1 for the lumbar spine, and 47.2, 83.1, 79.2,

#### Conclusions

As a result of this study, it has been seen that mandibular radiography and MCI can be used as an auxiliary diagnostic tool in osteoporosis developing in rheumatoid arthritis.

#### **Keywords**

Rheumatoid arthritis, Osteoporosis, Cortial index

# International Symposium

Vasculitis Session

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



# Somatic mutations in rheumatologic diseases: VEXAS syndrome and beyond

Peter C. Grayson Nat'l Institutes of Health, USA

Discovery of the VEXAS syndrome demonstrates that somatic mutations in blood can cause adult-onset, complex inflammatory diseases. Unlike germline mutations, somatic mutations occur throughout the lifespan, are restricted to specific tissue types, and may play a causal role in non-heritable rheumatologic diseases, especially conditions that start in later life. Improvements in sequencing technology has enabled researchers and clinicians to detect somatic mutations in various tissue types, especially blood. Alterations in the genome are dynamic events that can occur throughout life. Understanding the relationships between cell-specific acquired mutations and inflammation is likely to yield key insights into causal factors that underlie many rheumatologic diseases. The objective of this lecture is to detail how somatic mutations are likely to be relevant to clinicians who care for patients with rheumatologic diseases, including patients with the VEXAS syndrome. After the talk, participants should be able to identify the important clinical features of VEXAS syndrome, understand the pathogenetic mechanism of VEXAS, and recognize that somatic mutations play a role in an expanding list of non-malignant diseases.



## **Recent basic studies in ANCA-associated vasculitis**

### Akihiro Ishizu

Hokkaido Univ., Japan

ANCA-associated vasculitis (AAV) is a vasculitis that affects systemic small vessels especially in the kidneys and lungs, accompanied by the presence of ANCA in the serum. Similar to other autoimmune diseases, AAV develops in patients with a predisposing genetic background who have been exposed to causative environmental factors. Several genes such as HLA have been listed as susceptible or resistant genes, and it has been shown that environmental factors, including infectious agents and drugs, are involved in the development of this disease. The pathogenic mechanisms includes 1) priming of neutrophils, 2) ANCA binding to the primed neutrophils and an excessive activation of neutrophils with neutrophil extracellular trap (NET) release , 3) vascular endothelial cell injury due to NETs, and 4) disordered NET regulation and ANCA production. Recent studies have suggested the contribution of pro-inflammatory cytokines and the complements to the priming of neutrophils. Although NETs are essential elements in the innate immunity, decrease in serum activity of DNase I (physiological NET degradation factor), disorder of the semaphorin 4D and plexin B2 system (physiological NET regulation system), and acquired resistance to DNase I have been demonstrated in AAV patients. Therefore, a vicious cycle of NETs in AAV, some other important discoveries have been made in the last few years. Incorporating these new insights into our understanding of the pathogenesis of AAV is needed to fully understand and ultimately overcome this disease.



# Systemic vasculitis in Korea

Chan-Bum Choi

Hanyang Univ., Korea

Systemic vasculitis is a group of chronic systemic autoimmune diseases mainly affecting blood vessels. It can present with diverse manifestation from constitutional symptoms to specific symptoms according to organ involvements. There have been significant advances in classification and management of systemic vasculitis. Clinical studies in Korea have also shown significant growth in recent years.

First report of systemic vasculitis was a case report of granulomatosis with polyangiitis by an ophthalmologist in 1959 in Journal of Korean Ophthalmologist Society. Observational study of 18 patients with microscopic polyangiitis was published in Journal of Korean Medical Science in 2009. Since then, number of publications in peer-reviewed journal is in steady increase and 137 studies were listed in National Library of Medicine in 2021.

Many studies involved discovery and validation of biomarkers for disease activity assessment and prognosis prediction from a single center cohort of Antineutrophil cytoplasmic autoantibodies (ANCA)-associated vasculitis (AAV), mainly form the Severance Hospital ANCA-associated VasculitidEs (SHAVE) cohort. As AAV is a rare disease, studies using national claims database can have significant value and several studies have been conducted.

Korean Vasculitis Society of Korean College of Rheumatology have established a cohort of systemic vasculitis, mainly AAV, and have organized collection of clinical characteristics, management, and outcomes of Korean systemic vasculitis patients with blood samples with support from the Korean Disease Control and Prevention Agency. It will contribute to advancement of systemic vasculitis research in Korea.

# **Free Paper Session**

Rheumatoid Arthritis Clinical Research

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea





<u>KCR 2022</u>

May 19(Thu) - 21(Sat), 2022

## Comparative effectiveness of janus kinase inhibitors and biologic disease-modifying antirheumatic drugs in Korean patients with rheumatoid arthritis; an interim analysis of the real-world study

<u>Soo-Kyung Cho</u>^{1,2}, Hyoungyoung Kim^{1,2}, Yeo-Jin Song^{1,2}, Hye Won Kim², Eunwoo Nam², Shin-Seok Lee³, Jae Hoon Kim⁴, Seung-Ki Kwok⁵, Yeon Ah Lee⁶, Sung Hae Chang⁷, Hyun-Sook Kim⁸, Bo Young Yoon⁹, Min-Chan Park¹⁰, Yong-Gil Kim¹¹, Hae-Rim Kim¹², Hye soon Lee¹³, Jisoo Lee¹⁴, Hyoun-Ah Kim¹⁵, Sung-Hoon Park¹⁶, Jeongim Choi¹⁷, Wan-sik Uhm¹⁸, Yoon-Kyoung Sung^{1,2}

¹ Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea ²Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea 3 Department of rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea ⁴Department of rheumatology, Korea University College of Medicine, Republic of Korea ⁵Department of rheumatology, Seoul Saint Mary's Hospital, College of Medicine, The Catholic University of Korea, Republic of Korea ⁶ Department of rheumatology, School of Medicine, Kyung Hee University, Seoul, Republic of Korea ⁷ Department of rheumatology, Soonchunhyang University College of Medicine, Cheonan, Republic of Korea ⁸ Department of rheumatology, Soonchunhyang University Seoul Hospital, Seoul, Republic of Korea ⁹ Department of rheumatology, Inje University Ilsan Paik Hospital, Goyang, Republic of Korea ¹⁰ Department of rheumatology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea ¹¹ Department of rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea ¹² Department of rheumatology, Konkuk University School of Medicine, Seoul, Republic of Korea ¹³ Department of rheumatology, Hanyang University Guri Hospital, Guri, Republic of Korea ¹⁴ Department of rheumatology, Ewha Womans University College of Medicine, Seoul, Republic of Korea ¹⁵ Department of rheumatology, Ajou University School of Medicine, Suwon, Republic of Korea ¹⁶ Department of rheumatology, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea ¹⁷ Department of rheumatology, Busan Saint Mary's Hospital, Busan, Republic of Korea ¹⁸ Department of rheumatology, Uhm's Rheumatism Clinic, Seoul, Republic of Korea

#### Background

To evaluate the effectiveness and safety of Janus kinase inhibitors (JAKi) compared to biologic disease modifying anti-rheumatic drugs (bDMARDs) in Korean patients with rheumatoid arthritis (RA) who had an inadequate response to conventional synthetic DMARDs in a real-world setting.

#### Methods

This study is a prospective, real-world, observational, multicenter, phase 4 study, enrolled RA patients when initiating JAKi or bDMARDs. Treatment decisions were made by a shared decision-making process between RA patients and rheumatologists. An interim analysis was conducted. The primary endpoint was the proportion of achieving low disease activity (LDA) based on disease activity score (DAS) 28- erythroid sedimentation rate (ESR) at 24 weeks (<3.2) and other clinical outcomes and safety during 24 weeks were secondary outcomes. To adjust confounders for effectiveness outcomes, multivariable analyses were performed.

#### Results

Among the total of 407 patients enrolled from 17 institutions between Apr. 2020 and Feb. 2022, 223 patients (133 JAKi and 90 bDMARDs) were included in this analysis. After 24 weeks of treatment, 45.9% of JAKi users and 48.9% of bDMARDs users achieved LDA, respectively. Remission rates by DAS28-ESR were also comparable between JAKi users and bDMARDs users (26.3% and 30.0%, respectively). In the multivariable analyses, the rate of achieving LDA [odds ratio (OR) 0.75; 95% confidence interval (CI) 0.42 to 1.34] or remission [OR 0.69; 95% CI, 0.36 to 1.35] of JAKi users were comparable with those who used bDMARDs. There were clinically meaningful improvements for quality of life by EQ-5D or HAQ-DI in both groups.

#### Conclusions

Our interim finding of this ongoing real-world, pragmatic, multicenter, study revealed that JAKi has similar effectiveness compared to bDMARDs.

#### **Keywords**

Janus kinase inhibitor, effectiveness, rheumatoid arthritis



## Comparative effectiveness and safety profiles of baricitinib and tofacitinib in rheumatoid arthritis: A real-world, single center study

<u>Bong-Woo Lee</u>¹, Youngjae Park², Seung-Ki Kwok², Ji Hyeon Ju², Wan-Uk Kim², Sung-Hwan Park², Jennifer Lee²

¹ Division of Rheumatology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea ² Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

#### Background

In the midst of recent controversy over adverse events of janus kinase inhibitor (JAKi), we investigated the occurrence of adverse events in RA patients who were prescribed tofacitinib and baricitinib at Seoul St. Mary's Hospital, a single center, and additionally tried to compare effectiveness and retention rate at 12 months after starting the drug.

#### **Methods**

This retrospective study was conducted with patients with seropositive RA who started tofacitinib or baricitinib treatment between 2015 and 2020 at Seoul St. Mary's Hospital. Total 240 patients with RA, who were treated with tofacitinib (n = 136) or baricitinib (n = 104), were enrolled. We evaluated and compared the efficacy and safety between tofacitinib and baricitinib.

#### Results

The tofacitinib-treated patients showed a significantly improved DAS28-ESR from 5.19 (0.61) at baseline to 2.73 (0.95) at 6 months, 2.47 (0.78) at 12 months. The baricitinib-treated patients also showed a significantly improved DAS28-ESR from 5.09 (0.69) at baseline to 2.58 (0.94) at 6 months, 2.38 (0.75) at 12 months. The retention rate of tofacitinib was 88.2% at 12 months and that of baricitinib at 12 months was 83.7%. (log rank test: p value = 0.294) On adverse events, MACE occurrence was not observed in both groups, and VTE/PTE was observed in 2 cases only in the tofacitinib group. There was no significant difference in the incidence of herpes zoster, serious infection and malignancy between the two drugs. But, in the case of dyslipidemia, the incidence was higher in baricitinib. [IRR: 2.79 (1.81–4.32); p <0.001]

#### **Conclusions**

Our data shows that tofacitinib and baricitinib are being used in real world as effective RA therapeutic agents, considering high proportion of LDA or remission achievement and retention rate at 12 months. On adverse events, the incidence of dyslipidemia was higher in baricitinib. The occurrence of MACE was not observed in both groups.

#### **Figure & Table**

	Baricitinib (N=104)			Tofacitinib (N=136)			
	Event (%)	IR (95% CI) 100 patient -years	IRR (95%CI)	Event (%)	IR (95% CI) 100 patient -years	IRR (95%CI)	p-value
Herpes zoster	9 (8.7%)	5.51 (2.69-10.1)	1.23 (0.56-2.69)	20 (14.7%)	4.49 (2.82-6.81)	1 (ref)	0.611
Dyslipidemia	41 (39.4%)	25.08 (18.24-33.7)	2.79 (1.81-4.32)	40 (29.4%)	8.98 (6.50-12.11)	1 (ref)	< 0.001
Malignancy	1 (1%)	0.61 (0.03-3.02)	0.68 (0.08-6.09)	4 (2.9%)	0.90(0.29-2.17)	1 (ref)	0.7297
Serious infection	1 (1%)	0.61 (0.03-3.02)	0.34 (0.04-2.72)	8 (5.9%)	1.80 (0.83-3.41)	1 (ref)	0.2867

Table. Incidence Rates and Incidence Rate Ratios of Adverse Events by drugs (baricitinib and tofacitinib)

#### **Keywords**

Rheumatoid arthritis, Janus kinase inhibitor



# Comparative efficacy and safety of IL-6/JAK/STAT pathway inhibitors in rheumatoid arthritis: systematic review and network meta-analysis

Rudra Goswami¹, Pallavi Vij², Arindam Banerjee³

¹ Rheumatology, AIIMS, New Delhi, Assistant Professor, India ² Rheumatology, AIIMS, New Delhi, Senior Resident, India ³ Mathematics, IIT, Kharagpur, Assistant Professor, India

#### Background

Rheumatoid arthritis (RA) is one of the most common chronic inflammatory diseases. Treatment for RA has diversified in recent years with introduction of multiple small molecule inhibitor of the interleukin-6 (IL-6)/JAK/STAT pathway. No systematic reviews are available on these drugs. We conducted this systematic review and network-meta-analysis to assess the comparative efficacy and safety of IL-6/JAK/STAT pathway inhibitors (tocilizumb, tofacitinib, baricitinib, filgotinib and upadacitinib) in RA.

#### **Methods**

PubMed Database was searched to identify randomised controlled trials on RA and any of the above drugs confined to a predefined inclusion and exclusion criteria. A systematic review and network-meta-analysis was performed on the included studies on efficacy (ACR20 response) and safety signals (infections, major cardiac adverse events (MACE) and malignancy).

#### **Results**

Overall, 43 trials were included (five in naïve patients (n=2342), 23 in disease modifying drug inadequate-responders (DMARD-IR, n=8734) and seven in biologics inadequate-responders (BIR, n=1878).

Among naïve patients, tocilizumab, tofacitinib, baricitinib and upadacitinib monotherapy data were available, and all were superior to methotrexate. Data on all the drugs were available for DMARD-IR patients in combination with methotrexate, all of which were superior to methotrexate but regarding monotherapy tocilizumab (Odd's Rratio (OR): 2.52, 95% confidence interval (CI): 0.83-7.62) were similar to methotrexate. Data on BIR were available for tocilizumab, tofacitinib, baricitinib and upadacitinib, all of which were superior to control.

Serious infections were higher in tocilizumab group (OR: 1.73, 95% CI: 1.01-2.94); herpes zoster infections were higher with baricitinib (OR: 3.58, 95% CI: 1.2-10.7) and tofacitinib (OR: 3.05, 95% CI: 2.28-4.09). MACES were similar among all. Rates of malignancy were higher with tofacitinib (OR: 2.94, 95% CI: 1.56-5.53).

#### Conclusions

In DMARD-IR population, combination with methotrexate showed higher effect sizes. No increased risk of MACE was observed for any of the drugs. An increased risk of malignancy was seen with tofacitinib.

#### **Keywords**

Rheumatoid arthritis, IL-6/JAK/STAT pathway, Network meta analysis



### Impact of early age at menopause on disease outcomes in postmenopausal women with rheumatoid arthritis: Results from a large observational cohort of Korean patients with rheumatoid arthritis

Eun Hye Park¹, Sang Tae Choi¹, Jung Soo Song¹, Eun Ha Kang², Yun Jong Lee², You-Jung Ha²

¹ Division of Rheumatology, Department of Internal Medicine, Chung-Ang University College of Medicine, Republic of Korea ² Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Republic of Korea

#### Background

To assess the differences in clinical outcomes between RA patients with early menopause (EM) (age at menopause <45 years) and usual menopause (UM) (age at menopause ≥45 years), and identify potential impact of EM on longitudinal changes in RA activity and patient-reported outcomes (PROs) during follow-up.

#### **Methods**

A total of 2878 postmenopausal women with RA were included from the Korean Observational Study Network for Arthritis. Each patient was examined at baseline and for five consecutive years using the simplified disease activity index (SDAI), health assessment questionnaire-disability index (HAQ-DI), and other PROs. Among patients with a baseline SDAI >11, generalized estimating equation (GEE) analyses were performed to evaluate the impact of EM on longitudinal changes in RA activity and PROs during follow-up.

#### Results

The EM group (N=437) was younger than the UM group (N=2,441) [58.0±9.5 vs. 60.8±8.0 years, p<0.001], but RA duration was similar between the two groups. The EM group had higher education level and was more likely to be seronegative at enrollment. Moreover, the EM group demonstrated higher disease activity [SDAI 15.4±11.7 vs. 13.9±10.0, p=0.011] and patient-reported visual analogue scale (VAS) scores for global assessment, fatigue, and sleep disturbance (all p<0.05), and worse EQ-5D-VAS [59.9±22.2 vs. 63.0±19.5, p=0.006] at baseline. The rate of previous fracture and neoplastic disease, especially uterine/cervical neoplasm, was higher while that of hypertension was lower among the EM group. The GEE model revealed that EM significantly influenced the rate of SDAI change ( $\beta$ =1.265, p=0.004), after adjusting for age, RA duration, biologic use, and SDAI at baseline. The EM group was also significant-Iy associated with increase in HAQ-DI ( $\beta$ =0.088, p=0.003), and decrease in EQ-5D utility value (B=-0.031, p=0.016) during 5-year follow-up period.

#### Conclusions

RA patients with EM demonstrate higher disease activity and poorer health-related quality of life. EM significantly affects longitudinal changes in disease activity and PROs in RA.



## The implication of persistent pain in patients with rheumatoid arthritis albeit in DAS28-remission: Data from the KOBIO registry

#### Hyoun-Ah Kim¹, So Young Park², Kichul Shin²

¹ Department of Rheumatology, Ajou University School of Medicine, Republic of Korea ² Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Republic of Korea

#### Background

Patient-reported symptoms such as pain and fatigue may persist despite remission in rheumatoid arthritis (RA). We thereby assessed the prevalence of pain in patients after achieving remission according to the Disease Activity Score of 28 joints (DAS28)-erythrocyte sedimentation rate (ESR), and analyzed the demographic and clinical characteristics of these patients.

#### **Methods**

Data from 1891 patients with RA registered in the KOBIO (from Dec 2012 to Sep 2020) were obtained. DAS28-remission was defined as DAS28-ESR < 2.6. Pain Visual Analogue Scale (VAS) was evaluated. The intensity of pain was classified as severe (VAS  $\geq$  7 out of 10), moderate (VAS  $\geq$  4), and mild (VAS < 4). The association between baseline clinical characteristics and pain VAS after 1-year treatment with biologics or Jak inhibitors (JAKis) were assessed using a multivariate logistic regression model.

#### **Results**

Our analysis showed that 52.6% of the patients complained of severe pain at the time of starting biologics or Janus kinase inhibitors (JAKis). Despite 36.0% (n = 680) of these patients achieving remission after the use of biologics or JAKis at their 1-year follow-up, 21.5% (n = 146) had moderate to severe pain, lower frequency of married status, higher frequency of feet erosions, and comorbidities such as endocrine, renal, and neurological disorders than patients with a milder degree of pain. In the multiple regression analysis, higher values in patient global assessment or routine assessment of patient index data 3, and higher ESR were independently associated with moderate to severe pain in patients with RA despite achieving remission. In contrast, patients having renal disorders or using abatacept had a lesser likelihood to eliciting moderate to severe pain.

#### Conclusions

Displeasing pain is yet a lingering problem in a good deal of patients in clinical remission. New treatment guidelines need to incorporate strategies to better alleviate pain in patients with RA.



### Increased risk of dementia in patients with rheumatoid arthritis: A nationwide population-based cohort study

<u>Yeonghee Eun</u>¹, Kyungdo Han², Seonyoung Kang³, Seulkee Lee³, Hoon-Suk Cha³, Eun-Mi Koh³, Jaejoon Lee³, Hyungjin Kim^{3,4}

¹ Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Republic of Korea
 ² Department of Statistics and Actuarial Science, Soongsil University, Republic of Korea
 ³ Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Republic of Korea
 ⁴ Department of Medical Humanities, Samsung Medical Center, Sungkyunkwan University School of Medicine, Republic of Korea

#### **Methods**

Among patients diagnosed with RA between 2010 and 2017, patients who had undergone a national health examination within two years prior to RA diagnosis were included in the study (n = 138,592). Control group included age- and sex-matched non-RA controls who received a health check-up at the same time as RA patients (n = 692,960). The primary outcome of the study was incident dementia, which was defined by an ICD-10 code and the use of dementia medications. Kaplan-Meier curves and Cox proportional hazards regression analysis were used for the analysis.

#### **Results**

Mean follow-up duration of the study was  $4.7 \pm 2.2$  years. RA patients had a 1.2 times higher risk of dementia than controls (adjusted hazard ratio [aHR] 1.19, 95% CI 1.16– 1.23). In patients with RA, the aHR for Alzheimer's disease (AD) was 1.21 (95% CI 1.67-1.25) and the aHR for vascular dementia (VD) was 1.10 (95% CI 0.99-1.21). In a stratified analysis according to age, gender, lifestyle factors and comorbidities, the association between RA and dementia was consistently found.

#### Conclusions

In a large nationwide population-based cohort, RA was associated with an increased risk of incident dementia. Appropriate evaluation of dementia is required when cognitive impairment occurs in RA patients. Further studies are warranted to identify mechanisms of increased risk of dementia in RA patients.



## Retention rate and safety of biologics or targeted synthetic disease modifying anti-rheumatic drugs in patients with rheumatoid arthritis associated with interstitial lung disease: Results from the KOBIO registry

#### Sun-Kyung Lee¹, Kichul Shin², Hyoun-ah Kim³

¹ Department of Mathematics, College of Natural Sciences, Hanyang University, Republic of Korea ² Division of Rheumatology, Seoul Metropolitan Government-Seoul National University Boramae Medical Center, Republic of Korea ³ Department of Rheumatology, Ajou University School of Medicine, Republic of Korea

#### Background

The aim was to evaluate long-term drug retention and safety of biologics or targeted synthetic disease modifying anti-rheumatic drugs (tsDMARDs) and to identify predictors of adverse events (AE) to biologics or tsDMARDs in patients with rheumatoid arthritis (RA) associated with interstitial lung disease (ILD) enrolled in the Korean College of Rheumatology Biologics (KOBIO) registry.

#### **Methods**

Patients included adults with RA (n=2266) who received biologics or tsDMARDs between December 2012 and December 2021. Of 2266 patients, 169 had ILD. A propensity score-matching (PSM) analysis was conducted on data from patients with RA who had ILD or not. We compared the retention rate of biologics or tsDMARDs therapy between the two groups, and evaluated AE and its predictors in RA with ILD.

#### Results

PSM was effective in matching 159 RA with ILD and 477 RA without ILD. Five-year retention rates were 44.0 % for RA with ILD and 52.4% for RA without ILD (p=0.04). Overall, 31.5% (with ILD) and 24.3% (without ILD) of patients discontinued biologic or tsDMARDs therapy, and 24.5% (with ILD) and 23.3% (without ILD) changed biologics or tsDMARDs therapy. The cause of drug withdrawal was AE (45.2% in RA with ILD and 30.3% in RA without ILD, p<0.001), and inefficacy (35.5% in RA with ILD and 41.1% in RA without ILD, p=0.498). Among AE, infections were more common in RA with ILD than those in RA without ILD (p<0.001). Age and current smoking were associated with AE in RA with ILD treated with biologics or tsDMARDs.

#### Conclusions

RA patients with ILD more likely discontinued biologics or tsDMARDs than those without ILD. Occurrence of AE during biologic or tsDMARD treatment was associated with age and current smoking of patients with ILD.

#### **Keywords**

Rheumatoid arthritis, interstitial lung disease, biologic agents



## Tumor Necrosis Factor (TNF) inhibitors does not accelerate the progression of RA-ILD: Results from the KORAIL cohort

Yeon-Ah Lee¹, <u>Sang Wan Chung</u>¹, Sujin Jeong¹, Ji Sung Lee², Jeong Seok Lee³, Chan Ho Park⁴, Min Uk Kim⁵, You-Jung Ha⁶, Eun Ha Kang⁶, Sung Hae Chang⁷, Yongbeom Park⁸, Ji Won Kim⁹, Jung-Yoon Choe⁹, Eun Young Lee¹⁰

¹ Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Hospital, Republic of Korea
 ² Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center, Department of Medicine, Republic of Korea
 ³ GENOME INSIGHT Inc., GENOME INSIGHT Inc., Republic of Korea
 ⁴ Radiology, Soonchunhyang University College of Medicine, Republic of Korea
 ⁵ Radiology, SMG-SNU Boramae Medical Center, Republic of Korea
 ⁶ Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Republic of Korea

⁸ Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Republic of Korea

⁹ Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu College of Medicine, Republic of Korea ¹⁰ Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Republic of Korea

Background

There has been much controversy over the role of TNF-inhibitors and non-TNF biologics (abatacept, tocilizumab, and rituximab) on RA-ILD. The aim of this study was to compare the influence of TNF-inhibitors and non-TNF biologics on the progression of pre-existing ILD in patients with RA.

#### **Methods**

The Korean Rheumatoid Arthritis ILD (KORAIL) is the multi-center prospective cohort and aims to investigate the effect and safety of therapeutic options for RA-ILD. RA-ILD was diagnosed based on either 1987 or 2020 ACR criteria and by HRCT. We performed PFT, 6 minutes walking test, semi-quantitative scoring of HRCT and DAS28 at baseline and annually up to 36 months. For the inclusion in the present study, RA-ILD patients had to be initiated with a specific type of biologics within the 4 weeks of baseline chest HRCT and maintained at least 24 weeks.

#### Results

Patients who received TNF inhibitors (n=20), non-TNF biologics (n=45) and csDMARD only (n=146) were identified. Most of the patients had UIP pattern and early stage of ILD with CT extent less than 10% (103 patients). Generally, there were no significant differences in annual change of lung physiology and CT scoring between RA patients receiving TNF inhibitors and those receiving non-TNF biologics or csDMARD only. However, the change of DLCO (%) over the 3 years was relatively preserved in TNF inhibitor group (0.43  $\pm$  1.67) as compared with non-TNF biologics group (-1.96  $\pm$  2.72, p=0.53) or with csDMARDs group (-1.15  $\pm$  2.34, p=0.04). The change of total CT score for 3 years was less progressed in TNF inhibitor group when compared with csDMARD group (-0.25 vs 1.64, p=0.04).

#### Conclusions

The progression of RA-ILD does not seem to be increased following treatment with TNF inhibitors compared with non-TNF biologics and csDMARDs. TNF inhibition may provide a relatively safe option for early RA-ILD.

#### **Keywords**

RA-ILD, TNF-inhibitors, non-TNF biologics

# Symposium

Medical Humanities: Work Ethics and Labor Relation in the COVID-19 Era



# The ethics of hospital human resource development during the pandemic: Ethical principles

Ilhak Lee

Yonsei Univ., Korea

Ethical HRM is essential to maintain HCW's vitality and professionalism² throughout the crisis such as COVID-19 pandemics. To strengthen the institutional and professional identity and improve the quality of care, it is essential to increase the satisfaction of healthcare workers(HCW) and to maintain their loyalty.

The continuing COVID-19 pandemic necessiates the re-thinking every aspects of healthcare management. As for healthcare worker management, following tasks were given; (1)educating HCW to prepare for caring of the COVID-19 patients while protecting themselves from being infected, (2)allocating new work burdens and risks among the HCWs, (3)preparing fair rewards for the extra-works and risks, (4)maintaining the trust of the HCWs to the leadership, and (5)engaging the HCW in the practice of social responsibilities of healthcare institutes. To respond these tasks, it is necessary to affirm the role and priciples of leadership of HCW management.

The presentation will start with the review of the HCW's experiences of COVID-19 pandemic with the purpose of grasping the issues of human resource management (HRM) during the pandemics. The Korean HCW's experiences of COVID-19 can be summarised in a positive and negative way. The literatures show that the negative experiences such as fear, anxiety, depression, physical and mental exhaustion, loss of resilience, and losses of connection from the loved ones are common experiences while the positive experiences such as re-affirmation of professionalism and social responsibilities are also reported. These negative experiences may be explained by insufficient infra-structure of Korean health care delivery system., rapid progress of the pandemics, limited knowledge resources, and fear of the new infectious disease. These experiences are found among the medical trainees such as residents and fellows as well as nursing professionals. The experiences of abandonment by the institutes called institutional betrayal¹ can lead to the moral distress and injury of HCWs.

The second part of the presentation will sketch the ethical issues of HRM during COVID-19 pandemics: exhaustion and recovery, protecting HCWs by providing PPE and rewarding, dealing the conflics while allocating the burden of care, requirement of vaccinations and other counter measures on HCWs.

The final part of the presentation will explore the role of ethical reasoning and related ethical principles that will help HRM leaders during COVID-19 pandemics. The ethical principle of autonomy, beneficence, and fairness are standards of ethical reasoning of protecting HCW's personal rights and allocating works.

- 1. Brewer KC. Institutional betrayal in nursing: A concept analysis. Nurs Ethics 2021; 28: 1081–1089.
- 2. Pololi LH, Vasiliou V, Bloom-Feshbach K. Midcareer Medical School Research Faculty Perspectives on Vitality and Professionalism During the COVID-19 Pandemic. Jama Netw Open 2021; 4: e2120642.



Journal of Rheumatic Diseases Vol. 29, Suppl. 1, May, 2022

# Labor issues in the COVID-19 situation: Cases and alternatives

Dong Wook Yun

Law Firm Seo-Hee, Korea

COVID-19 caused new labor law problems in untact technology and the 4th industrial revolution.

Corporate personnel and labor managers were worried about whether they could cut the salaries of workers infected with COVID-19 and whether they could give them a week of paid leave.

Changes in the way of working and personnel and labor management before and after the outbreak of COVID-19 are inevitable.

Based on the current laws and the Ministry of Employment and Labor's guidelines for responding to workplaces, labor issues in the COVID-19 situation will be examined focusing on cases and alternatives.

In particular, hospitals and clinics should consider the method of disciplining expected legal issues such as calculating working hours, managing absenteeism, evaluating performance, protecting worker privacy, and working accidents while working from home.

In addition, it is also a question to consider whether it is necessary to change the direction of labor management that guarantees workers a work and life balance that pursues a balanced life.

# KCR 2022

42nd Korean College of Rheumatology Annual Scientific Meeting and the 16th International Symposium



# May 21(Sat)

# Breakfast Symposium IV Yuhan

Valuable Options for Treatment Rheumatic Disease



# **Biosimilar: Past, present and future**

Seung-Jae Hong

Kyung Hee Univ., Korea

In the 2000s, biologics began to be used in the treatment of rheumatic diseases.

From the beginning of the use of biological agents, problems such as an increase in the economic burden of patient treatment, a decrease in access to treatment, and the high cost and complexity of product development began to arise.

After 2010, as the patent for biologics was terminated, conditions were created for the release of biosimilars, and biosimilars began to be used in the treatment of many patients with drivers such as Technological Innovation and Regulatory Initiatives.

Currently, several biosimilars are approved and released in many countrys such as Korea, Europe, and the United States. We have data that meet the strict acceptance criteria required by the regulatory agency through technological innovation of biosimilars.

In addition, biosimilars are playing a role in increasing accessibility to patient treatment through the advantage of costeffectiveness.

Through these advantages, the clinical treatment through biosimilars is increasing, and the real world evidence is proving the equivalence with reference biologics.

In the future, patents for products in many therapeutic areas are expected to terminate, and biosimilars are expected to be released accordingly. Therefore, it is expected that more rheumatoid disease patients will have more opportunities to be treated with better quality products.

# Breakfast Symposium V Lilly

Ixekizumab: Recent Updates on the Treatment of Spondyloarthritis



## IL-17 inhibition in spondyloarthritis: The efficacy of Ixekizumab and clinical relevance

Yeon-Ah Lee

Kyung Hee Univ., Korea

The spondyloarthritides (SpA) comprise related but phenotypically distinct inflammatory diseases including axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA). AxSpA including ankylosing spondylitis (AS) usually starts with sacroiliac joint inflammation and progresses to irreversible spinal ankylosis. PsA is characterized by nail and skin changes, peripheral arthritis, enthesitis, dactylitis, and axial disease, which can be present alone or in combination with each other. Both diseases are progressive with joint damage accumulating over time with multifaceted symptoms that seriously degrade the quality of life.

Although the pathogenic mechanisms underlying axSpA and PsA are not fully understood, evidences suggest that immune responses mediated by interleukin 17A (IL-17A) play a pivotal role in both diseases. Following the TNF inhibitors that have been prescribed primarily as a treatment for axSpA in Korea, a new IL-17A inhibitor, ixekizumab, has been approved for the reimbursement from October 1st, 2020 in Korea. And ixekizumab has been expanded the 1st line reimbursement for the biologics-naive paitents with PsA from Aug 1st, 2021.

This talk addresses long-term efficacy and safety of ixekizumab in phase III study (SPIRIT P1) for biologics-naive paitents with active PsA and in COAST-Y, 2 years extension of the COAST-V, -W trials for axSpA, recently published. In the 3 years extension of the SPIRIT P1, ixekizumab showed significantly greater treatment responses vs placebo as early as week 4 for ACR50, persisted through week 156 and also significantly less progression of structural damage assessed by mTSS change at week 24, sustained up to 3 years in PsA. ASAS 40 response rates of ixekizumab 80 mg every 4 weeks at weeks 52 and 116 were 52.2% and 56.7%. Most patients treated with ixekizumab for 2 years did not show radiographic progression. There were no unexpected safety signals reported in 3 years extension of SPIRIT P1 study and in COAST-V, -W and COAST-Y trials.

Ixekizumab, one of the IL-17 inhibitors show efficacy in treating multiple facets of SpA, including psoriasis, enthesitis, synovitis, bone erosion, new bone formation and pain, which indicates the importance of IL-17A in disease pathophysiology.

# Breakfast Symposium VI Janssen

Redefine Persistence in AS Management



# Long-lasting Golimumab in AS: Learnings from real-world evidence

Bon San Koo

Inje Univ., Korea

Ankylosing spondylitis (AS) is a chronic inflammatory arthritis that predominantly affects the sacroiliac joint and spine and is characterized by chronic back pain and stiffness. The primary goals of treating ankylosing spondylitis (AS) patients are to maximize long-term health-related quality of life through control of symptoms and inflammation, prevention of progressive structural damage, and preservation of function. Knowledge of the pathogenesis of AS has led to number of improvements in its treatment, and in particular the development of biologic agents has been of great benefit. Tumor necrosis factor-a inhibitors (TNFis) are the main therapeutic agents used to treat patients with AS for whom non-steroidal anti-inflammatory drugs are ineffective or are contraindicated. And as far as drug survival of these treatment options, it is an important proxy measure for effectiveness of treatments for AS.

A study aimed to investigate drug retention rates for various TNF inhibitors (TNFis) commonly prescribed to Korean patients with ankylosing spondylitis (AS) in the Korean College of Rheumatology Biologics registry (KOBIO; December 2012–June 2016). And registry data provides a unique way to study the real-world use of medication. A fundamental limitation of clinical trials is that the included patients differ from patients seen in daily practice. Discontinuation was defined as switching or stopping the biologic agent. The drug retention rate for golimumab (82.2%) was highest, followed by adalimumab, infliximab biosimilar, etanercept, and infliximab originator. The rate of adverse events decreased to 9.7%, and the rate of significant clinical improvement also dropped to 6.5% for golimumab compared to another TNFi, although the inefficacy rate was similar among the TNFis from etanercept to golimumab ranging from 27.8 to 45.2%.

Thus, this real-life study showed that around 82% of patients with AS maintained golimumab at about 4-year follow-up. And it can be concluded that golimumab has demonstrated proven persistence in AS.

# **Keynote Lecture**



Journal of Rheumatic Diseases Vol. 29, Suppl. 1, May, 2022

# The future of rheumatology

Antony Rosen

The Johns Hopkins Univ. School of Medicine, USA

The autoimmune rheumatic diseases are a highly complex group of disorders, with complexity residing in numerous dimensions, including genetics, environment, phenotype, trajectory, outcomes, responses to therapy, and specificity of the immune response. In spite of this multi-dimensional complexity, the future is bright in terms of understanding disease mechanism, and more effective, patient-focused care. This optimism stems from two major opportunities: (i) the accumulated clinical wisdom that has recognized homogeneous disease subgroups within the larger inhomogeneous disease category; these subgroups are based on subtle but distinct phenotypic features and trajectories over time; and (ii) the exceptional tools that the current technology revolutions (measurement, computation and connectivity) are bringing forward for human discovery and clinical use. This presentation focuses on the power of the immune system, coupled with distinct clinical trajectories over time, and the co-occurrence of cancer and autoimmune disease presentations in deconvoluting mechanisms in the rheumatic diseases. It then focuses on the role of the target tissue in shaping and driving immune-mediated injury in the rheumatic diseases. Lastly, the talk will define the requirements and opportunities that will ensure that the revolutions in measurement and connectivity will drive real improvements in patient care in the rheumatic diseases.

# International Symposium

Treatment of Osteoarthritis: To be Used and Abused?



# Hype and truth - treatment paradigm of osteoarthritis

### **David Hunter**

Univ. of Sydney, Australia

Osteoarthritis is a prevalent and disabling disease that affects millions of people worldwide. Characteristic management of this disease is unfortunately low value and inappropriate. This lecture will focus on areas of care that are full of myths, misconceptions and hype. This will extend from our understanding of the pathophysiology of disease, the sources of pain, methods of diagnosing the disease, communicating with our patients about this and disease prognosis. Particular focus will be given to controversial therapeutic areas, including paracetamol, opioids, viscosupplements, arthroscopy. To ensure the audience gains value, each hype, myth, and misconception will be distilled, and clear messages about optimal management will be conveyed.



## Addicted to prescription, medical abuse of osteoarthritis

Yuqing Zhang

Massachusetts General Hosp., USA

Osteoarthritis (OA) is the most common joint disease. The World Health Organization estimated that 18% of women and 9.6% of men ages >60 years have symptomatic OA; of them, 80% have some limitation in mobility and 25% are unable to perform their major daily activities. Pain from OA is a major clinical manifestation and a key factor leading people to seek medical care. To date, there is no known cure. The main goals of contemporary management of OA continue to be control of pain and improvement in both function and health-related quality of life, with avoidance of therapeutic toxicity.

Most commonly used pain relief medication for OA consists of non-steroidal anti-inflammatory drugs (NSAIDs) and opioids. Numerous studies have shown that these medications, if used inappropriately, are associated with an increased risk of intestinal bleeding or ulcer, renal injury, cardiovascular disease and even deaths. Several guidelines have emphasized that the cornerstone of OA management should focus on patient education, weight loss, exercise, and self-efficacy and self-management. Topical NSAID is strongly recommended for knee OA. Oral NSAIDs and intraarticular steroid injections can be considered, if needed. The use of opioid analgesics should be avoided.

There is paucity of data on whether the physicians and OA patients follow the professional guidelines on OA management. Results from the United Kingdom indicated that topical NSAID prescription almost tripled from early 2000's to middle of 2010's. The initial prescription of oral Cox-2 inhibitors decreased. Oral opioid prescription increased from 2000 to early 2010's, and there was no indication that such a trend has changed recently. Results from epidemiological studies that describe the practice pattern of OA management, especially inappropriate medication use, secular trend of pain-relief medication use, and factors associated with inappropriate pain-relief medication use, will guide appropriate actions to take to improve OA management.



## Use or abuse? APM for degenerative meniscus in osteoarthritis

Hyun Ah Kim Hallym Univ., Korea

With the advent of sophisticated imaging, such as magnetic resonance imaging (MRI), noninvasive examination of pathologic changes in the joint and periarticular structures of the knee, which sometimes correlate with symptoms, is possible. Although MRI shows high sensitivity and specificity for the detection of abnormalities in the articular soft tissues, clinical significance of such lesions detected by MRI is in many cases unclear, and even consensus on when to perform MRI in knee OA subjects is not reached.

In previous studies of middle-aged and elderly men and women representative of the general population, incidental meniscal findings on MRI of the knee were common, and the majority of meniscal damage was found in persons without knee symptoms. In addition, meniscal damage was not significantly associated with the presence of knee pain or its severity among subjects with radiographic knee OA. These data suggest that the therapeutic efficacy of arthroscopic surgery for degenerative meniscal tears may not be high. Although arthroscopic partial meniscectomy (APM) is one of the most common type of knee surgery, evidence of its efficacy lags behind since a long time.

Rigorous outcome studies conducted after the 2000s began to shed light on the clinical value of arthroscopic surgery. Randomized controlled trials of arthroscopic management of degenerative meniscal tears showed that surgery was no better than physical therapy (PT) or even a sham surgery in improving pain or functional status.

In this lecture, the relationship between OA anatomical abnormality revealed by imaging and pain and knee function is examined. In addition, the evidence of clinical efficacy of arthroscopic meniscectomy for OA and degenerative meniscal tear is reviewed.

# **Free Paper Session**

Spondyloarthritis



### Physical trauma exacerbates arthritis and enthesitis in curdlan-administered SKG mice model

### Seung Hoon Lee¹, Chanhyeok Jeon^{1,2}, Sungsin Jo¹, Tae-Hwan Kim^{1,3}

¹ Rheumatology Research, Hanyang University Institute for Rheumatology Research, Republic of Korea
² Translational Medicine, Graduate School of Biomedical Science and Engineering, Hanyang University, Republic of Korea
³ Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Republic of Korea

#### Background

Ankylosing spondylitis (AS) is a chronic inflammatory disease accompanied by spinal and peripheral joint inflammation. Intriguingly, some of AS patients have experienced physical trauma before disease onset, but the contribution of trauma to the pathophysiology of AS is still debated. The aim of this study was to determine whether physical trauma affected curdlan-induced arthritis and/or enthesitis in SKG mice.

#### **Methods**

For physical reaction to trauma, the right hindlimb of 7 weeks male SKG mice were immobilized using a surgical sticking plaster and pipette tip for a week. After immobilization, the fixing tip was removed from the ankle and the mouse was intraperitoneally injected with 3mg curdlan. We monitored clinical arthritis for 5 weeks and scored every week. The physical changes in ankles were evaluated by H&E, Safranin O, and Toluidine blue staining. Various bone indicators for traumatic experienced right and non-traumatic experienced left (inflamed bone volume, structure separation, structure linear density, and structure thickness) ankles were measured by microCT.

#### **Results**

During arthritis induction, the arthritis scores of the traumatic experienced right hindlimb were obviously increased in curdlan-administered SKG mice compared to left hindlimb. Histological analysis showed that destruction of joint cartilage, frequency of enthesitis, and severity of arthritis at the ankle were significantly augmented in the traumatic experienced right hindlimb. Also, microCT analysis revealed that inflamed bone volumes significantly increased in traumatic experienced right hindlimb compared with non-traumatic experienced left hindlimb.

#### Conclusions

We conclude that physical right hindlimb with trauma is experienced to exacerbate the destruction of joint cartilage, frequency of enthesitis, and severity of arthritis in the curdlan-administered SKG mice model. Therefore, physical trauma might be a significant initiator or mediator of the ankylosing spondylitis.

#### **Keywords**

Physical Trauma, Curdlan-administered SKG mice, ankylosing spondylitis



## PPM1A promotes matrix mineralization of osteoblasts differentiation via FOX01A-RUNX2 pathway in ankylosing spondylitis

#### Subin Weon¹, Sungsin Jo¹, Ye-Soo Park², Yong-Gil Kim³, Tae-Hwan Kim^{1,4}

¹ Rheumatology Research, Hanyang University Institute for Rheumatology Research, Republic of Korea ² Orthopedic Surgery, Guri Hospital, Hanyang University College of Medicine, Republic of Korea ³ Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Republic of Korea ⁴ Rheumatology, Hanyang University Hostpital for Rheumatic Diseases, Republic of Korea

#### Background

Ankylosing spondylitis (AS) patients exhibited elevated protein phosphatase magnesium-dependent 1A (PPM1A) levels in sera, strongly associated with spinal radiographic progression. RUNX2 is also highly expressed in AS bone tissues, playing an essential role in osteoblast differentiation and bone formation. However, the precise molecular mechanism underlying the relationship between PPM1A and RUNX2 is not well understood. Here we investigate the potential mechanism of PPM1A and RUNX2 of the excessive bone formation in AS.

#### **Methods**

Primary osteoprogenitor cells of the interspinous process were obtained from 5 AS patients and 6 disease controls. The isolated progenitor cells were differentiated into mature osteoblasts and assessed by the bone formation in vitro assay. To investigate the effect of PPM1A on AS, we treated various doses of exogenous PPM1A in AS-osteoprogenitor cells and analyzed using RT-PCR and immunoblotting. Furthermore, we examined the alteration in FOXO1A-RUNX2 regulatory mechanism by exogenous treatment of PPM1A using various biochemistry and molecular methods.

#### **Results**

Expression levels of PPM1A and RUNX2 were increased in destructive bone tissues of AS and its osteoprogenitor cells compared to disease control. During osteoblast differentiation, exogenous treatment of PPM1A accelerated the matrix mineralization in AS-osteoprogenitor cells but not in disease control. Intriguingly, RUNX2 and PPM1A protein expressions were significantly upregulated at the matrix mineralization stage. Mechanically, exogenous treatment of PPM1A dephosphorylates FOXO1A and translocates FOX-01A protein into the nucleus to induce RUNX2 transcript level. Moreover, exogenous treatment of PPM1A promoted matrix mineralization of overexpressed FOXO1A in control during osteoblasts differentiation.

#### **Conclusions**

These results indicate that treatment with PPM1A induces RUNX2 transcript levels through dephosphorylation of FOXO1A in AS-osteoprogenitor cells, thereby accelerating the bone mineralization of osteoblast differentiation. Our results provide a regulatory mechanism whereby a high PPM1A level contributes to excessive bone mineralization of AS.



## A pilot study on deep learning-based grading of the corner of vertebral body for the assessment of radiographic progression in patients with ankylosing spondylitis

Bon San Koo¹, Jae Joon Lee², Jae-Woo Jung², Chang Ho Kang³, Kyung Bin Joo⁴, Tae-Hwan Kim⁴, Seunghun Lee⁵

¹ Internal medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Republic of Korea
 ² CRESCOM Co., Ltd., CRESCOM Co., Ltd., Republic of Korea
 ³ Department of Radiology, Korea University Anam Hospital, Republic of Korea
 ⁴ Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Republic of Korea
 ⁵ Department of Radiology, Hanyang University Hospital for Rheumatic Diseases, Republic of Korea

#### Background

This pilot study aimed to develop a deep learning model for grading the corners of the cervical and lumbar vertebral bodies for computer-aided detection of modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) in patients with ankylosing spondylitis (AS).

#### **Methods**

Using a key-point detection deep learning model, disc points were detected between the bodies in the cervical and lumbar spinal radiographs. After cropping vertebral regions around the disc point, the lower and upper corners of the vertebral bodies were classified as grade 3 (total bony bridges) or grades 0, 1, or 2 (non-bridges). We trained a convolutional neural network model to predict the grades in the lower and upper corners of the vertebral bodies. The performance of the model was evaluated in a validation set, which was separate from the training set.

#### **Results**

Among 1,280 patients with AS for whom mSASSS data were available, 5,083 cervical and 5,245 lumbar lateral radiographs were reviewed. The total number of corners where mSASSS was measured in the cervical and lumbar vertebrae, including the upper and lower corners, was 119,414. Among them, the number of corners in the training and validation sets was 110,088 and 9,326, respectively. The mean accuracy, sensitivity, and specificity for mSASSS scoring in one corner of the vertebral body were 0.91604, 0.80288, and 0.94244, respectively (Table 1).

#### Conclusions

A high-performance deep learning model for grading the corners of the vertebral bodies was developed for the first time. This model must be improved and further validated to develop a computer-aided tool for assessing mSASSS in the future.

#### Figure & Table

Grade	True positive	True negative	False positive	False negative	Sensitivity	Specificity	Positive predictive value	F1score	Accuracy
0	2250	6085	623	368	0.85943	0.90713	0.78315	0.81952	0.89374
1	2169	6034	500	623	0.77686	0.92348	0.81266	0.79436	0.87958
2	700	8005	225	396	0.63869	0.97266	0.75676	0.69273	0.93341
3	2641	6288	218	179	0.93652	0.96649	0.92375	0.93009	0.95743

Table. Performance for each scoring in the test set.

#### **Keywords**

Ankylosing spondylitis, mSASSS, Deep learing



## Analysis of radiographic progression in patients with ankylosing spondylitis: Using group-based trajectory modeling and decision trees

### Juyeon Kang¹, Tae-Han Lee², Bon San Koo³, Seo Young Park⁴, Seunghun Lee⁵, Tae-Hwan Kim⁶

¹ Division of Rheumatology, Internal Medicine, Inje University Busan Paik Hospital, Republic of Korea
 ² Division of Rheumatology, Internal Medicine, Keimyung University Dongsan Medical Center, Republic of Korea
 ³ Division of Rheumatology, Internal Medicine, Inje University Seoul Paik Hospital, Republic of Korea
 ⁴ Department of Statistics and Data Science, Korea National Open University, Republic of Korea
 ⁵ Department of Radiology, Hanyang University College of Medicine, Republic of Korea
 ⁶ Division of Rheumatology, Internal Medicine, Hanyang University Hospital for Rheumatic Diseases, Republic of Korea

#### Background

Ankylosing spondylitis (AS) is characterized by long-term disease progression. During progression, various radiographic changes occur in the spine, which eventually lead to disability in the patient's lifetime. Although the duration of the disease, aging, and passage of time are predicted to be highly associated with spinal progression of AS, it is difficult to accurately predict its progression in the spine of patients. Thus, we aimed to find ways to predict spinal progression over time in patients with AS and analyze its associated clinical factors.

#### **Methods**

Data from the medical records from Hanyang university hospital for rheumatic diseases were extracted between 2001 and 2018. We analyzed the data on patients who fulfilled the modified New York Criteria for AS and had two or more sets of radiographs taken during the observation period. The modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) was estimated by two independent radiologists. Group-based trajectory modeling (GBTM) was used to classify patients into distinct subgroups of longitudinal mSASSS. And when these trajectories and statistically associated factors acted on a patient, which group the patient was most likely to belong to was predicted using a decision tree analysis.

#### **Results**

The trajectories were evaluated by dividing them into three groups based on duration of the disease. We identified that sex, age at diagnosis, ocular involvement and peripheral joint involvement were associated with the classified spinal progression trajectories, and predictions through decision trees were similarly identified. AS onset in older age and ocular involvement were associated with worse radiographic progression, while female sex and peripheral joint involvement were associated with radiographic progression.

#### Conclusions

We identified three patterns of radiographic progression according to duration of the disease. The progression trend of patients with AS identified in this study is expected to be helpful in the treatment and management of patients in actual clinical settings.

#### **Figure & Table**




Figure. Longitudinal mSASSS trajectory groups for disease duration

Time in month is shown along the x-axis, and logarithmic transformed total mSASSS is shown along the y-axis. The solid line represents the estimated mean in the same-colored area representing the 95% confidence interval.

mSASSS, modified Stoke Ankylosing Spondylitis Spinal Score

#### **Keywords**

Ankylosing spondylitis, Radiographic progression, Trajectory analysis



# The spinal radiographic change correlates with past alkaline phosphatase levels in patients with ankylosing spondylitis

#### Bon San Koo¹, Seo Young Park², Ji Hui Shin³, Seunghun Lee⁴, Kyung Bin Joo³, Tae-Hwan Kim³

¹ Internal medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Republic of Korea
 ² Department of Statistics and Data Science, Korea National Open University, Republic of Korea
 ³ Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Republic of Korea
 ⁴ Department of Radiology, Hanyang University Hospital for Rheumatic Diseases, Republic of Korea

#### Background

ALP is generally produced in the liver, bone, and kidneys. In serum, bone and liver specific isoform of ALP form more than 90% of total serum ALP with 1:1 ratio. The aim of this study is to determine the relationship between alkaline phosphatase (ALP) levels and the radiographic change over time in patients with ankylosing spondylitis (AS).

#### **Methods**

Longitudinal electronic medical records of patients diagnosed with AS from January 2001 to December 2018 were analysed. To determine the relationship between the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) and ALP levels over time, linear mixed models with mSASSS and ALP levels with different lag times (3 month intervals) were used. Using the lag time of ALP levels with the highest beta coefficients, linear mixed models including clinical variables were further investigated.

#### **Results**

A total of 37,852 intervals were obtained from 1122 patients. Among different lag times, the ALP level in the previous 5 years and 3 months and mSASSS showed significant beta coefficients. In the linear mixed model that included clinical variables, the ALP level in the previous 5 years 3 months was significantly associated with mSASSS ( $\beta$ =0.021, 95% CI: 0.017-0.025, p<0.001) (Table 1).

#### Conclusions

The ALP level previous 5 years and 3 months were significantly correlated with the present spinal radiographic change. Therefore, ALP levels may be helpful in predicting long-term radiographic progression than CRP levels.

#### **Figure & Table**

	Model 1			Model 2				
	Beta estimat	95% CI		p-	Beta	95% CI		p-
	estimat	LB	UB	value	estimat e	LB	UB	value
(Intercept)	-2.917	- 3.711	- 2.123	< 0.001	-3.759	- 7.519	0.000	0.050
mSASSS.base	1.096	1.064	1.127	< 0.001	1.066	1.030	1.102	< 0.001
time (3month intervals)	0.211	0.206	0.217	< 0.001	0.218	0.212	0.223	< 0.001
ALP at previous 5 years 3 months	0.020	0.017	0.024	< 0.001	0.021	0.017	0.025	< 0.001
log CRP at previous 18 months	-0.140	- 0.262	- 0.018	0.025	-0.117	- 0.247	0.014	0.079
TNF inhibitor	-0.833	- 0.992	- 0.673	< 0.001	-0.850	- 1.020	- 0.680	< 0.001
AST at previous 5 years 3 months					0.001	- 0.007	0.010	0.794
ALT at previous 5 years 3 months					0.000	- 0.006	0.005	0.907
Female					-1.065	- 3.096	0.966	0.304
Eye involvement					2.973	1.761	4.185	< 0.001
Peripheral involvement1					-2.078	- 3.288	- 0.867	0.001
HLA-B27					-0.558	- 4.139	3.023	0.760
Smoking(ref: nonsmoker)								< 0.001
ex_smoker					3.139	1.603	4.675	< 0.001
smoker					2.159	0.673	3.646	0.004

mSASSS: the modified Stoke Ankylosing Spondylitis Spinal Score; ALP: alkaline phosphatase; CkP: Creactive protein; TNF: tumor necrosis factor; AST: aspartate aminotransferase; ALT: alanine aminotransferase; HLA: human leukocyte antigen.

Table. Linear mixed models including clinical variables

#### **Keywords**

Ankylosing spondylitis, Alkaline phosphatase, Radiogrpahic progression



### CCL20 inhibition for treating inflammation in ankylosing spondylitis

<u>Hui-Ju Kim</u>¹, Hae-in Lee¹, So-Hee Jin¹, Ah-Ra Choi¹, Soon Mi Choi¹, Moon-ju Kim², Yu Jeong Lee², Kyeong Hwan Byeon², Seong Hoon Kim², Eun Jeong Won², Tae-Jong Kim¹

¹ Department of Rheumatology, Chonnam National University Medical School and Hospital, Republic of Korea ² Department of Parasitology and Tropical Medicine, Chonnam National University Medical School and Hospital, Republic of Korea

#### Background

Ankylosing spondylitis (AS) is a rheumatic disease characterized by chronic inflammation. Several lines of evidence implicate interleukin (IL)-17A-secreting T helper (Th)17 cells in AS pathogenesis. One of the receptors of Th17, C-C motif chemokine ligand 20 (CCL20) is known to attract C-C chemokine receptor 6 (CCR6) expressing cells to the site of inflammation. However, the role and mechanism of CCL20 in AS are not well understood. Therefore, this study was to evaluate whether CCL20 inhibition could treat chronic inflammation in AS.

#### **Methods**

Peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) were obtained from AS patients. Inflammatory cytokine-producing cells were analyzed using flow cytometry and enzyme-linked immunosorbent assay (ELISA). To determine the direct effect of AS serum and synovial fluid on CCL20 positive cell migration, a Transwell migration assay was performed. Female SKG mice were treated with CCL20 blocking antibody or vehicle. Inflammation was evaluated using immunohistochemistry, and positron emission tomography image.

#### **Results**

Percentages of CCL20 positive cells were significantly higher in synovial fluid than those in peripheral blood.

IL-17A and GM-CSF level were highly increased in CCL20 positive cells, compared to CCL20 negative cells.

The migration of CCL20 cells was significantly increased in the presence of AS synovial fluid compared with AS serum. In animal study, the development of arthritis was significantly delayed in CCL20 Inhibitor-treated mice, compared to vehicle-treated mice. The mean values of maximum standardized uptake values of ankle joint from CCL20 Inhibitor were also significantly lower than those from vehicle-treated mice in PET image.

#### Conclusions

This study demonstrates CCL20 blockade ameliorated inflammation in AS. Thus, CCL20-target therapy could be a promising treatment for AS.

#### **Keywords**

Ankylosing Spondylitis, CCL20, Inflammation



### Metagonimus yokogawai-derived protein attenuates inflammation in ankylosing spondylitis

<u>Moon-Ju Kim²</u>, Yu Jeong Lee², Kyeong Hwan Byeon², Seong Hoon Kim², Hae-in Lee¹, Hui-Ju Kim¹, So-Hee Jin¹, Ah-Ra Choi¹, Soon Mi Choi¹, Sungsin Jo³, Tae-Hwan Kim³, Eun Jeong Won², Tae-Jong Kim¹

¹ Department of Rheumatology, Chonnam National University Medical School and Hospital, Republic of Korea
² Department of Parasitology and Tropical Medicine, Chonnam National University Medical School and Hospital, Republic of Korea
³ Department of Rheumatology, Hanyang University Institute for Rheumatology Research, Republic of Korea

#### Background

Helminth infections and their components have been shown to have a potential of immune modulation and could attenuate immune response. This study aimed to evaluate potential protective effect of Metagonimus yokogawai –derived protein (MYp) on ankylosing spondylitis (AS).

#### **Methods**

We assessed cytotoxicity of MYp treatment at different doses before performing experiments. The anti-inflammatory properties of MYp on cytokines (IFN-y, IL-17A) were assessed using peripheral blood mononuclear cells (PBMCs) obtained from AS patients. Inflammatory cytokine-producing cells were analyzed using flow cytometry. In SKG mouse model, inflammation was evaluated using immunohistochemistry and positron emission tomography.

#### **Results**

The frequencies of IFN- $\gamma$  and IL-17A producing cells were significantly reduced after MYp treatment in PBMCs from AS patients. In vivo mouse model, a remarkable regression of AS symptom score and reduced frequencies of IFN- $\gamma$ , IL-17A, and TNF- $\alpha$  producing cells among splenic cells were found in the MYp-treated mice. 18F-FDG uptake was significantly lower in MYp treated mice than in vehicle treated mice.

#### Conclusions

We provide the first evidence demonstrating the ameliorative effect of MY proteins on the clinical signs and cytokine derangements in AS.

#### **Keywords**

Ankylosing Spondylitis, Metagonimus yokogawai, Immune response



## Long-term treatment with ixekizumab in patients with axial spondyloarthritis: Two-year results from COAST-Y

Jürgen Braun¹, Uta Kiltz¹, Atul Deodhar², Tetsuya Tomita³, Maxime Dougados⁴, Rebecca Bolce⁵, David Sandoval⁵, David Adams⁵, Chen-Yen Lin⁵, Jessica Walsh⁶, <u>Young In Eom</u>⁷

¹ Rheumatology, Ruhr-Universität Bochum, Germany
 ² Rheumatology, Oregon Health & Science University, USA
 ³ Rheumatology, Osaka University Graduate School of Medicine, Japan
 ⁴ Rheumatology, Hôpital Cochin, France
 ⁵ Rheumatology, Eli Lilly and Company, USA
 ⁶ Rheumatology, University of Utah, USA
 ⁷ Rheumatology, Lilly Korea Ltd, Republic of Korea

#### Background

To study the efficacy and safety of the interleukin-17 inhibitor ixekizumab (IXE) in the treatment of patients with radiographic (r-) and non-radiographic axial spondyloarthritis (nr-axSpA) for up to 116weeks.

#### **Methods**

COAST-Y (NCT03129100) is the 2-year extension of the COAST-V, -W, and -X trials. Patients continued with the dose received at the end of the originating trial at Week52, either with 80mg IXE Q4W or Q2W. Patients who had been assigned to adalimumab or placebo were re-randomized to IXE Q4W or Q2W at Week16 in COAST-V and -W. Patients who had received placebo for 52weeks in COAST-X were switched to IXE Q4W in COAST-Y. Patients who switched from placebo or adalimumab treatment to IXE (COAST-V, -W, or -X) or from IXE Q4W to open-label IXE Q2W (COAST-X) during the originating studies were analyzed separately from patients continuously treated with IXE. Standardized efficacy measures were used (Table).

#### **Results**

Of the 773 patients enrolled in COAST-Y, 86.0% completed Week116 of treatment (52weeks of one of the originating trials and 64weeks of COAST-Y). Among the patients continuously treated with IXE for 116weeks (IXE Q4W: N=157; IXE Q2W: N=195), 46.9% achieved low disease activity (ASDAS <2.1), and 19.9% achieved ASAS partial remission at 116weeks (Table). In comparison to baseline, 56.0% achieved ASAS40 (Table). The mean change from baseline at Week116 was -1.70 for ASDAS, -2.98 for BASFI, and 9.22 for SF-36 Physical Component Summary (Table). Similar observed responses were achieved between the patients continuously treated with IXE and patients initially treated with placebo or adalimumab. For the 932 patients in the safety population, no new safety signals were identified.

#### Conclusions

IXE treatment led to consistent and sustained long-term improvements in disease activity and quality of life in patients with r- and nr-axSpA, with no new safety signals after up to 2 years of treatment.

#### Figure & Table

	IXE Q4V	V N=157	IXE Q2W N=195			
Demographics						
Age	42.7	(13.0)	41.8 (	11.2)		
Male (n, [%])	124	(79.0)	132 (67.7)			
Baseline ASDAS	3.92	(0.80)	3.95 (	3.95 (0.76)		
Baseline BASDAI	7.07	(1.26)	7.18 (1.35)			
Baseline BASFI	6.57	(1.76)	6.74 (1.86)			
Baseline BASMI	4.08	(1.46)	3.97 (1.52)			
Baseline SF-36 PCS	33.90	(7.27)	33.26 (6.88)			
Outcome measure						
Response (n, [%])	Week 52	Week 116	Week 52	Week 116		
ASDAS <2.1	75 (47.8)	69 (43.9)	88 (45.1)	96 (49.2)		
ASAS partial remission	34 (21.7)	31 (19.7)	35 (17.9)	39 (20.0)		
ASAS40	82 (52.2)	89 (56.7)	99 (50.8)	108 (55.4)		
BASDAI50	78 (49.7)	75 (47.8)	83 (42.6)	99 (50.8)		
Change from baseline						
ASDAS	-1.64 (1.05)	-1.60 (1.15)	-1.63 (1.03)	-1.78 (1.04)		
BASFI	-2.88 (2.31)	-2.76 (2.39)	-2.83 (2.38)	-3.15 (2.34)		
BASMI	-0.57 (0.95)	-0.57 (0.93)	-0.53 (0.92)	-0.60 (1.00)		
SF-36 PCS	9.03 (8.62)	8.43 (8.70)	8.87 (7.57)	9.86 (8.45)		

variables, and modified baseline observation carried forward for continuous variables.

Table. Demographic and efficacy results for patients continuously treated with IXE for 116 weeks

#### **Keywords**

Ixekizumab, Radiographic, Axial spondyloarthritis

# **Free Paper Session**

# Systemic Lupus Erythematosus



## B cell-specific deletion of Crif1 drives lupus-like autoimmunity by activation of IL-17, IL-6, and pathogenic Tfh cells

<u>Jin-Sil Park</u>¹, SeungCheon Yang¹, Sun-Hee Hwang¹, JeongWon Choi¹, Seung-Ki Kwok^{1,2} Young-Yun Kong³, Jeehee Youn⁴, Mi-La Cho^{1,5,6}, Sung-Hwan Park^{1,2}

¹ Rheumatism Research Center, Catholic University of Korea, Republic of Korea
 ² Divison of Rheumatology, Catholic University of Korea, Republic of Korea
 ³ School of Biological Sciences, Seoul National University, Republic of Korea
 ⁴ Laboratory of Autoimmunology, Hanyang University, Republic of Korea
 ⁵ Department of Medical Lifescience, Catholic University of Korea, Republic of Korea
 ⁶ Department of Biomedicine & Health Sciences, Catholic University of Korea, Republic of Korea

#### Background

CR6-interacting factor 1 (Crif1) is a nuclear transcriptional regulator and a mitochondrial inner membrane protein; however, its functions in B lymphocytes have been poorly defined. In this study, we investigated the effects of Crif1 on B-cell metabolic regulation, cell function, and autoimmune diseases.

#### Methods

Using mice with B cell-specific deletion of Crif1 (Crif1 $\Delta$ CD19), we assessed the relevance of Crif1 function for lupus disease parameters including anti-double-stranded DNA, cytokines, and kidney pathology. RNA sequencing was performed on B cells from Crif1 $\Delta$ CD19 mice. The phenotypic and metabolic changes in immune cells were evaluated in Crif1 $\Delta$ CD19 mice. Roquinsan/+ mice crossed with Crif1 $\Delta$ CD19 mice were monitored to assess the functionality of Crif1-deficient B cells in lupus development.

#### **Results**

Crif1 $\Delta$ CD19 mice showed an autoimmune lupus-like phenotype, including high levels of autoantibodies to double-stranded DNA and severe lupus nephritis with increased mesangial hypercellularity. While loss of Crif1 in B cells showed impaired mitochondrial oxidative function, Crif1-deficient B cells promoted the production of IL-17 and IL-6 and was more potent in helping T cells develop into T follicular helper cells. In an autoimmune lupus mouse model, depletion of Crif1 in B cells exacerbated lupus severity and Crif1 overexpression prevented lupus development in Roquinsan/san mice.

#### Conclusions

These results showed that Crif1 was negatively correlated with disease severity, and overexpression of Crif1 ameliorated disease development. Our findings suggest that Crif1 is essential for preventing lupus development by maintaining B cell self-tolerance.

#### **Keywords**

Systemic lupus erythematosus, CR6-interacting factor 1, B cells

## Biological insights into systemic lupus erythematosus through an immune cell-specific transcriptome-wide association study

Xianyong Yin^{1,2,3}, Kwangwoo Kim⁴, Hiroyuki Suetsugu^{5,6,7}, Chikashi Terao^{6,8,9}, Yong Cui³, Sang-Cheol Bae^{10,11}

¹ Biostatistics, University of Michigan, Ann Arbor, USA
² Department of Dermatology, Anhui Medical University, China
³ Department of Dermatology, China-Japan Friendship Hospital, China
⁴ Department of Biology, Kyung Hee University, Republic of Korea
⁵ Laboratory for Bone and Joint Diseases, RIKEN Center for Medical Sciences, Japan
⁶ Laboratory for Statistical and Translational Genetics Analysis, RIKEN Center for Integrative Medical Sciences, Japan
⁷ Department of Orthopaedic Surgery, Kyushu University, Japan
⁸ Clinical Research Center, Shizuoka General Hospital, Japan
⁹ Department of Applied Genetics, University of Shizuoka, Japan
¹⁰ Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Republic of Korea
¹¹ Hanyang University Institute for Rheumatology Research, Hanyang University Institute for Rheumatology Research, Republic of Korea

#### Background

Genome-wide association studies (GWAS) have identified >100 risk loci for systemic lupus erythematosus (SLE), but the effector genes at most loci remain unclear, hampering translation of these genetic discoveries. We aimed to prioritize genes underlying the 110 SLE loci identified in the latest East Asian GWAS meta-analysis.

#### Methods

We built gene expression predictive models from blood B-cells, CD4+ and CD8+ T-cells, monocytes, natural killer cells, and peripheral blood cells from 105 Japanese individuals. We performed a transcriptome-wide association study (TWAS) using data from the latest genome-wide association meta-analysis of 208,752 East Asians and searched for effector genes using TWAS and three data-driven computational approaches.

#### Results

The TWAS identified 171 genes for SLE (P<1.0x10-5); 114 (66.7%) showed significance only in a single cell type; 127 (74.3%) were in SLE GWAS loci. TWAS identified a strong association between CD83 and SLE (P<7.7×10-8). We subsequently found a novel single-variant association at rs72836542 (OR=1.11, P=4.5×10-9) around CD83 after add-ing 1,498 cases and 3,330 controls. For the 110 SLE loci, we identified 276 effector gene candidates, including 104 genes at recently-identified SLE novel loci. We demonstrated in vitro that the causal variant rs61759532 in ACAP1 exhibited an allele-specific regulatory effect on this gene, and that presence of the SLE risk allele decreased ACAP1 expression.

#### Conclusions

Cell-level TWAS in six types of immune cells complemented SLE gene discovery and guided the identification of novel genetic associations. The gene findings shed biological insights into SLE genetic associations.

#### **Keywords**

systemic lupus erythematosus, transcriptome-wide association study, effector genes



# The association between CD40 rs4810485 polymorphism and susceptibility of systemic lupus erythematosus: Systematic review and meta analysis

Rizki Febriawan¹, Nurul Fajri Widyasari²

¹ Medicine, Utama Hospital Belitung, Indonesia ² Medicine, PKU Muhammadiyah Sampangan Hospital Surakarta, Indonesia

#### Background

Some studies reported that CD40 rs 4810485 (T/G) gene polymorphism may related to Systemic Lupus Erythematosus (SLE) susceptibility, but there are great differences among study conclusion. The aim of this study was determined CD40 rs 4810485 Polymorphism and risk of SLE

#### **Methods**

Literature search was conducted using PubMed and scopus databese until January 2022 to find case-control studies on association between CD40 (rs4810485) Polymorphism and SLE risk. The Quality of study was determine using the New castle ottawa (NOS) Scale. Effect meassured with Odds ratio (OR) and 95%CI. We Performed data analysis using Revman 5.4.

#### **Results**

A total of seven studies involved 2377 SLE case and 4076 control participants in this meta analysis. Pooled analysis show that there is no significant association between CD40 rs4810485 polymorphism and SLE Risk in dominant model GG+GT vs TT (P=0.34), recessive model GG vs GT+TT (P=0.63) and Allelic model G vs T (P=0.92). In the Stratified analysis by region, dominant model of CD40 rs4810485 polymorphism contribute increased risk of SLE in Europe (OR 3.0, 95%CI: 2.0 - 4.49; P<0.001) and Turkish (OR 5.39, 95%CI: 2.3 - 12.67; P<0.001). Recessive model of CD40 rs4810485 polymorphism increased risk of SLE (Europe OR 1.28, 95%CI: 1.05 - 1.57; P=0.02), and decreased risk of SLE (Asia OR 0.79, 95%CI: 0.68 - 0.91; P=0.001; America OR 0.66, 95%CI: 0.47 - 0.92; P=0.01) significantly. Allelic model of CD40 rs4810485 polymorphism increased risk of SLE (Europe OR 1.4, 95%CI: 1.2 - 1.63; P<0.001; Turkish OR: 1.74, 95%CI: 1.26-2.42, P<0.001) and decreased risk of SLE (Asia OR 0.86, 95%CI: 0.78 - 0.95; P=0.004; America OR 0.69, 95%CI: 0.52 - 0.92; P=0.01) significantly.

#### Conclusions

CD40 rs4810485 Polymorphism was associated with SLE susceptibility. TT genotype and T Alelle decreased risk of SLE in Europe and Turkish, but increased risk of SLE in Asia and America.

#### Figure & Table




Figure. Forrest Plot Gene G vs T (Allelic Model)

#### **Keywords**

CD40 rs4810485, Systemic Lupus Erythematosus, Polymorphism



### The role of sphingolipids in patients with systemic lupus erythematosus

Ji-Won Kim¹, Ju-Yang Jung¹, Hyoun-Ah Kim¹, Chang-Hee Suh¹

¹ Department of Rheumatology, Ajou University School of Medicine, Republic of Korea

#### Background

Sphingolipids, an essential signaling molecules for the biological and structural functions of cells, are increasingly recognized as playing an important signaling role in the pathophysiology of chronic inflammatory diseases. We hypothesized that the pathogenesis of systemic lupus erythematosus (SLE), a chronic autoimmune disease, is related to altered composition and dysregulation of sphingolipids.

#### **Methods**

We performed liquid chromatography tandem mass spectrometry to evaluate the levels of sphingolipids in plasma from 38 women with SLE, including 11 lupus nephritis, and 30 controls. The receiver operating characteristic curve (ROC) was analyzed to calculate the area under the curves (AUC) to determine whether sphingolipids can be efficiently used to diagnose SLE. Further, Pearson's correlation coefficient was used to analyze the correlation between sphingolipids and the disease activity markers.

#### **Results**

The mean age of SLE patients was 44.5 years and the mean disease duration was 110.7 months. The levels of serum ceramide (Cer) and Cer to sphingosine-1-phosphate (S1P) ratio subspecies were increased in patients with SLE, while the levels of sphingomyelins were decreased compared to the controls. The ratio of Cer16:0 to S1P showed especially strong increments in patients with lupus nephritis, and the AUC value for discriminating lupus nephritis from controls was 0.739 (95% confidence interval, 0.58110.898). In addition, their levels were associated with disease duration, anti-double stranded DNA antibody, SLE disease activity index 2000, and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index.

#### Conclusions

Serum sphingolipids can be a good candidate for SLE diagnostic markers, and in particular, Cer16/S1P has the best ability to distinguish against lupus nephritis.

#### Figure & Table

-							
Sphingolipids (ng/mL)	SLE (n = 27)	LN (n = 11)	HC (n = 30)	p-value1	p-value ²		
SIP	$707.44 \pm 93.09$	644.89 ±	710.55 ±	0.208	0.380		
		114.86	119.28				
Sphingosine	$3.92 \pm 2.35$	$2.7 \pm 1.02$	$3.25 \pm 1.56$	0.155	0.680		
Cer14:0	$7.04 \pm 2.31$	$7.86 \pm 1.91$	$7.07 \pm 1.95$	0.512	0.671		
Cer16:0	$184.05 \pm 47.86$	$198.17 \pm 33.24$	$177.86 \pm 35.79$	0.372	0.140		
Cer18:0	$98.96 \pm 35.17$	$106.09 \pm 27.83$	$94.02 \pm 34.67$	0.591	0.081		
Cer18:1	$18.05 \pm 6.33$	$20.83 \pm 5.81$	$18.9 \pm 6.55$	0.479	0.649		
Cer20:0	$116.7 \pm 34.43$	$125 \pm 30.49$	$120.31 \pm 29.12$	0.754	0.319		
Cer24:0	$2,197.34 \pm 706.74$	1,977.69 ±	$2,314.07 \pm$	0.313	0.145		
		545.01	569.7				
Cer24:1	$770.97 \pm 217.36$	$795.61 \pm 149.6$	720.48 ±	0.406	0.387		
			155.08				
SM(d18:0/16:0)	25,902.07 ±	26,625.82 ±	27,659.76 ±	0.474	0.583		
	6,263.2	4,281.66	4,922.28				
SM(d18:0/18:0)	5,894.02 ±	6,290.09 ±	6,554.73 ±	0.231	0.140		
	1,498.08	1,070.86	1,498.31				
SM(d18:0/18:1)	$58,766.05 \pm$	62,823.39 ±	63,925.33 ±	0.277	0.546		
	12,976.89	11,531.87	11,869.54				
SM(d18:0/24:0)	17,126.86 ±	16,441.45 ±	19,453.68 ±	0.081	0.053		
	4,263.68	5,358.13	4,611.38				
SM(d18:0/24:1)	34,201.36 ±	34,652.83 ±	34,414.91 ±	0.986	0.934		
	9,038.26	6,113.78	7,179				
Cer14/S1P	$0.010 \pm 0$	$0.012 \pm 0$	$0.010 \pm 0$	0.110	0.031		
Cer16/S1P	$0.27 \pm 0.09$	$0.32 \pm 0.09$	$0.26 \pm 0.06$	0.027	0.019		
Cer18/S1P	$0.14 \pm 0.06$	$0.17 \pm 0.07$	$0.13 \pm 0.05$	0.189	0.107		
Cer18:1/S1P	$0.03 \pm 0.01$	$0.03 \pm 0.01$	$0.03 \pm 0.01$	0.209	0.519		
Cer20/S1P	$0.17 \pm 0.05$	$0.2 \pm 0.07$	$0.17 \pm 0.05$	0.215	0.283		
Cer24/S1P	$3.12 \pm 1$	$3.15 \pm 1.14$	$3.35 \pm 1.06$	0.691	0.198		
Cer24:1/S1P	$1.11 \pm 0.34$	$1.28 \pm 0.37$	$1.04 \pm 0.27$	0.111	0.031		
LN; lupus nephritis, HC; healthy control, Cer; ceramide, SM; sphingomyelin, S1P; sphingosine-1-							

phosphate

¹SLE+LN vs. HC, ²LN vs. HC. Bold values indicate significant P value.

Table. Sphingolipid profiles in patients with systemic lupus erythematosus and controls

#### **Keywords**

SLE, sphingolipid, Cer16/Sphingosine-1-Phosphate



## Combined model of renal histopathology and clinical parameters better predict one year renal outcomes in lupus nephritis: Analysis of 334 kidney biopsies

<u>Aishwarya Gopal</u>¹, Chengappa Kavadichanda¹, Devender Bairwa¹, Sanket Shah¹, BH Srinivas², Molly Thabah¹, Vir Negi¹

¹ Department of Clinical Immunology, Jawaharlal Institute of Postgraduate Medical Education and Research(JIPMER), India ² Department of Pathology, Jawaharlal Institute of Postgraduate Medical Education and Research(JIPMER), India

#### Background

Diagnosis of Lupus Nephritis (LN) is currently based on laboratory tests and renal histopathology. Role of histopathological features in determine long term outcomes is unclear.

**Objectives:** 

To assess if clinical and biochemical parameters at baseline could identify renal histopathological class.

To assess the clinico-histopathological predictors of renal response.

#### **Methods**

This is a single centre retrospective study comprising 334 LN renal biopsies. Clinical and biochemical parameters at the time of biopsy were noted and their association with histopathological class, activity and chronicity scores (AS/CS) (ISN/RPS -2016 criteria) were evaluated. Complete, partial or no response(CR, PR, NR) for renal outcome (EULAR/EDTA) at 1 year were calculated for 293 patients. Binary logistic regression was done to look for the predictors of NR.

#### Results


Class III/IV LN was seen in 240(71.8%). Hypertension was seen in (52.1%) of class III/IV and <25% each with class II, V and combined class(p<0.001). Class III/IV had lower eGFR [87.6(62.75-118.8)] (p<0.001) than the other classes. Nephrotic range proteinuria was seen in 32% of class V and 21% in class III/IV (p=0.004). Among class-III/IV AS had weak correlation with baseline UPCR (r=0.31) and eGFR (r=-0.172) (p<0.01). CS had weak negative correlation with eGFR (r=-0.212,p<0.01). NR at 1 year was higher in males (OR-4.6,95%CI-1.9-10.8,p<0.001), those with abnormal serum creatinine (OR-3.3,95%:CI1.6-7.02, p-0.001), higher

renal SLEDAI (p<0.05), higher AS, CS (p<0.001), interstitial inflammation and tubular atrophy(p<0.005). On binary logistic regression a combined clinico-histopathological model comprising of serum creatinine, UPCR, male sex and CS performed best in predicting NR (figure 1).

#### **Conclusions**

Clinical and biochemical parameters can predict the renal histological class to a fair extent but has limited value in predicting the activity and chronicity parameters. Since a combination of clinical and histopathology parameters are better in predicting renal outcomes, performing renal biopsies should be encouraged in LN.

#### Figure & Table



Model 1: Baseline serum creatinine, urine PCR, male sex; AUC – 0.694(0.609-0.779), p <0.001 Model 2: Baseline serum creatinine, urine PCR, male sex, chronicity score; AUC – 0.740(0.660-0.820), p<0.001 Model 3: Baseline serum creatinine, urine PCR, male sex, chronicity score, crescents, interstitial inflammation; AUC – 0.744(0.664-0.824), p<0.001

Figure. ROC curve and AUC for the three different models

#### **Keywords**

Lupus nephritis, Renal biopsy, Predictors



### Coexisting tubulointerstitial inflammation and damage is a risk factor for chronic kidney disease in patients with lupus nephritis: Results from the KORNET registry

#### Dong-Jin Park¹, Sung-Eun Choi¹, Ji-Hyoun Kang¹, Shin-Seok Lee¹

¹ Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Republic of Korea

#### Background

An increasing body of evidence suggests a prognostic role of tubulointerstitial lesions in patients with lupus nephritis (LN). Although persistent tubulointerstitial inflammation (TII) usually precedes tubulointerstitial damage (TID) in LN, the two conditions can be simultaneously present to varying degrees. Thus, we examined whether coexisting TII/TID predicts progression to chronic kidney disease (CKD) in LN patients.

#### **Methods**

The 175 LN patients enrolled in the study had clinical data obtained at the time of renal biopsy and stored in the KOR-NET registry. These patients were divided into two groups: those with and without coexisting TII/TID. The two groups were compared with respect to their demographic, clinical, histological, laboratory findings, and long-term prognosis. Uni- and multivariable Cox proportional hazard regression models were used to identify independent risk factors for CKD in LN patients.

#### **Results**

Of the 175 LN patients, 110 (62.9%) had coexisting TII/ TID and 65 (37.1%) did not. Patients with coexisting TII/TID were older, had higher ESR and 24 h proteinuria, and lower eGFR and hemoglobin levels than those without coexisting TII/TID. Anti-Ro and ribosomal-P antibodies were detected less frequently in patients with coexisting TII/TID. Patients with coexisting TII/TID more often had LN of the proliferative type and a larger proportion had a chronicity score > 4. During a mean follow-up of 89.9 months, CKD and ESRD developed more frequently in patients with than without coexisting TII/TID. Finally, the coexisting TII/TID was associated with a higher risk for CKD progression: adjusted HR = 2.677, p = 0.006 for all LN patients; HR = 3.265, for those with class III, IV and V LN; HR = 3.045, for those with class III, IV, V LN, and eGFR ≥ 30 mL/min/1.73 m2.

#### Conclusions

LN patients with coexisting TII/TID are at greater risk for deterioration of kidney function at LN onset and for developing CKD over time.

#### **Keywords**

tubulointerstitial inflammation, chronic kidney disease, lupus nephritis



## Subtherapeutic hydroxychloroquine concentration is associated with increased disease activity and greater organ damage during 5-year follow-up in patients with systemic lupus erythematosus

#### Ji-Hyoun Kang¹, Sung-Eun Choi¹, Dong-Jin Park¹, Shin-Seok Lee¹

¹ Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Republic of Korea

#### Background

Hydroxychloroquine (HCQ) is a cornerstone drug in patients with systemic lupus erythematosus (SLE), as it decreases the risk of flares and comorbidities and improves survival. This study investigated the effects of the serum HCQ concentration on clinical manifestations, disease activity, and organ damage in SLE patients.

#### **Methods**

The 338 SLE patients from the Korean Lupus Network registry were assessed with respect to their demographic, clinical and laboratory findings, PGA, and adjusted mean SLEDAI-2000 (AMS) and SLICC damage index scores annually for 5 consecutive years. Patients were divided into two groups according to their serum HCQ concentration at baseline: patients with a subtherapeutic level (< 500 ng/mL) and those with a therapeutic level ( $\geq$  500 ng/mL). The impact of the HCQ concentration on the clinical outcomes was evaluated in a longitudinal analysis using a generalized estimating equation (GEE) and a logistic regression analysis.

#### Results

Of the 338 patients, 287 (84.9%) were in the subtherapeutic group at baseline. This group had a higher incidence of newly developed lupus nephritis (P = 0.036) and had been prescribed higher mean and cumulative doses of prednisolone (P = 0.003 and P = 0.013) than the therapeutic group. In multivariable analyses by GEE, an association of the subtherapeutic group with both a higher PGA score ( $\beta$  coefficient = 0.328, P < 0.001) and a higher SLICC damage index score ( $\beta$  = 0.366, P = 0.019) was determined across all 5 years. In the multivariate logistic regression analysis, subtherapeutic HCQ was significantly associated with the AMS (OR = 1.142, P = 0.019), mean PGA (OR = 3.697, P < 0.001), and an annual increase in the SLICC damage index score (OR = 1.529, P = 0.047).

#### Conclusions

HCQ concentration may affect the development of new-onset LN, and had the significant association with higher disease activity and cumulative organ damage.

#### Keywords

hydroxychloroquine, concentration, lupus nephritis



## Effect of smoking on thrombotic events in antiphospholipid syndrome: A large prospective cohort study

#### Hui Jiang¹, Jiuliang Zhao^{1,2,3}, Mentao Li^{1,2,3}, Yan Zhao^{1,2,3}

¹ Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, China ² National Clinical Research Center for Dermatologic and Immunologic Diseases, Ministry of Science & Technology, China ³ State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical Co, China

#### Background

Cigarette smoking is an established risk factor for several autoimmune diseases and thrombosis. Previous investigations observed an increased smoking rate in antiphospholipid antibody (aPL) carriers. While no clearer role of smoking in antiphospholipid syndrome (APS) was determined. This study was designed to investigate effects of cigarette smoking on clinical manifestations and prognosis in APS.

#### **Methods**

This is a prospective single-clinical case-control study from 2013 to 2022, 388 patients fulfilled 2006 Sydney criteria of APS were included. Current smokers and former smokers with one-year consecutive smoking were both included. Investigation was carried between smokers (n=85) and non-smokers (n=303), 60 cases and controls were matched by gender and age.

#### **Results**

Main results focused on thrombotic events since most of the smokers were male. Patients with smoking habit were more frequent to have cardiovascular complications (P=0.017), especially coronary heart disease (13.33% vs. 3.33%, P=0.048). Smokers presented much more arterial thromboses in different territories before diagnosed (66.67% vs. 38.33%, P=0.002), including stroke (P=0.035), myocardial infarction (P=0.015), visceral (P=0.023) and retinal arterial thromboses (P=0.022). Venous thromboses were less frequent in smokers (55.00% vs. 81.67%, P=0.002), especially deep vein thromboses (P=0.044) and cranial venous sinus thromboses (P=0.048). During follow up of all patients treated, matched smokers presented increased arterial thrombosis recurrence, matched non-smokers presented increased venous thrombosis recurrence, though statistic analysis was not significant. Survival analysis of all-caused death also indicated poor outcome in smokers (4/60 vs. 0/60, P=0.047). While relation between smoking and antibody-positivity and inflammatory index were not found in this study.

#### Conclusions

Smoking is related to coronary heart disease, increased arterial events and all-caused death in APS. Patients with APS should be encouraged to avoid smoking.

#### Figure & Table




Figure. Baseline and outcomes of smokers and non-smokers in APS

#### **Keywords**

antiphospholipid syndrome, smoking



#### Efficacy of rivoraxaban in patients with antiphospholipid syndrome

Zumrad Ubaydullaeva¹, Anis Alyavi¹, Jamol Uzokov¹, Bekzod Karimov¹

¹ Internal Medicine, Republican Specialized Scientific Practical Medical Center of Therapy and Medical Rehabilitation, Uzbekistan

#### Background

Anticoagulants are cornerstone for the treatment of patients with antiphospholipid syndrome. Aim of the study was to evaluate comparative efficacy of rivaroxaban vs. warfarin in patients with antiphospholipid syndrome.

#### **Methods**

Eighty-two patients with previous thrombotic antiphospholipid syndrome were enrolled in this prospective study (Mean age 39.12±12.4 years, male=28%). Patients were divided into two groups by forty-one taking either rivaroxaban (Group I) or warfarin (Group II). Mean follow-up was 24±4.8 months. Primary endpoint was recurrent thrombosis and secondary endpoint consisted of fatal and non-fatal arterial and venous thrombosis, time to thrombosis. Overall safety outcome included major bleeding.

#### Results

Thrombotic events was observed in 12.2 % patients in Group I whilst thrombotic risk was in 15% patients in Group II during the mean follow-up period (P<0.05). In 7.0 % of patients were observed stroke in rivaroxaban group whereas in 12 % of patients were observed stroke in warfarin group (P<0.05). When we analyzed gender differences, there was not significant changes between men and women. There was similar rate of major bleeding in both groups (29% vs. 31%, P>0.05). Even though intracranial bleeding risk was lower in Group I than Group II, there was not any statistically significant changes between groups (P>0.05).

#### Conclusions

Rivaroxaban is superior to warfarin to prevent thrombotic complications in patients with antiphospholipid syndrome. Further studies are needed with large amount of participants to clarify.

#### **Keywords**

antiphospholipid syndrome, rivaroxaban, warfarin

# Luncheon Symposium VII Novartis

Understanding IL-17 Inhibition in SpA



## The role of IL-17A in Ankylosing spondylitis and axial PsA

Matthew Brown

King's College London, UK

The axial spondyloarthropathies are a heterogenous group of diseases, with differences in pathogenesis best demonstrated to date through genetic studies, in pattern of clinical disease, and in response to treatment. Axial spondyloarthritis can cooccur with psoriasis and inflammatory bowel disease. In these patients, HLA-B27 carriage is lower, prevalence of acute anterior uveitis is lower, peripheral arthritis is higher, and disease onset is later. Whether other differences observed in clinical features are real or relate to differences in ascertainment is unclear. Patients with axial spondyloarthritis with and without psoriasis both appear to respond well to interleukin-17 inhibition such as with secukinumab, which has been demonstrated in clinical trials and in clinical practice to be very effective for these diseases, and which also benefits additional features of psoriatic disease, including skin and nail disease, peripheral arthritis and dactylitis. These aspects will be discussed.

# Luncheon Symposium VIII Amgen

Move Forward with the Long-term Protection of Prolia



## **Denosumab key clinical questions**

Sung-Soo Kim Univ. of Ulsan, Korea

Denosumab is an effective and safe osteoporosis treatment option, with current data up to 10 years of continued use showing continued improvement in BMD with fracture risk reduction. Safety profiles overall are similar to placebo, with no new safety concerns in extension trials, though a theoretical increased risk of infection exists with RANKL inhibition. Denosumab has been available in Korea as a treatment for osteoporosis for 5 years. Clinical trial data for denosumab are limited to 10 years but these show important differences to oral or intravenous bisphosphonates.

RA is a chronic inflammatory condition affecting a significant number of patients and osteoporosis is a common manifestation of the disease. In RA, the activity of infiltrating macrophages and CD4+ T cells results in an increased expression of proinflammatory cytokines (TNF, IL-1, IL-6 and IL-17) which drive osteoclast formation via induction of RANKL in the synovium. Generalized bone loss in RA leading to osteoporosis and fragility fractures further increases the burden of the disease of RA patients. It is also well known that Use of glucocorticoids has been a well-known factor that affects bone and increases the risk of fracture. Denosumab has proven superior efficacy to BPs for BMD increasement in GC-C and GC-I.

FREEDOM and FREEDOM extension studies also show an increase in vertebral fractures and multiple vertebral fractures following denosumab treatment discontinuation. After switching to oral alendronate following only one year of denosumab, spine and hip BMD were generally maintained and did not fall below pretreatment baseline in most trial participants. A recent observational study showed therapy with either oral alendronate or a single intravenous zoledronic acid infusion is partially effective in reducing the increased vertebral fracture risk after denosumab withdrawal. In conclusion, to maintain its anti-fracture efficacy, denosumab treatment needs to be continued in the long-term; this has been demonstrated for up to 10 years in trials. Adverse events associated with long-term denosumab therapy such as atypical femur fractures or medication-related osteonecrosis of the jaw are very rare and treatment benefits far outweigh the risk of these events.

# Luncheon Symposium IX Astellas

Tacrolimus



## Tacrolimus in rhematoid arthritis

Chan-Bum Choi Hanyang Univ., Korea

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease mainly affecting synovium. It is usually presented with chronic polyarthritis of small joints. Management of RA have significantly improved over the years, especially with introduction of biologic disease modifying antirheumatic drugs (DMARDs) and more recently with target synthetic DMARDs. However, methotrexate still holds its throne as the anchor drug that is most important in management of RA.

Recommendations from various association around the world agree on recommending methotrexate as the first drug after diagnosis of RA, unless contraindicated. But there are subtle differences in guidelines owing to drug approval status, physician's preferences, and patients' preference difference among countries.

Prograf is approved for management of rheumatoid arthritis in Korea and Japan. It has demonstrated safety and efficacy in patients with RA in five randomized placebo-controlled studies in North America including United States of America and in Japan. Its' safety and efficacy were consistently demonstrated in real-world studies in Korea and Japan, including large long-term pharmacovigilance study in Japan. Effectiveness as an add-on therapy in biologic DMARD inadequate responders was demonstrated and its effectiveness in maintenance of remission after tumor necrosis factor inhibitor was demonstrated in a prospective open-label trial. Head-to-head trial with leflunomide showed non-inferiority.

Prograf is a valuable conventional DMARDs in management of RA with its safety and efficacy in various clinical situations.

# International Symposium

Synovial Macrophage and Fibroblast in RA



### Synovial macrophages as gatekeepers of inflammation

Gerhard Krönke

Univ. of Erlangen, Germany

Macrophages are considered to contribute to chronic inflammatory diseases such as rheumatoid arthritis¹. However, both the exact origin and the role of macrophages in inflammatory joint disease remain unclear. We used fate-mapping approaches in conjunction with three-dimensional light-sheet fluorescence microscopy and single-cell RNA sequencing to perform a comprehensive spatiotemporal analysis of the composition, origin and differentiation of subsets of macrophages within healthy and inflamed joints, and study the roles of these macrophages during arthritis. We observed that dynamic membrane-like structures, consisting of a distinct population of CX₃CR1⁺ tissue-resident macrophages, form an internal immunological barrier at the synovial lining and physically seclude the joint. These barrier-forming macrophages display features that are otherwise typical of epithelial cells, and maintain their numbers through a pool of locally proliferating CX₃CR1⁺ mononuclear cells that are embedded into the synovial tissue. Unlike recruited monocyte-derived macrophages, which actively contribute to joint inflammation, these epithelial-like CX₃CR1⁺ lining macrophages restrict the inflammatory reaction by providing a tight-junction-mediated shield for intra-articular structures. Additional data suggest that T cells interact with the layer of CX₃CR1⁺ lining macrophages prior to onset of arthritis, where they promote a barrier dysfunction and onset of autoantibody inflammation.



# Cellular deconstruction of inflamed synovium defines diverse inflammatory phenotypes in rheumatoid arthritis

Soumya Raychaudhuri

Soumya Raychaudhuri on behalf of the AMP RA Consortium

Rheumatoid arthritis (RA) is a prototypical autoimmune disease that causes destructive tissue inflammation in joints and elsewhere. Clinical challenges in RA include the empirical selection of drugs to treat patients, inadequate responders with incomplete disease remission, and lack of a cure. We profiled the full spectrum of cells in inflamed synovium from patients with RA with the goal of deconstructing the cell states and pathways characterizing pathogenic heterogeneity in RA. Our multicenter consortium effort used multi-modal CITE-seq, RNA-seq, and histology of synovial tissue from 79 donors to build a >314,000 single-cell RA synovial cell atlas with 77 cell states from T, B/plasma, natural killer, myeloid, stromal, and endothelial cells. We stratified tissue samples into six distinct cell type abundance phenotypes (CTAPs) individually enriched for specific cell states. These CTAPs demonstrate the striking diversity of RA synovial inflammation, ranging from marked enrichment of T and B cells (CTAP-TB) to a congregation of specific myeloid, fibroblast, and endothelial cells largely lacking lymphocytes (CTAP-EFM). Disease-relevant cytokines, histology, and serology metrics are associated with certain CTAPs. This comprehensive RA synovial atlas and molecular, tissue-based CTAP stratification reveal new insights into RA pathology and heterogeneity, which could lead to novel targeted-treatment approaches in RA.



## Roles of stromal cells and potential significance for future therapy in RA

#### Sang-il Lee Gyeongsang Nat'l Univ., Korea

In addition to various immune cells, it appears that several stromal cells such as fibroblast-like synoviocytes (FLS), lymph node fibro-reticular cells (LN-FRC), and mesenchymal stem/stromal cells (MSC), have been implicated in the pathophysiology of Rheumatoid arthritis (RA). Even though their protective character cannot be denied, in autoimmune pathogenesis, these stromal cells exhibit dysfunctional or aggressive properties influencing the activity of infiltrating immune and other tissue resident cells. Recently we have reported three important perturbations of stromal cells contributing to the immuno-pathogenesis and may providing directions for improving future therapy for RA. First, decreased Raf kinase inhibitory protein (RKIP) or Phospholipase C-eta2 (PLCH2), which are negative regulators in upstream cellular signaling pathway, mediate the aggressiveness of RA-FLS and promote arthritic inflammation and the joint destruction. Second, T cell zone FRCs of LNs (LN-TRCs) express CD25, and CD25-deficient LN-TRCs promote T helper 17 (Th17) cell differentiation and Th17 response-related gene expression in Th17-dependent autoimmune diseases. Third, cellular senescence, due to a long-term exposure to the chronic inflammatory milieu, attenuated immunomodulatory properties of synovial fluid derived-MSC in a long-term RA. Thus, in this lecture, we will summarize recent progress on the molecular signature and the roles of stromal cells contributing pathological progression or presenting promising therapeutic tools for RA and extra-articular complications.

# Symposium

## KCR-KSBMR Joint Symposium



## Anabolic therapy for osteoporosis

Ha Young Kim

Univ. of Ulsan, Korea

Osteoporosis is identified as a systemic skeletal disorder characterized by low BMD and qualitative changes in microarchitecture of bone tissue. There are two major categories of osteoporosis drugs, antiresorptive agents and bone forming agents. Antiresorptive agents increase bone mineral density and prevent the progression of structural damage but may not restore bone structure. However, bone-forming agents can reverse microarchitectural deterioration of bone tissue because they are associated with a larger increase in bone mass than antiresorptive agents.

In recent clinical guidelines, it is recommended to use bone forming agents as the primary treatment in patients with a very high risk of fracture. Currently, three drugs are available: teriparatide, abaloparatide, and romosozumab, and only teriparatide and romosozumab are available in Korea. Teriparatide, an N-terminal (1–34) fragment of human parathyroid hormone, is the first bone forming drug approved by Food and drug administration in 2003. Avaloparatide is a parathyroid hormone-related protein (PTHrP)-like drug and has a mechanism similar to that of teriparatide. Romosozumab is a new bone-forming agent that inhibits sclerostin with a dual effect on bone, increasing bone formation and decreasing bone resorption. In this session, I will review the characteristics and effects of each drug so that it can be helpful in clinical practice.



### Ideal sequential therapy in osteoporosis management

Kyoung Min Kim Yonsei Univ., Korea

The majority of osteoporosis medications are antiresorptive agents, which target osteoclasts and inhibits bone resorption. Bisphosphonates, Denosumab, and Selective Estrogen Receptor Modulator (SER) are this group. On the other hand, Teriparatide (PTH 1-34), daily or weekly regimen, and Romosozumab are currently available anabolic therapies for osteoporosis in Korea. Teriparatide acts by direct stimulation of osteoblast activity and recruitment of those cells and, then promotes bone formation, whereas Romosozumab inhibits sclerostin, a key regulator that has the dual properties of promoting bone formation and inhibiting bone resorption. Both anabolic and antiresorptive agents improve bone mineral density (BMD) and reduce risk of fracture. Osteoporosis is chronic disease and not easy to achieve treatment target, indicating osteopenic BMD T-score or absolute low risk of fractures. Therefore, osteoporosis may require treatment for many years to finally achieve the target goal. Moreover, to maintain or improve BMD further, changing the therapeutic regimen should be also considered. However, because osteoporosis drugs affect each other's mechanism of action, their effects differ depending on the order in which they are used. Therefore, in the sequential treatment of osteoporosis, the order of drug selection is very important and thus should be carefully considered.



### Prevention and treatment of fracture in RA

Jun-Ki Min The Catholic Univ. of Korea, Korea

Patients with rheumatoid arthritis (RA) are at an increased risk of sustaining osteoporotic fractures. In patients with RA, significant amounts of generalized skeletal bone are lost early in the disease which is associated with disease activity. Adults with RA are placed at high risk of falls and fall-related injuries such as fractures. RA-related risk factors including inflammation, presence of anti-citrullinated protein antibodies (ACPA), reduced mobility, sarcopenia, and glucocorticoid (GC) therapy contribute to the increased fracture occurrence in patients with RA. While vertebral fractures can occur without a fall and are often asymptomatic, they are clinically important due to their significant association with greater functional impairment, and an increased risk for future vertebral and non-vertebral fractures in patients with RA.

There is a study showing that the overall mortality rates of hip fractures at 1, 3, 6, and 12 months were 5.0%, 10.6%, 14.8%, 19.8% respectively. Use of opioids, SSRIs and GCs were associated with an increased risk of sustaining any type of fracture (vertebral and non-vertebral) in patients with RA. Bone loss and fracture risk are implicated in inflammatory autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease, and systemic lupus erythematosus. The network of inflammatory cytokines produced during chronic inflammation induces an uncoupling of bone formation and resorption, thereby resulting in significant bone loss in patients with inflammatory autoimmune diseases. Structural bone damage starts before the clinical onset of arthritis in subjects with ACPA. TNFi are associated with decreased vertebral fractures.

All patients taking more than 2.5 mg/day prednisolone or equivalent for more than 3 months are recommended to take adequate calcium and vitamin D. Patients at moderate to high fracture risk should be treated with additional osteoporosis medication. In every RA patient, clinicians should aim to prevent bone loss and reduce fracture risk at the lowest possible disease activity. Strategies must also be considered to reduce and prevent falls and fall-related fractures in patients with RA.

#### Reference

- 1. Xue AL, et al. Bone fracture risk in patients with rheumatoid arthritis Medicine (Baltimore) 2017;96:e6983
- 2. Dirven L, et al. Prevalence of vertebral fractures in a disease activity steered cohort of patients with early active rheumatoid arthritis. BMC Musculoskelet Disord. 2012;13:125.
- 3. Liu L, et al. Outcomes of Rheumatoid Arthritis Patients with Hip Fracture [abstract]. Arthritis Rheumatol. 2016;68 (suppl10)
- 4. OzenG, et al. Medications associated with fracture risk in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78:1041-7
- 5. Raterman HG, et al. Osteoporosis in patients with rheumatoid arthritis: an update in epidemiology, pathogenesis, and fracture preventionExpert Opin Pharmacother. 2020t;21:1725-37.

## **Free Paper Session**

Vasculitis and Metabolic Bone Disease



## Update on comparative cardiovascular safety of febuxostat versus allopurinol among patients with gout

#### Anna Shin¹, <u>Se Rim Choi</u>¹, Minji Han², You-Jung Ha^{1,3}, Yun Jong Lee^{1,3}, Eun Bong Lee^{3,4}, Eun Ha Kang^{1,3}

¹ Division of Rheumatology Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea
² Department of Health Science and Technology, Graduate School of Convergence Science and Technology, Seoul National University
³ Division of Rheumatology Department of Internal Medicine, Seoul National University College of Medicine, Seongnam, Korea
⁴ Division of Rheumatology Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea

#### Background

To update comparative cardiovascular (CV) safety of febuxostat versus allopurinol among patients with gout.

#### **Methods**

Using the 2011-2019 Korea National Health Insurance database, we conducted a cohort study comparing gout patients initiating febuxostat versus allopurinol, with study participants matched on a propensity score (PS) for >60 covariates at a 1:1 ratio. The primary outcome was composite CV outcome of myocardial infarction, coronary revascularization, and stroke. Secondary outcomes were CV and all-cause mortalities in addition to individual components of the primary outcome. Cox proportional hazards models estimated hazard ratios (HRs) and 95% confidence intervals (CIs), comparing febuxostat versus allopurinol initiators.

#### **Results**

We included 160,930 febuxostat users PS-matched on 160,930 allopurinol users (mean age 59.3 years, 79.6% male). During a mean follow-up of 250 days, the incidence rate of the primary outcome was 2.27 and 2.06 per 100 person-years for allopurinol and febuxostat users respectively, with the PS-matched HR [95% CI] of 1.03 [0.95-1.12]. Analysis on secondary outcomes also showed a similar result except for all-cause mortality with a significantly reduced risk among febuxostat users with a PS-matched HR [95% CI] of 0.84 [0.78-0.91] (Table 1).

#### Conclusions

This large population-based cohort study showed a similar CV safety profile between febuxostat and allopurinol users but found a 16% reduced all-cause mortality among febuxostat users compared to allopurinol, primarily derived from non-CV death reduction.

#### **Figure & Table**

	Febuxostat N = 160,930					Allopurir N= 16		HR (95% CI)
	Events	PY	^a IR [95% CI]		Events	PY	"IR(95% CI]	
Composite CV endpoint	2635	128,193	2.06 [1.98-2.13]	1	2,099	92,512	2.27 [2.17-2.37]	1.03 [0.95-1.12]
MI	468	129,873	0.36 [0.33-0.39]		341	93,808	0.36 [0.33-0.40]	1.13 [0.91-1.39]
Coronary revascularization	1085	129,233	0.84 [0.79-0.89]		856	93,293	0.92 [0.86-0.98]	1.10 [0.96-1.26
Stroke or TIA	1490	129,163	1.15 [1.10-1.21]		1,187	93,252	1.27 [1.20-1.35]	0.99 [0.90-1.10]
Death	2558	130,176	1.97 [1.89-2.04]		2,201	94,007	2.34 [2.24-2.44]	0.84 [0.78-0.91]
^a IR is per 100 person-years.	IR=incider	nce rate, HR	=hazard ratio, CI=co	onf	idence int	erval, MI=	myocardial infarctio	n, PY=person-

Table. Comparative cardiovascular safety between febuxostat and allopurinol



#### The utility of dual-energy computed tomography in predicting gout flares in gout patients after discontinuing colchicine prophylaxis

<u>Min Jung Kim</u>¹, Mi Hyeon Kim², Se Rim Choi², Youjin Jung², Jiin Jung², Ju Yeon Kim², Sang Hee Kim¹, Jee Won Chai³, Kichul Shin¹

¹ Division of Rheumatology, Seoul Metropolitan Government–Seoul National University Hospital Boramae Medical Center, Republic of Korea ² Division of Rheumatology, Seoul National University Hospital, Republic of Korea

³Department of Radiology, Seoul Metropolitan Government–Seoul National University Hospital Boramae Medical Center, Republic of Korea

#### Background

To investigate whether monosodium urate (MSU) deposition measured by dual-energy computed tomography (DECT) could help predict acute flares after discontinuing colchicine prophylaxis in gout patients.

#### **Methods**

This pilot, prospective observational study included patients with gout meeting the 2015 gout classification criteria who received urate lowering therapy (ULT) plus a prophylactic dose of colchicine for 6 months. DECT (Revolution CT ES, GE healthcare) was performed at the time point when colchicine was discontinued. Images of unilateral foot and ankle joints were analyzed for MSU deposits (set to moderate or high specificity) by a radiology specialist. Total amount of MSU deposits was calculated by the sum of MSU volume detected. Patients were followed up after 2 months. The odds ratio (OR) for developing an acute flare after colchicine discontinuation were determined using a logistic regression model.

#### **Results**

Twenty-two patients were enrolled and 19 of the 22 patients were evaluated for MSU volumes. The tophi area on physical exam well correlated with total MSU volume set to moderate specificity in DECT (rho 0.68, p=0.01). Presence of tophi on physical exam was significantly associated with acute flare after discontinuing colchicine prophylaxis (OR 13.33, 95% confidence interval (CI) 1.07-166.37, p=0.04, Table). Total volume of MSU in the foot and ankle joints was associated with an increased risk for acute flare, but it did not reach a statistical significance (OR 1.11, p=0.40 for moderate, OR 43.39, p=0.65 for high specificity). The volume of MSU in the foot set to high specificity yielded an AUC of 0.69 (95% CI 0.33-1.00).

#### Conclusions

Presence of tophi itself is a major urate burden in gout patients and requires a longer period of colchicine prophylaxis. DECT is useful in terms of identifying invisible, intraarticular tophi during ULT, yet its clinical application in measuring the overall urate burden needs further investigation.

#### Figure & Table

Variables	Odds ratio (95% CI)	P-value	
Age	1.129 (0.998-1.276)	0.053	
Duration of gout	1.261 (0.909-1.750)	0.165	
Baseline uric acid level	0.865 (0.361-2.073)	0.745	
Presence of tophi	13.333 (1.069-166.374)	0.044	
Tophi size, mm ²	1.098 (0.898-1.343)	0.364	
MSU volume assessed with DECT moderate specificity			
Total MSU volume	1.108 (0.875-1.402)	0.396	
Total MSU volume > 1.2115 ^a	1.333 (0.191-9.311)	0.772	
Foot MSU volume >0.4020 ^b	2.083 (0.298-14.549)	0.459	
MSU volume assessed with DECT high specificity			
Total MSU volume	43.390 (0.000-593442396.6)	0.653	
Total MSU volume >0.0265°	2.083 (0.298-14.549)	0.459	
Foot MSU volume >0.0005 ^d	2.400 (0.303-19.041)	0.407	

Cut-off value for total MSU volume assessed with DECT high specificity in ROC curve analysis "Cut-off value for total MSU volume assessed with DECT high specificity in ROC curve analysis "Cut-off value for foot MSU volume assessed with DECT high specificity in ROC curve analysis

Table. Logistic regression analysis predicting acute gout flares after discontinuing colchicine prophylaxis

#### **Keywords**

Gout, Dual-energy computed tomography, Monosodium urate



## Effects of long-term febuxostat or allopurinol on the progression of chronic kidney disease

#### Byeongzu Ghang¹, Jinseok Kim¹

¹ Rheumatology, Jeju National University School of Medicine, Jeju National University Hospital, Republic of Korea

#### Background

Elevated serum uric acid (sUA) levels are significantly associated with development and progression of chronic kidney disease (CKD). There is controversy over the role of urate-lowering therapy (ULT) in the progression of CKD. We investigated whether ULT has a beneficial effect on slowing the progression of CKD in gout patients.

#### **Methods**

We used the data of patients who took study medication for more than 1 year identified from the Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout (CARES) trial, which is a large, multicenter, randomized controlled trial. We analyzed the estimated glomerular filtration rate (eGFR) slope (mL/min/1.73 m2 per year) using the CKD-EPI equation estimates. Using logistic regression, we investigated risk factors for CKD progression, defined as eGFR slope of lower than 0 mL/min/1.73 m2 per year.

#### **Results**

During the study period [median (interquartile range, IQR) 3.1 (2.0-4.8) year], 4,144 patients performed median (IQR) 12 (9~15) creatinine tests, the GFR slope was analyzed as median (IQR) 0.5 (-0.8-1.6). The median (IQR) values of the GFR slope were -1.2 (-2.3--0.5) in the CKD progression group (n=1,590) and 1.3 (0.7-2.2) in the CKD progression delayed group (n=2,554). After adjusting well known factors associated with CKD progression, average level of sUA  $\geq$  6 mg/dL during study period was significantly associated with CKD progression (adjusted odds ratio 1.73; 95% confidence interval 1.49-2.01, p < 0.0001).

#### Conclusions

This study showed that eGFR did not decrease in more than half of gout patients after long term febuxostat or allopurinol administration. ULT may have a beneficial effect on slowing the progression of CKD in gout patients.

#### Figure & Table




Figure. Changes of estimated glomerular filtration rate during febuxostat or allupurinol administration.

#### **Keywords**

Febuxostat, Allopurinol, Chronic renal insufficiency



<u>KCR 2022</u>

May 19(Thu) - 21(Sat), 2022

#### A cross-sectional internet survey of gout management and outcomes during established COVID-19 pandemic in 2020-2021

#### Jasvinder Singh¹, N Lawrence Edwards¹

¹ Medicine/Rheumatology, UNIVERSITY OF ALABAMA AT BIRMINGHAM, USA

#### Background

Limited data are available for gout management during the COVID-19 pandemic. Our objective was to assess the management of gout in established COVID-19 pandemic.

#### **Methods**

We assessed medication use, healthcare utilization, gout-specific health-related quality of life (HRQOL), psychological distress using patient health questionnaire-4 (PHQ-4), resilience, illness perception, and health literacy in people with physician-diagnosed self-reported gout in established COVID-19 pandemic in a cross-sectional Internet survey.

#### **Results**

Among the 130 survey respondents with gout, the mean age was 62.8 years, 65% were male, 83% were White, 59% were prescribed urate-lowering therapy (ULT), and health literacy was adequate in 80%. A third of survey respondents reported more difficulty with their gout management since September 2020. Gout-specific HRQOL deficits were evident. Moderate-severe psychological distress was seen in 22% and resilience score was 6.5 (SD, 1.9; range 0-8). Adjusted for age, and sex, compared to no/mild psychological distress, moderate-severe psychological distress was associated with significantly higher odds ratio (OR; 95% confidence interval) of more difficulty with: (1) getting healthcare for gout in clinic, 3.7 (1.0, 13.2), emergency room/ urgent care, 8.1 (1.4, 45.0), and in the hospital, 9.8 (1.6, 59.6) ; (2) getting gout flares treated, 6.6 (1.6, 26.8), (3) avoiding gout complications, 4.5 (1.2, 16.7); and (4) daily activities at home, 4.2 (1.3, 14.1) and performing work, 4.1 (1.2, 13.6).

#### Conclusions

Respondents with gout reported healthcare gaps, low rates of ULT prescription, high psychological distress, and HRQOL deficits during established COVID-19 pandemic. Moderate-severe psychological distress was associated with difficulties in healthcare access and gout management. Interventions to address these challenges in gout management are needed.

#### **Keywords**

gout, COVID-19, management



#### The effect of Behçet's disease on carotid intima media thickness and its relationship with disease activity

#### Merve Polat¹, Gökhan Polat², Elshad İsmailov²

¹ HEALTH PHYSICS, Karadeniz Technical University, Turkey ² Department of Radiology, Ataturk University, Turkey

#### Background

It is known that atherosclerosis increases in patients with Behçet Disease(BD). In our study, we aimed to examine the effect on carotid intima-media thickness in patients followed up with the diagnosis of BD.

#### **Methods**

86 cases (mean age: 34.2) and 36 control cases (mean age: 39.12) followed up with the diagnosis of Behçet were included in the study. The clinical and demographic characteristics of the patients were recorded. Activity classification was made based on the Behçet's Disease Instant Activity Form (BHAAF) score: no activity (BHAAF=0), mild activity (BHAAF 1–2), moderate activity (BHAAF 3–5), high activity (BHAAF 6–12). Carotid ultrasonography was performed in all cases to evaluate subclinical atherosclerosis and intima-media thickness (IMT) was evaluated.

#### **Results**

There was no significant difference between the groups in terms of age and gender.The mean duration of disease was 29.6 months, the use of cyclophosphamide was 25.6%, the use of steroids 96.2%, and the use of Interferon alfa-2b was 29.9%. The carotid IMT of Behçet's patients (mean 0.812mm) was significantly higher than the control (mean 0.632mm) (p=0.031). There were 31 patients with BHAAF =0, 16 patients with BHAAF 1–2, 16 patients with BHAAF 3–5, and 22 patients with BHAAF 6–12.A moderate correlation was found between carotid IMT and disease activity (r=0.734, p=0.006).

#### Conclusions

An increase in carotid intima media thickness is observed in cases with Behçet's disease, and there is a correlation between disease activity and carotid intima media thickness.



#### Reclassification of patients with previously diagnosed GPA according to both the 2012 CHCC definitions and the 2007 EMA algorithm using the 2022 ACR/EULAR criteria

Jung Yoon Pyo¹, Sung Soo Ahn¹, Jason Jungsik Song¹, Yong-Beom Park¹, Sang-Won Lee¹

¹ Internal Medicine, Yonsei University College of Medicine, Republic of Korea

#### Background

This study applied the 2022 criteria for granulomatosis with polyangiitis (GPA) proposed by the American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) (the 2022 ACR/EULAR criteria) to Korean patients with previously diagnosed GPA to investigate the number of patients who could be reclassified as having GPA.

#### **Methods**

Sixty-five patients with GPA, who met the 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides and the 2007 European Medicines Agency algorithm for GPA, were included in this study. They were reclassified based on the 2022 ACR/EULAR criteria.

#### Results

Of the 65 patients, 48 patients (73.8%) were reclassified as having GPA. A patient could not be reclassified as having GPA if the patient did not have a total score of 5 despite granulomas on biopsy or clear GPA surrogate markers. Among the 17 patients unclassified as having GPA, 16 patients were reclassified as having MPA and one as having unclassifiable vasculitis, and furthermore, 94.1% of them harboured myeloperoxidase (MPO)-antineutrophil cytoplasmic antibody (ANCA) (or perinuclear (P)-ANCA).

#### Conclusions

The concordance rate between the 2022 ACR/EULAR criteria for GPA and the previous criteria in patients with previously diagnosed GPA was 73.8%. We carefully suggest three points when the 2022 ACR/EULAR criteria are applied to patients with previously diagnosed GPA: First, escalating the score assigned to granuloma on biopsy and cartilage involvement; second, strongly recommending performing a biopsy in cases of highly suspicious GPA; and third, reconsidering the highest weightage assigned to MPO-ANCA (or P-ANCA) positivity.

#### Figure & Table

Variables		Values
At the time of diagnosis		
Items for the 2022 ACR/EULAR criteria for GPA and assigned scores to each item (N (%	))	
Clinical criteria		
Nasal involvement (discharge, ulcers, crusting, congestion, septal defect/perforation)	+3	33 (50.8)
Cartilaginous involvement	+2	13 (20.0)
Conductive or sensorineural hearing loss	+1	20 (30.8)
Laboratory, imaging and biopsy criteria		
PR3-ANCA (or C-ANCA) positivity	+5	36 (55.4)
Pulmonary nodules, mass or cavitation	+2	41 (63.1)
Granuloma, granulomatous inflammation, or giant cells on biopsy	+2	30 (46.2)
Nasal/paranasal sinusitis or mastoiditis on imaging	+1	41 (63.1)
Pauci-immune glomerulonephritis on biopsy	+1	18 (27.7)
MPO-ANCA (or P-ANCA) positivity	-1	28 (43.1)
Serum eosinophil count $\geq 1000/\mu L$	-4	2 (3.1)
Total score for 10 items above		7.0 (7.0)
Patients with total score $\geq 5$ (N (%))		48 (73.8)

ACR: American College of Rheumatology; EULAR: European Alliance of Associations for Rheumatology; GPA granulomatosis with polyangiitis; PR3: proteinase 3; C: cytoplasmic; MPO: myeloperoxidase; P: perinuclear.

Table. Application of the 2022 ACR/EULAR criteria for GPA to patietns with previously diagnosed GPA

#### **Keywords**

granulomatosis with polyangiitis, 2022 ACR/EULAR classification criteria



#### Patterns of coronary involvement of antineutrophil cytoplasmic antibody (ANCA) - associated vasculitis in Korean patients

#### Jinseok Kim¹, Sang-won Lee¹

¹ Internal medicine, Yonsei University College of Medicine, Republic of Korea

#### Background

This study investigated the frequency and clinical features of acute coronary syndrome (ACS) in patients with antineutrophil cytoplasmic antibody (ANCA) -associated vasculitis (AAV).

#### **Methods**

Medical records of 262 patients with AAV were retrospectively reviewed (140 with microscopic polyangiitis [MPA], 69 with granulomatosis with polyangiitis [GPA], and 53 with eosinophil GPA [EGPA]). This study defined ACS as only myocardial infarction and unstable angina occurring at and after AAV diagnosis. The vessels affected and the period between diagnosis and ACS were also assessed.

#### **Results**

The median age at diagnosis and follow-up period were 59.0 years (92 men) and 37.0 months, respectively. ACS was found in 7 patients with AAV (2.7%; 5 with MPA and 2 with EGPA). Three patients (2 with MPA and 1 with EGPA) had ACS at AAV diagnosis and furthermore, all EGPA patients had ACS before 40 years of age. In particular, two patients who exhibited the refractory course of AAV after ACS experienced ACS recurrence.

#### Conclusions

EGPA may be associated with ACS occurring in not-elderly patients, and the refractory AAV may be related to ACS recurrence.

#### **Figure & Table**




Figure. Age at ACS in patients with AAV, B. Time form AAV diagnosis to ACS

#### **Keywords**

ANCA-associated vasculitis, acute coronary syndrome



## Comparison of ultrasound-guided trigger-point needling and blinded needling for myofascial pain syndrome

Recep Sade¹, Meltem Alkan melikoglu²

¹ Radiology, Ataturk University, Turkey ² Rheumatology, Ataturk University, Turkey

#### Background

Most myofascial pain syndromes in clinical practice are caused by the myofascial trigger point (MTrP) formation. Recent clinical studies show that MTrP dry needling is most effective to release myofascial pain after local twitch response (LTR) is elicited. The aim of this study was to compare trigger point dry needling (TrP-DN) under ultrasound (US) guidance with TrP-DN without US guidance for myofascial pain management.

#### **Methods**

This study consisted of intervention and control groups. The intervention group received dry needling with US guidance and the control group received dry needling without US guidance. This study included 60 patients who had myofascial pain diagnosed after assessment by clinical examination and necessary diagnostic tests. The intervention group consisted of 36 patients: 11 males and 25 females. After US scanning identified the MTrP, dry needling, steel acupuncture needles (28 gauge) were used to elicit the LTR. The needling was performed during 2–4 sessions to inactivate all available trigger points.

#### Results

TPain, as measured on a visual analogue scale (VAS; 0–10) showed a significant reduction (P < 0.001) from 8.1 to 1.3 at 24 hours after dry needling with US in the intervention group (pain level decreased in 88% of the subjects), compared to improvement from 8.4 to 2.5 at 24 hours after dry needling without US guidance (pain level decreased in 72.5% of the subjects) in the control group (P < 0.001). There were significant correlations between the level of eliciting LTR during needling and the pain-relief effect (VAS decreased more than average percentage in group; r = 0.812).

#### Conclusions

US guidance significantly increased the pain relief effect, increases the level of eliciting LTR, and significantly decreased the average number of needled trigger points and the average number of treatment sessions. This approach can be utilized further to address musculoskeletal pain and neuromuscular diseases.

#### **Figure & Table**




Figure. Ultrasound image of 52-year old females shows neddle (arrows) in the trigger point

#### **Keywords**

Myofascial Trigger Points, Ultrasound, Dry Needling

# International Symposium

New Horizon of Systemic Sclerosis



### Update in the pathogenesis of systemic sclerosis

Christopher Denton Royal Free Hosp., UK

Systemic sclerosis (SSc) is an uncommon disease autoimmune connective tissue disease with high medical impact and mortality. There is increasing understanding of aetiopathogenesis that is likely to reflect interplay between host and environmental factors. Host factors include age, gender, and ethnicity together with genetic susceptibility. Genetic aspects have been studies in large multicentric cohorts and have defined important immunogenetic factors as well as establishing genomic risk scores including different genetic traits. In addition, there are robust associations with major histocompatibility haplotypes that particularly link to hallmark antinuclear antibodies. As well as determining susceptibility to SSc, genetic factors that modify severity and organ involvement such as lung complications or renal crisis are being discovered. These may be important in determining clinical diversity in SSc.

Environmental triggers have been described including solvents, chemotherapeutic agents, and vaccination. These triggers have led to clusters of cases and provided additional insights into pathogenic mechanisms. The clinical diversity of SSc reflects shared and subtype specific mechanisms underlying subset classification and organ-based complications. It is likely that triggering events occur linked to the organ involved and this has been defined in preclinical models where lung epithelial injury may lead to fibrosis, or vascular endothelial injury may trigger pulmonary hypertension.

Tissue repair and wound healing provides the most relevant biological correlate of key pathogenic events in SSc, and growing understanding of the regulation and control of tissue repair is providing more insight into likely drivers of SSc fibrosis or vasculopathy. Defining the normal resolution and regression pathways that may operate in skin wound healing is likely to be important in understanding the spontaneous improvement of scleroderma skin fibrosis in SSc that can confound clinical trials testing of new therapies for skin.

Finally, recent studies have applied high dimensional analysis of gene or protein expression in skin or blood and started to map the keep cellular processes and interactions that are perturbed in SSc. Together with comparative studies of different stages or subsets of disease and different ANA subtypes this is giving insight into SSc diversity that will help improve clinical trial design and future treatment.



## Update in interstitial lung disease in SSc

Oliver Distler Univ. Hosp. Zurich, Switzerland

Systemic



## Update in pulmonary arterial hypertension in SSc

Eun Bong Lee

Seoul Nat'l Univ., Korea

Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of skin and internal organs. Pulmonary arterial hypertension (PAH) is one of the leading causes of death in patients with SSc. Unlike idiopathic PAH, the pathophysiology of SSc-related PAH is complex. Hypertrophy of pulmonary artery, interstitial lung disease and heart failure all can also contribute to development of PAH. Recently, the cut-off value for the diagnosis of PAH, which is measured by mean pulmonary arterial pressure through right heart catheterization, was changed from 25 mmHg to 20 mmHg. Since there are several effective medications, early diagnosis of PAH is essential. Three major classes of medications are used to treat PAH, which include prostaglandin analogues, endothelin receptor antagonists and phosphodiesterase V inhibitors. The effectiveness of early aggressive combination therapy is being more advocated now.

# **Free Paper Session**

Rheumatoid Arthritis Basic Research



#### Orosomucoid acid-2, an acute phase reactant, promotes rheumatoid inflammation

#### Kimyo Kim¹, Bong-Ki Hong¹, Seung-Ah Yoo¹, Wan Uk Kim¹

¹ Center for Intergrative Rheumatoid Transcriptomics and Dynamics, The Catholic University of Korea, Republic of Korea

#### Background

Acute phase proteins, including serum amyloid A and C-reactive proteins, potentially contribute to chronic inflammation, it remains unclear whether orosomucoid-2 (ORM2), one of acute phase proteins mainly produced from liver, directly promotes rheumatoid inflammation. In this study, we investigated the pathogenic mechanism of ORM2 in autoimmune inflammatory arthritis.

#### **Methods**

ORM2 expression was determined by ELISA and immunostaining. Fibroblast-like synoviocytes (FLSs) and macrophages were cultured in the presence of ORM2. NF-ØB and p38 MAPK expression was assessed by Western blot analysis. Knockdown experiments were carried out using siRNAs for NF-κB p65, p38, and glycophorin C (GYPC). Proximity ligation assay was performed to test whether ORM2 interacts with GYPC as its receptor. Recombinant ORM2 was injected in the affected joints of mice with IL-1induced arthritis.

#### Results

ORM2 expression was elevated in the sera, synovial fluids, and synovia of patients with rheumatoid arthritis (RA), and markedly increased by IL-1 $\beta$  and TNF- $\alpha$  stimulation. Major cell type producing ORM2 was synovial macrophages and fibroblasts. Recombinant ORM2 directly upregulated IL-6, TNF- $\alpha$ , IL-8, and CCL2 by macrophages and/or FLSs of RA patients via NF- $\kappa$ B and p38 MAPK pathways. GYPC was the receptor of ORM2. Such increase by ORM2 was reproduced in mouse macrophages and FLSs. Intra-articular injection of ORM2 promoted severity of IL-1-induced arthritis in mice, accelerating infiltration of macrophages in the affected joints. Moreover, in RA patients, circulating ORM2 levels correlated with disease activity, as assessed by DAS28, and represented well radiographic progression in 2 years.

#### Conclusions

Acute phase protein ORM2, mainly produced by synovial macrophages, directly increases production of pro-inflammatory cytokines/chemokines by macrophages and FLSs, and promotes chronic arthritis in mice, suggesting that it could be a diagnostic and therapeutic target of RA.

#### **Figure & Table**

Model of the ORM2 reciprocal activation between macrophages and FLSs in RA joints environments.

#### **Keywords**

orsomucoid-2, glycophorin C, rheumatoid arthritis



## LKB1 regulates the migration of fibroblast-like synoviocytes via oxidative stress-induced inflammatory cytokines in patients with rheumatoid arthritis

#### Ha-Reum Lee^{1,2}, Jinhyun Kim², Su-Jin Yoo^{1,2}, Ji Ah Park², Seong Wook Kang^{1,2}

¹ Research Institute for Medical Sciences, Chungnam National University School of Medicine, Republic of Korea ² Division of Rheumatology, Department of Internal Medicine, Chungnam National University Hospital, Republic of Korea

#### Background

Liver kinase B1 (LKB1) is known as a tumor suppressor gene and also inhibits reactive oxygen species (ROS) production. It is not clear about the role of LKB1 in rheumatoid arthritis (RA) until now.

#### **Methods**

Synovial tissues were obtained from RA patients who were undergoing synovectomy or joint replacement. Fibroblast-like synoviocytes (FLS) were used for experiments after four to six passages. Cells were transfected with siR-NA duplex targeting constructs of LKB1 or NOX4 (nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 4) using lipofectamine transfection reagent. After incubation for 24 h, downregulation of target expression was evaluated by real-time PCR and western blot analysis. The levels of inflammatory cytokines were analyzed by RT-qPCR and ELISA. ROS levels were stained using MitoSOX dye using flow cytometry. Cell migratory ability was analyzed using transwell migration assay.

#### **Results**

The mRNA expression of LKB1 was decreased by 91 % after transfection with LKB1 siRNA compared to scramble siRNA. LKB1 knock-down caused the increased expressions of NOX4, IL-6, tumor necrosis factor alpha (TNF-α), and VEGF in RA FLS (n=5). Following LKB1 deficiency, ROS levels and cell migration were increased in RA FLS. Because NOX4 catalyze intracellular ROS, NOX4 inhibitor (GLX351322; 2.5 or 5 µM) decreased intracellular ROS expression compared to no treatment in scramble siRNA. Unexpectedly, LKB1 knock-down FLS showed increased ROS rather than declining. To investigate the susceptibility to ROS, RA FLS were stimulated with hydrogen peroxide (1 mM) for 3 hr. Hydrogen peroxide increased ROS expression by 2.78 fold compared to no treatment in scramble siRNA transfected cells. Interestingly, LKB1 deficient FLS showed that hydrogen peroxide increased ROS production by 5.57 fold and elevated IL-1β expression by 6.90 fold compared to control.

#### **Conclusions**

LKB1 knockdown induced ROS-mediated pro-inflammatory cytokine productions and increased the susceptibility to oxidative stress than control in RA FLS.

#### **Keywords**

rheumatoid arthritis, reactive oxygen species, inflammation



#### Postranslational modification in mammals protects citrullinated MCP1/CCL2 chemokine from partial degradation

<u>Nataliia Korchynska</u>^{1,2}, Ken Yoshida³, Paul Peter Tak⁴, Ger J.M. Pruijn⁵, Takeo Isozaki³, Jeffrey H. Ruth³, Phillip L. Campbell³, M.Asif Amin³, Alisa E. Koch^{3,6}, Olexandr Korchynskyi^{1,4,7}

¹ Medicine, Rzeszow University, Rzeszow, Poland

² Ecology, National Forestry University, Lviv, Ukraine, Ukraine

⁴ Clinical immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, Netherlands

⁵ Department of Biomolecular Chemistry,, Institute for Molecules and Materials, Radboud University, Nijmegen, Netherlands

⁶ Department of Veterans Affairs, Medical Center, Ann Arbor, Michigan,, USA

⁷ Molecular Immunology, Institute of Biochemistry, National Academy of Sciences of Ukraine, Kyiv,, Ukraine

#### Background

Citrullination is a postranslational modification of specific proteins. Nowadays citrullination is a hallmark of rheutamoid arthritis and other autoimmune diseases. In our recent study we demonstrated citrullinated ENA78/CXCL5 as an efficient macrophage chemoattractant in a contrast with non-citrullinated chemokine. In our current work we found that citrullinated in vitro bacterially produced MCP1/ CCL2 chemokine undergoes partial degradation and cannot be efficiently used in biological assays designed to detect citrullinated chemokines and their activities.

Goal: In our work we aimed generate a procedure for preparation of stable citrullinated MCP1/CCL2 chemokine suitable for research applications and to validate a hypothesis that posttranslational modifications occurring in mammalian cells can stabilize and protect citrullinated chemokines from quick degradation.

#### **Methods**

MCP-1/CCL2 was cloned from total RNA isolated from synovial fibroblasts obtained from RA patient. Both bacterially-produced and mammalian cells-produced recombinant human chemokine were citrullinated by commercial rabbit peptidylarginine deiminase (PAD)2, or by HEK293 cells produced human recombinant PAD2, PAD3 or PAD4. Citrullination was confirmed with Western blotting, modified sandwich ELISA assays and mass-spectrometry.

#### **Results**

Both commercially available and self-made bacterially produced MCP1/CCL2, undergo quick partial degradation upon their in vitro citrullination by rabbit muscle PAD2, or overexpressed human recombinant PAD2 or PAD4 and cannot be detected with either Western blotting or mass-spectrometry. At the same time mammalian cells-produced properly glycosylated MCP1/CCL2, can be efficiently citrullinated, detected and successfully used as the standards in modified ELISA assays as well as in bioassays. At the same time, a site-directed inactivation of a single potential glycosylation site at asparagine 14 (N14) does not change the stability of mammalian cells produced MCP1/CCL2.

#### Conclusions

Glycosylation that is lucking in bacterially-produced proteins but occurs in mammalian cells stabilizes citrullinated chemokines thus protecting them from quickly ongoing partial degradation.

#### **Keywords**

Monocyte chemotactic protein 1, rheumatoid arthritis, citrullination, peptidylarginine deiminase, glycosylation

³ Division of Rheumatology, University of Michigan Medical School,, USA



## Assessment of disease activity in patients with rheumatoid arthritis utilizing plasma tumor M2-pyruvate kinase test

#### Sung Soo Ahn¹, Younhee Park²

¹ Internal Medicine, Division of Rheumatology, Yongin Severance Hospital, Yonsei University College of Medicine, Republic of Korea
² Laboratory Medicine, Severance Hospital, Yonsei University College of Medicine, Republic of Korea

#### Background

Pyruvate kinase M2 (PKM2) is an enzyme regulating the final process of glycolysis, which exists in tetrameric and dimeric form. The dimeric form of PKM2  $\blacksquare$  also known as tumor M2-PK  $\blacksquare$  increases when aerobic glycolysis is augmented, which is a feature observed in rheumatoid arthritis (RA). We evaluated whether plasma tumor M2-PK is elevated in RA patients and correlated to disease activity.

#### **Methods**

Plasma obtained from RA (n=151) and osteoarthritis (OA) (n=37) patients, as well as controls (n=37) were utilized to measure tumor M2-PK level. Associations of plasma tumor M2-PK with continuous variables was evaluated by Pearson's analysis, and logistic regression analysis was carried out to determine the relationship between plasma tumor M2-PK with disease activity status.


#### Results

Tumor M2-PK level significantly correlated with disease activity score (DAS)28-erythrocyte sedimentation rate (ESR) (r=0.546, p<0.001) and DAS28-C-reactive protein (CRP) (r=0.589, p<0.001). Serial tumor M2-PK level testing in 20 patients exhibited a significant decline of tumor M2-PK level after reduction of inflammation (p<0.001). Area under the receiver operator curve analysis demonstrated that incorporation of tumor M2-PK, ESR, and CRP had an area under the curve 0.962 in discriminating between moderate/high and remission/low disease activity. Furthermore, adjusted logistic regression analysis revealed that tumor M2-PK > 43.9 U/mL (OR 3.672, p=0.042) independently predicted moderate/high disease activity status. Finally, tumor M2-PK level in RA patients was significantly higher than OA patients and controls (all p<0.001).

#### Conclusions

Plasma tumor M2-PK level might be a clinically useful indicator for evaluating disease activity and diagnosis of RA.

#### Figure & Table



#### **Keywords**

Tumor M2-pyruvate kinase, rheumatoid arthritis, disease activity



#### Association analysis of a MUC5B promoter variant rs35705950 with rheumatoid arthritis-interstitial lung disease in Korea

Young Bin Joo¹, So-Young Bang^{1,2}, Soo-Kyung Cho^{2,3}, Chan-Bum Choi^{2,3}, Yoon-Kyoung Sung^{2,3}, Tae-Hwan Kim^{2,3}, Jae-Bum Jun^{2,3}, Dae Hyun Yoo^{2,3}, Sang-Cheol Bae^{2,3}, Hye-Soon Lee^{1,2}

¹ Division of rheumatology, Department of internal medicine, Hanyang University Guri Hospital, Guri, Republic of Korea
 ² Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea
 ³ Department of rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea

#### Background

It has been suggested that idiopathic pulmonary fibrosis and rheumatoid arthritis-interstitial lung disease (RA-ILD) share genetic background, among which a MUC5B promoter variant rs35705950 has been reported to be the most significant risk variant for RA-ILD in Caucasian populations. However, this MUC5B variant has shown different genetic traits according to ethnicity. Until recently. little is known about the significant association of MUC5B with RA-ILD in Asian populations. This study aimed to identify the association of MUC5B variant rs35705950 with Korean RA-ILD patients.

#### **Methods**

Patients were recruited from Hanyang university hospital for rheumatic diseases (n=1,846). RA-ILD was defined based on chest CT or chest x-ray. The MUC5B variant rs35705950 was genotyped by TaqMan genotyping assays. The chi-square test was used to test for differences in MUC5B variant between RA-ILD and RA without ILD group (RA-noILD).

#### **Results**

The minor allele frequency of MUC5B variant was 0.0046. The number of wild-type (GG), heterozygous (GT) and mutant genotype (TT) were 1,829, 17, and 0, respectively. There was no difference of heterozygous between two groups (n=2/75, 2.7% for RA-ILD, n=15/1770, 0.8% for RA-noILD, P=0.150). Among the 350 RA patients who had chest CT, the prevalence of RA-ILD was 16.3% (n=57/350). UIP pattern (45.6%) was the most frequent, followed by nonspecific interstitial pneumonia (22.8%), indeterminate (15.8%) and organizing pneumonia (14.0%). No association was observed in chest CT-confirmed RA-ILD with MUC5B variant (heterozygous number=2/57, 3.5% for RA-ILD, n=8/293, 2.7% for RA-noILD, P=0.669)

#### Conclusions

Although MUC5B variant is common and strongly associated with RA-ILD in Western population, it is rare in Korean RA patients and appears to be insignificant as a genetic risk factor for Korean RA-ILD patients. These results support the concept that the genetic background of RA-ILD differs according to ethnicity, raising the need to search for novel genetic risk factors for RA-ILD in Korean.

#### **Keywords**

rheumatoid arthritis-interstitial lung disease, MUC5B, genetic risk factor



#### Therapeutic effect of folic acid in collagen-induced arthritis mouse model

Kijun Lee¹, Young Woo Ryu¹, Ji Hyeon Ju^{1,2}

¹ Catholic iPSC Research Center, The Catholic University of Korea, Republic of Korea ² Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, Institute of Medical Science, College of Medicine, The Catholic University of Korea, Republic of Korea

#### Background

Folic acid (FA) supplements are commonly prescribed to rheumatoid arthritis (RA) patients suffering side effects of methotrexate (MTX). But patients are still suffering from the side effects of MTX. We undertook this study with the expectation that FA can be a substitute for MTX with its anti-inflammatory effect. This study investigated the anti-inflammatory effects of FA and demonstrated the possibility of FA as an anti-inflammatory drug.

#### **Methods**

In vivo and ex vivo experiments were set up to figure out whether the administration of FA induces an anti-inflammatory response. DBA/1J mice were induced into the collagen-induced arthritis model (CIA model) and randomly assigned to six groups. Five groups were each assigned to one of five treatments, and the other group was assigned as the control group. FA, MTX, vehicle was administered through the peritoneum (intraperitoneal injection, i.p.). Histological examination and CIA Scoring were done to examine the severity of RA. In vitro experiments were done with LPS-stimulated mouse splenocytes to observe the anti-inflammatory effects of immune cells. The effect of treatments with different dosages of FA and MTX were analyzed by qRT-PCR, FACS, human phospho-kinase array, and western blot assay.

#### **Results**

Histological examination of tarsal joints in the hind paws of mice showed that FA and MTX treatment alleviates synovial inflammation. While normal control showed clear identified joint spaces, the CIA model presented severe inflammatory infiltration resulting in tarsal bone and cartilage destruction. Treatment of FA and MTX alleviated inflammatory lesions of the CIA model. Moreover, a higher dose(500ug/mouse) of FA shows more alleviated inflammatory lesions and cleaner cartilage zone.

#### Conclusions

According to the results, FA has anti-inflammatory effects on RA. But there's a lack of evidence for whether FA can be a complete substitute for MTX to human RA patients. Practical applications and ideas for further research are suggested.

#### Figure & Table




Figure. Effects of folic acid on the severity of CIA demonstrated by clinical arthritis score, incidence rate, visual examination

#### **Keywords**

Rheumatoid arthritis, Folic acid, Collagen-induced arthritis model

# Symposium

Coding and Insurance Guideline in Rheumatic Disease



## **Rheumatic diseases and KCD 8th revision**

#### Sukil Kim

The Catholic Univ. of Korea, Korea

Most of rheumatic diseases are rare and subject to be the target of benefit extension policy by the government. From the patient's point of view, the policy is a favorable to the patients because it relieves the patients from the economic burden caused by the diseases.

On the other hand, to be classified as a rare disease, the incidence should be calculated through coding with proper classification. KCD-8 (Korean Classification of Diseases version 8), which is based on ICD-10 (International Classification of Diseases version 10), has long been used in Korea for the purpose. Some of new diseases have been found by recent medical knowledge and there have been new infectious diseases, such as COVID-19. Any diseases should be listed on the ICD to be utilized for disease epidemiology and health care system. However, the structure of ICD-10 reached a technical limitation and was not able to include new diseases. It is one of the main reasons for the revision of ICD-11.

The World Health Assembly adopted ICD-11 in May 2019. Most countries using ICD-10 are conducting various research or planning for the full-scale introduction of ICD-11, which has a large impact on the health care system of their own. The latest Korean version of ICD-10, KCD-8, was announced in 2020 by Statistics Korea. But none of ICD-11 contents was included in it.

During the national audit for the Health Insurance Review and Assessment Service (HIRA) in the National Assembly in October of last year, Rep. Hye-young Choi addressed inadequate use of the KCD-8 for calculation of rare and incurable diseases. pointed out the problem, and the director of the HIRA said that the ICD-11 would be introduced as an alternative.

The Ministry of Health and Welfare and the HIRA have the governance of ICD-11 required to operate the Korean healthcare system and are planning to introduce ICD-11. They also want to work together with the medical community. The medical community is expected to participate in the management ICD-11 organized by either the Ministry of Health and Welfare in local level or WHO in global level. It will be of great help to the development of related fields.



## Principles and future prospects of insurance benefits in rheumatoid diseases

## Gihyeon Seo

Health Insurance Review and Assessment Service, Korea



## Insurance Guideline and Tips for Treatment of Rheumatic Disease

Seung-Jae Hong Kyung Hee Univ., Korea

In this lecture, the causes for the most frequent denial of insurance coverage are presented along with the real-world cases. Some causes are reasonable such as extractable nuclear antigen (ENA) panel/anti-dsDNA test, some genetic maker studies, and radiographic findings, while many other causes are irrational, such as a few days gap in csDMARDs coverage before bDMARD/tsDMARDs prescription. Along with efforts to improve insurance coverage criteria, keen efforts on behalf of clinicians are required to reduce the losses and harm incurred by such denial.

# KCR 2022

42nd Korean College of Rheumatology Annual Scientific Meeting and the 16th International Symposium

May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea

# E-POSTER PRESENTATION

May 19(Thu) - 21(Sat), 2022

# **E-poster Presentation**

RA-pathogenesis and animal model & Cytokines and mediators

> KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



## Anti-arthritic activities of the eleutherococcus senticosus, achyranthes japonica, and atractylodes japonica mixed extract fermented with nuruk in a type II collagen-induced arthritis mouse model

<u>Chong Hyuk Chung</u>¹, Ju-Young Kim², Yoon-Hee Cheon², So-Young Eun², Chang-hoon Lee¹, Myeung-Su Lee¹

¹ Rheumatology Department, School of Medicine, Wonkwang University, Republic of Korea 2 Musculoskeletal and Immune Disease Research Institute, School of Medicine, Wonkwang University, Republic of Korea

#### Background

Rheumatoid arthritis (RA) is an autoimmune disease that is accompanied by chronic synovitis, progressive cartilage, and bone destruction and is affected by inflammatory-associated factors. Vigeo is a mixture of fermented extracts of Eleutherococcus senticosus Maxim (ESM), Achyranthes japonica (Miq.) Nakai (AJN), and Atractylodes japonica Koidzumi (AJK) manufactured using the traditional Korean nuruk fermentation method. Although the bioactive effects of ESM, AJN, and AJK have already been reported, the pharmacological effects of Vigeo have not been proven. Therefore, in this study, we investigated whether Vigeo had inhibitory effects on RA and its intracellular mechanisms using a type II collagen-induced arthritis (CIA) mouse model.

#### **Methods**

CIA was induced in DBA/1 mice by immunization with bovine type II collagen. The mice were administered orally with Vigeo (200 and 500 mg/kg/day, i.g.) from days 21 to 42 after immunization. The clinical scores, hind paw swelling, and histopathological finding were evaluated in the paw of CIA mice. The levels of tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ), interleukin (IL)-6, and IL-1 $\beta$  in the serum were measured by enzyme-linked immunosorbent assay.

#### Results

The results showed that Vigeo 500 mg/kg treatment significantly alleviated the severity of the disease, based on the reduced hind paw swelling and clinical scores, compared with untreated CIA mice. Comparing with untreated CIA mice, Vigeo 500 mg/kg treatment inhibited the levels of TNF- $\alpha$ , IL-6, and IL-1 $\beta$  in the serum.

#### Conclusions

In conclusion, our results suggest that anti-inflammatory effects of Vigeo against collagen-induced arthritis in mice may be due to its ability to inhibit pro-inflammatory mediators. Vigeo may be a promising potential therapeutic reagent for arthritis treatment.



## A green-lipped mussel prevents rheumatoid arthritis via regulation of inflammatory response and osteoclastogenesis

#### Seungcheon Yang¹, <u>Hong Ki Min</u>², Jin-Sil Park¹, Hyun Sik Na^{1,3}, Jooyeon Jhun¹, Mi-La Cho^{1,5}, Sung-Hwan Park^{1,4}

¹ The Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Republic of Korea
 ² Division of Rheumatology, Department of Internal Medicine, Konkuk University Medical Center, Republic of Korea
 ³ Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Republic of Korea
 ⁴ Division of Rheumatology, Department of Internal Medicine, College of Medicine, Seoul St. Mary's Hospital, The Catholic University of Korea, Republic of Korea
 ⁵ Department of Medical Lifescience, College of Medicine, The Catholic University of Korea, Republic of Korea

#### Background

Rheumatoid arthritis (RA) is a chronic inflammatory disorders characterized by progressive joint destruction. The green-lipped mussels (GLM) are known to have chondro-modulator and anti-inflammatory properties, but studies on the effects and action mechanism of GLM on RA are still insufficient.

#### **Methods**

Collagen-induced arthritis (CIA) mice was used, and treated with vehicle, methotrexate, and GLM. The incidence of arthritis, arthritis score, histological score were assessed. Immunohistochemical stains for tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ), interleukin (IL)-1 $\beta$ , IL-6, IL-17, and TRAP on ankle joint were evaluated. Splenocytes were used to measure IL-17+ CD4+ cells, and confocal stain for CD4+ IL-17+ in spleen was evaluated. Bone marrow-derived monocyte/macrophage of mice and peripheral blood monocytes of human were used to evaluate osteoclastogenesis.

#### **Results**

Application of GLM attenuated the arthritic severity and histologic score in CIA mice than vehicle group. Expression of pro-inflammatory cytokines (TNF- $\alpha$ , IL-1 $\beta$ , and IL-17) were decreased in the ankle joints from GLM-treated CIA mice. Frequencies of IL-17+ CD4+ cells decreased in ex vivo splenocytes from GLM-treated CIA mice, and decrease of IL-17+ CD4+ cells were also observed in confocal stain of GLM-treated CIA mice spleen. Moreover, GLM inhibited osteoclastogenesis of mice BMMs and human monocytes in vitro.

#### Conclusions

These results suggest that GLM has potential as a therapeutic agent for RA by controlling pathologic immune cells and osteoclastogenesis.



## HLA-DRB1 non-SE fine specificity associations with anti-RA33 autoantibody positivity in rheumatoid arthritis patients stratified by different serological phenotypes

Nurul Aain Ahmad fauzi¹, Shereen Ch'ng suyin², Hazlyna Baharuddin^{2,3}, Mollyza Mohd zain², Ing Soo Lau², Habibah Yusoof², Azlin Ahmad², Azmillah Rosman², Siti Aisyah Abdul ahmad¹, Wahinuddin Sulaiman⁴, Heselynn Hussein⁵, Nor Shuhaila Shahril⁵, Suk Chyn Gun6, Eashwary Mageswaran⁵, Mohd Shahrir Mohamed said⁷, Ainon Mohd mokhtar⁸, Muhaini Othman⁴, Shahnaz Murad¹, Leonid Padyukov¹⁰, Lars Alfredsson¹¹, Lars Klareskog¹⁰, Johan Rönnelid¹², Chun Lai Too^{1,10}

¹ Immunogenetic Unit, Allergy and Immunology Research Centre, Institute for Medical Research, National Institutes of Health Complex,

² Department of Internal Medicine, Selayang Hospital, Ministry of Health Malaysia, Malaysia

³ Faculty of Medicine, Universiti Teknologi MARA, Malaysia

⁴ Department of Internal Medicine, Raja Permaisuri Bainun Hospital, Ministry of Health Malaysia, Perak, Malaysia
 ⁵ Department of Internal Medicine, Putrajaya Hospital, Ministry of Health Malaysia, Putrajaya, Malaysia
 ⁶ Department of Internal Medicine, Tuanku Ja'afar Seremban Hospital, Ministry of Health Malaysia, Negeri Sembilan, Malaysia
 ⁷ Faculty of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Kuala Lumpur, Malaysia
 ⁸ Department of Internal Medicine, Tengku Ampuan Afzan Hospital, Ministry of Health Malaysia, Kuantan, Pahang, Malaysia
 ⁹ Department of Internal Medicine, Raja Permaisuri Bainun Hospital, Ministry of Health Malaysia, Ipoh, Perak, Malaysia
 ¹⁰ Division of Rheumatology, Department of Medicine, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden
 ¹¹ Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Malaysia
 ¹² Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden

#### Background

Development of seropositive RA is well-associated with presence of HLA-DRB1 SE alleles (i.e., DRB1*01, *04 and *10). We investigated the role of HLA-DRB1 non-SE alleles as risk for anti-RA33 autoantibody positivity in diverse RA serological subsets, as defined by anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) status.

#### **Methods**

A total of 550 RA cases comprising seronegative (negative for anti-CCP2, IgG and IgM, n=250), singular anti-CCP2 positive (n=100), double RF positive RA (n=50), seropositive (triple-autoantibody positive, n=150) and triple-autoantibody negative normal controls (n=300) were included from the Malaysian Epidemiological Investigations of RA (My-EIRA) case-control study. All subjects were assayed for anti-RA33 autoantibody and genotyped for four-digit HLA-DRB1 alleles using the PCR-SSO method.

#### Results

Our data demonstrated that anti-RA33 positivity was 20.9% in all RA cases (i.e., 34% in RF only positive RA; 25% in seropositive RA; 18% in seronegative RA and 18% in anti-CCP2 only positive RA). Carriage of HLA-DRB1 nonshared epitope alleles were 64.5% among RA cases and 81.6% among normal controls. In both the seropositive and RF-only positive subgroups, a trend of association was observed between DRB1*03 and anti-RA33 positivity (odds ratio, OR>1.5; p>0.05). Meanwhile, DRB1*15 was significantly associated with anti-RA33 autoantibody positivity regardless of RF and ACPA status (p<0.05). In the seronegative RA subgroup, carriage of DRB1*08 was significantly associated with risk of anti-RA33 positivity (OR 2.80, 95% CI 1.06 - 7.43, p<0.05) whereas DRB1*07 was found to be negatively associated with anti-RA33 autoantibody (OR 0.12, 95% CI 0.02 - 0.90, p<0.05).

#### Conclusions

Our findings suggest that different HLA-DRB1 fine specificity alleles are associated with different subsets of RA in the context of anti-RA33 positivity, independent of the well-established risk of DRB1 SE alleles.

#### **Keywords**

HLA-DRB1 alleles, Anti-RA33 autoantibody, Rheumatoid arthritis

Ministry of Health Malaysia, Malaysia



# Precision nanomedicine in rheumatoid arthritis: Customized multifunctional polymeric nanocarriers for alleviation of inflammation severity in rheumatoid arthritic rats

#### ANAS Ahmad¹

¹ 1 Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, Alberta T2N 4N1, Canada., Canada

#### Background

Rheumatoid arthritis (RA) is among some of the most prevailing autoimmune disorder which affects around 1% of global population. In spite of significant advancements in RA treatments, limitations like higher drug biotransformation and their rapid elimination form the body causes poor drug bioavailabilities. Current research studies have stressed the formulation and development of suitable, biocompatible and biodegradable nanocarriers for drug encapsulation and delivery such that the existing limitations of drugs could be surpassed and their ultimate pharmacological efficacy could be enhanced. For this purpose, customized polymeric core shell nanocarriers were formulated and optimised for delivering two drugs simultaneously in the arthritic rat model.

#### **Methods**

Nanocarriers were formulated with two highly biocompatible and biodegradable polymers by the method of nanoprecipitation and solvent evaporation. These were assessed optimized for their particle size, shape, and surface morphology by DLS, TEM, SEM, and AFM, for their drug loading capacity and encapsulation efficiency, biocompatibility, and normal fibroblast cell lines and their anti-inflammatory therapeutic efficacy in arthritic rats, in terms of macroscopic disease index, clinical severity, histopathology, immunohistochemistry and ELISA assays for inflammatory biomarkers.

#### **Results**

The nanocarriers were 125-150 nm in diameter, spherical in shape with smooth surfaces, exhibited higher biocompatibility, and considerably brought down the severity of inflammation on Wistar rats. All the macroscopic, histological, immunohistochemical observations demonstrated the amelioration of inflammation in RA. These nanocarriers reduced swellings of joints, and erythema significantly ameliorated bone-erosion noted in radiological observations, inhibited destruction of collagen, reinstated normalcy of synovial tissues, bones, and cartilage histology with suppressed inflammatory cellular infiltrations. Nanocarriers further suppressed several inflammation biomarkers viz. iNOS, COX-2, IL-1 $\beta$  and TNF- $\alpha$ 

#### Conclusions

Outcomes of the present study indicate that these nanocarriers exercised better therapeutic efficacies in RA in comparison to naïve compounds which can be assigned to sustained and controlled release of drugs, and nanocarriers' capability to suppress inflammatory markers.

#### **Keywords**

Nanocarriers, Rheumatoid Arthritis, Drug Delivery



# APE1 inhibits the inflammation of fibroblast-like synoviocytes via oxidative stress regulation in patients with rheumatoid arthritis

<u>Ha-Reum Lee^{1,2}</u>, Jinhyun Kim², Su-Jin Yoo^{1,2}, Ji Ah Park², Hee Kyoung Joo^{1,3}, Yu Ran Lee^{1,3}, Sungmin Kim^{1,3}, Byeong Hwa Jeon^{1,3}, Seong Wook Kang^{1,2}

¹ Research Institute for Medical Sciences, Chungnam National University School of Medicine, Republic of Korea
² Division of Rheumatology, Department of Internal Medicine, Chungnam National University Hospital, Republic of Korea
³ Department of Physiology, College of Medicine, Chungnam National University, Republic of Korea

#### Background

Although apurinic/apyrimidinic endonuclease 1 (APE1) is highly expressed in synovial fluids from patients with rheumatoid arthritis (RA), the effect of APE1 in RA pathogenesis remains unclear. This study aimed to examine the role of APE1 in fibroblast-like synoviocytes (FLS) from patients with RA.

#### **Methods**

Synovial tissues were obtained from RA patients (n=5) who were undergoing synovectomy or joint replacement. After removing fat and fibrous tissues, the synovium was cut into small pieces and incubated with 0.1% collagenase in Dulbecco's modified Eagle's medium (DMEM) at 37°C for 2 h. Cells were used for experiments after three to six passages. FLS were stimulated with or without recombinant interleukin 17 (IL-17; 10 ng/ml), tumor necrosis factor alpha (TNF-a; 10 ng/ml), and long-lasting recombinant human APE1 (MR201; 1, 10, 100 ng/ml) for 24 h. The mRNA and protein levels of inflammatory cytokines were analyzed by RT-qPCR and ELISA, respectively. Reactive oxygen species (ROS) levels were stained using MitoSOX dye using flow cytometry. Cell migratory ability was examined using wound migration assay and transwell migration assay.

#### **Results**

RA FLS treated with APE1 showed slightly decreased level of inflammatory cytokines and mitochondrial specific ROS. When RA FLS were stimulated with IL-17/TNF- $\alpha$ , recombinant APE1 significantly decreased the expression of inflammatory cytokines, including IL-1 $\beta$ , IL-6, and IL-8. IL-17/TNF- $\alpha$ -induced mitochondrial specific ROS production was also downregulated by cotreatment with recombinant APE1. When FLS cultures were approximately 90% confluent, FLS monolayers were wounded with pipette tips and treated with IL-17/TNF- $\alpha$  and APE1 for 24 hr. IL-17/TNF- $\alpha$ -enhanced cell migration was inhibited by cotreatment with recombinant APE1.

#### Conclusions

Recombinant APE1 significantly inhibited mitochondrial specific ROS production and IL-17/TNF- $\alpha$ -induced cell migration in RA FLS. These data suggested that APE1 is a key mediator to cytokine-enhanced migration via ROS modulation in RA FLS.

#### **Keywords**

rheumatoid arthritis, reactive oxygen species, inflammation



# A novel cytokine consisting of p40 and EBI3 subunits suppresses experimental autoimmune arthritis via reciprocal regulation of Th17 and Treg cells

<u>Seon-Yeong Lee</u>¹, Young-Mee Moon¹, Su-Jin Moon², A Ram Lee^{1,4}, Chae Rim Lee^{1,4}, Seung-Ki Kwok², Sung-Hwan Park², Mi-La Cho^{1,3,4}

 ¹ The Rheumatism Research Center, The Catholic University of Korea, Republic of Korea
 ² Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Republic of Korea
 ³ Department of Medical Lifescience, College of Medicine, The Catholic University of Korea, Republic of Korea
 ⁴ Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Republic of Korea

Background

The interleukin (IL)-12 cytokine family is closely related to the development of T helper cells, which are responsible for autoimmune disease enhancement or suppression. IL-12 family members are generally heterodimers that share three  $\alpha$ -subunits (p35, p19, p28) and two  $\beta$ -subunits (p40, EBI3). However, a  $\beta$ -sheet p40 homodimer has been shown to exist and antagonize IL-12 and IL-23 signaling 1. Therefore, we assumed the existence of a p40-EBI3 heterodimer in nature, and sought to investigate its role in immune regulation.

#### **Methods**

The presence of p40-EBI3 heterodimer was confirmed by ELISA, immunoprecipitation, and western blotting. A p40-EBI3 vector and p40-EBI3-Fc protein were synthesized to confirm the immunological role of the protein in mice with collagen-induced arthritis (CIA). The anti-inflammatory effects of p40-EBI3 were analyzed with regard to clinical, histological, and immune cell regulatory aspects in mice with CIA.

#### **Results**

Clinical arthritis scores and expression levels of proinflammatory cytokines (e.g., IL-17, IL-1β, IL-6, and TNF-α) were significantly attenuated in p40-EBI3-overexpressing and p40-EBI3-Fc-treated mice with CIA, in comparison to vehicle-treated mice with CIA. Structural joint damage and vessel formation-related genes were also reduced by p40-EBI3 heterodimer treatment. In vitro, p40-EBI3-Fc protein significantly suppressed the differentiation of Th17 cells; it reciprocally induced CD4+CD25+Foxp3+ (regulatory T) cells. p40-EBI3 also inhibited osteoclast formation in a concentration-dependent manner.

#### Conclusions

In this study, p40-EBI3 antagonized proinflammatory conditions both in vivo and in vitro. We propose that p40-EBI3 is a novel anti-inflammatory cytokine involved in suppressing the immune response through the expansion of Treg cells and suppression of Th17 cells and osteoclastogenesis.

# **E-poster Presentation**

**RA-clinical aspects** 

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



### Seasonal analysis of relative search volume of rheumatoid arthritis in Korea

#### Eunsung Kim¹

¹ Internal Medicine, Bumin hospital, Republic of Korea

#### Background

This study aims to investigate the searching interest of seasonal variation in rheumatoid arthritis (RA) by evaluating search term trends.

#### **Methods**

We included relative search term trends for RA(searched in Korean) from January 2018 to December 2021 in Naver DataLab. For seasonal analysis, we fitted a cosinor model for monthly relative RA searching terms. In addition monthly mean rate ratio and 95% confidence interval were studied using December as a reference month.

#### **Results**

The cosinor analysis showed a significant seasonality that amplitude was 7.0 (absolute scale) and phase was 5.8 months (adjusted p-value 0.025). Relative RA search volume was highest in June and was lowest in December.

#### Conclusions

The seasonal analysis results show that searching interests show significant seasonal variation. Based on the result of this study, the seasonal analysis model is helpful to estimate the interests of the people about RA in Korea.

#### Figure & Table




Figure. Relative search volume of 'rheumatoid arthritis'. Boxplots show concentration of relative search volume, number per

#### **Keywords**

relative search volume, seasonal analysis, cosinor analysis



KCR 2022

## Cardiac hydatid cyst in a patient with rheumatoid arthritis

Giorgi Apkhazava¹, Grigol Nemsadze², Megi Kurtanidze¹

¹ Radiology Department, Tbilisi City Medical, Georgia ² Radiology Department, TSSU First University, Georgia


#### **Description**

A 33-year-old male presented to the cardiology clinic with complaints of intermittent atypical chest pain, resembling acute myocardial infarction. The patient had been followed up and treated for rheumatoid arthritis for 5 years. An electrocardiography revealed non-specific T wave changes, whereas physical examination was unremarkable. Transthoracic echocardiography showed the cystic lesion with compressing the left cardiac ventricle. Cardiac magnetic resonance imaging(MRI) was performed. MRI revealed left ventricular myocardial cyst that was hyperintense T2-weighted (T2W) images, and it was peripheral enhanced after contrast administration (Fig.1). The blood level of Echinococcus IgG by ELISA was 158 RU/mL, which was considered as a positive serologic test for Echinococcus infection. According to radiological and laboratory findings, the lesions were evaluated hydatid cyst infection involvement of the ventricular. Therefore, albendazole therapy was introduced. The patient underwent surgical treatment. The lesion was identified as a hydatid cyst infection via pathological examination.

#### Conclusions

Hydatid cyst infections is a parasitic epidemiological infection caused by larvae of Echinococcus granulosus, although less frequently Echinococcus multilocularis . Hydatid cyst infections can be located in various tissues, although they are most common in the liver and the lung . As a conclusion, cardiac hydatid cyst is extremely uncommon. Therefore, cardiac localization, which is an atypical location for clinicians in non-endemic countries, should be kept in mind as it may cause lethal complications.

#### Figure & Table





## Course of COVID-19 in patients with rheumatoid arthritis (own data)

Eugenia Aronova¹, Galina Gridneva¹, Boris Belov¹

¹ department of comorbid infections, V.A. Nasonova Research Institute of Rheumatology, Russian Federation

#### Background

The aim of study was to characterize the features of the course of COVID-19 in patients with rheumatoid arthritis (RA).

#### **Methods**

We studied the material of questionnaires filled out by patients who underwent COVID-19, verified by RT-PCR to SARS-CoV-2 RNA, for the period from 05/15/2020 to 12/01/2021.

#### **Results**

The study included 42 adult (over 18 years old) patients (38 women, 90.5%) with a reliable diagnosis of RA. The average age of patients was 51.17±15.78 years. At the time of development of COVID-19, the severity of RA symptoms, assessed by VAS, was 4.68±2.94. As an antirheumatic therapy, 11 (26.2%) patients took glucocorticoids at an average dose of 5.7±3.4 mg/day (prednisolone equivalent), 31 (73.8%) - DMARDs. 22 patients received biologics, incl. 15 - rituximab (66.6%, of which received the last infusion within 6 months or less before the onset of the first symptoms of COVID-19).

Among the clinical manifestations of COVID-19, the most common were weakness, fatigue - in 38 (90.5%), fever - in 30 (71.4%), anosmia - in 28 (66.7%), dysgeusia - in 24 (57.1%), increased arthralgia - in 24 (57.4%). There was a significant positive correlation between increased arthralgia during COVID-19 and RA activity. On average (median), each patient reported 13 [9.25;13.75] symptoms associated with COVID-19. 14 patients (33.3%) were hospitalized, of which 10 required oxygen support. Patients treated with rituximab were hospitalized more frequently (RR 2.7, 95% CI 1.192–6.117). Complications were registered in 5 cases (11.9%): venous thrombosis in 2 patients, acute respiratory failure in another 2 patients, and cerebrovascular accident in 1 patient.

#### Conclusions

33.3% of COVID-19 patients in the study group required inpatient treatment. In 11.9% - COVID-19 proceeded with complications. The number of symptoms associated with COVID-19 did not correlate with RA activity. However, patients with higher RA activity more often noted increased arthralgia.

#### **Keywords**

COVID-19, rheumatoid arthritis, Rituximab



### Study of the features of post-covid syndrome in patients with rheumatoid arthritis

#### Eugenia Aronova¹, Galina Gridneva¹, Boris Belov¹

¹ department of comorbid infections, V.A. Nasonova Research Institute of Rheumatology, Russian Federation

#### Background

We conduct a comparative assessment of clinical and demographic indicators in groups of patients with rheumatoid arthritis who underwent COVID-19, with and without PCS.

#### **Methods**

The material of the questionnaires filled in by patients of the V.A. Nasonova Research Institute of Rheumatology, who underwent COVID-19, verified by RT-PCR for SARS-CoV-2 RNA.

#### **Results**

The study included 42 adult (over 18 years old) patients with a reliable diagnosis of rheumatoid arthritis (ACR/ EULAR). Of these, 22 (52.4%) patients noted the development of PCS (Group 1), and 20 patients underwent COV-ID-19 without consequences (Group 2). Both groups were represented predominantly by women (90.9% and 90%, respectively). The average age in both groups did not differ significantly and amounted to 55.04±13.92 years in group 1, and 46.90±16.64 years in group 2. The median number of comorbid diseases was 2 [1;2.75] in group 1 and 1 [0;2] in group 2. PCS was represented by the following symptoms: memory impairment - in 13 patients; weakness, problems with attention - in 12; increased pain in the joints - in 12. The number of COVID-19 symptoms in the infectious phase in group 1 was higher than in group 2 (P<0.05): 18 [13;21.75] and 10.5 [7;13], respectively. At the time of development of COVID-19, the severity of RA symptoms, assessed by VAS, was 5.0±3.02 in group 1 and 4.35±2.88 in group 2.

#### Conclusions

Even though when assessing the socio-demographic characteristics, no statistically significant differences were found between the study groups, the average age, the number of comorbid diseases, and the severity of RA symptoms at the time of COVID-19 were higher in the group of patients with RA and PCS. Patients with PCS reported higher rates of hospitalizations and more severe COVID-19. There were also repeated cases of COVID-19 in this group. It is necessary to continue the study on a larger cohort.

#### **Keywords**

post-covid syndrome, rheumatoid arhritis, COVID-19



## Ultrasound as a potential tool to detect interstitial lung disease in daily clinical setting of patients with rheumatoid arthritis

<u>MARWIN Gutierrez</u>¹, Santiago Ruta², Denise Clavijo-cornejo¹, Gabriela Fuentes-moreno¹, Samuel Reyes-long³, Chiara Bertolazzi¹

> ¹ Division of Musculoskeletal and Reumatic Diseases, Instituto Nacional de Rehabilitacion, Mexico ² Rheumatology Unit, Hospital Italiano, La Plata, Argentina ³ División de Neurociencias, Instituto Nacional de Rehabilitacion, Mexico

#### Background

In the last years, the pulmonary ultrasound (US) has been proposed to assess ILD in rheumatic diseases. The aim of this study is to investigate the potential role of the US in the detection of ILD in a real-life cohort of patients with rheumatoid arthritis RA.

#### **Methods**

Patients with a diagnosis of RA were consecutively enrolled. All patients underwent pulmonary examination, laboratory data, DLCO measure, chest HRCT and radiographs, and US examination. A healthy group was included as a control group.

US was performed according the 14-intercostal space scanning protocol using the following semiquantitative scale [0= normal ( $\leq$ 5 B-lines); 1=slight ( $\geq$ 6 and  $\leq$ 15 B-lines); 2=moderate, ( $\leq$ 16 and  $\geq$ 30 B-lines); 3=severe ( $\geq$ 30 B-lines)]

#### Results

74 RA patients and 74 healthy controls were included. Thirty of 74 patients (40.5%) showed US signs of ILD with respect to the healthy (4.1%) (p=0.0001); whereas HRCT showed ILD in 27 (36.4%) of 74 patients.

Among the 30 patients with US findings of ILD, 17 (56.6%) were asymptomatic. The sensitivity and specificity of US were 92% and 89% respectively.

A positive correlation between US and HRCT findings was found (p= < 0.0001) whereas no correlation was found with chest radiographs and DLCO findings (p = 0.2971 and 0.7856 respectively). Positive association between US and DAS28, RF and anti-CCP (p=0.0076, 0.0044, 0.0074) was found.

#### Conclusions

Our results support the potential of the US in detecting accurately ILD in a real-life cohort of patients with RA and provide a rationale to consider it as a friendly screening tool to be implemented in the early phases of the disease.



## Rheumatoid factor (RF) and anti-cyclic citrullinated protein autoantibodies (ACPA) seroconversion and seroreversion in rheumatoid arthritis patients between 2005 and 2021

<u>Chun Lai Too</u>^{1,2}, Nurul Aain Ahmad-fauzi¹, Haziqah Itqan Alias¹, Nur Aida Sabrina Mohd-rashid¹, Siti Aisyah Abdul-ahmad¹, Mollyza Mohd-zain³, Ing Soo Lau³, Hazlyna Baharuddin³, Diana Lee Min Ang⁴, Lisa Mohamed-nor⁴, Rashidah Bahari⁴, Amnahliza Abdul-rahman⁴, Ping Seung Ong⁵, Noraini Mat-husin⁵, Wahinnudin Sulaiman⁵, Suk Chyn Gun⁶, Nadiah Mohd-nor⁶, Heselynn Hussein⁴, Eashwary Mageswaran⁴, Mohd Shahrir Mohamed-said⁷, Ainon Mohd-mokhtar⁸, Azmillah Rosman³, Muhaini Othman⁵, Mohd Zainuldin Taib⁹, Shahnaz Murad¹, Leonid Padyukov², Lars Alfredsson¹⁰, Lars Klareskog², Johan Ronnelid¹¹, Nor Shuhaila Shahril⁴

¹ Ministry of Health Malaysia, Immunogenetic Unit. Allergy and Immunology Research Center. Institute for Medical Research. MOH, Malaysia
 ² Department of Medicine, Division of Rheumatology. Karolinska Institutet and Karolinska University Hospital. Stockholm., Sweden
 ³ Department of Medicine, Selayang Hospital. Ministry of Health Malaysia. Selangor., Malaysia
 ⁴ Department of Medicine, Putrajaya Hospital. Ministry of Health Malaysia. Putrajaya., Malaysia
 ⁵ Department of Medicine, Raja Permaisuri Bainun Hospital. Ipoh. Perak, Malaysia
 ⁶ Department of Medicine, Tuanku Ja'afar Seremban Hospital. Ministry of Health Malaysia, Malaysia
 ⁷ Medical Deparment, Universiti Kebangsaan Malaysia Medical Centre. Cheras. Kuala Lumpur, Malaysia
 ⁸ Department of Medicine, Tengku Ampuan Afzan Hospital. Ministry of Health Malaysia. Selangor., Malaysia
 ⁹ Medical Resource Research Centre, Institute for Medical Research. Ministry of Health Malaysia. Selangor., Malaysia
 ¹⁰ Institute of Environmental Medicine, Karolinska Institute. Stockholm., Sweden
 ¹¹ Department of Immunology. Genetics and Pathology, Uppsala University. Uppsala, Sweden

#### Background

Previous studies demonstrated that RF and ACPA seroconversion/seroreversion is possible, but rarely occurs. We determined the proportions of RA patients who underwent autoantibodies conversion or reversion at two time-points and described the clinical characteristics of these subgroups.

#### **Methods**

A total of 240 RA patients enrolled during the Malaysian Epidemiological Investigation of RA study (MyEIRA, 2005-2009) were followed up in the RA progression study (RAPID, 2018-2021). ACPA and RF isotypes (i.e., IgG, IgM, and IgA) were measured using the commercial ELISA kits, similar to the kits used for baseline measurement. RA patients with one or more autoantibodies converted between baseline (MyEIRA) and follow-up (RAPID) time point were defined as seroconverters. RA patients with one or more autoantibodies disappeared during study period were defined as seroreverters. Paired samples test, univariate and multivariate analysis were performed. The clinical characteristics of seroconverters and seroreverters were assessed.

#### Results

The proportion of overall RA patients who experienced seroconversion (n=91, 37.9%) ranged from 3.7% (ACPA) to 22.8% (IgA RF), while seroreversion (n=52, 21.7%) ranged from 3.7% (IgM RF) to 14.1% (IgG RF). When data from RAP-ID were compared to MyEIRA, the seroconverters demonstrated significant differences for IgG RF (p=0.01), IgM RF (p<0.0001) and IgA RF (p<0.0001). We observed significant differences for ACPA (p=0.004), IgG RF (p<0.0001) and IgA RF (p=0.02) for the seroreverters. Clinical characteristics revealed that hand and feet deformities were common among the seroconverters. Ocular and pulmonary associated extra articular manifestations were more prevalent in seroconverters. Comorbidities profile was comparable between the seroconverters and seroreverters.

#### Conclusions

Our data suggest that one fifth of the overall RA patients experienced antibody conversion for IgA RF (22.8%), while IgG RF (14.1%) is commonly disappeared (i.e., reverted) for 10 years follow up. Interestingly, ACPA is the most stable RA autoantibody with only approximately 5% conversion or reversion.

#### **Keywords**

seroconversion, seroreversion, RF isotypes and ACPA



## Autoantibodies sustainability in rheumatoid arthritis (RA) patients and their clinical characteristics: Malaysian real-world data between 2005 and 2021

<u>Chun Lai Too</u>^{1,2}, Nurul Aain Ahmad-fauzi¹, Haziqah Itqan Alias¹, Nur Aida Sabrina Mohd-rashid¹, Siti Aisyah Abdul-ahmad¹, Mollyza Mohd-zain³, Ing Soo Lau³, Hazlyna Baharuddin³, Diana Lee Min Ang⁴, Lisa Mohamed-nor⁴, Rashidah Bahari⁴, Amnahliza Abdul-rahman⁴, Ping Seung Ong⁵, Noraini Mat-husin⁵, Wahinuddin Sulaiman⁵, Suk Chyn Gun⁶, Nadiah Mohd-noor⁶, Heselynn Hussein⁴, Eashwary Mageswaran⁴, Mohd-shahrir Mohamed-said⁷, Ainon Mohd-mokhtar⁸, Azimillah Rosman³, Muhaini Othman⁵, Mohd Zainuddin Taib⁹, Shahnaz Murad¹, Leonid Padyukov², Lars Alfredsson¹⁰, Lars Klareskog², Johan Ronnelid¹¹, Nor Shuhaila Shahril⁴

¹ Ministry of Health Malaysia, Immunogenetic Unit. Allergy and Immunology Research Center. Institute for Medical Research. MOH, Malaysia
 ² Department of Medicine, Division of Rheumatology. Karolinska Institutet and Karolinska University Hospital. Stockholm, Sweden
 ³ Department of Medicine, Selayang Hospital. Ministry of Health Malaysia. Selangor, Malaysia
 ⁴ Department of Medicine, Putrajaya Hospital. Ministry of Health Malaysia. Putrajaya, Malaysia
 ⁵ Department of Medicine, Raja Permaisuri Bainun. Ministry of Health Malaysia. Ipoh. Perak, Malaysia
 ⁶ Department of Medicine, Tuanku Ja'afar Seremban Hospital. Ministry of Health Malaysia. Putrajaya, Malaysia
 ⁷ Medical Department, Universti Kebangsaan Malaysia Medical Centre. Cheras. Kuala Lumpur., Malaysia
 ⁸ Department of Medicine, Tengku Ampuan Afzan Hospital. Ministry of Health Malaysia. Kuantan. Pahang., Malaysia
 ⁹ Medical Resource Research Centre., Institute for Medical Research. Ministry of Health Malaysia. Malaysia.
 ¹⁰ Institute of Environmental Medicine, Karolinska Institutet. Stockholm., Sweden
 ¹¹ Department of Immunology, Genetics and Pathology, Uppsala University. Uppsala., Sweden

#### Background

We aimed to examine the autoantibody sustainability (i.e., positivity versus negativity) over more than 10 years period in rheumatoid arthritis (RA) patients and their clinical characteristics in each studied groups.

#### **Methods**

Serum measurement and analysis for rheumatoid factor isotypes (i.e., IgG, IgM and IgA) and anti-citrullinated protein antibody (ACPA) was performed on 240 blood samples taken at baseline (2005-2009) and follow-up (2018-2021), using similar commercial ELISA kits. RA patient positive for one or more autoantibodies during baseline and remained positive upon follow-up were defined as antibody positive sustainer (APS). RA patient negative for one or more autoantibodies during baseline and remained negative upon follow-up were defined as antibody negative sustainer (ANS). The disease characteristics for APS and ANS groups were assessed.

#### **Results**

Seventy-one percent RA cases sustained one or more autoantibodies, while 46% remained negative between the two study time points. Clinical assessment revealed that the prevalence of various hand and feet deformities were higher among the APS group. Similarly, a trend of increased tender joint counts was found among APS, with higher zero counts observed among ANS group. Functional status assessment showed that the patient and physician reported outcomes were comparable between APS and ANS groups. Notably, overall functional status scores were comparatively lower when assessed by physicians than RA patients. We observed higher proportion of HLA-DRB1 shared epitope alleles (SE) among APS as compared to ANS (p=0.0009). Paired samples analysis in APS group revealed significant differences between baseline and follow-up data, with tendency of increased titers of anti-CCP2 (p<0.0001), RF IgM (p<0.0001) and IgA (p=0.001), and only RF IgM in ANS group (p=0.004).

#### Conclusions

The disease characteristics (i.e., disease activity, deformity and functional status) are differed between APS and ANS groups. In addition, the autoantibodies titers profile are significantly different for baseline and follow-up period.

#### **Keywords**

Autoantibody sustainability, rheumatoid arthritis, RF and anti-CCP  $% \left( {{\left| {{{\rm{A}}} \right|_{{\rm{A}}}}} \right)$ 



## Use of disease-modifying anti-rheumatic drugs after cancer diagnosis in rheumatoid arthritis patients

#### Kyung-Su Park¹, Young-Bin Joo², Seung Min Jeong¹, Yune-Jung Park¹, Ki-Jo Kim¹

¹ Rheumatology, Catholic University St. Vincent's Hospital, Republic of Korea ² Rheumatology, Hanyang University Guri Hospital, Republic of Korea

#### Background

There is no recommendation for the use of disease-modifying anti-rheumatic drugs (DMARDs) in patients with rheumatoid arthritis (RA) who developed cancer. We examined changes in the prescription patterns of DMARDs associated with cancer diagnosis in RA patients.

#### **Methods**

We reviewed the medical records of 2,161 RA patients who visited rheumatology clinics between January 2008 and February 2017 and found 40 patients who developed cancer during RA treatment. In these patients, we examined DMARDs prescription before and right after cancer diagnosis and at recent outpatient clinic visits.

#### **Results**

Before cancer diagnosis, methotrexate (MTX)-combined conventional synthetic DMARDs (csDMARDs) were most commonly prescribed (22, 55.0%) and biological DMARDs (biologics) in nine patients (22.5%). For cancer treatment, 19 patients received chemotherapy (including adjuvant chemotherapy) and 21 patients had surgery only. Right after cancer diagnosis, DMARDs prescription patterns were similar in discontinuation (13, 32.5%), switching (14, 35.0%), and maintenance (13, 32.5%). DMARDs were discontinued more frequently in the chemotherapy group (9/19, 47.4%) than the surgery only group (4/2, 19.0%) (p = 0.015). Among the 13 patients who discontinued DMARDs, nine (69.2%) resumed DMARDs after a median of 5.5 months (interquartile range <IQR> 2.9, 18.3) due to arthritis flare. At a median of 4.6 years (IQR 3.3, 6.7) after cancer diagnosis, 25 patients were evaluated at recent outpatient clinic visits. Four patients received no DMARD, three MTX monotherapies, 11 combined csDMARDs, and seven biologics.

#### Conclusions

A significant number of RA patients who developed cancer during RA treatment were still receiving DMARDs after cancer treatment.

#### **Keywords**

cancer, Disease-modifying anti-rheumatic drugs, Rheumatoid arthritis



## The relationship between Anti-CCP, C-reactive protein in serum and rheumatoid factor in synovial fluid in patients with rheumatoid arthritis in the Kyrgyz Republic

#### Nazgul Omurzakova¹, Akpay Sarybaev¹

¹ Rheumatology and High Mountain Diseases, National Center of Cardiology and Internal Medicine, Kyrgyzstan

#### Background

Study of the clinical-functional peculiarity of clinical course in patients with rheumatoid arthritis with determining of relationship between Anti-CCP, C-reactive protein (CRP) in serum and rheumatoid factor (RF) in synovial fluid in rheumatoid arthritis (RA).

#### **Methods**

We have conducted a 8-year study (5,2  $\pm$  2,5 years) and monitoring of 390 (average age 41,2  $\pm$  25,2 years) patients with early RA, diagnosed according to criteria ACR (American College of Rheumatology, 1987). 281 of them are women and 109 are men. They measured the concentration of Anti-CCP, RF and titers of CRP in serum and synovial fluid of different degree of disease activity (DAS 28).

#### Results

The close relationship between the level of Anti-CCP, RF, CRP in the serum and the titer of RF in synovial fluid has been determined. According to studies, the specificity of RF in the synovial fluid in the diagnosis of RA in the early stages is 81%, the combination of RF in synovial fluid + Erythrocyte Sedimentation Rate (ESR) - 88%. RF and CRP titers in the serum and RF in synovial fluid - 91%; Anti-CCP +RF in the blood serum + synovial fluid titers CRP + ESR - 94%; Anti-CCP in serum + RF in synovial fluid + polyarticular pain - 94%; Anti-CCP + RF in synovial fluid + morning stiffness - 97%. With a high degree of activity of the process increases the level of Anti-CCP, RF and CRP in the blood (1:192 mg / L and above) and increases the titer of RF (96 IU/ml and above) in the synovial fluid.

#### Conclusions

Anti-CCP in serum can be very useful in early diagnosis of RA, when manifest only a few clinical symptoms. In addition, noted a high risk of atherosclerotic complications in patients with elevated CRP levels, which persisted for a long time during the treatment.



## Impact of comorbidity on disease activity and functional status in patients with rheumatoid arthritis receiving biologic DMARDs, a longitudinal analysis of the KOBIO-RA

Ju Yeon Kim¹, Kichul Shin², Eun Bong Lee¹, Jun Won Park¹

¹ Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Republic of Korea ² Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National Boramae Medical Center, Seoul, Republic of Korea

#### Background

This study aims to evaluate the impact of comorbidities on disease activity and functional disability in patients with RA treated with biological disease-modifying anti-rheumatic drugs (bDMARDs).

#### **Methods**

We analyzed longitudinal data of 2127 patients in a nationwide cohort of RA receiving bDMARD in South Korea (KOBIO-RA). Patients were enrolled at the time of starting bDMARD and followed up yearly thereafter. In this study, follow-up was censored when initial bDMARD was discontinued or at seventh visit, whichever came first. Functional status was assessed using Routine Assessment of Patient Index Data 3 (RAPID3). In each follow-up visit, we assessed whether the patient attained the minimal clinically important difference (MCID, defined as a 3.6-point decrease from baseline) in RAPID3 and low disease activity (LDA) based on Clinical Disease Activity Index (CDAI). Effect of comorbidities on these responses was analyzed using generalized estimating equations (GEE).


#### Results

At baseline, the mean (SD) disease activity was 15.25 (5.67) for RAPID3 and 26.85 (11.15) for CDAI. During the follow-up encompassing 5244 1-year intervals, 3489 (66.5%) and 3788 (74.0%) intervals achieved the MCID-RAPID3 and CDAI-LDA, respectively. Ischemic heart disease (adjusted OR 0.41 [0.22-0.76]), interstitial lung disease (adjusted OR 0.49 [0.33-0.72]), obstructive lung disease (adjusted OR 0.46 [0.25-0.85]), and depression (adjusted OR 0.56 [0.29-0.97]) were associated with poor RAPID3 response (Figure). Other comorbidities did not significantly influence the functional status. Presence of comorbidities was not associated with disease activity of RA except for pulmonary disease. Patients with interstitial lung disease or obstructive lung disease showed a significantly less likelihood of achieving CDAI-LDA (adjusted OR 0.58 [0.40-0.83] and 0.33 [0.19-0.57], respectively).

#### Conclusions

Pulmonary diseases were associated with higher patient reported functional index and disease activity in RA, while ischemic heart disease and depression were associated function index independent of the disease activity.

#### **Figure & Table**



#### Keywords

Rheumatoid arthritis, comorbidity

# **E-poster Presentation**

**RA-treatment** 

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



## Is a cumulative dose of methotrexate important for rapid remission in rheumatoid arthritis?

Galina Gridneva¹, Eugenia Aronova¹, Natalia Baymeeva², Svetlana Glukhova¹, Yury Muraviev¹

¹ Comorbid Infections and Safety of Drug Therapy, V.A.Nasonova Rheumatology Research Institute, Russian Federation ² Drug Monitoring, Mental Health Centre, Russian Federation

#### Background

To determine the correlations between the cumulative dose of methotrexate (MTX), the concentration of MTX metabolites in cells and the achievement of remission in patients with RA.

#### Methods

A prospective follow-up study included 79 patients, 65(82%) women and 14(18%) men, aged 53±11 years, naiive to MTX. All patients were prescribed MTX at the rate of 10-15 mg/m2 of body surface. After 4, 12 and 24 weeks of therapy, RA activity was assessed by DAS28, the total dose of methotrexate was calculated, MTX monogluta-mate, polyglutamates with 2, 3 and 4 glutamate residues (MTXPGs 2-4), 7-hydroxymethotrexate (7-OH-MTX) were determined in erythrocytes (ER) and mononuclear cells (MO) by tandem chromatomass spectrometry. Statistical data was performed using Statistica 10 for Windows (Stat-Soft Inc., USA).

#### **Results**

The total dose of MTX after 4 weeks of treatment was  $58\pm15$  mg and directly correlated with the concentration of MTXPG4 in the ER(CC=0.29) and MO(CC=0.31) and MTX-PG3 in the ER(CC=0.27), p<0.05 in all cases. The total dose of MTX in week 12 was  $202\pm54$  mg and directly correlated with the concentration of MTXPG4 in the MO(CC=0.3), p<0.05. The total dose of MTX after 24 weeks was  $398\pm100$  mg, no correlations were found between its value and the concentration of various metabolites. The correlation analysis with the achievement of remission in week 24 direct-ly correlates the level of 7-OH-MTX in the ER in week 12 (CC=0.27), the level of 7-OH-MTX in the MO in week 24 (CC=0.355) and cumulative dose of MTX in week 12.

#### Conclusions

Conclusion: high values of 7-OH-MTX and the cumulative dose of MTX at week 12 of therapy may be a predictor of remission after 24 weeks of treatment.

#### **Keywords**

methotrexate, therapeutic drug monitoring, poliglutamate



## Clinical predictors of inadequate response to conventional synthetic and biologic DMARDs in Chinese patients with rheumatoid arthritis

<u>Hui Zhong</u>¹, Yanhong Wang², Jiuliang Zhao¹, Nan Jiang¹, Qian Wang¹, Xinping Tian¹, Dong Xu¹, Mengtao Li¹, Xiaofeng Zeng¹

¹ Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, China ² Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, China

#### Background

To describe the characteristics of patients with csDMARDs inadequate response (IR) and patients with bDMARDs-IR, and identify risk factors for csDMARDs-IR and bDMARDs-IR in Chinese patients with rheumatoid arthritis (RA).

#### **Methods**

This study was conducted based on the online registry established by Chinese Rheumatism Data Center. Patients with active RA(DAS28-CRP>3.2) were included. IR was defined as either of the following: Patients used  $\geq 1$  csD-MARDs or bDMARDs for 6 to 12 months but failing to reach DAS28 $\leq$ 3.2; patients used  $\geq 1$  csDMARDs or bDMARDs for 3 to 6 months but failing to reach DAS28 $\leq$ 3.2 or at least 50% improvement. Patients with prior use of bDMARDs were excluded in analysis of csDMARDs-IR. Baseline clinical characteristics and multivariable logistic regression were analyzed in csDMARDs-IR and bDMARDs-IR groups respectively.

#### **Results**

A total of 8326 out of 72737 RA patients in the database were eligible for inclusion, and 3705(55.50%) out of 6676 patients treated by csDMARDs were csDMARDs-IR and 819(49.64%) out of 1650 patients treated by bDMARDs were bDMARDs-IR. Compared with adequate responders, patients in both IR groups were older at RA diagnosis, with longer disease duration and higher baseline DAS28-CRP and DAS-ESR; while adequate responders to csDMARDs had more structural joint damage. Age at diagnosis  $\geq$  65 years (OR 1.24, 95% CI 1.07-1.43), disease duration ≥ 1 year(OR 1.49, 95%CI 1.35-1.65), and higher baseline DAS28-CRP(OR 1.40, 95%CI 1.35-1.47) were risk factors for csDMARDs-IR; while the existence of structural joint damage (OR 0.556, 95%CI 0.465-0.664) was a protective factor. Similarly, disease duration  $\geq$  1 year (OR 1.39, 95%Cl 1.41-1.69), and higher baseline DAS28-CRP (OR 1.25 95%CI 1.15-1.35) were risk factors for bDMARDs-IR.

#### Conclusions

Based the large RA registry in China, we identified longer disease duration and higher baseline DAS28-CRP were independent risk factors for IR, which may be helpful for clinicians to make therapeutic decisions.

#### **Keywords**

rheumatoid arthritis, treatment, inadequate response



## "Stereotypical" adverse reactions to non-biologic Disease Modifying Anti-Rheumatic Drugs in patients with rheumatoid arthritis requiring biological therapy

#### Elena Matianova¹, Galina Gridneva¹, Eugenia Aronova¹

¹ Comorbid Infections and Safety of Drug Therapy, V.A.Nasonova Rheumatology Research Institute, Russian Federation

#### Background

To study the frequency of the same (so-named "stereotypical") adverse drug reactions (SADRs), to different non-biologic DMARDs, in patients with rheumatoid arthritis (RA) who need therapy with a genetically engineered biological agents (GEBA) or targeted synthetic DMARDs (tsDMARDs).

#### **Methods**

We analyzed medical history of 522 RA patients, 9%men, 91%women, aged 54±11 years, duration of RA was 9[4;24] years, RF-positive were 87%(n=47), ACCP-positive were 79.6%(n=43), extra-articular symptoms had 53.7%(n=29). They were hospitalized from Jan,2021 to Jan,2022 due to an exacerbation of the disease, and required therapy with GEBAs/tsDMARDs. Group 1 were 54(10.3%) patients with a history of SARDs, that occur when taking different DMARDs(not in co-administration). Group 2 were patients without a history of SARDs.

#### **Results**

The most common SARD was nausea - in 14(2.7%) patients. Of these, 12 were treated with methotrexate (MTX), 7 with leflunomide(LEF), 7 with sulfasalazine(SSZ) and 3 with hydroxychloroquine(HQ). A stereotypic increase of liver enzymes was noted in 13(2.5%) patients while taking MTX, in 2 when switch on LEF, in 2 when switch on SSZ, in 1 when switch on HQ. In 4 of them (38.8%), chronic hepatitis was detected (in 3 viral, in 1 non-viral). Skin rash as SARD (n=12(2.3%)) was:in 9 patients with MTX, in 9 with SS, in 6 with LEF, in 2 with HQ. In 5 (0.96%) patients, leukopenia was observed as SARDs: on MTX (in 5), on SSZ(in 4), on LEF(in 2), on HQ (in 1). SARDs such as diarrhea, stomatitis and infections were observed each in 3 cases; shortness of breath - in 2 cases. Increased blood pressure, intestinal bleeding and dizziness were presented in single cases.

#### **Conclusions**

The frequency of "stereotypical" ADRs on DMARDs in history of RA patients who need GEBAs/tsDMARDs was 10.3%. The most common SARDs were nausea (n=14(2.7%)), increased liver enzymes (n=13(2.5%)), skin rash (n=12(2.3%)), leukopenia (n=5(0.96%)).

#### **Keywords**

adverse reactions, medical history, safety



## The efficacy and safety of biologic DMARDs on progression of RA-ILD

Sang Wan Chung¹, Sujin Jeong¹, Ji Sung Lee², Jeong Seok Lee³, Chan Ho Park⁴, Min Uk Kim⁵, You-Jung Ha⁶, Eun Ha Kang⁶, Sung Hae Chang⁷, Yongbeom Park⁸, Jung-Yoon Choe⁹, Eun Young Lee¹⁰, Yeon Ah Lee¹

¹ Rheumatology, Kyung Hee University Medical Center, Republic of Korea
 ² Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center, Department of Medical Stastics, Republic of Korea
 ³ GENOME INSIGHT Inc., GENOME INSIGHT Inc., Republic of Korea
 ⁴ Department of Radiology, Soonchunhyang University College of Medicine, Republic of Korea
 ⁵ Department of Radiology, SMG-SNU Boramae Medical Center, Republic of Korea
 ⁶ Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Republic of Korea
 ⁷ Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Republic of Korea
 ⁹ Division of Rheumatology, Department of Internal Medicine, Catholic University of Daegu College of Medicine, Republic of Korea
 ⁹ Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Republic of Korea
 ⁹ Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Republic of Korea
 ⁹ Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Republic of Korea

#### Background

RA-ILD is associated with significant increase in mortality and worse quality of life compared to patients who do not have ILD. However, nowadays there are no therapeutic recommendations for the treatment of RA-ILD. The aim of this study was to evaluate the efficacy and safety of biologic DMARDs on progression of RA-ILD

#### **Methods**

The Korean Rheumatoid Arthritis ILD (KORAIL) cohort is the prospective observational cohort and aims to investigate the natural course of RA-ILD. Based on either 1987 or 2020 ACR criteria, patients diagnosed with RA and ILD based on CT scan were recruited from six tertiary medical hospitals in Korea since January 2015. Pulmonary function tests (PFT) and CT scan were conducted annually. 47 Patients who started bDMARDs within one month before and after baseline CT and maintained treatment with one type of bDMARDs for more than 24 weeks were enrolled.

#### Results

We analyzed 139 patients at baseline, 122 at 1-year, 112 at 2-year, and 101 at 3-year follow-up. At baseline, there were no significant differences in demographic features between two groups, only the disease duration of RA was longer in bDMARDs group than that of non-bDMARDs group. UIP is the most common CT pattern and 46 patients (33%) had CT extent greater than 10%. There was no significant difference between the two groups in PFT at baseline, however, the change in DLCO and FVC, predicted at 3 years was -1.45 and 0.06 in the biologics group, whereas it was -3.09 and -0.39 in the non-biologics group (p=0.68, p=0.74, respectively) indicating that the decrease in DLCO and FVC was small in the biologics group. The change of total CT score at 3 years was 1.11 in the biologics group, wheareas it was 2.02 in the non-biologics group (p=0.09).

#### Conclusions

Biologics may contribute to slowing the progression of RA-ILD

#### **Keywords**

**RA-ILD**, Biologics, PFT



<u>KCR 2022</u>

# Management of rheumatoid arthritis in China: a study of the implementation of 2021 ACR guideline

Shangyi Jin¹, Nan Jiang¹, Qian Wang¹, Mengtao Li¹, Xinping Tian¹

¹ Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, China

#### Background

Implementation of evidence-based guidelines for the management of rheumatoid arthritis (RA) in clinical practice has lagged behind expectations. This study aimed to examine the concordance between management of RA in China and the 2021 ACR guideline.

#### **Methods**

Newly diagnosed and DMARD-naïve RA patients were screened from the Chinese Registry of rhEumatoiD arthrl-Tis (CREDIT). Initial treatment for patients with moderate to high or low disease activity at baseline was analyzed separately. Comparison between different initial therapies was made to identify potential factors associated with therapeutic decisions. A follow-up study was conducted to evaluate whether timely treatment escalation occurred if treatment targets were not achieved.

#### **Results**

A total of 15220 patients were included. Among 12723 patients with moderate to high disease activity at baseline, 3633 (28.6%) received csDMARD monotherapy, and 1737 were methotrexate monotherapy users. Combination csD-MARDs were initiated in 6474 patients (50.9%), and 1721 (13.5%) initiated biologics or JAK inhibitors (291 as monotherapy and 1421 in combination with csDMARDs). Initiating monotherapy as recommended by ACR was associated with younger age, shorter disease duration, lower disease activity and more experienced providers. In 2497 patients with low disease activity at baseline, 778 (31.1%) undertook csDMARD monotherapy as the first strategy. Hydroxychloroquine was given to only 132 patients, though it was recommended over other csDMARDs in the ACR guideline. In the follow-ups of MTX monotherapy users, 8.7% patients had treatment escalated after the failure of the first strategy. Among patients initiating biologics or JAK inhibitors, when the treatment targets were not achieved within 3 or 6 months, none of them received timely treatment adjustment

#### Conclusions

Management of RA in China showed insufficient concordance with the 2021 ACR guideline for RA. Future collaborative efforts of patients and physicians are required to improve the implementation of international guidelines in China.

#### **Figure & Table**

	Total
N (%)	15220 (100)
Demographic features	
Female (%)	11694 (76.8)
Age (y)	$51.9 \pm 13.5$
Clinical characteristics	
RF/CCP+ (%)	13528 (88.9)
RA duration (m)	0 (0-2)
DAS28-CRP	$4.6\pm1.6$
DAS28-ESR	$5.2 \pm 1.7$
CDAI	23.4 (13.7-37.0)
SDAI	25.8 (15.1-40.7)
HAQ-DI	0.63 (0.13-1.13)
Joint replacement (%)	101 (0.66)
CAD (%)	280 (1.8)
Stroke (%)	159 (1.0)
Fragility fracture (%)	203 (1.3)
Malignancy (%)	137 (0.9)
GC combination (%)	4533 (29.8)

Table. Baseline Characteristics of study population

#### **Keywords**

rheumatoid arthritis, ACR guideline, implementation study



### Study of methotrexate metabolism in patients taking statins

#### Galina Gridneva¹, Eugenia Aronova¹, Elena Samarkina¹, Natalia Baymeeva²

¹ Comorbid Infections and Safety of Drug Therapy, V.A.Nasonova Rheumatology Research Institute, Russian Federation ² Drug Monitoring Department, Mental Health Research Center, Russian Federation

#### Background

To describe the clinical and pharmacokinetic characteristics of a group of patients with rheumatoid arthritis (RA) treated with statins and methotrexate (MTX).

#### **Methods**

The study included 79 MTX-naiive RA patients, 65(82%) women and 14(18%) men, aged 53±11 years. All patients were prescribed MTX at the rate of 10-15 mg/m2 of body surface. After 12, 24 and 36 weeks of therapy, RA activity was assessed by DAS28, a blood test was performed to determine MTX monoglutamate (MGMTX), polyglutamates with 2, 3 and 4 glutamate residues (MTXPGs2-4), 7-hy-droxymethotrexate (7-OH-MTX) in erythrocytes (ER) and mononuclear cells (MO) by tandem chromatography-mass spectrometry.

#### **Results**

Statins were taken by 8 patients (group 1), 3 men, 5 women. Comparison group(2), n=71, were not prescribed statins. The groups did not differ in gender, body mass index, disease activity, cumulative dose of MTX. Group 1 patients were older (63±7 years versus 52±11 years in the comparison group, p=0.03). Only 2 (25%) patients from group 1 achieved the targets of therapy (remission or low disease activity) by week 24, while in group 2 this figure was 42% (p<0.05). At the same time, the levels of MTXMG(ER), MTXPGs(MO) and 7-OH-MTX(MO) on week 12, as well as MTXPG4(ER) on week 36, were higher than in group 2. The frequency of achieving therapy targets by week 36 did not differ between the groups.

#### **Conclusions**

Our finding was the detection of higher levels of MTX metabolites in the cells of patients with RA treated with statins, however, the groups differed significantly in number, and patients in group 1 were older. Statins has a positive effect on the accumulation of MTX metabolites, however, despite this, the treatment response by 24 weeks in these patients may be worse due to other clinical characteristics, such as age.

#### **Keywords**

methotrexate, statins, poliglutamates



## Digital Aging and Mental Health Deteriorations: How Can We Mitigate the Risk Among the Elderly with Rheumatoid Arthritis Disease in Indonesia?

#### Rosinta Hotmaida Pebrianti Purba¹

¹ Poverty Alleviation and Community Empoerment, Bappenas, Indonesia

#### Background

Indonesia is entering an aging society, with an older population of 26.82 million people (9.92 percent), and 18.95 percent of them are predicted to have rheumatoid arthritis. This proportion is nearly three times higher than the national average of 7.3 percent (MoH, 2018). Due to comorbidities and inadequate digital literacy, the older person is the covid-19 most at risk. This problem contributes to Indonesia's aging market, yet insufficient digital literacy has a negative impact on QoL.

#### **Methods**

The purpose of this study is to examine mental health issues and mobile phone ownership in older persons (60+) with Rheumatoid Arthritis illness using data from the 2014 Indonesia Family Life Survey (IFLS) wave 4th.

#### **Results**

According to the results, the proportion of older adults with RA is 22.7%, with women contributing for 44%. Furthermore, 26.47 percent of them had mental health problems, with men having a higher proportion. However, using a cellphone reduces the percentage of seniors with RA disease reporting mental health difficulties by 6,78%. In Indonesia, the senior SES is distributed fairly diverse throughout provinces. 55,8 percent of them continue to work. Elementary school, which accounts for 46.05 percent of older people's educational attainment, accounts for nearly half of their educational achievement. They report feeling not trying enough, sleeping restless, bothered by things, hopeless, unable to concentrate, and feeling unhappy. The least disturbance felt by them was feeling afraid. In general, the elderly who are more digitally literate prefer to seek care from a formal health facility rather than traditional practitioners such as shamans. They prefer to receive outpatient care at a community health center or Puskesmas (44,11%), a specialist (29,41%), or a private hospital (11,76%).

#### Conclusions

Increased digital aging promotes older health literacy while minimizing mental health issues. Integrating the digital aging issue can assist the elderly get the knowledge

#### **Figure & Table**



#### **Keywords**

Mental health, Rheumatoid arthritis, Elderly with RA Disease



## Comparison of drug persistence between tumor necrosis factor-α inhibitors and tocilizumab in patients as first-line treatment with rheumatoid arthritis using the Korean Health Insurance Review and Assessment Service database

#### Byung Wook Song¹, Dong-Hyuk Moon¹, Aran Kim¹, Seung-Geun Lee¹

¹ Division of Rheumatology, Department of Internal Medicine, Pusan National University Hospital, Republic of Korea

#### Background

Drug persistence represents long-term therapeutic performance in real clinical setting. We aimed to compare persistence rate between tumor necrosis factor-alpha (TNF- $\alpha$ ) inhibitors and tocilizumab in patients with rheumatoid arthritis (RA) using the Korean Health Insurance Review and Assessment Service (HIRA) database.

#### **Methods**

In this retrospective cohort study, patients with RA who started TNF- $\alpha$  inhibitors such as adalimumab, etanercept, infliximab and golimumab or tocilizumab as first-line biologic therapy between Jan 2014 and Dec 2017 on HIRA database were analyzed and were followed up to Dec 2019. Drug persistence was defined as the duration from the initiation to the first discontinuation including stopping and switching to other biologic therapy.

#### **Results**

A total of 5,449 RA patients were analyzed in this study. Mean age was 53.4 years and 4,423 (81.2%) patients were female. TNF-a inhibitors and tocilizumab were prescribed for 4,202 (adalimumab, 1,413; etanercept, 1,100; infliximab, 769; golimumab 920) and 1,247 RA patients, respectively. RA patients treated with tocilizumab was significantly older and had a significantly higher frequency of female compared with those treated with TNF- $\alpha$  inhibitors. During the study period, 2,090 (49.7%) and 477 (38.3%) RA patients discontinued TNF-a inhibitors and tocilizumab, respectively. Drug persistence was significantly lower in TNF-a inhibitors group than tocilizumab group (log-rank test, p<0.001). In multivariable Cox regression model, TNF-α inhibitors was significantly associated with a higher risk of discontinuation compared with tocilizumab (HR=1.63, 95% CI=1.47-1.81, p<0.001). In subgroup analyses, adalimumab (HR=1.73, 95% CI=1.54-1.95, p<0.001), etanercept (HR=1.87, 95% CI=1.66-2.11, p<0.001) and golimumab (HR=1.57, 95%

CI=1.37-1.79, p<0.001) but not infliximab (HR=1.23, 95% CI=1.06-1.42, p=0.054) showed a significantly higher risk of discontinuation compared with tocilizumab after adjusting confounding factors.

#### Conclusions

Our findings indicate that tocilizumab had a better long-term persistence than TNF- $\alpha$  inhibitors in patients in RA in real clinical setting.

#### **Keywords**

Rheumatoid Arthritis, Tumor necrosis factor-alpha inhibitors, Tocilizumab



## Impact of Korean red ginseng on fatigue in patients with rheumatic disease: A randomized, double-blind study

<u>Soo-Kyung Cho</u>¹, Hyoungyoung Kim^{1,2}, Yeo-Jin Song^{1,2}, Hye Won Kim², Eunwoo Nam², Yoon-Kyoung Sung^{1,2}

¹ Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea ² Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea

#### Background

In this randomized clinical trial, we evaluated impact of Korean Red Ginseng (KRG) on fatigue in patients with rheumatic diseases.

#### **Methods**

A total 120 patients [Sjogren syndrome (n=53), rheumatoid arthritis (n= 43), and both diseases (n=24)] were randomly assigned to either KRG (2g/day, n=60) or placebo (n=60) groups for 12 weeks of blind phase. Primary outcomes were improvement rate for fatigue using fatigue visual analogue scale (VAS) and Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue at 12 weeks. Multiple imputations by chained equations generated 20 complete datasets based on variables such as; age, sex, type of rheumatic diseases, rheumatoid factor positivity, erythrocyte sedimentation rate, drug compliance, medications, two fatigue scales for intention to treatment analysis. Adverse events (AEs) were presented in each treatment group for 24 weeks.

#### **Results**

Total 120 patients were aged 50.9 ±11.6 years with 117 female (97.5%), and baseline characteristics were similar between two groups. After treatment, fatigue was significantly improved in both groups (P <0.001 in each group). The primary endpoints analysis of improvements rates in fatigue VAS and FACIT-Fatigue after 12 weeks showed that there were not different between two groups [50.0% vs 43.3%; odds ratio (OR) with 95% confidence interval (CI), 1.31 (0.64, 2.68), P=0.583 for fatigue VAS; 38.3% vs placebo 26.7%; OR with CI, 1.71 (0.79, 3.71), P=0.242 for FACIT-Fatigue, respectively). However, numerical improvements favoring KRG were observed, in which both response rates were higher in KRG than placebo group. Nine and seven patients reported AEs during whole study period in each KRG and placebo group, respectively.

#### Conclusions

Fatigue was significantly improved in both the KRG and placebo groups, and there was no significant difference between the two groups. Considering the positive perceptions of KRG in Korea, a long-term study with a large sample is needed to elucidate the effectiveness of KRG.

#### **Keywords**

Korean Red Ginseng, Rheumatic diseases, fatigue



KCR 2022

May 19(Thu) - 21(Sat), 2022

## The preoperative patient's expectations and it's clinical outcomes after rheumatoid forefoot deformity surgery

#### Dong Hong Kim¹, Il-Hoon Sung¹

¹ Department of Orthopaedic surgery, Hanyang University Hospital, Republic of Korea

#### Background

Rheumatoid forefoot deformity (RFD) is common and several surgical techniques include joint sacrificing and saving procedures. Currently, there are only few studies about patient's expectation for RFD. We evaluated patient's expectation and its fulfillment following RFD surgery.

#### Methods

We retrospectively analyzed 40 feet which underwent RFD surgery of joint sacrificing-modified Dwyer's operation. Overall satisfaction was measured in 5-digit scale (5; very high, 4; high, 3; average, 2; low, 1; very low). Questionnaire of the expectation of surgery and its fulfillment for greater toe and lesser toes were given to all patients, and the answers were based on a 5-digit scale in 5 different categories, prevention of deformity progression(D), reduction in pain(P), improvement in shoe wearing(S), improvement in foot function(F) and improvement in appearance(A). Multiple regression analysis was done for correlation with postoperative satisfaction.

#### Results

Female; male was 39;1, Age was 55.1±8.2. VAS was reduced from 7.2±2.1 to 2.2±1.8. Overall satisfaction was 4.0±0.82. Preoperative hallux valgus angle (HVA), intermetatarsal angle (IMA) was 47.5±9.9, 16.7±4.3 in average which improved postoperatively to 14.0±4.2, 9.9±3.5, respectively. For the greater toe, expectation (D, P, S, F, A) was 4.2, 4.1, 2.9, 2.8, 2.6 in average and its fulfilment was 4.1, 4.0, 3.4, 3.5, 3.2, respectively. For the lesser toes, expectation (D, P, S, F, A) was 3.9, 4.1, 3.3, 3.0, 2.8 and its fulfilment was 3.3, 4.0, 3.4, 3.6, 2.8, respectively. D and P were the highest expectation. Multiple regression analysis showed P for the greater toe (p=0.009) and F for the lesser toes (p=0.009) showed a significant positive correlation with postoperative satisfaction.

#### Conclusions

Rheumatoid forefoot surgery is a salvage procedure and so, it is important to discuss expectation of patients and its fulfilment before surgery which will have an effect on clinical outcome.

#### Figure & Table

**Postop Foot Radiograph** 



**IMA 10.6** 

Figure. Preop and Postop Foot Radiograph

IMA 16.1

#### **Keywords**

Rheumatoid forefoot deformity, Expectation, Patient satisfaction

# **E-poster Presentation**

## SLE-clinical aspects, APS

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



# Effect of systemic lupus erythematosus on carotid intima media thickness and its relationship with disease activity

#### Gökhan Polat¹, Elshad Ismailov¹, Merve Polat²

¹ Radiology, Atatürk University, Turkey ² Health Physics, Karadeniz Technical University, Turkey

#### Background

It is known that atherosclerosis increases in patients with systemic lupus erythematosus (SLE). In our study, we aimed to examine the effect on carotid intima-media thickness in patients followed up with the diagnosis of SLE.

#### **Methods**

183 cases (mean age: 36.2) and 104 control subjects (mean age: 38.1) followed up with the diagnosis of SLE were included in the study. The clinical and demographic characteristics of the patients were recorded. Activity classification was made based on the SLEDAI score: no activity (SLEDAI=0), mild activity (SLEDAI 1–5), moderate activity (SLEDAI 6–10), high activity (SLEDAI 11–19), very high activity (SLEDAI)  $\geq$ 20). Carotid ultrasonography was performed in all cases to evaluate subclinical atherosclerosis and intima-media thickness (IMT) was evaluated. Presence of IMT>1 mm was evaluated as subclinical atherosclerosis.

#### **Results**

There was no significant difference between the groups in terms of age and gender. The mean disease duration was 49.6 months, cyclophosphamide use was 35.6%, steroid 97.8%, and azathioprine use was 29.9%. Hematological involvement was 72%, serositis was 14.8%, renal involvement was 48.9%, arthritis was 73.4%, and neurological involvement was 22.7%. Carotid IMT of SLE patients (mean 0.724mm) was significantly higher than the control (mean 0.618mm) (p=0.0414). While the rate of IMK>1mm was 13.2% in the SLE group, it was 3.1% in the control group (p=0.135). There were 84 patients with SLEDAI=0, 36 patients with SLEDAI 1-5, 28 patients with SLEDAI=0, 24 patients with SLEDAI 11-19, and 11 patients with SLEADI  $\geq$ 20.A moderate correlation was found between carotid IMT and disease activity (r=0.639, p=0.009.

#### Conclusions

An increase in carotid intima-media thickness is observed in patients with SLE, and there is a correlation between disease activity and carotid intima-media thickness.

#### **Keywords**

Systemic lupus erythematosus, Carotis Intima media thickness, Carotid ultrasonography



## Wernicke encephalopathy secondary to systemic lupus erythematosis enteropathy

#### Arzu Shahveranova¹

¹ Department of Radiology, Adana Çukurova Üniversity, Turkey


#### Description

A 24-year-old female patient was followed for 1 year with the diagnosis of Systemic Lupus Erythematosis(SLE). The patient was receiving oral prednisone and oral azathioprine for the diagnosis of SLE. The patient applied to our clinic with complaints of vomiting, diarrhea, and weight loss. In laboratory tests, hemolytic anemia, positive antinuclear antibodies, positive anti-Smith antibodies, and hypoalbuminemia were observed. physical examination revealed drowsiness and truncal and limb ataxia. A spinal MRI was performed. In MRI, there was an increase in signal in the posterior column in fluid-sensitive sequences. The signal increase was observed in the cervical and thoracic regions(Figure 1). Radiological involvement suggested Wernicke's encephalopathy due to SLE enteropathy. The patient was started on IV methylprednisolone and thiamine treatment. Improvement was observed in the patient's neurological symptoms.

#### Conclusions

Vitamin B1 absorption may be impaired as a result of severe vomiting and diarrhea, causing SLE enteropathy. Thiamine deficiency should be kept in mind in neurological symptoms following SLE enteropathy.

#### Figure & Table





## Prognostic factors for the development of systemic lupus erythematosus in patients with immune thrombocytopenia

Soo Min Ahn¹, Eun-Ji Choi², Ji Seon Oh¹, Yong Gil Kim¹, Chang-Keun Lee¹, Bin Yoo¹, Seokchan Hong¹

¹ Department of Rheumatology, Asan Medical Center, Republic of Korea ² Department of Hematology, Asan Medical Center, Republic of Korea

#### Background

Patients with immune thrombocytopenia (ITP) have a risk of developing systemic lupus erythematosus (SLE). We sought to examine the clinical characteristics of patients with primary ITP who later developed SLE, and identified the risk factors for the development of SLE.

#### **Methods**

We retrospectively examined patients who were diagnosed with primary ITP at a tertiary hospital between August 2001 and November 2019. We compared the clinical characteristics according to the development of SLE. Logistic regression analysis was performed to identify the factors associated with the development of SLE.

#### Results

Of 130 patients with primary ITP, 10 (7.7%) were later diagnosed with SLE during follow-up (median, 30 months [IQR, 15.5-105]). The presence of skin bleeding, organ bleeding, lymphocytopenia, anemia, and positive antinuclear antibody (ANA) titer (> 1:160) were more common among patients who later developed SLE than did those who did not develop SLE. Multivariate analysis showed that young age (< 40 years; odds ratio [OR], 8.359 [95% confidence interval (CI), 1.230-56.793]; p = 0.033), organ bleeding (OR, 18.349 [95% CI, 2.771-121.517]; p = 0.003), and ANA positivity (>1:160; OR, 7.692 [95% CI, 1.482–39.910]; p = 0.015) were significantly associated with the development of SLE.

#### Conclusions

Young age (< 40 years), organ bleeding, and ANA positivity (> 1:160) were risk factors for the development of SLE in patients with primary ITP. Close follow-up is needed to detect the development of SLE in patients with ITP and the abovementioned risk factors.

#### Figure & Table

		Univariate		Multivariate			
	OR	95% CI	P value	OR	95% CI	P value	
Young age ^a	5.444	1.332-22.250	0.018	8.359	1.230-56.793	0.033	
Female	4.333	0.530-35.422	0.17				
BMI	0.873	0.717-1.070	0.20				
Skin bleeding	8.419	1.034-68.533	0.046				
Mucosa bleeding	1.250	0.247-6.330	0.79				
Organ bleeding	14.864	3.633-60.815	< 0.001	18.349	2.771-121.517	0.003	
Platelet counts, × 10 ⁹ /L	0.911	0.828-1.002	0.055				
ANA positivity (>1:160)	16.500	3.984-68.341	< 0.001	7.692	1.482-39.910	0.015	
Leukopenia ^b	2.786	0.653-11.892	0.17				
Neutropenia ^e	2.111	0.229-19.499	0.51				
Lymphocytopenia ^d	4.846	1.189-19.759	0.028				
Anemia ^e	10.118	2.044-50.091	0.005				

SLE: systemic lupus erythematosus, ITP: immune thrombocytopenia, BMI: body mass index, ANA: antinuclear antibody, OR: odds ratio, CI: confidence interval.

^aYoung age = age < 40 years ^bLeukopenia = white blood cell count < 4000 /μL

°Neutropenia = Absolute neutrophil count <  $1500 / \mu L$ ^dLymphocytopenia = Absolute lymphocyte count <  $1500 / \mu L$ 

°Anemia = Hemoglobin < 12 g/dL

Table. Factors associated with the development of SLE in patients with primary ITP

#### **Keywords**

Thrombocytopenia, Systemic lupus erythematosus, Antinuclear antibody



## A case of portal and hepatic vein occlusion in systemic lupus erythematosis

#### Mehmet Selim Kan¹, Muhammed Eyyüp Çelik¹, Elshad İsmailov²

¹ medical faculty, Atatürk University, Turkey ² Department of Radiology, Ataturk University, Turkey


#### **Description**

A 47-year-old woman was diagnosed with SLE based on malar rash, positive ANA, high anti-dsDNA titer (160 IU/ mL, normal <10). The patient was admitted to the hospital because of his right upper quadrants. Laboratory data revealed the following results: WBC 6,800/mm3 (normal 4,500- 11,000); hemoglobin, 14.3 g/dL (normal 12-16); platelets, 198,000/mm3 (normal 150,000-400,000); BUN, 26 mg/dL (normal 7-20); creatinine, 0.6 mg/dL (normal 0.5-1); alanine aminotransferase, 61 U/L (normal <31); aspartate transaminase, 64 U/L (normal <31); albumin, 1.4 g/ dL (normal 3.4–4.8); d-dimer, 4016 ng/mL (normal < 500); fibrinogen, 848 mg/dL (normal 200-400). in examinations. No filling was observed in the left branch of the portal vein and in the left hepatic vein in the upper abdomen magnetic resonance imaging of the patient(Figure 1). Therefore, thrombus was considered. The patient's thrombus was confirmed by Doppler ultrasonography. The patient was initially given anticoagulants (low molecular weight heparin) and intravenous methylprednisolone 250 mg daily for three days.

#### **Conclusions**

Antiphospholipid syndrome(APS) is an autoimmune disorder characterized by venous or arterial thrombosis, thrombocytopenia, and recurrent spontaneous abortions. There are few seronegative APS in the literature. A significant proportion of APS cases are associated with SLE. Other conditions associated with secondary APS include lupus-like syndrome, rheumatoid arthritis, primary Sjögren's syndrome, systemic vasculitis, systemic sclerosis, and dermatomyositis. Most cases of APS show peripheral or pulmonary thrombosis and neurologic manifestations, but intra-abdominal involvement is much rarer. It should be kept in mind in cases where liver functions are affected in SLE patients.

#### Figure & Table





## Disease flare of systemic lupus erythematosus in patients with end-stage renal disease on dialysis

<u>Young-Eun Kim</u>¹, Su Jin Choi², Doo-Ho Lim², Soo Min Ahn¹, Ji Seon Oh³, Yong-Gil Kim¹, Chang-Keun Lee¹, Bin Yoo¹, Seokchan Hong¹

¹ Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Republic of Korea ² Department of Rheumatology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Republic of Korea, Republic of Korea ³ Information Medicine, Big Data Research Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Republic of Korea

#### Background

The systemic lupus erythematosus (SLE) disease activity in patients with lupus nephritis (LN) generally declines after the initiation of renal replacement therapy (RRT); this is known as the "burn out" phenomenon that possibly occurs due to the suppression of cellular and humoral immunity in the end-stage renal disease (ESRD) state and elimination of disease pathogenic factor by dialysis. However, several studies showed that SLE flares could occur even during RRT. Nevertheless, the details of disease flares of SLE in patients under dialysis have not been studied yet. We aimed to investigate the clinical features, risk factors, and treatment details of SLE patients experiencing disease flare under RRT.

#### **Methods**

The medical records of SLE patients who received dialysis at two tertiary referral hospitals in Seoul and Ulsan, South Korea were reviewed. All patients in this study were either clinically or histologically diagnosed with LN.

#### Results

Of a total of 121 patients with SLE on dialysis, 96 (79.3%) were on hemodialysis (HD) and 25 (20.6%) were on peritoneal dialysis (PD). During a median follow-up of 45 months (IQR, 23–120) after the initiation of dialysis, 32 (26.4%) patients experienced SLE flare (HD, n = 25; PD, n = 7). The most common features of SLE flare were hematologic (40.6%) and constitutional manifestations (40.6%). Treatments for disease flares were based on corticosteroids, and 11 (34.3%) patients required additional immunosuppressants including cyclophosphamide and mycophenolate mofetil. There was no case of severe adverse events related to medication. non-renal SLE Disease Activity Index (SLEDAI) score before dialysis initiation (HR 1.235; 95% Cl, 1.122–1.359; P = 0.001) was a significant risk factor for disease flare during dialysis.

#### Conclusions

More than one-quarter of SLE patients experienced disease flare during dialysis, which most commonly had hematologic manifestations. Continued follow-up and appropriate treatments including immunosuppressants should be considered for patients with SLE under dialysis.

#### Figure & Table

	Hazard ratio	95% CI	P-value
Non-renal SLEDAI at the initiation of dialysis	1.235	1.122-1.359	0.001
Hematologic manifestation prior to dialysis	1.256	0.690-2.826	0.150
Cumulative amount of steroid during 1 year prior to the initiation of dialysis	1.040	0.995-1.087	0.086
Dialysis modality: hemodialysis	0.766	0.262-2.243	0.630

Table. Multivariable analysis of factors associated with SLE flare under dialysis

#### **Keywords**

Lupus nephritis, Renal replacement therapy, SLE



## Clinical relevance according to staining patterns and titers of antinuclear antibody

Mi Ryoung Seo¹, Jina Yeo¹, Hyo-Jin Choi¹, Han Baek¹

¹ Division of Rheumatology, Department of IM, Gil Medical Center, Gachon University College of Medicine, Republic of Korea

#### Background

Immunofluorescent antinuclear antibody (ANA) test using HEp-2 cells still plays an important role in the diagnosis of autoimmune diseases. The aim of this study was to investigate the clinical relevance of ANA according to titers and patterns.

#### **Methods**

We identified patients who were newly positive in the ANA test between December 2010 to November 2016, and collected data such as, diagnosis, ANA titer and pattern, and specific autoantibody test results.

#### **Results**


In total, 7591 patients were included in this study. The average age was 51 (IQR 35-63) years, and 69.4% were women. Figure 1 showed the patient distribution according to ANA patterns and titers. The diseases with a difference in prevalence according to ANA titer were systemic lupus erythematosus (SLE), Sjögren syndrome (SjS), polymyositis/ dermatomyositis (PM/DM), systemic sclerosis (SSc), autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), liver cirrhosis, hemolytic anemia, immune thrombocytopenic purpura, interstitial lung disease (ILD), chronic obstructive pulmonary disease/bronchiectasis (COPD/BE), cerebrovascular accident, and crystal induced arthropathy (CIA). In multivariable analysis, diseases with increased prevalence with increasing ANA titer were SLE, SjS, PM/ DM, SSc, AIH, PBC, and ILD, and the opposite result showed in COPD/BE and CIA.

SLE was the most prevalent in patients with mixed pattern of nuclear and cytoplasmic (6.4% in  $\geq$ 1:40, 40% in  $\geq$ 1:2560) (Figure3). SjS and SSc showed the similar results. The prevalence of PM/DM, AIH, PBC and ILD was highest in mixed pattern of nuclear and cytoplasmic in all patients, but it was highest in cytoplasmic pattern from 1:160 or more of ANA titer.

#### Conclusions

SLE, SjS, PM/DM, SSc, AIH, PBC and ILD were the diseases in which ANA titer independently affected disease prevalence. Patients with mixed pattern of nuclear and cytoplasmic had a higher prevalence of SLE, SjS and SSc than purely nuclear pattern.

#### **Figure & Table**



#### **Keywords**

antinuclear antibody, systemic rheumatic disease



### Long-term renal outcomes of patients with non-proliferative lupus nephritis

Eunsong Kang¹, Seokchan Hong¹, Yong Gil Kim¹, Ji Seon Oh², Soomin Ahn¹, Chang Keun Lee¹, Bin Yoo¹

¹ Rheumatology, Asan medical center, Republic of Korea ² Department of Information Medicine, Asan medical center, Republic of Korea

#### Background

Although proliferative (class III or IV) lupus nephritis (LN) is the most common finding in the classification of LN, non-proliferative LN can occur as a form of pure membranous (class V) or mesangial (class I or II) LN. Even though non-proliferative LN has been considered as a less severe LN with good outcomes, data on long-term renal prognosis are limited. Thus, we investigated the long-term outcomes and prognostic factors in non-proliferative LN.

#### **Methods**

We retrospectively reviewed the medical records of patients with systemic lupus erythematosus who were diagnosed with LN class I, II, V or II+IV by kidney biopsy between 1997 and 2021 at a tertiary referral center. Poor renal outcome was defined as an estimated glomerular filtration rate (eGFR) of < 60 mL/min/1.73m2. Univariate and multivariate analyses were performed with the Cox proportional hazard model to identify the factors associated with poor renal outcomes.

#### Results

We included 71 patients with non-proliferative LN (4:class I; 17:class II; 48:class V; 2:class II+V). Median follow-up duration was 103 months (interquartile range 27–185) and the overall rate of poor renal outcomes was 29% (21/71), including end-stage renal disease (n=2). Univariate analysis indicated that older age (HR 1.05; 95% CI: 1.00–1.09), low eGFR (HR 0.97; 95% CI: 0.95–0.99), failure to reach complete remission at 6 months (HR 0.33; 95% CI: 0.12–0.92) and LN chronicity score >4 (HR 3.81; 95% CI: 1.19–12.14) or activity score >6 (HR 20.51; 95%CI: 2.13-197.37) were significantly associated with poor renal outcomes. Multivariate analysis revealed that low eGFR at 6 months (HR 0.97; 95%CI: 0.95–0.99, p=0.035) was significantly associated with poor renal outcomes.

#### Conclusions

Poor renal outcomes occurred in approximately 30% of patients with non-proliferative LN after long-term follow-up. Our findings suggest that more active management may be needed for non-proliferative LN.

#### **Figure & Table**




Figure. Long-term outcomes of total patients according to the renal function

eGFR, estimated glomerular filtration rate (ml/min/1.73m²)

#### **Keywords**

Lupus nephritis, Renal function



KCR 2022

May 19(Thu) - 21(Sat), 2022

## Computer aided detection of the white matter lesions associated with systemic lupus erythematosus in cranial magnetic resonance imaging

## Ahmet Yalcin¹, Fatih Alper¹

¹ Radiology, Ataturk University, Faculty of Medicine, Turkey

#### Background

Specific vasculitis-related white matter lesions detected in cranial magnetic resonance imaging (MRI) are crucial as those lesions might also be encountered in various other pathologies such as multiple sclerosis (MS) and small vessel disease (SVD) (1). In this study, we aim to differentiate brain involvement of SLE from other white matter diseases by using a computer-assisted white matter lesion detection algorithm.

#### **Methods**

MRI of 11 patients with SLE, 13 patients with MS, and 18 patients with SVD were analyzed retrospectively. T1 weighted and FLAIR images were extracted from the patients' DICOM image folders and uploaded to the online vol-Brain segmentation application (https://www.volbrain.upv. es/) (2). Total intracranial volume (cm3), total white matter volume (cm3), gray matter volume (cm3), total lesion count, lesion location, absolute lesion volume (cm3), and lesion burden (total lesion volume/white matter volume) were automatically calculated for each patient. Statistical analyses were conducted depending on these parameters in three groups.

#### **Results**

The difference of mean age and gender distribution were insignificant in all groups (p for ANOVA= 0.526 and p for chi-square = 0.148 respectively). Total intracranial volume and gray matter volume were similar in all groups (p for Kruskal-Wallis= 0.369 and 0.426 respectively). White matter volume was significantly lower in SVD with no difference between MS and SLE (p for Kruskal-Wallis= 0.039). Total lesion count and absolute lesion volumes were insignificant in all groups (p for ANOVA= 0.896 and 0.692 respectively). Juxtacortical lesion burden was more prominent in SLE-related white matter disease compared to MS and SVD (p for Kruskal-Wallis=0.023) whereas periventricular lesion burden was significantly higher in SVD (p for Kruskal-Wallis < 0.001).

#### Conclusions

A computer-aided lesion detection algorithm can detect and classify the lesion burden in white matter lesions. SLE-related white matter lesions were associated with increased juxta cortical lesion burden with no significant white matter volume loss.

#### **Keywords**

systemic lupus erythematosus, magnetic resonance imaging, white matter lesion



## Internuclear ophthalmoplegia in lupus cerebritis: double jeopardy

#### Paul Shiu¹, Navneet Kaur², Anil Harrison³, Howard Feinberg²

¹ Department of Internal Medicine, St Joseph's Medical Center - Graduate Medical Education, USA ² Department of Rheumatology, Touro University Medical Group, USA ³ Department of Internal Medicine, Touro University Medical Group, USA

#### Description

We report this case of a 42-year-old woman with a history of systemic lupus erythematosus (SLE) who presented in June 2021 with profound encephalopathy and a left internuclear ophthalmoplegia (INO) in the setting of lupus cerebritis. This patient was initially diagnosed with lupus in 2016 when she developed a photosensitive rash and further evaluation revealed immune thrombocytopenia as well as a positive antinuclear antibody (ANA), chromatin, and sm-RNP. She had been non-compliant with immunosuppressive regimens since 2016. Neurological examination was remarkable for somnolence and a left-sided INO without evidence of any additional focal cortical dysfunction. She was also noted to have oral ulcers. Initial blood work showed multiple electrolyte abnormalities, anemia and thrombocytopenia. Blood cultures and toxicology screens were negative. Cerebrospinal fluid analysis was unremarkable (WBC 1/mm3, RBC 5/mm3, glucose 56 mg/ dL, protein 38 mg/dL). A CT and MRI of the brain revealed no acute intracranial abnormalities including for masses, midline shifts, hemorrhagic or ischemic changes. Because her altered sensorium did not improve after correction of underlying electrolyte and metabolic derangements, a consideration of lupus cerebritis was suspected. Erythrocyte sedimentation rate (ESR) was 102 mm/hour. C3 and C4 levels were within normal limits. Following the initiation of intravenous steroids, this patient had a dramatic recovery within 24 hours achieving a normal sensorium and was discharged on oral steroids and cyclophosphamide. During her two week follow up, she was noted to have a near complete resolution of her INO.

#### Conclusions

The development of internuclear ophthalmoplegia as a consequence of lupus cerebritis is rare. Herein, we report a woman with neurological manifestations of SLE with encephalopathy and internuclear ophthalmoplegia with prompt resolution of the aforementioned following early diagnosis and treatment.

#### **Keywords**

internuclear ophthalmoplegia, systemic lupus erythematosus, encephalopathy



## Working memory and processing speed in systemic lupus erythematosus: correlation with disease activity

#### Rudrani Chatterjee¹, Rudra Goswami², Parasar Ghosh³

¹ Clinical Psychology, IOP (COE), Clinical Psychologist, India ² Rheumatology, Assistant Professor, AIIMS, New Delhi, India

³ Rheumatology, Professor and Head, IPGMER, Kolkata, India

#### Background

Systemic lupus erythematosus (SLE) is a chronic, autoimmune multisystem inflammatory disorder. Cognitive impairment is difficult to monitor in SLE and relationship with disease activity is dubious. Attention, working memory (WM) and processing speed (PS) are closely related cognitive domains that are commonly disrupted in SLE.

Our goal was to determine whether WM and PS dysfunction in SLE patients are related to disease activity.

#### Methods

Adult female patients with SLE were without known neurologic or psychiatric co-morbidity, medications, co-morbid clinically manifest antiphospholipid syndrome (APS) or SLE damage index (SDI) >0 were enrolled. Patients were grouped as "active lupus" (BILAG A or B) or "persistent remission" (SLEDAI=0 on ≤7.5mg/day prednisolone). Age matched female control subjects were recruited. Cognitive assessments were done including tests for working memory (WM): verbal and visual n - back tests (1 and 2 back); and digit symbol substitution test (DSST) for processing speed (PS).

#### Results

We recruited 71 female patients with lupus (mean age 27.5±7.6 years, mean disease duration 30.4 ± 28.6 months, 39 with active disease) and 31 female control subjects (mean age 29.4 ± 7.5 years). Antiphospholipd antibody (aPL) were positive in 17 patients.

In univariate analysis patients both lupus groups performed worse on all cognitive domains compared to controls (Table 1). Patients with active lupus had worse PS compared to patients in remission. In multivariate Poisson regression visual 1-back (Odd's ratio (OR): 0.54, 95% confidence interval (CI): 0.32-0.91, p=0.022) was associated with lupus activity. In gamma regression PS was associated with disease activity (OR: 0.988, 95% CI: .982-0.994, p<0.001) and positive aPL (OR: 1.006, 95% CI: 1.001-1.011, p=0.031).

#### Conclusions

SLE patients have WM dysfunction as a disease-specific trait. PS dysfunction was associated with disease activity. The association PS and WM seemed to follow the Independent Consequence Model of cognition theory.

#### Figure & Table

Parameters		Patients with active lupus n=39	Patients with persistent remission n=32	Control subjects n=31	p-value a	p-value b	p-value ^c	p-value ^d
Demographics	Age in years	$27.8 \pm 8.2$	$27 \pm 6.9$	$29.4 \pm 7.5$	0.35	ND	ND	ND
	Duration of disease in months	$31.6\pm33.7$	$28.9\pm21.1$		0.28			
Tests for	Digit span forward	$4.62 \pm 0.96$	$5.22 \pm 1.16$	$6.55 \pm 1.09$	< 0.001	< 0.001	< 0.001	0.006
Attention	Digit span backward	$3.05 \pm 1.02$	$4.19 \pm 0.97$	$4.97 \pm 1.2$	< 0.001	< 0.001	0.012	< 0.001
Tests for	Verbal 1-back no of hits	$6.95 \pm 2.36$	7.66 ± 1	$8.16 \pm 0.9$	0.027	0.012	0.045	0.425
Working	Verbal 1-back no of errors	$2.72 \pm 2.7$	$1.53 \pm 1.02$	$0.94 \pm 1.12$	0.003	0.002	0.013	0.175
Memory	Verbal 2-back no of hits	$4.21 \pm 2.54$	$4.34 \pm 1.98$	$6.03 \pm 1.28$	0.001	0.002	0.001	0.958
	Verbal 2-back no of errors	$6.38 \pm 3.09$	$5.5 \pm 2.11$	$3.68 \pm 1.4$	< 0.001	< 0.001	0.003	0.201
	Visual 1-back no of hits	$4.33 \pm 3.39$	$3.22 \pm 3.03$	$8.06 \pm 1.39$	< 0.001	< 0.001	< 0.001	0.119
	Visual 1-back no of errors	$8.62 \pm 4.72$	$9.59 \pm 3.83$	$2.87 \pm 2.74$	< 0.001	< 0.001	< 0.001	0.203
	Visual 2-back no of hits	$1.9 \pm 1.45$	$2 \pm 1.52$	$4.13 \pm 1.63$	< 0.001	< 0.001	< 0.001	0.885
	Visual 2-back no of errors	11.41 ± 3.61	$10.44\pm1.19$	$7.87\pm2.23$	< 0.001	< 0.001	< 0.001	0.436
Tests for Processing speed	Digit symbol substitution test	25.18 ± 11.61	43.41 ± 11.48	57.65 ± 17.61	< 0.001	< 0.001	< 0.001	<0.001

ells represent mean = satanau oc - anno. biorvaitors: NO: not done Kruskal Wallis test p - value Mann Whiney U test p value: comparison between patients with active lupus versus control subjects Mann Whiney U test p value: comparison between patients with active lupus versus gateries with per Mann Whiney U test p value: comparison between patients with active lupus versus gateries with per

Table. Univariate association of cognitive domain test results and SLE disease activity

#### **Keywords**

Systemic lupus erythematosus, Working memory, Processing speed



## Etiology of raised serum creatinine in patients with systemic lupus erythematosus at presentation and association of number of crescents in renal biopsy with rapidly progressive renal failure

#### RAJAT Kharbanda¹, Able Lawrence²

¹ Clinical Immunology and Rheumatology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Senior Resident, India ² Clinical Immunology and Rheumatology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Professor, India

#### Background

Systemic lupus erythematosus (SLE) commonly involve kidney, with increase in creatinine due to lupus related or unrelated cause. Renal biopsy remains gold standard in diagnosis of lupus nephritis (LN). Higher number of crescents had a significantly worse prognosis compared to no crescents. In this study, we analysed the causes of raised serum creatinine in patients with SLE at presentation and assessed association of number of crescents with renal failure.

#### **Methods**

This was a retrospective single centre observational study where medical records of all SLE patients visiting tertiary care hospital 2001 to 2021 was reviewed. Data was retrieved from the case sheets, clinic files and electronic records using the hospital information system. The cause of raised serum creatinine (serum creatinine >1.5) was assessed. Renal biopsy of patients with impaired renal function was compared with renal biopsy of LN patients presenting with normal renal function. Data was analyzed using Strata 15, p value of <0.5 was taken as statistically significant.

#### **Results**

1606 SLE clinic files were screened, of which 121 patients had elevated creatinine at presentation. Amongst the causes of elevated creatinine, lupus nephritis was most common (70.2%, 85/121) followed by infections (13. 2%, 16/121), Chronic kidney disease (4.9%, 6/121), cardiorenal syndrome (4.1%,5/121), drugs (3.3%, 4/121), catastrophic antiphospholipid syndrome (2.5%, 3/121), thrombotic thrombocytopenia purport (1.7%, 2/121). 68 renal biopsies of patient with elevated creatinine were compared with 319 renal biopsies with normal creatinine (Table 1). There was significant association of elevated creatinine with number of crescents in renal biopsy [p: 0.00, OR: 2.7 (1.63-4.75)].

#### Conclusions

Apart from lupus nephritis as cause for increased creatinine, infections should always be screened. Crescents have significant association with elevated creatinine and timely and aggressive management in such patients can give favourable outcome.

#### **Figure & Table**

Variables	Lupus nephritis with elevated creatinine (n-68)	Lupus nephritis with normal creatinine (n-319)
Disease duration (months)	18 (6-24)	12 (5-30)
median±IQR)	()	
Age (median±IQR) (years)	26 (20-33.3)	25 (19-32)
Female n (%)	59 (86.8)	300 (94)
Creatinine at baseline (mg/dl) (median±IQR)	2 (1.8-2.8)	0.8 (0.7-1)
% patients with proteinuria and active sediments	47 (69.1)	165 (51.7)
dsDNA n (%)		26 (8.1)
negative (0-30 mg/dl)	5 (7.3)	49 (15.4)
positive (>30 mg/dl)	8 (11.7)	145 (45.5)
31-90mg/dl	28 (41.2)	99 (31)
91-300 mg/dl	27 (39.7)	
>300mg/dl		
24-hour urine protein (g/24-hour)	1.75 (1.1-3.6)	2 (1.9-3)
(median±IQR)		
24-hour urine protein n (%)		
<500 (g/ 24h)	6 (8.8)	14 (4.3)
501-1000	12 (17.5)	57 (17.9)
1.1-2.5	25 (36.8)	141 (44.2)
>2.5	25 (36.8)	110 (34.5)
.ow C3 n (%)	46 (67.6)	206 (64.6)
.ow C4 n (%)	54 (79.4)	250 (78.4)
Histologic class n (%)		
Class 1	· ·	1
Class 2	2 (2.9)	45 (14.1)
Class 3	16 (23.5)	103 (32.3)
Class 4	38 (55.9)	89 (27.9)
Class 5	4 (5.9)	52 (16.3)
Class 3+5/4+5	5 (7.3)	28 (8.8)
Crescentic	3 (4.4)	-
Patients with crescents	35 (51.4)	88 (27.6) p: 0.00 DR:2.7 (1.63-4.75)

Table. Patient characteristics who underwent renal biopsy and comparison of crescents

#### **Keywords**

SLE, creatinine, crescents



KCR 2022

May 19(Thu) - 21(Sat), 2022

## CRP elevation in SLE pericarditis: Not all patients with SLE pericarditis have an elevated CRP value

#### Hyunsue Do¹, Yong-Beom Park¹

¹ Division of Rheumatology, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea

#### Background

In systemic lupus erythematosus(SLE) flares, C-reactive protein(CRP) dose not increase generally. Exceptionally, in SLE with organ involvement such as SLE pericarditis, CRP have been known to be rise. There have been reports in previous studies that CRP increases a lot as in infection with CRP > 60 mg/L. So, when there is an increase in CRP, it is sometimes important to distinguish whether it is due to SLE pericarditis by cardiac invasion or infection. Differentiation is important because the treatment direction is different in clinical practice. The aim of this study was to reveal the correlation with SLE pericarditis and C-reactive protein(CRP) and CRP values in infection and SLE pericarditis.

#### **Methods**

This study included 112 patients diagnosed with SLE from 2005.1.1. to 2021.8.1. at Severance Hospital with pericardial effusion on the echocardiography with or without symptom. CRP were checked when echocardiography were performed. The results of echocardiography were mainly described as pericardial effusion amount. The possibility of infection was screened by EMR record, infection consultation, culture study.

#### **Results**

Among the target patients, a total of 27 patients had the potential for infection, and excluding them, the Median value of CRP values in the remaining patients was confirmed to be 8.86 mg/L. Not all patients with SLE pericarditis had an elevated CRP value. The number of patients with CRP > 60 mg/L higher was 20. Among them 6 patients were confirmed to have infection. As a result of the analysis of the remaining 14 patients, two of them had other reason for pericarditis such as cancer, Off-pump coronary arterial by-pass grafting surgery.

#### Conclusions

Not all patients with SLE pericarditis had an elevated CRP value.

In some cases, CRP values were high (CRP>60mg/L) in patients with SLE pericarditis without infection, which was about 14.1%. The cause of CRP elevation was SLE pericarditis.

#### Figure & Table

	Number of patients
Total patients :	
Diagnosed with SLE	
2005.1~2021.8 at severance	112
hospital and have Pericardial	
effusion on Echocardiography	
Patients without Infections	85
Patients with CRP > 60mg/L	20
Patients with CRP > 60mg/L	6
and infections	б
Patients with CRP > 60mg/L	14
and without infections	14
Patients with CRP > 60mg/L	
and without infections and	2
have other possible cause of	۷.
pericarditis	

Table. Characteristics of subjects

#### **Keywords**

systemic lupus erythematosus(SLE), pericarditis, C-reactive protein(CRP)



<u>KCR 2022</u>

## Prevalence of latent tuberculosis infection and its associations with clinical and serological parameters in systemic lupus erythematosus

<u>Gayathri Ms</u>¹, Prakash Babu Narasimhan¹, Chengappa Kavadichanda¹, Aishwarya Gopal¹, Devender Bairwa¹, Molly Mary Thabah¹, Sonali Sarkar², Vir Singh Negi³

¹ Clinical immunology, Jawaharlal Institute of Postgraduate Medical Education and Research, India
 ² Preventive and Social Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, India
 ³ Clinical Immunology, All India Institute of Medical Sciences, Bilaspur, India

#### Background

Systemic Lupus Erythematosus (SLE) and Tuberculosis are complicatedly related and shown increased risk of TB in SLE. Studies of Latent TB and SLE are inadequate. This study intended to assess the prevalence of latent TB and its association with disease parameters in SLE

#### **Methods**

This is a single center cross sectional study. 124 adult patients with SLE without past h/o TB were recruited. SLE demography, disease activity indices, autoantibody profile, steroid use were noted. Presence of Latent TB infection was assessed in all patients based on the IFN-g release assay (TB-IGRA). Based on the results of IGRA, SLE cases were divided into 2 groups-IGRA positive and IGRA negative

#### **Results**

Among 124 patients, 19 had latent TB resulting in a point prevalence of 15.4 %. The average disease duration was 4.3 years in IGRA positive and 4.6 in IGRA negative group(p>0.05). Among antibody profile, though no statistical significance among the groups, proportion of antibodies like anti Ku, Ro 60, Ro 52 and La were numerically higher in the IGRA positive group (21.1%, 42.1%, 42.1%) and 21.1% respectively) as compared to the IGRA negative group (11.5%, 28.8%, 28.1% and 7.7% respectively). Anti nucleosome, histone, U1RNP, PCNA, aCLA IgG and IgM, beta 2 GPI IgG and LAC were numerically higher in IGRA negative group (42.3%, 40.4%, 43.3%, 8.7%, 23%, 18.3%, 28.8%, 14.4%) when compared to IGRA positive group (31.6%, 21.1%, 31.6%, 0, 15.8%, 5.3%, 15.8%, 5.3%). Mean clinical SLEDAI was 2.37 ±5.1 in IGRA positive and 3.5 ±5.77 in IGRA negative group. Comparison of organ manifestations yielded no statistically significant difference in the 2 groups at this

#### Conclusions

Prevalence of latent TB in SLE cases was 15.4%. Although comparison of demographic, clinical and autoantibody profile did not yield any statistically significant differences, the early turnover from this pilot study mandates further evaluation with larger sample size

#### **Keywords**

systemic lupus erythematosus, tuberculosis, IGRA



## Comparison of physical functions of systemic lupus erythematosis and healthy persons and their relationship with disease activity

#### Yasin Baki Baydas¹

¹ Department of internal medicine, Bezmialem University, Turkey

#### Background

We aimed to examine how physical function is affected in individuals with Systemic Lupus Erythematosus (SLE) and its relationship with disease activity.

#### **Methods**

112 patients diagnosed with SLE and 62 healthy individuals were included in this study. Activity classification based on SLEDAI score: Activity classification based on SLEDAI score: no activity (SLEDAI=0), mild activity (SLEDAI 1–5), moderate activity (SLEDAI 6–10), high activity (SLEDAI 11– 19) , very high activity (SLEDAI ≥20). Cases in both groups filled out a questionnaire including demographic characteristics and the SF-36's Physical Function and Physical Role sub-domains, and Sit to Stand test, Timed Up and Go test were performed.

#### Results

112 patients with SLE (mean age: 38.11+/-8.32 years) and 62 healthy subjects (39.28+/- 7.8 years) participated in this study. There was no significant difference between the groups in terms of age and gender.When the groups are compared; Sit to Stand test, Timed Up and Go test, SF-36's Physical Function and Physical Role subdomain scores were found to be statistically lower in patients with SLE than in healthy subjects (Respectively;, p= 0.032; p= 0.027; p= 0.046). ; p= 0.041). There were 47 patients with SLE-DAI=0, 31 patients with SLEDAI 1-5, 28 patients with SLE-DAI 6-10, 21 patients with SLEDAI 6-10, 18 patients with SLEDAI 11-19, and 14 patients with SLEDAI ≥20. As disease activity increased, there was a moderate negative correlation in Sit to Stand test, Timed Up and Go test scores, and a moderate positive correlation in SF-36's Physical Function and Physical Role subdomain scores (r=-0.443 p<0.001; r=-0.582), p < 0.001; r=0.486, p<0.001; r=0.502, p<0.001).

#### Conclusions

According to the results obtained, it was determined that there was a significant decrease in physical capacity in patients with SLE compared to healthy individuals. In addition, as disease activity increases, there is a moderately correlated decrease in physical capacity.

# **E-poster Presentation**

SLE-pathogenesis and animal model

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



## Vitronectin, a novel urinary proteomic biomarker, promotes cell pyroptosis in Juvenile systemic lupus erythematosus

### Zhe Cai^{1,2,3}, Song Zhang¹, Huasong Zeng¹

¹ Department of Allergy, Immunology and Rheumatology, Guangzhou Women and Children's Medical Center, China., China
 ² Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, China., China
 ³ Institute of Chinese Medicine and State Key Laboratory, The Chinese University of Hong Kong, Hong Kong., Hong Kong

#### Background

To identify the potential urine biomarkers from juvenile systemic lupus erythematosus (JSLE) patients fit for the urgent demands in clinical diagnosis. Therefore, our aim of the present study is to analyze alteration of protein expression and potential valuable biomarkers in JSLE urine.

#### **Methods**

Based on this aim, proteomics assay analyzed the changes of urinary proteins among active JSLE patients (n=10), inactive JSLE patients (n=9) and healthy controls (n=9). The correlationship between clinical pathological parameters of JSLE patients and level of urinary VTN was qualified. The effect of VTN on cell pyroptosis was verified by the results of Western blot, qPCR and ELISA assay.

#### **Results**

Herein, we have identified a group of 105 differentially expressed proteins with ≥1.3 fold up-regulation or ≤0.77 fold down-regulation in JSLE patients. We found these proteins were involved in several important biological processes such as acute phase inflammatory responses, complement activation, hemostasis, and immune system regulation in gene ontology and functional enrichment analysis. Interestingly, we found and confirmed that urinary Ephrin type-A receptor 4 (EPHA4) and Vitronectin (VTN) were significantly reduced in both inactive and active JSLE patients. Moreover, VTN treatment in THP-1 derived macrophages significantly promoted the cell pyroptosis through the activation of inflammasome NLRP3. There is an activation of Caspase-1 and an upregulated secretion of cleaved GSDMD and IL-18 in VTN treated macrophages. Most importantly, the urinary VTN was also linear correlated with clinical characteristics of JSLE, implying VTN could be a specific diagnostic biomarker to distinguish inactive and active JSLE.

#### Conclusions

In summary, this study provided a urinary proteomic reference profile for JSLE to assist clinical diagnoses. Patients with active and inactive JSLE have differentially obvious metabolic proteins in the urine. VTN as a novel diagnostic biomarker supplied a new insight to distinguish inactive and active JSLE.

#### **Keywords**

Vitronectin, JSLE, Pyroptosis



## Effect of tumor necrosis factor-α gene polymorphisms in risk of systemic lupus erythematosus patients susceptibility: Update meta-analysis

Steven Irving¹, Bastomy Eka Rezkita¹, Rabbinu Rangga Pribadi², Marcellus Simadibrata²

¹ General Medicine, Faculty of Medicine, University of Sebelas Maret, Indonesia ² Gastroenteroloy, Pancreatobiliary, and Digestive Endoscopy, Department of Internal Medicine, University of Indonesia, Indonesia

#### Background

Tumor Necrosis Factor (TNF- $\alpha$ ) is a cytokine involved in the pathogenesis of the several inflammatory diseases, including Systematic Lupus Erythematosus (SLE). Polymorphisms in TNF- $\alpha$  gene have been proposed to be partly responsible for auto-antibody production in several studies. However, the results were inconsistent. We performed this meta-analysis to investigate the effect of TNF- $\alpha$  gene polymorphisms in risk of SLE patients susceptibility.

#### **Methods**

This meta-analysis was conducted based on the PRISMA guideline. Literature searches from Pubmed and EMBASE were conducted until December 2021 and were limited to English-only literature. Studies included in this meta-analysis were accessed using The Newcastle Ottawa Score (NOS). The primary outcome was the association between TNF  $\alpha$  gene polymorphism and the risk of SLE. The sufficient data count is pooled by OR and 95% Cl.

#### **Results**

Four studies (560 case / 590 control) met the inclusion criteria. G allele and GG genotype were associated with decreased risk of SLE (OR= 0.49[0.32 - 0.75], p= 0.0009 and OR= 0.52[0.40-0.69]. p= 0.0001). Meanwhile, A allele with AG and AA genotype were significantly associated with increased risk of SLE (OR= 2.05[1.34-3.13], p= 0.0009; OR=1.41 [1.05-1.87], p= 0.02; OR= 3.91[2.14-7.13], p= 0.00001).

#### Conclusions

In summary our meta-analysis suggested that G allele and GG genotype may serve as protective factor of SLE, while A allele with AG and AA genotype may act as risk factor for SLE. Further study about interaction between genetic-environment interactions with larger sample is needed.

## Figure & Table

Test for overall effect Z = 4.43 (P ≤ 0.00001)       Control       Disease         Study or Subgroup       Versits       Total       Versits       M44, Fixed, 95% CI         Anned 2014       32       100       26       161       35       100       62       161       62       100       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64       64	Ct. 1	Disea		Contr			Odds Ratio	Odds Ratio
Angelo 2012 12 2 88 0 76 40% 2211 [123, 378.71] Li 2009 3 161 2 211 1375. 198 [33, 12.02] Umae 2017 11 200 3 201 22.8% 384 [1.06, 13.98] Total (95% CI) 559 588 100.0% 3.91 [2.14, 7.13] Total works 52 15 Heterogeneity Ch ⁺ = 2.28, df = 0 (= 0.52), ff = 0 % Total works Total works 7 Total works 10 2 2 10 2.8 100 2.4 (2.4 ) 221 (0.6 ) 2.27 Angelo 2012 20 8 88 15 76 15.3% 15.3 (0.6 ) 3.33 Umae 2017 51 200 30 201 28.3% 1.95 [1.6 ] 3.22] Umae 2017 51 200 30 201 28.3% 1.95 [1.6 ] 3.22] Umae 2017 51 200 30 201 28.3% 1.95 [1.6 ] 3.22] Umae 2017 51 200 30 201 28.3% 1.95 [1.6 ] 3.22] Umae 2017 51 200 30 201 28.3% 1.95 [1.6 ] 3.22] Umae 2017 51 200 30 201 28.3% 1.95 [1.6 ] 3.22] Umae 2017 51 200 30 201 28.3% 1.95 [1.6 ] 3.22] Umae 2017 51 200 30 201 28.3% 1.95 [1.6 ] 3.22] Umae 2017 51 200 30 201 28.3% 1.95 [1.6 ] 3.22] Umae 2017 51 200 30 201 28.3% 1.95 [1.6 ] 3.22] Umae 2017 51 200 30 201 28.3% 1.95 [1.6 ] 3.22] Total events Total Weight M4.1 (andom, 95% CI Anmed 2014 116 200 152 200 27.1% 0.44 [0.20, 0.67] Umae 2017 327 400 366 402 27.2% 0.44 [0.20, 0.67] Umae 2017 327 400 366 402 27.2% 0.44 [0.20, 0.67] Umae 2017 327 400 366 402 27.2% 0.44 [0.20, 0.67] Total events Total Weight M4.1 (andom, 95% CI Anmed 2014 412 [10 10 62 100 25.1% 0.44 [0.25, 0.78] Umae 2017 138 2000 162 201 32.3% 0.44 [0.25, 0.78] Umae 2017 138 2000 162 201 32.3% 0.44 [0.25, 0.78] Umae 2017 138 2000 162 201 32.3% 0.44 [0.25, 0.78] Umae 2017 138 2000 162 201 32.3% 0.44 [0.25, 0.78] Umae 2017 138 2000 162 201 32.3% 0.44 [0.25, 0.78] Umae 2017 138 2000 162 201 32.3% 0.44 [0.25, 0.78] Umae 2017 138 2000 162 201 32.3% 0.44 [0.25, 0.78] Umae 2017 138 2000 168 201 33.3% 0.44 [0.25, 0.78] Umae 2017 138 2000 168 201 33.3% 0.44 [0.25, 0.78] Umae 2017 138 2000 168 201 33.3% 0.44 [0.25, 0.78] Umae 2017 138 2000 168 201 33.3% 0.44 [0.25, 0.78] Umae 2017 138 2000 168 201 32.3% 0.44 [0.25, 0.78] Umae 2017 138 2000 168 201 32.3% 0.44 [0.25, 0.78] Umae 2017 138 2000 168 201 32.3% 0.44 [0.25, 0.78] Umae 2017 138 2000 168 202 3								M-H, Fixed, 95% CI
Lin 2009 3 161 2 211 137% 199 [0.33, 12.02] Total events $52$ 153 589 100.0% 3.31 [2.14, 7.13] Total events $52$ 153 589 100.0% 3.31 [2.14, 7.13] 10 - 1 $0 - 1$ $0 - 1$ $0 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1$ $0 - 1 - 1 - 1$ $0 - 1 - 1 - 1$ $0 - 1 - 1 - 1$ $0 - 1 - 1 - 1 - 1$ $0 - 1 - 1 - 1$ $0 - 1 - 1 - 1 - 1 - 1$ $0 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 - 1 -$								
Umare 2017 11 200 3 201 22.8% $3.84[1.06, 13.06]$ Total (9%) CD 559 598 100.0% $3.91[2.14, 7.13]$ Heterogenehy: Ch ² = 2.5, df = 3 (P = 0.52), P = 0% Test for overall effect Z = 4.43 (P < 0.0001) Control Disease Control Versity of Subgroup Events Total Events Total Weight M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI M44, Fixed, 95% CI								the T
Total (95% C)       559       588       1012 (24, 7, 13)         Total events       52       52       559       588       100         Study or Subgroup       Desease       Control       Odds Ratio         A.         Study or Subgroup       Desease       Control       Odds Ratio         Ammed 2014       A         Disease       Control       Odds Ratio         Mudgroup       Desease       Control       Odds Ratio         Mudgroup       Disease       Control       Odds Ratio         Study or Subgroup       Disease       Control       Odds Ratio         Stud		10.50						State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State State
Total events $52 = 15$ (Here $74 = 0.52$ ), $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$	Umare 2017	11	200	3	201	22.8%	3.84 [1.06, 13.98]	
Total events $52 = 15$ (Here $74 = 0.52$ ), $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$ , $F = 0.52$	Total (05% CI)		550		600	100.0%	3 04 /2 44 7 431	
Heterogenehr, $Ch^{\mu} = 2.25$ , $d^{\mu} = 0.52$ , $l^{\mu} = 0.9$ , Test for overall effect $Z = 4.43$ ( $\rho = 0.0001$ ) <b>A</b> . <b>Suby or Subgroup</b> Events Total Verifist M41, Enced. 95% CI Amend 2014 A 23 100 28 100 24.2% 1.21 [0.68, 2.21] Amopto 2012 28 98 15 7.6 153% 1.53 [0.83 0.33] Lin 2009 26 161 35 211 32.2% 0.37 [0.56, 1.69] Umare 2017 51 200 30 201 28.3% 1.95 [1.18, 3.22] Umare 2017 51 200 30 201 28.3% 1.95 [1.18, 3.22] Total (95% CI) 559 588 100.0% 1.41 [1.05, 1.37] Total (95% CI) 559 588 100.0% 1.41 [1.05, 1.37] Total (95% CI) 1118 1176 100.0% 0.49 [0.32, 0.57] Total events 17 di 10 100 152 200 152 200 201 251.5% 0.44 (0.29, 0.67] Total events 2017 327 400 366 402 27.2% 0.44 (0.29, 0.67] Total events 2017 327 400 366 402 27.2% 0.44 (0.29, 0.67] Total events 877 1038 Heterogenehr, Ch ⁺ = 3.7, df = 9.19, df = 3 ( $\rho = 0.03$ ), $l^{\mu} = 67\%$ . Total events 877 1038 Heterogenehr, Ch ⁺ = 3.7, df = 0.91, df = 200 251.5% 0.44 (0.29, 0.67] Total events 877 1038 Heterogenehr, Ch ⁺ = 3.7, df = 0.91, df = 3 ( $\rho = 0.03$ ), $l^{\mu} = 67\%$ . Total events 877 1038 Heterogenehr, Tau ⁺ = 0.12, Ch ⁺ = 9.19, df = 3 ( $\rho = 0.03$ ), $l^{\mu} = 67\%$ . Test for overall effect $Z = 3.31 (\rho = 0.009)$ C. <b>Suby or Subgroup</b> Events Total Events Total Weight M4, Fixed. 95% CI Amed 2014 42 100 62 100 251 5% 0.44 (0.29, 0.67] Total events 703 Heterogenehr, Tau ⁺ = 0.12, Ch ⁺ = 9.19, df = 3 ( $\rho = 0.03$ ), $l^{\mu} = 67\%$ . Test for overall effect $Z = 4.84 (\rho < 0.0001)$ C. <b>Suby or Subgroup</b> Events Total Events Total Weight M4, Fixed. 95% CI Amend 2014 44 200 64 200 27.1% 0.44 (0.27, 0.71] Total events 70.9, df = 3 ( $\rho = 0.07$ ), $l^{\mu} = 50\%$ . Test for overall effect $Z = 4.84 (\rho < 0.0001)$ Test for overall effect $Z = 4.84 (\rho < 0.0001)$ <b>Disease</b> Control Otdes Ratio <b>Disease</b> Control <b>Disease</b> Control <b>Disease</b> Control <b>Disease</b> Co	ALCOLOGY ALCOLOGY	50	228	4.5	200	100.0%	5.91 [2.14, 7.15]	
UNU UNU UNU UNU UNU UNU UNU UNU UNU UNU			0.00		0.01			
A. Suby or Subgroup Events Total Versity Total Weight M.H. Fixed, 95% CI Ammed 2014 28 00 28 100 24 28 00 211 32 28 037 055, 168 03, 333 Lin 2009 26 181 35 211 32 28 037 055, 168 044 032, 044 032, 044 032, 044 044 044 044 044 044 044 044 044 04					= 0%		6	
Study or Subgroup         Disease Form         Control         Odds Ratio         Odds Ratio           Ammed 2014         32         100         24         121 (0.66, 22.2)         MH, Fixed, 95% CI           Ammed 2014         32         100         24         128         121 (0.66, 22.2)           Apple 2012         28         88         15         76         15.3%         16.31 (0.0.3)           Umare 2017         51         200         30         201 22.38         0.97 (10.56, 1.68)           Umare 2017         51         200         30         201 22.38         1.97 (10.5, 1.87)           Total (95% CI)         559         588         100.0%         1.41 (10.5, 1.87)           Total (95% CI)         559         588         100.0%         1.44 (0.28, 0.57)           Ammed 2011         116         100         152         20.8%         0.30 (0.16, 0.56)           Lin 2009         290         322         383         422         24.9%         0.32 (0.5, 0.51)           Umare 2017         114         196         137         10.3         0.30 (0.16, 0.56)           Lin 2009         290         322         383         422         24.9%         0.32 (0.5, 0.5) <tr< td=""><td></td><td></td><td>, 0.0</td><td></td><td></td><td></td><td></td><td>Control Disease</td></tr<>			, 0.0					Control Disease
Study or Subgroup         Events         Total         Weight         M-H, Fixed, 95% C1         M-H, Fixed, 95% C1           Ahmed 2014         32         100         24         26         100         24/2%         1.21 (0.66, 2.22)           Angelo 2012         28         161         35         211         32.22%         0.97 (0.56, 1.69)           Umare 2017         51         200         30         201         28.3%         1.41 (1.05, 1.87)           Total events         137         108         1.41 (1.05, 1.87)         1.01         0.1         1.01         1.01           Heterogeneity: Chi* 3.77, dr 3.0 (* 0.28), fr = 20%         Testfor overall effect: Z = 2.32 (P = 0.02)         27.1%         0.44 (0.28, 0.87)	4.							
Amed 2014 32 100 28 100 24 2% 121 (06, 222) Angelo 2017 28 98 15 76 153% 163 (08, 033) Lin 2008 26 161 35 211 32.2% 0.97 (0.56, 1.69) Umare 2017 51 200 30 201 28.3% 1.95 (1.18, 3.22) Total events 137 108 Heterogenely(Ch ² = 3.77, df -3 (P = 0.29); P = 20% Test for overall effect Z = 2.32 (P = 0.02) 3. Sudy or Subgroup Disease Control Odds Ratio MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% CI MH, Random, 95% C	Study or Subgroup				55 C	Moight		
Angelo 2012 28 98 15 76 15 3% 183 (80 0; 33 3) Lin 2009 26 161 35 211 32.2% 0.97 (0.5, 169) Umare 2017 51 200 30 201 28.3% 1.95 (1.18, 3.22) Total events 137 108 Heterogeneity, Chi* 3.77, df 3 (P = 0.29); P = 20% Test for overall effect: Z = 2.32 (P = 0.02) 3. Suby or Subgroup Events Total Events Total Weight M-H, Random, 95% CI Angelo 2012 144 196 137 152 20.9% 0.30 (1.6, 0.56) Lin 2009 290 22 383 422 24.9% 0.30 (1.6, 0.56) Lin 2009 290 220 27.1% 0.44 (0.29, 0.67) Total events 0 327 400 366 402 27.2% 0.44 (0.29, 0.67) Total events 0 327 400 366 402 27.2% 0.44 (0.29, 0.67) Total events 0 327 400 366 402 27.2% 0.44 (0.29, 0.67) Total events 0 31 (P = 0.00); P = 67% Test for overall effect: Z = 3.31 (P = 0.00); P = 67% Test for overall effect Z = 3.31 (P = 0.00); P = 67% Test for overall effect Z = 3.31 (P = 0.00); P = 67% Test for overall effect Z = 3.31 (P = 0.00); P = 67% Test for overall effect Z = 3.31 (P = 0.00); P = 67% Test for overall effect Z = 3.31 (P = 0.00); P = 67% Test for overall effect Z = 0.31 (P = 0.00); P = 67% Test for overall effect Z = 0.31 (P = 0.00); P = 67% Test for overall effect Z = 0.000 9) C. C. Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI Angelo 2012 42 00 62 100 25.1% 0.44 (0.27, 0.71) Total events 370 465 Test for overall effect Z = 4.64 (P < 0.0001) Disease C. Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI Angelo 2012 59 588 100.0% 0.52 [0.40, 0.69] Total events 370 465 Test for overall effect Z = 4.64 (P < 0.0001) Disease C. Study or Subgroup Events Total Events Total Weight M-H, Randon, 95% CI Angelo 2012 52 196 15 152 208% 330 (1.77, 6.13] M-H, Randon, 95% CI Angelo 2012 62 196 01 51 52 20.8% 330 (1.77, 6.13] M-H, Randon, 95% CI Angelo 2012 62 196 01 61 52 22.08% 330 (1.77, 6.13] M-H, Random, 95% CI Angelo 2012 62 196 01 61 62 22 7.2% 2.27 (1.48, 3.48] Total events 241 138 Total events 241 138 Total events 241 138 Total events 241 138 Total events 241 138 Total events 241 138 To								Mi-n, Fixeu, 95% CI
Lin 2009 26 161 35 211 22.2% 0.97 [0.56] 1.69] Umare 2017 51 200 30 201 28.3% 1.95 [1.18, 3.22] Total (95% Cf) 559 558 100.0% 1.41 [1.05, 1.87] Total events 137 108 Heterogeneity, Chi = 3.77, df = 3.07 [0.62] (1.19, 3.22] <b>3.</b> <b>S.</b> <b>S.</b> <b>Disease</b> Control Odds Ratio MH, Random, 95% Cl MH, Fixed, 95% Cl Anned 2014 116 200 152 200 27.1% 0.44 [0.28, 0.67] Angelo 2012 144 146 137 152 20.9% 0.30 [0.16, 0.56] Lin 2009 290 322 333 422 24.9% 0.92 [0.56, 1.51] Umare 2017 327 400 366 402, 9.087] Total events Total Events Total Weight MH, Kandom, 95% Cl MH, Random, 95% Cl MH, Random, 95% Cl MH, Fixed, 95% Cl Anned 2014 118 1176 100.0% 0.49 [0.32, 0.75] Total events 877 1038 Heterogeneity, Tau* = 0.12, Chi* = 9.19, df = 3 (P = 0.03); P = 67% Testfor overall effect Z = 3.31 (P = 0.009) C. <b>Study or Subgroup</b> Events Total Events Total Weight MH, Fixed, 95% Cl Angelo 2012 59 88 61 7.6 18.6% 0.44 [0.25, 0.78] Angelo 2012 59 88 61 7.6 18.6% 0.44 [0.25, 0.78] Angelo 2012 59 598 100.0% 0.52 [0.40, 0.69] Total events 370 465 Heterogeneity, Chi* = 7.09, df = 3 (P = 0.07); P = 67% Total (95% Cf) 559 598 100.0% 0.52 [0.40, 0.69] Total events 370 465 Heterogeneity, Chi* = 7.09, df = 3 (P = 0.07); P = 69% Total events 370 465 Heterogeneity, Chi* = 7.09, df = 3 (P = 0.07); P = 69% Total (95% Cf) 559 598 100.0% 0.52 [0.40, 0.69] <b>Out</b> 0.1 Control Disease Total (95% Cf) 559 598 100.0% 0.52 [0.40, 0.69] <b>Out</b> 0.1 Control Disease Total (95% Cf) 559 598 100.0% 0.52 [0.40, 0.69] <b>Out</b> 0.1 Control Disease Total (95% Cf) 559 598 100.0% 0.52 [0.40, 0.69] <b>Out</b> 0.1 Control Disease Total (95% Cf) 1118 1176 100.0% 2.05 [1.34, 3.13] Total events 241 138 1176 100.0% 2.05 [1.34, 3.13] Total events 241 138 (3 (P = 0.07); P = 576 Disease 2014 73 (3 (P = 0.07); P = 576 Disease 2014 73 (3 (P = 0.07); P = 576 Disease 2014 73 (3 (P = 0.07); P = 576 Disease 2014 73 (3 (P = 0.07); P = 576 Disease 2014 73 (3 (P = 0.07); P = 576 Disease 2014 73 (3 (P = 0.07); P = 576 Disease 2014 73 (3 (P = 0.07); P = 576								
Umare 2017       51       200       30       201       28.3%       195[1.18, 3.22]         Total (9%) Ch       559       588       100.0%       1.41[1.05, 1.87]         Total events       137       108         Helerogeneiky Ch#= 3.77, df= 3 (P = 0.29); P = 20%       Odds Ratio         Study or Subgroup       Disease       Control       Odds Ratio         Anned 2012       144       196       137       152       20.8%       0.30 (1.6, 0.56)         Lin 2009       200       22       23.3       0.44 (0.28, 0.67)       MH, Random, 95% Cl         Anned 2012       144       196       137       152       20.8%       0.30 (1.6, 0.56)         Umare 2017       327       400       366       402       27.2%       0.44 (0.29, 0.67)         Total events       877       1038       100 (2.5, %)       0.44 (0.29, 0.67)         Total events       877       1038       100 (2.5, %)       0.44 (0.29, 0.67)         Total events       877       1038       100 (2.5, %)       0.44 (0.29, 0.67)         Total events       877       1038       100 (2.5, %)       0.44 (0.27, 0.7)]         Total events       877       1038       200       168 (2.0, 27, 0.7)]								and the second second second second second second second second second second second second second second second
Total (95% CI)       559       588       100.0%       1.41 [1.05, 1.87]         Total events       137       108         Heterogenety, Chi = 3.77, dr = 3 ( $p = 0.29$ ); $p = 20\%$ 0.01       0.1       Control         Study or Subgroup       Events       Total events       Total events       Total events         Anned 2014       116       200       27.1%       0.44 (0.28, 0.67)       MH, Random, 95% CI         Anned 2014       116       120       152       20.8%       0.30 (0.16, 0.56)       Image 2017         Umare 2017       327       400       36       0.30 (0.16, 0.56)       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017       Image 2017								
Total events       137       108         Helerogene(): Chir = 3.77, dr = 3.02, (P = 0.02)       0.01       0.1       0.01       0.1       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01 <td>Umare 2017</td> <td>51</td> <td>200</td> <td>30</td> <td>201</td> <td>28.3%</td> <td>1.95 [1.18, 3.22]</td> <td></td>	Umare 2017	51	200	30	201	28.3%	1.95 [1.18, 3.22]	
Total events       137       108         Helerogene(): Chir = 3.77, dr = 3.02, (P = 0.02)       0.01       0.1       0.01       0.1       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01       0.01 <td>Total (95% CI)</td> <td></td> <td>550</td> <td></td> <td>588</td> <td>100.0%</td> <td>1 4 1 1 1 0 5 1 8 7 1</td> <td><b>A</b></td>	Total (95% CI)		550		588	100.0%	1 4 1 1 1 0 5 1 8 7 1	<b>A</b>
Heterogeneity: Chi [#] = 3.77, df = 3 (P = 0.29); P = 20% Testfor overall effect. Z = 2.32 (P = 0.02) 3. Sudy or Subgroup Events Total Events Total Weight M-H, Random, 9% CI Angelo 2012 144 196 137 152 208% 0.30 (0.16, 0.56) Umare 2017 327 400 366 402 27.2% 0.44 (0.29, 0.67) Total events 877 1038 Heterogeneity: Tau [#] = 0.12; Chi [#] = 9.19, df = 3 (P = 0.03); P = 67%. Testfor overall effect. Z = 3.31 (P = 0.009) C. Sudy or Subgroup Events Total Events Total Weight M-H, Random, 95% CI Angelo 2012 144 196 137 152 20.8% 0.30 (0.16, 0.56) Umare 2017 327 400 366 402 27.2% 0.44 (0.29, 0.67) Total events 877 1038 Heterogeneity: Tau [#] = 0.12; Chi [#] = 9.19, df = 3 (P = 0.03); P = 67%. Test for overall effect. Z = 3.31 (P = 0.009) C. Study or Subgroup Events Total Events Total Weight M-H, Fixed, 95% CI Angelo 2012 58 98 61 76 19.6% 0.36 [0.18, 0.71] Umare 2017 138 200 168 201 36.3% 0.44 [0.27, 0.71] Total events 370 465 Total events 370 465 Total events 370 465 Testfor overall effect. Z = 4.64 (P < 0.0001)		127	333	109	300	100.070	1.41[1.05, 1.07]	
Testfor overall effect: Z = 2.32 (P = 0.02)       0.01       0.1       Control Disease       10       100         Study or Subgroup       Events       Total Events       Total Verifs       0.44 Random, 95% CI       M.H. Random, 95% CI         Ammed 2014       116       200       27.1%       0.44 (0.28, 0.67)			2 /P =		20.95		⊢	
Statuty or Subgroup         Disease         Control         Odds Ratio         MH, Random, 95% CI           Amed 2011         116         200         72.1 %         0.44 (0.28, 0.67)         MH, Random, 95% CI           Amed 2012         144         196         137         152         200 %         0.30 (0.16, 0.56)           Lin 2009         220 322         333         422 24.9%         0.30 (0.16, 0.56)         Image 2017         327         400         366         402         27.2 %         0.44 (0.29, 0.67)         Image 2017         327         400         366         402         27.2 %         0.44 (0.29, 0.67)         Image 2017         327         400         366         402         27.2 %         0.44 (0.29, 0.67)         Image 2017         Image 2017         Image 2012         Charlenetts         877         1033         Image 2012         0.01         0.1         Image 2017         Image 2012         0.03         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017 <t< td=""><td></td><td></td><td></td><td></td><td>20.90</td><td></td><td>0.0</td><td></td></t<>					20.90		0.0	
Disease         Control         Odds Ratio           Study or Subgroup         Events         Total         Vents	restror overall ellect.	. 2 - 2.32 (	r = 0.0	2)				Control Disease
Study or Subgroup         Events         Total         Weight         M.H., Random, 95% Cl         M.H., Random, 95% Cl           Ammed 2014         116         200         221         30         4410.26.06.71            Amgelo 2012         144         196         137         152         20.9         0.3010.16.0.561            Umare 2017         237         400         366         402.02.0.571             Total (95% Cl)         1118         1176         100.9%         0.49 [0.32, 0.75]             Total events         877         1038         Heirogeneiky: Tau*=0.12; Chr#= 9.19; df= 3 (P = 0.03); P = 67%              Test for overall effect Z= 3.31 (P = 0.009)         Control         Odds Ratio         Odds Ratio         Odds Ratio           Study or Subgroup         Events         Total (wight M.H. Fixed, 95% Cl         M.H. Fixed, 95% Cl         M.H. Fixed, 95% Cl           Anmed 2012         59         98         100.0%         0.52 [0.40, 0.69]            Total (wight M.H. Fixed, 95% Cl         M.H. Fixed, 95% Cl         M.H. Fixed, 95% Cl         M.H. Fixed, 95% Cl           Angelo 2012         59         588         100.0% </td <td>B.</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>	B.							
Study or Subgroup         Events         Total         Weight         M.H., Random, 95% Cl         M.H., Random, 95% Cl           Ammed 2014         116         200         221         30         4410.26.06.71            Amgelo 2012         144         196         137         152         20.9         0.3010.16.0.561            Umare 2017         237         400         366         402.02.0.571             Total (95% Cl)         1118         1176         100.9%         0.49 [0.32, 0.75]             Total events         877         1038         Heirogeneiky: Tau*=0.12; Chr#= 9.19; df= 3 (P = 0.03); P = 67%              Test for overall effect Z= 3.31 (P = 0.009)         Control         Odds Ratio         Odds Ratio         Odds Ratio           Study or Subgroup         Events         Total (wight M.H. Fixed, 95% Cl         M.H. Fixed, 95% Cl         M.H. Fixed, 95% Cl           Anmed 2012         59         98         100.0%         0.52 [0.40, 0.69]            Total (wight M.H. Fixed, 95% Cl         M.H. Fixed, 95% Cl         M.H. Fixed, 95% Cl         M.H. Fixed, 95% Cl           Angelo 2012         59         588         100.0% </td <td></td> <td>Diena</td> <td>60</td> <td>Contr</td> <td>ol</td> <td></td> <td>Odde Patio</td> <td>Odde Patio</td>		Diena	60	Contr	ol		Odde Patio	Odde Patio
Ahmed 2014       116       200       52       200       271%       0.44 [0.28, 0.67]         Angelo 2012       144       146       137       152       20.8%       0.30 [0.16, 0.56]         Lin 2009       290       322       383       422       24.9%       0.92 [0.56, 0.57]         Umare 2017       327       400       366       402       27.2%       0.44 [0.29, 0.67]         Total (95% CI)       1118       1176       100.0%       0.49 [0.32, 0.75]	Study or Subgroup					Weight		
Angelo 2012       144       196       137       152       20.8%       0.30 (16, 0.56)         Lin 2009       209       22       323       322       24.9%       0.30 (0.16, 0.56)         Umare 2017       327       400       366       402       27.2%       0.44 (0.29, 0.67)         Total (9%) Ch       1118       1176       100.0%       0.49 (0.32, 0.75)								
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $								
Umare 2017       327       400       366       402       27.2%       0.44 [0.29, 0.67]         Total (95% CI)       1118       1176       100.0%       0.49 [0.32, 0.75]         Heterogeneity, Tau*= 0.12; Chi*= 9.19, df= 3 (P = 0.03); P = 67%       0.01       0.1       10         Test for overall effect Z = 3.31 (P = 0.0009)       0/00 25.1%       0/01       0.1       10         Study or Subgroup       Disease       Control       Odds Ratio       Odds Ratio         Anned 2012       58       98       61       76       186%       0.39 [10.57, 165]         Umare 2017       138       200       168       201       36.3%       0.44 [0.27, 0.71]								
$\begin{array}{c c c c c c c c c c c c c c c c c c c $								
Total events 877 1038 Heterogeneity: Ch ⁺ = 7.09, df = 3 (P = 0.03); P = 67% Test for overall effect: Z = 3.31 (P = 0.0009) C. Disease Control Odds Ratio MH, Fixed, 95% Cl Angelo 2012 42 100 62 100 25 1% 0.44 [0.25, 0.78] Angelo 2012 56 98 61 76 18.65% 0.36 [0.16, 0.71] Total 2001 128 201 188 200 38, 35% 0.44 [0.27, 0.71] Total 2001 559 588 100.0% 0.52 [0.40, 0.69] Heterogeneity: Ch ⁺ = 7.09, df = 3 (P = 0.07), P = 58% Heterogeneity: Ch ⁺ = 7.19, df = 3 (P = 0.07), P = 57% C. Disease Control Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Rat	Office 2017	527	400	- 300	402	27.270	0.44 [0.20, 0.07]	S S S S S S S S S S S S S S S S S S S
Heterogeneiky. Tau"= 0.12; Chi"= 9.13; df = 3 (P = 0.03); P = 67%. Test for overall effect. Z = 3.31 (P = 0.009) C. C. Study or Subgroup Events Total Events Total Weight MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI MLH, Exed, 95% CI	T-A-LOFAL CB							
Testfor overall effect Z = 3.31 (P = 0.0009)         0.01         0.1         Control         Disease         0.01         0.1         Control         Disease         0.01         0.1         Control         Disease         0.01         0.1         Control         Disease         0.01         0.1         Control         Disease         0.01         0.1         Control         Disease         0.01         0.1         Control         Disease         0.01         0.1         Control         Disease         0.01         0.1         Control         Disease         0.01         0.1         Control         Disease         0.01         0.1         Control         Disease         0.01         0.1         Control         Disease         0.01         0.1         Control         Disease         0.01         0.1         0.01         0.1         0.01         0.1         0.01         0.1         0.01         0.1         0.01         0.01         0.1         0.01         0.1         0.01         0.1         0.01         0.1         0.01         0.1         0.01         0.1         0.01         0.1         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01			1118		1176	100.0%	0.49 [0.32, 0.75]	•
Disease         Control         Odds Ratio           Study or Subgroup         Events         Total         Weight         M.H., Fixed, 95% CI           Anmed 2014         42         100         62         100         25.1%         0.44 [0.25, 0.76]           Anmed 2014         42         100         62         100         25.1%         0.44 [0.25, 0.76]           Anmed 2014         42         100         62         18.6%         0.46 [0.25, 0.76]         Image 2017           Anmed 2014         42         100         51%         0.44 [0.27, 0.71]         Image 2017         132 a 200         188 200         0.87 (0.77, 1.65]         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Image 2017         Imag	Total events							•
Study or Subgroup         Events         Total         Weight         M.H., Fixed, 95% CI         M.H., Fixed, 95% CI           Angelo 2014         44         02         00         62         100         25.1%         0.44         02.5         0.71           Angelo 2012         50         98         61         76         19.6%         0.36         0.71            Umare 2017         132         151         174         211         18.0%         0.37         105.7, 1.65            Total events         300         168         200         30.3%         0.52         20.7, 1.0            Total events         370         465         +              Test for overall effect Z= 4.64 (P < 0.000, 1%	Total events Heterogeneity: Tau [#] =	= 0.12; Chi	i² = 9.1!	9, df = 3 (				
Study or Subgroup         Events         Total         Weight         M.H., Fixed, 95% CI         M.H., Fixed, 95% CI           Angelo 2014         44         02         00         62         100         25.1%         0.44         02.5         0.71           Angelo 2012         50         98         61         76         19.6%         0.36         0.71            Umare 2017         132         151         174         211         18.0%         0.37         105.7, 1.65            Total events         300         168         200         30.3%         0.52         20.7, 1.0            Total events         370         465         +              Test for overall effect Z= 4.64 (P < 0.000, 1%	Total events Heterogeneity: Tau [#] = Test for overall effect	= 0.12; Chi	i² = 9.1!	9, df = 3 (				
Ahmed 2014     42     100     62     100     25.1%     0.44     0.25,0.78       Angelo 2012     56     98     61     76     19.6%     0.36     0.18,0.71       In 2009     132     161     174     211     19.0%     0.36     0.18,0.71       Umare 2017     138     200     168     201     33.3%     0.44     0.27,0.71       Total (95% CI)     559     588     100.0%     0.52     0.41     0.27,0.71       Total events     370     465       Heterogeneily: Chif = 7.09, df = 3 (P = 0.07), P = 58%     0.01     0.1     0.1     0.01       Total events     370     465     0.01     0.1     0.01     0.1       Study or Subgroup     Events     Total     Verints     Total     Verints     10     10       Total events     22     23     42.00     27.1%     3.30 (1.77, 6.13)     0.01     0.1     0.1       Lin 2009     32     322     39     42.02     2.2%     3.30 (1.77, 6.13)     0.01       Lin 2009     32     32.2     3.32     3.32 (1.77, 6.13)     0.01     0.1     0.01       Lin 2009     32     32.2     3.32 (1.77, 6.13)     0.01     0.01 <td< th=""><th>Total events Heterogeneity: Tau[#] = Test for overall effect</th><th>= 0.12; Chi : Z = 3.31 (</th><th>i[#] = 9.1! (P = 0.0</th><th>9, df = 3 ( 1009)</th><th>P = 0.0</th><th></th><th>%</th><th>Control Disease</th></td<>	Total events Heterogeneity: Tau [#] = Test for overall effect	= 0.12; Chi : Z = 3.31 (	i [#] = 9.1! (P = 0.0	9, df = 3 ( 1009)	P = 0.0		%	Control Disease
Angelo 2012 58 98 61 76 18.6% 0.36 [0.18, 0.71] Lin 2009 132 151 174 211 18.0% 0.37 [0.57, 165] Umare 2017 138 200 168 201 36.3% 0.44 [0.27, 0.71] Total (95% Ct) 559 588 100.0% 0.52 [0.40, 0.69] Total events 370 465 Test for overall effect Z = 4.64 (P < 0.00001) Disease Control Control Disease Control Disease Control Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Odds Ratio Total events 152 208 3 300 177, 613] Umare 2017 73 400 48 200 27.1% 3.20] Total events 211 118 1176 100.0% 2.05 [1.34, 3.13] Total events 211 128 Total events 211 128 Total events 211 128 Total events 211 128 Total events 211 128 Total events 241 138	Total events Heterogeneity: Tau*= Test for overall effect C•	= 0.12; Chi : Z = 3.31 ( Disea	1 ² = 9.1 (P = 0.0 ISE	9, df = 3 ( 1009) Cont	P = 0.0	3); I ^z = 67	% Odds Ratio	Control Disease Odds Ratio
Lin 2009 132 161 174 211 190% 0.97 [0.57, 1.65] Umare 2017 138 200 168 201 36.3% 0.44 [0.27, 0.71] Total (95% Ct) 559 588 100.0% 0.52 [0.40, 0.69] Heterogeneity: Ch ² = 7.09, df = 2 (P = 0.07), P = 58% Test for overall effect: Z = 4.64 (P < 0.00001) Disease Control Disease Control Disease Control Odds Ratio Study or Subgroup Events Total Events Total Weight M-H, Random, 95% Cl Angelo 2012 52 196 15 152 20.8% 3.30 (1.77, 6.13) Lin 2009 32 322 39 422 24.9% Umare 2017 73 400 36 402 27.2% 2.27 [1.48, 3.46] Total events 2.24 118 Heterogeneity: Tau ² = 0.13, P = 0.03), P = 67% Disease Control Disease Control Odds Ratio 0.01 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1	Total events Heterogeneity: Tau [#] = Test for overall effect C. Study or Subgroup	= 0.12; Chi : Z = 3.31 ( Disea Events	1 [#] = 9.11 (P = 0.0 ISE Total	9, df = 3 ( 1009) Cont Events	P = 0.0 rol Total	3); I² = 67 Weight	% Odds Ratio M-H, Fixed, 95% Cl	Control Disease Odds Ratio
Umare 2017 138 200 168 201 36.3% 0.44 [0.27, 0.71] Total events 370 465 Total events 370 465 Test for overall effect Z = 4.64 (P < 0.00001) Disease Control Control Disease Control Disease Control Odds Ratio Study or Subgroup Events Total Events Total Weight MH, Random, 95% Cl Anned 2012 52 196 15 152 208% 330(177, 6.13) Umare 2017 73 400 36 402 27.2% 2.27 [1.48, 3.46] Total events 241 118 1176 100.0% 2.05 [1.34, 3.13] Total events 241 128 Total events 241 138	Total events Heterogeneity. Tau [#] = Test for overall effect C. <u>Study or Subgroup</u> Ahmed 2014	= 0.12; Chi : Z = 3.31 ( Disea <u>Events</u> 42	P = 9.19 P = 0.0 ISE Total 100	3, df = 3 ( 1009) Cont <u>Events</u> 62	P = 0.0 rol <u>Total</u> 100	3); F = 67 Weight 25.1%	% Odds Ratio M-H, Fixed, 95% Cl 0.44 [0.25, 0.78]	Control Disease Odds Ratio
Disease         Control         Odds Ratio           Study or Subgroup         Events         Total (95% CI)         0.01         0.1         10         10           Control         Disease         Control         Disease         Control         Disease         0.01         0.1         0.01         0.01         10         10         10           Control         Disease         Control         Odds Ratio         Odds Ratio         0.04         0.01         0.1         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01         0.01	Total events Heterogeneity: Tau [#] = Test for overall effect C. Study or Subgroup Ahmed 2014 Angelo 2012	= 0.12; Chi : Z = 3.31 ( Disea <u>Events</u> 42 58	i [#] = 9.1! (P = 0.0 Ise <u>Total</u> 100 98	3, df = 3 ( 1009) Cont Events 62 61	P = 0.0 rol <u>Total</u> 100 76	3); I [#] = 67 [′] Weight 25.1% 19.6%	% Odds Ratio M-H, Fixed, 95% CI 0.44 [0.25, 0.78] 0.36 [0.18, 0.71]	Control Disease Odds Ratio
Total events     370     465       Heterogeneity: Ch [#] = 7.09, df = 3 (P = 0.07); P = 58%     0.01     0.1     10     10       Testfor overall effect Z = 4.64 (P < 0.00001)	Total events Heterogeneity: Tau [*] = Test for overall effect C. Study or Subgroup Ahmed 2014 Angelo 2012 Lin 2009	= 0.12; Chi : Z = 3.31 ( Disea Events 42 58 132	r = 9.1! (P = 0.0 ise <u>Total</u> 100 98 161	a, df = 3 ( 1009) Events 62 61 174	P = 0.0 rol <u>Total</u> 100 76 211	3); F = 67 Weight 25.1% 19.6% 19.0%	% Odds Ratio M-H, Fixed, 95% Cl 0.44 [0.25, 0.78] 0.36 [0.18, 0.71] 0.37 [0.57, 1.65]	Control Disease Odds Ratio
Total events     370     465       Heterogeneity: Ch [#] = 7.09, df = 3 (P = 0.07); P = 58%     0.01     0.1     10     10       Testfor overall effect Z = 4.64 (P < 0.00001)	Total events Heterogeneity: Tau [*] = Test for overall effect C. Study or Subgroup Ahmed 2014 Angelo 2012 Lin 2009	= 0.12; Chi : Z = 3.31 ( Disea Events 42 58 132	r = 9.1! (P = 0.0 ise <u>Total</u> 100 98 161	a, df = 3 ( 1009) Events 62 61 174	P = 0.0 rol <u>Total</u> 100 76 211	3); F = 67 Weight 25.1% 19.6% 19.0%	% Odds Ratio M-H, Fixed, 95% Cl 0.44 [0.25, 0.78] 0.36 [0.18, 0.71] 0.37 [0.57, 1.65]	Control Disease Odds Ratio
Heterogeneity: ChP = 7, 09, df = 3 (P = 0.07); P = 58% Testfor overall effect: Z = 4.64 (P < 0.00001) Control Disease Disease Control Disease Control Dise	Total events Heterogeneity: Tau [*] = Test for overall effect C. Study or Subgroup Ahmed 2014 Angelo 2012 Lin 2009 Umare 2017	= 0.12; Chi : Z = 3.31 ( Disea Events 42 58 132	I [#] = 9.11 (P = 0.0 ISE <u>Total</u> 100 98 161 200	a, df = 3 ( 1009) Events 62 61 174	rol Total 100 76 211 201	3); <b>P</b> = 67 <b>Weight</b> 25.1% 19.6% 36.3%	% Odds Ratio M-H, Fixed, 95% Cl 0.44 [0.25, 0.78] 0.38 [0.18, 0.71] 0.97 [0.57, 1.65] 0.44 [0.27, 0.71]	Control Disease Odds Ratio
Test for overall effect: Z = 4.64 (P < 0.00001)	Total events Heterogeneity: Tau [≠] = Test for overall effect C. Study or Subgroup Ahmed 2014 Angelo 2012 Lin 2009 Umare 2017 Total (95% CI)	= 0.12; Chi : Z = 3.31 ( Disea <u>Events</u> 42 58 132 138	I [#] = 9.11 (P = 0.0 <b>Total</b> 100 98 161 200 <b>559</b>	9, df = 3 ( 1009) <b>Events</b> 62 61 174 168	rol Total 100 76 211 201 588	3); <b>P</b> = 67 <b>Weight</b> 25.1% 19.6% 36.3%	% Odds Ratio M-H, Fixed, 95% Cl 0.44 [0.25, 0.78] 0.38 [0.18, 0.71] 0.97 [0.57, 1.65] 0.44 [0.27, 0.71]	Control Disease Odds Ratio
Disease         Control         Odds Ratio         Odds Ratio           Study or Subgroup         Events         Total         Events         Total         Weight         M.H., Random, 95% CI         M.H., Random, 95% CI           Amed 2014         64         200         27.1%         2.29 [1.40, 5.52]         —         —           Angelo 2012         52         196         15         152         20.8%         30 [1.77, 5.13]         —         —           Umare 2017         73         4.00         36         22.27 [1.48, 3.46]         —         —           Total (95% CI)         1118         1176         100.0%         2.05 [1.34, 3.13]         —         —           Total events         2.01 ; ChiP = 9.19, dr 3 (P = 0.03), P = 67%	Total events Heterogeneity: Tau [*] = Test for overall effect C. Study or Subgroup Anned 2014 Angelo 2012 Lin 2009 Umare 2017 Total events	= 0.12; Chi : Z = 3.31 ( Disez Events 42 58 132 138 370	P = 9.19 (P = 0.0 Total 100 98 161 200 559	0, df = 3 ( 009) Events 62 61 174 168 465	P = 0.0 Total 100 76 211 201 588	3); <b>P</b> = 67 <b>Weight</b> 25.1% 19.6% 36.3%	% Odds Ratio M-H, Fixed, 95% CI 0.44 (0.25, 0.78) 0.36 (0.18, 0.71) 0.97 (0.57, 1.65) 0.44 (0.27, 0.71) 0.52 [0.40, 0.69]	Control Disease
Disease         Control         Odds Ratio         Odds Ratio           Study or Subgroup         Events         Total         Events         Total         Weight         M.H., Random, 95% CI         M.H., Random, 95% CI           Amed 2014         64         200         27.1%         2.29 [1.40, 5.52]         —         —           Angelo 2012         52         196         15         152         20.8%         30 [1.77, 5.13]         —         —           Umare 2017         73         4.00         36         22.27 [1.48, 3.46]         —         —           Total (95% CI)         1118         1176         100.0%         2.05 [1.34, 3.13]         —         —           Total events         2.01 ; ChiP = 9.19, dr 3 (P = 0.03), P = 67%	Total events Helerogeneity: Tau ² = Test for overall effect C. Study or Subgroup Ahmed 2014 Angelo 2012 Lin 2009 Umare 2017 Total (95% CI) Total events Heterogeneity; Chf ⁻²	= 0.12; Chi : Z = 3.31 ( Disea Events 42 58 132 138 370 = 7.09, df =	P = 9.19 (P = 0.0 Total 100 98 161 200 559 = 3 (P =	009) Cont Events 62 61 174 168 465 0.07); P	P = 0.0 Total 100 76 211 201 588	3); <b>P</b> = 67 <b>Weight</b> 25.1% 19.6% 36.3%	% Odds Ratio M-H, Fixed, 95% CI 0.44 (0.25, 0.78) 0.36 (0.18, 0.71) 0.97 (0.57, 1.65) 0.44 (0.27, 0.71) 0.52 [0.40, 0.69]	Control Disease
Study or subgroup         Events         Total         Weints         < th="">         Total         Total         Weints         Total         Weints         Total         Weints         Total         Weints         Total         Total         Weints         Total         Weints         Total         Weints         Total         Weints         Total         Weints         Total         Total         Total         Total         Total         Total         Total         Total         Total         Total         Total         Total         Total         Total         Total         Total         Total         Total         Total         Total         Total         <thtotal< th="">         Total         Total</thtotal<></thtotal<>	Total events Helerogeneity, Tau ⁺ Test for overall effect C. <u>Study or Subgroup</u> Anmed 2014 Angelo 2012 Lin 2009 Umare 2017 Total (95% CI) Total events Helerogeneity, ChF = Test for overall effect	= 0.12; Chi : Z = 3.31 ( Disea Events 42 58 132 138 370 = 7.09, df =	P = 9.19 (P = 0.0 Total 100 98 161 200 559 = 3 (P =	009) Cont Events 62 61 174 168 465 0.07); P	P = 0.0 Total 100 76 211 201 588	3); <b>P</b> = 67 <b>Weight</b> 25.1% 19.6% 36.3%	% Odds Ratio M-H, Fixed, 95% CI 0.44 (0.25, 0.78) 0.36 (0.18, 0.71) 0.97 (0.57, 1.65) 0.44 (0.27, 0.71) 0.52 [0.40, 0.69]	Control Disease
Ahmed 2014         64         200         27.1%         2.29 (1.49, 5.52)           Angelo 2012         52         196         15         152         20.8%         3.30 (1.77, 6.13)           Lin 2009         32         322         39         422         27.9%         2.27 (1.49, 5.48)           Umare 2017         7.3         400         36         402         27.2%         2.27 (1.49, 3.48)           Total (95% Ct)         1118         1176         100.0%         2.05 (1.34, 3.13)            Heterogeneity, Tau"= 0.12; ChP= 9.19, df= 3 (P = 0.03); P = 67%         0.01         0.1         1         10	Total events Helerogeneity: Tau ² = Test for overall effect C. Study or Subgroup Ahmed 2014 Angelo 2012 Lin 2009 Umare 2017 Total (95% CI) Total events Heterogeneity; Chf ⁻²	= 0.12; Chi : Z = 3.31 ( Disea Events 42 58 132 138 370 = 7.09, df = t Z = 4.64	I [#] = 9.1! (P = 0.0 Total 100 98 161 200 559 = 3 (P = (P < 0.1	3, df = 3 ( 1009) Cont Events 62 61 174 168 465 0.07); P 00001)	P = 0.0 Total 100 76 211 201 588 = 58%	3); <b>P</b> = 67 <b>Weight</b> 25.1% 19.6% 36.3%	% Odds Ratio M-H, Excd, 95% C1 0.44 [0.25, 0.78] 0.39 [0.18, 0.77] 0.44 [0.27, 0.71] 0.52 [0.40, 0.69]	Control Disease
Angelo 2012 52 196 15 152 20.8% 3.30 [1.77, 6.13] Lin 2008 32 322 39 422 24.9% 1.08 [0.66, 1.77] Umare 2017 73 400 36 402 27.2% 2.27 [1.48, 3.48] Total sevents 241 128 Total sevents 241 128 Heterogeneity, Tat"= 0.12, Chi"= 9.18 (d= 3 (P = 0.03), P = 67% 0.001 0.1 10 10	Total events Helerogeneity, Tau ⁺ 3 Testfor overall effect C. <u>Study or Subgroup</u> Ahmed 2014 Angela 2012 Lun 2009 Umare 2017 Total eyents Helerogeneity, ChP ⁼ Testfor overall effect D.	= 0.12; Chi ; Z = 3.31 ( Disea Events 42 58 132 138 370 = 7.09, df t Z = 4.64 Disea	i [≠] = 9,1! (P = 0.0 Total 100 98 161 200 559 = 3 (P = (P < 0, (P < 0,	2, df = 3 ( 009) <u>Contr</u> <u>Events</u> 61 174 168 465 0.07); P 00001) <u>Contr</u>	P = 0.0 <u>Total</u> 100 76 211 201 588 = 58% ol	3); I [#] = 67 <u>Weight</u> 25.1% 19.0% 36.3% 100.0%	% Odds Ratio MH, Fixed, 95% CT 0.44 [0.25, 0.76] 0.39 [0.15, 7165] 0.44 [0.27, 0.71] 0.52 [0.40, 0.69] Odds Ratio	Control Disease
Lin 2009 32 322 39 422 24.9% 1.08[0.66,1.77] Umare 2017 73 400 36 402 27.2% 2.27[1.48,3.48] Total (95% CI) 1118 1176 100.0% 2.05[1.34,3.13] Heterogeneity Tau ⁺ = 0.12; Chi ⁺ = 9.18; df = 3 (P = 0.03); P = 67% Lin 2009 32 32 24.9% 1.08[0.66,1.77] ==- Total (95% CI) 1.118 1176 100.0% 2.05[1.34,3.13] + 1176 1000(Heterot = 7.2.0% 0.000)	Total events Helerogenety, Tau* Test for overall effect C. <u>Study of Subgroup</u> Ammed 2014 Angelo 2012 Lin 2009 Umare 2017 Total (95% C) Total events Helerogenety, Ch7= Test for overall effect D. <u>Study of Subgroup</u>	= 0.12; Chi Z = 3.31 ( Disea Events 42 58 132 138 370 = 7.09, df = t Z = 4.64 Diseas Events	P = 9.19 P = 0.0 Total 1000 98 161 200 559 = 3 (P = (P < 0.) se Total	2, df = 3 ( 0009) Contr Events 62 61 174 168 465 0.07); P 00001) Contr Events	P = 0.0 Total 1000 76 211 201 588 = 58% ol Total	3); №= 67 Weight 25.1% 19.0% 36.3% 100.0% Weight	% Odds Ratio M-H, Fixed, 95% C1 0.4 (10 25, 0.78) 0.3 (0 18, 0.07) 0.44 [0.27, 0.71] 0.52 [0.40, 0.69] Odds Ratio M-H, Random, 95% C1	Control Disease Odds Ratio M-H, Fixed, 95% CI
Umare 2017 73 400 36 402 27.2% 2.27 [1.4s, 3.4s] Total (95% Ct) 1118 1176 100.0% 2.05 [1.34, 3.13] + Total events 241 128 + Heterogeneity, Tau*= 0.12; Chi*= 9.18, df= 3 (P= 0.03); P= 67%	Total events Helerogeneity, Tau ⁺ 3 Test for overall effect C. <u>Study or Subgroup</u> Ammed 2014 Angelo 2012 Lin 2009 Umare 2017 Total events Helerogeneity: ChF ⁺ Test for overall effect D. <u>Study or Subgroup</u> Anmed 2014	= 0.12; Chi = Z = 3.31 ( Disea <u>Events</u> 42 58 132 138 370 = 7.09, df = t Z = 4.64 <u>Diseas</u> <u>Events</u> 84	I ² = 9,11 (P = 0.C Isse Total 100 98 161 200 559 = 3 (P = (P < 0.1 See Total 200	2, df = 3 ( 1009) Contr Events 62 61 174 168 465 0.07); P 00001) Contr Events 48	rol Total 201 588 = 58% ol Total 200	3); I ² = 67 Weight 25.1% 19.0% 36.3% 100.0% Weight 27.1%	% Odds Ratio M-H, Fixed, 95% CI 0.44 [0 25, 0.76] 0.37 [0.57, 165] 0.44 [0 27, 0.77] 0.52 [0.40, 0.69] Odds Ratio M-H, Random, 95% CI 2.29 [1.49, 3.52]	Control Disease Odds Ratio M-H, Fixed, 95% CI
Total (95% CI)         1118         1176         100.0%         2.05 [1.34, 3.13]           Total events         241         138           Heterogeneity, Tau"=0.12; Chi™=9.19; df=3 (P=0.03); I"=67%         0.01         0.1         10         10	Total events Helerogeneity, Tau?= Test for overall effect C. Study of Subgroup Anmed 2014 Angelo 2012 Lin 2009 Umare 2017 Total (95% C) Total (95% C) Total (95% C) Total (95% C) Total (95% C) Total (95% C) Anmed 2014 Anmed 2014	= 0.12; Chi Z = 3.31 ( Disea <u>Events</u> 42 58 132 138 370 = 7.09, df = t Z = 4.64 Disea <u>Events</u> 84 52	P = 9,1! P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P = 0.C P	2, df = 3 ( 1009) Cont Events 62 61 174 168 465 0.007); P 00001) Contr Events 48 15	rol Total 100 76 211 201 588 = 58% ol Total 200 152	3); F = 67 Weight 25.1% 19.6% 19.0% 36.3% 100.0% Weight 27.1% 20.8%	% Odds Ratio M-H, Fixed, 95% C1 0.4 [0 25, 0.78] 0.36 [0.18, 0.77] 0.52 [0.40, 0.69] Odds Ratio M-H, Random, 95% C1 2.29 [1.49, 35% C1 2.30 [1.77, 5.13]	Control Disease
Total events 241 138 Heterogeneity: Tau ² = 0.12; Ch ² = 9.19; df = 3 (P = 0.03); P = 67% Tauf for were the form of the 0.0000 0.1 1 10 100	Total events Helerogeneity, Tau ⁺ Test for overall effect C. Study or Subgroup Anmed 2014 Angelo 2012 Lin 2009 Umare 2017 Total events Heterogeneity, ChP ⁺ Test for overall effect D. Study or Subgroup Anmed 2014 Angelo 2012 Lin 2009	= 0.12; Chi Z = 3.31 ( Events 42 58 132 138 370 = 7.09, df = t Z = 4.64 Diseas Events 84 52 32	P = 9,11 (P = 0.0 ISSE Total 100 98 161 200 559 = 3 (P = 0.) (P < 0.) 100 190 322	2, df = 3 ( 1009) Cont Events 62 61 174 168 465 0.07); P 00001) Contr Events 48 15 39	rol Total 2010 588 = 58% ol Total 2000 152 422	3); F = 67 Weight 25.1% 19.6% 36.3% 100.0% Weight 27.1% 20.8% 24.9%	% Odds Ratio M-H, Exed, 95% C1 0.44 (0.27, 0.71) 0.52 [0.40, 0.69] Odds Ratio M-H, Random, 95% C1 2.29 [149, 3.52] 3.30 (17.7, 6.13) 1.09 (0.66, 1.77)	Control Disease
Total events 241 138 Heterogeneity: Tau ² = 0.12; Ch ² = 9.19; df = 3 (P = 0.03); P = 67% Tauf for were the form of the 0.0000 0.1 1 10 100	Total events Helerogeneity, Tau ⁺ Test for overall effect C. Study or Subgroup Anmed 2014 Angelo 2012 Lin 2009 Umare 2017 Total events Heterogeneity, ChP ⁺ Test for overall effect D. Study or Subgroup Anmed 2014 Angelo 2012 Lin 2009	= 0.12; Chi Z = 3.31 ( Events 42 58 132 138 370 = 7.09, df = t Z = 4.64 Diseas Events 84 52 32	P = 9,11 (P = 0.0 ISSE Total 100 98 161 200 559 = 3 (P = 0.) (P < 0.) 100 190 322	2, df = 3 ( 1009) Cont Events 62 61 174 168 465 0.07); P 00001) Contr Events 48 15 39	rol Total 2010 588 = 58% ol Total 2000 152 422	3); F = 67 Weight 25.1% 19.6% 36.3% 100.0% Weight 27.1% 20.8% 24.9%	% Odds Ratio M-H, Exed, 95% C1 0.44 (0.27, 0.71) 0.52 [0.40, 0.69] Odds Ratio M-H, Random, 95% C1 2.29 [149, 3.52] 3.30 (17.7, 6.13) 1.09 (0.66, 1.77)	Control Disease Odds Ratio M-H, Fixed, 95% CI
Heterogeneity: Tau [#] = 0.12; Chi [#] = 9.19; df = 3 (P = 0.03); I [#] = 67% 1 1 10 10	Total events Helerogeneity, Tau7- Test for overall effect C. Study or Subgroup Anmed 2014 Angelo 2012 Lin 2009 Umare 2017 Total events Helerogeneity; ChF= Test for overall effect D. Study or Subgroup Anmed 2014 Angelo 2012 Lin 2009 Umare 2017	= 0.12; Chi Z = 3.31 ( Events 42 58 132 138 370 = 7.09, df = t Z = 4.64 Diseas Events 84 52 32	P [≠] = 9.11 (P = 0.0 <b>sse</b> Total 200 559 = 3 (P = (P < 0.) 200 196 322 400	2, df = 3 ( 1009) Cont Events 62 61 174 168 465 0.07); P 00001) Contr Events 48 15 39	rol Total 201 588 588 ol Total 200 152 422 402	3); P = 67 25.1% 19.6% 19.6% 100.0% Weight 27.1% 24.9% 24.9% 27.2%	% Odds Ratio M-H, Exed, 95% C1 0.44 (0.27, 0.71) 0.52 [0.40, 0.69] Odds Ratio M-H, Randon, 95% C1 2.29 (1.49, 3.52) 3.00 (1.77, 6.13) 1.09 (0.66, 1.37) 1.09 (0.66, 1.37) 2.27 (1.48, 3.48)	Control Disease Odds Ratio M-H, Fixed, 95% CI
Test for sussell affects 7 - 2.24 (P = 0.0000) U.U U.U U.U U.U U.U U.U U.U	Total events Helerogeneity, Tau* Test for overall effect C. Study or Subgroup Anmed 2014 Angelo 2012 Lin 2009 Umare 2017 Total (95% CI) Chevents Helerogeneity, Ch* Test for overall effect D. Study or Subgroup Anmed 2014 Angelo 2012 Lin 2009 Umare 2017 Total (95% CI)	= 0.12; Chi ; Z = 3.31 ( Events 42 58 132 138 370 = 7.09, df = t Z = 4.64 Diseas Events 8 8 4 2 2 370 73	P [≠] = 9.11 (P = 0.0 <b>sse</b> Total 200 559 = 3 (P = (P < 0. 196 322 400	3, df = 3 ( 0009) Events 62 61 174 168 465 0.07); P Contr Events 48 15 39 36 36	rol Total 201 588 588 ol Total 200 152 422 402	3); P = 67 25.1% 19.6% 19.6% 100.0% Weight 27.1% 24.9% 24.9% 27.2%	% Odds Ratio M-H, Exed, 95% C1 0.44 (0.27, 0.71) 0.52 [0.40, 0.69] Odds Ratio M-H, Randon, 95% C1 2.29 (1.49, 3.52) 3.00 (1.77, 6.13) 1.09 (0.66, 1.37) 1.09 (0.66, 1.37) 2.27 (1.48, 3.48)	Control Disease Odds Ratio M-H, Fixed, 95% CI
Control Disease	Total events Helerogeneity, Tau7- Test for overall effect C. Study or Subgroup Anmed 2014 Angelo 2012 Lin 2009 Umare 2017 Total events Heterogeneity, ChF = Test for overall effect D. Study or Subgroup Anmed 2014 Angelo 2012 Lin 2009 Umare 2017 Total events	= 0.12; Chi ; Z = 3.31 ( Disea Events 42 58 132 138 370 = 7.09, df t Z = 4.64 Disea Events 84 52 22 32 73 241	P [≠] = 9,11 (P = 0.0 1000 98 161 200 559 = 3 (P = 0. (P < 0.) 196 322 400 11118	2, df = 3 ( 2, df = 3 ( 2, 009)	rol Total 100 76 211 201 588 = 58% ol Total 200 152 402 402 402 1176	3); P = 67 Weight 25.1% 10.6% 10.6% 10.0% 100.0% Weight 27.1% 20.8% 24.9% 27.2% 100.0%	% Odds Ratio MH, Exed, 95% C1 0.44 (0 25, 0.78) 0.39 (0 18, 0 27, 0.71) 0.52 (0.40, 0.69) Odds Ratio Cdds Ratio 2.29 (1.49, 3.62) 3.30 (1.77, 6.13) 1.08 (0.66, 3.48) 2.05 (1.34, 3.13)	Control Disease
	Total events Helerogeneity Tau* Test for overall effect C. Study or Subgroup Anmed 2014 Angelo 2012 Lin 2009 Umare 2017 Total (95% CI) Total events Helerogeneity, Ch* Test for overall effect D. Study or Subgroup Anmed 2014 Angelo 2012 Lin 2009 Umare 2017 Total (95% CI) Total (95% CI)	0.12, Ch.C. 2 = 3.31 ( Z = 3.31 ( 2 = 3.31 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.331 ( 2 = 2.	P = 9.11 P = 0.0 ISE Total 1000 98 161 200 559 = 3 (P = (P < 0, 106 322 400 1118 [*] = 9.15	3, df = 3 ( 0009) Events 62 61 174 465 465 0.07), P 00001) Contr Events 48 15 39 36 138 8, df = 3 (	rol Total 100 76 211 201 588 = 58% ol Total 200 152 402 402 402 1176	3); P = 67 Weight 25.1% 10.6% 10.6% 10.0% 100.0% Weight 27.1% 20.8% 24.9% 27.2% 100.0%	% Odds Ratio MH, Exed, 95% C1 0.44 (0 25, 0.78) 0.39 (0 18, 0 27, 0.71) 0.52 (0.40, 0.69) Odds Ratio Cdds Ratio 2.29 (1.49, 3.62) 3.30 (1.77, 6.13) 1.08 (0.66, 3.48) 2.05 (1.34, 3.13)	Control Disease

Figure. Forest plot of bassociation between TNF- $\alpha$  gene polymorphisms and Systemic Lupus Erythematosus A) AA vs AG + GG; B) AG vs AA + GG; C) G vs A; D) GG vs AG + AA; E) A vs G

#### **Keywords**

gene polymorphism, systemic lupus erythematosus, tumor necrosis factor  $\boldsymbol{\alpha}$ 

# **E-poster Presentation**

SLE-treatment

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



## A retrospective single center study of the clinical response of tacrolimus treatment in patients with lupus nephritis

<u>Ji-Won Kim¹</u>, Ju Jung¹, Hyoun-Ah Kim¹, Chang-Hee Suh¹

¹ Department of Rheumatology, Ajou University School of Medicine, Republic of Korea

#### Background

Lupus nephritis (LN) is a severe manifestation of systemic lupus erythematosus (SLE), however, current treatment for LN is still associated with severe adverse effects, treatment failures, and relapse rates. Tacrolimus (TAC) has recently become increasingly interested in its role as a potential therapeutic agent in SLE. The aim of this study was to evaluate the efficacy of TAC as a treatment for LN.

#### **Methods**

We retrospectively reviewed the medical records of patients with LN from January 1999 to December 2021. One-hundred seventy biopsy proven cases of LN were enrolled, with 92 in the TAC group and 87 in the non-TAC group. The clinical response of TAC treatment in patients with LN was evaluated by proteinuria, estimated glomerular filtration rate (eGFR), anti-double-stranded DNA (anti-dsDNA) antibody, complement 3 (C3), C4, and renal SLE disease activity index (SLEDAI). Complete renal response was defined as urine protein/creatinine <0.5, normal serum creatinine or, if normal at baseline, not increased by  $\geq$ 15%, and partial renal response was defined as a normal or near-normal GFR with a  $\geq$ 50% reduction in proteinuria to sub-nephrotic levels.


#### Results


The baseline clinical manifestations between the two groups showed no significant differences. Most of TAC group received combination therapy with other immunosuppressants, and only 19 (20.7%) patients maintained TAC monotherapy. After 5 years, there were no statistically significant differences in proteinuria, eGFR levels, anti-dsDNA, serum C3, C4, and renal SLEDAI. The overall (complete and partial) renal response rate was not significantly different: 72.9% of patients receiving TAC and 85.5% of patients not receiving TAC (p=0.1). The poor outcomes including end stage renal disease or death were similar in both groups.

#### Conclusions

Our results indicate that TAC is potentially effective in treating LN, and may be a reasonable option for patients with LN. TAC can help patients with LN achieve a renal response and slow progression.

#### Figure & Table





#### **Keywords**

Lupus nephritis, Tacrolimus, Combination therapy



## Acute pancreatitis after corticosteroid pulse therapy in rheumatic disease: Acute pancreatitis is common adverse reaction after corticosteroid pulse therapy

#### Jinseok Kim¹, Yong-Beom Park¹

¹ Internal medicine, Yonsei University College of Medicine, Republic of Korea

#### Background

Many drugs are known to cause drug-induced pancreatitis. This study investigated acute pancreatitis after corticosteroid pulse therapy in patients with rheumatic disease.

#### **Methods**

We retrospectively reviewed all patients with rheumatic disease who had received corticosteroid pulse therapy (at least methylprednisolone 500mg a day for less than 5 days) at Severance hospital, Yonsei University since electronic medical record system was set (June 2005 - December 2021). This study defined acute pancreatitis as the presence of two of three following criteria: acute onset of persistent, severe, epigastric pain often radiating to the back, elevation in serum lipase or amylase to three times or greater than the upper normal limit, and characteristic findings of acute pancreatitis on imaging (Computerized tomography (CT), Magnetic resonance imaging (MRI), or ultrasonography (USG)). Co-administered drugs that are known to be associated with drug-induced pancreatitis (Pancreatitis-associated drugs) during pulse therapy were analyzed. Autoantibodies and laboratory findings before pulse therapy were also collected in SLE patients.

#### Results

The total number of patients who had received corticosteroid pulse therapy due to rheumatic disease is 230 (131 patients with systemic lupus erythematosus (SLE), 63 with vasculitis, 15 with adult-onset stills' disease, 14 with inflammatory myositis, 5 with rheumatoid arthritis, 1 with relapsing polychondritis, 1 with becet disease). Seven patients (3.0%; 6 with SLE and 1 with vasculitis) had suffered from acute pancreatitis within a week after corticosteroid pulse therapy. No patients had died of acute pancreatitis. More use of pancreatitis-associatied drugs (i.e., furosemide, omeprazole, trimethoprim/sulfamethoxazole. atorvastatin, cyclophosphamide) during pulse therapy was related to high incidence of acute pancreatitis. No autoantibodies and laboratory data before pulse therapy had an impact on the events in patients with SLE.

#### Conclusions

Acute pancreatitis is common adverse drug reaction (ADR) after corticosteroid pulse therapy. Concomittant use of pancreatitis-associating drugs could increase the risk of acute pancreatitis after corticosteroid pulse therapy.

#### Figure & Table

Variables	All patients (n=230)	Patients without acute pancreatitis (n=223)	Patient with Acute pancreatitis (n= 7)	p-value
Demographic data				
Age at steroid pulse treatment	$41.0 \pm 26.3$	$41.0 \pm 27.0$	$31.0 \pm 33.0$	0.277
Sex, female (%)	185 (80.4%)	178 (79.8%)	7 (100%)	0.350
Body weight	$57.2 \pm 13.0$	$57.40 \pm 13.0$	$57.0 \pm 19.9$	0.325
BMI	$22.1\pm2.6$	$22.1\pm2.6$	$22.3 \pm 5.4$	0.727
Type of underlying rheumatic disease				
SLE	131 (57.0%)	125 (56.1%)	6 (85.7%)	0.244
Vasculitis	63 (27.4%)	62 (27.8%)	1 (14.3%)	0.677
AOSD	15 (6.5%)	15 (6.7%)	0 (0.0%)	1.000
Inflammatory myositis	14 (6.1%)	14 (6.3%)	0 (0.0%)	1.000
Rheumatoid arthritis	5 (2.2%)	5 (2.2%)	0 (0.0%)	1.000
Relapsing polychondritis	1 (0.4%)	1 (0.4%)	0 (0.0%)	1.000
Behcet disease	1 (0.4%)	1 (0.4%)	0 (0.0%)	1.000
Corticosteroid pulse total dose (Methylprednisolone)		Linear-by-L	inear Association	0.917
1500mg (500mg for 3days)	17 (7.4%)	17 (7.6%)	0 (0.0%)	
2000mg (1000mg for 2days)	1 (0.4%)	0 (0.0%)	1 (14.3%)	
2500mg (500mg for 5days)	22 (9.6%)	21 (9.4%)	1 (14.3%)	
3000mg (1000mg for 3days)	190 (82.6%)	185 (83.0%)	5 (71.4%)	
Amylase/Lipase				
Amylase level before pulse	$63.0 \pm 49.0$	$63.0 \pm 49.5$	$88.5 \pm 112.8$	0.336
Lipase level before pulse	$36.0 \pm 30.5$	$36.0 \pm 30.5$	$38.0 \pm 51.8$	0.854
Peak amylase level after pulse	$90.0 \pm 80.3$	$86.0 \pm 76.0$	$316.0 \pm 1461.0$	0.000
Peak lipase level after pulse	$52.0 \pm 59.3$	$50.0 \pm 52.0$	$629.0 \pm 1222.0$	0.000
Amylase or Lipase elevation (>3 *UNL)	20 (8.7%)	14 (6.3%)	6 (85.7%)	0.000
Amylase or Lipase elevation (>2 *UNL)	32 (13.9%)	26 (11.7%)	6 (85.7%)	0.000
Amylase or Lipase elevation (>1 *UNL)	77 (33.5%)	70 (31.4%)	7 (100%)	0.000
Total number of co-administered pancreatitis-associating drugs during pulse	$2.00\pm2.00$	$2.00\pm2.00$	$4.00\pm1.00$	0.009

All statistical analysis was done by nonparametric test for continuous variables or by chi-square test / Fisher's

All statistical analysis was cone by nonparametric test for commutues variables of by emergence (ext rest for categorical variables.) exact test for categorical variables. SLE: Systemic lupus erythematosus; AOSD: Adult-onset stills disease; UNL: Upper-normal limit Pancreatitis-associating drugs were defined using review article by Badalov, Nison, et al. "Drug-induced acute pancreatitis: an evidence-based review." Clinical gastroenterology and hepatology 5.6 (2007): 648-641

661 (i.e., furosemide, omeprazole, trimethoprim/sulfamethoxazole. Atorvastatin, cyclophosphamide)

Table. Comparison of variables between patients who had received corticosteroid pulse therapy with and without acute pancreatitis.

#### **Keywords**

Corticosteroid pulse therapy, acute pancreatitis, drug induced pancreatitis





## Myelodysplastic syndrome occurrence in post-therapeutic systemic lupus erythematosus patients

### Ninda Devita¹

¹ Biomedical Study Programme, Faculty of Medicine Public Health and Nursing, Universitas Gadjah Mada, Indonesia

#### **Description**

A 4-year-old boy comes to the hospital complaining of shortness of breath. He is a Systemic Lupus Erythematosus (SLE) patient with ongoing treatment. The history of the results of the ANA IF examination revealed a nuclear speckled pattern. Previously, the patient received Methylprednisolone 8-8-4 mg, Mycophenolate Mofetil 360-0-360, and Hydroxychloroquine 100 mg/day. Physical examination revealed rhonchi on both lungs. The results of a complete blood count revealed pancytopenia with a leukocyte count of 1.31 x 10³ cells/uL, Hb 6.7 g/dL, and platelets 7 x 10³ cells/uL. Follow-up examination with bone marrow aspiration revealed an increase in thrombopoiesis, erythropoiesis, and granulopoiesis accompanied by dysplasia in all three lineages showing the picture of Myelodysplastic Syndrome-Multilineage Dysplasia. The patient was then managed with the Myelodysplastic Syndrome protocol while continuing MP 8-8-4 mg therapy and discontinuing Hydroxychloroquine. Clinical improvement was found at follow-up 1 month after.

#### Conclusions

Systemic Lupus Erythematosus is a complex autoimmune disease, with many clinical features. Organ involvement in SLE cases often has an impact on the emergence of other diseases that have a picture of organ involvement. SLE therapy given is immunosuppressive to relieve the symptoms that arise. The incidence of Myelodysplastic Syndrome that occurs can be associated with the primary condition of this patient which is suspected to involve the bone marrow organ. However, it is undeniable that some immunosuppressive medications can trigger dysplasia. Cellular apoptosis that occurs because of treatment can trigger the development of other lineages that are not affected by the drug and eventually become dysplastic. In this case, it is not known with certainty the cause of MDS whether it is related to the pathophysiology of SLE or is the impact of treatment. This case demonstrates the need for clinician vigilance in providing SLE treatment protocols.

#### Figure & Table




Figure. Bone marrow examination showing multi lineage dysplasia

#### **Keywords**

SLE, MDS, Dysplasia

# **E-poster Presentation**

Spondyloarthropathies and psoriatic arthritis

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



## Vitronectin-derived bioactive peptide prevents spondyloarthritis by modulating Th17/Treg imbalance in mice with curdlan-induced spondyloarthritis

<u>Hong Ki Min</u>¹, JeongWon Choi³, Seon-Yeong Lee³, A Ram Lee⁵, Byung-Moo Min⁴, Mi-La Cho^{3,5}, Sung-Hwan Park²

¹ Rheumatology, Konkuk University Medical Center, Republic of Korea

² Rheumatology, College of Medicine, The Catholic University of Korea, Republic of Korea

³ Rheumatism Research Center, Catholic Research Institute of Medical Science, The Catholic University of Korea, Republic of Korea

⁴ Department of Oral Biochemistry and Program in Cancer and Developmental Biology, Dental Research In, Seoul National University School of Dentistry,

Republic of Korea

⁵ Department of Biomedicine & Health Sciences, College of Medicine, The Catholic University of Korea, Republic of Korea

#### Background

Spondyloarthritis (SpA) is a systemic inflammatory arthritis mediated mainly by interleukin (IL)-17. The vitronectin-derived bioactive peptide, VnP-16, exerts an anti-osteoporotic effect via  $\beta$ 1 and  $\alpha\nu\beta$ 3 integrin signaling. SpA is associated with an increased risk of osteoporosis, and we investigated the effect of VnP-16 in mice with SpA.

#### **Methods**

SpA was induced by curdlan in SKG ZAP-70W163C mice, which were treated with vehicle, celecoxib, VnP-16, or VnP-16+celecoxib. The clinical score, arthritis score, spondylitis score, and proinflammatory cytokine expression of the spine were evaluated by immunohistochemical staining. Type 17 helper T cell (Th17) and regulatory T cell (Treg) differentiation in the spleen was evaluated by flow cytometry and in the spine by confocal staining. Splenocyte expression of signal transducer and activator of transcription (STAT) 3 and pSTAT3 was evaluated by in vitro Western blotting.

#### **Results**

The clinical score was significantly reduced in the Vn-P16+celecoxib group. The arthritis and spondylitis scores were significantly lower in the VnP-16 and VnP16+celecox-ib groups than the vehicle group. In the spine, the levels of IL-1 $\beta$ , IL-6, tumor necrosis factor- $\alpha$ , and IL-17 expression were reduced and Th17/Treg imbalance was regulated in the VnP-16 alone and VnP-16+celecoxib groups. Flow cytometry of splenocytes showed increased polarization of Tregs in the VnP-16+celecoxib group. In vitro, VnP-16 suppressed pSTAT3.

#### Conclusions

VnP-16 plus celecoxib prevented SpA progression in a mouse model by regulating the Th17/Treg imbalance and suppressing the expression of proinflammatory cytokines.

#### **Figure & Table**




Figure. Anti-arthritic effects of vitronectin-derived bioactive peptide (VnP-16) in spondyloarthritis (SpA) mice.

#### **Keywords**

Spondyloarthritis, VnP-16, Type 17 helper T cell



## The relationship between the osteoporosis and cortial index of the mandibular bone in psoriatic arthritis

#### Viliam Gasanova¹, Gürkan İden²

¹ Department of Radiology, Bahçeşehir İstinye University, Turkey ² orthopedics and traumatology, R. Yaşar Eryılmaz Doğubeyazıt Devlet Hastanesi, Turkey

#### Background

The aim of this study is to determine the detectability of systemic osteoporosis in psoriatic arthritis using mandibular radiography and indices.

#### **Methods**

In our study, 54 patients with psoriatic arthritis who had radiographs were evaluated. Data consist of DXA, mandibular radiography and rheumatological status, body mass index (BMI), and demographic values. The morphology of the mandibular inferior cortex (MCI) was determined by two observers and classified according to the Klemetti scale (1) (G1-G2-G3). Student's t-test, ANOVA, and Kappa statistics were applied. In addition, sensitivity, specificity, and positive and negative predictive values of MCI were determined in the detection of systemic bone loss.

#### **Results**

54 psoriatic arthritis patients were included in the study. Considering the lumbar spine values, 20% of the patients were found to have osteoporosis (G3), 34% to have osteopenia (G2), and 46% to be healthy (G1). Considering the femoral head values, 15% of the patients were found to have osteoporosis (G3), 21% to have osteopenia (G2), and 64% to be healthy (G1). There was no significant difference between the groups in terms of age and gender. A strong agreement (kappa: 0.784) was found between the 2 observers in the evaluation of MCI on mandibular radiography. The mean sensitivity, specificity, and positive and negative predictive values were 63.4, 84.2, 62.6, and 83.7 for the lumbar spine, while 49.5, 82.4, 76.2, and 57.9 for the femoral head.

#### Conclusions

As a result of this study, it has been seen that mandibular radiography and MCI can be used as an auxiliary diagnostic tool in osteoporosis resolving in psoriatic arthritis.



## Evaluation of the relationship between ankylosing spondylitis and its inflammation indicator calprotectin and its relationship with disease activity

#### Mehmet Alperen Tezcan¹, Ekin Başak Doğancı²

¹ Department of Radiology, Ataturk University, Turkey ² Physical Medicine and Rehabilitation, Rheumatology Department, Ataturk University, Turkey

#### Background

This study investigated whether there is a relationship between ankylosing spondylitis (AS) and calprotectin, an indicator of intestinal inflammation.

#### **Methods**

Patients who met the 1984 Modified New York criteria for AS were included in the study. Patients using infliximab, adalimumab and non-steroidal anti-inflammatory drugs for the last 8 weeks were excluded from the study. In the study, 248 AS patients and 120 healthy population without known intestinal inflammation complaints and symptoms were evaluated. Disease activity in the AS group was divided into two groups as those with Bath AS disease activity index (BASDAI) 4< and 4>. Calprotectin levels, an indirect indicator of intestinal inflammation, were measured in each patient. Patients with a fecal calprotectin level >70 ug/g were considered positive. The relationship between healthy population and AS patients and between AS disease activity and fecal calprotectin levels were examined.

#### **Results**

There was no significant difference between the groups in terms of age and gender. Calprotectin levels were high in 61 patients with ankylosing spondylitis, while high calprotectin levels were detected in two people in the healthy population. There was a significant difference in calprotectin levels between the two groups (p=0.0063). In addition, while the number of patients with BASDAI <4 was 169, the number of patients with >4 was 79. The mean fecal protein level was 24.2 ug/g in the group with high disease activity and 14.6 ug/g in the group with low activity, and there was a significant difference between the groups in fecal protein levels (p<0.001).

#### Conclusions

The incidence of intestinal inflammation is increased in patients with ankylosing spondylitis and the risk of bowel inflammation is associated with disease activity.



## Investigation of the relationship of ankylosing spondylitis and varicocele

Muhammed Emre Isiktas¹, Cafer Koçak¹, Halid Yener¹

¹ Department of Radiology, Atatürk University, Turkey

#### Background

Varicocele is defined as abnormal dilatation and increased tortuosity of the veins of the pampiniform plexus and poses a risk for male infertility. We aimed to investigate the effect of sedative life developed in patients with ankylosing spondylitis on the development of varicocele with this study.

#### **Methods**

The study groups consisted of 87 AS and 51 healthy controls. Scrotal physical examination and Doppler ultrasonography were performed by two doctors who were unaware of the patient's diagnosis. Varicocele frequencies were determined and the correlation between physical examination and ultrasonographic examination was calculated. Panpiniform plexus diameter >2mm was evaluated as varicocele. In addition, reflux was evaluated with the Valsalva maneuver

#### Results

There was no significant difference between the groups in terms of age and gender. Varicocele was found in 26.4% (n=23) in the AS group and 23.5% (n=12) in healthy controls by physical examination. In Doppler ultrasonography, these rates were observed as 29.8% (n=26), and 27.4% (n=14), respectively. Valsalva and reflux in pampiniform plexuses were 13.8% (12) in Behçet's patients and 9.8% (5) in the healthy population. detected. While the mean pampiniform plexus diameter was 2.12 mm in BD patients, it was 1.87 mm in the healthy population. No significant difference was observed between the two groups (p=0.052). There was moderate agreement between physical examination results and Doppler ultrasonographic examination results (kappa value=0.684).

#### Conclusions

The incidence of varicocele in AS does not increase compared to the healthy control group. This may indicate that the sedative life in Ankylosing sponditis does not significantly affect varicocele.



## The effect of ankylosing spondylitis on carotis intima media thickness and its relationship with disease activity

#### Elshad İsmailov¹, Merve Polat², Gökhan Polat¹

¹ Department of Radiology, Atatürk University, Turkey ² HEALTH PHYSICS, Karadeniz Technical University, Turkey

#### Background

It is known that atherosclerosis increases in ankylosing spondylitis cases. In our study, we aimed to examine the effect on carotid intima media thickness in patients followed up with AS diagnosis

#### **Methods**

244 cases (mean age: 46.2) and 124 control subjects (mean age: 42.5) followed up with the diagnosis of AS were included in the study. The clinical and demographic characteristics of the patients were recorded. Activity classification was made based on the BASDAI score: disease activity in the RA group, no activity (BASDAI =0), mild activity (BASDAI 1–2), moderate activity (BASDAI 3–5), high activity (BASDAI) according to the Bath AS disease activity in dex (BASDAI). Carotid ultrasonography was performed in all cases to evaluate subclinical atherosclerosis and intima-media thickness (IMT) was evaluated.

#### **Results**

There was no significant difference between the groups in terms of age and gender.The mean disease duration is 94.6 months. Carotid IMT of RA patients (mean 0.694mm) was significantly higher than the control (mean 0.598mm) (p=0.035). The number of patients with BASDAI =0 was 108, the number of patients with BASDAI 1–2 was 59, the number of patients with BASDAI 3–5 was 35, and the number of patients with BASDAI 3–5 was 40. A very high correlation was found between carotid IMT and disease activity (r=0.801, p<0.001).

#### Conclusions

An increase in carotid intima-media thickness is observed in patients with AS, and there is a significant correlation between disease activity and carotid intima-media thickness.



## Predictive role of neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio and platelet-to-lymphocyte ratio in the assessment of clinical response and drug persistence of tumor necrosis factor-alpha inhibitors in patients with ankylosing spondylitis

#### Dong Hyuk Moon¹, Seung-Geun Lee¹, Aran Kim¹, Byung Wook Song¹

¹ Rheumatology, Pusan National University School of Medicine, Pusan National University Hospital, Republic of Korea

#### Background

Recently, neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR) and platelet-to-lymphocyte ratio (PLR) are recognized as surrogate markers for systemic inflammation in various disorders including ankylosing spondylitis (AS). We aimed to investigate whether baseline NLR, MLR and PLR can predict treatment response to tumor necrosis factor-alpha (TNF- $\alpha$ ) inhibitors at 12 weeks and their long-term persistence in patients with ankylosing spondylitis (AS) in real practice.

#### **Methods**

In this retrospective cohort study, we investigated 279 patients with RA who started on anti-TNF- $\alpha$  agents as the first-line biologic and 171 sex- and age-matched (±2 years) healthy subjects. AS patients were divided into high and low baseline NLR, MLR or PLR subgroups using median split. Response to TNF- $\alpha$  inhibitors at 12 weeks was defined as Bath AS Disease Activity Index (BASDAI) improvement  $\geq$  2 and persistence was defined as the time interval between the initiation and the first discontinuation of TNF- $\alpha$  inhibitors.

#### **Results**

Patients with AS had significantly higher median NLR (1.99 vs 1.45, p<0.001), MLR (0.24 vs 0.16, p<0.001) and PLR (117.29 vs 115.11, p=0.036) compared with healthy controls. One hundred and eighty-five (66.3%), 65 (23.3%) and 29 (10.4%) AS patients started with adalimumab, etanercept and infliximab, respectively, and mean BASDAI was 6.8. The frequency of non-response at 12 weeks was 3.7% and 113 (40.5%) patients stopped TNF- $\alpha$  inhibitors (lack of efficacy: 29, adverse events: 23 and poor health literacy: 61) during the study period. After adjusting confounding factors, high baseline NLR was related with a higher risk of non-response (OR=11.57, p=0.028) to TNF- $\alpha$  inhibitors at 12 weeks. In addition, high baseline NLR was independently associated with a higher risk for TNF- $\alpha$  inhibitors discontinuation (HR=1.66, p=0.01).

#### Conclusions

Our findings suggest that baseline NLR may play a predictive role for response and persistence of TNF- $\alpha$  inhibitors in patients with AS.



KCR 2022

May 19(Thu) - 21(Sat), 2022

## A deep-learning-based approach for automated assessment of modified Stoke ankylosing spondylitis spine score (mSASSS) on spine radiographs: a preliminary study

<u>Sun Yeop Lee</u>¹, Dong Hyun Kim², Hee-Dong Chae³, Hongjun Yoon¹, Hyo Jin Kim², Jiwoon Seo², Jee Won Chai², Sung Hwan Hong³, Ja-Young Choi³, Burnyoung Kim¹, Ara Seo¹, Songhwan Lim¹

¹ Department of Medical AI, Deepnoid, Inc., Republic of Korea

² Department of Radiology, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Republic of Korea ³ Department of Radiology, Seoul National University Hospital, Seoul National University College of Medicine, Republic of Korea

#### Background

A deep learning (DL) algorithm is developed for the automatic detection of ankylosis in spine radiographs of patients with ankylosing spondylitis as a first step for the development of automatic mSASSS assessment.

#### **Methods**

We retrospectively collected 2,000 radiographs from 500 patients with ankylosing spondylitis from two hospitals. For each patient, lateral cervical and lumbar radiographs at baseline and follow-up were collected. Each radiograph was evaluated for mSASSS assessment, and two radiologists performed manual segmentations on the vertebra and syndesmophytes. Among 24,000 vertebral corners from 2,000 radiographs (train: 1,700, validation: 100, test: 200), 3,928 (16.4%) were ankylosis, while 873 (3.6%) were not clearly visible and excluded. A DL algorithm was developed to first segment vertebra including syndesmophytes, then extract vertebral corners to identify ankylosis. A Mask region-based convolutional neural network (R-CNN) was used in the detection and segmentation of the vertebra including syndesmophytes. Using the DL model results, ankylosis was determined if two adjacent segmented vertebral corners were overlapped.

#### **Results**

In the test set, the dice score coefficient (DSC) for the vertebra including syndesmophyte was 0.94. The sensitivity for each vertebra including syndesmophytes to be predicted with DSC higher than 0.50 was 99.66% and the precision was 99.98%. Sensitivity, specificity, precision, and accuracy for per-vertebral corner detection of ankylosis were 82.6%, 95.6%, 78.4%, and 93.3%, respectively.

#### Conclusions

The DL model for segmentation of vertebra including syndesmophyte showed high segmentation performance. Using this model, we develop a detection algorithm for ankylosis at the vertebra corner. Such algorithm is also helpful in future model development of automated mSASSS assessment. Further development of the classification of vertebral corner abnormalities is in progress for automated mSASSS assessment.

#### Figure & Table




Figure. Segmentation results and identification of ankylosing spondylitis on a cervical spine

radiograph. The ground truth manual segmentations (red contour) are on the image to the left,

and the predicted segmentations (blue contour) are on the image to the right. Identified cases

of ankylosis are visualized on the predicted segmentation (red boxes).

#### **Keywords**

mSASSS, ankylosing spondylitis, deep learning



## Intra-articular corticosteroids for sacroiliitis in treatment of spondyloarthritis

Pallavi Vij¹, Rudra P Goswami¹, Danveer Bhadu¹, Uma Kumar¹

¹ Rheumatology, All India Institute of Medical Sciences, New Delhi, India

#### Background

Management of sacroiliitis in patients of spondyloarthritis (SpA) includes physiotherapy, NSAIDs and biologics. Intra-articular corticosteroid injection in sacroiliac (SI) joints is an underutilized procedure. The present study investigates its effectiveness among patients with SpA.

#### **Methods**

Patients with SpA attending the Department of Rheumatology, AIIMS, New Delhi were screened for inclusion using the following criteria: ASAS criteria for spondyloarthritis; predominant axial involvement; imaging evidence of active sacroiliitis; sacroiliac joint tenderness. Patients with any contraindication towards intra-articular procedure were excluded. Intra-articular triamcinolone acetonide 40 mg was administered in the sacroiliac joints with or without sonographic (USG) guidance. Baseline pain VAS and BAS-DAI were obtained and repeated at 7 days, 3 months and 6 months.

#### **Results**

A total of 50 SI joints (26 patients, 25 male, mean age of 26.4 ±7.7 years, mean disease duration 6.1±3.2 years) were injected (38 USG guided and 12 blind). Baseline BASDAI was 4.5±1. Mean pain VAS was reduced from baseline to all points of follow-up (baseline: 8.26 ± 0.8 (n=50), 4.8±2.2 (7th day, n=50), 4.3±1.99 (1st month, n=42) and 5.6±2.5 (3rd month, n=30), all p<0.0001 compared to baseline). Immediate response was not seen in six patients and 44 patients had a durable response (88%, 95% confidence interval (CI): 76.2-94.4) which lasted till 3-months in 20%, till 6-months in 12% and beyond six-months in 12%. Median duration of response was 75 days (95%CI: 54-96). Relapse after initial response was seen in 16 patients (36.4%, 95% CI: 23.7-51.1). In Cox regression, patients with early response had a lesser chance of relapse (Table 1). There were no significant adverse effects.

#### Conclusions

Intra-articular steroid injection is an effective and safe treatment alternative in spondyloarthritis with sacroiliitis and can be performed with or without USG guidance and can be tried in patients who cannot immediately afford biologics or as a bridging therapy for biologics.

#### Figure & Table

Independent variables	Hazard ratio	95% CI	P – value
Age	0.98	0.9–1.06	0.56
Disease duration	1.11	0.91-1.35	0.30
Baseline BASDAI	0.99	0.58-1.67	0.96
Percentage reduction of pain VAS by 7 days			0.007
<25%	Refer	ence categor	y
25-50%	0.08	0.02-0.39	0.002
>50%	0.27	0.06–1.1	0.06
Method (USG versus Blind)	0.87	0.17-4.42	0.86

Table. Multivariate Cox Proportional Hazard model predicting relapse by 3 months of follow up after SI joint injection

#### **Keywords**

Sacroiliac joint, spondyloarthritis, intra-articular corticosteroids



## Drug retention of biologic agents in Korean patients with psoriatic arthritis

<u>Ju Yeon Kim¹</u>, Min Jung Kim², Sun Im Yun², So Young Park², Jiyu Sun³, Jung Hee Koh⁴, Hyoun-Ah Kim⁵, Jinhyun Kim⁶, Kichul Shin²

 ¹ Division of Rheumatology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Republic of Korea
 ² Division of Rheumatology, Department of Internal Medicine, Seoul Metropolitan Government-Seoul National Boramae Medical Center, Seoul, Republic of Korea
 ³ Medical Research Collaborating Center, Seoul Metropolitan Government-Seoul National Boramae Medical Center, Seoul, Republic of Korea
 ⁴ Division of Rheumatology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

⁵ Division of Rheumatology, Department of Internal Medicine, Ajou University Hospital, Suwon, Republic of Korea

⁶ Division of Rheumatology, Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon, Republic of Korea

#### Background

Clinical studies of psoriatic arthritis (PsA) in Korea are scarce than those of ankylosing spondylitis (AS), especially regarding biologic therapy. We aimed to investigate the clinical characteristics and drug retention of biologics in patients with PsA registered in a nationwide cohort.

#### **Methods**

We analyzed the data of KOBIO-PsA (Dec 2012-Jan 2022) including demographics, disease activity and concomitant medications, and drug survival of biologic therapy. Patients were divided into two groups: patients initially registered as anti-TNF users (group A) and anti-IL-17 or anti-IL-12/13 users (group B). Reasons of switching or discontinuation were also assessed . Kaplan-Meier curve for drug survival was plotted in total subjects, by group, and according to line of biologic therapy.

#### **Results**

Among a total of 107 patients, 53.2% were males and the mean age was 43.7 years. Twenty-five percent of patients had spondyloarthritis. Baseline demographic and clinical characteristics were comparable between group A and B, except for a longer disease duration in group B (p= 0.020). Psoriasis was present in 95.6% (group A), and 100% (group B). The most used first- and second-line biologic agent were Humira (46.0%) and Cosentyx (47.8%), respectively. Methotrexate was prescribed with biologics in 77.6% of cases. Oral glucocorticoid was continued in 49.5% of patients (mean daily dose of prednisolone or its equivalent 5.99 mg). The overall drug survival of biologic agents after 60 months was 41% in the study patients (Figure). The

P-value of log-rank test of second- and third or more-line therapy comparing with first-line therapy was 0.5839 and 0.5022, respectively.

#### Conclusions

Oral glucocorticoid use is yet prevalent in PsA patients, contrary to treatment guidelines. Biologic therapy retention in Korean patients with PsA is substantially lower than what is in the literature of AS, despite the limited choice of agents in terms of mode of action.

#### **Figure & Table**




Figure. Drug survival of biologic therapy in Korean patients with PsA

#### **Keywords**

Psoriatic arthritis, KOBIO Registry



## Safety profile of Ixekizumab for the treatment of psoriatic arthritis and axial spondyloarthritis up to 3 Years: An updated integrated safety analysis

Sergio Schwartzman¹, Atul Deodhar², Bernard Combe³, Ana Accioly⁴, Andris Kronbergs⁴, Boris Janos⁴, Danting Zhu⁴, David Sandoval⁴, Proton Rahman⁵, Denis Poddubnyy⁶, <u>Young In Eom</u>⁷

¹ Rheumatology, The Hospital for Special Surgery, USA
 ² Rheumatology, Oregon Health & Science University, USA
 ³ Rheumatology, Montpellier University, France
 ⁴ Rheumatology, Eli Lilly and Company, USA
 ⁵ Rheumatology, Memorial University of Newfoundland, Canada
 ⁶ Rheumatology, Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Germany
 ⁷ Rheumatology, Lilly Korea Ltd, Republic of Korea

Background

We report ixekizumab (IXE) safety outcomes with over 2000patient-years (PY) of exposure up to 3years in patients with psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).

#### **Methods**

Long-term safety of IXE was assessed from 8 randomized trials. Treatment-emergent adverse events (TEAEs) adjusted incidence rates (IRs) per 100PY within 1-year time periods through 19 March 2021 were calculated for all patients treated with  $\geq$ 1 dose of IXE.

#### **Results**

Overall, 1401 PsA and 932 axSpA patients with a cumulative IXE exposure of 2247.7PY and 2096.2PY, respectively, were included in this analysis. IRs per 100PY for any TEAE were 50.3 for PsA and 38.1 for axSpA. Serious AEs were reported by 134 PsA patients (IR=6.0), and 101 axSpA patients (IR=4.8). Nine deaths were reported (6 in PsA [IR=0.3] and 3 in axSpA [IR=0.1]). IRs per 100PY of discontinuation from the study drug due to AE were 5.1 (PsA) and 3.1 (axSpA). IRs of serious infections were low (PsA: IR=1.2, axSpA: IR=1.1). IRs of opportunistic infections (PsA: IR=1.8, axSpA: IR=0.8) and Candida infections (PsA: IR=2.0, axSpA: IR=1.2) were low. There were no confirmed cases of reactivation of tuberculosis. Injection-site reactions occurred with IRs of 11.6 (PsA) and 7.4 (axSpA). IRs for allergic/hypersensitivity reactions were 4.5 (PsA) and 4.2 (axSpA). No confirmed events of anaphylaxis were reported. Across indications, IRs were low for cytopenia ( $\leq 2.5$ ), malignancies (≤0.7), major adverse cerebro-cardiovascular event ( $\leq 0.5$ ), depression ( $\leq 1.6$ ), and iridocyclitis ( $\leq 2.8$ ). Per external adjudication, 20 patients had inflammatory bowel disease (3 patients with PsA and 17 with axSpA) of which 1 was ulcerative colitis for PsA (IR=0.0) and 10 for axSpA (IR=0.5); 2 events were Crohn's disease for PsA (IR=0.1) and 7 for axSpA (IR=0.3).

#### Conclusions

IXE maintained a safety profile consistent to that previously reported, with no new or unexpected safety events through exposure up to 3years.

#### **Keywords**

Ixekizumab, Axial spondyloarthritis, Psoriatic arthritis



<u>KCR 2022</u>

May 19(Thu) - 21(Sat), 2022

## A comparison of physical functions and its relationship with disease activity of persons with ankylosing spondilitis

#### Aysenur Kara¹

¹ Department of Family Physicians, Atatürk University, Turkey

#### Background

We aimed to examine how physical function is affected in individuals with Ankylosing Spondylitis (AS) and its relationship with disease activity.

#### **Methods**

148 patients diagnosed with AS and 63 healthy individuals were included in this study. Activity classification was made based on the BASDAI score: disease activity in the AS group, no activity (BASDAI =0), mild activity (BASDAI 1–2), moderate activity (BASDAI 3–5), high activity (BASDAI) according to the Bath AS disease activity index (BASDAI). BASDAI >5). Cases in both groups filled out a questionnaire including demographic characteristics and the SF-36's Physical Function and Physical Role sub-domains, and Sit to Stand test, Timed Up and Go test were performed.

#### **Results**

148 patients with AS (mean age: 48.12+/- 10.52 years) and 63 healthy subjects (44.38+/- 9.8 years) participated in this study. There was no significant difference between the groups in terms of age and gender. When the groups are compared; Sit to Stand test, Timed Up and Go test, Physical Function and Physical Role subdomain scores of SF-36 were found to be statistically lower in patients with BD than healthy subjects (Respectively; t= -5.15, p< 0.0001; t= -6.38, p< 0.0001; t=5.87, p< 0.0001; t=6.48, p< 0.0001). There were 67 patients with a BASDAI =0, 39 patients with a BASDAI 1-2, 28 patients with a BASDAI 3-5, and 14 patients with a BASDAI >5. As the disease activity increased, there was a high negative correlation in Sit to Stand test, Timed Up and Go test scores, and a highly positive correlation in SF-36's Physical Function and Physical Role subdomain scores (r=-0.743 p<0.001; r=-0.782) , p < 0.001; r=0.756, p<0.001; r=0.801, p<0.001).

#### **Conclusions**

According to the results obtained, it was determined that there was a significant decrease in physical capacity in AS patients compared to healthy individuals.

# **E-poster Presentation**

Behçet's disease & Vasculitis

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



KCR 2022 May 19(Thu) - 21(Sat), 2022

P-057

## Diagnostic value of 3D T1-weighted sampling perfection with application optimized contrast evolution (SPACE) magnetic resonance imaging in patients with giant cell arteritis

Recep Sade¹, Meltem Alkan melikoglu²

¹ Radiology, Ataturk University, Turkey ² Rheumatology, Ataturk University, Turkey

#### Background

Imaging techniques have an increasing place in the diagnosis of giant cell arteritis (GCA). Achieving a confident diagnosis of GCA is often challenging and temporal artery biopsy is still considered as the gold standard despite the delayed results. The aim is evaluate 3D T1 weighted sampling perfection with application optimized contrast evolution MRI (SPACE) sequences for diagnosis of giant cell arteritis

#### **Methods**

Ten patients with clinically suspected GCA were included and 4 had a diagnosis of GCA. We evaluated the diagnostic performance of fat-suppressed 3D T1 SPACE with 3D time of flight (TOF) coregistration

#### **Results**

Sensitivity and specificity of 3D T1 SPACE were 70% and 100% respectively. Therefore, the positive predictive value of post contrast 3D T1 SPACE was 100% and the negative predictive value was 80%. Intra- and inter-observer agreement for mural enhancement on 3D T1 SPACE was 1 and 1, respectively.

#### Conclusions

We demonstrate that 3D T1 SPACE is accurate for the diagnosis of GCA. The reproducibility and, short, scan duration of the technique support a wider use of MRI in the diagnosis process.

#### **Keywords**

giant cell arteritis, magnetic resonance imaging, diagnosis



<u>KCR 2022</u>

May 19(Thu) - 21(Sat), 2022

## Determination of the frequency of entositis and its relationship with disease activity in Behçet's disease by ultrasonography

#### Serhat Kaya¹

¹ Department of Radiology, Tunceli Devlet Hastanesi, Turkey

#### Background

Evaluation of the relationship between the frequency of enthesitis and disease activity in Behçet's disease by ultrasonography

#### **Methods**

86 Behçet's patients were included as the study group and 26 healthy individuals were included as the control group. Ultrasonography was performed on bilateral proximal plantar fascia, Achilles tendon, proximal and distal patellar ligament, distal quadriceps and brachial triceps tendons of all patients. Entezeal regions were evaluated according to thickness, structure, calcification, erosion, bursitis and power Doppler signals and scored according to the Madrid Sonographic Enthesitis index (MASEI). Activity classification was made based on the Behçet's Disease Instant Activity Form (BHAAF) score: no activity (BHAAF=0), mild activity (BHAAF 1–2), moderate activity (BHAAF 3–5), high activity (BHAAF 6–12).

#### **Results**

There was no significant difference between the groups in terms of age and gender. The mean total enthesitis score was found to be  $18.2\pm9.1$  in Behçet's patients and  $2.0\pm1.8$ in healthy individuals out of a maximum possible total of 136 points. According to MASEI, a significant difference was found between Behçet's patients and the control group (p<0.001). There were 38 patients with BHAAF=0, 23 patients with BHAAF 1–2, 17 patients with BHAAF=0, 23 patients with BHAAF 1–2, 17 patients with BHAAF 3–5, and 8 patients with BHAAF 6–12. MASEI scores, respectively; It was  $8.6\pm3.8$ ,  $14.6\pm5.7$ ,  $19.6\pm8.3$ ,  $21.6\pm11.3$ . There was a significant and strong correlation between disease activity and enthetic scores (r=0.824, p<0.0001).

#### Conclusions

The frequency of enthesitis is significantly increased in Behçet's disease, and there is a strong linear relationship between disease activity and the frequency of enthesitis.



KCR 2022

May 19(Thu) - 21(Sat), 2022

## NeuroBehçet with spinal leptomeningeal involvement

#### Oğuzhan Mete¹, Gökhan Polat²

¹ medical faculty, Atatürk University, Turkey ² Department of Radiology, Ataturk University, Turkey


#### **Description**

A 28-year-old male patient, who was diagnosed with Behçet's disease for 2 years and followed up with uveitis, was admitted to our hospital with the complaint of severe headache. The patient was receiving adalimumab treatment. Pain increased with head and neck movements. Lumbar puncture was performed on the patient with the suspicion of meningitis. However, there was no increase in microprotein in favor of meningitis. Brain and spinal MRI was planned for Neurobehçet and methylprednisolone was started. In the MRI of the patient, there was an increase in signal on T2-weighted images in the basal ganglia and mesencephalon of the brain parenchyma. In the spinal MRI of the patient, leptomeningeal enhancement was observed. With the present findings, the patient was evaluated in favor of neurobehçet and neurobehçet spinal involvement.

#### Conclusions

Neurobehçet should definitely be evaluated with radiological imaging methods in the headache clinic in patients followed up for Behçet's disease. Leptomeningeal involvement should be considered in the differential diagnosis even if the LP is normal, and MRI with spinal contrast should be performed on the patient.

#### **Figure & Table**





# Investigation of the frequency of varicocele in Behçet's disease

Cafer Koçak¹, Halid Yener¹, Emre Işıktaş¹

¹ Department of Radiology, Atatürk University, Turkey

#### Background

Determining the effect and relationship of Behçet's disease, which is an important cause of systemic vasculitis, with varicocele, which is an important predisposing factor in male infertility.

#### **Methods**

Study groups consisted of 67 BD and 42 healthy controls without the rheumatologic disease. Scrotal physical examination and Doppler ultrasonography were performed by two doctors, unaware of the patient's diagnosis, respectively. Varicocele frequencies were determined and the correlation between physical examination and ultrasonographic examination was calculated. Panpiniform plexus diameter >3mm was evaluated as varicocele. In addition, reflux was evaluated with the Valsalva maneuver.

#### Results

There was no significant difference between the groups in terms of age. Varicocele was detected by a physical examination in 41.8% (n=28) in the BD group and 19% (n=8) in healthy controls. In Doppler ultrasonography, these rates were 59.7% (n=40), and 26.1% (n=11), respectively. Valsalva and reflux in pampiniform plexuses were 26.8%(18) in Behçet's patients and 7.1%(3) in the healthy population. detected. The odds ratio for the risk of developing varicocele in BD patients compared to healthy controls was 3.42. While the mean pampiniform plexus diameter was 3.6mm in BD patients, it was 1.95mm in the healthy population. There was a significant difference between the two groups (p=0.032). A high level of agreement was found between physical examination results and Doppler ultrasonographic examination results (kappa value=0.702).

#### Conclusions

The frequency of varicocele in BD was found to be increased compared to the healthy control group. Considering the negative effects of this finding on male infertility, Behçet's disease may affect male infertility.



# The relationship of venous involvement with disease activity in Behçet's syndrome

Muhammed Halid Yener¹, Emre Isıktas¹, Cafer Koçak¹

¹ Department of Radiology, Atatürk University, Turkey

#### Background

In this study, we examined the disease activity levels of Behçet's patients with lower extremity DVT and examined the relationship.

#### **Methods**

186 patients with BS were included in the study. (163 M/23 F) Behçet's disease activity levels, Venous Clinical Severity Score (VCSS) were used. The presence of DVT of the patients was evaluated by Doppler ultrasonography. Activity classification was made based on the Behçet's Disease Instant Activity Form (BHAAF) score: no activity (BHAAF=0), mild activity (BHAAF 1–2), moderate activity (BHAAF 3–5), high activity (BHAAF 6–12).

#### Results

There was no significant difference between the groups in terms of age and gender. There were 76 patients with BHAAF=0, 49 patients with BHAAF 1–2, 37 patients with BHAAF 3–5, and 24 patients with BHAAF 6–12. The number of patients with DVT detected by Doppler ultrasonography in these groups, respectively; 6(7.9%), 9(18.3%), 8(21.6%), 7(29.1%). Venous Clinical severity score in patients with DVT diagnosed with BD, respectively; It was  $5.4\pm4.9$ ,  $6.2\pm5.8$ ,  $5.7\pm5.4$ ,  $6.8\pm6.3$ . There was a significant but moderate correlation between disease activity and DVT (r:0.486, P<0.01). There was no significant correlation between disease activity and venous clinical severity in patients with DVT (p=0.68).

#### Conclusions

Disease activity increases the risk of DVT but does not affect venous clinical severity in patients with DVT.



# Serum albumin, prealbumin, and ischemia-modified albumin levels in patients with ANCA-associated vasculitis: a prospective cohort study

Sung Soo Ahn¹, Taejun Yoon², Jason Jungsik Song², Yong-Beom Park², Sang-Won Lee²

¹ Internal Medicine, Division of Rheumatology, Yongin Severance Hospital, Yonsei University College of Medicine, Republic of Korea ² Internal Medicine, Division of Rheumatology, Severance Hospital, Yonsei University College of Medicine, Republic of Korea

## Background

Acute phase reactants (APRs) are proteins altered by inflammation and are regarded as surrogate markers representing inflammatory status. This study evaluated changes of albumin (Alb), prealbumin (Palb), and ischemia-modified albumin (IMA) in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) in response to alterations in disease activity and the correlation between disease activity and Alb, Palb, and IMA.

## **Methods**

Fifty-nine patients with AAV registered in the prospective SHAVE cohort, who had available serial blood samples at least three months apart were included (indicated as pre and post). Correlation analysis and linear regression were carried out to determine the relationship between continuous variables. Alb, Palb, and IMA levels in 40 healthy controls (HCs) were compared with patients with AAV.


## **Results**

Comparison of Alb, Palb, and IMA levels in HCs and in patients at initial (pre) and follow-up (post) time points revealed that Alb levels significantly increased following the improvement of disease activity and were comparable between HCs and patients at follow-up (post). Meanwhile, there was no significant difference noted in Palb and IMA levels after the decrease of disease activity. While initial (pre) Alb and Palb were significantly associated with BVAS, a subgroup analysis of patients with new-onset disease showed Palb was no longer significantly associated with Birmingham Vasculitis Activity Score (BVAS). Multivariate linear regression showed Alb level (standardized  $\beta$ =-0.377; 95% confidence interval: -5.623, -1.260; p=0.003) was an independent predictor of BVAS.

# Conclusions

Among Alb, Palb, and IMA, we found that Alb could be a useful marker indicating disease activity.

# Figure & Table



### **Keywords**

antineutrophil cytoplasmic antibody, albumin, prealbumin



KCR 2022 May 19(Thu) - 21(Sat), 2022

P-063

# Comparison of physical functions of people with Behçet's disease and healthy and their relationship with disease activity

# Yusuf Geylani¹

¹ internal medicine department, Bitlis State Hospital, Turkey

## Background

We aimed to examine how the physical function is affected in individuals with BD.

## **Methods**

Patients diagnosed with BD and healthy individuals were included in this study. Activity classification was made based on the Behçet's Disease Instant Activity Form (BHAAF) score: no activity (BHAAF=0), mild activity (BHAAF 1–2), moderate activity (BHAAF 3–5), high activity (BHAAF 6–12). Subjects in both groups filled out a questionnaire containing questions about demographic characteristics and SF-36's Physical Function and Physical Role subdomains.

#### **Results**

There was no significant difference between the groups in terms of age and gender.82 patients with BD (mean age: 42.12+/- 9.48 years) and 36 healthy subjects (40.38+/- 9.52 years) participated in this study. Body mass index values were similar in both groups. When the groups are compared; Sit to Stand test, Timed Up and Go test, Physical Function and Physical Role subdomain scores of SF-36 were found to be statistically lower in patients with BD than healthy subjects (Respectively; t= -3.14, p= 0.00024; t = -3.39, p= 0.00018; t= 5.87, p< 0.0001; t=4.88, p< 0.0001). There were 36 patients with BHAAF=0, 22 patients with BHAAF 1-2, 14 patients with BHAAF 3-5, and 10 patients with BHAAF 6-12. As disease activity increased, there was a high negative correlation in Sit to Stand test, Timed Up and Go test scores, and a highly positive correlation in SF-36's Physical Function and Physical Role subdomain scores (r=-0.603 p<0.001; r=-0.648). , p < 0.001; r=0.678, p<0.001; r=0.634, p<0.001).

#### Conclusions

According to the results obtained, it was determined that there was a significant decrease in physical capacity in patients with BD compared to healthy individuals. In addition, as the disease activity increases, the decrease in physical capacity increases.



# COVID-19 vaccination related small vessel vasculitis with multi-organ involvement

# Yunkyung Kim¹, Geun-Tae Kim¹

¹ Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Republic of Korea

#### **Description**

Since its first outbreak in 2019, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has been ongoing, and the pandemic is not over yet. Vaccines developed against COVID-19 have been approved and widely used since 2020; however, vaccine safety concerns need to be addressed. Autoimmune symptoms have been reported as a side effect of many COVID-19 vaccines. In particular, several cases of COV-ID-19 vaccine-induced vasculitis have recently been reported. We report the case of a 77-year-old woman who developed small-vessel vasculitis with multi-organ involvement after receiving the Pfizer-BioNTech COVID-19 vaccine. She experienced general weakness, dyspnea and acute renal injury after vaccination. It was diagnosed with conjunctivitis, otitis media, livedo reticularis, acute interstitial pneumonia and pauci-immune crescentic glomerulonephritis suggestive multi-organ involved small vessel vasculitis (Fig 1).

#### Conclusions

We believe that this case, with its radiological and histological findings, will help in the management of vaccine-induced vasculitis in the future.

# Figure & Table




Figure. A. tympanogram of left ear B. CT image of chest C. image of PET-CT D. microscopy of glomerulus

#### **Keywords**

COVID-19 vaccine, small vessel vasculitis, multiorgan involvement



# **BVAS version 3 and BVAS/GPA**

# Jangwoo Ha¹, Sung Soo Ahn¹, Yong-Beom Park^{1,2}, Sang-Won Lee^{1,2}

¹ Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Republic of Korea ² Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Republic of Korea

#### Background

Birmingham vasculitis activity score (BVAS) version 3 (BVAS 3.0) and BVAS/Granulomatosis with polyangiitis (BVAS/GPA) are used as indicators of disease activity in anti-neutrophil cytoplasmic antibody-associated vasculitis. We evaluated the association between these indices and the significance in patients with GPA and microscopic polyangiitis (GPA/MPA).

#### **Methods**

We retrospectively reviewed the records of 203 patients with GPA/MPA in our hospital. The correlation between BVAS 3.0 and BVAS/GPA with the five-factor score (FFS) and laboratory data was investigated. The episodes of all-cause mortality, end-stage renal disease, and disease relapse were counted as adverse clinical outcomes. Multivariate Cox hazard analyses were performed to assess the relationships between both indices and patient outcomes.

#### **Results**

Sixty-five (32.0%) and 138 (68.0%) patients with GPA and MPA were included. The median BVAS 3.0 was significantly higher in patients with MPA than in those with GPA (13.0 vs. 11.0, p=0.015), whereas BVAS/GPA was higher in patients with GPA (4.0 vs. 3.0, p=0.001). BVAS 3.0 and BVAS/ GPA correlated significantly (r=0.670, p<0.001); both BVAS 3.0 and BVAS/GPA were shown to be associated with the outcomes investigated in separate Cox models. However, the correlation between BVAS 3.0 and BVAS/GPA was especially higher in a subgroup of patients with MPA than in those with GPA (MPA: r=0.817, p<0.001 vs. GPA: r=0.570, p<0.001) and with renal involvement (r=0.676, p<0.001).

## Conclusions

Although both BVAS 3.0 and BVAS/GPA significantly correlated and predicted outcomes well in those with GPA/ MPA, a discord was observed based on disease subtypes and organ involvement.

## **Figure & Table**

	BVAS version 3	BVAS/GPA	FFS	WBC count	Platelet count	ESR	CRP
BVAS version 3	n/a						
BVAS/GPA	0.670 (<0.001)	n/a					
FFS	0.416 (<0.001)	0.317 (<0.001)	n/a				
WBC count	0.182 (0.009)	0.248 (<0.001)	0.168 (0.017)	n/a			
Platelet count	0.062 (0.378)	0.138 (0.049)	0.031 (0.658)	0.479 (<0.001)	n/a		
ESR	0.158 (0.024)	0.129 (0.067)	0.144 (0.040)	0.287 (<0.001)	0.503 (<0.001)	n/a	
CRP	0.263 (<0.001)	0.283 (<0.001)	0.220 (0.002)	0.426 (<0.001)	0.450 (<0.001)	0.570 (<0.001)	n/a

Table. Correlation analysis between BVAS version 3, BVAS/ GPA, FFS, and laboratory data

Data are presented as correlation coefficient and p-value. BVAS: Birmingham vasculitis activity score; GPA: Granulomatosis with polyangiitis; FFS: Five-factor score; WBC: White blood cell; ESR: Erythrocyte

sedimentation rate; CRP: C-reactive protein.

#### **Keywords**

antineutrophil cytoplasmic antibody associated vasculitis, Birmingham vasculitis activity score version 3, Birmingham vasculitis activity score/Granulomatosis with polyangiitis



# Application of the 2022 new criteria for microscopic polyangiitis to patients with previously diagnosed microscopic polyangiitis

Jung Yoon Pyo¹, Sung Soo Ahn¹, Jason Jungsik Song¹, Yong-Beom Park¹, Sang-Won Lee¹

¹ Internal Medicine, Yonsei University College of Medicine, Republic of Korea

## Background

In 2022, the ACR and European Alliance of Associations for Rheumatology proposed new classification criteria for AAV (the 2022 ACR/EULAR criteria). This study applied the 2022 ACR/EULAR criteria to Korean patients with previously diagnosed MPA based on the old criteria to investigate the number of patients who could be reclassified as having MPA.

## **Methods**

One-hundred seventeen patients with MPA, who met the 2007 EMA algorithm and the 2012 CHCC definitions, were included in this study. They were reclassified based on the 2022 ACR/EULAR classification criteria.

## **Results**

Of the 117 patients, 113 patients (96.6%) were reclassified as having MPA. Of the 117 patients included in the study, there were three MPO-ANCA negative patients, all of which were not classified as MPA by the 2022 ACR/EULAR criteria. Furthermore, there were four patients having both MPO-ANCA and PR3-ANCA, three of them met both MPA and GPA criteria based on the 2022 ACR/EULAR criteria.

## Conclusions

The concordance rate between the 2022 ACR/EULAR criteria and both the 2007 EMA algorithm and the 2012 CHCC definitions was 96.6%. The 2022 ACR/EULAR criteria have several issues, in particular, those regarding a too high assigned score to MPO-ANCA and ignorance of MPA-specific histopathologic findings. Therefore, we suggest that the 2007 EMA algorithm and the 2012 CHCC definitions be applied as supplementary classification criteria in these difficult cases.

# Figure & Table

Variables		Values
At the time of enrolment in the cohort	Score	
Items for the 2022 ACR/EULAR criteria for MPA and assigned scores to each item (N (%))		
Clinical criteria		
Nasal involvement (discharge, ulcers, crusting, congestion, septal defect/perforation)	-3	1 (0.9)
Laboratory, imaging and biopsy criteria		
MPO-ANCA (or P-ANCA) positivity	+6	114 (97.4)
Fibrosis or interstitial lung disease on chest imaging	+3	58 (49.6)
Pauci-immune glomerulonephritis on biopsy	+3	61 (52.1)
PR3-ANCA (or C-ANCA) positivity	-1	4 (3.4)
Serum eosinophil count $\geq 1000/\mu L$	-4	5 (4.3)
Total score for 6 items above		9.0 (3.0)
Patients with total score $\geq 5$ (N (%))		113 (96.6)

Table. Frequencies of each criterion of the 2022 ACR/EU-LAR criteria for MPA fulfilled by patients with previously diagnosed MPA (N=117)

Values are expressed as number (percentage).

ACR: American College of Rheumatology; EULAR: European Alliance of Associations for Rheumatology; MPA: microscopic polyangiitis; MPO: myeloperoxidase; P: perinuclear; PR3: proteinase 3; C: cytoplasmic.

## **Keywords**

Microscopic polyangiitis, 2022 ACR/EULAR classification criteria



KCR 2022

May 19(Thu) - 21(Sat), 2022

# Effect of the number of metabolic syndrome components on all-cause mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis

# PIL GYU Park¹

¹ Department of Rheumatology, Severance Hospital, Republic of Korea

#### Background

AAV and metabolic syndrome both are systemic inflammatory disease that can increase the incidence of all-cause mortality. Since inflammation is associated with obesity, insulin resistance, cardiovascular risks, and MetS, it can be hypothesised that patients with AAV may have an increased incidence of MetS. We recently demonstrated that the prevalence of MetS was significantly higher in Korean patients with AAV than in healthy controls. in this study, we investigated the effect of MetS severity, assessed according to the number of MetS components, on all-cause mortality in AAV patients diagnosed with MetS at the time of AAV diagnosis.

#### **Methods**


This study included 186 patients with AAV and age, sex, smoking history, and body mass index (BMI), MetS components, and MetS diagnosis were also obtained. MetS was diagnosed when three or more of the following five MetS components for Asians were present: increased waist circumference, high blood pressure, hypertriglyceridaemia, low level of high-density lipoprotein, and impaired fasting glucose or T2DM.

#### **Results**

Seven patients (3.8%) had all five MetS components, 30 (16.1%) had four components, 56 (30.1%) had three components, 26 (14.0%) had one component, and 11 (5.9%) had no MetS component. There were also no significant differences in cumulative survival rates during the follow-up among AAV patients with zero to five MetS components at baseline. Among 93 of AAV patient whom were diagnosed with MetS, as the number of MetS components increased, the cumulative patient survival rate significantly decreased. Moreover, AAV patients with MetS who had all five MetS components were approximately 62 times more susceptible to all-cause mortality than those who had only three components.

#### Conclusions

The presence of many MetS components at the initial diagnosis of AAV is an independent and significant predictor of all-cause mortality in AAV patients with MetS. Therefore, the presence or absence of MetS should be confirmed at diagnosis.



# Figure & Table

Figure. Comparison of cumulative survival rates in AAV patients with MetS

#### **Keywords**

antineutrophil cytoplasmic antibody, vasculitis, metabolic syndrome



# Aortic involvement as a rare complication of granulomatosis with polyangiitis: a case report

# Su Jin Choi¹, Doo Ho Lim1, Seung Won Choi¹

¹ Rheumatology, Ulsan University Hospital, University of Ulsan College of Medicine, Republic of Korea

#### **Description**

Granulomatosis with polyangiitis (GPA) affects small and medium-sized vessels and rarely involves the aorta. We report a case of a 50-year-old man who presented an aortic involvement as the initial presentation of GPA along with the involvement of the upper and lower respiratory tract. He visited our hospital with pain and morning stiffness in the bilateral shoulder and hip girdle for a year. He also complained of weight loss and mild lower abdominal pain. Computed tomography (CT) scan demonstrated pulmonary nodules in both lower lobes and mildly dilated abdominal aorta with mural thrombosis. Polymyalgia rheumatica was suspected based on clinical symptoms and elevated inflammatory markers, and symptoms improved rapidly after empirical glucocorticoid treatment. However, pulmonary nodules increased with cavity formation three months later. Transbronchial lung biopsy revealed chronic lymphocytic inflammation with necrosis. The tissue polymerase chain reaction test for tuberculosis was negative, but the interferon-gamma release assays were positive. The test for anti-proteinase 3 (PR3) antibodies was positive with titers of 4.4 IU/mL. The patient was treated with anti-tuberculosis drugs over a month. However, follow-up CT scans showed an increase in the size of pulmonary nodules and an abdominal aortic aneurysm. Periaortic soft tissue thickening involving aortic arch and nasal septal perforation were also newly identified. GPA was diagnosed by video-assisted thoracoscopic surgery (VATS) wedge biopsy. He was started on high-dose glucocorticoid treatment while excluding infection conditions by blood culture, and his clinical and radiological findings improved three weeks later. Since then, improvement has been maintained with cyclophosphamide and glucocorticoid treatment.

## Conclusions

This case suggests that aortic involvement can occur as an unusual complication of GPA.

#### **Keywords**

Granulomatosis with polyangiitis, Aortic aneurysm, Periaortitis



KCR 2022

May 19(Thu) - 21(Sat), 2022

# ANCA sero-positivity and AAV occurrence after SARS-CoV-2 infection

<u>Eunju Lee^{1,2}</u>, Wooyong Jeong³, Jung Yoon Pyo¹, Jason Jungsik Song^{1,4}, Yong-Beom Park^{1,4}, Su Jin Jeong⁵, Sang-Won Lee^{1,4}

¹ Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Republic of Korea
 ² Division of Rheumatology, Department of Internal Medicine, Dongguk University Ilsan Hospital, Republic of Korea
 ³ Division of Infectious Diseases, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Republic of Korea
 ⁴ Institute for Immunology and Immunological Diseases, Yonsei University College of Medicine, Republic of Korea
 ⁵ Division of Infectious Diseases, Department of Internal Medicine, Yonsei University College of Medicine, Republic of Korea

#### Background

The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has been linked to the onset or worsening of autoimmune diseases (1). Previously reported cases of new-onset antineutrophil cytoplasmic antibody (AN-CA)-associated vasculitis (AAV) following SARS-CoV-2 infection raised the possibility of SARS-CoV-2 infection as a trigger for AAV, by provoking the formation of autoantibodies (2, 3).

#### **Methods**

We investigated the prevalence of proteinase 3 (PR3)-AN-CA and myeloperoxidase (MPO)-ANCA in 187 patients with polymerase chain reaction-confirmed SARS-CoV-2 infection who were admitted to Yonsei University Severance Hospital from June 2020 to October 2021. Blood samples were collected between 14 and 30 days after the onset of the first symptoms. PR3- and MPO-ANCA levels were measured using enzyme-linked immunosorbent assay (ELISA) kits (Euroimmun, Lübeck, Germany) according to the manufacturer's protocol. Electronic medical records of the patients were retrospectively reviewed.

#### Results

Overall, 18.5% of the tested patients were confirmed positive for ANCAs, with PR3 and MPO accounting for 42.4% and 66.7%, respectively. Of 33 patients who were positive for ANCAs, 31 patients were classified as GPA (12 patients) or MPA (20 patients) based on 2022 ACR/EULAR classification criteria. One patient satisfied both criteria for GPA and MPA, and no patient was classified as EGPA. There was no significant association between ANCA status and mechanical ventilation (OR: 1.11, 95% CI: 0.50–2.48, P = 0.837) or death (OR: 2.18, 95% CI: 0.53–8.14, P = 0.387).

## Conclusions

A high prevalence of ANCAs among hospitalized patients with SARS-CoV-2 infection was observed. Although the AN-CA-positivity is not significantly associated with the prognosis, most of the sero-positive patients were classified as AAV according to 2022 ACR/EULAR classification criteria. Long-term follow-up may be needed for the development of clinical manifestations and the levels of antibodies.

# Figure & Table

Variables	GPA	MPA	EGPA	Values
At the time of first symptom				
Clinical criteria				
Nasal involvement	+3	-3		0
Cartilaginous involvement	+2			0
Conductive or sensorineural hearing loss	+1			0
Obstructive airway disease			+3	3 (9.1)
Nasal polyp			+3	0
Mononeuritis multiplex			+1	0
Laboratory criteria				
PR3-ANCA positivity	+5	-1	-3	14 (42.4)
MPO-ANCA positivity	-1	+6		22 (66.7)
Serum eosinophil $\geq 1000/\mu L$	-4	-4	+5	2 (6.1)
Hematuria ≥ 10 RBC/HPF			-1	20 (60.6)
Biopsy criteria				
Granuloma, granulomatous inflammation, or giant cells	+2			N/A
Pauci-immune glomerulonephritis	+1	+3		N/A
Extravascular eosinophilic-predominant inflammation			+2	N/A
Imaging criteria				
Pulmonary nodules, mass, or cavitation on chest imaging	+2			3 (9.1)
Fibrosis or ILD on chest imaging		+3		4 (12.1)
Nasal/paranasal sinusitis or mastoiditis on imaging	+1			6 (18.2)
Number of patients with total score $\geq$ 5 for GPA/MPA	12	20	0	Total 31
or $\geq 6$ for EGPA				

Values are expressed as number (percentage).

ACR: American College of Rheumatology; EULAR: European Alliance of Associations for Rheumatology; GPA: granulomatosis with polyangiitis; MPA: microscopic polyangiitis; EGPA: eosinophilic granulomatosis with polyangiitis; SARS-CoV-2: severe acute respiratory syndrome coronavirus-2; ANCA: Antineutrophil cytoplasmic antibody; PR3: proteinase 3; MPO: myeloperoxidase; ILD: interstitial lung disease

Table. Application of 2022 ACR/EULAR criteria for GPA, MPA, or EGPA to patients with SARS-CoV-2 infection and ANCA positivity

#### **Keywords**

Antineutrophil cytoplasmic antibody-associated vasculitis, SARS-CoV-2, Sero-positivity



# New-onset IgA vasculitis in adult patients following SARS-CoV-2 vaccines

Yunjung Choi¹, Wan-Hee Yoo¹

¹ Internal medicine, Jeonbuk National University Hospital, Republic of Korea

#### Description

Recently, the occurrence of autoimmune disease after the COVID-19 vaccination has been reported. Among the autoimmune phenomena following vaccination, we herein report the three cases of new-onset IgA vasculitis.

Our first patient presented 10days after second dose of the AstraZeneca vaccine with purpuric rash on extremities. He developed the abdominal pain and melena several days after and visited our emergency room. The enteritis and mesenteric panniculitis were shown in his abdominal CT and gross hematuria and urine protein-creatinine ratio (UPCR) 3902mg/g was detected. He was started on steroid of 1mg/kg/day and resolved with the therapy. Our second patient complained with abdominal pain, purpura on both lower leg and arthralgia developed 1 day after receiving the first dose of Moderna vaccine. He showed gross hematuria, proteinuria, and elevated level of serum creatinine. He was administrated with steroid of 1mg/kg/ day. A week after discharge, he presented melena due to small bowel bleeding with distal ileum wall thickening. The re-escalation dose of steroid was prescribed to the patient, he showed clinical improvement and discharged. Our third patient presented 14 days after second dose of the Astra-Zeneca vaccine with purpuric rash, myalgia, and melena. The overt hematuria and proteinuria were noted, and his abdominal CT showed enteritis. The empirical high dose steroid therapy was started. However, during hospitalization, he presented massive hematochezia and received small bowel resection from proximal to mid ileum. The histology of resected bowel showed vasculitis. He is being prescribed immunosuppressive agent and low dose steroid on regular-basis follow-up.

#### Conclusions

Although it remains unclear how the COVID vaccination leads the IgA vasculitis development, but our cases suggest that the COVID vaccination is responsible for the occurrence of IgA vasculitis. Therefore, further researches are warranted for the postvaccination monitoring setting regarding development of autoimmune phenomena such as IgA vasculitis after vaccination.

#### **Figure & Table**

Patient Characteristics	Patient 1	Patient 2	Patent 3
Age	60	63	70
Sex	М	М	М
Type of vaccination	ChAdOx1 (Oxford/AstraZeneca)	mRNA- 1273 (Moderna)	ChAdOx1 (Oxford/AstraZeneca)
Time to present symptoms	10 days	1 days	14 days
Baseline Cr level (mg/dL)	0.76	0.67	0.59
Peak Cr level after COVID-19 vaccine (mg/dL)	0.98	1.29	3.34
Gross hematuria before COVID-19 vaccine	0-2/HPF	0-2/HPF	0-2/HPF
Gross hematuria after COVID-19 vaccine	21-50/HPF	21-50/HPF	21-50/HPF
Proteinuria before COVID-19 vaccine	Neg	+	+
Peak UPCR after COVID-19 vaccine	3902	2214	15764
(mg/g) UPCR 2 months after COVID-19 vaccine (mg/g)	584	454	6618
Other clinical symptoms	Purpura, Abdominal pain, Melena	Purpura, Abdominal pain, Melena, Arthralgia	Purpura, Abdominal pain, Melena, Arthralgia, Pulmonary thromboembolism
Current treatment	PD	PD	AZA, PD

Table. Characteristics of new-onset IgA vasculitis after COVID-19 vaccination

#### **Keywords**

IgA vasculitis, COVID-19, Vaccination



# A case of microscopic polyangiitis with periaortitis treated with cyclophosphamide

#### Seoung Wan Nam¹

¹ Rheumatology, Wonju Severance Christian Hospital, Republic of Korea

# Description

Microscopic polyangiitis (MPA) is a rare autoimmune disease that involves small to medium sized vessels. The formation of a large vessel lesion in patients with MPA has been scarcely reported, and it can cause confusion in the diagnosis.

A 73-year-old woman presented with high fever and myalgia that started one month prior. She also complained of headache, dizziness, and exertional dyspnea. Initial blood test revealed increased levels of inflammatory markers. No evidence of the infection was noted despite various efforts including culture tests and imaging studies. However, CT scan showed features of periaortitis with dense aortic wall thickening in descending aorta (Figure 1-A). 18F-FDG PET/ CT showed increased FDG metabolism of the aortic wall. Additional laboratory test results showed positive myeloperoxidase-ANCA. During the work-up period, her general condition deteriorated and showed progressive proteinuria and hematuria with dysmorphic cells. Accordingly, we performed renal biopsy that showed pauci-immune crescentic glomerulonephritis. Final diagnosis of MPA was made and we started cyclophosphamide pulse therapy with high dose glucocorticoid. Afterwards, she gradually showed improvements in both clinical symptoms and laboratory findings. Her proteinuria and hematuria disappeared in 3 months. Follow-up CT scan after total 8 cycles of cyclophosphamide therapy for 5-month duration showed prominently improved periaortitis with minimal periaortic soft tissue densities (Figure 1-B). Thereafter, the patient was well-maintained with azathioprine and low dose glucocorticoid which were all discontinued in 3 years.

# Conclusions

Here, we present an unusual manifestation of MPA that presented with periaortitis, which was successfully treated with cyclophosphamide therapy.

# **Figure & Table**




Figure. Postcontrast CT scans before and after cyclophosphamide pulse therapies

## **Keywords**

Microscopic Polyangiitis, Periaortitis, Cyclophosphamide



# Churg-strauss syndrome presenting as acute abdomen- A case report

#### Subbarayudu Boda¹

¹ General medicine, GITAM Institute of Medical Sciences and Research (GIMSR), India

#### Description

A 40-year-old female came to ER with pain abdomen, vomiting and loose stools for 3 days. Her past history consisted of mild intermittent asthma and hypertension. The patient had symmetric polyarthritis 6 months ago for which she was prescribed steroids. Later patient developed paranesthesia in both upper and lower limbs, right foot drop and progressive distal weakness of both upper and lower limbs. On examination, she had pallor, desquamating palpable purpuric rash over both lower limbs and extensive tinea corporis. There was tenderness on palpation in the right hypochondrium. Neurological examination revealed distal sensorimotor impairment in both upper and lower limbs without any cranial nerve involvement. Initial laboratory evaluation revealed hemoglobin, 13 g/dL; white blood cell count, 42,300/mm3 (neutrophils 78%, lymphocytes 10%, eosinophils 10%); platelet count, 476 × 109 /L; Peripheral smear showed neutrophilic leukocytosis with shift to left. ESR- 61mm 1st hour, CRP - 48 mg/L(<5); Serum C3 was 0.3 g/L (0.9-1.8 g/L), serum C4, 0.4 g/L (0.1-0.4 g/L). The patient tested negative for human immunodeficiency virus, HbsAg and hepatitis C virus RNA. Random plasma glucose, 77 mg/dl; Serum creatinine, 0.6 mg/dl. MRCP showed cholelithiasis with prominent gall bladder walls and moderate pneumoperitoneum. The patient was operated for hollow viscous perforation. Intra-operative findings include single ileal perforation of 5mm size on the mesenteric border (2.5cm from IC junction), and multiple ulcers present all over the ileum. Histopathological examination showed vascular rich fibro collagenous tissue with perivascular eosinophilic infiltrate. p-ANCA ,c-ANCA and ANA were negative. RA Factor,494 U/L (<12 U/L); Anti-CCP was negative. We made a final diagnosis of Churg-Strauss syndrome. During follow-up, the patient was treated with cyclophosphamide pulse therapy, low dose steroid and cotrimoxazole prophylaxis.

#### Conclusions

To conclude, a high degree of suspicion is required for diagnosis of Churg-Strauss syndrome with GI involvement.

#### **Figure & Table**




Figure. Ileal perforation in Churg-Strauss syndrome

#### **Keywords**

vasculitis, Churg-Strauss, ileal perforation

# **E-poster Presentation**

Crystal induced arthropathies

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



# Identification of tofuses and diagnosis of gout disease with dual-energy CT

Iraklı Tortladze¹, Giorgi Apkhazava², Grigol Nemsadze¹

¹ Radiology Department, TSSU First University Clinic, Georgia ² Radiology Department, Tbilisi City Medical, Georgia


#### **Description**


A 62-year-old male patient was admitted to the emergency room with severe foot pain. Clinical examination revealed redness and swelling on the first metatarsophalangeal joint. It was seen that the patient had recurrent pain in the patient's history. The patient had old magnetic resonance(MR) imaging examination for the foot. MR images showed lesions and degenerative changes in the bone structures forming the joint(Figure 1). It was seen that the level of uric acid in the patient's laboratory tests was high. Dual-energy computed tomography(DECT) was performed in the emergency department because of the suspicion of gout disease. Multiple monosodium urate deposits (tofus) were observed around the foot in DECT(Figure 1).

#### Conclusions

Gout is characterized clinically by acute onset of inflammatory oligo/mono arthritis and is generally difficult to distinguish from other inflammatory arthritides (rheumatoid arthritis, septic arthritis, psoriasis, reactive arthritis etc.) without confirmation by synovial fluid analysi. Various radiological techniques can be used for diagnosis (radiography, ultrasound, computed tomography(CT), and magnetic resonance imaging). However, these methods are not specific enough to facilitate the diagnosis of gout disease. DECT is a very important technique in the noninvasive assessment of gout. It is the only technique of imaging that enables direct visualization of monosodium urate deposition. DECT has therefore emerged as a leading tool for clinicians to reliably assess and diagnose acute or early-stage gout in a noninvasive manner. Moreover, DECT can help clinicians distinguish gouty tophi from a mass or infection.

#### **Figure & Table**







<u>KCR 2022</u>

May 19(Thu) - 21(Sat), 2022

# Spondylodiscitis and paravertebral abscess associated with calcium pyrophosphate dihydrate deposition disease

# Burak Sarılar¹

¹ Department of Radiology, Pamukkale University, Turkey


## **Description**

A 75-year-old male patient was admitted to our clinic with back pain and limitation of movement. The patient had a synovial examination one year ago with the suspicion of acute calcium pyrophosphate (CPP) crystal arthritis. Synovial calcifications were detected by synovial histological examination and radiography evaluation. Therefore, the patient was under colchicine treatment for one year. Lumbar magnetic resonance imaging was performed for pain and limitation of movement. There were areas of spondylodiscitis and paravertebral abscess accompanied by marked contrast enhancement in the lumbar region(Figure 1). Laboratory examination revealed a high CRP level at 90 mg/L. demonstrated that Staphylococcus aureus infections, antibiotic treatment with Daptomycin was prescribed for three months and resulted in the progressive improvement of the pain and inflammatory biological tests.

## Conclusions

The differential diagnosis of spondylodiscitis should be kept in mind if back pain develops in the presence of previously known peripheral CPPD disease in elderly patients.

# Figure & Table





KCR 2022

# Urate-lowering efficacy and renal safety of febuxostat in patients with advanced chronic kidney disease not yet on dialysis: A meta-analysis of observational studies

# Changnam Son¹, Hye-Jin Jeong¹, Woo Yeong Park², Sang-Hyon Kim¹

¹ Division of Rheumatology, Department of Internal Medicine, Keimyung University School of Medicine, Republic of Korea ² Division of Nephrology, Department of Internal Medicine, Keimyung University School of Medicine, Republic of Korea

## Background

The efficacy and safety of febuxostat in patients with stage 4-5 chronic kidney disease (CKD) remain unclear, although it is commonly used in clinical practice. Clinical trials are lacking due to ethical issues related to the enrollment of advanced CKD patients. We aimed to evaluate the efficacy and safety of febuxostat in patients with stage 4-5 CKD not yet on dialysis through a meta-analysis of observational studies.

#### **Methods**

We performed a systematic search in PubMed, Ovid MED-LINE, Embase, and the Cochrane Library to find observational studies on cohorts of advanced CKD patients starting febuxostat. Articles describing changes from baseline in serum urate levels and renal function assessed by estimated the glomerular filtration rate (eGFR) were included. The articles were screened by two independent reviewers (YP and HJ). We performed a meta-analysis using a random-effects model and used R software with the 'meta' and 'Rcpp' packages for statistical analyses.

#### **Results**

Among 148 retrieved studies, five relevant observational studies involving 327 patients were included in the meta-analysis. Daily febuxostat doses of 10-120 mg were administered treatment periods of 3-12 months. The urate-lowering effect after febuxostat use was statistically significant (weighted mean difference, -1.85; 95% Cl, -2.04 to -1.67; I²; 0%, Figure 1A). Three studies involving 145 patients included eGFR assessments. Renal function as assessed by eGFR did not decrease after febuxostat use (weighted mean difference, 0.11; 95% Cl, -0.25 to 0.47; I²; 45%, Figure 1B).

# Conclusions

Febuxostat has acceptable urate-lowering efficacy and renal safety in hyperuricemia patients with stage 4-5 CKD who are not yet on dialysis.

# Figure & Table




Figure. Meta-analyses of A) serum urate levels and B) eG-FRs in hyperuricemia patients with stage 4-5 chronic kidney disease

## **Keywords**

febuxostat, chronic kidney disease, meta-analysis



# A rare coexistence of quadriceps tendon calcification and patellar tendon calcification

Muhammed Eyyüp Çelik¹, Mehmet Selim Kan¹, Elshad İsmailov²

¹ medical faculty, Atatürk University, Turkey ² Department of Radiology, Ataturk University, Turkey

#### **Description**

A 41-year-old male patient presented with a complaint of movement restriction in his right knee. On the right knee x-ray, calcification of the patellar tendon was observed(Fig 1A, arrow). In addition, calcification was present in the right quadriceps femoris muscle tendon (Fig 1A, arrowhead). There was a significant irregularity in the patellar tendon and quadriceps femoris muscle tendon on T1-weighted magnetic resonance imaging(Fig 1B). Calcium pyrophosphate deposition in tendons was confirmed histopathologically.

#### Conclusions

Calcific tendinopathy (CT) calcium deposits in the substance of the tendon. CT is particularly common in the supraspinatus tendon and patellar tendon and Achilles tendon. The coexistence of quadratus femoris muscle-tendon calcification and patellar tendon calcification is very rare.

## Figure & Table





# Diagnosis and treatment of gout patients at emergency room

<u>Mi Ryoung Seo</u>¹, Jina Yeo¹, Hyo-Jin Choi¹, Han Joo Baek¹

¹ Division of Rheumatology, Department of IM, Gil Medical Center, Gachon University College of Medicine, Republic of Korea

#### Background

Gout is the most common inflammatory arthritis and is gradually increasing in Korea. Emergency room (ER) visits of patients with gout are also increasing. However, it was reported that patients with gout have not been properly managed in ER. We investigated the diagnosis and treatment of gout patients who visited the ER.

#### **Methods**

This was a retrospective study on patients with gout who visited the ER of a single tertiary center between January 2012 and December 2017. The data including demographics, clinical characteristics, diagnosis and treatment were collected.

#### **Results**

A total of 282 patients were included in this study. The number of gout patients visited the ER increased annually. Age at visit the ER was 45 years (IQR 36-62) and 90% were men. The affected areas were foot (74%) and knee (19%). Only 18% of patients had symptoms on first metatarsophalangeal joint. 39% of patients had their first gout attack at the ER visit. Patients with performed of arthrocentesis for diagnosis of gout were 20%. The patients with presumed gout in the ER were 86%. Patients without presumed gout in the ER were older age, women or patients with symptom on midfoot. They were hospitalized more, and received more MRI, antibiotic therapy and surgery. In the ER, 3% of patients were referred to a rheumatologist. 9% of patients visited the rheumatology outpatient clinic after ER visit. 36% of the patients admitted after ER visit were hospitalized in rheumatology department. Patients admitted to the rheumatology department had shorter hospital days, less magnetic resonance imaging, and fewer antibiotic therapy and surgery than those admitted to other departments.

#### Conclusions

Early diagnosis of gout in the ER may reduce unnecessary hospitalization, examination and treatment for patients. There is a need to improve referral or follow-up to rheumatologists for proper management of gout patients visiting the ER.

#### Figure & Table

	Presumed gout (n=242)	No presumed gout (n=40)	$p^{\dagger}$
Age (years)	44 (35-59)	57 (43-75)	< 0.01
Male gender	225 (92.6)	31 (77.5)	< 0.01
Areas affected by gout 1 st MTP Midfoot	46 (18.9) 21 (8.7)	3 (7.5) 8 (20.0)	0.11 0.03
Precipitating factors-alcohol	29 (11.9)	0	0.02
Similar symptom before ER visit	155 (64.6)	15 (38.5)	< 0.01
Gout diagnosis history before ER visit	137 (56.2)	9 (22.5)	< 0.01
Treatment at ER NSAIDs Colchicine Antibiotics	210 (86.4) 13 (5.3) 38 (15.6)	21 (52.5) 0 23 (57.5)	<0.01 0.23 <0.01
Consultation OS/IF/RH	46 (18.9) 38/3/8	22 (55.0) 19/2/1	< 0.01
Admission OS/IF/RH	53 (21.8) 12/15/29	27 (67.5) 12/15/2	< 0.01
Hospital days	7 (5-12)	10 (7-15)	0.48
Treatment –antibiotics surgery	19 (35.8) 13 (5.4)	20 (74.1) 10 (25.0)	<0.01 <0.01
MRI	12 (4.9)	9 (22.5)	0.02

*The data are presented as % for categorical variables and the median (interquartile range) for continuous variables;  $\uparrow$ Comparisons performed with the  $\chi^2$  test or Fisher's exact test for categorical variables and the *t*-test for continuous variables, statistical significance was p<0.05.

 $E\!R$  emergency room,  $l^{ii}$  MTP first metatarsophalangeal, NSAIDs nonsteroidal anti-inflammatory drugs, OS orthopedic surgery,  $I\!F$  infection,  $R\!H$  rheumatology

Table. Comparison between patients with or without presumed gout in the  $\mathsf{ER}^*$ 



# Genetic analysis for inflammasome genes polymorphisms in the gout susceptibility

Denise Clavijo-cornejo¹, Alberto Lopez-reyes², Esteban Cruz-arenas³, Leonor Jacobo-albavera⁴, Gabriela Fuentes-moreno¹, Adriana Francisco-balderas⁵, Mayra Dominguez-perez⁴, Janitzia Vazquez-mellado⁶, Luis H Silveira⁷, Carlos Pineda¹, Gabriela Martínez-nava², Marwin Gutierrez¹

¹ Division of Musculoskeletal and Rheumatic Diseases, Instituto Nacional de Rehabilitación, Mexico
 ² Gerosciences Laboratory, Instituto Nacional de Rehabilitación, Mexico
 ³ Hospital Epidemiological Surveillance Unit, Instituto Nacional de Rehabilitación, Mexico
 ⁴ Laboratory of Genomics of Cardiovascular Diseases, Instituto Nacional de Medicina Genómica, Mexico
 ⁵ Graduate Studies Department, Instituto Politécnico Nacional, Mexico
 ⁶ Rheumatology Department, Hospital General de México, Mexico
 ⁷ Rheumatology Department, Instituto Nacional de Cardiología Ignacio Chávez, Mexico

#### Background

Recent reports have demonstrated that polymorphisms within NLRP3 inflammasome signaling pathway are key factors in the risk to develop some joint inflammatory diseases (1). To date, there is still uncertain information about the presence of these genetic variants and their association with risk of gout. The aim is to determine the association between the single nucleotide polymorphisms (SNPs), within NLRP3 inflammasome genes, and the risk of developing gout.

#### **Methods**

We included 220 gout patients and 243 healthy subjects as control group. Clinical examination was performed and laboratory including glucose concentration, total cholesterol and triglycerides were obtained. The frequency and the allelic distribution of eight SNPs from seven different genes within the NLRP3 inflammasome signaling pathway were analyzed using the Step One Plus Real-Time PCR Systems. SNPs were selected by the criterion of minor allele frequency (MAF) (above 1 %), using the 1000 Genomes Project. Genetic variation data for all the SNPs were obtained from the HapMap project (http://www.hapmap.ncbi.nlm.nih.gov/) and the public National Center for Biotechnology Information dbSNP database (http://www.ncbi.nlm.nih.gov/snp). The SNPs did not to be in linkage disequilibrium . Ancestry was analyzed using ancestry informative markers differentiating mainly Amerindian, African, and European ancestries.

#### **Results**

The missense SNP rs45520937 in PPARGC1B, showed enhanced association with the risk of developing gout when it was analyzed using the dominant model, evidencing that gout patients carried the A/G-A/A genotype have an elevated risk compared to the control group [OR (95% CI) = 2.30 (1.09-4.86), p=0.030]. The adaptor molecule CD14 rs2569190 SNP could be associated with lower risk of gout under an additive model [OR (95 % CI)= 0.41 (0.16-1.05), p= 0.064]. No significant association were identified for the remaining SNPs.

#### Conclusions

Our findings suggest that genetic variant rs45520937 of PPARGC1B is significantly associated with the gout susceptibility.

#### **Figure & Table**

		MAF			p-value
Gene	SNP	Controls Gout (n=243) (n=220)		OR (95 % CI)	
TLR4	rs2149356	28.7	31.8	0.68 (0.33-1.40)	0.295
CD14	rs2569190	48.7	45.9	0.53 (0.25-1.13)	0.101
				0.41 (0.16-1.05)	0.064 ^{&amp;}
NLRP3	rs3806268	41.9	39.0	0.70 (0.33-1.47)	0.346
NLRP3	rs10754558	16.3	15.6	0.56 (0.26-1.22)	0.147
CARD8	rs2043211	24.7	24.1	1.35 (0.67-2.71)	0.407
L-1β	rs1143623	44.7	37.0	1.20 (0.57-2.48)	0.632
P2RX7	rs3751142	41.0	39.3	1.12 (0.48-2.61)	0.802
PPARGC1B	rs45520937	28.3	34.9	2.30 (1.09-4.86)	0.030

logistic regression, using dominant model and ⁸additive model . MAF, minor allele frequency; OR, Odds ratio; CI, confidence interval.

Table. Genetic analysis of 8 inflammasome genes SNPs in the gout susceptibility.

#### **Keywords**

Gout, NALP3 inflammasome, polymorphism



KCR 2022

# Depletion, activation, and stimulation of bone destruction of innate and innate-like immune cells in gout

<u>Ki-Jeong Park</u>¹, Young-Nan Cho¹, Hye-Mi Jin¹, Hye-Min Jeong¹, Sung-Eun Choi¹, Ji-Hyoun Kang¹, Dong-Jin Park¹, Tae-Jong Kim¹, Shin-Seok Lee¹, Yong-Wook Park¹

¹ Department of Rheumatology, Chonnam National University Hospital, Republic of Korea

## Background

Gout is considered an autoinflammatory disease in which innate immunity is a crucial stage of disease progression. Thus, examining the behavior of innate and innate-like immune cells such as mucosal-associated invariant T (MAIT) cells, natural killer T (NKT) cells, and natural killer (NK) cells is of importance in understanding the pathophysiology of gout.

## **Methods**

Patients with gout (n=30) and healthy controls (n=20) were enrolled, and their peripheral blood and synovial fluid samples were collected. MAIT cells, NKT cells, NK cells, cytokines, CD69, programmed death-1 (PD-1), and lymphocyte-activation gene 3 (LAG-3) levels depending on the presence of MSU crystal were analyzed by flow cytometry. In vitro osteoclastogenesis experiments were performed using peripheral blood mononuclear cells in the presence of M-CSF and RANK ligand.


## **Results**

The frequency analysis revealed that MAIT cells and NK cells decreased in the peripheral blood of gout patients, but NKT cells frequency showed no difference. For the circulating MAIT cells, activation markers such as CD69, PD-1, and LAG3 were increased in the gout patients. For the NK cells of gout patients, the expression of CD69 was more prominent in the synovial fluid, but their level in the synovial fluid was lower than that of peripheral blood. Of note, CD69 expression of both MAIT cells and NK cells in the PBMC were increased in the presence of MSU crystal, suggesting that their activation might be triggered by the MSU crystal deposition. Furthermore, activated MAIT cells secreted pro-resorptive cytokines (i.e. IL-6, IL-17, and TNF-a) that contribute to osteoclastogenesis.

## Conclusions

Circulating MAIT cells and NK cells are numerically reduced but functionally activated in gout patients. Besides, activated MAIT cells and NK cells could potentially induce bone resorption and damage. These findings imply that these immune cells could be critical contributors in amplifying and controlling the inflammation in gout.

## Figure & Table



## **Keywords**

Gout, Innate immunity, Osteoclastogenesis





# Gout disease modification: Proposal for a definition

### Jasvinder Singh¹

¹ Medicine/Rheumatology, University of Alabama at Birmingham, USA

# Background

Our objective was to identify a provisional set of domains for disease modification in gout with an aim to develop a provisional definition of disease modification in gout in the future.

#### **Methods**

We performed qualitative nominal group (NG) study with 19 gout experts (15 were authors/expert panel members of the 2012 and/or 2020 ACR gout guidelines, and/or 2015 ACR/EULAR gout classification criteria) about what constitutes "disease modification" in gout.

#### **Results**

Decrease in gout flares was rated #1 rank in all six NGs as indicative of disease modification in gout, followed by serum urate (SU) lowering, which was rated #1 rank in 1 of the 6 NGs (tied score with flares in one NG). Other components of gout disease modification were to improve quality of life/productivity; restore function; reduce/eliminate pain; reduce tophi burden; and joint preservation or resolution of joint damage. Potential addition components that were not ranked in the top 3 votes within each NG were: Decrease healthcare cost/utilization; cardiovascular/renal morbidity/ mortality reduction; and stop urate crystals formation.

### Conclusions

Our qualitative study provides a provisional set of domains for disease modification in gout. Future studies for the development of thresholds for disease modification domains are needed.

#### **Keywords**

gout, disease modification



# Predictors of increased vascular stiffness in gout patients

Wooseong Jeong¹, Jinseok Kim¹, Joon Hyouk Choi²

¹ Internal medicine, Division of Rheumatology, Jeju National University School of Medicine, Republic of Korea ² Internal medicine, Division of Cardiology, Jeju National University School of Medicine, Republic of Korea

#### Background

There are many reports that gout and hyperuricemia increase vascular stiffness. It is also well known that gout and hyperuricemia are significantly correlated with the occurrence of cardiovascular disease. Arterial stiffness is an independent prognostic indicator in coronary heart disease. Therefore, we conducted this study to find out what factors increase vascular stiffness in gout patients.

#### **Methods**

Augmentation index (Alx) was measured in gout patients without a history of uric acid lowering treatment who visited Jeju National University Hospital from March 2019 to March 2021.

#### **Results**

One hundred ninety nine patients participated in this study and Alx was measured. The average age of patients was 48.1±14.77 years, the mean gout duration was 4.63±6.3 years, the average of uric acid level was 8.9±1.1 mg/dL, the average of AIx was 21.2±9.4% which was higher than the reference value (16.9%). When comparing the high and low groups based on the Alx reference value, the high Alx group had a younger age (42.3 vs 59.8 years, p<0.001), had fewer DM (6.0 vs 19.7 %, p=0.003), had fewer HTN (16.5 vs 57.6 %, p<0.001), had fewer hyperlipidemia patients (16.5 vs 33.3%, p=0.007), had a higher CCr (111.6 vs 80.4mL/min, p<0.001), and had a higher uric acid level (9.0 vs 8.6 mg/dL, p=0.012). But there was no significant difference in disease duration, total cholesterol, BMI, tophi, between the two groups. Multivariate linear regression analysis showed that age (b=0.355, 95% CI 0.186-0.518), CCr (b=0.058, 95% CI 0.001-0.115, p=0.046), uric acid level (b=1.997, 95% CI 0.747-3.247) and BMI (0.730, 95% CI 0.355-1.104, p<0.001) are the predictor of increased vascular stiffness.

#### Conclusions

Based on the results of our study, there is a possibility that managing the uric acid level, CCr, and BMI can prevent the increase in vascular stiffness in gout patients.

#### **Keywords**

gout, vascular stiffness, predictor

# Clinical features of Korean patients with calcium pyrophosphate crystal deposition disease: A retrospective multicenter study

Eun Hye Park¹, Ji Hyoun Kim², Sang Wan Chung³, You-Jung Ha⁴, Eun Ha Kang⁴, Yun Jong Lee⁴, Jong Jin Yoo⁵

¹ Division of Rheumatology, Department of Internal Medicine, Chung-Ang University College of Medicine, Republic of Korea
 ² Division of Rheumatology, Department of Internal Medicine, Chungbuk National University Hospital, Republic of Korea
 ³ Division of Rheumatology, Department of Internal Medicine, Kyung Hee University Medical Center, Republic of Korea
 ⁴ Division of Rheumatology, Department of Internal Medicine, Seoul National University Bundang Hospital, Republic of Korea
 ⁵ Division of Rheumatology, Department of Internal Medicine, Kangdong Sacred Heart Hospital, Republic of Korea

#### Background

To assess the clinical features of Korean patients with calcium pyrophosphate crystal deposition disease (CPPD).

#### **Methods**

Clinical data of 283 patients with CPPD from five university hospitals between January 2000 and September 2020 were reviewed. Patients with arthritis and the presence of CPP crystals in synovial fluid or tissue, typical x-ray chondrocalcinosis (CC), or CPP crystal deposits identified by ultrasonography or computed tomography were included; those with asymptomatic CPPD were excluded.

#### **Results**

The median age at diagnosis of CPPD was 82.0 (IQR 76.2-87.3) years, and 214 (75.6%) were female. Acute CPP crystal arthritis was the most common form of CPPD (60.4%), followed by osteoarthritis with CPPD (37.1%), and chronic CPP crystal inflammatory arthritis (2.5%). Most patients presented with monoarticular (57.2%) or oligoarticular (37.9%) arthritis [median 1.0 (1.0-2.0) joint]. Knee (73.1%) was the most common joint, followed by wrist (22.3%), shoulder (3.2%), spine (2.8%), metacarpophalangeal (2.8%), and acromioclavicular (1.1%) joints, symphysis pubis (0.7%) and hip joint (0.4%). Systemic symptoms including fever (48.4%) and confusion (5.3%) occurred. The median duration of first symptom to resolve was 8.0 (5.0-13.0) days. Recurred CPPD attacks were observed in 37 (13.1%); the median interval among the attacks was 173.5 (56.5-739.5) days. 207 (73.9%) had undergone synovial fluid examination; CPP crystals were identified in the synovial fluid of 157 (75.8%) patients. Radiographic CC was observed among 209 (73.9%); sonographic evidence of CPP crystal deposit was found in 24 (8.5%). The majority (83.0%) of patients have received nonsteroidal anti-inflammatory drugs for CPPD. Colchicine and systemic glucocorticoids were given to 159 (56.2%) and 140 (49.5%) patients, respectively. 101 (35.7%) have received intra-articular glucocorticoid injection, mostly in the knee joint (71.3%). 17 (6.0%) used conventional synthetic disease-modifying anti-rheumatic drugs, including methotrexate (4.2%), hydroxychloroquine (4.6%), sulfasalazine (0.7%), and leflunomide (0.4%).

#### Conclusions

This is the largest study on clinical findings among Korean patients with CPPD.



# Effect of lifestyle change on incident gout: a nationwide population-based cohort of young men

<u>Yeonghee Eun</u>¹, Kyungdo Han², Seung Woo Lee³, Seonyoung Kang⁴, Seulkee Lee⁴, Hoon-Suk Cha⁴, Eun-Mi Koh⁴, Jaejoon Lee⁴, Hyungjin Kim^{4,5}

¹ Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Republic of Korea ² Department of Statistics and Actuarial Science, Soongsil University, Republic of Korea

³ Department of Biomedicine & Health Science, College of Medicine, Catholic University of Korea, Republic of Korea

⁴ Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Republic of Korea

⁵ Department of Medical Humanities, Samsung Medical Center, Sungkyunkwan University School of Medicine, Republic of Korea

#### Background

Although gout in young people is increasing, studies on the risk factors for gout in these people are lacking. In this study, we explored the risk factors of gout and effect of lifestyle change on the development of gout in large nationwide population-based cohort of young men.

#### **Methods**

Between 2009–2012, men aged 20–39 years who participated in two national health examinations at 2-year intervals were included in the study. The outcome was occurrence of gout, which was defined using the diagnosis code of gout (ICD-10 code M10) in the claims database. Cox proportional hazard model was used to evaluate the association between incident gout and baseline factors or lifestyle change.

#### **Results**

A total of 1,977,849 subjects were included in the study, and the mean follow-up period was 5.5 ± 4.3 years. Gout occurred in 38,839 subjects (incidence rate = 3.59/1,000 person-years). A high body mass index, alcohol drinking, and comorbidities such as hypertension, diabetes mellitus, and hyperlipidemia were associated with an increased risk of gout. Among lifestyle factors, change in obesity had the greatest impact on gout, followed by drinking. Development of obesity increased the risk of gout by 1.75 times (95% CI 1.68–1.81), and recovery from obesity decreased the risk of gout by 40% (aHR 0.60, 95% CI 0.57-0.64). Heavy drinking increased the risk of gout by 38% (aHR 1.38, 95% CI 1.33-1.43), and stopping heavy drinking decreased the risk of gout by 11% (aHR 0.89, 95% CI 0.85-0.94). The effect of obesity on gout was evident in the younger age group, and the effect of heavy drinking on gout was weak in the severely obese group.

#### Conclusions

Obesity and heavy drinking in young men are important modifiable risk factors for gout. Therefore, the management of these risk factors in young men should be emphasized.



# Gout is associated with the risk of osteoporosis: a population-based study

<u>Jihyoun Kim¹</u>, So Rae Kim², Gilwon Kang³, In Ah Choi⁴

¹ Division of Rheumatology, Department of internal medicine, Chungbuk National University Hospital, Republic of Korea
 ² Internal medicine, Chungbuk National University Hospital, Republic of Korea
 ³ Department of Health Information and Management, College of Medicine, Chungbuk National University, Republic of Korea
 ⁴ Division of Rheumatology, College of Medicine, Chungbuk National University, Republic of Korea

#### Background

It is known that uric acid has both role as an antioxidant effect and a pre-oxidant that induces oxidative stress related to inflammation. Inflammatory cytokines can stimulate osteoclast bone resorption. The effects of gout on osteoporosis due to paradoxical function of uric acid also showed conflicting results in the previous studies. This study aimed to investigate the association between gout, which is considered the hallmark disease of hyperuricemia, and osteoporosis.

#### **Methods**

This retrospective cohort study used data from the Korean National Health Insurance Service (NHIS) database. In total, 628,565 participants with a diagnosis of gout (ICD-10, M10) who were prescribed medications for gout, such as colchicine, allopurinol, febuxostat, and benzbromarone for at least 90 days were selected from the NHIS database. Patients with osteoporosis were assigned thorough a diagnosis code for osteoporosis with or without pathologic facture (ICD M80, M81). The control cohort was defined as patients who had never had a gout diagnostic code and had never been administered any gout medication. Age and sex 1:1 propensity score matching was performed in the selected control cohort.

#### **Results**

Finally, total of 305,810 patients with gout met the study criteria. Compared with the control group, both male (incidence rate ratio: IRR 1.38; 95% CI: 1.35-1.40), and female patient (IRR 1.21; 95% CI: 1.16-1.27) with gout showed increased IRR of osteoporosis. In stratified analysis by age, gout patients showed an increased IRR of osteoporosis in all age groups except for those over 80 years old (p<0.001). In cox proportional hazard model analysis, gout showed increased Hazard ratio (HR) 1.48 (95% CI; 1.45–1.51, p<0.001). Female sex and old age were risk factors for osteoporosis (HR was 4.49,95% CI; 4.38–4.61 in female group, 20.93, 95% CI; 19.55–22.41 in 70's, respectively).

#### Conclusions

Gout is significantly associated with the risk of osteoporosis in Korean patients.

#### **Figure & Table**




Figure. Flow chart for the selection of the study population from the National Health Insurance Service database. In total, 305,810 patients with gout and 305,810 control participants were compared via propensity score matching.

#### **Keywords**

gout, uric acid, osteoporosis

# **E-poster Presentation**

Pediatric rheumatology

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



KCR 2022

May 19(Thu) - 21(Sat), 2022

# Vascular imaging findings with high-pitch low-dose dual-source CT in atypical Kawasaki disease

Mecit Kantarci¹, Elif Güven¹, Naci Ceviz2, Hayri Oğul¹, Recep Sade¹

¹ Radiology, Ataturk University, Turkey
 ² Pediatric Cardiology, Ataturk University, Turkey

## Description

Determining the presence of aneurysms, thrombosis, and stenosis is very important for the diagnosis of atypical Kawasaki disease (AKD) and in the follow-up of AKD patients with aneurysms. We aimed to demonstrate high-pitch lowdose dual-source computed tomography (CT) angiography findings in pediatric patients with AKD.

#### **Methods**

Over a 5-year period, high-pitch low-dose CT angiography was performed to determine vascular aneurysms or occlusions in 17 patients who had suspected AKD. The patients ranged from 2 months of age to 11.3 years, with a mean age of 3 years. The American Heart Association's criteria were used to diagnose AKD.

#### **Results**

We did not detect any vascular problems in 6 of the patients, and they were not included in our study. Arterial aneurysms were present in 11 patients (aged 2 months to 11.3 years; mean age, 4.2 years; 7 males). In one patient, there was also a thrombus at an arterial aneurysm. Coronary artery aneurysms were detected in 7 patients and systemic artery aneurysms were detected in 7 patients. Three patients had both systemic and coronary aneurysms.

## Conclusions

Our results suggest that high-pitch low-dose dual-source CT can detect all types of aneurysms, stenosis and occlusions of vessels in patients with AKD who were not previously diagnosed. This useful, easy, robust and fast technique may be preferred to diagnose AKD.

# Figure & Table




Figure. Left main coronary artery (LMCA) and left anterior descending (LAD) artery aneurysms in a 6-month-old male with unexplained  ${\rm f}$ 



# **Bilateral calcification of ear cartilage**

Gökhan Polat¹, Recep Sade¹

¹ Radiology, Atatürk University, Turkey


### **Description**

A 17-year-old boy children presented to rheumatology clinic complaining of intermittent hearing loss, dyspnea, swelling of the joints, hardening of the ear. The patient is followed up with the diagnosis of rheumatoid arthritis. On physical examination, the auriculars were of normal appearance, with no visible changes in the derm. Radiography and computed tomography(CT) was performed. Radiography, coronal CT and three-dimensional volume rendering CT images showed bilateral auricular cartilage calcification (Figure 1A,1B, and 1C).

#### **Conclusions**

Rheumatoid arthritis is a systemic disorder affecting mesenchymatous tissues, It seems possible that change in the connective tissue may be a predisposing agent in its development. For this reason, rheumatoid arthritis may cause calcification in structures such as the vertebral disc and costal cartilage. Ear cartilage calcification was most commonly caused by adrenal insufficiency. However, rheumatoid arthritic secondary ear cartilage calcification has not been reported in the literature. Ear cartilage calcification is important for the clinician to be able to diagnosis this pathological disorder as it may sometimes be the only indicator of an underlying endocrinologic, immunologic and metabolic disorder that can generally be subclinical.

# Figure & Table



Keywords rheumatoid arthritis, CALCIFICATION, young boy



# The treatment effect of tofacitinib on Blau syndrome: A case series of Chinese pediatric patients

# Zhe Cai^{1,2,3}, Song Zhang¹, Huasong Zeng¹

¹ Department of Allergy, Immunology and Rheumatology, Guangzhou Women and Children's Medical Center, China., China
 ² Guangzhou Institute of Pediatrics, Guangzhou Women and Children's Medical Center, China., China
 ³ Institute of Chinese Medicine and State Key Laboratory, The Chinese University of Hong Kong, Hong Kong., Hong Kong

## **Description**

Blau syndrome (BS) is characterized by the autoinflammatory syndromes of granulomatous recurrent uveitis, dermatitis and symmetric arthritis. It is associated with the nucleotide-binding oligomerization domain containing 2 (NOD2) gene mutations. Therefore, the missense heterozygous mutation in NOD2 gene could cause an activation of NF-kB pathway that could cause a secretion of the pro-inflammatory cytokines like IL-1β, IL-6 and TNF-a. While the biologic agent tocilizumab, a Janus kinase (JAK) inhibitor, can prevent inflammatory cytokines from increasing in rheumatoid arthritis patients. However, whether tofacitinib has a similar effectiveness in child patients with BS is not clear. Our aim is to assess the efficacy of tofacitinib in these patients. Tofacitinib was regularly given to thee BS patients (termed as Patient-1, -2, and -3) in different dosage: 1.7 mg/ day (0.11 mg/kg), 2.5 mg/day (0.12 mg/kg), and 2.5 mg/day (0.33 mg/kg), respectively. The clinical manifestations of patients, magnetic resonance imaging, serological diagnosis, and therapeutic measures and outcomes of treatments were recorded. The inflammatory cytokines (IL-1β, IL-2, IL-4, IL-6, IL-10, TNF- $\alpha$ , IFN- $\gamma$ ) were measured by ELISA assay. The clinical characteristics and serological diagnosis of all BS patients were drastically improved after they received tofacitinib treatment such as the relieved joint pain and swelling. All mutations were located on exon 4 of the NOD2 gene in these patients, and a novel unreported mutation (p.M513K) in NOD2 was found in Patient-3. All the patients have reached clinical remission of polyarthritis and improvements in erythrocyte sedimentation rate, levels of C-reactive protein and inflammatory cytokines after 12 month treatment with tofacitinib. Most importantly, no side effects were seen during tofacitinib treatments.

# Conclusions

The improvement of inflammatory symptoms in BS suggests that tofacitinib treatment is a promising and effective therapeutic approach for BS patients who have an unsatisfactory response to the corticosteroids, biological reagents and traditional disease-modifying antirheumatic drugs like tocilizumab.

#### **Keywords**

Blau syndrome, tofacitinib, pediatric patients



# The evaluation of MRI findings of sacroiliitis in patients with Juvenile idopathic arthritis for detection of active and structural damage lesions according to updated preliminary OMERACT pediatric JAMRIS scoring system

Berhan Pirimoglu¹, Alperen Tezcan¹, Cagatay Engin², Gokhan Polat¹, Ahmet Yalcin¹, Recep Sade¹

¹ Radiology, Ataturk University School of Medicine, Erzurum/TURKEY, Turkey
² Pediatric Orthopedics, Ataturk University School of Medicine, Erzurum/TURKEY, Turkey

#### Background

Magnetic resonance imaging (MRI) is the best imaging technique for detection of sacroiliac joint (SIJ) involvement in juvenile idiopathic arthritis (JIA). Therefore, we aimed to evaluate the active and structural damage lesions in patients with juvenile idiopathic arthritis on sacroiliac joint MRI examinations according to updated pediatric JAMRIS (Juvenile Idiopathic Arthritis MRI Score) scoring system.

#### **Methods**

The acquired MRI examinations between January 2018 and December 2021 of children ≤18 years with confirmed imaging and clinical diagnosis of JIA. Patients with comorbidities such as primary or metastatic bone cancer, SIJ fractures and not containing the minimum imaging protocol for this study were excluded. The study sacroiliac joint MRI examinations were reviewed for presence of SIJ pathologies by two radiologists with consensus (BP and AT) who were blinded to the clinical history and other imaging findings. The final 22 cases included in the study were randomly selected. They were evaluated by using the JAMRIS-SIJ scoring methods.


#### Results

Out of the 22 patients who had MRI examinations selected for the study 12 (54.5%) were males. The median age of the patients was 12 years (8.4–16.4, range 6–18 years). The incidence of JAMRIS-SIJ pathologies among the study MRI examinations were 14 (63.6%) BME, 9 (40.9%) osteitis, 5 (22.7%) erosions, 5 (22.7%) sclerosis, 4 (18.1%) joint space enhancement, 3 (13.6%) fat lesions, 2 (9.1%) inflammation in erosion cavity, 1 (4.5%) capsulitis, 1 (4.5%) enthesitis and 1 (4.5%) backfill. Four (18.1%) of the MRI examinations were normal for patient's age, exhibiting varying normal growth and age-related variants of the bone marrow signal in the SIJ region.

## Conclusions

Multiple features of imaging findings are visible on sacroiliac joint MRI examinations. We suggest the updated pediatric JAMRIS scoring system can be widely used for evaluation the active and structural damage lesions in juvenile idiopathic arthritis on SIJ MRI examinations.

#### **Figure & Table**



Intense than presscral veins (white arrows) (Intensity score-2). Samm deep with continuous signal (depth score-2) and bilateral BME score was 8. Axial contrast-enhanced 11-weighted image (C) shows a 14-year-old boy with bilateral scleris in both scare] quadrants (white arrows, ostelitis score-2). The semicoronal STR (D) and 11-weighted [E] images show a 11-year-old boy with bilateral sclerois (white arrows), and fat lesions (black arrows) in both liac and scare) quadrants (sclerois score-8 and fat metaplasis score-2). Axial contrast-enhanced 11-weighted image shows an 8-year-old boy in both liac and scare) quadrants (sclerois score-8 and fat metaplasis score-2). Axial contrast-enhanced 11-weighted image shows an 8-year-old boy in both liac and scare quadrants (sclerois accer-8 and fat metaplasis score-2). Axial contrast-enhanced 11-weighted image shows an 8-year-old boy in both liac and scare quadrants (sclerois accer-8). A scale accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer accer acce

#### **Keywords**

Juvenile idiopathic arthritis, JAMRIS, Magnetic resonance imaging



# The clinical characteristics of 15 IgG4 related disease in pediatric patients

# Zheng Liu¹, Wen Zhang¹

¹ Department of Rheumatology, Peking Union Medical College Hospital, China

### Description

To investigate the clinical characteristics and treatment efficacy of IgG4 related disease (IgG4-RD) in pediatrics.

#### **Methods**

A total of 15 patients newly diagnosed with IgG4-RD in pediatric were enrolled from prospective IgG4-RD cohort of Peking Union Medical College Hospital between January 2010 and January 2021. The patients' demographic characteristics, baseline laboratory parameters, clinical symptoms onset, organs involvement and treatment efficacy were analysed.

#### **Results**

Fifteen IgG4-RD in pediatric patients accounted for 1.6% of the total number of IgG4-RD patients in our cohort, including 9 males (60%) and 6 females(40%). The mean age of disease onset was (13.3±3.9) years old, 9 males (60%) and 6 females (40%). The average number of organs involvement was (2.8±1.6), 86.7% patients had more than one organ involvement. The most common involved organs were lymph nodes and submandibular glands (53.3%) I Other affected organs include lacrimal glands (46.7%), pancreatitis (26.7%), parotid gland (20%, bile duct and lung (13.3%) and sinus, liver, pituitary gland, kidney@skin, periaortitis, gastrointestinal tract, thyroid gland (6.7% II. 33.3%, 80%, and 86.7% of patients had an elevation of serum IgGIIgG4 and total IgE, respectively. 3(20%) patients who had normal serum IgG4 level at baseline suffered from serum IgG4 elevation in follow-up. The serum IgG4 level of the remaining patients decreased after treatment. 9\23.3% patients received glucocorticoids combined with immunosuppressive agents treatment 1(6.7% patients treated with glucocorticoids alone 2 (13.3% patients received immunosuppressant only and 3020% patients with surgical treatment and symptomatic treatment. 4(26.7%) patients suffered clinical relapse, which may relate to the high number of organs involved at baseline, high IgG4 level at baseline, glucocorticoids treatment alone, or re-elevation of IgG4 during maintenance therapy and follow-up.

#### Conclusions

Lymph nodes and submandibular glands are the most commonly involved organs in IgG4-RD in pediatric patients. The clinical characteristics and treatment response of pediatric patients were similar to IgG4-RD of adult patients.

#### **Keywords**

IgG4 related disease in pediatric, Rare disease, Cohort study



# Predictors of long-term functional outcomes of enthesitis related arthritis (ERA) category of Juvenile idiopathic arthritis (JIA) in adulthood: A single centre experience from a tertiary care hospital

Naveen R¹, Shivika Guleria¹, Anu Balakrishnan¹, Sanjukta Majumder¹, Amita Aggarwal¹

¹ Clinical Immunology and Rheumatology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, India

#### Background

Long term functional outcomes in JIA-ERA (the commonest category of JIA) is scant. This study assessed the longterm functional outcomes of JIA-ERA in adulthood and the factors (clinical and genetic) predicting the same.

## **Methods**

Patients with ERA (ILAR classification) having >5 years of disease and above the age of 16 years were included. Data on clinical features, Bath indices (BASMI, BASDAI, BASFI), health assessment questionnaire disability index (HAQ-DI) was collected. Clinical features within 6 months of disease onset was recorded. Poor functional outcome was defined as BASFI>0.9 or HAQ-DI>0.5. Genetic factors looked for were HLA-B27, ERAP polymorphisms (rs27044, rs27037), and IL23R. All data were expressed as median (IQR) or as frequency.

## Results

135 patients (127-male) with age of disease onset 13(10-15) years and disease duration 7(5-11) years were recruited. There was delay in diagnosis of 3(1-6) years. Most had active disease (81%-ASDAS-ESR>1.3). Ninety-two (68%) had functional disability with median HAQ-DI of 0.43(0-1), BASFI of 1.8(0.37-3.12).

Poor functional outcome was seen in three-fourths (n=92, 68%). Those with poor functional outcomes had longer delay in diagnosis (4 vs 1 years, p<0.001), higher school years lost (p=0.01). They also had higher Bath indices now. ERAP (rs27044) polymorphism heterozygous state was also more frequent in them [OR 4.8 (1.2-19)]. HLA-B27, ERAP rs23037 and IL23R polymorphisms were similar. None of the clinical features at disease onset predicted poor functional outcomes. In multivariate analysis, those with poor outcomes had higher BASDAI [OR 3.14 (1.5-6.2)](Table 1).

# Conclusions

Poor functional outcome was seen in 68% of adults with JIA-ERA 7 years into disease. Longer delay in diagnosis and school years lost characterised those with poor functional outcomes. ERAP rs27044 heterozygous state was more frequent in those with poor outcomes. None of the clinical features at disease onset predicted long term functional outcomes in adulthood.

# Figure & Table

	Poor functional	No poor functional	OR (CI) (U/M)	Р
	outcome (n=92)	outcome (n=43)		
Age in years	20 (18-23)	19 (17-22)		NS
Age of onset of disease (years)	13 (10-15)	12 (11-15)		NS
Gender (M:F)	88:4	39:4		NS
Delay in diagnosis (years)	4 (2-6)	1 (1-4)		< 0.001
ichool years lost (in years)	0 (0-2)	0 (0-0)		0.010
Clinical features at onset (within 6 months) n				
%)				
Arthritis	79 (86)	41 (95)		NS
Clinical Hip joint involvement	17 (71)	7 (16)		NS
BP	48 (44)	23 (59)		NS
arsitis	42 (45)	18 (42)		NS
Jveitis	2 (2)	4 (9)		NS
nthesitis	77 (83)	36 (83)		NS
endoachilles enthesitis	59 (64)	27 (63)		NS
Axial site enthesitis	44 (48)	19 (44)		NS
Peripheral site enthesitis	71 (77)	34 (79)		NS
Radiological features at onset (within 1				
vear)				
(-ray sacroiliitis at onset	55 (64)	20 (60)		NS
(-ray hip arthritis at onset	21 (25)	3 (9)		NS
Senetic markers				
RAP 1 (rs 27044) Homozygous (out of 103)	24 (33)	10 (33)		NS
RAP 1 (rs 27044) Holitozygous (out of 103)	45 (92)	14 (70)	4.8 (1.2-19)	0.019
RAP 1 (rs 27044) At least one variant gene	69 (94)	24 (80)	4.3 (1.1-16)	0.019
RAP 1 (rs 27044) at least one variant gene RAP 1 (rs 27037) Homozygous (out of 101)	26 (36)	11 (37)	4.5 (1.1-10)	0.024 NS
RAP 1 (rs 27037) Homozygous (out of 101) RAP 1 (rs 27037) Heterozygous (out of 101)	39 (55)	15 (50)		NS
RAP 1 (rs 27037) at least one variant gene	65 (91)	26 (87)		NS
L-23R Homozygous (out of 100)	15 (21)	4 (13)		NS
L23R Heterozygous (out of 100)	28 (40)	15 (50)		NS
L23R at least one variant gene	43 (61)	19 (63)		NS
ILA B27 positivity (out of 122)	79 (86)	36 (84)		NS
Dutcome measures	75 (80)	50 (04)		IN S
BASDAI	4.9 (3.1-6.5)	1 (1-2)	3.14 (1.5-6.2)#	0.001@
ASMI	1.6 (1-2.15)	1 (0-1.6)	5.14 (1.5-0.2)#	0.001@
BASEI	2.9 (1.6-4)	0 (0-0.4)		<0.002
IAQ DI	0.87 (0.28-1)	0 (0-0)		<0.001
AQ DI BASDAI > 4 (%)	61 (67)	3 (7)	27 (7.7-95)	<0.001
ASDAL 24 (%) ASDAS-ESR	3 (2.5-7)	3(7)	21 (1.1-55)	<0.001
ASDAS-ESK ASDAS-CRP	3(2.5-7) 3.35(2.4-3.8)	2.2 (1.3-2.9)		<0.001
reatment received	3.35 (2.4-3.8)	2.2 (1.3-2.9)		<0.001
SAIDS alone	27 (20)	12 (20)	1	NS
NSAIDS alone DMARDS+ NSAIDS	27 (29) 64 (69)	13 (30) 28 (65)		NS
			l I de de sie e se sechel	
QR Interquartile range, BASDAI Bath ankylosing netrological index, BASFI Bath ankylosing spon				

# OR (CI) in significant in binary logistic regression, @ P value as per Binary logistic regress

Table. Differences in baseline characteristics between those with and without poor functional outcomes

#### **Keywords**

Functional outcomes, juvenile idiopathic arthritis, Enthesitis related arthritis



# Secondary hemophagocytic lymphohistiocytosis: overwhelming clinical manifestations may cause more chemotherapy than necessary

# Hye Yeon Choi¹, Jung Woo Rhim¹, Dae Chul Jeong¹, Soo-Young Lee¹

¹ Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

#### Background

Secondary hemophagocytic lymphohistiocytosis (HLH) is a rare but fatal disease, so early recognition and aggressive chemotherapy are essential to achieve a good prognosis. However, overwhelming clinical manifestations that meet the HLH-2004 diagnostic criteria may lead to overtreatment. Here, we report an experience of the 40-week intensive chemotherapy including etoposide in secondary HLH patients that could have been replaced by the 8-week immune modulators.

#### **Methods**

In this retrospective study, medical records were reviewed for patients who were diagnosed with secondary HLH at the study hospital over the past 5 years. Diagnosis of HLH was based on HLH-2004 criteria. Six patients met the diagnostic criteria and were included in this study.

#### **Results**

Of the 6 patients with secondary HLH, 2 had juvenile idiopathic arthritis (JIA), 1 had Kawasaki disease, and the remaining 3 had no underlying disease. There was an important difference in treatment modalities among the patients: 3 patients were treated with the 8-week immune modulators (i.e., corticosteroids and cyclosporine A), while the remaining 3 patients were treated with the 40-week chemotherapy (i.e., the HLH-2004 therapeutic protocol). Regardless of treatment modality, all recovered without sequelae. When medical records were compared in detail between 2 patients with JIA and between 2 patients without underlying disease, we noted that 1 patient with JIA and 1 patient without underlying disease could have received the 8-week immune modulators instead of the 40-week chemotherapy and would have obtained similar outcomes.

#### Conclusions

Prompt initiation of adequate treatment for secondary HLH is very important. It is also necessary to avoid overtreatment in the subset of secondary HLH patients. Many patients with secondary HLH can be successfully treated with short-term immune modulators. The choice of treatment modalities should be determined on the basis of therapeutic response, in addition to initial clinical and laboratory features.

#### **Keywords**

Hemophagocytic lymphohistiocytosis, HLH-2004 guidelines, Overtreatment



# Interstitial lung disease in pediatric systemic lupus erythematosus: A case report

<u>Soo-Young Lee</u>¹, Hye Yeon Choi¹, Jung Woo Rhim¹, Hye Jin Lee¹, Hyun Mi Kang¹, Dae-Chul Jeong¹

¹ Pediatrics, College of Medicine, The Catholic University of Korea, Republic of Korea

#### Description

Systemic lupus erythematosus (SLE) is multisystem autoimmune disease. Clinical presentations are variable according to the involved organs. Interstitial lung disease (ILD) is rarely presented in pediatric SLE and limited data exist on treatment of the patients with ILD in SLE. Here, we reported a 13-year old girl with exertional dyspnea without fever during the treatment with oral steroid and hydroxychloroquine after diagnosed of SLE. At initial diagnosis of SLE, she presented skin rash, hair loss with thrombocytopenia in spite of intravenous immunoglobulin and steroid therapy, and did not complain any respiratory symptoms. Chest radiologic finding showed bilateral infiltration of lung fields and high resolution chest CT showed bilateral diffuse ground glass attenuation with lower lobe predominance, and ill-defined small nodules with variable sized cysts in both lungs. Pulmonary function test showed restrictive pattern compatible with ILD. We identified high level of KL-6 such as surrogate marker of ILD. Lung biopsy revealed subpleural fibrosis with bulla formation, and focal interstitial thickening with fibrosis, edema and lymphoid aggregates. She received oral prednisolone with mycophenolate mofetil (MMF) after methylprednisolone pulse therapy. Her respiratory symptom and pulmonary function test and the level of KL-6 were showed improvement after treatment.

#### Conclusions

We emphasize that careful evaluation for respiratory involvement should be considered in pediatric SLE patient, especially when the patient shows respiratory symptoms such as dyspnea on exertion and cough. And MMF combined with corticosteroids could be the useful treatment options for pediatric ILD-SLE.

#### **Keywords**

Systemic lupus erythematosus, Pediatric, Interstitial lung disease



<u>KCR 2022</u>

# A20 Haploinsufficiency identified in a girl presented with systemic juvenile idiopathic arthritis: A case report

Jung-Woo Rhim¹, Hye Yeon Choi¹, In Hyuk Yoo¹, Soo Youn Lee¹, Dae-Chul Jeong¹

¹ Pediatrics, College of Medicine, The Catholic University of Korea, Republic of Korea

#### **Description**

Haploinsufficiency of A20 (HA20) is a newly described autoinflammatory disease caused by mutations in tumor necrosis factor- $\alpha$ -induced protein 3 (TNFAIP3) gene. Patients present wide spectrum of manifestations with early-onset systemic inflammation like Behcet's disease or other autoimmune features. Here, we report the case of HA20 initially diagnosed with systemic juvenile idiopathic arthritis (sJIA).

An 11-year-old girl has presented recurrent episodes of fever with vomiting, diarrhea since 11-month of age. She was diagnosed with sJIA presenting fever with skin rash, lymphadenopathy and arthritis when she was 27-month-old. The patient developed fever with gastrointestinal symptoms including abdominal pain with vomiting about five times per year in spite of disease-modifying anti-rheumatic drugs (DMARDs) therapy. Acute phase reactants were markedly increased during the period of her symptoms and improved by conservative treatment with hydration, but still showed elevated levels when she was well-being state. At the age of 7, familial genetic study for Mediterranean fever (MEF) syndrome identified that the patient and her father had two heterozygous mutations regarding variant of uncertain significance in MEFV gene by Sanger method.

At the age of 11, she admitted due to the recurrent gastrointestinal symptoms with high acute phase reactants. Colonoscopy showed multiple ulcers on intestinal mucosa compatible with Crohn's disease. The next generation sequencing identified the pathogenic heterozygous mutation (c.427C>T) at TNFAIP3 gene, leading to HA20. This genetic mutation presents to fail to the negative feedback mechanism for nuclear factor kappa B (NF- $\kappa$ B) activation, developing autoinflammatory features such as fever and systemic inflammation.

#### Conclusions

HA20 should be considered in the patient with recurrent inflammatory disease that presented with fever and gastrointestinal symptoms which might be regarded as respective episodes of acute infections.

#### **Keywords**

Tumor necrosis factor alpha-induced protein 3, autoinflammatory disease, acute phase reactants



<u>KCR 2022</u>

May 19(Thu) - 21(Sat), 2022

# Flare-up of juvenile idiopathic arthritis (JIA) the day after receiving a booster shot of BNT162b2 mRNA vaccine

## Kwang Nam Kim¹, Hyong Suk Park¹

¹ Pediatrics, Myongji Hospital, Republic of Korea

#### **Description**

Vaccine is an effective public health measurement to control the global COVID-19 pandemic. Patients with rheumatoid arthritis (RA) are twofold more vulnerable to infections that result in hospitalization and impaired quality of life. So, with consideration to the benefits of vaccination outweighing the risks, EULAR recommends that patients with RA should receive COVID-19 vaccines without needing major adjustment to their ongoing treatment regimens.

However, concerns about the safety of the vaccines are a major hurdle to widespread vaccination to the adolescent and children. Here, we report a JIA flare patient the day after receiving the booster shot of BNT162b2 mRNA vaccine.

A 18-year-old male, previously completely remission state of JIA, developed right knee joint swollen the day after 3rd dose of BNT162b2 mRNA vaccine. He is on medication state, MTX 3tab weekly, Folic Acid 1tab daily and Enbrel 1.0 twice/week since May 2019. He was given the third vaccination on Dec. 16, 2021. The next day after the vaccination, his right knee was swollen and felt pain on Dec. 17, 2021. The swollen joint was not improved with NSAID. So, prednisolone 15mg (3tab) was added on Jan. 3, 2022.

US of right knee showed large amount of joint effusion on right knee and US guided aspiration and IntraArticular steroid injection on Jan. 5, 2022.

Physical examination revealed that right knee swollen joint was aggravated on Jan. 26, 2022, nevertheless IA steroid injection on Jan 5, 2022. It is still swollen and painful on Feb. 10, 2022.

#### Conclusions

We experienced that after full vaccination with BNT162b2 patient with JIA, showed an increased risk of possible arthritis flare. So, to understand the association between arthritis flare and vaccination is important to overcome vaccine hesitancy.

#### **Figure & Table**

	12/20/2021	12/27/2021	12/29/2021	1/17/2022	1/26/2022	2/10/2022
D-dimer	1.79	1.73	1.85			
Troponin	0.16	2.51				
CK-MB	0.79	0.18				
Hs-CRP	2.38 mg/dL	6.51 mg/dL	8.54 mg/dL	1.44 mg/dL	2.32 mg/dL	1.72 mg/dL
ESR	12 mm/hr	32 mm/hr	41 mm/hr	32 mm/hr	37 mm/hr	38 mm/hr

Table. ESR and hs-CRP change

#### **Keywords**

Juvenile Idiopathic Arthritis, BNT162b2 vaccine, Flare-up JIA



# Challenges and management for pediatric rheumatology patient's in the COVID-19 era: Perspectives from several countries

## Putri Ayu¹

¹ Economics, Andalas University, Indonesia

#### Background

A global public health problem that threatens millions of lives around the world today is the COVID-19 pandemic This pandemic can have severe clinical manifestations such as acute respiratory distress syndrome or a cytokine storm that causes death. Pediatric rheumatology doctors during the Covid-19 pandemic have gone the extra mile to protect patients from COVID-19 infection without compromising disease prognosis. The management of cancer patients has so far been carried out mainly on rheumatology patients, including pediatric rheumatology because they have the risk of getting infections when they are children and it is very difficult to treat immunosuppression. This study aims to analyze the management of health workers in pediatric rheumatology patients in the era of the COV-ID-19 pandemic in various countries.

#### **Methods**

This study uses published international journals such as MEDLINE/PubMed and Scopus databases on the management of pediatric rheumatology health workers during the COVID-19 pandemic in patients using comparative analysis methods and descriptive studies. The countries taken in this study were France, Italy, India, the United States, Europe, and Germany.

#### Results

The results of the study concluded several categories in the health management of pediatric rheumatology patients during the COVID-19 pandemic. First, management of outpatient visits using teleconsultation, Favor Home Hospitalization or home care, telemedicine. Second, clinical trials for patients whose visits must be replaced by teleconsultation. Clinical and New patient registration is temporarily suspended. Third, Supportive Care is given for pediatric rheumatology, and vaccination is highly recommended.

## Conclusions

During the COVID-19 pandemic, it was concluded that there were several non-evidence-based practices in institutions to reduce the risk of exposure to COVID-19 for both pediatric rheumatology patients. The results show the need to test patients for SARS-CoV-2 infection, Pharmacists should be able to prescribe doses during treatment at once, Support hospitalization at home.

#### **Keywords**

Pediatric Rheumatologists, Challenges, Managements

# **E-poster Presentation**

Fibromyalgia and soft tissue disorders

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



# The use of shear-wave elastography for myofascial pain syndrome's severity

Recep Sade¹, Meltem Alkan melikoglu²

¹ Radiology, Ataturk University, Turkey
² Rheumatology, Ataturk University, Turkey

#### Background

Manual palpation is a subjective procedure for identifying and differentiate Myofascial Trigger Points (MTrPs), the use of Shear Wave Elastography (SWE) as an objective alternative is increasing. This study aimed to analyze pain pressure thresholds (PPTs) and SWE differences.

For analysis between active MTrPs, latent MTrPs and control points located in the upper trapezius Association of SWE features with clinical severity indicators (eg, area of pain expansion, PPTs, and neck pain).

#### Methods

This study was conducted to calculate the correlation. and to analyze the differences in sociodemographic, clinical and SWE characteristics in 24 asymptomatic patients subjects with latent MTrPs and 16 patients with neck pain and active MTrPs.

#### **Results**

Significant PPT differences between active with latent MTrPs (p < 0.001) and control points (p < 0.001) were found, but no differences between latent MTrPs and control points (p > 0.05). There were no stiffness differences between active MTrPs with latent MTrPs or control points (p > 0.05). However, significant control point stiffness differences between-samples were found (p < 0.05). SWE showed no significant correlation with clinical severity indicators (p > 0.05). No stiffness differences between active and latent MTrPs were found.

#### **Conclusions**

Neck pain patients showed increased control point stiffness compared with asymptomatic subjects. SWE showed no association with clinical severity indicators.

#### **Figure & Table**




Figure. Shear Wave Elastography image of 39-year old females shows Myofascial Trigger Point and its elasticity score

#### **Keywords**

elasticity imaging techniques, myofascial pain syndromes, trigger points



<u>KCR 2022</u>

# Amigos de fibro (Fibro Friends): Validation of an educational program for health promotion in fibromyalgia

## Mateus Antunes¹, Ana Carolina Schmitt¹, Amélia Marques¹

¹ Department of Physiotherapy, Speech Therapy and Oc, University of São Paulo (USP), Brazil

#### Background

Health education is one of the main items to enable the health promotion of patients with fibromyalgia and should prepare them to assume control and responsibility for their own health and the health of their territory, as well as prepare them for empowerment. decision-making, participation, social control and acting on the conditions and determinants of their health and quality of life. Therefore, the "Amigos de Fibro" was created in Brazil, an educational program to promote the health of patients with fibromyalgia. The objective was to validate a health promotion program focused on health education for patients with fibromyalgia in Brazil.

#### **Methods**

A study with a methodological approach was carried out with the participation of health professionals (n=23) (specialist judges) and patients with fibromyalgia (target audience) (n=45) who answered an instrument to assess the objectives, themes and proposed actions, relevance, writing style and program structure using the Delphi technique. Content Validity Index (CVI)  $\geq$  0.78 and Kappa Coefficient  $\geq$  0.61 were used for data analysis.

#### **Results**

All items evaluated in both groups had a considerable minimum CVI by CVI and Kappa Coefficient. The Kappa Coefficient of expert judges was 0.90 and that of target audience judges was 0.85. Finally, in the global assessment of "Amigos de Fibro", the CVI of the expert judges was 0.90, whereas the values of the target audience judges were 0.95.

#### **Conclusions**

"Amigos de Fibro" was considered adequate when its content and internal consistency were evaluated, in this sense, it can be used by health professionals with patients who have fibromyalgia, allowing them to act as agents that promote their health. New studies are being carried out to show more positive effects of "Amigos de Fibro".

#### **Keywords**

Fibromyalgia, Health education, Health Promotion



KCR 2022

May 19(Thu) - 21(Sat), 2022

# Amigos de fibro (Fibro Friends): Validation of an educational E-book to promote the health of patients with fibromyalgia in Brazil

## Mateus Antunes¹, Ana Carolina Schmitt¹, Amélia Marques¹

¹ Department of Physiotherapy, Speech Therapy and Oc, University of São Paulo (USP), Brazil

#### Background

Promoting the health of fibromyalgia patients is very important and recommended by leading health bodies and researchers. Patient education is the primary tool for managing symptoms. In Brazil, "Friends of Fibro" was created, an educational program that will promote the health of patients with fibromyalgia. In addition, an e-book was developed to be offered to patients using the public health system in Brazil. The aim of the study was to develop and validate an e-book to promote the health of individuals with fibromyalgia.

#### **Methods**

This is a methodological study, which through a bibliographic survey, the available publications on the subject were analyzed. Then, this knowledge was used to build the theoretical content addressed and the art and layout of the e-book was elaborated. In the last stage, the validation of the constructed material was carried out, by content specialists (n=23), technicians (n=23) and design (n=23) and fibromyalgia patients (n=45) evaluated the e-book through qualitative (Delphi methodology). For data collection, different questionnaires were used, according to the focus of evaluation of each group of participants, analyzed for agreement using the Content Validity Index (CVI) and reliability using Cronbach's Alpha ( $\alpha$ C).

#### **Results**

In reliability, all groups also had an acceptable  $\alpha$ C: content (0.960), technical (0.963), design (0.977), and target audience (1.08). In the global assessment of the agreement of all groups of judges, the CVI presented a considerable minimum, being: content (0.79), technical (0.89), design (0.92), and target audience (0.97).

#### Conclusions

The e-book was developed and validated in terms of content and relevance, and can be used to promote the health of individuals with fibromyalgia. New studies are being carried out to show more positive effects of "Amigos de Fibro".

#### **Keywords**

Fibromyalgia, Health education, Health Promotion

# **E-poster Presentation**

Idiopathic inflammatory myositis and muscle biology

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



KCR 2022

May 19(Thu) - 21(Sat), 2022

# Erdheim-Chester disease mimicking coronary artery disease in a systemic lupus erythematosus patient

Grigol Nemsadze¹, Megi Kurtanidze², Tamar Melkadze¹


¹ Radiology Department, TSSU First University Clinic, Georgia ² Radiology Department, Tbilisi City Medical, Georgia

## Description

A 38-year-old male patient presented to the emergency clinic with progressive atypical chest pain suggestive of unstable angina. The patient had been followed up and treated for systemic lupus erythematosus for 6 years. His elevated cardiac troponin biomarker. For this reason, we suspected coronary artery disease. A physical examination revealed a heart rate of 80 beats per minute and blood pressure of 130/60mm Hg. Electrocardiographic findings were unremarkable. It was seen that the patient occasionally referred to our hospital with these complaints. A Cardiac computed tomography (CT) scan revealed soft tissue surrounding the aorta and coronary artery (Figure 1A (asterisks) and 1B). It showed decreased coronary artery calibration (Figure 1B, white arrow). Rheumatologic and immunological diseases were investigated for the reason CT findings. Urine protein electrophoresis, Serum IgG4 level, and hepatitis panel were normal. Autoimmune workup, including antinuclear antibody, rheumatoid factor, anti-double-stranded DNA antibodies, complement levels, and antitopoisomerase, was similarly unremarkable. Fibroadipose tissue with exceeding histiocytes, highlighted by CD68-PGM1 and CD163 immunostaining, was evidenced from a biopsy of the left paravertebral tissue mass surrounding the descending aorta. He was treated with interferon alpha.

#### **Conclusions**

Erdheim-Chester disease (ECD) is an uncommon multisystem non-Langerhans cell histiocytosi. ECD cardiovascular involvement is usually asymptomatic and therefore under-diagnosed but linked to poor prognosi. As a conclusion, Erdheim-Chester's disease with coronary artery involvement is extremely uncommon. Due to the narrowing of coronary arteries, Erdheim-Chester disease should be kept in mind as atypical chest pain reason.





# New onset clinically amyopathic dermatomyositis following SARS-CoV-2 vaccine: A case report

## Eric Ranniel Guevarra¹, Sandra Teresa Navarra¹

¹ Section of Rheumatology, Department of Internal Medicine, University of Santo Tomas Hospital, Manila, Philippines, Philippines

#### Description

Amyopathic dermatomyositis is a rare autoimmune skin disease with similar cutaneous manifestations as classic dermatomyositis (CDM), but with absent or subclinical muscle involvement i.e. Clinically Amyopathic Dermatomyositis (CADM). Inciting agents including vaccines have been linked to CADM. We describe a case of new-onset CADM associated with COVID-19 vaccine.

To illustrate the occurrence of new-onset Clinically Amyopathic Dermatomyositis (CADM) in a 27-year-old male following COVID-19 immunization.

A previously well 27-year-old male developed joint and muscle aches accompanied by scattered erythematous patches on the face and both upper and lower extremities, a week after receiving first dose of viral vector SARS-CoV-2 vaccine. He took an anti-histamine and paracetamol with some relief of pains and slight clearing of the rashes. He proceeded to receive a second dose of the same vaccine 2 months later. A few days following the second dose, there was exacerbation of the skin lesions and was referred to Rheumatology clinics. Physical exam disclosed an ambulatory well-built male with normal vital signs and no objective muscle weakness. Skin involvement included facial rash, and the characteristic Heliotrope rash, Gottron's papules, and Holster sign. Complete blood counts, chemistries and muscle enzymes were within normal. Antinuclear antibody (ANA), erythrocyte sedimentation rate (ESR) and Smith/ ribonucleoprotein (Sm/RNP) antibody were positive. He was managed with tapering prednisone and maintained on methotrexate and folic acid with significant improvement at time of this report.

#### Conclusions

This is the first reported case of adverse reaction to COV-ID-19 vaccine that had studied in detail the skin and systemic autoimmune reaction. Development of autoimmune reaction following SARS-CoV-2 vaccine has been described extensively; however, evidence of autoimmunity following vaccination is still relatively scant. Our case suggests that in predisposed subjects' vaccination could trigger an autoimmune reaction similar to the natural infection.

#### **Figure & Table**



Figure. Skin lesions showing heliotrope and malar rash, Gottron's papules, hyperpigmentation and Holster sign

#### **Keywords**

Clinically amyopathic dermatomyositis, COVID-19 vaccine



KCR 2022

## Rare case of dermatomyositis following SARS-CoV-2 vaccination

Mark Andrian Yano¹, Geraldine Zamora¹

¹ Division of Rheumatology, Department of Medicine, Philippine General Hospital, Philippines

#### Description

We report a case of 51-year-old male who developed erythematous maculopapular rash on the upper anterior chest and upper back along with symmetric proximal muscle weakness two months after receiving his second dose of Sinovac (CoronaVac) COVID 19 vaccine. His symptoms were followed by periorbital edema which eventually involved the upper and lower extremities. He also had dysphagia and unintentional weight loss. His medical history was notable for hypertension which was well controlled and a 15-pack year smoking history. He had no family history of autoimmune diseases.

Physical examination revealed areas of poikiloderma on the lower anterior neck (V sign), upper back (shawl sign), heliotrope rash and hyperkeratotic pink ill-defined papules with scale on bilateral lateral second digits (mechanic's hands). Symmetric proximal muscle weakness in the upper and lower extremities was objectified. Onychoscopy revealed erythema on the proximal nailfold with no telangiectasias.

Blood tests revealed elevated muscle enzymes (total CK 3899 U/L, CK MB mass 15.4 ng/mL, LDH 683, AST 232 U/L and ALT 66 IU/L) elevated ESR (36) and normal CRP. Anti Jo 1 and anti U1 RNP were negative. Work up for systemic infection, thyroid function and malignancy were unremarkable. Chest and abdominal CT scan revealed diffuse subcutaneous edema with no evidence of intrathoracic or intraabdominal mass lesions.

Patient was started on hydrocortisone 1 mg/kg/day and later shifted to prednisone 80 mg per day. Azathioprine was introduced on the 3rd hospital day. Gradual subjective improvement of muscle strength was noted.

#### Conclusions

We hypothesize that among patients with genetic predisposition, the possibility of vaccines triggering dermatomyositis and other autoimmune event is possible and as vaccine inoculation increases, data will accumulate, and comparisons will become possible.

#### Figure & Table



Figure. V sign in the upper anterior chest of the patient

#### **Keywords**

Dermatomyositis, COVID 19 vaccine



KCR 2022

May 19(Thu) - 21(Sat), 2022

## Clinical characteristics and outcomes of adult patients with anti-MDA5 dermatomyositis- A single centre experience from South India

<u>Shivraj Padiyar</u>¹, Aswin Nair¹, Prathyusha Manikuppam¹, Avanish Jha¹, Abhilasha Manwatkar¹, John Mathew¹

¹ Clinical Immunology and Rheumatology, Christian medical College, Velore, India

#### Background

To study the demographic, clinical characteristics, and treatment outcomes of patients with anti-MDA5 dermatomyositis

#### Methods

This is a retrospective study done between 2019 and 2021 in a tertiary care centre from South India. All consecutive patients, presenting to the adult rheumatology department, classified as idiopathic inflammatory myositis (IIM), and positive for anti-MDA5 antibody were included in the study. Baseline characteristics of anti-MDA5 patients were compared with the data of non-MDA5 patients over the last 10 years. Clinical, biochemical, and treatment responses were assessed on follow-up. Complete and partial responders were identified using predefined criteria. Factors predicting mortality were determined by logistic regression analysis. Data were analyzed using the Statistical Package for the Social Sciences (SPSS) version 20.

#### Results

A total of 29 adult patients of dermatomyositis were positive for anti-MDA5 antibody during the study period. The mean (±SD) age of the patients was 40.3 (±13.02) yrs with the female: male ratio of 1.4:1. Panniculitis, calcinosis, palmar papules, and ulcerated gottron's were the specific cutaneous manifestations, seen in 3(10 %), 7(24 %), 4(13.4%), and 7(24%) patients respectively. 14 patients (48.1%) had clinically amyopathic dermatomyositis. 17 patients (60.7%) had interstitial lung disease by CT scan, of which organizing pneumonia was the predominant pattern. Complete response was seen in 10 patients (43%), while the partial response was seen in 8 patients (34%). Five patients died on follow-up, accounting for a mortality of 21%. Age >50 yrs was significantly associated with mortality (p=0.025)

#### Conclusions

Anti-MDA5 dermatomyositis represents a distinct and unique subset of Idiopathic inflammatory myositis with characteristic clinical manifestations. A combination of high-dose steroids with mycophenolate led to improvement in all the patients with anti-MDA5 antibodies with non-RP-ILD presentations. Elderly age is a poor prognostic factor of mortality.

#### Figure & Table

Parameter	Anti-MDA5	Non Anti-	P value
	DM	MDA5 DM	
	(N-29)	(N=421)	
Age, mean (± SD), yrs	40.3(±13.02)	38.4(±13.5)	0.45
Duration of disease, months	15.6(±22.79)	14.04(±22.18)	0.71
mean (± SD),			-
Female/Male	17/12	292/129	0.22
Cutaneous lesions			
Gottron's sign	20(69%)	109 (25.9%)	< 0.001
Heliotrope rash	13(44.8%)	153(36.3%)	0.36
Panniculitis	3(10.3%)	9(2.1%)	<0.001
Calcinosis	6(20.7%)	53(12.7%)	<0.001
Mechanics Hands	4(13.8%)	40(9.5%)	0.45
Cutaneous ulcers	9 (31%)	18(4.3%)	<0.001
Ulcerated Gottron's	7(24.1%)	0	<0.001
Cutaneous vasculitis	4(13.8%)	28(6.9%)	0.16
Raynauds phenomenon	5(17.2%)	43(10.2%)	0.23
Systemic manifestations			
Fever	7(24.1%)	150(35.6%)	0.209
Dysphagia	4(13.8%)	112(26.7%)	0.19
Arthritis	24(82.8%)	139(33%)	<0.001
Clinical Muscle weakness	14(48.3%)	380(90.5%)	<0.001
ILD	17(60.7%)	158(37.5%)	0.015
Type of ILD			
NSIP	3(17.6%)	94(59%)	
OP	6(35.2%)	19(11.9%)	
NSIP-OP	6(35.2%)	4(2.5%)	
UIP	0	4(2.5%)	
Unclassified	2(11.7%)	38(24%)	
CPK levels, units/L, mean (±	244(±623.8)	2375(±5520)	<0.001
SD)			
LDH, units/L, mean (± SD)	780(±364)	1156(±783)	<0.001
Anti-Ro52 positivity *	7(24.1%)	71(16.9%)	0.21

* Done using EUROIMMUNE assay, a titre of 2+ or more is considered positive

ILD- Interstitial lung disease, NSIP- Non specific Interstitial pneumonitis,OP-Organizing pneumonia, RP-ILD- Rapidly progressive ILD, CPK- Creatinine phosphokinase, LDH- lactate

dehydrogenase, ANA- antinuclear antibody, IIF- Indirect Immunoflurescence,

Table. Clinical and demographic characteristics of individuals with anti-MDA-5 antibody dermatomyositis

#### **Keywords**

Anti-MDA5, Ulcerated Gottron's, Rapidly progressive ILD, panniculitis, Palmar papules



# Changes in quantitative interstitial lung disease scores on high-resolution CT in idiopathic inflammatory myositis

<u>Jina Yeo</u>¹, Soon Ho Yoon², Ju Yeon Kim³, Jeong Seok Lee⁴, Eun Young Lee³, Jin Mo Koo², Lila Pourzand⁵, Jonathan G Goldin⁵, Grace-Hyun J Kim⁵, You-Jung Ha⁶

¹ Rheumatology, Gil Medical Center, Gachon University College of Medicine, Republic of Korea
 ² Radiology, Seoul National University Hospital and College of Medicine, Republic of Korea
 ³ Rheumatology, Seoul National University Hospital and College of Medicine, Republic of Korea
 ⁴ Clinic Pappalardo Center, Korea Advanced Institute of Science and Technology (KAIST), Republic of Korea
 ⁵ Radiology, David Geffen School of Medicine, University of California, Los Angeles (UCLA), USA
 ⁶ Rheumatology, Seoul National University Bundang Hospital, Republic of Korea

#### Background

To investigate longitudinal changes of the quantitative interstitial lung disease (QILD) scores and their clinical impact in idiopathic inflammatory myositis (IIM) associated ILD.

#### **Methods**

A total of 80 patients with IIM-ILD who underwent at least 2 times of serial HRCT scans were included. Quantitative analysis of HRCT was presented as total extent of QILD scores (%) in whole lung (WL) and most severe zone (MSZ). Individual time-estimated yearly  $\Delta$ QILD score between first 2 visits was derived using a linear approximation.

#### **Results**

Baseline median score of WL-QILD and MSZ-QILD were 28.1% (19.1-43.8) and 68.0% (45.5-81.8), respectively, and QILD score showed significant correlations with %FVC (r=-0.349) and %DLCO (r=-0.381), (p<0.05). The ΔQILD score presented that approximately half of the patients showed improvement in QILD scores; however, when patients were sorted by visual assessment in ILD subtype on HRCT, approximately two-thirds of the patients with usual interstitial pneumonia (UIP) pattern were aggravated in QILD scores and <50% of subjects with nonspecific interstitial pneumonia and organizing pneumonia were aggravated (Figure 1, UIP 80% vs. Non-UIP 44.4%, p=0.013). While there was no immunosuppressive drugs related to meaningful improvement in QILD scores during first 2 visits, significant aggravation was observed in tacrolimus users (n=7) compared with tacrolimus non-users (n=73) (+20.3 (2.7-38.4) vs. -1.2 (-8.3-6.5), p=0.013). Higher baseline QILD scores were noted in deaths (n=6) than survivors (n=74) (45.4 (32.9-56.5) vs. 26.9 (19.0-42.4), p=ns) and poor survival rate was observed in patients with high grade of ground glass opacity

by visual assessment in right upper lobe (p=0.042). In patients with 3 serial HRCT scans (n=41), dynamic changes of four distinct patterns (improving/worsening/convex/ concave) were observed.

#### **Conclusions**

The changes in QILD score in IIM-ILD are dynamic and present different by visual assessment. QILD score has the potential for evaluation of the severity changes, prognosis and medication response in patients with IIM-ILD.

#### Figure & Table




Figure. Cleveland dot plot of individual time-estimated yearly  $\Delta$ QILD during fist 2 visits

#### **Keywords**

quantitative score, interstitial lung disease, idiopathic inflammatory myositis



# Time-dependent changes in rapidly progressive-interstitial lung disease and mortality risk in anti-MDA5 antibody positive dermatomyositis patients: A cohort study of 272 cases in China

Hanxiao You¹, Lingxiao Xu¹, Lei Wang¹, Chengyin Lv¹, Fenghong Yuan², Ju Li³, Min Wu⁴, Shiliang Zhou⁴, Zhanyun Da⁵, Jie Qian⁵, Hua Wei⁶, Wei Yan⁶, Lei Zhou⁷, Yan Wang⁷, Songlou Yin⁸, Dongmei Zhou⁸, Jian Wu⁹, Yan Lu¹⁰, Dinglei Su¹¹, Zhichun Liu¹², Lin Liu¹³, Longxin Ma¹⁴, Xiaoyan Xu¹⁵, Yinshan Zang¹⁶, Huijie Liu¹⁷, Tianli Ren¹⁸, Fang Wang¹⁹, Miaojia Zhang¹, Wenfeng Tan¹

> ¹ Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, China ² Department of Rheumatology, the Affiliated Wuxi People's Hospital of Nanjing Medical University, China ³ Department of Rheumatology, Huai'an First People's Hospital, China ⁴ Department of Rheumatology, The First People's Hospital of Changzhou, China ⁵ Department of Rheumatology, Affiliated Hospital of Nantong University, China ⁶ Department of Rheumatology, Northern Jiangsu People's Hospital, China ⁷ Department of Rheumatology, Changzhou No.2 People's Hospital, China ⁸ Department of Rheumatology, Affiliated hospital of Xuzhou Medical University, China ⁹ Department of Rheumatology, The First Affiliated Hospital of Soochow University, China ¹⁰ Department of Rheumatology, Jiangsu Province Hospital of Chinese Medicine, China ¹¹ Department of Rheumatology, Nanjing First Hospital, China ¹² Department of Rheumatology, The Second Affiliated Hospital of Soochow University, China ¹³ Department of Rheumatology, Xuzhou Central Hospital, China ¹⁴ Department of Rheumatology, Yancheng No.1 People's Hospital, China ¹⁵ Department of Rheumatology, Zhongda Hospital Southeast University, China ¹⁶ Department of Rheumatology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, China ¹⁷ Department of Rheumatology, The First People's Hospital of Lianyungang, China ¹⁸ Department of Rheumatology, Wuxi No.2 People's Hospital, China ¹⁹ Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, China

#### Background

Anti-melanoma differentiation-associated gene 5 (MDA5) positive dermatomyositis (DM) is a rare but distinct subtype of DM with a poor prognosis. We conducted this study to investigate the clinical characteristics and outcomes in anti-MDA5 antibody positive dermatomyositis and whether the risk of RP-ILD and death were time-dependent or not.

#### **Methods**

We assessed a cohort of 272 patients with anti-MDA5-positive DM. We summarized the clinical characteristics of patients with MDA5+ DM, and used COX regression to analyze independent risk factors for RPILD and death. We also described changes in risk of RPILD and death over time and their potential clinical implications.

#### **Results**

There were 272 anti-MDA5+ DM patients enrolled in this historical prospective clinical study. According to the multivariate cox regression analysis, short disease course, high ESR level, anti-Ro52 positive and anti-MDA5 titer (++~+++) were independent risk factors of RP-ILD. Arthritis, high CK level, high CRP level and RPILD were independent risk factors of death. Hazards regarding RPILD and mortality diminished over time from diagnosis, declined faster in the first six months.

## Conclusions

Short disease course, high levels of muscle enzymes and high inflammation state are risk factors for poor prognosis. Our data regarding time-dependent hazards of RPILD and death reflect the disparate change of risks and this change of risk should be considered in clinical decision making.

#### **Figure & Table**




Figure. The survival of RP-ILD in anti MDA5+ DM patients smoothed hazard plots. Smoothed hazard plots more clearly demonstrate changes in risk at different time intervals than Kaplan-Meier plots do.

#### **Keywords**

Dermatomyositis, MDA5, Interstitial lung disease



Journal of Rheumatic Diseases Vol. 29, Suppl. 1, May, 2022

P-107

# Coexisting of anti-Ro52 autoantibodies on anti-MDA5 autoantibodies-positive dermatomyositis is highly associated with rapidly progressive interstitial lung disease and mortality risk

<u>Hanxiao You</u>¹, Chengyin Lv¹, Lingxiao Xu¹, Lei Wang¹, Fenghong Yuan², Ju Li³, Min Wu⁴,
 Shiliang Zhou⁴, Zhanyun Da⁵, Jie Qian⁵, Hua Wei⁶, Wei Yan⁶, Lei Zhou⁷, Yan Wang⁷, Songlou Yin⁸,
 Dongmei Zhou⁸, Jian Wu⁹, Yan Lu¹⁰, Dinglei Su¹¹, Zhichun Liu¹², Lin Liu¹³, Longxin Ma¹⁴,
 Xiaoyan Xu¹⁵, Yinshan Zang¹⁶, Huijie Liu¹⁷, Tianli Ren¹⁸, Fang Wang¹⁹, Miaojia Zhang¹, Wenfeng Tan¹

¹ Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, China ² Department of Rheumatology, the Affiliated Wuxi People's Hospital of Nanjing Medical University, China ³ Department of Rheumatology, Huai'an First People's Hospital, China ⁴ Department of Rheumatology, The First People's Hospital of Changzhou, China ⁵ Department of Rheumatology, Affiliated Hospital of Nantong University, China ⁶ Department of Rheumatology, Northern Jiangsu People's Hospital, China ⁷ Department of Rheumatology, Changzhou No.2 People's Hospital, China ⁸ Department of Rheumatology, Affiliated hospital of Xuzhou Medical University, China ⁹ Department of Rheumatology, The First Affiliated Hospital of Soochow University, China ¹⁰ Department of Rheumatology, Jiangsu Province Hospital of Chinese Medicine, China ¹¹ Department of Rheumatology, Nanjing First Hospital, China ¹² Department of Rheumatology, The Second Affiliated Hospital of Soochow University, China ¹³ Department of Rheumatology, Xuzhou Central Hospital, China ¹⁴ Department of Rheumatology, Yancheng No.1 People's Hospital, China ¹⁵ Department of Rheumatology, Zhongda Hospital Southeast University, China ¹⁶ Department of Rheumatology, The Affiliated Suqian First People's Hospital of Nanjing Medical University, China ¹⁷ Department of Rheumatology, The First People's Hospital of Lianyungang, China ¹⁸ Department of Rheumatology, Wuxi No.2 People's Hospital, China ¹⁹ Department of Cardiology, The First Affiliated Hospital of Nanjing Medical University, China

## Background

Interstitial lung disease (ILD) is a common extramuscular complication contributing to significant morbidity and mortality in anti-melanoma differentiation associated gene five dermatomyositis (anti-MDA5+ DM). We conducted this study to investigate the association of anti-Ro52 antibodies with clinical characteristics and prognosis in anti-MDA5 + DM patients.

#### **Methods**

We assessed a cohort of 246 patients with anti-MDA5-positive DM. To calculate hazard ratios (HRs) and 95% confidence intervals (95% Cls) for RP-ILD and death while controlling for potential confounders, variables selected by univariate COX regression analysis were included in a multivariate COX regression model with the stepwise forward selection method. A 2-tailed P value <0.05 was considered to indicate statistical significance.

#### **Results**

246 anti-MDA5+ DM patients enrolled, 70 cases male, with an average age of 53.1±12.35 years. Anti-Ro52 coexisted in 64.22% (158/246) patients. Anti-Ro52 autoantibodies positive anti-MDA5+ DM patients had a higher rate of RP-ILD (log-rank p<0.001) and a higher mortality rate (log-rank p=0.01). For anti-MDA5+ DM patients with positive anti-Ro52 antibodies, patients with short disease course, high inflammation are at high risk of RP-ILD and death. The appearance of the active rash is an independent protective factor of death.

#### Conclusions

Anti-Ro52 antibodies is highly prevalent in anti-MDA5-positive DM patients and their coexistence correlates with a higher rate of RP-ILD and mortality. Patients with a short disease course, increased inflammation and without rash are more likely to have a poor prognosis.

#### Figure & Table




Figure. Difference of cumulative survival rate anti-MDA5+ DM patients with versus without anti-Ro52 autoantibodies. Patients with anti-Ro52 antibodies positive had a significant higher mortality rate (log-rank p = 0.01).

#### **Keywords**

Dermatomyositis, MDA5, anti-Ro52

# Galectin-9 and CXCL-10 as biomarkers in assessing disease activity in Dermatomyositis and Polymyositis - A single centre cohort study

<u>SAI KUMAR Dunga^{1,2}</u>, Chengappa Kavadichanda¹, Devender Bairwa¹, Molly Mary Thabah¹, Vir Singh Negi¹

¹ Department of Clinical Immunology, Jawaharlal institute of postgraduate medical education and research, India ² Department of Clinical Immunology and Rheumatology, Apollo Hospitals, Vishakapatnam, India

#### Background

Biomarkers are important in diagnosing, treating and prognostication of Idiopathic inflammatory myositis (IIM). Traditional biomarkers have a great extent of variability in their levels and poor correlation with disease activity. Hence there is a dire need for new biomarkers.

#### **Methods**

This cohort study included 42 IIM patients satisfying 2017 EULAR/ACR criteria. Patients were classified as active (n=18) and inactive disease (n=24) based on clinical status at baseline. Apart from routine investigations, serum samples (5 ml of peripheral venous blood) were collected at enrollment and at 3 months and 6 months for biomarker analysis. Galectin-9, CXCL-10, IL-10, TNFRII, BAFF and APRIL, were measured at baseline, at 3 months and at 6 months using ELISA. Data were analysed using SPSS version 19.0.

#### **Results**

All patients followed up at 3 months and 39 completed 6 months follow-up. There was a significant change(p<0.05) in the Galectin-9, CXCL10, APRIL, TNFRII levels in the active disease subgroup at 3 months and 6 months from baseline. Upon posthoc analysis of the significant variables, the change between baseline and at 3 months as well as change between 3 months and at 6 months was also significant(p<0.001). Galectin-9, CXCL10, APRIL, TNFRII were able to differentiate(p<0.05) between patients with active disease and inactive disease at baseline. Based on the coordinates of the ROC curve we obtained a cut-off value of 1455.47pg/ml for galectin-9 (with a sensitivity of 69% and specificity Of 76%), 86 pg/ml for CXCL10 (with a sensitivity of 87.5% and specificity Of 66%). Change in galectin-9 (r=0.534), CXCL-10 (r=0.409) and BAFF (r=0.534) showed moderate correlation with change in MMT8 at 6 months.

## **Conclusions**

Galectin-9, CXCL10, APRIL, TNFRII are reliable markers for assessing treatment response and differentiating patients with active and inactive disease. Galectin-9 was more specific and CXCL10 was more sensitive in differentiating active versus inactive patients with IIM.

#### **Figure & Table**

	Baseline (n=18)	3 months (n=18)	6 months (n=16)	P value
Galectin-9 pg/ml	1849.67	937.49	616.95	0.001
	(699-6735)	(486-6174)	(287-4407)	
CXCL10 pg/ml	460.52	80.58	73.81	0.001
	(109-460.5)	(18-460.5)	(12-460.5)	
APRIL ng/ml	0.78	0.23	0.03	0.005
	(0.194-4.15)	(0.01-2.87)	(0.01-0.475)	
TNFRII ng/ml	13.34	6	4.43	0.001
	(2.7-25.2)	(3.5 - 19.3)	(0.9-16)	
BAFF ng/ml	0.017	0.01	0.01	0.204
	(0.01-1.1)	(0.01-0.34)	(0.01-0.05)	
IL-10 pg/ml	0.01	0.01	0.01	0.343
	(0.01-24.7)	(0.01-14.3)	(0.01-12.2)	1
<i>,</i> ,	00,	AFF, B cell–activating our necrosis factor rec	, , , ,	-X-C motif

Table. Comparison of biomarker levels among the active disease subgroup at baseline, 3 months and 6 months

#### **Keywords**

Biomarkers, Inflammatory myopathy, Disease activity



KCR 2022

May 19(Thu) - 21(Sat), 2022

# Role of Semiquantitative thigh Magnetic Resonance Imaging (tMRI) in determining skeletal muscle outcomes at baseline and on follow up in idiopathic inflammatory myopathies (IIMs)

<u>Mamatha Gorijavolu</u>¹, Devender Bairwa¹, Chengappa Kavadichanda¹, Aishwarya Gopal¹, Sai Kumar Dunga¹, Molly Mary Thabah¹, Vir Negi¹

¹ Clinical Immunology, Jawaharlal institute of postgraduate medical education and research, India

#### Background

Idiopathic Inflammatory Myopathies (IIMs) are characterized by muscle inflammation and associated muscle weakness. Semiquantitative scoring of thigh Magnetic Resonance Imaging (tMRI) has shown contradictory results in associating muscle inflammation, damage, and clinically assessed muscle weakness. Moreover, there are no studies assessing the role of tMRI detected muscle damage in determining long-term recovery of muscle strength and endurance.

Objectives: To correlate baseline tMRI scores with consecutively collected manual muscle testing 8 (MMT-8) scores.

#### **Methods**

This is a retrospective analysis of a single-center myositis cohort. Baseline demographic, clinical, and serological parameters of IIM patients (n=55) who underwent baseline tMRI (STIR and T1 sequences) at the time of diagnosis were noted. MRI images were assessed for intramuscular and fascial edema, atrophy and fatty replacement using a semiquantitative score. MMT-8 values and muscle enzyme levels which remained unchanged at least for 6 months during follow-up were noted for 42 patients. For statistical analysis, Spearman correlation and multiple linear regression were performed.

#### **Results**

The median age was 36 (27.25-44.75) years, median duration of disease at presentation was 4 months (2-10), median duration of follow up was 24 months (6.75-38.25). Baseline muscle enzymes CPK(r=0.531), AST(r=0.535) and ALT(r=0.442) showed significant positive correlation(p<0.01) with muscle edema. Baseline MMT-8 showed significant negative correlation with muscle edema(r=-0.657) and fascial edema(r=-0.522) (p<0.01).

Follow up MMT-8 showed significant negative correlation with muscle edema(r=-0.359), muscle atrophy (r=-0.319) and fatty infiltration(r=-0.308) (p<0.05). Baseline MMT-8 and MRI fatty infiltration were significantly different between patients who achieved and did not achieve MMT-8 of  $\geq$ 74 on follow-up. Multiple regression analysis revealed adjusted R² value of 0.386. Baseline MMT-8( $\beta$ =0.372) and muscle atrophy( $\beta$ =-0.459) significantly predicted MMT-8 on follow-up.

#### Conclusions

Low baseline MMT-8 and presence of muscle atrophy at baseline are predictors of poor outcome. Hence performing a baseline MRI will help in the prognosis.

#### Figure & Table




Figure. Correlation between baseline and Follow up MMT-8 with tMRI scores.

#### **Keywords**

Idiopathic inflammatory myositis, Thigh Magnetic Resonance Imaging, MMT-8

# **E-poster Presentation**

Sjögren's syndrome

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



# Hyperglobulinemia in primary Sjögren's syndrome predicts the poor outcome: From multicenter registration study

<u>Hui Zhong</u>¹, Yanhong Wang², Pingting Yang³, Xinwang Duan⁴, Yongfu Wang⁵, Jian Xu⁶, Lijun Wu⁷, Qin Li⁸, Xiaodan Kong⁹, Liyun Zhang¹⁰, Xiaomei Li¹¹, Dong Xu¹, Mengtao Li¹, Yan Zhao¹, Xiaofeng Zeng¹

¹ Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, China
 ² Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, China
 ³ Department of Rheumatology and Immunology, The First Affiliated Hospital, China Medical University, China
 ⁴ Department of Rheumatology and Immunology, The Second Affiliated Hospital Nanchang University, China
 ⁵ Department of Rheumatology, First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science&Technology, China
 ⁶ Department of Rheumatology and Immunology, The First Affiliated Hospital of Kunming Medical University, China
 ⁷ Department of Rheumatology and Immunology, Xinjiang Uygur Autonomous Region People's Hospital, China
 ⁸ Department of Rheumatology and Immunology, The First People's Hospital of Yunnan Province, China
 ⁹ Department of Rheumatology and Immunology, The Second Affiliated Hospital, Dalian Medical University, China
 ¹⁰ Department of Rheumatology and Immunology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, China
 ¹¹ Department of Rheumatology and Immunology, the first affiliated hospital of USTC(Anhui Province Hospital), China

## Background

Primary Sjogren's syndrome(pSS) is an autoimmune disease characterized by exocrine gland involvements and B cell hyperactivity. About half of pSS patients have hyperglobulinemia, and whether treatment should be initiated for hyperglobulinemia is still controversial. The aim of this study to investigate the all-cause mortality of pSS with hyperglobulinemia, based on a multicenter cohort.

#### **Methods**

Patients who met 2002 AECG criteria or 2016 ACR/EU-LAR classification criteria for SS and did not overlap other connective tissue diseases in Chinese Rheumatism Data Center from May 2016 to July 2021 were included in this study. Data of demographic and clinical characteristics, laboratory results, disease activity and damage scores were used. Hyperglobulinemia was defined as IgG>17.0g/L, or IgA>4.0g/L, or IgM>2.6g/L. The primary outcome is allcause death until July 15, 2021.

## Results

A total of 9527 pSS patients were included in the study, and 4236(44.5%) pSS had at least one kind of elevated immunoglobulin levels among IgG, IgA and IgM. Patients with hyperglobulinemia had significantly increased risk of death, with crude HR 2.6(95%CI 1.91-3.55). After adjustment for sex, age, disease course, ILD and PAH, pSS patients with hyperglobulinemia still had significant increased risk of all-cause death (adjusted HR 1.87 95%CI 1.36-2.57) than those without. The 5-year and 10-year survival rates of patients with hyperglobulinemia were 96.9%, 92.3%, which were significantly lower than those with normal immunoglobulin level. In subgroup analysis, pSS patient with both elevated IgG and IgA had the highest risk of death (HR 3.88, 95%CI 2.766-5.44). Death risk positively correlated with IgG levels (P for trend <0.001).

#### Conclusions

hyperglobulinemia is an independent risk factor for increased all-cause mortality in pSS patients. Therefore, treatments should be given to pSS patients with hyperglobulinemia, especially to those with both increased IgG and IgA.

#### **Keywords**

Sjogren's syndrome, hyperglobulinemia, prognosis

# Primary Sjögren's syndrome is associated with increased risks of not just lymphoma: a systematic review and meta-analysis

Hui Zhong¹, Siyao Liu¹, Yanhong Wang², Dong Xu¹, Mengtao Li¹, Yan Zhao¹, Xiaofeng Zeng¹

¹ Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, China ² Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences Chinese Academy of Medical Sciences, China

## Background

To investigate the association between primary Sjogren's syndrome(pSS) and the risks of malignancy, with a focus on solid tumors and hematological malignancies other than non-Hodgkin lymphoma (NHL) through a systematic review and meta-analysis.

## **Methods**

We searched PubMed and EMBASE by March 21st 2021. Inclusion criteria were as follows: (1) pSS was the exposure of interest; (2) newly developed malignancies were the outcome of interest; (3) standardized incidence ratio or relative risk with 95% confidence interval or essential data to calculate them were reported. (4) Study design was cohort study. Patient with other connective diseases were excluded. Quality assessment was conducted according to Newcastle-Ottawa Scale for cohort study. Random or fixed effect models were used to calculate the pooled SIR according to the heterogeneity.

## **Results**

A total of 1003 articles were found by a comprehensive search in PubMed and EMBASE. Twenty-eight articles were eligible. Since 4 of them were from the same database, the one with longest observational span was chosen. Therefore, twenty-five articles were included for final analysis, which involved more than 47607 pSS patients with the follow-up of more than 452468 person-year. We found that pSS was associated with increased risks of overall malignancy(pooled SIR 2.17, 95%1.57-3.00), hematological malignancy(pooled SIR 11.55, 95%CI 4.32-30.90) including NHL(pooled SIR 13.71, 95%CI 8.83-21.29), Hodgkin lymphoma(pooled SIR 8.84, 95%CI 5.00-15.61), multiple myeloma(pooled SIR 8.27, 95%CI 3.08-22.24), leukemia(pooled SIR 2.56, 95%CI 1.78-3.69) and solid tumors(pooled SIR 1.39, 95%CI 0.90-2.13) including lung cancer(pooled SIR 1.55, 95%CI 1.29-1.85), thyroid cancer(pooled SIR 2.05, 95%CI 1.20-3.48), non-melanoma skin cancer(pooled SIR 1.71, 95%CI 1.08-2.72), kidney/urinary tract cancer(pooled SIR 1.36, 95%CI 1.03; 1.80), liver cancer(pooled SIR 1.70, 95%CI 1.13-2.57) and prostate cancer(pooled SIR 1.50, 95%CI 1.02-2.22).

## **Conclusions**

This meta-analysis shows that pSS patients have increased overall cancer risk, which not only contributed by NHL, but also by other hematological malignancies and solid tumors.

## **Keywords**

Sjogren's syndrome, malignancy, prognosis



# Salivary ultrasonography and histopathologic evaluation of secondary Sjögren's syndrome in rheumatoid arthritis patients

## Minae Oh¹, Youngjae Park¹, Youn Soo Lee², Wan-Uk Kim¹

¹ Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's hospital, The Catholic University of Korea, Republic of Korea ² Department of Hospital Pathology, Seoul St. Mary's Hospital, The Catholic University of Korea, Republic of Korea

#### Background

Sjogren's syndrome (SS) is one of the most frequent autoimmune conditions overlapped in rheumatoid arthritis (RA). Recently, novel modalities such as salivary ultrasonography (SGUS) and shear wave elastography (SWE) are introduced for evaluating SS. However, in patients with secondary SS, diagnostic performance of SGUS and its relationship with clinicopathological characteristics have not been clearly defined. In this study, we aimed to investigate prevalence of secondary SS in RA patients using new modalities and clarify their clinicopathological features.

#### **Methods**

Thirty-one RA patients presented with sicca symptoms were included for being evaluated on SS, and were compared with 18 primary SS (pSS) patients as a control. All subjects were assessed through SGUS and SWE as well as conventional diagnostic approaches for SS, including minor salivary gland biopsy (MSGB). In SGUS evaluation, two separate scoring systems were used. MSGB specimens were digitally scanned and evaluated by a specialized pathologist.

#### **Results**

Among 31 RA patients with sicca symptoms, 19 (61.2%) were diagnosed as secondary SS according to the 2016 classification criteria for SS. Interestingly, secondary SS patients had significantly lower positivity for anti-Ro anti-body and anti-La antibody than pSS patients. Both SGUS scoring systems demonstrated good diagnostic performance in differentiating secondary SS from RA patients with sicca symptoms. As expected, in histopathologic assessment of MSGB, secondary SS and pSS patients exhibited significantly higher lymphocytic infiltration areas than RA patients without SS. Focus score and lymphocytic infiltration areas in were correlated well with sonographic severity by the two scoring systems. The pathologic severity of fibrosis was positively correlated with SWE, but failed to have correlations with SGUS findings.

#### Conclusions

Secondary SS is more frequent in RA patients than reported earlier and presents less positivity for anti-Ro/La antibodies. Similar to for pSS, SGUS shows good diagnostic performance for secondary SS, reflecting well histopathologic severity on MSGB.



# STAT4 gene polymorphisms in risk of Sjögren's syndrome patients susceptibility: Update systematic review and meta-analysis

Rendra Ristian wibowo¹, Bastomy Eka rezkita¹, Ambar Mudigdo², Dyah Ratna²

¹ Internal Medicine, Sebelas Maret University, Indonesia ² Pathological Anatomy, Sebelas Maret University, Indonesia

#### Background

Sjögren's syndrome (SS) is chronic autoimmune condition typically known by autoantibody generation, sicca syndrome, and periepithelial lymphocytic lesions in target tissues. STAT4 genes encode transcription factor that transmits signal induced by interleukin 12(IL-12) IL-23, and type 1 interferon. STAT4 also play important role in developing IL-17 secreting Th cells in response to IL-23. Both lineages are key role in developing SS. Objectives of this paper is to investigate the possible association of the polymorphism of the STAT4 with susceptibility to SS and with phenotypic disease features.

#### **Methods**

This meta-analysis was conducted based on the PRISMA guideline. Literature searches from Cochrane, Pubmed and EMBASE were conducted until December 2021 and were limited to English-only literature. Inclusion criteria of these meta-analysis include case control and cohort study. Studies included in this meta-analysis were accessed using The Newcastle Ottawa Score (NOS). The primary outcome was the association between STAT4 gene polymorphism and the risk of SS. The sufficient data count is pooled by OR and 95% CI.

#### **Results**

Four studies (652 case / 1052 control) met the inclusion criteria. G allele and GG genotype were associated with decreased risk of SS (OR= 0.65[0.56 - 0.76], p= 0.0001 and OR= 0.59[0.48-0.73]. p= 0.0001). Meanwhile, T allele and GT genotype were significantly associated with increased risk of SS (OR= 1.53[1.31-1.79], p= 0.0001 and OR=1.38 [1.12-1.69], p= 0.002).

#### **Conclusions**

Our meta-analysis suggested that G allele and GG genotype may serve as protective factor of SS, while A allele and GT genotype may increase risk factor for SS. Further study about interaction between genetic-environment interactions with larger sample is needed

#### Figure & Table

	Case	e	Healt	th		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Ciccacci 2019	262	390	387	486	29.1%	0.52 [0.39, 0.71]	-
Mirkazemi 2013	329	560	383	562	40.5%	0.67 [0.52, 0.85]	-
Palamino 2010	91	138	418	592	13.8%	0.81 [0.54, 1.20]	
Palamino 2 2010	155	216	354	454	16.6%	0.72 [0.50, 1.04]	
Fotal (95% CI)		1304		2094	100.0%	0.65 [0.56, 0.76]	•
Total events	837		1542				
Heterogeneity: Chi ² =				= 11%			0.01 0.1 1 10
Test for overall effect:	Z= 5.39 (	(P < 0.0	00001)				Health Case
(B) GG genotype							
	Case	е	Healt	th		Odds Ratio	Odds Ratio
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Ciccacci 2019	92	195	150	243	29.7%	0.55 [0.38, 0.81]	
Mirkazemi 2013	99	280	138	281	37.5%	0.57 [0.40, 0.80]	
Palamino 2010	28	69	152	296	14.4%	0.65 [0.38, 1.10]	
Palamino 2 2010	55	108	138	227	18.4%	0.67 [0.42, 1.06]	
fotal (95% CI)		652		1047	100.0%	0.59 [0.48, 0.73]	•
Total events	274		578				
Heterogeneity: Chi ² =				= 0%			0.01 0.1 1 10
Test for overall effect:	Z = 4.99 (	(P < 0.0	00001)				Health Case
(C) T allele							
	Case		Healt			Odds Ratio	Odds Ratio
Study or Subgroup						M-H, Fixed, 95% CI	
Ciccacci 2019	128	390	99	486	23.3%	1.91 [1.41, 2.59]	
Mirkazemi 2013	231	560	179	562	41.4%	1.50 [1.18, 1.92]	
Palamino 2010	47	138	174	592	17.1%	1.24 [0.84, 1.84]	
Palamino 2 2010	61	216	100	454	18.2%	1.39 [0.96, 2.02]	
fotal (95% CI)	4271-0	1304		2094	100.0%	1.53 [1.31, 1.79]	•
Fotal events	467		552				
Heterogeneity: Chi ² =				= 11%			0.01 0.1 1 10
Test for overall effect:	Z = 5.39 (	(P < U.L	10001)				Health Case
(D) GT genotype							
Study of Calendary	Case		Healt Events		Maria lat	Odds Ratio	Odds Ratio M-H, Fixed, 95% Cl
Study or Subgroup						M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
Ciccacci 2019	78 131	195 280	87 107	243 281	30.2% 36.9%	1.20 [0.81, 1.76]	
Mirkazemi 2013 Palamino 2010	131	280	107	281	36.9%	1.43 [1.02, 2.00]	
Palamino 2010 Palamino 2 2010	35 45	108	78	296	13.8%	1.64 [0.97, 2.78] 1.36 [0.85, 2.18]	
		652		1047	100.0%	1.38 [1.12, 1.69]	•
Fotal (95% CI) Fotal events	289	652	386	1047	100.0%	1.38 [1.12, 1.69]	•

Table. Forest Plot from 4 studies.

#### **Keywords**

Gene polymorphism, Sjögren's syndrome, STAT4



## Interstitial lung disease in Sjögren's syndrome: Prevalence, Patterns, Treatment, and prognosis

## Jung Hee Koh¹, Su-Jin Moon¹, Yong Hyun Kim², Jun-Ki Min¹

¹ Division of Rheumatology, Department of Internal medicine, College of Medicine, The Catholic university of Korea, Republic of Korea ² Division of Pulmonary, Allergy and Critical Care Medicine, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Republic of Korea

#### Background

Interstitial lung disease (ILD) is a potentially serious yet underdiagnosed manifestation of primary Sjogren's syndrome (pSS). This observational study aimed to investigate the clinical, functional, and imaging characteristics of ILD in pSS, together with treatment and prognosis.

#### **Methods**

Longitudinal clinical and laboratory data for patients with pSS at a single center between January 1, 2010, and December 31, 2021, were collected from the clinical data warehouse (CDW). Predisposing factors for the development of ILD and acute exacerbation were identified using a logistic regression model.

#### **Results**

In total, 284 patients with pSS were included in this study (Female, 96%; median age, 53 years). Among them, 32 patients with pSS (11%) were comorbid with ILD (13 biopsy-proven cases). Age, immunoglobulin G level, and C-reactive protein (CRP) level were associated with ILD. Usual interstitial pneumonia (UIP) or fibrosing nonspecific interstitial pneumonia (NSIP) was the most prevalent CT pattern in pSS-ILD (44%), followed organizing pneumonia (22%). Three-quarters of patients showed reduced diffusion capacity, and 35% of patients with pSS-ILD showed a restrictive functional pattern. The median follow-up period was 2.2 years. During follow-up, one patient died (3%), 13 patients (41%) experienced acute exacerbation (AE), and 4 patients (13%) were progressed. Patients with AE were treated with a high-dose steroids-based regimen and 64% of them presented improvement in the CT scan after at least 6 months. The pulmonary function was stationary in all patients with SS-ILD.

## Conclusions

ILD was prevalent in pSS patients. Elder age and higher CRP and immunoglobulin G levels were associated with pSS-ILD. Most pSS-ILD patients responded to high-dose steroids, however, a few patients progressed. Our data highlighted the importance of screening for ILD in high-risk pSS patients.

#### **Keywords**

Sjogren's syndrome, Interstitial lung disease, prevalence



# Distinct metabolic biomarkers to distinguish immunoglobulin G4-related disease from Sjögren's syndrome and pancreatic cancer and predict disease prognosis

## Yu Peng¹, Wen Zhang¹

¹ Rheumatology, Peking Union Medical College Hospital, China

#### Background

The pathogenesis of immunoglobulin G4-related disease (IgG4-RD) remains unclear. IgG4-RD often mimics other diseases, including pancreatic cancer (PC) and Sjogren's syndrome (SS), which may easily lead to misdiagnosis. This study was performed to explore the underlying mechanisms and potential biomarkers of IgG4-RD and other misdiagnosed diseases.

#### Methods


Untargeted liquid chromatography-tandem mass spectrometry metabolomics profiling of plasma samples from a cohort comprising healthy controls (HCs) and patients with IgG4-RD, PC, and SS was performed. A random forest machine learning model was used to verify the relevance of the identified metabolites in the diagnosis of different diseases and the prediction of disease prognosis.

#### **Results**

The ATP-binding cassette transporters pathway was found to be most closely related to IgG4-RD, which was significantly upregulated in the IgG4-RD group than in all the paired groups. Six metabolites were proved to be valuable biomarkers for IgG4-RD. Caftaric acid, D-glutamic acid, 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine, hydroxyproline, 1,2-dilauroyl-sn-glycero-3-phosphatidylcholine, and 2-(5-oxovaleryl) phosphatidylcholine were useful in distinguishing between IgG4-RD, PC, SS, and HC (AUC = 1). A combination of Ps 40:4, 3-methyl-2-oxopentanoate, 1-palmitoyl-2-lauroyl-sn-glycerol-3-phosphorylcholine, and Pc(16:0e/13hode) showed a moderate value in predicting relapse in patients with IgG4-RD (AUC = 0.72).

## Conclusions

Our findings revealed the underlying mechanisms of IgG4-RD and provide new insights for deepening our understanding of IgG4-RD. Metabolomic biomarkers have significance in the clinical diagnosis and disease prognosis of IgG4-RD.





# Predictors of the future development of systemic lupus erythematosus (SLE) in Korean primary Sjögren's syndrome (pSS) patients with anti-DNA antibody (+) by the Farr method.

## Bong-Woo Lee¹, Youngjae Park², Jennifer Lee², Sung-Hwan Park², Seung-Ki Kwok²

 ¹ Division of Rheumatology, Department of Internal Medicine, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
 ² Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea

#### Background

Primary Sjögren's syndrome (pSS) and systemic lupus erythematosus (SLE) can coexist and pSS can precede SLE. Some pSS patients are positive for anti-DNA antibody, but SLE is not diagnosed at that time. Therefore, we aimed to clarify the predictors of the future development of SLE in pSS patients with anti-DNA antibody (+).

#### **Methods**

This retrospective study assessed 174 pSS patients with positive for anti-DNA antibody by the Farr method, who regularly visited Seoul St. Mary's Hospital between 2013 and 2021. All patients did not meet the 2019 EULAR/ACR Classification Criteria for SLE at baseline. 174 patients were classified into a group that later developed SLE and a group that did not. Data were compared between the two groups, including demographic features, extra-glandular manifestations (EGMs), clinical indices, and laboratory values at baseline. Additionally, predictors of the onset of SLE were analyzed.

#### **Results**

Among 174 pSS patients with positive for anti-DNA antibody by the Farr method, 47 patients met the 2019 EU-LAR/ACR Classification Criteria for SLE in the future from the baseline. In the future SLE development group, lower Schirmer test positive proportion, higher ESSDAI score in biological and hematological domain, and higher frequency of autoimmune thyroiditis were found. In addition, that group showed lower WBC counts, C3, and C4 at baseline. The multivariate logistic regression analysis revealed leukopenia (<4000/mm3) (OR: 7.43 (2.75-20.6) p = <0.001), low C3 (OR: 16.71 (6.00-46.56) p = <0.001) and low C4 (OR: 16.71 (6.00-46.56) p = <0.001) at baseline to be associated with the development of SLE in anti-DNA (+) pSS patients.

#### Conclusions

Leukopenia and low C3/C4 at baseline were associated with the future development of SLE in anti-DNA (+) pSS patients. For the anti-DNA (+) pSS patients with those predictors, it is necessary to periodically check the symptoms and laboratory tests included in the SLE classification criteria.

#### **Figure & Table**

	Future SLE development (+)	Future SLE development (-)	
	anti-DNA (+) pSS	anti-DNA (+) pSS	p value
	(n=47)	(n= 127)	
a seline characteristics			-
Age (at baseline)	47.38 (± 1.85)	53.24 (±1.16)	0.009
Age (at diagonsis)	42.49 (±1.64)	48.38 (±1.15)	0.006
Disease duration (month)	57.81 (± 7.83)	58.21 (±5.20)	0.967
Female sex	46 (97.9%)	126 (99.2%)	0.468
Ocular drvness	42 (89.4%)	114 (89.8%)	1.000
Oral dryness	46 (97.9%)	114 (89.8%)	0.116
Schirmer test (< 5mm/5min)	21 (44,7%)	82 (64.6%)	0.024
No. of EGM	1.47 (±0.17)	1.34 (±0.096)	0.496
OSS by SICCA method (≥ 5 )	11 (23.4%)	46 (36.2%)	0.145
Unstimulated salivary flow rate (< 0.1 mL/min)	40.40%	47.20%	0.602
FGMs			
Articular involvement	22 (46.8%)	52 (40.9%)	0.495
Ravnaud's phenomenon	6 (12.8%)	24 (18.9%)	0.498
Lymphadenopathy	9 (19.1%)	17 (13.4%)	0.346
Pulmonary involvement	4 (8.5%)	16 (12.6%)	0.596
Cutaneous involvement	5 (10.6%)	18 (14.2%)	0.623
Liver involvement	1 (2.1%)	10 (7.9%)	0.292
Splenomegaly	0	0	
Lymphoma	1 (2.1%)	3 (2.4%)	1.000
Renal involvement	3 (6.4%)	5 (3.9%)	0.447
Myositis	0	0	
Peripheral neuropathy	2 (4.3%)	5 (3.9%)	1.000
Central nerve system	2 (4.3%)	3 (2.4%)	0.613
Autoimmune thyroiditis	14 (29.8%)	17 (13.4%)	0.024
ESSDAI (by domain)	(22070)	17 (10040)	0.024
Total score	6.96 (±0.805)	5.51 (±0.483)	0.123
Constitutional	0.21 (±0.07)	0.12 (±0.03)	0.149
Lymphadenopathy	0.23 (±0.10)	0.27 (±0.14)	0.884
Glandular	0.23 (±0.1)	0.17 (±0.06)	0.599
Articular	0.38 (±0.08)	0.29 (±0.05)	0.308
Cutaneous	0.49 (±0.22)	0.29 (± 0.05) 0.24 (± 0.07)	0.156
Pulmonary	0.49 (±0.22) 0.3 (±0.22)	0.24 (±007) 0.35 (±0.11)	0.156
Pulmonary Renal	0.3 (±0.22)		0./98
		0.05 (±0.04)	
Muscular	0	0	-
Peripheral nerve system	0.02 (±0.02)	0.03 (±0.02)	0.722
Central nerve system	0.21 (±0.21)	0.06 (±0.04)	0.294
Hematological	0.87 (±0.14)	0.4 (±0.06)	< 0.001
Biological	1.3 (±0.11)	0.97 (± 0.08)	0.021
Laboratory data	r		
WBC count	3.85 (±0.20)	4.98 (±0.15)	< 0.001
Leukopenia (< 4000/mm3)	31 (66%)	36 (28.3%)	< 0.001
ANC count	2.02 (±0.17)	2.75 (±0.12)	0.001
Neutropenia (< 1500/mm3)	16 (3496)	14 (1196)	0.001
Hb	12.46 (±0.18)	12.65 (±0.1)	0.329
Anemia, < 12 g/dL	17 (36.2%)	34 (26.8%)	0.262
Platelet count	205.51 (± 10.52)	225.06 (±5.18)	0.068
Thrombocytopenia, < 150.000/mm3	7 (14.9%)	9 (7.1%)	0.14
Immunoglobulin G	2177.06 (±132.35)	2068.54 (±75.24)	0.463
Elevation of Immunoglobulin G (> 1,600 mg/dl)	34 (72.3%)	80 (63.0%)	0.285
C3	79.68 (±2.69)	97.46 (± 1.303)	< 0.001
C4	16.73 (±0.88)	21.34 (±0.51)	< 0.001
Cryoglobulin	1 (2.1%)	0 (0%)	0.27
Rheumatoid factor positivity	25 (53.2%)	80 (60.0%)	0.295
Anti-CCP positivity	1 (2.1%)	4 (3.1%)	1
Anti-Ro/SSA antibody positivity	46 (97.9%)	115 (90.6%)	0.19
Anti-La/SSB antibody positivity	26 (55.3%)	66 (52%)	0.735
Anti-RNP antibody positivity	5 (10.6%)	12 (9.4%)	0.78

Table. Basal demographics , secretory function-related values, EGMs, ESSDAI and laboratory data

#### **Keywords**

pSS, SLE, Anti-DNA antibody

# **E-poster Presentation**

Systemic sclerosis and Raynaud's phenomenon

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



# Analysis of clinical features of myocardial involvement in systemic sclerosis

## Huilin He¹

¹ Rheumatology, Peking Union Medical College Hospital, Beijing, China, China

## Background

To analyze the clinical characteristics of systemic sclerosis (SSc) with myocardial involvement.

## **Methods**

Data of SSc patients with myocardial involvement who admitted in Peking Union Medical College Hospital from 2012 to 2021 were retrospectively collected. SSc patients without myocardial involvement were randomly selected as control according to 1:3 matched age and sex during the same time. Clinical characteristics, laboratory, imaging examinations and treatment data were analyzed.

## **Results**

There were 26 patients with SSc with myocardial involvement, including 21 females (80.8%). The onset age of SSc was 44.8±15.1 years. Patients with SSc with myocardial involvement had fewer puffy finger (15.4% vs. 56.4%, P<0.001), loss of finger pad substance(11.5% vs. 34.6%, P=0.024), pulmonary arterial hypertension(7.7% vs. 32.1%, P=0.017), gastroesophageal reflux(19.2% vs. 52.6%, P=0.003), and interstitial lung disease(61.5% vs. 83.6%, P=0.020) compared with controls, but more myositis(38.5% vs. 9.0%, P=0.001) and renal crisis(11.5% vs. 1.3%, P=0.047). In terms of laboratory examination, patients combined with cardiac involvement had more elavated CK (30.8% vs. 6.9%, P=0.006) and positive anti-SCL70 antibody (65.4% vs. 37.2%, P=0.012). The age of cardiac involvement in SSc patients was 48.0±15.2 years, and the median duration of cardiac involvement was 22.0 (5.8, 56.5) months. Among the 26 patients, 16 (61.5%) had cardiovascular symptoms. Among the 10 patients (38.4%) without cardiovascular symptoms, 6 had elevated CTnI, 7 had elevated NT-proBNP and 7 presented with cardiomyopathy or myocardial fibrosis in UCG or cardiac MRI. Four patients underwent methylprednisolone pulse therapy, and cardiac radionuclide TATE showed diffuse inflammation in two of them. Thirteen patients with a median follow-up time of 13.4 (6.15, 29.2)/month, and four patients developed new-happened LVEF < 50%.

#### Conclusions

Nearly half of patients are subclinical, SRC and myositis were more common in these patients. These patients usually have poor prognosis. Regular monitoring of CTnl, NT-proBNP and UCG is helpful for patients.

#### **Keywords**

Systemic sclerosis, Myocardial involvement, Treatment

# **E-poster Presentation**

Miscellaneous rheumatic and inflammatory diseases

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



## Brain magnetic resonance imaging finding in autoimmune rheumatic disease

Recep Sade¹, Meltem Alkan melikoglu²

¹ Radiology, Ataturk University, Turkey ² Rheumatology, Ataturk University, Turkey

#### Background

Autoimmune rheumatic diseases (ARDs) may affect the brain. We evaluate and compare brain magnetic resonance imaging (MRI) findings of patients with ARD and non-ARD patients.

#### **Methods**

Retrospectively, 30 patients with ARD and 30 age and gender-matched controls with non-ARD, were evaluated and compared brain MRI findings.

#### **Results**

25 (83,3%) ARD patients and 20 (66,6%) controls had white matter hyperintensities (p < 0.001) in at least one brain area (subcortical/deep/periventricular white matter, basal ganglia, pons, brainstem, or mesial temporal lobe). Only the frequency and number of subcortical and deep white matter lesions were significantly greater in ARD patients (p < 0.012 and 0.032, respectively). ARD vs. control status was the only independent predictor of having any brain lesion. Penalized logistic regression selected only ARD vs. control status as the most important feature for predicting whether brain lesions were present on brain MRI (odds ratio: 4.32, marginal false discovery rate = 0.021).

#### Conclusions

Subclinical brain involvement of ARD patients was highly prevalent in this study. However, further research is required to determine the clinical relevance of these findings.

#### **Keywords**

Autoimmune rheumatic disease, magnetic resonance imaging, diagnosis



# Spontaneous knee hemarthrosis associated with enoxaparin treatment in a post COVID-19 patient

## Mark Andrian Yano¹, Geraldine Zamora¹, Karen Anne Claridad², Ralph Elvi Villalobos²

¹ Division of Rheumatology, Department of Medicine, Philippine General Hospital, Philippines ² Division of Pulmonary Medicine, Department of Medicine, Philippine General Hospital, Philippines

## **Description**

We report a case of a 66-year-old Filipino male who developed spontaneous hemarthrosis of the left knee following enoxaparin use as venous thromboembolism prophylaxis. Pertinent in the medical history was the diagnosis of chronic kidney disease and chronic respiratory failure as sequelae of COVID 19 infection. During the course of admission, the patient developed acute pain and swelling of the left knee. The patient was bedridden and no prior traumatic events were noted. Coagulation parameters were within normal range. Arthrocentesis revealed viscous hemorrhagic synovial fluid (25 ml) with fluid analysis showing predominance of red blood cells (RBC 680,000 WBC 7200) with no crystals seen on polarizing microscopy. Microbial cultures did not reveal any growth. Methylprednisolone was given and enoxaparin continued. One day post arthrocentesis, there was improvement of pain and joint function. Joint swelling resolved. Patient had no recurrence of joint pain and swelling.

## Conclusions

This is an elderly patient with chronic kidney disease who recently recovered from COVID 19 infection. He received prophylactic dose of enoxaparin at 40 mg every 24 hours. No other drugs that can affect hemostasis were given. The patient's bleeding parameters were within normal limits during admission and at the onset of hemarthrosis. We hypothesize that elderly patients with chronic kidney disease may be prone to bleeding and can present with hemarthrosis even with low dose enoxaparin. Whether the association between history of COVID-19 infection and hemarthrosis is co incidental or causal remains to be elucidated. Prompt aspiration can provide early diagnosis and facilitate proper treatment.

## Figure & Table



Figure. Viscous hemorrhagic synovial fluid

#### **Keywords**

Hemarthrosis, COVID 19, Enoxaparin



<u>KCR 2022</u>

May 19(Thu) - 21(Sat), 2022

# Clinical profile and outcome of adult Filipino patients with septic arthritis in a tertiary hospital in the Philippines

## Mark Andrian Yano¹, Alfonso Juan Miranda²

¹ Department of Internal Medicine, Chong Hua Hospital, Philippines ² Division of Rheumatology, Department of Internal Medicine, Chong Hua Hospital, Philippines

#### Background

Septic arthritis is the invasion of a joint by an infectious agent resulting in joint inflammation. Considered a medical emergency, it requires prompt diagnosis followed by rapid and aggressive treatment. However, recent local data of septic arthritis among Filipinos is still limited despite medical advancement.

#### **Methods**

This is a retrospective descriptive study. The medical records of admitted patients diagnosed with pyogenic arthritis, septic or infectious arthritis, and tuberculous arthritis at Chong Hua Hospital, Cebu City, Philippines from January 1, 2012 to December 31, 2019 were identified and reviewed. Epidemiological, clinical and laboratory data regarding septic arthritis were gathered. Descriptive statistics such as frequency and percentage distribution were used in expressing the data.

#### **Results**

Fifty-seven patients were identified as having septic arthritis based on discharge diagnoses. Twenty-five of the patients (43.86%) were between the ages of 45 to 64 years old. Comorbidities such as diabetes mellitus (49.12%, n=28) and hypertension (43.86%, n= 25) were commonly identified. Twenty (35%) of the patients had primary joint disease, with gout (21%) as the most prevalent. Majority of the patients (94%) patients presented with monoarthritis. Gram negative bacilli was the most common pathogen isolated in eighteen (31.5%) cases. Ceftriaxone was the most commonly used empiric antibiotic in eighteen (31.5%) cases. The empiric antibiotic treatment was adequate in 66.67% (n=38) of the cases with identified septic arthritis.

#### Conclusions

This study highlights the unique characteristics of septic arthritis in this population such as its prevalence in the middle-aged population, isolation of gram-negative bacilli as the most common isolate, and normal initial of levels of WBC, CRP, and ESR. Thus, maintaining a high clinical suspicion and being cognizant of predisposing risk factors, adequate treatment and care may be provided to septic arthritis patients.

## **Figure & Table**




Figure. Causative organisms of septic arthritis

#### Keywords

Septic arthritis, Filipino



<u>KCR 2022</u>

# Tuberculosis fasciitis of the neck in Behçet's patient

#### Yunus Fersan¹, Mehmet Aksit¹, Gökhan Polat²

¹ medical faculty, Atatürk University, Turkey ² Department of Radiology, Ataturk University, Turkey

#### Description

A 44-year-old male patient had complaints of widespread pain and erythema in the floor of the mouth in the neck. The patient has a known 16-year-old diagnosis of Behçet's disease. He was administered 110 mg of methylprednisolone acetate, intramuscularly for immediate pain relief. He was prescribed azathioprine, 145 mg/d, and adalimumab, 40 mg subcutaneously every other week. Computed tomography was performed on the patient and there was an increase in density in favor of inflammation in the superficial fascia and subcutaneous areas(Figure 1). The patient was diagnosed with superficial fasciitis by imaging.

Histopathological examination of the biopsy taken from the fascia revealed diffuse necrosis without epithelioid cell granuloma. Acid-fast bacilli were seen by acid-fast staining and Mycobacterium tuberculosis was detected in cell culture. Therefore, the patient was diagnosed with tuberculous fasciitis. The patient was treated with antituberculosis for 12 months.

#### Conclusions

It can mimic tuberculous fasciitis, cellulitis, and autoimmune fasciitis; therefore diagnosis may be delayed. Although rare, it has also been reported in patients receiving immunosuppressive therapy for rheumatic disease, including polymyositis and rheumatoid arthritis. To our knowledge, this is the first documented case of tuberculous fasciitis in a patient with BD.







KCR 2022

May 19(Thu) - 21(Sat), 2022

# Chronic inflammatory demyelinating polyneuropathy (CIDP) in polyangiitis granulomatosis with cyclophosphamide

Kadem Tüysüz¹, Mehmet Aksit¹, Gökhan Polat²

¹ medical faculty, Atatürk University, Turkey ² Department of Radiology, Ataturk University, Turkey


## Description

A 49-year-old male patient was being followed up and treated with the diagnosis of Polyangiitis Granulomatosis. The patient was receiving oral Cyclophosphamide therapy. The patient presented with abdominal pain and stool incontinence. In addition, the patient had a complaint of weakness in his legs, which had started for two months. On examination, the patient had 3/5 motor weakness in the legs. A progressive loss of sensation was also observed. Abdominal CT was first performed on the patient. There was increased thickness and diffuse nodularity in the bilateral lumbar peripheral nerves(Figure 1). The diagnosis of CIDP was considered based on clinical findings and radiological images. Electromyography (EMG) confirmed the diagnosis of CIDP. The patient's neuropathy and muscle weakness improved on treatment with intravenous immunoglobulin (IVIG) and high-dose steroids.

#### **Conclusions**

The diagnosis of CIDP should be considered in the differential diagnosis of motor and sensory loss that starts in the lower extremities in rheumatological diseases under immunosuppressive therapy.







# A rare combination of autoimmune pancreatitis and focal cranial eosinophilic granuloma

Tamar Melkadze¹, Iraklı Tortladze¹, Giorgi Apkhazava²


¹ Radiology Department, TSSU First University Clinic, Georgia ² Radiology Department, Tbilisi City Medical, Georgia

## Description

A 35-year-old male patient was admitted to our hospital 1 year ago with complaints of severe abdominal pain and jaundice. Computed tomography performed on the patient revealed pancreatic diameter increase, edematous density loss, and peripancreatic mesenteric inflammation findings. The patient was diagnosed with acute pancreatitis with these findings. In the process, no specific finding to explain pancreatitis was detected, and the patient was followed up with the diagnosis of autoimmune pancreatitis due to the high Ig G4 level and response to steroids. The patient was admitted to our hospital with complaints of swelling and pain in his head that had been growing steadily for the last 1 month and could be palpated by hand. Cranial magnetic resonance imaging(MRI) was performed on the patient. On MRI, there was a focal bone-destroying lesion in the parietal bone(Figure 1). Because of its invasion in the form of a target, eosinophilic granuloma was first considered radiologically. The diagnosis was confirmed immunohistochemically with CD1a and S100 positivity.

## Conclusions

Autoimmune pancreatitis is a chronic disease characterized by acute necrosis and inflammation. Autoimmune pancreatitis and eosinophilic granuloma are two independent entities. Co-occurrence is rare and has not been described in the literature.





## Diagnostic value of the inflammatory scores in polymyalgia rheumatica

<u>Ji-Won Kim</u>¹, Hyoun-Ah Kim¹, Ju-Yang Jung¹, Chang-Hee Suh¹

¹ Department of Rheumatology, Ajou University School of Medicine, Republic of Korea

## Background

Polymyalgia rheumatica (PMR) is a chronic inflammatory rheumatic disease in the elderly, characterized by bilateral shoulder and hip stiffness and elevated inflammatory markers, however, there are no specific diagnostic features. This study aimed to investigate the value of various serological inflammatory scores, including the systemic immune-inflammation index (SII), C-reactive protein/albumin ratio (CAR), albumin/globulin ratio (AGR), and prognostic nutritional index (PNI), as diagnostic markers in PMR.

## **Methods**

We reviewed medical records of 156 patients diagnosed with PMR and 408 patients diagnosed with rheumatoid arthritis as a control group between January 1999 and September 2020. For each individual inflammatory scores, we estimated the sensitivity, specificity, and the area under the curve (AUC) with 95% confidence intervals for PMR diagnosis using receiver operating characteristic (ROC) curve analysis.

## **Results**

A total of 156 patients with PMR had higher values of SII, and CAR, as well as lower values of AGR and PNI, than RA patients. The CAR showed the best value for diagnosis with an AUC of 0.823 (95% confidence interval [CI], 0.784-0.861) with a cutoff value of 0.75, and had diagnostic value in the order of SII (AUC 0.797 [95% CI 0.757-0.837], cutoff value 877.8), AGR (AUC 0.696 [95% CI 0.648-0.743], cutoff value 1.33), and PNI (AUC 0.691 [95% CI 0.641-0.741], cutoff value 12.5). Furthermore, elevated levels of SII or CAR, and decreased levels of AGR or PNI were associated with fever, weight loss, and headache.

## Conclusions

Serological inflammatory scores, such as SII, CAR, AGR, and PNI, were useful as a diagnostic laboratory marker for PMR, and among these markers, CAR had the highest value.

## Figure & Table

	AUC	P-value	Cut-off	Sensitivity	Specificity
SII	0.797	< 0.001	877.8	72.4	72.5
CAR	0.823	< 0.001	0.75	70.5	80.6
AGR	0.696	< 0.001	1.33	60.5	69.2
PNI	0.691	< 0.001	12.5	72.5	60.9

Table. Utility of serological inflammatory scores for diagnosing polymyalgia rheumatica

SII, systemic immune-inflammation index; CAR, C-reactive protein/albumin ratio; AGR, albumin/globulin ratio; PNI, prognostic nutritional index

## **Keywords**

Polymyalgia rheumatica, Diagnostic marker, Inflammatory scores



# A short long way from juvenile idiopathic arthritis to pachydermoperiostosis (Touraine–Solente–Gole syndrome)

Bogdan Ion Gavrila¹, Ioan Ancuta¹, Mihai Bojinca¹, Claudia Silvia Ciofu¹

¹ Bucharest, University of Medicine and Pharmacy "Carol Davila", Romania

#### **Description**

We present the case of a 19-year-old man, presented in April 2021 in our Clinic for polyarticular painless swellings, especially in the knees.

In 2018 he was diagnosed with Juvenile idiopathic arthritis(JIA) and treatment with Methotrexate started (15mg/wk), stopped becauase of nausea by the patient after 6 months.

At the time of evaluation we found multiple skin lesions facial seborrhea, acnee, highly marked skin creases in the forehead, thickened eyelids, skin ankles sweating.

Osteoarticular system with clubbing of the fingers and toes, enlergement of bilateral forearm and legs, effusion of bilateral knee joints.

Biologically mild anemia with biologic inflammatory syndrome.Immunology RF,anti-CCP, ANA negative,normal levels of IgA,M,G

X rays of the hands and forearms showed enlargement of distal ulna and radius with cortical thickening,carpitis.Pelvis x rays with cortical thickening of the femur.Knee x rays decreased joints space.

Diagnostic and therapeutic arthrocentesis was perfromed with intraarticular Betamethasone administration.Results showed negative cultures,exsudates characteristics,citology negative for the presence of ragocytes.

At that time were considered the following diagnoses:Pachydermoperiostosis,SAPHO syndrome,acromegaly,thyroid acropachy,secondary hypertrophic osteoarthropathy.

The patient is discharged with the following treatment:Methylprednisolone 16mg/day,potassium and Vitamin D 3 supplements colchicine 1 mg/day,Sulfasalazine 3 mg/day.

Endocrinological evaluation was performed with Somatomedin C (IGF-I), thyroid hormone within normal limits.

CT scan was performed with pericardic fluid blade,gynecomastia.

He returns to our clinic after 6 months, and at the time of the evaluation we find in addition to the previous evaluation the appearance of a typical skin manifestation - tick transversely folded skin of the scalp-cutis verticis gyrate. Also he had significant effusion of bilateral knee joins and pronounced biological inflammatory syndrome.

The imaging investigations are completed with skull x rayskull.

The final diagnosis was established: pahidermoperiostosis –complete form.

#### Conclusions

What therapeutic options should we take into consideration for this rare case, considering only few cases reported using NSAIDs, cortisone, colchicine and bisphosphonates?

#### **Figure & Table**



#### **Keywords**

Pachydermoperiostosis, Rare disease, Juvenile idiopathic arthritis



## Allopurinol and febuxostat hypersensitivity in a patient with young onset gout

## Mark Andrian Yano¹

¹ Division of Rheumatology, Department of Medicine, Philippine General Hospital, Philippines

#### **Description**

We report a case of a 29-year-old Filipino male with young onset gout. Patient had a typical gout history which started since he was 18 years old with joint pain and swelling initially involving the 1st MTP joint and later progressed to arthritis involving the ankles and knees. He has multiple tophi in both hands and toes causing deformity and limitation of movement. His laboratory tests consistently showed elevated uric acid at a range of 12-14 mg/dL. His creatinine was elevated at 1.6 mg/dL (eGFR 59 ml/min). He was initially started on allopurinol 100 mg daily, however, after seven days of allopurinol intake, he developed generalized pruritus, facial swelling, painful erythematous papules and vesicles along with mucosal involvement. He was admitted as a case of Steven Johnsons Syndrome. Allopurinol was withdrawn and he was given corticosteroid with noted relief of symptoms.

The frequency of gout flares increased up to ten times a year necessitating monthly intake of prednisone. Thus, febuxostat was commenced at a dose of 40 mg daily, but after 5 days, he developed generalized pruritus and angioedema. Febuxostat was discontinued and IV corticosteroids was given with relief of symptoms.

In view of the persistently elevated uric acid and recurrent gout flares, febuxostat was restarted at a dose of 20 mg daily. However, the patient had recurrence of generalized urticaria a week after intake. Discontinuation of febuxostat and a short course of prednisone led to resolution of symptoms.

Considering the limited therapeutic options, the patient was referred to an allergy specialist for febuxostat desensitization.

#### Conclusions

Although rare, febuxostat hypersensitivity has been reported and can be severe. It is unclear whether a previous allopurinol adverse reaction might have a role in the subsequent development of hypersensitivity to febuxostat.

#### **Figure & Table**



Figure. A photograph of the patient's right hand showing multiple tophi formation

#### **Keywords**

Febuxostat hypersensitivity, Steven Johnsons syndrome, Young onset gout



KCR 2022

## Curative-intent resection is a strong indicator of steroid-free remission in IgG4-related disease

Jung Gon Kim¹, Sunhee Jang², Jennifer Lee¹, Ji Hyeon Ju¹, Wan-Uk Kim¹, Sung-Hwan Park¹, Seung-Ki Kwok¹

¹ Department of Internal Medicine, Division of Rheumatology, Seoul St. Mary's Hospital, College of Medicine, Seoul, Republic of Korea ² Department of Internal Medicine, Yonsei Hangang Hospital, 25 Mapodaero, Mapogu, Seoul, Republic of Korea

#### Background

Long-term prescription of corticosteroids is common for IgG4-related disease (IgG4-RD) despite corticosteroid-related adverse reactions. To the best of our knowledge, studies on determinants of steroid-free remission (SFR) in IgG4-RD have not been reported yet. Thus, we examined various clinical factors affecting achievement of SFR in IgG4-RD.

#### **Methods**

A total of 155 patients had newly diagnosed IgG4-RD, autoimmune pancreatitis, or idiopathic retroperitoneal fibrosis at our unit between 2005 and 2021. Among them, 58 patients who met the 2019 ACR/EULAR criteria for IgG4-RD were finally included. SFR was defined as meeting all of the followings: 1) clinically asymptomatic state; 2) disappearance or > 50% reduction in the size of IgG4-RD lesion without occurrence of a lesion in a different site; 3) being free of glucocorticoids for six months or more. Patient demographics, laboratory parameters, early use of steroid-sparing agents within three months, and curative-intent resection of IgG4-RD lesions were examined regarding SFR from the date of diagnosis using Cox regression analysis.

#### Results

Sixteen (27.6%) of 58 patients with IgG4-RD achieved SFR during the follow-up period (median: 38.2 months). Univariable Cox regression analysis showed that curative-intent resection (hazard ratio (HR): 5.11 [95% confidence interval (CI): 2.13–12.23]), and multiple organ involvement ( $\geq$  2) (HR: 0.39 [95% CI: 0.17-0.90]) were significantly associated with SFR in the opposite way. In the univariable Cox regression analysis, age, sex, head and neck phenotype, elevated inflammatory markers, elevated serum IgG4, and early use of steroid-sparing agents did not have any significant associ-

ations with SFR. In the multivariable Cox regression analysis, curative-intent resection (HR: 4.26 [95% CI: 1.5-12.14]) was the only predictor of SFR. Multiple organ involvement ( $\geq 2$ ) did not show meaningful prediction (HR: 0.73 [95% CI: 0.26-2.01]).

#### Conclusions

Curative-intent resection of IgG4-RD lesions was the only strong predictor of SFR in IgG4-RD in our study.

#### Figure & Table

	Unadjusted HR (95% CI)	Р	Adjusted HR [†] (95% CI)	Р
Demographics				
Male	0.66 (0.28-1.52)	ns	-	-
Elderly ( $\geq$ 65 year)	0.65 (0.22-1.23)	ns		-
Phenotype of IgG4-RD				
Multiple organs involved ( $\geq 2$ ),	0.39 (0.17-0.90)	< 0.05	0.73 (0.26-2.01)	ns
Head and neck limited phenotype	0.62 (0.23-1.69)	ns	-	-
Laboratory markers				
Elevated ESR ( $\geq 20$ mm/hour)	0.52 (0.22-1.23)	ns	-	-
Elevated CRP ( $\geq 6$ mg/L)	0.84 (0.33-2.15)	ns	-	-
Serum IgG4 > 1 ULN	0.95 (0.35-2.59)	ns	-	-
Treatment modality				
*Early use of steroid-sparing agents	0.98 (0.38-2.51)	ns	-	-
Curative-intent surgery	5.11 (2.13-12.23)	< 0.001	4.26 (1.5-12.14)	< 0.01

"Prescription of azatnioprine, methotrexate, or hydroxychioroquine within 5 months after diagnosis of IgG4-RD.

[†]Variables of the multivariable Cox regression model=multiple organs involved ( $\geq$  2), and curative-intent resection.

HR, hazard ratio; CI, confidence interval; IgG4-RD, IgG4-related disease; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ULN, upper limit normal.

Table. Cox regression analysis for steroid-free remission

#### **Keywords**

IgG4-related disease, steroid-free remission, surgical treatment

## Application of HScore and MS score in diagnosis of macrophage activation syndrome associated with adult onset Still's disease

Zhao Peng^{1,2,3}, Shuang Zhou^{1,2,3}, Qian Wang^{1,2,3}, Xinping Tian^{1,2,3}, Mengtao Li^{1,2,3}, Yan Zhao^{1,2,3}, Xiaofeng Zeng^{1,2,3}

¹ Department of Rheumatology and Clinical Immunology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
² National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China
³ State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Beijing, China

#### Background

AOSD-associated MAS is traditionally identified based on the HLH-2004 criteria. Due to the different pathogenesis and clinical manifestations between MAS and primary HLH, HLH-2004 could not diagnosis MAS timely, particularly in the early stage. The sensitivity of diagnosing MAS using HLH-2004 criteria was only 56.6%. In order to diagnosis MAS timely, Study developed and validated weighted scores, named Hemophagocytic syndrome diagnostic (H) score and MAS/ juvenile idiopathic arthritis(MS)Score. However, there are no criteria that are specific for AOSD-associated MAS, It is also unclear whether the HScore and MS-Score were more timely than HLH-2004 criteria in diagnosis AOSD-associated MAS. The purpose of our study was to compare whether the HScore and MScore are more timely than the HLH-2004 criteria in diagnosing AOSD-associated MAS.

#### **Methods**

The demographic, clinical and laboratory features, pathological findings of patients with AOSD-associated MAS were collected in Peking Union Medical College Hospital (PUMCH) from January 2013 to December 2020. HLH-2004 criteria, MS-Score and HScore were used to diagnosis of AOSD-associated MAS. And compare the different time points in diagnosis of AOSD-associated MAS between these methods.

#### **Results**

33 patients with AOSD-associated MAS were identified. 27 (81.8%) were female, the median duration of AOSD-associated MAS was 49 (31, 157) days, and 3 (9.1%) died. The median time of diagnosis AOSD-associated MAS was 46 (27.5, 57.0) days by HLH-2004, 31 (19.0, 54.0) days by HScore, and 20.0 (10.5, 44.5) days by MS-Score( $\chi$ =31.147, P<0.001). The median time of diagnosis AOSD-associated MAS by MS-Score was 19.0 (4.5, 31.0) days earlier than by HLH-2004 criteria( $\chi$ =-1.344, P<0.001), And 13.5 (0.5, 21.5) days earlier than HScore ( $\chi$ =-0.766, P=0.007). The median time of diagnosis AOSD-associated MAS by HScore was 4.5 (0.0, 10.5) days earlier than by HLH-2004 criteria ( $\chi$ =-0.578, P=0.062).

#### Conclusions

MS-Score could identification of AOSD-associated MAS earlier than HLH-2004 criteria, while HScore can not.

#### **Keywords**

Macrophage activatin syndrome, adult onset Still's disease, MS score; HScore



KCR 2022

May 19(Thu) - 21(Sat), 2022

## The role of interleukin-18 as a diagnostic biomarker to differentiate active adult-onset Still's diseas from COVID-19

#### Roland Helmizar¹

¹ Internal Medicine, Indonesian University, Indonesia

#### Background

The coronavirus disease 2019 (COVID-19) outbreak has rapidly extended globally within a short period. Adult Onset Still's Disease (AOSD) is a rare systemic inflammatory disease with various manifestations and can mimic other diseases. Hyperinflammation and cytokine storm play an important role in the pathogenesis of both COVID-19 and AOSD. Interleukin (IL)-18 is one of the leading cytokines markedly elevated in systemic inflammatory diseases that cause the 'cytokine storm' in both diseases. Given the similar clinical features, it is necessary to identify potential biomarkers that can differentiate COVID-19 from AOSD.

#### **Methods**

A systematic search through Pubmed/MEDLINE, Cochrane Library, EBSCO, and EMBASE was conducted to find studies about the role of IL-18 as a diagnostic biomarker to differentiate active Adult-Onset Still's Disease from COVID-19. Two studies were selected and critically appraised. Data were then summarized descriptively.

#### **Results**

The two studies included consist of cross-sectional and single-arm meta-analysis. A cross-sectional study stated active AOSD patients had 68-fold higher IL-18 levels than severe COVID-19 patients (p<0.001). IL-18 levels at the cut-off value 190.5 pg/mL had the highest discriminative power for active AOSD and severe COVID-19, with AUC 0.948, sensitivity 91.3%, specificity 95.8%, and accuracy of 91.5% (p<0.005). Multivariate regression analysis revealed IL-18 as a significant predictor of active AOSD (p<0.05). Single-arm meta-analysis stated fold changes of IL-18 were defined as the mean expression level ratio of severe COVID-19 and AOSD to healthy controls. Noteworthy, the fold change of IL-18 in patients with active AOSD was approximately 594, which was much higher than that in severe COVID-19 (fold change 2.17), without statistical comparability.

#### Conclusions

IL-18 is a potential biomarker discriminator between AOSD and COVID-19 and may significantly predict active AOSD. Further studies with good quality evidence are still needed to confirm these findings.

#### **Keywords**

interleukin-18, Adult-Onset Still's Disease, COVID 19



## Cancer-associated vasculitis: A single-centre pilot study

#### Hyunsue Do¹, Sangwon Lee¹

¹ Division of Rheumatology, Severance Hospital, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul, Republic of Korea

#### Background

This study investigated the clinical features of cancer-associated vasculitis within 3 years before and after the diagnosis of the corresponding underlying cancer in 73 Korean patients.

#### **Methods**

Based on the inclusion criteria, 73 patients with cancer-associated vasculitis were included in this study, and their medical records were retrospectively reviewed. The time gap between cancer and vasculitis was set as within 3 years before and after the diagnosis of the corresponding underlying cancer, and was partitioned into 90-day increments and included 25 time-compartments.

#### **Results**

The median age was 53.0 years and 42.5% were male. The incidence rate of cancer-associated vasculitis was 0.034%. The most frequently observed cancer was thyroid cancer (28.8%), followed by lymphoma (13.7%) and stomach cancer (9.6%). Whereas, the most common cancer-associated vasculitis was Behcet disease (52.1%), followed by granulomatosis with polyangiitis (12.3%), and Takayasu arteritis (11.0%). Behcet disease exhibited a tendency of association with several cancers but granulomatosis with polyangiitis and Takayasu arteritis exhibited no predominant association with the types of the corresponding underlying cancer. Forty-two (57.5%), 7 (9.6%) and 24 (32.9%) patients had vasculitis before, at the time of, and after the diagnosis of the corresponding underlying cancer, respectively. The time compartment with the largest distribution of patients was between 1 day and 90 days after the diagnosis of cancer.

#### Conclusions

The incidence rate of cancer-associated vasculitis was 0.034%. The most common cancer-associated vasculitis was Behcet disease, and the types of cancer-associated vasculitis and each underlying cancer seemed to be dependent on ethnic and geographic differences.

#### **Figure & Table**




Figure. Frequency of vasculitis according to each underlying cancer

#### **Keywords**

cancer, vasculitis, ethnicity



### Cerebellar infarction as the initial presentation of IgG4-Related Disease

#### Gaurav Nepal¹, Vikash Jaiswal²

¹ Internal Medicine, Tribhuvan University Institute of Medicine, Nepal ² Internal Medicine, Larkin Community Hospital, USA

#### **Description**

A 60-year-old man came to the ER with dizziness and blurred vision. He also mentioned numbness and discomfort in his right hand that started months ago. His right finger was likewise discolored. A little purple discoloration of the right fingertip was noted on the physical exam. Inpatient treatment was given. Initial ESR 48 mm/hr and CRP 13.9 mg/L. Initial lab work showed an ESR of 48 mm/hr and CRP of 13.9 mg/L. His basic metabolic panel, complete blood count, and autoimmune tests were all unremarkable. MRI brain revealed a small, acute right cerebellar infarct, subacute left cerebellar infarct, and mild bifrontal chronic microvascular ischemic changes. Echocardiogram was normal. CT chest, abdomen, and pelvis showed a solid partially calcified right retroperitoneal mass arising from the pancreatic head/duodenum. Associated mild retroperitoneal lymphadenopathy was noted. Endoscopic-ultrasound with biopsy showed lymph-node tissue with plasmacytosis and >40% plasma-cells positive for IgG4, compatible with IgG4-lymphadenopathy. The specimen was composed of lymphoid tissue lacking germinal-centers with plasmacytosis. Immunohistochemical staining was performed. The sample was negative for epithelial malignancy. CD20 demonstrated an increase in B-cells, and CD138 showed an increase in plasma cells. Kappa and lambda in situ hybridization showed polytypic expression. CD3 and CD43 highlighted background T cells. The stroke team discharged the patient on apixaban, clopidogrel, and aspirin prior to the pathology results. As stroke was thought to be caused by cardiovascular risk factors or pancreatic CA, hence steroids were not provided initially. The patient was then lost to follow-up.

#### Conclusions

Cerebellar symptoms in IgG4-RD are a rare initial manifestation. The early start of corticosteroids has been shown to result in significant improvement. While the disease's exact cause is unknown, practitioners should be aware of its unusual presentation and have a high clinical index of suspicion.

#### Figure & Table




Figure. Magnetic resonance (MR) imaging of the brain with and without contrast revealed a small, acute right cerebellar infarct, subacute left cerebellar infarct, and mild bifrontal chronic microvascular ischemic changes.

#### **Keywords**

IgG4-Related Disease, IgG4-RD, IgG4RD

# **E-poster Presentation**

Epidemiology & Public health

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



KCR 2022

### **Relationship between Lung Involvement and Gout in Covid-19 disease**

Fatih Işık¹, Zeynep Tüzün², Fatma Beyza Isık³

¹ Department of Radiology, Atatürk University, Turkey
 ² Internal Medicine , Rheumatology Department, Ataturk University, Turkey
 ³ health practice and research center, Ataturk University, Turkey

#### Background

We aimed to evaluate the joint deposit accumulation of covid-19 infection with dual-energy CT in patients followed up for gout disease.

#### **Methods**

Thirty-four patients who were followed up for gout and who had COVID-19 infection were evaluated in the study. Of these patients, 18 patients whose joint uric acid accumulation was examined with dual-energy up to 1 year before the COVID-19 infection were included in the study. A radiologist examined the accumulation of uric acid in the dual-energy CT images of the patients. Covid radiological severity classification in patients was made according to the percentage of radiological involvement on CT imaging. Mild radiological findings were classified as = 0-50%, severe radiological findings = 51-100%.

#### **Results**

5 of 18 patients had acute joint pain attacks during the Covid-19 infection process. An increase in the amount of joint uric acid was observed in 5 of 18 patients. There was no difference in 13 of them. Of the 5 patients with increased uric acid content, 3 patients had severe pulmonary involvement and 2 patients had mild lung involvement. Of the 13 patients with increased uric acid content, 3 patients had severe pulmonary involvement and 10 patient had mild lung involvement. There was a weak inverse correlation between uric acid deposition and lung involvement (P = 0.047, r = -0.3924). While the radiological findings of 3 patients who had acute joint attacks during Covid infection were severe, 2 of them were observed in the mild severity classification. Of the 13 patients who did not have an acute attack, 3 had severe pulmonary involvement and 10 had mild pulmonary involvement. There was a weak inverse relationship between radiological findings and acute joint pain (P = 0.04950, r = -0.4082).

#### Conclusions

Although Covid-19 radiological involvement does not significantly change the gout disease attack and joint deposit accumulation.



## Post-COVID mesial temporal sclerosis

#### Megi Kurtanidze¹, Tamar Melkadze², Iraklı Tortladze²

¹ Department of Radiology, Tbilisi City Medical, Georgia ² Radiology Department, TSSU First University, Georgia


#### **Description**

A 29-year-old young patient was admitted to our hospital with seizures. In her history, she had a history of covid 19 that had been passed 20 days ago. Due to severe lung involvement in Covid-19 infection, the patient was treated as an inpatient. After the Covid infection, the patient's complaints such as bad odor perception and dizziness continued. Brain magnetic resonance imaging(MRI) was performed because of the seizure. There was an increase in edematous signal at the level of the right temporal lobe (Figure 1A). The patient was first evaluated in favor of encephalitis. The patient was started on treatment for encephalitis and epilepsy. As the patient's epilepsy complaints continued during the process, a control MRI was performed 3 months later. Control MRI showed volume loss consistent with sclerosis in the temporal lobe hippocampal region (Figure 1B).

#### **Conclusions**

Covid infection is a viral infection that causes the activation of cytokines. Mesial temporal sclerosis was found to be associated with cytokines, especially interleukin 1beta (IL-1 $\beta$ ), IL-6, tumor necrosis factor-alpha (TNF-a). Therefore, the immune response seen in Covid patients may cause limbic encephalitis in the mesial temporal region and cause mesial temporal sclerosis by creating an autoantibody response in the process.

#### Figure & Table





May 19(Thu) - 21(Sat), 2022 P-135

KCR 2022

## Incidence of rheumatic diseases during the COVID-19 pandemic in Korea: A nationwide claims study

<u>Soo Min Ahn</u>¹, Seongho Eun², Seokchan Hong¹, Chang-Keun Lee¹, Bin Yoo¹, Ji Seon Oh³, Yong-Gil Kim¹

¹ Department of Rheumatology, Asan Medical Center, Republic of Korea
 ² Department of Management Engineering, College of Business, KAIST, Republic of Korea
 ³ Department of Information Medicine, Big Data Research Center, Asan Medical Center, Republic of Korea

#### Background

The recent COVID-19 pandemic has been reported to change the epidemiology of not only infectious or respiratory diseases but also several non-infectious diseases such as Kawasaki disease. This study investigated the change in the incidence of various rheumatic diseases during the COVID-19 pandemic.

#### **Methods**

The number of patients for each disease from January 2016 to December 2020 was obtained from the Korea Health Insurance Review and Assessment Service database. We compared the incidence of nine rheumatic diseases [systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), ankylosing spondylitis (AS), Sjogren syndrome (SJS), Behçet disease (BD), idiopathic inflammatory myositis (IIM), systemic sclerosis (SSc), polymyalgia rheumatica (PMR), and gout] and hypertension before and after the COVID-19 outbreak. The incidence before and after the COVID-19 outbreak was compared using the ARIMA analysis and quasi-Poisson analysis.

#### Results

Compared with the predicted incidence in 2020 by the ARIMA model, the monthly incidence of SLE, BD, AS, SJS, IIM, and SSc temporarily and significantly decreased, while the monthly incidences of gout, RA, PMR, and hypertension were within the 95% confidence interval (CI) of predicted values in the first half of 2020, the early stage of COVID-19 outbreak. In age and sex-adjusted quasi-Poisson regression analysis, the annual incidences of IIM (Rate ratio [RR]: 0.473, 95% CI: 0.307–0.697), SLE (RR: 0.845, 95% CI: 0.798–0.895), and BD (RR: 0.850, 95% CI: 0.796–0.906) were significantly decreased compared with the previous 4 years.

#### Conclusions

In conclusion, we found that the annual incidence of some rheumatic diseases including IIM, SLE, and BD decreased during the COVID-19 pandemic.

#### **Figure & Table**

Discourse		Observed	Rate ratio				
Diseases	Mean	Observed	Hate ratio				
	(2016–2019)	(2020)	(95% CI)				
IIM	839.8	397	0.473 (0.307-0.697)		•		
SLE	5371.3	4541	0.845 (0.798-0.895)				
BD	3598.3	3057	0.850 (0.796-0.906)				
SJS	7913.5	7280	0.920 (0.839-1.007)				
AS	11679.5	10934	0.936 (0.848-1.031)				
SSc	592.8	557	0.940 (0.806-1.090)				
RA	17490.3	17342	0.992 (0.944-1.041)				
Gout	129543	131133	1.012 (0.916-1.117)				_
PMR	1072	1152	1.075 (0.928-1.239)				
HTN	680943.2	696391	1.023 (0.929-1.124)				
				0.30	0.50	0.70	0.90 1.0 1.1 1.2

Table. Annual incidence of various diseases in 2020 versus 2016-2019

#### **Keywords**

Incidence, COVID-19, Rheumatic disease



<u>KCR 2022</u>

May 19(Thu) - 21(Sat), 2022

## Changes in the lungs that develop with COVID-19 in patients with rheumatoid arthritis

#### Eugenia Aronova¹, Galina Gridneva¹, Boris Belov¹

¹ department of comorbid infections, V.A. Nasonova Research Institute of Rheumatology, Russian Federation

#### Background

The aim of our study was to analyze the severity of changes in the lungs obtained with computed tomography (CT) in patients with COVID-19 and rheumatoid arthritis

#### **Methods**

We studied the data of discharge reports after inpatient treatment of COVID-19, verified by RT-PCR to SARS-CoV-2 RNA, in patients with RA. The results of the correlation analysis were considered reliable at p<0.05.

#### **Results**

The study included 42 adult (over 18 years old) patients (38 women, 90.5%) with a reliable diagnosis of RA (ACR/ EULAR). The mean age of the patients was  $51.17\pm15.78$  years. In 14 patients, RA proceeded with extra-articular manifestations in the form of Sjögren's syndrome. High RA activity at the time of COVID-19 disease was in 10 patients (23.8%), moderate - in 19 (45.2%), low - in 10 (23.8%). During the COVID-19 period, CT scan was performed in 26 patients. When assessed according to the "empirical visual scale", CT-0 was noted in 2 patients (7.7%), CT-1 - in 12 (46.2%), CT-2 - in 7 (26.9%), CT- 3 - in 4 (15.4%), CT-4 - in 1 (3.8%). There were no statistically significant correlations between the severity of changes in the lungs and RA activity, as well as the presence of extra-articular manifestations.

27 patients (64.3%) underwent COVID-19 on an outpatient basis. For the treatment of COVID-19, 26 cases were prescribed antibacterial drugs, 13 cases - injectable and 20 - oral anticoagulants, 20 cases - glucocorticoids, also 20 - antiviral drugs, 4 patients required IL-6 inhibitors and 2 - janus inhibitors -kinase. Three patients did not require any therapy other than standard care.

#### Conclusions

In the study group, COVID-19 proceeded predominantly with moderate lung involvement. No statistically significant correlations were found between the severity of changes in the lungs and RA activity, as well as the presence of extra-articular manifestations.

#### **Keywords**

rheumatoid arthritis, COVID-19, lung involvement



## Incidence, prevalence, and clinical characteristics in ANCA-associated vasculitis: A National Health Insurance Service Database (2002-2018)

#### Sung Ahn¹, Hyunsun Lim², Chan Hee Lee³, Young-Beom Park⁴, Sang-Won Lee⁴, Jinsu Park³

¹ Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine, Republic of Korea
 ² Research and Analysis Team, National Health Insurance Service IIsal Hospital, Republic of Korea
 ³ Department of Internal Medicine, National Health Insurance Service IIsal Hospital, Republic of Korea
 ⁴ Department of Internal Medicine, Yonsei University College of Medicine, Republic of Korea

#### Background

To evaluate the incidence and prevalence of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) by analyzing the nationwide healthcare administrative database.

#### **Methods**

Patients with claim data from a general or tertiary hospital with ICD-10 code for AAV (microscopic polyangiitis [MPA], granulomatosis with polyangiitis [GPA], and eosinophilic granulomatosis with polyangiitis [EGPA]) were identified from the National Health Insurance Service Database (2002-2018). A patient with AAV was defined when at least one of the following criteria was satisfied; i) registered in the individual copayment beneficiaries program with the corresponding code of AAV; ii) prescribed with glucocorticoids. We calculated the incidence of AAV after applying a 2-year washout period.

#### **Results**

A total of 2,113 patients had AAV, of which 708 had MPA, 638 had GPA, and 767 had EGPA. The overall incidence and prevalence of AAV tended to increase continuously during the observed years. The highest incidence of AAV was reported as 0.48/100,000 people year (PY) in 2017 and the prevalence of 2.40/100,000 PY in 2018 (Figure 1). The proportion of females in patients with AAV was 53.9%, and AAV was the most common in those aged 60–69 years. At the time of onset, patients with MPA were the oldest at 64.3  $\pm$  14.1, patients with GPA were 57.5  $\pm$  15.2, and patients with EGPA were the youngest at 52.9  $\pm$  15.9. In addition, patients with MPA had the highest mean CCI (3.3  $\pm$  1.62) compared to patients with GPA (2.83  $\pm$  1.58) and EGPA (2.75  $\pm$  1.43).

#### Conclusions

By searching through the national healthcare database, the following results were obtained: i) even though AAV is still rare, the annual incidence of AAV in South Korea is increasing, with the highest incidence of 0.48/100,000 persons reported in 2017; ii) MPA patients are the oldest at the time of diagnosis and have more comorbidities.

#### **Keywords**

vasculitis, ANCA, healthcare claim data



KCR 2022

## Association between sarcopenia and rheumatoid arthritis in the Korean population: A nationwide cross-sectional study

Jae Hyun Jung¹, Yu Jin Lee¹, Eui Seop Song¹, Gwan Gyu Song¹

¹ Internal Medicine, Korea University College of Medicine, Republic of Korea

#### Background

Rheumatoid arthritis (RA) includes musculoskeletal symptoms and leads to disuse atrophy of skeletal muscles and change in body composition. The musculoskeletal symptoms and loss of physical function in may be associated with the prevalence of sarcopenia, which is characterized by muscle loss. This study aimed to investigate the prevalence of sarcopenia and its association with RA in the general Korean population.

#### **Methods**

We conducted a nationwide cross-sectional study using data from the Korea National Health and Nutrition Examination Survey and included 7,389 men and 9,798 women. Binominal logistic regression models were used to calculate the odds ratios (ORs) and 95% confidence intervals (Cls) for sarcopenia prevalence in RA patients.

#### **Results**

The prevalence of sarcopenia was 23.0% in men, 25.0% in women, 61.5% in men with RA, 32.3% in women with RA, 22.8% in men without RA, and 24.9% in women without RA. After adjusting for potential confounding variables, the prevalence of sarcopenia was significantly higher in men with RA than in men without RA (OR, 3.11; 95% Cl, 1.29\vertical{R4}), but this was not seen in women.

#### Conclusions

The presence of sarcopenia was more than three-fold in Korean men with RA than in those without RA.

#### Figure & Table

-		Men				
	OR	95% CI	Р	OR	95% CI	Р
Crude	5.41	2.45-11.95	< 0.001	1.44	0.99-2.08	0.054
Model I	2.95	1.25-6.97	0.014	1.32	0.88-1.97	0.183
Model II	3.15	1.32-7.50	0.010	1.32	0.88-1.98	0.174
Model III	3.02	1.26-7.20	0.013	1.32	0.88-1.97	0.184
Model IV	3.11	1.29-7.46	0.011	1.36	0.91-2.04	1.139

Model I has been adjusted for age, BMI, and current menstrual status especially in women

Model II has been adjusted for Model I + DM, HTN, and dyslipidemia

Model III has been adjusted for Model II + alcohol consumption and smoking status

Model IV has been adjusted for Model III + household income and education

OR, odds ratio; CI, confidence interval; BMI, body mass index; DM, diabetes mellitus; HTN, hypertension

Table. Odds ratios and 95% confidence intervals for sarcopena in patients with rheumatoid arthritis

#### **Keywords**

Rheumatoid arthritis, Sarcopenia, Prevalence



KCR 2022

## Psychometric properties of the PHQ-8 in individuals with osteoarthritis

#### Patrick Brzoska1

¹ Health Services Research, Witten/Herdecke University, Faculty of Health, School of Medicine, Germany

#### Background

Osteoarthritis is one of the most common musculoskeletal illnesses. It may affect quality of life and is associated with limitations in daily activities and depressive symptoms, which may severely impair patients' capacity to cope with the disease. Frequently used instruments to study depressive symptoms among individuals with osteoarthritis and other musculoskeletal disorders are the CES-D und PHQ-8. While the psychometric properties of the CES-D have been studied among patients with musculoskeletal diseases, including osteoarthritis, little is known about the PHQ-8 in this respect. The present study investigates the psychometric properties of the PHQ-8 in a sample of people with osteoarthritis in Austria.

#### **Methods**

Data from a representative population-based survey conducted in Austria in 2018/2019 on 15,461 men and women was used, of which 2,206 (14.3%) reported to have been diagnosed with osteoarthritis. The psychometric properties of the PHQ-8 were examined by means of confirmatory factor analysis (CFA) and multiple indicators multiple causes (MIMIC) models.

#### **Results**

The baseline 8-item, one-factor measurement model of the PHQ-8, most often proposed in previous studies, showed an acceptable fit (RMSEA=0.06, TLI=0.92, CFI=0.95, SRMR=0.04); however, some factor loadings were only moderate in size (see Fig. 1). Measurement non-invariance related to sex was observed in items 3 and 4, measurement non-invariance related to age was observed in items 2, 6, 7 and 8. Effects of sex and age slightly differed between analyzes adjusted (beta=0.059 and beta=0.075, respectively) and not-adjusted (beta=0.136 and beta=0.118, respectively) for measurement non-invariance.

#### Conclusions

While the PHQ-8 shows an acceptable validity in the assessment of depression in patients with osteoarthritis, comparisons between sociodemographic categories such as sex and age may be biased by measurement non-invariance. As the findings show, this may either over- or underestimate the true effects. Instead of the comparison of manifested means, therefore, latent variable modeling should be employed to obtain valid estimates.

#### **Figure & Table**




Figure. Factor structure of the PHQ-8 in individuals with osteoarthritis in Austria



<u>KCR 2022</u>

May 19(Thu) - 21(Sat), 2022

## The Barriers Of Patients With Osteoporosis In Various Countries During The COVID-19 Pandemic

#### Nuraliah Nuraliah¹

¹ Public Health, West Sulawesi Research and Empowerment Center, Indonesia

#### **Description**

During the Covid-19 pandemic, it is very difficult for patients to access good health services. This situation has affected the management of many long-term conditions including patients with osteoporosis as resources are diverted to cover urgent care. Drawing on literature review research, the author analyzed the information on how the COVID-19 pandemic has impacted the diagnosis and management of osteoporosis in some countries. Data were collected through a comprehensive review of the literature using suitable keywords on the search engines of PubMed, SCOPUS, Google Scholar and Research Gate in the first week of May 2020 on developments and guidance during the current COVID-19 pandemic. This study found two main the barriers of patien with osteoporosis during the COVID-19 pandemic, namely (1) process of care, (2) the governance and strategy. The osteoporosis care stagnated and lower quality of care was provided. During the initial phase of the COVID-19 pandemic, there was no guidance of professional societies or guidelines on the organization of osteoporosis care in case of such a crisis, and treatment relied on local ad hoc strategies.

#### **Conclusions**

This review has provided information that the COVID-19 pandemic was impacting the diagnosis and management of osteoporosis patients. Therefore, a comprehensive approach is needed for future improvement to osteoporosis service by managing the standardization of osteoporosis care delivery in situations of crisis.

#### **Keywords**

Osteopororis, COVID-19, Osteoporosis Management,



## Use of telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak: A randomized controlled trial

Ho So¹, Everlyn Chow¹, Isaac Cheng¹, Xerox Chow¹, Tena Li¹, Cheuk Chun Szeto¹, Lai Shan Tam¹

¹ Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong

#### Background

Patients with SLE are at increased risk of severe COV-ID-19. An alternative option would be to adopt telemedicine (TM) to maintain medical care while minimizing exposure. Despite being widely adopted during the pandemic, the evidence supporting the use of TM in rheumatology has been limited.

#### **Methods**

This was a 1-year, single-center, RCT. From May 2020, adult patients with SLE according followed up at the LN clinic were invited to participate in the study. Participants were randomized 1:1 to either TM (TM group) or standard FU (SF group). Patients randomized to receive TM FU were scheduled for a video consultation. Patients in the SF group received standard in-person outpatient care.

#### **Results**

A total of 141 patients with LN completed the study. There were no baseline differences, including demographics, SLEDAI-2k and SLE damage index, between the 2 groups. At one year, 80.0% and 80.2% of the patients in the TM group and SF group were in LLDAS or remission respectively. SLE disease activity indices including SLEDAI-2k, PGA, proteinuria amount and serum anti-ds-DNA level remained similar between the 2 groups. The overall patient satisfaction score was higher in the TM group with a significantly shorter waiting time before seeing doctors. The mean indirect costs of illness and the out-of-pocket costs for health care services were similar between the 2 groups in one year. The total number of FU was similar. However, significantly more patients in the TM group requested change mode of FU. The proportion of patients requiring hospitalization during the study period was also higher in the TM group. After adjustment, not being in not being in LLDAS at baseline was the predictor of hospitalization.

#### Conclusions

TM FU resulted in similar disease activity control and better satisfaction in patients with LN but needs to be complemented by physical visits, particularly in those with unstable disease.

#### **Keywords**

SLE, COVID, telemedicine



<u>KCR 2022</u>

May 19(Thu) - 21(Sat), 2022

### Immunopathological process in the Chronic arthritis and Rheumatic Heart Diseases caused by streptococcus of Group A

#### Nazgul Omurzakova¹, Akpay Sarybaev¹

¹ Rheumatology and High Mountain Diseases, National Center of Cardiology and Internal Medicine, Kyrgyzstan

#### **Description**

Antigens of cell wall of Group A streptococcus (GAS) and (or) their antibodies has an effect in the development of immunopathological conditions, which differs by their characteristics.

For the last years we observe trends of the heavy invasive streptococcal infection proceeding with a hypotension, coagulopathy and multiple functional insufficiencies of a «streptococcal toxic shock syndrome ». This syndrome presents as a toxic and toxic septic conditions with elements of SLE-like eruption, connected with ability of GAS cross-reaction with DNA, forming like lupus reactions.

SGA promotes development of chronic arthritis variant, which debut has clinical lines rheumatic fever and developed stage (after decades) – RA. This form of disease begins from childhood (arthritis of small joints, carditis) as the rheumatic fever with repeated acute attack of arthritis without deformations of joints and following exacerbation (women usually after childbirth). Rheumatic heart diseases is revealed in more advanced age - 20 years old (that is in 14 years) and at a mature age (45 years) there are symptoms of chronic arthritis on seronegative type.

It is necessary to understand, why in one cases SGA causes development rheumatic fever with or without heart disease but in other cases there is arthritis exhibit tendency to synchronisation.

#### **Conclusions**

At patients with chronic arthritis (ChA), joints are organs of the maximum accumulation of fragments of peptidoglycan (PPG)- polysaccharide (PSH). Long-lasting not biodegraded cytodermes can induce synthesis of RF and cause development of chronic arthritis.

Though rheumatic fever (RF) and chronic arthritis (ChA) very much differ from each other and have nosologic independence, but at fundamental level they can have general pathogenetic ways. Probably, this general level consists in a trigger role of the same component of streptococcus of group A.



## Comparison of renal outcomes and mortality in early and delayed onset lupus nephritis

<u>Soo-Kyung Cho</u>^{1,2}, Hyoungyoung Kim^{1,2}, Jungyong Han^{1,2}, Yena Jeon³, Sun-Young Jung⁴, Eun Jin Jang⁵, Yoon-Kyoung Sung^{1,2}

¹ Department of rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
 ² Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea
 ³ Department of statistics, Kyungpook National University, Daegu, Republic of Korea
 ⁴ College of Pharmacy, Chung-Ang University, Republic of Korea
 ⁵ Department of information statistics, Andong National University, Andong, Republic of Korea

#### Background

To compare the renal outcomes and mortality in patients with early and delayed onset lupus nephritis (LN).

#### Methods

We constructed a retrospective cohort of incident cases of Systemic Lupus Erythematosus (SLE) using the nationwide Korean National Health Insurance Service databases between 2008 and 2018. Then we selected LN patients according to our operational definitions; renal biopsy after urine analysis and creatinine test. Patients who developed LN within 12 months of diagnosis (Early LN group) were compared with patients in whom LN was diagnosed after 12 months of SLE diagnosis (Delayed LN). The hazard ratio (HR) of progression to end-stage renal disease (ESRD) was estimated by the Kaplan-Meier and the Cox model, and by the Fine-Gray model when deaths present as competing events.

#### **Results**

We identified 3,779 incident SLE patients who developed LN; 2,291 early LN patients and 1,489 delayed LN patients. The median duration from SLE diagnosis to the development of LN in early LN and delayed LN groups were 0.23 months and 34 months, respectively. Early LN patients showed a similar risk of progression to ESRD compared with the delayed LN group [HR 1.14, 95% confidence interval (CI); 059 to 2.21] after adjusting the confounders such as age, sex, lupus severity, type of insurance, comorbidity, and medications. However, early LN patients had a nearly two-fold increased risk of mortality than the late LN group (HR 1.94, 95% CI; 1.85 to 2.03].

#### Conclusions

The mortality of early LN patients was higher compared with the delayed LN patients, while their risk of progression to ESRD was comparable.

#### **Keywords**

systemic lupus erythematosus, lupus nephritis, mortality



## Level of knowledge on systemic lupus erythematosus among nursing students in selected universities in the Philippines

#### Cherry Ann Garcia Durante^{1,2}, Jeeno Jay Frani²

¹ Center for Research and Publication, Emilio Aguinaldo College - Manila, Philippines ² School of Nursing, Emilio Aguinaldo College - Manila, Philippines

#### Background

Systemic Lupus Erythematosus (SLE) is estimated to affect approximately 1.5 million individuals. As future nurses, it is vital that students would know about its pathogenesis and clinical manifestation to appropriate relevant nursing interventions to the patients. This study aimed to describe the level of knowledge of student nurses about SLE.

#### **Methods**

Among 250 nursing students, 231 consented to be respondents (response rate: 92.4%) from three universities in the Philippines. A self-administered online questionnaire was used to gather data on level of knowledge about SLE from January to February 2022. Informed consent was secured from the participants.

#### **Results**

Among the study participants, 28.14% had low knowledge on SLE, while 10.82% had high knowledge. 88% of those with high knowledge were female participants. In the 34item knowledge questions, the average score was 21. 49, ranging from a score of 3-31 points. Low scores were noted on manifestations of SLE with correct responses of only 12.5%, diagnosis of SLE (16.88%), and risk factors and co-morbidities (26%). A one-way ANOVA was conducted to determine if knowledge was different for different year levels. There was a statistically significant difference between groups as determined by one-way ANOVA (F=5.41 , p = 0.001). Higher year level was associated with higher level of knowledge.

#### Conclusions

Based on the results of the study, almost 3 out of 10 students nurses had low knowledge about SLE. There is a need to educate the student nurses about SLE and its manifestations, diagnostic tests, risk factors and co-morbidities to ensure appropriate nursing interventions will be provided to future patients.

#### **Keywords**

SLE, Knowledge level on Systemic Lupus Erythematosus, Nursing Students



## Comparative safety of tofacitinib and TNF inhibitor in Korean patients with rheumatoid arthritis: A prospective, single-center cohort study

<u>Yeo-Jin Song</u>^{1,2}, Soo-Kyung Cho^{1,2}, Hyoungyoung Kim^{1,2}, Hye Won Kim², Eunwoo Nam², Ja-Young Jeon³, Hyun-Jeong Yoo³, Chan-Bum Choi^{1,2}, Tae-Hwan Kim^{1,2}, Jae-Bum Jun^{1,2}, Sang-Cheol Bae^{1,2}, Dae Hyun Yoo^{1,2}, Yoon-Kyoung Sung^{1,2}

¹ Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea
² Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea
³ Pfizer Pharmaceuticals Korea Ltd., Seoul, Republic of Korea

#### Background

To evaluate the safety of tofacitinib compared with tumor necrosis inhibitor (TNFi) treatment in Korean patients with rheumatoid arthritis (RA).

#### **Methods**

Data were extracted from prospective cohorts of RA patients starting tofacitinib or TNFi in Hanyang University Hospital for Rheumatic Diseases between March 2017 and May 2021. Data on adverse events (AEs) were collected through interviews and medical records and classified by Common Terminology Criteria for AEs. The observation started from enrollment until discontinuation of each agent or November 2021. Among overall AEs, we estimated the crude incidence rate (IR) and incidence rate ratio (IRR) of each treatment-related AEs (TAEs) between tofacitinib and TNFi users. Serious AEs (SAEs) were also presented.

#### **Results**

This study included 200 tofacitinib users (474.2 person-years [PYs], mean 2.4 years) and 223 TNFi users (473.8 PYs, mean 2.1 years). Tofacitinib users were older and had a longer disease duration than TNFi users. Disease activity at enrollment was also higher in tofacitinib users. In the tofacitinib group, infection including herpes zoster was the most common TAE (9.07/100 PYs), and in the TNFi group, infection (5.49/100 PYs) and injection site reaction (5.28/100 PYs) were most common. The incidences of AE leading to drug discontinuation (IRR 0.70, 95% CI 0.27-1.84) and SAEs (IRR 2.00, 95% CI 0.81-4.95) were similar in both groups. As AEs of special interest, there were 4 cases of acute coronary syndrome and 1 case of venous thromboembolism only in the tofacitinib group, of which 1 case each was of TAE. We observed 2 cases of malignancy in the tofacitinib group and 1 case of malignancy in the TNFi group.

#### Conclusions

Our unmatched cohort study showed a similar incidence of SAEs in Korean RA patients treated with either tofacitinib or TNFi, while their baseline characteristics or patterns of AE differed between the two groups.

#### **Figure & Table**

	Tofacitinib (n=200)				TNF inhibitor (n=223)				Incidence rate		
Category	Number Num		er of	Incidence	Number	Numb	er of	Incidence	ratio	Р	
	of cases	patients (%)		rate*	of cases	patients (%)		rate*	(95% CI)		
Total	72	52	(26.0)	15.18	96	68	(30.5)	20.26	0.75 (0.55-1.02)	0.064	
Blood and lymphatic system disorders	1	1	(0.5)	0.21	0	0	(0.0)	0.00			
Cardiac disorders	1	1	(0.5)	0.21	0	0	(0.0)	0.00			
Endocrine disorders	0	0	(0.0)	0.00	1	1	(0.4)	0.21			
Eye disorders	2	2	(1.0)	0.42	1	1	(0.4)	0.21	2.00 (0.18-22.04)	0.572	
Gastrointestinal disorders	11	9	(4.5)	2.32	6	6	(2.7)	1.27	1.83 (0.68-4.95)	0.233	
General disorders and administration site conditions	0	0	(0.0)	0.00	25	25	(11.2)	5.28			
Hepatobiliary disorders	0	0	(0.0)	0.00	1	1	(0.4)	0.21			
Infections and infestations	43	34	(17.0)	9.07	26	22	(9.9)	5.49	1.65 (1.02-2.69)	0.043	
Injury, poisoning and procedural complications	1	1	(0.5)	0.21	1	1	(0.4)	0.21	1.00 (0.06-15.97)	1.00	
Investigations	0	0	(0.0)	0.00	6	4	(1.8)	1.27			
Musculoskeletal and connective tissue disorders	1	1	(0.5)	0.21	3	3	(1.3)	0.63	0.33 (0.03-3.20)	0.34	
Neoplasms benign, malignant and unspecified	0	0	(0.0)	0.00	1	1	(0.4)	0.21			
Nervous system disorders	2	1	(0.5)	0.42	1	1	(0.4)	0.21	2.00 (0.18-22.04)	0.57	
Renal and urinary disorders	0	0	(0.0)	0.00	1	1	(0.4)	0.21			
Reproductive system and breast disorders	0	0	(0.0)	0.00	3	3	(1.3)	0.63			
Respiratory, thoracic and mediastinal disorders	3	3	(1.5)	0.63	2	2	(0.9)	0.42	1.50 (0.25-8.97)	0.658	
Skin and subcutaneous tissue disorders	6	5	(2.5)	1.27	18	17	(7.6)	3.80	0.33 (0.13-0.84)	0.020	
Vascular disorders	1	1	(0.5)	0.21	0	0	(0.0)	0.00			
Serious adverse event	14	11	(5.5)	2.95	7	7	(3.1)	1.48	2.00 (0.81-4.95)	0.13	
Adverse event leading to discontinuation	7	3	(1.5)	1.48	10	8	(3.6)	2.11	0.70 (0.27-1.84)	0.468	

RA, rheumatoid arthritis; TNF, tumor necrosis factor; CI, confidence interval.

Table. Treatment-related adverse events in RA patients who used tofacitinib or TNF inhibitor

#### **Keywords**

safety, rheumatoid arthritis, tofacitinib



## A tale of three paths: Singaporean patient journeys from initial symptoms of gout to presentation for health care

<u>Aloysius Chow</u>¹, Laurie J. Goldsmith¹, Delfinn Tan¹, Madelynn Chan², Richard Lee³, Christian Mallen⁴, Bernadette Bartlam⁴, Helen Elizabeth Smith¹

¹ Family Medicine and Primary Care, Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
 ² Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore
 ³ Woodlands Polyclinics, National Healthcare Group Polyclinics, Singapore
 ⁴ School of Medicine, Keele University, United Kingdom

#### Background

Gout is a common form of arthritis with a rising incidence worldwide. Early intervention is important, yet there is evidence from many countries that gout is inadequately treated. To address this issue, we conducted a qualitative study of patients' experiences of gout diagnosis and initial treatment in Singapore.

#### **Methods**

Our study consisted of semi-structured interviews with adults with gout about their initial symptoms and journey to receiving a diagnosis from a provider of Western medicine. Interviewees were recruited from healthcare and non-healthcare settings and snowball techniques. Data were analyzed using thematic analysis by multiple analysts.

#### **Results**

Fifty-six participants varied by age, gender, ethnicity, and time since getting diagnosed. The interviewees' experiences of receiving their diagnoses were grouped into three major pathways. Pain is the main driver of the first two pathways. The more intense the pain, the less the individual needs to be aware of or know about gout to immediately seek out healthcare. The delay and duration of delay of presentation to healthcare can be due to assumptions that the pain resulted from a sprain/injury and that adequate rest was sufficient. Other interviewees first visit an alternative medicine provider before arriving at a provider of Western medicine. The third pathway was driven by individual health beliefs that prioritize self-care and self-management over seeking care from a healthcare provider.

#### Conclusions

Patients' understandings of gout and the need for timely presentation can be facilitators of seeking diagnosis and treatment early. Not all patients prioritize seeking healthcare even when their symptoms of gout disrupted their daily activities. Improved patient education has potential to accelerate some pathways of presentation to healthcare (i.e., Pathways #1 and #2). Other pathways (i.e., Pathway #3) are likely more resistant to a change despite patient education, and may require other interventions.

#### **Keywords**

Gout, Patient experience, Qualitative research

# **E-poster Presentation**

Osteoporosis and metabolic bone diseases

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



## Two novel mutations in TCIRG1 induced infantile malignant osteopetrosis: A case report

### Ping Wu¹

¹ Department of Allergy, Immunology and Rheumatology, Guangzhou Women and Children's Medical Center, Guangzhou, Guangdong, China., China

#### Description

We present the case of a 4-month-old male infant with abnormal skull development, hypocalcemia and premature closure of the cranial sutures. Due to the hyper bone density showed by his radiographic examination, which are characteristic patterns of IMO, we speculated that he might be an IMO patient. In order to confirm this diagnosis, a high-precision whole exome sequencing of the infant and his parents was performed. The analysis of high-precision whole exome sequencing results lead to the identification of two novel heterozygous mutations c.504-1G > C (a splicing site mutation) and c.1371delC (p.G458Afs*70, a frameshift mutation) in gene TCIRG1 derived from his parents. Therefore, we propose that there is a close association between these two mutations and the onset of IMO.

#### **Conclusions**

To date, these two novel mutations in gene TCIRG1 have not been reported in the reference gene database of Chinese population. These variants have likewise not been reported outside of China in the Genome Aggregation Database (gnomAD). Our case suggests that the use of whole exome sequencing to detect these two mutations will improve the identification and early diagnosis of IMO, and more specifically, the identification of homozygous individuals with TCIRG1 gene mutation. We propose that these mutations in gene TCIRG1 could be a novel therapeutic target for the IMO in the future.

#### Figure & Table




Figure. The pathogenesis mechanism of infantile malignant osteopetrosis.



### Relationship between vitamin d, body mass index with bone mineral density of Mongolian miners

<u>Garamjav Khishigdavaa</u>¹, Tuvshinjargal Dashdavaa², Agiimaa Ulziibadrakh¹, Buyankhishig Lhagvatogoo¹, Uuriintuya Altankhuyg¹, Ariuntungalag Khishigbadrakh³

¹ Radiology, Medipas hospital, Mongolia
 ² Radiology, Mongolian National University of Medical Science, Mongolia
 ³ Rheumatology, Medipas hospital, Mongolia

#### Background

Osteoporosis is a worldwide health problem and is considered as the most common bone disease. Body mass index (BMI) and vitamin D level are being risk factors to bone mineral density (BMD). However, there are very few studies on BMD and its associated factors among miners in Mongolia. Our study aimed to investigate the relationships between serum 25-hydroxyvitamin D (25(OH) D) levels, BMI and BMD among Mongolian miners.

#### **Methods**

Included were 120 miners (60 males and 60 females) were recruited for this cross-sectional study at Medipas hospital. Miners body mass index was calculated. Serum 250HD tests were performed. BMD was determined by quantitative ultrasound. Bivariate regression models were used to investigate the relationships between serum 25(0H) D, BMI and BMD.

#### **Results**

Total of 120 miners with a mean age of  $45.8 \pm 8.5$  years were included in the study. Thirty two participants had osteopenia. Osteoporosis was present in 9 miners. The mean BMI of subjects was  $27.6 \pm 4.3$  kg m2. The mean values for serum 25(OH) D levels were  $21.0 \pm 9.1$  ng/ml. In 86.7% of participants, serum 25(OH) D levels were below 30 ng/ml, confirming vitamin D deficiency. The BMI significantly negative correlated with BMD (r = -0.313, p = 0.012). There was no association between 25(OH) D levels and BMD (r = 0.102, p=0.430).

#### Conclusions

This study showed that the BMI significantly influences BMD in survey participants miners. However, there was no direct relationship between vitamin D level and BMD among miners.

#### **Keywords**

Body mass index, Bone mineral density, Vitamin D



KCR 2022

## Application of Machine Learning to identify osteoporosis based on the extreme learning machine (ELM) model algorithm

Rifaldy Fajar^{1,2}, Asfirani Umar², Sahnaz Vivinda Putri²

¹ Applied and Interdisciplinary Mathematics, University of L'Aquila, Italy, Italy ² Computational Biology and Medicine Laboratory, Yogyakarta State University, Indonesia

#### Background

Osteoporosis is a condition in which bones lose strength and are prone to fractures. Osteoporosis has no external symptoms and the first sign of osteoporosis is often broken bone. Broken and broken bones are the same thing. The bones that most often fracture due to osteoporosis are the wrists, hips, and spine. Osteoporosis cannot be seen with the naked eye. Therefore, in this study, osteoporosis identification was carried out using x-ray images (bone radiograph) based on machine learning.

#### **Methods**

In this study, the bone radiograph dataset was used. Bone radiographs were obtained from IEEE-ISBI 2014 competition dataset. The method used to identify is the extreme learning machine, in which previously the feature values in the image were taken using invariant moment feature extraction. The characteristic value of the bone radiograph image will go through the classification stage using ELM, then the results of normal or osteoporosis images will be obtained. Regarding classification, the stages are determining the number of nodes in the hidden layer, determining the activation function, the training process, the testing process, and the output calculation.

#### **Results**

This study uses 86 images as training data and 30 images as testing data. Image testing using several parameters such as epoch 1000, hidden node 50, threshold 170, and a learning rate of 0.2 has the ability to be quite successful in identifying osteoporosis to get a system accuracy of 90%.

#### Conclusions

Through several tests, it can be concluded that hidden nodes affect system accuracy. If the hidden node is the greater the value, the better the accuracy, if the hidden node is the smaller the value, the more error the image will get. The accuracy value obtained is quite good at 90% so the osteoporosis identification system can help make it easier to see osteoporosis and normal bone radiograph images.

#### **Keywords**

ELM Algorithm, Osteoporosis, Machine Learning



KCR 2022

## FRAX model is useful for prediction of major fractures in RA patients with glucocorticoid-induced osteoporosis

<u>Yoon-Kyoung Sung</u>^{1,2}, Hyoungyoung Kim^{1,2}, Yeo-Jin Song^{1,2}, Tae-Han Lee³, Hye Won Kim², Eunwoo Nam², Soo-Kyung Cho^{1,2}

¹ Department of rheumatology, Hanyang University Hospital for Rheumatic Diseases, Republic of Korea ² Hanyang University Institute for Rheumatology Research, Seoul, Republic of Korea ³ Department of rheumatology, Keimyung University Dongsan Medical Center, Daegu, Republic of Korea

#### Background

To evaluate the fracture risk in patients with rheumatoid arthritis (RA) according to Korean clinical practice guidelines for glucocorticoid-induced osteoporosis (GIOP)

#### **Methods**

A retrospective study was conducted on a cohort of RA patients  $\ge$  40 years old receiving glucocorticoids for more than 3 months in a single academic hospital from 2008 to 2019. Patients who could be assessed with the fracture risk assessment (FRAX) tool were selected and further divided into two groups according to the presence of bone mineral density (BMD). After categorizing the patients according to WHO criteria and Korean guidelines for GIOP, we observed the patients from their first visit to the last visit or the development of fracture, until September 2021. The incidence rate (IR) of major osteoporotic fracture per 100 person-year (PY) was calculated in each risk group.

#### **Results**

Among the 753 patients included in this study, 428 patients (56.8%) had BMD and the other 325 patients (43.2%) did not for 2 years after first visit. Among the patients having BMD, 30% (n=129, 769.74 PYs) were osteoporosis and they were also included in moderate/high fracture risk group based on FRAX. Although they had received anti-osteoporotic treatment, their IR of major fracture was 1.95/100 PYs. The other patients without osteoporosis (n=299), 285 patients (1728.47 PYs) are in moderate/high-risk group based on FRAX and their IR of major fracture was 0.42/100 PYs. In patients without BMD, 80.3% of them (n=261, 1706.90 PYs) were categorized as moderate/high-risk group based on FRAX, and their IR of major fracture was 0.41/100PYs. No fracture was observed in patients who were low-risk group based on FRAX (n=64, 412.52 PYs).

#### Conclusions

In RA patients who are using glucocorticoids, especially who had osteopenia/normal BMD or not available BMD, fracture risk assessment by FRAX might be a good indicator for fracture prevention.

#### **Keywords**

Fracture risk assessment, glucocorticoid-induced osteoporosis, bone mineral density



<u>KCR 2022</u>

May 19(Thu) - 21(Sat), 2022

## Genetic variation of susceptibility gene of osteoporosis, measuring method of oste- oporosis risk

#### Ahmad Ahmad¹

¹ Govermental Science, Universitas Al Asyariah Mandar, Indonesia

#### **Description**

Osteoporosis is a bone disorder characterized by reduced bone strength, increasing the risk of fracture. Osteoporosis occurs due to an imbalance between the formation of new bone and the resorption of old bone. Osteoporosis usually has no specific signs or symptoms until a fracture occurs. Genetic variation is the variation that occurs in the genome of an organism, either in nucleotide bases, genes or chromosomes. Genetic variation at the elementary level is indicated by differences in the sequence of the nucleotide bases that make up DNA in cells. Genes can be used as markers for cell recruitment and activation molecules. This study aims to evaluate the genetic variation of susceptibility gene of osteoporosis, measuring method of osteoporosis risk.

Data obtained from 27 nucleotide sequences of susceptibility gene of osteoporosis, measuring method of osteoporosis risk on secondary data form on https://www.ncbi. nlm.nih.gov/. The phylogeny analysis of DNA sequences was inferred using the UPGMA method, the evolutionary history (Neighbor-Joining method), the evolutionary distances (Maximum Composite Likelihood method) using MEGA 7.0 software.

The result shown that on the phylogenetic tree (Figure 1.) 27 sequences were divided into 3 main groups, namely group I consisting of 10 sequence, group II consisting of 6 sequence, and the group III consisting of 11 sequence. The optimal tree with the sum of branch length = 131.14792886 is shown. The tree is drawn to scale, with branch lengths in the same units as those of the evolutionary distances used to infer the phylogenetic tree. The proportion of sites where at least 1 unambiguous base is present in at least 1 sequence for each descendent clade is shown next to each internal node in the tree.

#### Conclusions

The genetic variation of susceptibility gene of osteoporosis, measuring method of osteoporosis risk sequence have highly variation.

#### **Figure & Table**




Figure. Phylogenetic tree of Osteophorosis

#### **Keywords**

Genetic Variation, Susceptibility Gene, Osteoporosis



KCR 2022

May 19(Thu) - 21(Sat), 2022

## Patient preference and efficacy of zoledronic acid in the treatment of glucocorticoid-induced osteoporosis in patients with autoimmune diseases

Ji-Won Kim¹, Ju-Yang Jung¹, Hyoun-Ah Kim¹, Chang-Hee Suh¹

¹ Department of Rheumatology, Ajou University School of Medicine, Republic of Korea

#### Background

The most commonly used drugs for glucocorticoid-induced osteoporosis (GIOP) is bisphosphonate (oral alendronate and risedronate, and intravenous zoledronic acid). Zoledronic acid is a convenient treatment option that allows compliance to be advantageous over other bisphosphonates. Our aim is to evaluate the efficacy compared to other bisphosphonates as well as the preference and patient satisfaction of zoledronic acid.

#### **Methods**

We recruited 50 patients with new fractures or osteoporosis found in follow-up bone densitometry after taking oral bisphosphonates for at least 1 year in patients diagnosed with GIOP during treatment for autoimmune diseases. After 1 year of treatment with zoledronic acid, patients completed the survey to rate their preference and satisfaction. The treatment efficacy was analyzed by comparing the changes in bone density and fractures with patients maintaining oral bisphosphonates as controls.

#### Results

Mean age was 64.1 years, 96% were female, and the mean duration of GIOP was 5.5 years. There was no difference in the cumulative glucocorticoid doses of the two groups. Thirty-nine patients (78%) preferred and were more satisfied with intravenous zoledronic acid over oral bisphosphonates, and satisfaction was strongly affected by the administration interval and convenient regimen. The infusion-related adverse events of zoledronic acid were only 2 patients (4%). In addition, there were no significant differences in annualized percentage change in bone density in the lumbar spine (1.9±3.91g/cm2 vs. 1±5.3g/cm2, p=0.355), femur neck (-0.91±6.31g/cm2 vs. 0.41±5.07g/ cm2, p=0.264), and hip (0.29±2.91g/cm2 vs. 0.41±5.07g/ cm2, p=0.888) between patients who received zoledronic acid and those who took oral bisphosphonates. The occurrence of new fractures was two in each of the two groups, showing no difference.

#### **Conclusions**

Zoledronic acid was preferred and more satisfactory by patients, and the treatment efficacy for osteoporosis was similar to oral bisphosphonates. Therefore, zoledronic acid is recommended as an appropriate treatment for GIOP in patients with autoimmune disease.

# **E-poster Presentation**

Osteoarthritis and biology of bone and joint

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



## The potential targets of San-Miao-San in the treatment of osteoarthritis

#### Zhe Cai^{1,2}, Ping Wu¹, Yu Feng³

¹ Department of Allergy, Immunology and Rheumatology, Guangzhou Women and Children's Medical Center, China., China ² Institute of Chinese Medicine and State Key Laboratory, The Chinese University of Hong Kong, Hong Kong., Hong Kong ³ Department of Sports Medicine and Arthroscopy, General Hospital of Ningxia Medical University, China., China

#### Background

To examine the potential therapeutic targets of Chinese medicine formula San-Miao-San (SMS) in the treatment of osteoarthritis (OA), we analyzed the active compounds of SMS and key targets of OA, and investigated the interacting pathways using network pharmacological approaches and molecular docking analysis.

#### **Methods**

The active compounds of SMS and OA-related targets were searched and screened by TCMSP, Drugbank, Genecards, OMIM, DisGeNet, TTD, and PharmGKB databases. Venn analysis and PPI were performed for evaluating the interaction of the targets. The topological analysis and molecular docking were used to confirm the sub-networks and binding affinity between active compounds and key targets, respectively. The GO and KEGG functional enrichment analysis for all targets of each sub-network were conducted.

#### **Results**

A total of 57 active compounds and 203 targets of SMS were identified by the TCMSP and Drugbank database; while 1791 OA-related targets were collected from the Genecards, OMIM, DisGeNet, TTD, and PharmGKB databases. By Venn analysis, 108 intersection targets between SMS-targets and OA-targets were obtained. Most of these intersecting targets involve quercetin, kaempferol and wogonin. Moreover, intersecting targets identified by PPI analysis were introduced into Cytoscape plug-in CytoNCA for topological analysis. Hence, nine key targets of SMS for OA treatment were obtained. Furthermore, the potential binding conformations between active compounds and key targets were found through molecular docking analysis. According to the DAVID enrichment analysis, the main biological processes of SMS in the treatment of OA include oxidative stress, response to reactive oxygen species and apoptotic signaling pathways. Finally, we found wogonin, the key compound in SMS, might play a pivotal role on Tolllike receptor, IL-17, TNF, osteoclast differentiation, and apoptosis signaling pathways through interacting with four key targets.

#### Conclusions

Therefore, this study elucidated the potential active compounds and key targets of SMS in the treatment of OA based on network pharmacology.

#### **Keywords**

San-Miao-San, Osteoarthritis, Network pharmacology



## Serum, synovial visfatin level during flare-up and remission of primary knee OA

#### Haytham Abd elaal¹

¹ Rheumatology, MOH, Egypt

#### Background

Osteoarthritis (OA) causes pain and dysfunction and is the leading cause of disability in elderly people in industrialized countries . Several epidemiologic studies have shown a positive association between obesity and hip and knee OA, highlighting the key role of mechanical loading on Cartilage metabolism . fat cells secrete a variety of proteins with the functional and structural properties of cytokines; these are termed "adipokines." Adiponectin, leptin, and resistin are the most abundant adipokines produced by Adipose tissue, and production of leptin and resistin is increased in obese individuals. One recently described adipokine is visfatin. It is secreted by mature adipocytes, and its plasma concentration markedly increases in parallel with the amount of visceral fat. Visfatin exerts insulin-mimetic effects in vivo and in vitro, results in breakdown of articular cartilage.

#### **Methods**

in order to achieve the target of our study which was to measure serum and synovial fluid Visfatin in patients with primary OA in two clinical settings, 20 patients with primary OA of the knee in flare-up, were selected from the out-patients clinic. The patients were followed up every two weeks after the first setting until they entered into remission i.e. returned to the base line before the last flare up. Twenty normal controls age, sex and body mass index (BMI) matched were recruited.

#### **Results**

We could demonstrate from our results that the serum level of Visfatin in OA patients were higher than the control group with high significant difference.

#### Conclusions

1-Visfatin was elevated both systemically and locally in the patients with primary knee OA

2-Visfatin was elevated during OA flare ups and decrease during OA remission.

3-The level of visfatin was higher in serum in comparison to synovial fluid in OA patients.

4-There was no difference in the level of visfatin in relation to aging or gender difference.

#### **Figure & Table**

	group	Number	Mean	Std. Deviation	t	Р
	1.00	20	53.8500	5.36509	1.71	0.096
age	2.00	20	50.8000	5.93473		
	1.00	20	89.1500	13.02336	0.63	0.534
weight	2.00	20	86.6500	12.14507		
h - i - h t	1.00	20	163.8500	10.44421	3.28	0.002
height	2.00	20	154.6500	6.93029		
вмі	1.00	20	33.6018	6.69692	1.39	0.172
BMI	2.00	20	36.3591	5.78994		
	1.00	20	92.6000	11.60943	0.151	0.138
waist_circ	2.00	20	99.1000	15.28639		
hin sins	1.00	20	105.5000	11.42251	2.98	0.005
hip_circ	2.00	20	119.1500	16.98382		
	1.00	20	.8832	.11957	1.86	0.071
w/h_ratio	2.00	20	.8312	.03739		

Group1= cases group2=control

There was significant difference between cases and control in height (cases were taller) and hip circumference (control group had wider waist circumference).

Table. Demography and patient characteristics in both groups.



## Influence of metabolic syndrome in patients with knee osteoarthritis

Jamol Uzokov¹, Anis Alyavi¹, Bakhromkhon Alyavi¹

¹ Internal Medicine, Republican Specialized Scientific Practical Medical Center of Therapy and Medical Rehabilitation, Uzbekistan

#### Background

Metabolic syndrome (MetS) is a cluster of several risk factors and risk for future type 2 diabetes mellitus and cardiovascular disease. Knee osteoarthritis is a degenerative disorder and widespread in older generation. Aim of the study was to evaluate the influence of metabolic syndrome and its components in patients with knee osteoarthritis

#### **Methods**

One hundred and twenty patients with knee osteoarthritis were enrolled in this study (Mean age-58.12±12.6 years; male-41%). Patients were divided into two groups by sixty whether diagnosed with concomitant MetS or not. Group I consisted of 60 patients with knee osteoarthritis whilst Group II made up 60 patients with knee osteoarthritis and MetS. All anthropometry, laboratory and instrumental data were collected for the assessment and all statistical analysis were performed by STATA.

#### Results

Patients with knee osteoarthritis and MetS significantly affected with varus deformity, tenderness over knee joint and flexion deformation than those without MetS (P<0.05). Kellgren and Lawrence radiological score were significantly higher in Group II than Group I participants (P<0.001). Even though, Lequesne functional score was higher in Group II there were not statistically significant changess between groups (P>0.05). Among MetS components abdominal obesity (AO, 2.2; CI 95%; 1.7-3.6; P<0.05), hypertension (1.8; CI 95%; 1.4-2.5; P<0.05), dyslipidemia (1.4; CI 95%; 1.1-2.2; P<0.05) were positively associated with knee osteoarthritis.

#### Conclusions

MetS is associated with more severe clinical picture and radiological changes in knee osteoarthritis. Among MetS components, AO, hypertension, dyslipidemia might influence course of action of the knee osteoarthritis. Further studies are required with large amount of participants.

#### **Keywords**

knee osteoarthritis, metabolic syndrome, dyslipidemia



<u>KCR 2022</u>

## Efficacy of joint treatment with metformin and NSAIDS in patients with knee osteoarthritis and metabolic syndrome

#### Bakzod Karimov¹, Jamol Uzokov¹, Anis Alyavi¹

¹ Rheumatology, Republican specialized scientific practical medical center of therapy and medical rehabilitation, Uzbekistan

#### Background

Knee osteoarthritis is widespread among older population. Co-incidence of knee osteoarthritis and metabolic syndrome exaggerates the course of disease and was associated with poor long-term prognosis. Aim of the study was to evaluate the combined therapy with metformin and NSAIDs in patients with knee osteoarthritis and MetS.

#### **Methods**

82 patients with knee osteoarthritis and metabolic syndrome were enrolled in the study (Mean age-60.22±14.8 years; male-39%). Patients were divided into two groups by 60. Group I were assigned additional metformin to NSAIDs whereas Group II were assigned only NSAIDs. Anthropometry, laboratory and instrumental data (including MRI) were assessed at baseline and in 3 years period for the follow-up. All statistical analysis were performed using STATA.

#### Results

Group I patients tended to have lower BMI (27.2 vs. 29.4, P<0.05), less knee pain (4.6 vs. 7.2, P<0.05) and less severe knee osteoarthritis (K-L grade 3.2 vs 4.3, P<0.05) than Group II. The medium rate of medial cartilage volume loss was significantly lower in patients with metformin and NSAIDs users than those without metformin users (P<0.05). Even though, the medium rate of lateral cartilage volume loss were lower in metformin group, there were not any statistically significant changes between groups (P>0.05). Risk of total knee replacement was higher in Group II than Group I over the period of 3 years (OR 0.45; Cl 95%; 0.12-0.74; P<0.05).

#### Conclusions

Combination therapy with metformin and NSAIDs may be beneficial in long-term prognosis in patients with knee osteoarthritis and metabolic syndrome. Further studies are needed to clarify.

#### **Keywords**

knee osteoarthritis, metabolic syndrome, metformin

## Detection of the sesamoid bone of the metacarpal joint in patients with osteoarthritis using the deep learning model

#### Bon San Koo¹, Wonjung Kim², Gaeun Lee², Seunghun Lee³, June-Goo Lee², Jae-Bum Jun⁴

¹ Internal medicine, Inje University Seoul Paik Hospital, Inje University College of Medicine, Republic of Korea
 ² Biomedical Engineering Research Center, Asan Institute for Life Sciences, Asan Medical Center, Republic of Korea
 ³ Department of Radiology, Hanyang University Hospital for Rheumatic Diseases, Republic of Korea
 ⁴ Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Republic of Korea

#### Background

The purpose of this study is to develop a deep learning model to detect sesamoid bone using previous digital tomosynthesis and radiograph images, and to find out the distribution and characteristics of sesamoid bone in the metacarpo-phalangeal (MCP) joint on hand radiographs in patients with osteoarthritis.

#### **Methods**

The model to detect sesamoid bone using the deep learning algorithm (Mask R-CNN) were developed. Hand radiograph images and distribution information of sesamoid bones of 5 MCP joints found on tomosynthesis in previous study were used for training (180 hand radiograph) and test set (50 hand radiograph). The accuracy of sesamoid bone detection was determined in test set. The sesamoid bone was detected on the radiograph in patients with osteoarthritis using the deep learning model, and the difference in the number of sesamoid bone according to the age, sex, and time was investigated with statistical analysis.


#### **Results**

In test set, accuracy, recall, precision, and F1 score were 0.84, 0.74, 0.76, and 0.75, respective. Using this model, sesamoid bones were analyzed on 1,474 hand radiographs and a total of 4,754 sesamoid bones were detected. The number of sesamoid bone in radial and ulnar side was 1,472 (99.9%) and 1,471 (99.8%) in first finger, 727 (49.3%) and 8 (0.5%) in second finger, 7 (0.5%) and 0 in third finger, 12 (0.8%) and 1057 (71.7%) in fifth finger, respectively. Most of the sesamoid bones are found at the first, second, and fifth MCP joints, and they are largely clustered into two groups. Group 1 includes the ulnar

#### Conclusions

The sesamoid bone, which is difficult to confirm in the radiograph, was detected using a deep learning model. In addition, more sesamoid bone was identified in osteoarthritis patients than reported in previous studies and found particularly in MCPs that are primarily stressed in the hands.

#### Figure & Table



#### **Keywords**

sesamoid bone, osteoarthritis, metacarpophalangeal joint



## Blood D-dimer level after COVID-19 in patients with knee osteoarthritis

Zumrad Ubaydullaeva¹, Jamol Uzokov¹, Anis Alyavi¹, Daler Orziev¹, Omina Mukhitdinova¹

¹ Internal Medicine, Republican Specialized Scientific Practical Medical Center of Therapy and Medical Rehabilitation, Uzbekistan

#### Background

Covid-19 was emerged in Wuhan and disseminated to the rest of the world. The virus may impact any kind of human organs. Aim of the study was to estimate the blood D-dimer level after Covid-19 in patients with knee osteoarthritis.

#### **Methods**

72 patients who were undergone Covid-19 (mild to moderate severity) without knee osteoarthritis (Group 1; aged 44-75 years, mean age 57.6±12.6 years) and 72 patients with knee osteoarthritis who was influenced by Covid-19 (Group 2; aged 44-73 years, mean age 56.8±12.4 years) have been enrolled in this prospective study. Baseline characteristics were collected when first admitted to the hospital due to Covid-19, and follow-up characteristics were collected when they admitted to our hospital for the rehabilitation after undergoing Covid-19 in 3 months. Baseline and follow-up anthropometric, laboratory and instrumental data were assessed. All statistical analysis were performed by STATA software.

#### Results

Mean blood D-dimer level significantly reduced in both groups (from 856 ng/mL to 482 ng/mL in the first group, P<0.05 vs. from 823 ng/mL to 463 ng/mL in the Group 2, P<0.05), however there were not observed statistically significant changes when compared to groups, P>0.05. In the first group mean D-dimer level tended to be higher in men, with high fibrinogen level, and older patients. In the second group, D-dimer level tended to be higher in patients with higher body mass index (BMI) with high fibrinogen level and in men. In the first group in 29% of patients was observed high level of D-dimer (>500 ng/mL) after 3 months whereas in the second group elevated D-dimer level maintained in 38% of patients.

#### Conclusions

Elevated blood D-dimer level are common after Covid-19, however concomitant knee osteoarthritis does not effect on it. Further studies are required to clarify exact mechanisms.

#### **Keywords**

knee osteoarthritis, Covid-19, D-dimer



## Lactobacillus (LA-1) and butyrate inhibit osteoarthritis by controlling autophagy and inflammatory cell death of chondrocytes

Keun-Hyung Cho¹, <u>JooYeon Jhun</u>¹, Hyun Sik Na^{1,2}, Jin Seok Woo¹, A Ram Lee^{1,2} Seon-Yeong Lee¹, JeongWon Choi¹, Sung-Hwan Park³, Mi-La Cho^{1,4}

¹ Rheumatism research center, The catholic university of Korea, Republic of Korea

² Department of Biomedicine & Health Sciences, College of Medicine, The catholic university of Korea, Republic of Korea

³ Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Med, Catholic University of Korea, Republic of Korea ⁴ Department of Medical Lifescience, College of Medicine, Catholic University of Korea, Republic of Korea

#### Background

Osteoarthritis (OA) reduces quality of life as a result of the pain caused by continuous joint destruction. Inactivated Lactobacillus (LA-1) ameliorated osteoarthritis and protected cartilage by modulating inflammation.

#### Methods

In this study, we evaluated the mechanism by which live LA-1 ameliorated OA. To investigate the effect of live LA-1 on OA progression, we administered LA-1 into MIA-induced OA animals.

#### Results

The pain threshold, cartilage damage, and inflammation of the joint synovial membrane were improved by live LA-1. Furthermore, the analysis of intestinal tissues and feces in disease model has been shown to affect the systems of the intestinal system and improve the microbiome environment. Interestingly, inflammation of the intestinal tissue was reduced, and the intestinal microbiome was altered by live LA-1. The number of short-chain fatty acid (SCFA)-producing bacteria was increased by live LA-1. In addition, daily supply of butyrate, a bacterial SCFA, showed a tendency to decrease necroptosis, a type of abnormal cell death, by inducing autophagy and reversing impaired autophagy by the inflammatory environment. These results suggest that OA is modulated by changes in the gut microbiome, suggesting that activation of autophagy can reduce aberrant cell death.

#### Conclusions

In summary, live LA-1 or butyrate ameliorates OA progression by modulating the gut environment and autophagic flux. Our findings suggest regulation of the gut microenvironment as a therapeutic target for OA.

#### **Keywords**

Osteoarthritis, Inflammation, Microbiota

# **E-poster Presentation**

## **Orthopedics & Rehabilitation**

KCR 2022 May 19(Thu) - 21(Sat), 2022 Seoul Dragon City, Seoul, Korea



## Effects of conventional rehabilitative and aerobic training in patients with idiopathic inflammatory myopathy

Guangyu Zhang², <u>Mingwei Tang</u>¹, Xiao Zhang¹, Shuang Zhou¹, Chanyuan Wu¹, Jiuliang Zhao¹, Dong Xu¹, Qian Wang¹, Mengtao Li¹, Lixia Chen², Xiaofeng Zeng¹

¹ Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Science, China ² Department of Physical Medicine and Rehabilitation, Peking Union Medical College Hospital, Chinese Academy of Medical Science, China

#### Background

Idiopathic inflammatory myopathies (IIMs) are a group of chronic autoimmune diseases mainly involving the muscular tissue. Physical therapy has recently become major means of intervention to help IIM patients regain muscle strength and the physical capacity in addition to conventional medications. This research is to investigate the efficacy of conventional rehabilitation alone and conventional rehabilitation combined with aerobic training on muscle strength and function, health condition, and quality of life for patients with stable idiopathic inflammatory myopathy.

#### **Methods**

This is a historical retrospective cohort study, in which the medical records of IIM patients who received the combination of conventional rehabilitative therapy and aerobic training (combined training group, CTG), from February 2015 to December 2017 were reviewed. IIM patients who received conventional therapy alone were matched based on their age, gender, and disease activity as the control group (CG). Manual Muscle Testing (MMT8) was the primary outcome, and Myositis Functional Index (FI-2), Health Assessment Questionnaire (HAQ), and Short Form 36 (SF-36) scores at 12 weeks during training were the secondary outcomes.

#### Results

56 patients were included in this analysis: 28 in CTG, 28 in CG. Patients in both groups had improved MMT8, FI-2, HAQ, and SF-36 scores after 12 weeks' physical therapy. There was a significantly higher score of MMT8 and HAQ in CTG than CG at the 12th week. FI-2 scores were significantly higher in the CTG in 4 items (P<0.05) of hip flexion, step test, heel lift, and toe lift. SF-36 scores of the CTG were also higher than CG in 5 items (P<0.05) of physical functioning, general health, vitality, social functioning, and mental health.

#### Conclusions

Physical exercise training including conventional rehabilitation and aerobic training improved muscle function, health condition, and quality of life. Conventional rehabilitative training combined with aerobic training achieved better improvement compared with conventional rehabilitation training alone.

#### Figure & Table




Figure. Mean Manual Muscle Test (MMT8) scores of the combined training group(CTG) and control group(CG) before and after training

#### **Keywords**

myositis, rehabilitation, aerobic Training

## JOURNAL OF RHEUMATIC DISEASES

#### Journal of Rheumatic Diseases Vol. 29, Suppl. 1, May, 2022

#### 2022년 5월 19일 발행

발행인 이상헌 편집인 이영호 기획인 성윤경

- 발 행 대한류마티스학회 (우: 04378) 서울특별시 용산구 한강대로 95 래미안 용산 오피스텔 A동 1917호 Tel: 02-794-2630, Fax: 02-794-2631 E-mail: webmaster@rheum.com Homepage: www.rheum.or.kr
- 편집제작 (주)엠씨아이코리아 (우:06154)서울특별시 강남구 봉은사로 460 금척타워 8층 Tel:02-6263-2060, Fax:02-579-2662 E-mail: seoul@mci-group.com

<pISSN 2093-940X><eISSN 2233-4718>

Publisher Sang-Heon Lee Editor in Chief Young-Ho Lee

Published by Korean College of Rheumatology

Office of Executive Secretary Raemian Yongsan A Building 1917, 95 Hangang-daero, Yongsan-gu, Seoul 04378, Korea Tel 82-2-794-2630 | Fax 82-2-794-2631 E-mail webmaster@rheum.com Homepage www.rheum.or.kr

본 사업은 기획재정부의 복권기금 및 과학기술정보통신부의 과학기술진흥기금으로 추진되어 사회적 가치 실현과 국가 과학기술 발전에 기여합니다. This work was supported by the Korean Federation of Science and Technology Societies (KOFST) Grant funded by the Korean Government.